export default [
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26574" target="_blank" rel="noopener noreferrer">26574</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NY61" target="_blank" rel="noopener noreferrer">Q9NY61</a>', 'HUGO Gene symbol': 'AATF', 'Protein name': 'Apoptosis-antagonizing transcription factor / Rb-binding protein Che-1', 'Function': 'May function as a general inhibitor of the histone deacetylase HDAC1. Binding to the pocket region of RB1 may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22909821%2C%2018004398%5Buid%5D" target="_blank" rel="noopener noreferrer">22909821, 18004398</a>', 'Notes': '1) AATF amplification is associated with increased resistance of lung cancer cell lines against cisplatin.\xa02) p53 expression might be increased by the apoptosis-antagonizing transcription factor (AATF, also known as CHE-1), which is phosphorylated and activated by CHK2 and ATM in response to DNA-damaging agents. 3) AATF negatively regulates p53-driven apoptosis by preventing efficient DNA damage-induced transactivation of the pro-apoptotic p53 target genes PUMA, BAX and BAK. 4) AATF amplification in tumours results in worse prognosis of neuroblastoma patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AATF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10351" target="_blank" rel="noopener noreferrer">10351</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94911" target="_blank" rel="noopener noreferrer">O94911</a>', 'HUGO Gene symbol': 'ABCA8', 'Protein name': 'ATP-binding cassette sub-family A member 8', 'Function': 'ATP-dependent lipophilic drug transporter', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25891226%5Buid%5D" target="_blank" rel="noopener noreferrer">25891226</a>', 'Notes': '1) 489 TCGA ovarian cancer patient samples with mRNA expression value were selected, the high expression of\xa0ALDH1A2\xa0and\xa0ABCA8\xa0predicted a poor prognosis (39.400±2.202 vs. 47.600±2.884 months, and 41.000±2.427 vs. 45.100±2.476 months, respectively). 2) mRNA expression of ALDH1A2, ADH1B, HBB and ABCA8 was significantly increased in ovarian cancer patients after chemotherapy in comparison with patients who did not receive chemotherapy. 3) The expression of ADH1B and ABCA8 were significantly upregulated in SKOV3-DDP cells, A2780-DDP and -CBP cells. In particular, the expression of ALDH1A2 and ADH1B was extremely highlighted in drug-resistant cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCA8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5243" target="_blank" rel="noopener noreferrer">5243</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08183" target="_blank" rel="noopener noreferrer">P08183</a>', 'HUGO Gene symbol': 'ABCB1', 'Protein name': 'ATP-binding cassette sub-family B member 1', 'Function': 'Translocates drugs and phospholipids across the membrane', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15262121,15863151,16026610,10810398,20189873" target="_blank" rel="noopener noreferrer">15262121, 15863151, 16026610, 10810398, 20189873</a>', 'Notes': '1) The mRNA for MDR-1 was uniquely overexpressed in the cisplatin-resistant cell line A2780-CR9 initially treated with low doses of cisplatin and paclitaxel, but was not amplified in A2780 (P < 0.01). 2) Inhibition of P-gp and GST expression by siRNA enhanced the intracellular accumulation of and restored sensitivity to DDP. In 3) 8/16 paired esophageal biopsies, there was an increase in MDR1 following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy. 4) P-glycoprotein negative cases responded significantly better to cisplatin-based chemotherapy (P < .001) in advanced ovarian cancer. In the multivariate survival analysis P-glycoprotein expression was an independent predictor of both overall (P = .045) and progression free (P = .006) survival. 5) gene polymorphisms in MDR1G2677T/A may be a predictive marker of platinum-based treatment response and of secondary effects, especially gastrointestinal toxicity for advanced NSCLC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNCHANGED in S; UP in R', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/340273" target="_blank" rel="noopener noreferrer">340273</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q2M3G0" target="_blank" rel="noopener noreferrer">Q2M3G0</a>', 'HUGO Gene symbol': 'ABCB5', 'Protein name': 'ATP-binding cassette sub-family B member 5', 'Function': 'Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug doxorubicin. Specifically present in limbal stem cells, where it plays a key role in corneal development and repair.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31107974%5Buid%5D" target="_blank" rel="noopener noreferrer">31107974</a>', 'Notes': '1) Compared to differentiated/adherent cells (AC), MPM-initiating cells (ICs) had upregulated the drug efflux transporter ABCB5 that determined resistance to cisplatin and pemetrexed. 2) ABCB5-knocked-out (KO) IC clones were resensitized to the drugs in vitro and in patient-derived xenografts. 3) ABCB5 was transcriptionally activated by the Wnt/GSK3β/β-catenin/c-myc axis that also increased IL-8 and IL-1β production. 4) IL-8 and IL-1β-KO IC clones reduced the c-myc-driven transcription of ABCB5 and reacquired chemosensitivity. 5) ABCB5-KO clones had lower IL-8 and IL-1β secretion, and c-myc transcriptional activity, suggesting that either Wnt/GSK3β/β-catenin and IL-8/IL-1β signaling drive c-myc-mediated transcription of ABCB5. 6) ABCB5 correlated with lower time-to-progression and overall survival in MPM patients treated with cisplatin and pemetrexed. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCB5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4363" target="_blank" rel="noopener noreferrer">4363</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P33527" target="_blank" rel="noopener noreferrer">P33527</a>', 'HUGO Gene symbol': 'ABCC1', 'Protein name': 'Multidrug resistance-associated protein 1', 'Function': 'Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20005867,25308861,20082278" target="_blank" rel="noopener noreferrer">20005867, 25308861, 20082278</a>', 'Notes': '1) Ovarian cancer IGROV-1/OHP exhibited high levels of resistance to oxaliplatin, cross-resistance to cisplatin and topotecan and displayed a marked accumulation of Pt drugs. 2) This feature was associated with increased expression and altered N-linked glycosylation of MRP1 and MRP4. 3) overexpression of fully glycosylated MRP1 or MRP4 in tumor cell line of ovarian origin was associated with resistance to oxaliplatin and cisplatin. 4) siRNA inhibition of expression of MRP1 could decrease the cisplatin resistance of SKOV3/DDP cells.  5) NSCLC patients of stage IIIA (p=0.011), N1 and N2 status (p=0.008), high expression of MRP1 (p=0.034) and LRP (p=0.018) were associated with shorter TFS after cisplatin-based chemotherapy. Stage IIIA (p=0.0105), N1 and N2 status (p=0.009), high expression of MRP1 (p=0.021) and ERCC1 (p=0.012) were related to a shorter overall survival. Low MRP1 expression (p=0.022 and p=0.035) were independent predictors of favorable TFS and overall survival, respectively. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1244" target="_blank" rel="noopener noreferrer">1244</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92887" target="_blank" rel="noopener noreferrer">Q92887</a>', 'HUGO Gene symbol': 'ABCC2', 'Protein name': 'Canalicular multispecific organic anion transporter 1', 'Function': 'Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15688364%2C%2016213010%2C%2017145840%2C%209230284%2C%2020204280%5Buid%5D" target="_blank" rel="noopener noreferrer">15688364, 16213010, 17145840, 9230284, 20204280</a>', 'Notes': '1) human cisplatin-resistant cell lines, A2780RCIS, D43/86RCIS and MeWoCIS1 all showed overexpression of MRP2. 2) anti-MRP2 hammerhead ribozymes reversed the drug-resistant phenotype. 3) The level of DNA platination corresponded inversely to the level of MRP2 expression. 4) Primary hepatocyte cultures from Mrp2-deficient TR- rats were over threefold more sensitive to cisplatin and accumulated a twofold greater amount of platinum on DNA than wild-type rat hepatocytes. 5) Cases with relapse of cisplatin-based chemotherapy showed higher ABCC2 nuclear membrane expression at primary and secondary surgery. 6) weak nuclear membrane ABCC2 expression before treatment was associated with significantly longer overall and progression-free survival; following cisplatin-based chemotherapy, it correlated with significantly longer progression-free survival (P = 0.038). 7) Tissue microarrays confirmed nuclear membranous localization of ABCC2, in particular, in poorly differentiated cells. In ovarian carcinoma cells, it correlated with resistance against cisplatin, whereas localization in the cytoplasmic membrane did not. 8) overexpression of MRP2 correlates with a lower percentage of tumor necrosis in patients treated with cisplatin-based neoadjuvant chemotherapy for HCC.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8714" target="_blank" rel="noopener noreferrer">8714</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15438" target="_blank" rel="noopener noreferrer">O15438</a>', 'HUGO Gene symbol': 'ABCC3', 'Protein name': 'Canalicular multispecific organic anion transporter 2', 'Function': 'cisplatin conjugate efflux', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24176985,11223551" target="_blank" rel="noopener noreferrer">24176985, 11223551</a>', 'Notes': '1) 99 non-small cell lung cancer NSCLC fresh tissue samples were tested for chemosensitivity by MTT assay. 2) cDNA microarray was done with 5 samples with highest\xa0resistance\xa0and 6 samples with highest sensitivity. 3) 44 genes were upregulated and 168 downregulated in the chemotherapy-resistant group.\xa04) ABCC3\xa0was one of the most up-regulated genes in the resistant group.\xa05) ABCC3-positive expression correlated with lymph node involvement, advanced TNM stage, more malignant histological type,\xa0multiple-resistance\xa0to anti-cancer\xa0drugs, and reduced OS.\xa06) The two MRP3 antisense transfectants showed 2- to 5-fold increases in drug sensitivity to etoposide and cisplatin compared with glioma NHG2 cells. 7) Two MRP3 cDNA sense transfectants of pig kidney cell lines showed 4- to 6-fold drug resistance to etoposide, but only 1.4- to 1.5-fold to cisplatin. 8) In situ hybridization revealed that glioma cells were stained with MRP3 probe. MRP3 may modulate drug sensitivity to certain anticancer agents in human gliomas.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10257" target="_blank" rel="noopener noreferrer">10257</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15439" target="_blank" rel="noopener noreferrer">O15439</a>', 'HUGO Gene symbol': 'ABCC4', 'Protein name': 'Multidrug resistance-associated protein 4', 'Function': 'organic anion pump relevant to cellular detoxification', 'Putative_mechanism_associated_with_Pt_resistance': 'PKA signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20005867%2C%2020200426%5Buid%5D" target="_blank" rel="noopener noreferrer">20005867, 20200426</a>', 'Notes': '1) As ABCC1 2) We observed suggestive associations between survival and GSTT1 copy number (P = 0.017), and GSTA5, GSTM4, and ABCC4 SNPs, adjusted for covariates (P = 0.018, 0.002, and 0.002, respectively) or not (P = 0.005, 0.011, and 0.002). 3) GSTM4, GSTT1, and ABCC4 overexpression significantly decreased cisplatin sensitivity in lung cancer and HEK293T cell lines.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCC4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10057" target="_blank" rel="noopener noreferrer">10057</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15440" target="_blank" rel="noopener noreferrer">O15440</a>', 'HUGO Gene symbol': 'ABCC5', 'Protein name': 'Multidrug resistance-associated protein 5', 'Function': 'Acts as a multispecific organic anion pump which can transport nucleotide analogs', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25248111,10728601,17982673" target="_blank" rel="noopener noreferrer">25248111, 10728601, 17982673</a>', 'Notes': '1) miR-128 expression was significantly reduced in the cisplatin-resistant human epithelial ovarian cancer cell line SKOV3/CP and 2) decreased upon treatment with cisplatin in a concentration-dependent manner in SKOV3, OVCAR3, and PEO14 cells. 3) Overexpression of miR-128 resensitized SKOV3/CP cells to cisplatin and 4) reduced the expression of cisplatin-resistant-related proteins ABCC5 and Bmi-1. 5) Cisplatin combined with miR-128 agomirs inhibited the growth of SKOV3/CP xenograft tumors more effectively than cisplatin alone. 6) Diminished expression of ABCC5 and Bmi-1 and higher cisplatin concentrations were observed in tumor tissue of mice treated with miR-128 agomirs in addition to cisplatin. 7) The MRP5 expression levels in normal lung tissues and in tumors from patients exposed to platinum drugs during their lifetime were significantly higher than those in tissues from non-exposed patients. On the other hand, the MRP5 expression levels were not rapidly induced by platinum drugs either in lung cancer cell lines or in PMN within 24 hr. 8) The cisplatin-resistant hepatocellular carcinoma cells showed 14.1-fold higher resistance to cisplatin, and they expressed higher levels of MRP2 (6.29-fold), MRP3 (3.2-fold), MRP4 (11.3-fold) and MRP5 (3.39-fold) mRNAs than the parent cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCC5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/225" target="_blank" rel="noopener noreferrer">225</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBJ2" target="_blank" rel="noopener noreferrer">Q9UBJ2</a>', 'HUGO Gene symbol': 'ABCD2', 'Protein name': 'ATP-binding cassette sub-family D member 2', 'Function': 'The function of this peroxisomal membrane protein is unknown; however this protein is speculated to function as a dimerization partner of ABCD1 and/or other peroxisomal ABC transporters.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24739237%5Buid%5D" target="_blank" rel="noopener noreferrer">24739237</a>', 'Notes': '1) one SNP (rs11138019), which was associated with the expression of both miR-30d and the gene ABCD2, which were themselves correlated with both carboplatin and cisplatin drug-specific phenotype in the lymphoblastoid cell lines HapMap samples. 2) Knocking down ABCD2 in vitro led to increased apoptosis in ovarian cancer cell line SKOV3 after cisplatin treatment. 3) Over-expression of miR-30d in vitro caused a decrease in ABCD2 expression, suggesting a functional relationship between the two.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10061" target="_blank" rel="noopener noreferrer">10061</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UG63" target="_blank" rel="noopener noreferrer">Q9UG63</a>', 'HUGO Gene symbol': 'ABCF2', 'Protein name': 'ATP-binding cassette sub-family F member 2', 'Function': 'ATP-binding cassette proteins transport various molecules across extra- and intracellular membranes. Alterations in this gene may be involved in cancer progression.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14973057%2C%2028112439%5Buid%5D" target="_blank" rel="noopener noreferrer">14973057, 28112439</a>', 'Notes': '1) transient overexpression of ABCF2 in the parental cells decreased apoptosis and increased cell viability following cisplatin treatment. 2) knockdown of ABCF2 using specific siRNA notably increased apoptosis and decreased cell viability in cisplatin-resistant cells treated with cisplatin. 3) The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin-induced apoptosis compared to its control cell line; 4) the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9429" target="_blank" rel="noopener noreferrer">9429</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UNQ0" target="_blank" rel="noopener noreferrer">Q9UNQ0</a>', 'HUGO Gene symbol': 'ABCG2', 'Protein name': 'ATP-binding cassette sub-family G member 2', 'Function': 'High-capacity urate exporter functioning in both renal and extrarenal urate excretion.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hedgehog signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20354527%2C%20%2022112610%2C%2023423781%2C%2015014021%5Buid%5D" target="_blank" rel="noopener noreferrer">20354527,¬† 22112610, 23423781, 15014021</a>', 'Notes': '1) The side-population (SP) cells from ascites derived from ovarian cancer patients expressed ABCG2/BCRP1, OCT4, STELLAR, and NANOG, detected by immunocytochemistry and RT-PCR. 2) ABCG2/BCRP1 expression was higher in SP than in non-SP cells. 3) Xenogeneic mice inoculated with SP cells yielded more tumours than did mice inoculated with non-SP cells. 4) SP cell culture resulted in extensive cell proliferation, which was markedly more than in non-SP cells. 5) SP cells resisted chemotherapy compared with non-SP cells, both in vivo and in vitro. 6) The C421A variant (CA+AA versus CC) in ABCG2 was associated with a 6-month longer median PFS (22.7 versus 16.8 months, p=0.041). 7) the response rate to Pt-based chemotherapy of patients with BCRP-negative tumors was 44%, as opposed to 24% in patients with BCRP-positive tumors. 8) BCRP-positive patients had also shorter PFS (P = 0.0003) and overall survival (P = 0.004) than BCRP-negative patients. Multivariate analysis confirmed BCRP status as an independent variable related to PFS (P = 0.001).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABCG2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11057" target="_blank" rel="noopener noreferrer">11057</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08910" target="_blank" rel="noopener noreferrer">P08910</a>', 'HUGO Gene symbol': 'ABHD2', 'Protein name': 'Progesterone-dependent acylglycerol lipase 2, alpha/beta hydrolase family', 'Function': 'Acts as a progesterone receptor: mediating degradation of 2AG, leading to calcium influx and sperm activation; Also regulates calcium release from ER (28684316)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Calcium signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27323405%5Buid%5D" target="_blank" rel="noopener noreferrer">27323405</a>', 'Notes': '1) shRNA knockdown of ABHD2 in OVCA420 cells increased phosphorylated p38 and ERK, platinum resistance, and side population (SP) cells. 2) Overexpression of ABHD2 decreased resistance to anoikis and the amount of phosphorylated p38 and ERK in OVCA420 and SKOV3 cells. 3) In clinical serous ovarian cancer specimens, low expression of ABHD2 was associated with platinum resistance and poor prognosis. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABHD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25" target="_blank" rel="noopener noreferrer">25</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00519" target="_blank" rel="noopener noreferrer">P00519</a>', 'HUGO Gene symbol': 'ABL1', 'Protein name': 'Non-receptor tyrosine-protein kinase ABL1', 'Function': 'linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23117882%2C%2010098743%2C%2023660976%5Buid%5D" target="_blank" rel="noopener noreferrer">23117882, 10098743, 23660976</a>', 'Notes': '1) CDDP induced p-c-ABL(Y412) and p-p73β(Y99). 2) a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage.\xa03) The DNA mismatch repair system plays an important part in the recognition of cisplatin adducts, and activation of both the JNK and c-Abl kinases in response to cisplatin damage. 4) Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity', 'Up / down in Pt-resistant cells': 'DEPHOS/out of nuclear', 'Up / down to promote Pt-resistance': 'DEPHOS/out of nuclear', 'Up / down after Pt-treatment': 'PHOS/nuclear loc', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23172" target="_blank" rel="noopener noreferrer">23172</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15018" target="_blank" rel="noopener noreferrer">Q15018</a>', 'HUGO Gene symbol': 'ABRAXAS2', 'Protein name': 'BRCA1-A complex subunit Abraxas 1', 'Function': 'Involved in DNA damage response and double-strand break (DSB) repair. Component of the BRCA1-A complex, acting as a central scaffold protein that assembles the various components of the complex and mediates the recruitment of BRCA1. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22357538%2C%2028569838%5Buid%5D" target="_blank" rel="noopener noreferrer">22357538, 28569838</a>', 'Notes': '1) 31% of ovarian carcinomas had a deleterious germline (24%) and/or somatic (9%) mutation in one or more of the 13 HR genes:\xa0BRCA1,\xa0BRCA2,\xa0ATM,\xa0BARD1,\xa0BRIP1,\xa0CHEK1,\xa0CHEK2,\xa0FAM175A,\xa0MRE11A,\xa0NBN, PALB2,\xa0RAD51C, and\xa0RAD51D. 2) The presence of germline and somatic HR mutations was highly predictive of primary platinum sensitivity (p=0.0002) and improved overall survival (p=0.0006). 3) RAP80 helps recruit BRCA1 to double-strand breaks  through the scaffold protein CCDC98 (Abraxas) and facilitates DNA damage response (DDR). 4) a deubiquitinase, USP13, regulates DDR by targeting RAP80. 5) USP13 is phosphorylated by ATM following DNA damage; USP13 deubiquitinates RAP80 and promotes RAP80 recruitment. 6) Depleting or inhibiting USP13 sensitizes ovarian cancer cells to cisplatin and PARP inhibitor (olaparib) while overexpression of USP13 renders ovarian cancer cells resistant to chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ABRAXAS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55902" target="_blank" rel="noopener noreferrer">55902</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NR19" target="_blank" rel="noopener noreferrer">Q9NR19</a>', 'HUGO Gene symbol': 'ACSS2', 'Protein name': 'Acetyl-coenzyme A synthetase', 'Function': 'Activates acetate so that it can be used for lipid synthesis or for energy generation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Metabolism/OXPHOS<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29883801%5Buid%5D" target="_blank" rel="noopener noreferrer">29883801</a>', 'Notes': '1) Real-time live metabolomics revealed that Cisplatin-resitant T24R bladder cancer cells consume more glucose, leading to higher production of glucose-derived acetate and fatty acids.\xa02) The relevance of ACSS2 in cisplatin resistance was further confirmed by the abrogation of resistance by an ACSS2 inhibitor. 3) By the higher expression of ACSS2 in the patient tissues with cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ACSS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/59" target="_blank" rel="noopener noreferrer">59</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P62736" target="_blank" rel="noopener noreferrer">P62736</a>', 'HUGO Gene symbol': 'ACTA2', 'Protein name': 'alpha-actin-2 / alpha smooth muscle actin (alpha-SMA)\xa0', 'Function': 'Actins are highly conserved proteins that are involved in various types of cell motility', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM/stroma', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27133165%5Buid%5D" target="_blank" rel="noopener noreferrer">27133165</a>', 'Notes': '1) high stromal a-SMA expression was associated with poor overall survival of HGSOC paitents. 2) increased tumor stromal fibroblasts strongly correlated with platinum-based chemoresistance, 3) the proportion of high levels of stromal fibroblasts were elevated in chemoresistant patients compared to chemosensitive patients', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ACTA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/81" target="_blank" rel="noopener noreferrer">81</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43707" target="_blank" rel="noopener noreferrer">O43707</a>', 'HUGO Gene symbol': 'ACTN4', 'Protein name': 'Alpha-actinin-4', 'Function': 'F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures; enhancing cell motility; free form can enter nucleus and serve as a TF to promote EMT (31766144)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25960282%2C%2022110952%2C%2017873890%2C%2029867145%5Buid%5D" target="_blank" rel="noopener noreferrer">25960282, 22110952, 17873890, 29867145</a>', 'Notes': '1) Significant changes in the expression of proteins involved in actin cytoskeletal signalling, integrin linked kinase (ILK) signalling, epithelial adherens junctions signalling and remodelling of epithelial adherens junctions pointed towards a mesenchymal phenotype developed by cisplatin resistant SK-N-ASCis24. 2) Among these genes, elevated levels of MYH9 and ACTN4 and reduced levels of ROCK1 contribute to the increased ROCK1-independent migratory potential of SK-N-ASCis24. 3) ACTN4 is one of the top 30 proteins associated with neoadjuvant chemotherapy resistance in docetaxel and carboplatin-treated TNCBC. 4) High expression of actinin-4 was demonstrated in 137 (57%) ovarian cancer cases and was associated with a high degree of residual disease after initial surgery, poor patient outcome in platinum-based chemotherapies, and also with reduced E-cadherin and preserved β-catenin expressions. 5) NHERF1 attenuated β-catenin expression via suppression of α-actinin-4 expression; downregulation of NHERF1 was involved in the development and progression of cervical cancer and may serve as a potential predictor of prognosis and cisplatin response for CC patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ACTN4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/130399" target="_blank" rel="noopener noreferrer">130399</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NER5" target="_blank" rel="noopener noreferrer">Q8NER5</a>', 'HUGO Gene symbol': 'ACVR1C', 'Protein name': 'Activin receptor type-1C kinase 7', 'Function': 'forms a receptor complex on ligand binding, binds and activates SMAD transcriptional regulators, regulates cell differentiation, growth arrest and apoptosis.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21224400%5Buid%5D" target="_blank" rel="noopener noreferrer">21224400</a>', 'Notes': '1) miR-376c targets ALK7, overexpression of miR-376c blocked cisplatin-induced cell death, whereas anti-miR-376c enhanced the effect of cisplatin in human ovarian cancer cells, OV2008 and A2780s. 2) In serous carcinoma samples taken from ovarian cancer patients who responded well to chemotherapy, strong ALK7 staining and low miR-376c expression was detected. By contrast, ALK7 expression was weak and miR-376c levels were high in samples from patients who responded poorly to chemotherapy. 3) treatment with cisplatin led to an increase in expression of mRNA encoding Nodal and ALK7 but a decrease in miR-376c levels. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ACVR1C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/102" target="_blank" rel="noopener noreferrer">102</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14672" target="_blank" rel="noopener noreferrer">O14672</a>', 'HUGO Gene symbol': 'ADAM10', 'Protein name': 'Disintegrin and metalloproteinase domain-containing protein 10', 'Function': 'Cleaves (shedding) the membrane-bound precursor of TNF-alpha to its mature soluble form leading to NF-kB signaling. Proteolytical release of soluble JAM3, ephrin-A2, CD44, CDH2; contributed to cell motility via regulation of CD44 cleavage and Notch1 signaling (22586143, 22940701)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> NF-kB signaling<br><br> Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24935471%2C%2028703811%5Buid%5D" target="_blank" rel="noopener noreferrer">24935471, 28703811</a>', 'Notes': '1) ADAM10 is upregulated in several cancers and associates with malignant cancer progression. 2) ADAM10 overexpression in 51 of 105 (48.5 %) bladder cancer specimens. 3) ADAM10 overexpression associated with advanced tumor stage (p\u2009=\u20090.001) and tumor grade (p\u2009=\u20090.018). 4) siRNA mediated ADAM10 depletion decreased cell proliferation, migration, and invasion and increased the level of cisplatin-induced apoptosis.\xa05) CD147 shedding mediated by ADAM10 leads to further procession of residual CD147 in the lysosome produces nuclear-localized CD147-ICD (intracellular domain of CD147), which contributes to autophagy through NF-κB–TRAIL–caspase8–ATG3 axis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ADAM10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6868" target="_blank" rel="noopener noreferrer">6868</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78536" target="_blank" rel="noopener noreferrer">P78536</a>', 'HUGO Gene symbol': 'ADAM17', 'Protein name': 'Disintegrin and metalloproteinase domain-containing protein 17', 'Function': 'Cleaves the membrane-bound precursor to its mature soluble form (e.g. AREG/EGFR; TNFa); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29662625%2C%2029171106%5Buid%5D" target="_blank" rel="noopener noreferrer">29662625, 29171106</a>', 'Notes': '1) EGFR ligands like amphiregulin (AREG) has recently been detected in ascites of advanced stage ovarian cancer patients. 2) ADAM17 as an essential upstream regulator of AREG release under chemotherapeutic treatment in ovarian cancer cell lines and patient derived cells. 3) ADAM17 inhibition sensitized cancer cells to cisplatin-induced apoptosis. 4) In oral squamous cell carcinoma (OSCC), high CD44, ABCB1 and ADAM17 expressions were correlated with higher tumour grades and poor differentiation and show significant correlation in their co‐expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ADAM17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8754" target="_blank" rel="noopener noreferrer">8754</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13443" target="_blank" rel="noopener noreferrer">Q13443</a>', 'HUGO Gene symbol': 'ADAM9', 'Protein name': 'Disintegrin and metalloproteinase domain-containing protein 9', 'Function': 'Cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis. proteolytic substrates include pro-HB-EGF, kit ligand, IGFBP-1, ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29247567%2C%2020672324%5Buid%5D" target="_blank" rel="noopener noreferrer">29247567, 20672324</a>', 'Notes': '1) ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death. 2) When two clear cell carcinoma cell lines (RMG-I and TOV21G cells) with ADAM9m expression were treated with cisplatin, viability was significantly reduced and apoptosis increased in ADAM9m knockdown cells compared with mock transfectants. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ADAM9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/155465" target="_blank" rel="noopener noreferrer">155465</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TD06" target="_blank" rel="noopener noreferrer">Q8TD06</a>', 'HUGO Gene symbol': 'AGR3', 'Protein name': 'Anterior gradient protein 3', 'Function': 'part of the Protein Disulfide Isomerase (PDI) family and harbors core thioredoxin folds (CxxS motifs) that have the potential to regulate protein folding and maturation', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22361111%5Buid%5D" target="_blank" rel="noopener noreferrer">22361111</a>', 'Notes': '1) AGR3 protein is expressed in four distinct ovarian cancer subtypes and 2) is not linked to oestrogen receptor expression, 3) may act as a novel biomarker for ovarian cancer, in particular the endometrioid, clear cell, and mucinous subtype. 4) In mouse xenograft systems, cells that over-produce AGR3 were resistant and continued to grow in the presence of cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AGR3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9131" target="_blank" rel="noopener noreferrer">9131</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95831" target="_blank" rel="noopener noreferrer">O95831</a>', 'HUGO Gene symbol': 'AIFM1', 'Protein name': 'Apoptosis-inducing factor 1', 'Function': 'mitochondrial, NADH oxidoreductase and as regulator of apoptosis. plays an important role in caspase-independent apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18283299%5Buid%5D" target="_blank" rel="noopener noreferrer">18283299</a>', 'Notes': '1) in chemosensitive ovarian cancer cells, cisplatin induces the mitochondrial release and nuclear translocation of AIF, and AIF-dependent apoptosis. 2) Cisplatin failed to induce these effects in the chemoresistant variant cells. 3) Overexpression of AIF sensitised resistant cells to cisplatin-induced apoptosis. 4) activation of Akt attenuated the cisplatin-induced mitochondrial release and nuclear accumulation of AIF and apoptosis in chemosensitive cells, 5) inhibition of Akt activity facilitated these effects and sensitised chemoresistant cells to AIF-dependent, cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AIFM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57016" target="_blank" rel="noopener noreferrer">57016</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60218" target="_blank" rel="noopener noreferrer">O60218</a>', 'HUGO Gene symbol': 'AKR1B10', 'Protein name': 'Aldo-keto reductase family 1 member B10', 'Function': 'Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27417252%5Buid%5D" target="_blank" rel="noopener noreferrer">27417252</a>', 'Notes': '1) In the nonresistant gastrointestinal cancer MKN45\xa0cells, the sensitivity to CDDP was decreased by overexpression of AKR1B10 and increased by silencing of AKR1B10, respectively. 2) the AKR1B10 overexpression markedly suppressed accumulation and cytotoxicity of 4-hydroxy-2-nonenal that is produced during lipid peroxidation by CDDP treatment, suggesting that the enzyme acts as a crucial factor for facilitation of the CDDP resistance through inhibiting induction of oxidative stress by the drug. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKR1B10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1645" target="_blank" rel="noopener noreferrer">1645</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q04828" target="_blank" rel="noopener noreferrer">Q04828</a>', 'HUGO Gene symbol': 'AKR1C1', 'Protein name': 'Aldo-keto reductase family 1 member C1', 'Function': 'Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentrations of NADPH', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23165153%2C%2015790446%2C%2027698389%5Buid%5D" target="_blank" rel="noopener noreferrer">23165153, 15790446, 27698389</a>', 'Notes': '1) AKR1C1 and AKR1C3 are highly induced with the CDDP resistance. 2) The resistance lowered the sensitivity toward cellular damages evoked by oxidative stress-derived aldehydes, 4-hydroxy-2-nonenal and 4-oxo-2-nonenal that are detoxified by AKR1C1 and AKR1C3. 3) Overexpression of AKR1C1 or AKR1C3 in the parental HCT15\xa0cells\xa0mitigated the cytotoxicity of the aldehydes and CDDP.\xa04) Knockdown of both AKR1C1 and AKR1C3 in the resistant cells or treatment of the cells with specific inhibitors of the AKRs increased the sensitivity to CDDP toxicity. 5) DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases than in cisplatin-sensitive cases. 6) Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. 7) In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKR1C1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1646" target="_blank" rel="noopener noreferrer">1646</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52895" target="_blank" rel="noopener noreferrer">P52895</a>', 'HUGO Gene symbol': 'AKR1C2', 'Protein name': 'Aldo-keto reductase family 1 member C2', 'Function': 'See AKR1C1', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32678482%2C%2024527071%2C%2022534668%5Buid%5D" target="_blank" rel="noopener noreferrer">32678482, 24527071, 22534668</a>', 'Notes': '1) AKR1C2 expression was found to be up-regulated in ESCC tissues and was significantly associated with pathological stage, lymph node metastasis and worse outcomes. 2) an ectopic expression of AKR1C2 in ESCC cells resulted in increased proliferation, migration and cisplatin resistance, while knockdown led to inversing effects. 3) AKR1C2 activated the PI3K/AKT signalling pathway, furthermore, the inhibitor of PI3K or the selective inhibitor of AKR1C2 enzyme activity could reverse the aggressiveness and showed synergistic antitumour effect when combined with cisplatin, both in vitro and in vivo. 4) In the human HT1376 bladder cancer cell line and the cisplatin-resistant HT1376-CisR subline: AKR1C2 was expressed in HT1376-CisR cells, but not in the parental cells. 5) Silencing of AKR1C2 mRNA or inhibition of AKR1C2 by 5β-cholanic acid resulted in a decrease in the survival of cells following cisplatin exposure. 6) The ROS levels in HT1376-CisR cells were significantly lower than those in HT1376 cells and knockdown of AKR1C2 mRNA significantly restored ROS levels. 7) Cisplatin exposure did not increase intracellular ROS in HT1376-CisR cells, although the level of intracellular ROS increased in HT1376 cells following cisplatin exposure. Silencing of AKR1C2 mRNA restored the ROS increase response to cisplatin and menadione as an oxidative stressor in HT1376-CisR cells. 8) the secreted protein DDH2 was overexpressed in lung cancer A549/DDP line as compared to its DDP-sensitive parental A549. 9) baseline serum DDH2 level in the NSCLC patients with a progression disease was significantly higher than the patients of response or stable disease and serum DDH2 levels were significantly increased after cisplatin-based doublet chemotherapy.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UNKNOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKR1C2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8644" target="_blank" rel="noopener noreferrer">8644</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42330" target="_blank" rel="noopener noreferrer">P42330</a>', 'HUGO Gene symbol': 'AKR1C3', 'Protein name': 'Aldo-keto reductase family 1 member C3,', 'Function': 'Catalyzes the conversion of aldehydes and ketones to alcohols. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23165153%2C%2015790446%5Buid%5D" target="_blank" rel="noopener noreferrer">23165153, 15790446</a>', 'Notes': 'As AKR1C1', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKR1C3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/207" target="_blank" rel="noopener noreferrer">207</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31749" target="_blank" rel="noopener noreferrer">P31749</a>', 'HUGO Gene symbol': 'AKT1', 'Protein name': 'RAC-alpha serine/threonine-protein kinase', 'Function': 'One of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> mTOR signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20032415%2C%2027935869%2C%2028664915%5Buid%5D" target="_blank" rel="noopener noreferrer">20032415, 27935869, 28664915</a>', 'Notes': '1) An increase in\xa0Akt\xa0and\xa0ERK\xa0phosphorylation after\xa0chemotherapy\xa0was observed in 5 and 8 patients, respectively out of 10 patients examined.\xa02) Akt\xa0and\xa0ERK\xa0activation\xa0by\xa0chemotherapy\xa0were\xa0associated\xa0with a\xa0favorable\xa0overall survival. 3) The combination of cisplatin, DNA-PK inhibitor NU7441, and AKT inhibitor TCN can overcome drug resistance, increase apoptosis, and re-sensitize PEO4 cells to cisplatin treatment. 4) Advanced EOCs were characterised by a heterogeneous kinase-driven metabolic signature and decreased phosphorylation of the AMPK-AKT-mTOR axis compared to early EOC (P<0.05 for AMPKα T172, AMPKα1 S485, AMPKβ1 S108, AKT S473 and T308, mTOR S2448, p70S6 S371, 4EBP1 S65, GSK-3 α/β S21/9, FOXO1 T24/FOXO3 T32, and FOXO1 S256). 5) Advanced tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin-paclitaxel resistance..', 'Up / down in Pt-resistant cells': 'PHOS/DEPHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84335" target="_blank" rel="noopener noreferrer">84335</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96B36" target="_blank" rel="noopener noreferrer">Q96B36</a>', 'HUGO Gene symbol': 'AKT1S1', 'Protein name': 'Proline-rich AKT1 substrate 1', 'Function': 'Subunit of mTORC1, which regulates cell growth and survival in response to nutrient and hormonal signals.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> mTOR signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=33287446%5Buid%5D" target="_blank" rel="noopener noreferrer">33287446</a>', 'Notes': ' 1) W1 OC cell binding to COL1 upregulates integrin-associated signals via FAK/PRAS40/mTOR, confirmed by ITGB1 knockdown; mTOR appears as key for resistance, its blockade reversed COL1 effects on cisplatin resistance completely. ', 'Up / down in Pt-resistant cells': 'PHOS', 'Up / down to promote Pt-resistance': 'UNKNOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT1S1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/208" target="_blank" rel="noopener noreferrer">208</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31751" target="_blank" rel="noopener noreferrer">P31751</a>', 'HUGO Gene symbol': 'AKT2', 'Protein name': 'RAC-beta serine/threonine-protein kinase 2', 'Function': 'One of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> mTOR signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12697749%2C%2012517798%5Buid%5D" target="_blank" rel="noopener noreferrer">12697749, 12517798</a>', 'Notes': '1) constitutively active AKT2 renders cisplatin-sensitive A2780S ovarian cancer cells resistant to cisplatin, 2) phosphatidylinositol 3-kinase inhibitor or dominant negative AKT2 sensitizes A2780S and cisplatin-resistant A2780CP cells to cisplatin-induced apoptosis through regulation of the ASK1/JNK/p38 pathway. 3) AKT2 interacts with and phosphorylates ASK1 at Ser-83 resulting in inhibition of its kinase activity. Accordingly, activated AKT2 blocked signaling down-stream of ASK1, including activation of JNK and p38 and the conversion of Bax to its active conformation. 4) Overexpression of AKT2/Protein Kinase Bβ Leads to Up-Regulation of β1 Integrins, Increased Invasion, and Metastasis in Vivo. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AKT2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/216" target="_blank" rel="noopener noreferrer">216</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00352" target="_blank" rel="noopener noreferrer">P00352</a>', 'HUGO Gene symbol': 'ALDH1A1', 'Protein name': 'Retinal dehydrogenase 1 / Aldehyde dehydrogenase-1A1', 'Function': 'Can convert/oxidize retinaldehyde to retinoic acid.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27813328,20889728,25916979,22222226" target="_blank" rel="noopener noreferrer">27813328, 20889728, 25916979, 22222226</a>', 'Notes': '1) ALDH1A1 is overexpressed in\xa0cisplatin\xa0resistant\xa0human lung adenocarcinoma cell\xa0line\xa0A549/DDP, compared with A549. 2) ALDH1A1 depletion significantly decreased A549/DDP proliferation, increased apoptosis, and reduced cisplatin resistance. 3) ALDH1A1 expression and activity was significantly higher in taxane- and platinum-resistant ovarian cancer cell lines. 4) In patient samples, 72.9% of ovarian cancers had ALDH1A1 expression in which the percentage of ALDH1A1-positive cells correlated negatively with progression-free survival. 5) In an in vivo orthotopic mouse model of ovarian cancer, ALDH1A1 silencing using nanoliposomal siRNA sensitized both taxane- and platinum-resistant cell lines to chemotherapy, significantly reducing tumor growth in mice compared with chemotherapy alone. 6) Fourteen patients (26.9 %) had ALDH1-positive tumors pre-NAC, and ALDH1 expression pre-NAC was significantly associated with a low clinical chemotherapy response rate and clinical non-response. 7) Immunohistochemical staining for ALDH1 on a tissue microarray containing 84 epithelial ovarian cancer samples revealed that patients with higher ALDH1 expression (>50%) had poor overall survival, compared with those with lower ALDH1 (P = 0.004). The results did not support ALDH1 alone as an ovarian cancer stem cell marker, but demonstrated that ALDH1 is associated with CD44 expression, chemoresistance, and poor clinical outcome. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ALDH1A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/218" target="_blank" rel="noopener noreferrer">218</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30838" target="_blank" rel="noopener noreferrer">P30838</a>', 'HUGO Gene symbol': 'ALDH3A1', 'Protein name': 'Retinal dehydrogenase 1', 'Function': 'Can convert/oxidize retinaldehyde to retinoic acid.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28881734%5Buid%5D" target="_blank" rel="noopener noreferrer">28881734</a>', 'Notes': '1) Chemoresistant cancer cells express high levels of aldehyde dehydrogenases (ALDHs), particularly in head and neck squamous cell carcinoma (HNSCC).\xa02) many chemotherapeutic agents, such as cisplatin, result in the generation of cytotoxic aldehydes and oxidative stress. 3) Activation of ALDH3A1 by a small molecule activator (Alda-89) increased survival of HNSCC cells treated with cisplatin. Conversely, treatment with a small molecule ALDH inhibitor (Aldi-6) resulted in a greater reduction in tumor burden in vivo than what was observed with cisplatin alone.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ALDH3A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/226" target="_blank" rel="noopener noreferrer">226</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04075" target="_blank" rel="noopener noreferrer">P04075</a>', 'HUGO Gene symbol': 'ALDOA', 'Protein name': 'Fructose-bisphosphate aldolase A', 'Function': 'catalyzes the reversible conversion of\xa0fructose-1,6-bisphosphate\xa0to\xa0glyceraldehyde 3-phosphate\xa0(G3P) and\xa0dihydroxyacetone phosphate\xa0(DHAP).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25215901%2C%2021080034%2C%2025096996%5Buid%5D" target="_blank" rel="noopener noreferrer">25215901, 21080034, 25096996</a>', 'Notes': '1) Overexpression of ALDOA in Osteosarcoma MG-63 cells significantly increased in vitro cell invasion, matrix metalloproteinase (MMP)-2 expression, and cell survival against cisplatin-induced apoptosis. 2) On the other hand, knockdown of ALDOA in U-2 cells markedly decreased in vitro cell invasion, MMP-2 expression, and cell survival against cisplatin-induced apoptosis.\xa03) expressions of glycolytic enzymes pyruvate kinase, glucose-6-phosphate isomerase, fructose-bisphosphate aldolase, lactate dehydrogenase, and phosphoglycerate kinase 1 were down-regulated in CDDP resistant cells, indicating drug resistance in ovarian cancer is directly associated with a decrease in glycolysis.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ALDOA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/221120" target="_blank" rel="noopener noreferrer">221120</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96Q83" target="_blank" rel="noopener noreferrer">Q96Q83</a>', 'HUGO Gene symbol': 'ALKBH3', 'Protein name': 'Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3', 'Function': 'DNA alkylation damage repair. Dioxygenase that mediates demethylation of DNA and RNA containing 1-methyladenosine (m1A). Repairs alkylated DNA containing 1-methyladenosine (m1A) and 3-methylcytosine (m3C) by oxidative demethylation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/direct repair', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21285982%2C%2022826605%2C%2029415318%5Buid%5D" target="_blank" rel="noopener noreferrer">21285982, 22826605, 29415318</a>', 'Notes': '1) AlkB homolog 3 was overexpressed in HCC compared with adjacent non-tumorous specimens. 2) ALKBH3 expression was closely related to tumor differentiation and tumor-node-metastasis stage. 3) the ALKBH3 high expression in tumor tissues of HCC patients had more poor disease-free survival and overall survival than low-expression patients. 4) knockdown of ALKBH3 inhibits HCC cell proliferation in vitro and xenograft tumor formation in vivo 5) overexpressing ALKBH3 showed the opposite results. 6) ALKBH3 knockdown may inhibit cell proliferation, presumably through p21/p27-mediated cell-cycle arrest at G1\xa0phase in human HCC. 7) ALKBH3 may also play some role on chemosensitivity to certain genotoxic reagents, such as cisplatin (CDDP) and epirubicin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ALKBH3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55626" target="_blank" rel="noopener noreferrer">55626</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9C0C7" target="_blank" rel="noopener noreferrer">Q9C0C7</a>', 'HUGO Gene symbol': 'AMBRA1', 'Protein name': 'Activating molecule in BECN1-regulated autophagy protein 1', 'Function': 'Involved in autophagy in controlling protein turnover', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26763392%2C%2028224423%5Buid%5D" target="_blank" rel="noopener noreferrer">26763392, 28224423</a>', 'Notes': '1) cisplatin treatment induced autophagy in OVCAR-3 cells in association with Ambra1 upregulation in the ovarian cancer cells. 2) When Ambra1 expression was reduced by shRNA, the ovarian cancer cells were more sensitive to cisplatin. 3) Survival analysis indicated the high expression of AMBRA1 and Beclin- 1 was an independent factor in predicting poor overall survival (OS) of Gastric adenocarcinoma (GC) patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AMBRA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/267" target="_blank" rel="noopener noreferrer">267</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UKV5" target="_blank" rel="noopener noreferrer">Q9UKV5</a>', 'HUGO Gene symbol': 'AMFR', 'Protein name': 'E3 ubiquitin-protein ligase / Autocrine motility factor', 'Function': 'activated by AMF in an autocrine manner, results in signaling cascades relying on PKC and activates Rho-like GTPase, RhoA, and Rac1, which enhance cell motility, adhesion, and angiogenesis; and growth ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9610690%2C%2025149074%2C%2030439707%5Buid%5D" target="_blank" rel="noopener noreferrer">9610690, 25149074, 30439707</a>', 'Notes': '1) The expression patterns of c‐met,\xa0AMFR, and uPAR may be closely associated with the progression and invasion of gastric carcinoma as well as the poorer prognoses of the patients during PMUE therapy (a combination of cisplatin, mitomycin C, etoposide, and UFT. 2) MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. 3) Recovery of miR-139-5p suppressed the expression of c-Jun and thus reversed cisplatin-resistance in ovarian cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AMFR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27063" target="_blank" rel="noopener noreferrer">27063</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15327" target="_blank" rel="noopener noreferrer">Q15327</a>', 'HUGO Gene symbol': 'ANKRD1', 'Protein name': 'Ankyrin repeat domain-containing protein 1', 'Function': 'a putative transcription factor, a target of TGF-β/Wnt signalling, binding to p53 to upregulate p21WAF1/CIP1. a component of a Titin-based signalling complex', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> p53 signaling<br><br> TGF-β signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18980987%2C%2024531715%5Buid%5D" target="_blank" rel="noopener noreferrer">18980987, 24531715</a>', 'Notes': '1) ANKRD1 mRNA levels were correlated with platinum sensitivity in cell lines 2) decreasing ANKRD1 using siRNA increased cisplatin sensitivity >2-fold. 3) ANKRD1 was expressed in the majority of ovarian adenocarcinomas tested (62/71, 87%). 4) higher tumor levels of ANKRD1 were found in patients with worse outcome (overall survival, P=0.013). 5) overexpression of ANKRD1 increased resistance to cisplatin cytotoxicity and apoptosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ANKRD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/302" target="_blank" rel="noopener noreferrer">302</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07355" target="_blank" rel="noopener noreferrer">P07355</a>', 'HUGO Gene symbol': 'ANXA2', 'Protein name': 'Annexin A2', 'Function': 'Calcium-regulated membrane-binding protein. May be involved in heat-stress response', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling/MAPK<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28886730%2C%2028224423%5Buid%5D" target="_blank" rel="noopener noreferrer">28886730, 28224423</a>', 'Notes': '1) knockdown of Annexin A2\xa0increased\xa0cisplatin\xa0sensitivity of\xa0cisplatin-resistant non-small cell lung cancer (NSCLC) A549/DDP cells both in vitro and in vivo. 2) overexpression of ANXA2\xa0increased\xa0cisplatin\xa0resistance of A549, H460 and H1650 cells.\xa03) Annexin A2 depletion increased the expression of both p53 mRNA and protein. 4) High ANXA2 mRNA levels in stage III serous ovarian cancers were associated with reduced progression-free survival (PFS; P = 0.023) and overall survival (OS; P = 0.0038). Using The Cancer Genome Atlas data sets, ANXA2 expression was associated with higher clinical stage (P = 0.005). 5) both ANXA2 and S100A10 expressions were associated with the mesenchymal molecular subtype (P < 0.0001). 6) high stromal annexin A2 immunostaining was significantly associated with reduced PFS (P = 0.013) and OS (P = 0.044). 7) Patients with high stromal annexin A2 and high cytoplasmic S100A10 expressions had a 3.4-fold increased risk of progression (P = 0.02) and 7.9-fold risk of ovarian cancer death (P = 0.04). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ANXA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/306" target="_blank" rel="noopener noreferrer">306</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12429" target="_blank" rel="noopener noreferrer">P12429</a>', 'HUGO Gene symbol': 'ANXA3', 'Protein name': 'Annexin A3', 'Function': 'Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.', 'Putative_mechanism_associated_with_Pt_resistance': 'Calcium signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30868675%2C%2024375474%5Buid%5D" target="_blank" rel="noopener noreferrer">30868675, 24375474</a>', 'Notes': '1) CAF decreased the sensitivity of lung cancer cells to cisplatin. 2) CAF expressed a higher level of Annexin A3 (ANXA3) than normal fibroblasts (NF), and CAF-CM incubation increased the ANXA3 level in lung cancer cells. 3) Overexpression of ANXA3 in lung cancer cells increased cisplatin resistance and activated JNK, whereas knockdown of ANXA3 increased cisplatin sensitivity. 4) CAF-CM enhanced cisplatin resistance by inhibiting caspase-3 and caspase-8, through activation of the ANXA3/JNK pathway. 5) suppression of JNK activation by specific inhibitor retarded the effect of CAF-CM and ANXA3 on cisplatin sensitivity.\xa06) Elevated ANXA3 expression was associated with tumor size, number of lesions, tumor stage, and poor prognosis in liver cancer patients. 7) In hepatoma cell lines, exogenous ANXA3 transduction promoted the tumorigenic activity and metastatic potential;  siRNA silencing of ANXA3 inhibited these processes. 8) in vitro and in vivo experiments revealed that ANXA3 overexpression enhanced resistance to platinum chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ANXA3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/307" target="_blank" rel="noopener noreferrer">307</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09525" target="_blank" rel="noopener noreferrer">P09525</a>', 'HUGO Gene symbol': 'ANXA4', 'Protein name': 'Annexin A4', 'Function': 'Calcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19598262%2C%2024244679%5Buid%5D" target="_blank" rel="noopener noreferrer">19598262, 24244679</a>', 'Notes': '1) Immunohistochemical analysis of Anx A4 was performed in 126 epithelial ovarian cancer tissue samples and demonstrated significantly elevated levels of Anx A4 protein levels in ovarian CCC tumors compared with ovarian serous and endometrioid tumors (p < 0.01). 2) Anx A4-transfected ovarian non-CCC cells were more resistant to carboplatin (IC50 = 42 microM) 3) Intracellular platinum levels were significantly lower in Anx A4-transfected cells. 4) ANXA4 knockdown (KO) resulted in significant growth retardation and greater sensitivity to carboplatin in OVTOKO cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ANXA4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/317" target="_blank" rel="noopener noreferrer">317</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14727" target="_blank" rel="noopener noreferrer">O14727</a>', 'HUGO Gene symbol': 'APAF1', 'Protein name': 'Apoptotic protease-activating factor 1', 'Function': 'Oligomeric Apaf-1 mediates the cytochrome c-dependent autocatalytic activation of pro-caspase-9 (Apaf-3), leading to the activation of caspase-3 and apoptosis. This activation requires ATP. Isoform 6 is less effective in inducing apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20925046%2C%2012543167%5Buid%5D" target="_blank" rel="noopener noreferrer">20925046, 12543167</a>', 'Notes': '1) the resistance of ovarian cancer cells to the pro-apoptotic effects of chemotherapy is due in part to deficient Apaf-1 activity. 2) Although Apaf-1 is expressed in most ovarian cancers, the functional activity is impaired as Apaf-1 has a diminished ability to recruit and activate caspase-9. 3) a histone deacetylase inhibitor (HDACi), trichostatin A (TSA) increases both the expression and activity of Apaf-1. 4) Treatment of ovarian cancer cells with TSA results in restoration of Apaf-1 function independent of alterations in Apaf-1 expression. 5) Treating chemoresistant cells with sublethal doses of TSA restores Apaf-1 function and sensitizes cells to cisplatin induced apoptosis. 6) Pt-sensitive HNSCC HSC-2 cells expressed 2-fold higher levels of Apaf-1 compared with Pt-resistant HSC-2CR cells. 7) following cisplatin treatment, the same degree of increase in cytoplasmic Cyt c was detected in both HSC-2 and HSC-2CR. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=APAF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/324" target="_blank" rel="noopener noreferrer">324</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25054" target="_blank" rel="noopener noreferrer">P25054</a>', 'HUGO Gene symbol': 'APC', 'Protein name': 'Adenomatous Polyposis Coli', 'Function': 'Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Platinum efflux<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26049416%2C%2033423038%5Buid%5D" target="_blank" rel="noopener noreferrer">26049416, 33423038</a>', 'Notes': '1) Cells obtained from MMTV-PyMT;ApcMin/+ tumors express increased MDR1, which is augmented by treatment with paclitaxel or doxorubicin. 2) MMTV-PyMT;ApcMin/+ cells are more resistant to cisplatin and doxorubicin-induced apoptosis, 3) show a larger population of ALDH positive cells. 4) In the human metaplastic breast cancer cell line MDA-MB-157, APC knockdown led to paclitaxel and cisplatin resistance. 5) APC loss-of-function significantly increases resistance to cisplatin-mediated apoptosis in both MDA-MB-157 and the PyMT derived cells. 6) ovarian cancer patients with low FAM83B levels had shorter survival time, tissues with cisplatin resistance also had low FAM83B levels. 7) FAM83B interacted with APC to inhibit Wnt pathway activity; FAM83B levels were negative with Wnt pathway activity in clinic samples. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=APC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/328" target="_blank" rel="noopener noreferrer">328</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27695" target="_blank" rel="noopener noreferrer">P27695</a>', 'HUGO Gene symbol': 'APEX1', 'Protein name': 'DNA-(apurinic or apyrimidinic site) lyase', 'Function': 'has a disordered N-terminus, a redox, and a DNA repair domain (27835927); DNA repair and redox regulation of transcriptional factors. a apurinic/apyrimidinic (AP) endodeoxyribonuclease in BER induced by oxidative and alkylating agents; N-terminal (1-20) inhibits Caspase 3 cleavage and apoptosis\xa0(27835927)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR/BER<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26164266%2C%2020087352%2C%2021357694%5Buid%5D" target="_blank" rel="noopener noreferrer">26164266, 20087352, 21357694</a>', 'Notes': '1) Blocking BER with BER inhibitor MX as well as deficiency of Polβ and UNG conferred resistance to cisplatin treatment. 2) In ovarian cancer, nuclear APE1 expression was seen in 71.9% (97 out of 135) of tumours and correlated with worse overall survival (P=0.05). 3) In gastro-oesophageal cancers previously exposed to neoadjuvant chemotherapy, 34.8% (16 out of 46) of tumours were APE1 positive in the nucleus and this correlated with shorter overall survival (P=0.005).  4) APE1 knockdown gives rise to cisplatin resistance in breast cancer MDA-MB-231 cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=APEX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/359" target="_blank" rel="noopener noreferrer">359</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P41181" target="_blank" rel="noopener noreferrer">P41181</a>', 'HUGO Gene symbol': 'AQP2', 'Protein name': 'Aquaporin-2', 'Function': 'ADH water channel', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27933604%2C%2024643204%5Buid%5D" target="_blank" rel="noopener noreferrer">27933604, 24643204</a>', 'Notes': '1) Lung cancer stem cells (LCSCs)\xa0be more stem‐like, and more resistant to cisplatin‐induced cytotoxicity than dLCSCs. 2) LCSCs accumulated less cisplatin intracellularly than dLCSCs and showed less DNA damage, potentially due to their ability to down‐regulate AQP2 and CTR1. 3) The results of the transcription‐coupled repair of cisplatin‐DNA cross‐links indicated a higher level of repair of DNA damage in LCSCs than in dLCSCs; this involved the activation of various DNA repair pathways. 4) TMEM205 rs896412, OCT2 rs1869641 and rs195854, AQP9 rs1516400 and AQP2 rs7314734 polymorphism showed significant relation to chemotherapy response. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AQP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/374" target="_blank" rel="noopener noreferrer">374</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15514" target="_blank" rel="noopener noreferrer">P15514</a>', 'HUGO Gene symbol': 'AREG', 'Protein name': 'Human amphiregulin', 'Function': 'Human amphiregulin (AREG) is a glycoprotein composed of 84 amino acids and is one of the ligands for the epidermal growth factor receptor (EGFR). Autocrine growth factor as well as a mitogen. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28459431%5Buid%5D" target="_blank" rel="noopener noreferrer">28459431</a>', 'Notes': '1) CDDP-resistant ovarian cancer cells had increased expression of amphiregulin (AREG) and decreased expression of its conserved regulatory microRNA, miR-34c-5p, when compared with the OVS1 parental cells. 2) AREG is a direct target of miR-34c-5p. 3) AREG-mediated increase of sphere formation, drug resistance toward docetaxel and carboplatin, as well as tumorigenicity of SKOV-I6 and OVS1 cells could be abrogated by miR-34c-5p. 4) miR-34c-5p inhibited ovarian cancer stemness through downregulation of the AREG-EGFR-ERK pathway. 5) Overexpression of AREG was found to be correlated with advanced ovarian cancer stages and poor prognosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AREG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/397" target="_blank" rel="noopener noreferrer">397</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52566" target="_blank" rel="noopener noreferrer">P52566</a>', 'HUGO Gene symbol': 'ARHGDIB', 'Protein name': 'Rho GDP-dissociation inhibitor 2 / Rho GDI 2\xa0', 'Function': 'Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21752536%5Buid%5D" target="_blank" rel="noopener noreferrer">21752536</a>', 'Notes': '1) RhoGDI2 contributes to another important feature of aggressive cancers, i.e., resistance to chemotherapeutic agents such as cisplatin. 2) Forced expression of RhoGDI2 attenuated cisplatin-induced apoptosis, whereas RhoGDI2 depletion showed opposite effects in vitro. 3) the increased anti-apoptotic effect of RhoGDI2 on cisplatin was further validated in RhoGDI2-overexpressing SNU-484 xenograft model in nude mice. 4) Bcl-2 as a major determinant of RhoGDI2-mediated cisplatin resistance in gastric cancer cells. 5) Depletion of Bcl-2 expression significantly increased cisplatin-induced apoptosis in RhoGDI2-overexpressing gastric cancer cells, whereas overexpression of Bcl-2 blocked cisplatin-induced apoptosis in RhoGDI2-depleted gastric cancer cells.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARHGDIB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8289" target="_blank" rel="noopener noreferrer">8289</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14497" target="_blank" rel="noopener noreferrer">O14497</a>', 'HUGO Gene symbol': 'ARID1A', 'Protein name': 'AT-rich interactive domain-containing protein 1A', 'Function': 'Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities; exerts various tumor suppressor functions in cancer.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29660381%5Buid%5D" target="_blank" rel="noopener noreferrer">29660381</a>', 'Notes': '1) ARID1A ablation leads to the transcriptional activation of MRP2 via a chromatin remodeling mechanism. 2) In ARID1A-mutated ovarian cancer cells, the ectopic expression of ARID1A increases sensitivity to chemotherapeutic reagents. 3) IHC analysis of both ARID1A and MRP2 expression in human ovarian cancer specimens shows a strong negative correlation. 4) low ARID1A expression was positively correlated with chemoresistance and contributed to poor overall survival (OS) and progression-free survival (PFS), while MRP2 expression exhibited the opposite correlations. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARID1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10620" target="_blank" rel="noopener noreferrer">10620</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IVW6" target="_blank" rel="noopener noreferrer">Q8IVW6</a>', 'HUGO Gene symbol': 'ARID3B', 'Protein name': 'AT-rich interactive domain-containing protein 3B', 'Function': 'TF that induces expression of genes associated with metastasis and cancer stem cells (CD44, LGR5, PROM1 (CD133), and Notch2)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25327563%2C%2019881956%2C%2030139993%5Buid%5D" target="_blank" rel="noopener noreferrer">25327563, 19881956, 30139993</a>', 'Notes': '1) ARID3B is overexpressed in human ovarian tumors. 2) Overexpression of ARID3B increased tumor burden and decreased survival in nude mice. 3) ARID3B boosts production of CD133+ cells and increases ovarian cancer progression in vivo. 4) ARID3B was downregulated in non- TPF (docetaxel, cisplatin, and 5-fluoruracil) sensitive hypopharyngeal carcinoma patients’ samples. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARID3B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25820" target="_blank" rel="noopener noreferrer">25820</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y4X5" target="_blank" rel="noopener noreferrer">Q9Y4X5</a>', 'HUGO Gene symbol': 'ARIH1', 'Protein name': 'E3 ubiquitin-protein ligase ARIH1', 'Function': 'Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear; promoting clearance of damaged mitochondria (mitophagy) (28930681);', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30844312%2C%2028930681%2C%2025624349%5Buid%5D" target="_blank" rel="noopener noreferrer">30844312, 28930681, 25624349</a>', 'Notes': "1) Overexpression of ARIH1 but not EIF4E2 dramatically increased cellular resistance to cisplatin. 2) ARIH1/HHARI polyubiquitinates damaged mitochondria, leading to their removal via autophagy. 3) ARIH1 is widely expressed in cancer cells, notably in breast and lung adenocarcinomas; ARIH1 expression protects against chemotherapy-induced death. 4) ARIH1 protein abundance increased after DNA damage through attenuation of proteasomal degradation that required ATM signaling. 5) Accumulated ARIH1 associated with 4EHP, leading to increased nondegradative ubiquitination of 4EHP and  its association with the mRNA 5' cap as well as mRNA translation arrest. This agrees well with the notion that down‐regulation of global protein translation enhances cisplatin resistance.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARIH1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10550" target="_blank" rel="noopener noreferrer">10550</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75915" target="_blank" rel="noopener noreferrer">O75915</a>', 'HUGO Gene symbol': 'ARL6IP5', 'Protein name': 'PRA1 family protein 3', 'Function': 'Regulates intracellular concentrations of taurine and glutamate. Negatively modulates SLC1A1/EAAC1 glutamate transport activity by decreasing its affinity for glutamate in a PKC activity-dependent manner. May be involved in membrane traffic.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25476899%2C%2025925371%5Buid%5D" target="_blank" rel="noopener noreferrer">25476899, 25925371</a>', 'Notes': '1) in gastric cancer cells,\xa0JWA\xa0enhanced\xa0cisplatin-induced cell death through regulation of DNA damage-induced apoptosis. 2) The protein expression of\xa0JWA\xa0was significantly decreased in\xa0cisplatin-resistant cells and contributed to\xa0cisplatin\xa0resistance. 3) as\xa0JWA\xa0upregulated XRCC1 expression in normal cells,\xa0JWA downregulated XRCC1 expression through promoting the degradation of XRCC1 in\xa0cisplatin-resistant gastric cancer cells. 4) the negative regulation of\xa0JWA\xa0to XRCC1 was blocked due to the mutation of 518S/519T/523T residues of XRCC1, and indicating that the CK2 activated 518S/519T/523T phosphorylation is a key point in the regulation of\xa0JWA\xa0to XRCC1.\xa05) cisplatin-based treatments could improve mOS of patients with low JWA expression (P<0.05), especially in those with low BRCA1 expression simultaneously (P<0.001) in patients with advanced esophageal squamous cell carcinoma. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARL6IP5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/405" target="_blank" rel="noopener noreferrer">405</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27540" target="_blank" rel="noopener noreferrer">P27540</a>', 'HUGO Gene symbol': 'ARNT', 'Protein name': 'Aryl hydrocarbon receptor nuclear translocator / Hypoxia-inducible factor-1 beta subunit', 'Function': 'binds to ligand-bound aryl hydrocarbon receptor (dioxin) and helps to translocate to nucleus to promote transcription; also a co-factor for transcriptional regulation by hypoxia-inducible factor 1', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26967059%2C%2010928066%2C%2023907215%5Buid%5D" target="_blank" rel="noopener noreferrer">26967059, 10928066, 23907215</a>', 'Notes': '1) Targeting HIF1 activity by silencing HIF-1β re-sensitised cells to cisplatin in vitro and 2) reduced tumour formation of A2780-Rab25 expressing cells in vivo in a mouse ovarian peritoneal carcinomatosis model. 3)Similar effects on cisplatin resistance in vitro and intraperitoneal tumourigenesis in vivo were obtained after HIF1b knockdown in the ovarian cancer cell line SKOV3, which expresses endogenous Rab25 and HIF-1α at atmospheric oxygen concentrations. 4) Of 111 NSCLC FFPE samples, patients with HIF-positive lung carcinomas had significantly longer median survival times than patients with HIF-negative carcinomas (HIF-1 alpha: 191 vs. 60 weeks; P = 0.05; HIF-1 beta: 111 vs. 41 weeks; P = 0.003). 5) the downregulation of multidrug resistance 1 (MDR1) expression and retention of drugs in cells caused by suppression of ARNT, resulting in the resensitization of drug-resistant cells to cisplatin, was observed. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ARNT" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/445" target="_blank" rel="noopener noreferrer">445</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00966" target="_blank" rel="noopener noreferrer">P00966</a>', 'HUGO Gene symbol': 'ASS1', 'Protein name': 'Argininosuccinate synthase', 'Function': 'Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP. One of the enzymes of the urea cycle. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/amino acid<br><br> Oncogene signaling/PKG<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19533750%2C%2026982031%2C%2027765932%5Buid%5D" target="_blank" rel="noopener noreferrer">19533750, 26982031, 27765932</a>', 'Notes': '1) aberrant methylation in the ASS1 promoter correlated with transcriptional silencing in ovarian cancer cell lines. 2) ASS1 silencing conferred selective resistance to platinum-based drugs and conferred arginine auxotrophy and sensitivity to arginine deprivation. 3) In ovarian cancer, ASS1 methylation at diagnosis was associated with significantly reduced overall survival (p = 0.01) and relapse-free survival (p = 0.01). In patients who relapse, ASS1 methylation was significantly more frequent at relapse (p = 0.008). 4) Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids to the pro-apoptotic effects of bortezomib and of cisplatin plus pemetrexed. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN/Methylation/UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ASS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1386" target="_blank" rel="noopener noreferrer">1386</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15336" target="_blank" rel="noopener noreferrer">P15336</a>', 'HUGO Gene symbol': 'ATF2', 'Protein name': 'Cyclic AMP-dependent transcription factor ATF-2 ', 'Function': 'the transcription of various genes, including those involved in anti-apoptosis, cell growth, and DNA damage response.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Oncogene signaling/MAPK<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28120035%2C%2025359574%5Buid%5D" target="_blank" rel="noopener noreferrer">28120035, 25359574</a>', 'Notes': '1) Phosphorylation of ATF2 is related to its interaction with JNK and/or p38 and this interaction playing a role in modulating sensitivity to cisplatin. 2) High expression levels of both ATF2 transcript and proteins were observed in lung cancer specimens (p << 0.01, Log2 (FC)\u2009=\u2009+4.7). 3) CDDP-resistant NSCLC cell lines expressed high levels of ATF2 protein. 4) Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP. 5) ATF2 protein activation correlates with worse outcome in advanced CDDP-treated patients. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/467" target="_blank" rel="noopener noreferrer">467</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18847" target="_blank" rel="noopener noreferrer">P18847</a>', 'HUGO Gene symbol': 'ATF3', 'Protein name': 'Cyclic AMP-dependent transcription factor ATF-3 (repressor)', 'Function': 'Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. Isoform 2 activates transcription presumably by sequestering inhibitory cofactors away from the promoters.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ER stress response<br><br> Immune response<br><br> PKA signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%2026241884%2C%2020651982%2C%2024554706%5Buid%5D" target="_blank" rel="noopener noreferrer">26241884, 20651982, 24554706</a>', 'Notes': '1) 2-Deoxy-d-Glucose (2-DG) sensitizes human Ovarian Cancer Cells to Cisplatin by increasing ER stress and decreasing ATP stores in acidic vesicles. 2) Cytotoxic doses of cisplatin and carboplatin treatments consistently induced ATF3 expression in five tumor-derived cell lines. 3) In A549 lung carcinoma cells, targeting ATF3 with specific shRNA attenuated the cytotoxic effects of cisplatin. 4) A role for ATF3 in tumorigenesis has been implicated through its ability to affect the transcription of a number of regulators of apoptosis and cell proliferation including CHOP and cyclin D1, respectively. 5) ATF3 repressed mutp53-induced NFKB2 expression and sensitized R175H-expressing cancer cells to cisplatin and etoposide treatments. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATF3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/468" target="_blank" rel="noopener noreferrer">468</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18848" target="_blank" rel="noopener noreferrer">P18848</a>', 'HUGO Gene symbol': 'ATF4', 'Protein name': 'Cyclic AMP-dependent transcription factor ATF-4, ', 'Function': 'modulate the expression of nuclear factor-erythroid 1- and 2-related factors, which are recruited to the antioxidant response element', 'Putative_mechanism_associated_with_Pt_resistance': 'PKA signaling<br><br> Redox/Glutathione<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14695168%2C%2017297441%2C%2022338651%5Buid%5D" target="_blank" rel="noopener noreferrer">14695168, 17297441, 22338651</a>', 'Notes': '1) Expression of ATF4 was found to correlate with cisplatin sensitivity (P = 0.01) (from 11 lung cancer cell lines).\xa02) ATF4 was overexpressed in about 50.7% of HCC tissues. 3) knockdown of ATF4 significantly increased the cytotoxicity of cisplatin in both in vitro and in vivo assays, 4) overexpression of this molecule dramatically decreased the sensitivity of HCC cell lines to cisplatin. 5) synthesis of glutathione was significantly reduced in HCC cell lines subjected to ATF4 knockdown.. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATF4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22926" target="_blank" rel="noopener noreferrer">22926</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18850" target="_blank" rel="noopener noreferrer">P18850</a>', 'HUGO Gene symbol': 'ATF6', 'Protein name': 'Cyclic AMP-dependent transcription factor ATF-6 alpha', 'Function': 'Transmembrane glycoprotein of the endoplasmic reticulum that functions as a transcription activator and initiates the unfolded protein response (UPR) during endoplasmic reticulum stress.', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> ER stress response<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32080166%2C%2031029032%5Buid%5D" target="_blank" rel="noopener noreferrer">32080166, 31029032</a>', 'Notes': '1) STAT3 functions to promote the transcription of ATF6, which induces ER stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin. 2) patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival in ovarian cancer patients. 3) knockdown of ATF6α enhanced sensitivity of OS cells against cisplatin induced cell death. 4) Pharmacologic inhibition or knock-down of downstream targets of ATF6α, protein disulfide isomerases (PDI) and ERO1β, a thiol oxidase that is involved in the re-oxidation of PDIs also independently induced pronounced killing of OS cells following chemotherapy. 5) primary tumors from OS patients with high levels of nuclear ATF6α: (1) also had increased expression of its downstream targets the chaperone BiP and enzyme PDI, (2) had a significant likelihood of developing metastasis at diagnosis, (3) had significantly poorer overall and progression free survival, and (4) had poorer response to chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATF6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9140" target="_blank" rel="noopener noreferrer">9140</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94817" target="_blank" rel="noopener noreferrer">O94817</a>', 'HUGO Gene symbol': 'ATG12', 'Protein name': 'Ubiquitin-like protein ATG12', 'Function': 'Ubiquitin-like protein involved in autophagy vesicles formation', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/28553083,24817946" target="_blank" rel="noopener noreferrer">28553083, 24817946</a>', 'Notes': '1) Inhibition of cisplatin-induced autophagy using Baf A1, CQ, or ATG7/ATG12 shRNAs significantly enhanced cytotoxicity of cisplatin toward BC cells. 2) cisplatin could induce the formation of autophagosomes and upregulate the expression of autophagy-related genes Atg3, Atg6 and Atg12 in OC cells.  ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATG12" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22863" target="_blank" rel="noopener noreferrer">22863</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6ZNE5" target="_blank" rel="noopener noreferrer">Q6ZNE5</a>', 'HUGO Gene symbol': 'ATG14', 'Protein name': 'Beclin 1-associated autophagy-related key regulator', 'Function': 'Required for both basal and inducible autophagy.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25650716,31885310,24337183" target="_blank" rel="noopener noreferrer">25650716, 31885310, 24337183</a>', 'Notes': '1) MIR152 expression was dramatically downregulated in the cisplatin-resistant cell lines A2780/CP70, SKOV3/DDP compared with their respective parental cells, in ovarian cancer tissues associated with cisplatin-resistance. 2) ATG14 is a functional target of MIR152 in regulating autophagy inhibition. 3) Knockdown of ATG14 inhibits basal autophagy and promotes cisplatin-induced cell death in ovarian cancer cells. 4) In the DDP-sensitive OC cell lines, over expression of ATG14 promoted DDP resistance. In the DDP-resistant cell lines, siRNA knockdown of ATG14 diminished DDP-resistance. 5) Silencing of ATG14 significantly increased the sensitivity to cisplatin in osteosarcoma cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATG14" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9474" target="_blank" rel="noopener noreferrer">9474</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H1Y0" target="_blank" rel="noopener noreferrer">Q9H1Y0</a>', 'HUGO Gene symbol': 'ATG5', 'Protein name': 'Autophagy protein 5', 'Function': 'Involved in autophagic vesicle formation', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29512762%5Buid%5D" target="_blank" rel="noopener noreferrer">29512762</a>', 'Notes': '1) Cisplatin induced autophagy by upregulating the mRNA and protein expression levels of autophagy protein (Atg)5 and Beclin 1 in A549 human lung cancer cells. 2) knockdown of Atg5 and Beclin 1 by siRNA impaired cisplatin‑induced activation of autophagic responses, increased caspase‑3 cleavage and inhibited cell viability.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATG5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10533" target="_blank" rel="noopener noreferrer">10533</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95352" target="_blank" rel="noopener noreferrer">O95352</a>', 'HUGO Gene symbol': 'ATG7', 'Protein name': 'Ubiquitin-like modifier-activating enzyme ATG7', 'Function': 'E1-like activating enzyme that is essential for autophagy and cytoplasmic to vacuole transport. The encoded protein is also thought to modulate p53-dependent cell cycle pathways during prolonged metabolic stress.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31160576%2C%2028553083%5Buid%5D" target="_blank" rel="noopener noreferrer">31160576, 28553083</a>', 'Notes': '1) TRIM65 was significantly increased in NSCLC A549/DDP cells as compared to A549 cells. 2) Knockdown of TRIM65 can inhibit autophagy and enhance cisplatin-induced apoptosis in A549/DDP cells. 3) knockdown of TRIM65 significantly decreased the expression of an important autophagy mediator, ATG7, which was a potential target of miR-138-5p. 4) miR-138-5p inhibitor significantly abolished the effects of TRIM65 knockdown on autophagy and cisplatin-induced apoptosis. 5) TRIM65 induced the ubiquitination and degradation of TNRC6A, resulting in the suppressed expression of miR-138-5p. 6) TRIM65 knockdown inhibited the growth of tumors derived from A549/DDP cells. 7) cisplatin-resistant NSCLC tissues displayed higher expression of TRIM65 mRNA and lower expression of miR-138-5p as compared to cisplatin non-resistant ones. 8) miR-138-5p expression was negatively correlated with TRIM65 mRNA in NSCLC tissues. 8) Inhibition of cisplatin-induced autophagy using Baf A1, CQ, or ATG7/ATG12 shRNAs significantly enhanced cytotoxicity of cisplatin toward BC cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATG7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/472" target="_blank" rel="noopener noreferrer">472</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13315" target="_blank" rel="noopener noreferrer">Q13315</a>', 'HUGO Gene symbol': 'ATM', 'Protein name': 'Serine-protein kinase ATM', 'Function': "Activates checkpoint upon DSBs, apoptosis and genotoxic stresses; necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C; Phosphorylates 'Ser-139' of H2AX at DSBs", 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26674120%2C%2022312557%5Buid%5D" target="_blank" rel="noopener noreferrer">26674120, 22312557</a>', 'Notes': '1) High ATM protein expression was associated with serous cystadenocarcinomas (p\xa0=\xa00.021) and platinum resistance (p\xa0=\xa00.017). 2) High DNA-PKcs protein expression was associated with serous cystadenocarcinomas (p\xa0=\xa00.006) and advanced stage tumours (p\xa0=\xa00.018). 3) High ATM protein (p\xa0=\xa00.001), high ATM mRNA (p\xa0=\xa00.018), high DNA-PKcs protein (p\xa0=\xa00.002), high DNA-PKcs mRNA (p\xa0=\xa00.044) and high ATR protein (p\xa0=\xa00.001) expressions are correlated with poor ovarian cancer specific survival (OCSS). 4) In multivariate Cox model, high DNA-PKcs (p\xa0=\xa00.006) and high ATR (p\xa0=\xa00.043) protein expressions remain independently associated with poor OCSS. 5) several kinases in the DNA-repair pathway are activated after cells are exposed to cisplatin. These include ATM, p53, and Chk2.', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23300" target="_blank" rel="noopener noreferrer">23300</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43313" target="_blank" rel="noopener noreferrer">O43313</a>', 'HUGO Gene symbol': 'ATMIN', 'Protein name': 'ATM interactor', 'Function': 'Transcription factor. Plays a crucial role in cell survival and RAD51 foci formation in response to methylating DNA damage. Involved in regulating the activity of ATM in the absence of DNA damage. May play a role in stabilizing ATM. Binds to the DYNLL1 promoter and activates its transcription', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30464262%5Buid%5D" target="_blank" rel="noopener noreferrer">30464262</a>', 'Notes': '1) DYNLL1 was among the top-ranked factors that cause resistance in both the olaparib and platinum screen, as was the transcriptional regulator of DYNLL1, the ATM-interacting protein ATMIN. 2) loss of ATMIN or DYNLL1 leads to significant resistance to PARPi drugs, olaparib and niraparib, and the platinum drugs, cisplatin and carboplatin. 3) restoration of DYNLL1 expression in ATMIN−/− cells also restored sensitivity to cisplatin and olaparib, suggesting that the effect of ATMIN loss in resistance to PARPi and platinum in BRCA1-mutant cells is mediated by DYNLL1. 4) ATMIN is altered in approximately 30% of HGSOCs.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATMIN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23200" target="_blank" rel="noopener noreferrer">23200</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y2G3" target="_blank" rel="noopener noreferrer">Q9Y2G3</a>', 'HUGO Gene symbol': 'ATP11B', 'Protein name': 'phospholipid-transporting ATPase IF', 'Function': 'may contribute to secretory vesicle transport of cisplatin from Golgi to plasma membrane', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23585472%5Buid%5D" target="_blank" rel="noopener noreferrer">23585472</a>', 'Notes': '1) ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin resistance in human ovarian cancer cell lines. 2) ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin in vitro. 3) Combined therapy of cisplatin and ATP11B-targeted siRNA significantly decreased cancer growth in mice bearing ovarian tumors derived from cisplatin-sensitive and -resistant cells. 4) In vitro mechanistic studies on cellular platinum content and cisplatin efflux kinetics indicated that ATP11B enhances the export of cisplatin from cells. The colocalization of ATP11B with fluorescent cisplatin and with vesicular trafficking proteins, such as syntaxin-6 (STX6) and vesicular-associated membrane protein 4 (VAMP4), strongly suggests that ATP11B contributes to secretory vesicular transport of cisplatin from Golgi to plasma membrane. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP11B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/476" target="_blank" rel="noopener noreferrer">476</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05023" target="_blank" rel="noopener noreferrer">P05023</a>', 'HUGO Gene symbol': 'ATP1A1', 'Protein name': 'Sodium/potassium-transporting ATPase subunit alpha-1', 'Function': 'This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/16044341" target="_blank" rel="noopener noreferrer">16044341</a>', 'Notes': '1) Compared with the resistant cells, platinum accumulation in the parental cells was clearly decreased by low temperature or ATP depletion. 2) the Na+, K+-ATPase inhibitor ouabain and the K+ channel inhibitor tetraethylammonium decreased platinum accumulation in parental cells but did not change the accumulation in resistant cells. 3) Amphotericin B, an antifungal agent, increased the intracellular platinum accumulation in resistant cells to the same level as in parent cells. 4) the Na+, K+-ATPase alpha1 subunit was reduced in resistant cells compared with the parental cells, although there was no difference in the expression of the beta1 subunit between the two cell lines. 5) the Na+, K+-ATPase alpha1 subunit of H4-II-E was decreased following a 24-h exposure to CDDP.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP1A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/481" target="_blank" rel="noopener noreferrer">481</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05026" target="_blank" rel="noopener noreferrer">P05026</a>', 'HUGO Gene symbol': 'ATP1B1', 'Protein name': 'Sodium/potassium-transporting ATPase subunit beta-1', 'Function': 'exchange of Na+\xa0and K+\xa0ions across the plasma membrane', 'Putative_mechanism_associated_with_Pt_resistance': 'PKA signaling<br><br> Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/19322565,10487609" target="_blank" rel="noopener noreferrer">19322565, 10487609</a>', 'Notes': '1) Oxaliplatin resistant ovarian carcinoma cell line C10B cells express highly reduced levels of Na,K-β1\xa0subunit. 2) Exogenous expression of Na,K-β1 increased platinum accumulation and sensitized C10B cells to oxaliplatin. 3) The pharmacological inhibitor of Na,K-ATPase ouabain did not alter the oxaliplatin accumulation indicating that Na,K-β1\xa0sensitizes cells in a Na,K-ATPase enzyme activity independent manner. 4) a decrease of Na+,K+-ATPase activity in human prostate cancer LNCaP-FGC cells results in reduced sensitivity of these cells to cisplatin-treatment. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP1B1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/533" target="_blank" rel="noopener noreferrer">533</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99437" target="_blank" rel="noopener noreferrer">Q99437</a>', 'HUGO Gene symbol': 'ATP6V0B', 'Protein name': 'V-type proton ATPase 21 kDa proteolipid subunit', 'Function': 'Proton-conducting pore forming subunit of the membrane integral V0 complex of vacuolar ATPase.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183</a>', 'Notes': 'As ATP6V1A', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V0B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9114" target="_blank" rel="noopener noreferrer">9114</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61421" target="_blank" rel="noopener noreferrer">P61421</a>', 'HUGO Gene symbol': 'ATP6V0D1', 'Protein name': 'V-type proton ATPase subunit d 1', 'Function': 'Subunit of the integral membrane V0 complex of vacuolar ATPase.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183</a>', 'Notes': 'As ATP6V1A', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V0D1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/523" target="_blank" rel="noopener noreferrer">523</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P38606" target="_blank" rel="noopener noreferrer">P38606</a>', 'HUGO Gene symbol': 'ATP6V1A', 'Protein name': 'V-type proton ATPase catalytic subunit A', 'Function': 'Catalytic subunit of the peripheral V1 complex of vacuolar ATPase.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%2C%2028592880%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183, 28592880</a>', 'Notes': '1) induced by CDDP in various cancer cell lines (including ovarian cancer A2780 cell line). 2) Expression elevated in CDDP-resistant cell lines (including ovarian cancer A2780/E80 cell line). 3) higher pH inhibit binding of CDDP to DNA. 4) Cellular pH was significantly higher in cisplatin-resistant cells than in sensitive parental cells. 5) proton pump inhibitors (PPIs) sensitized tumor cell lines to the effects of cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/526" target="_blank" rel="noopener noreferrer">526</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21281" target="_blank" rel="noopener noreferrer">P21281</a>', 'HUGO Gene symbol': 'ATP6V1B2', 'Protein name': 'V-type proton ATPase subunit B, brain isoform', 'Function': 'Non-catalytic subunit of the peripheral V1 complex of vacuolar ATPase.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183</a>', 'Notes': 'As ATP6V1A', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V1B2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/528" target="_blank" rel="noopener noreferrer">528</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21283" target="_blank" rel="noopener noreferrer">P21283</a>', 'HUGO Gene symbol': 'ATP6V1C1', 'Protein name': 'V-type proton ATPase subunit C 1', 'Function': 'Subunit of the peripheral V1 complex of vacuolar ATPase. Subunit C is necessary for the assembly.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183</a>', 'Notes': 'As ATP6V1A', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V1C1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/529" target="_blank" rel="noopener noreferrer">529</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P36543" target="_blank" rel="noopener noreferrer">P36543</a>', 'HUGO Gene symbol': 'ATP6V1E1', 'Protein name': 'V-type proton ATPase subunit E 1', 'Function': 'Subunit of the peripheral V1 complex of vacuolar ATPase essential for assembly or catalytic function.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'pH/Pt-toxicity', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11519050%2C%2015547183%5Buid%5D" target="_blank" rel="noopener noreferrer">11519050, 15547183</a>', 'Notes': 'As ATP6V1A', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6V1E1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/538" target="_blank" rel="noopener noreferrer">538</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q04656" target="_blank" rel="noopener noreferrer">Q04656</a>', 'HUGO Gene symbol': 'ATP7A', 'Protein name': 'Copper-transporting ATPase 1', 'Function': 'May supply copper to copper-requiring proteins within the secretory pathway, when localized in the trans-Golgi network. Under conditions of elevated extracellular copper, it relocalized to the plasma membrane where it functions in the efflux of copper from cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18610736%2C%2014676106%2C%2015269138%5Buid%5D" target="_blank" rel="noopener noreferrer">18610736, 14676106, 15269138</a>', 'Notes': '1) elevated in CDDP-resistant cancer cell lines. 2) ATP7A was expressed in some of the most common human malignancies, including prostate (7 of 7), breast (10 of 10), lung (8 of 8), colon (5 of 8), and ovary (6 of 7), as well as in a wide variety of other types of malignancy. 3) ATP7A staining was detected in 28 of 54 ovarian carcinomas before treatment. 4) Patients with increased ATP7A expression after platinum drug treatment (18 of 54) exhibited poorer actuarial survival (P < 0.0057 by log-rank test). 5) Expression of ATP7A either before or after treatment was not associated with other clinical factors. 6) The 1.5-fold higher expression of ATP7A was sufficient to render the 2008/MNK cells resistant to cisplatin, carboplatin, and oxaliplatin. Resistance was associated with increased rather than decreased whole-cell Pt drug accumulation and increased sequestration of Pt into the vesicular fraction.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP7A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/540" target="_blank" rel="noopener noreferrer">540</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35670" target="_blank" rel="noopener noreferrer">P35670</a>', 'HUGO Gene symbol': 'ATP7B', 'Protein name': 'Copper-transporting ATPase 2', 'Function': 'Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12216079%2C%2018610736%2C%2015790435%5Buid%5D" target="_blank" rel="noopener noreferrer">12216079, 18610736, 15790435</a>', 'Notes': '1) The expression level of ATP7B gene was significantly increased (p < 0.05) in patients with moderately-/poorly-differentiated ovarian carcinomas treated with cisplatin-based chemotherapy, thus ATP7B may serve as an independent prognostic factor in these patients. 2) As ATP7A. 3) The endometrial cancer patients with ATP7B-positive tumors had a worse prognosis than that with ATP7B-negative tumors in overall survival and disease-free survival, respectively (P < 0.01) with cisplatin-based chemotherapy.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP7B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/545" target="_blank" rel="noopener noreferrer">545</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13535" target="_blank" rel="noopener noreferrer">Q13535</a>', 'HUGO Gene symbol': 'ATR', 'Protein name': 'Serine/threonine-protein kinase ATR', 'Function': "Activates checkpoint;  phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53; phosphorylates 'Ser-139' of H2AX at sites of DNA damage; required for FANCD2 ubiquitination. ", 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25560806%5Buid%5D" target="_blank" rel="noopener noreferrer">25560806</a>', 'Notes': '1) A panel of human ovarian, endometrial and cervical cancer cell lines were treated with platinum drugs or ionizing radiation (IR). 2) Pharmacologic inhibition of ATR significantly enhanced platinum drug response in all GYN cancer cell lines tested, whereas inhibition of ATM did not enhance the response to platinum drugs. Co-inhibition of ATM and ATR did not enhance platinum kill beyond that observed by inhibition of ATR alone. 3) By contrast, inhibiting either ATR or ATM enhanced the response to IR in all GYN cancer cells, with further enhancement achieved with co-inhibition.', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84126" target="_blank" rel="noopener noreferrer">84126</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8WXE1" target="_blank" rel="noopener noreferrer">Q8WXE1</a>', 'HUGO Gene symbol': 'ATRIP', 'Protein name': 'ATR-interacting protein', 'Function': 'Required for checkpoint signaling after DNA damage. Required for ATR expression, possibly by stabilizing the protein.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25560806%2C%2023723247%5Buid%5D" target="_blank" rel="noopener noreferrer">25560806, 23723247</a>', 'Notes': '1) As in ATR 2) following cellular exposure to DNA cross-linking damage, the FA core complex enhances binding and localization of ATRIP within damaged chromatin. In cells lacking the core complex, ATR-mediated phosphorylation of two functional response targets, ATRIP and FANCI, is defective. 3) the canonical ATR activation pathway involving RAD17 and TOPBP1 is largely dispensable for the FA pathway activation.', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATRIP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6790" target="_blank" rel="noopener noreferrer">6790</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14965" target="_blank" rel="noopener noreferrer">O14965</a>', 'HUGO Gene symbol': 'AURKA', 'Protein name': 'Mitotic Aurora kinase A', 'Function': 'Regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> p53 signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/28417568,27209210,23499911" target="_blank" rel="noopener noreferrer">28417568, 27209210, 23499911</a>', 'Notes': '1) Overexpression of AURKA and phosphorylation of eIF4E was found in acquired and de novo CDDP-resistant gastric cancer models. 2) Inhibition of AURKA with MLN8237 (alisertib) alone or in combination with CDDP significantly suppressed viability of CDDP-resistant gastric cancer\xa0cells. 3) In vivo tumor xenografts data confirmed that inhibition of AURKA was sufficient to overcome CDDP resistance in gastric cancer.  4) Inhibition or knockdown of AURKA decreased protein expression of p-eIF4E (S209), HDM2, and c-MYC in CDDP-resistant cell models. This was associated with a significant decrease in cap-dependent translation levels. 5) In this retrospective study, an immunohistochemical evaluation of AURKA was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). 6) AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). 7) Forced overexpression of AURKA reversed AEG-1 shRNA effect on cytotoxicity enhancement to cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AURKA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/558" target="_blank" rel="noopener noreferrer">558</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30530" target="_blank" rel="noopener noreferrer">P30530</a>', 'HUGO Gene symbol': 'AXL', 'Protein name': 'TAM sub-family tyrosine-protein kinase receptor', 'Function': 'transduces signals from the extracellular matrix by binding growth factor GAS6, regulating cell survival, cell proliferation, migration and differentiation', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23117882%5Buid%5D" target="_blank" rel="noopener noreferrer">23117882</a>', 'Notes': '1) AXL overexpression was detected in more than 50% of tumors examined. 2) Elevating AXL in nonoverexpressing cells doubled the CDDP IC(50) and increased cell survival three-fold, 3) attenuating AXL in overexpressing cells reduced survival two-fold. 4) AXL blocked CDDP-induced activation of endogenous p73β (TP73), reducing its protein half-life, and 5) inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73β(Y99). 6) a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AXL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/572" target="_blank" rel="noopener noreferrer">572</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92934" target="_blank" rel="noopener noreferrer">Q92934</a>', 'HUGO Gene symbol': 'BAD', 'Protein name': 'Bcl2-associated agonist of cell death', 'Function': 'Promotes cell death. BAD function is regulated by phosphorylation (serine-112, -136, and -155). When phosphorylated, BAD is unable to heterodimerize with Bcl-2 or Bcl-xL, freeing Bcl-xL to dimerize and functionally sequester Bax, such that it is no longer free to induce apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Oncogene signaling/AKT<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/21849418,22397496" target="_blank" rel="noopener noreferrer">21849418, 22397496</a>', 'Notes': '1) Induced in vitro OVCA cisplatin resistance was associated with BAD-pathway expression (P < 0.001). 2) In OVCA cell lines and primary specimens, increased BAD protein phosphorylation was associated with platinum resistance (n = 147, P < 0.0001) and also with overall patient survival (n = 134, P = 0.0007). 3) Targeted modulation of BAD-phosphorylation levels influenced cisplatin sensitivity. 4) Gene expression of BAD, Bid, caspases 4 and 6 were clearly decreased in the resistant NSCLC cell lines, and the differential phosphorylation status of BAD also seemed to play a role in the development of cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'DOWN/PHOS', 'Up / down to promote Pt-resistance': 'DOWN/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BAD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9531" target="_blank" rel="noopener noreferrer">9531</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95817" target="_blank" rel="noopener noreferrer">O95817</a>', 'HUGO Gene symbol': 'BAG3', 'Protein name': 'Bcl2-associated athanogene (BAG)', 'Function': 'a family of co-chaperones that interact with Hsp70 through a specific structural domain known as the BAG domain (110–124 amino acids)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24992675%2C%2028628188%5Buid%5D" target="_blank" rel="noopener noreferrer">24992675, 28628188</a>', 'Notes': '1) BAG3 knockdown increased the chemosensitivity to paclitaxel of ES2 ovarian clear cell carcinoma cells to a greater degree than AMOC2 serous adenocarcinoma cells. 2) miR-29b expression was significantly upregulated in primary cancer tissue expressing low levels of BAG3, as compared to tissue expressing high levels. 3) levels of miR-29b correlated significantly with progression-free survival. 4) Upregulation of miR-29b also reduced levels of Mcl-1 and sensitized ES2 cells to low-dose paclitaxel. 5) cisplatin-induced autophagy protected ovarian cancer cells from the toxicity of the drug and that this process was regulated by BAG3. 6) Silencing of BAG3 increased cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BAG3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/578" target="_blank" rel="noopener noreferrer">578</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16611" target="_blank" rel="noopener noreferrer">Q16611</a>', 'HUGO Gene symbol': 'BAK1', 'Protein name': 'Bcl-2 homologous antagonist/killer', 'Function': 'Plays a role in the mitochondrial apoptosic process. Upon arrival of cell death signals, promotes mitochondrial outer membrane (MOM) permeabilization by oligomerizing to form pores within the MOM.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21823019%2C%2026406239%5Buid%5D" target="_blank" rel="noopener noreferrer">21823019, 26406239</a>', 'Notes': '1) As compared with cisplatin-sensitive ovarian cancer cell line (OV2008), the expression levels of miR-125b in CDDP-resistant C13* cells were increased. 2) the up-regulation of microRNA-125b caused a marked inhibition of cisplatin-induced cytotoxicity and apoptosis and a subsequent increase in the resistance to cisplatin in OV2008 and C13* cells. 3) Bak1 was a direct target of miR-125b, and down-regulation of Bak1 suppressed cisplatin-induced apoptosis and led to an increased resistance to cisplatin.\xa04) lower Bak expression was positively associated with the clinical TNM stage of breast cancer with a significant decrease in overall survival compared with those with higher Bak expression especially in the Luminal and HER2 subtypes. 5) higher Bak expression predicted a favorable clinical outcome in the cases treated with Taxol indicated by a higher overall survival than that of patients with lower Bak expression especially in Luminal and HER2 subtypes. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BAK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8314" target="_blank" rel="noopener noreferrer">8314</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92560" target="_blank" rel="noopener noreferrer">Q92560</a>', 'HUGO Gene symbol': 'BAP1', 'Protein name': 'BRCA-1 associated protein / Ubiquitin carboxyl-terminal hydrolase', 'Function': 'Plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1; BAP1 deubiquitinates H2Aub at the promoter of the cystine transporter SLC7A11, reducing cystine uptake (32877777); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30395583%2C%2033547197%5Buid%5D" target="_blank" rel="noopener noreferrer">30395583, 33547197</a>', 'Notes': '1) Suppressed expression of\xa0BAP1\xa0occurred in 22 Gallbladder carcinoma (GBC) cases (46.8%) and showed a strong trend toward a worse median survival. 2) In a training cohort of MPM patients (n=28), mutations or deletions of BAP1 each predicted resistance to chemotherapy in primary MPM patients. 3) Preliminary mechanistic studies using siRNA-based knockdown of BAP1 in MPM cell culture models along with immunoprecipitation assays confirmed chemoresistance in vitro, possibly through inhibition of apoptosis and transcriptional regulation of the BAP1/HCF1/E2F1 axis.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/580" target="_blank" rel="noopener noreferrer">580</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99728" target="_blank" rel="noopener noreferrer">Q99728</a>', 'HUGO Gene symbol': 'BARD1', 'Protein name': 'BRCA1-associated RING domain protein 1 / E3 ubiquitin-protein ligase', 'Function': "The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates  DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. ", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23147994%2C%2021693656%2C%2018089818%20%5Buid%5D" target="_blank" rel="noopener noreferrer">23147994, 21693656, 18089818¬†</a>', 'Notes': '1) BARD1 expression is minimal in the parental A2780ip2 line, but increases at baseline (“Untreated”) with each degree of platinum resistance (A2780cp20 and A2780cp55). 2) when exposed to carboplatin, BARD1 mRNA production is significant increased in both A2780ip2 and A2780cp20. Levels were unchanged with carboplatin exposure in A2780cp55, likely due to its high baseline expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BARD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/581" target="_blank" rel="noopener noreferrer">581</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q07812" target="_blank" rel="noopener noreferrer">Q07812</a>', 'HUGO Gene symbol': 'BAX', 'Protein name': 'Apoptosis regulator BAX', 'Function': 'Under normal conditions, BAX is largely cytosolic via constant retrotranslocation from mitochondria to the cytosol mediated by BCL2L1/Bcl-xL. Under stress conditions, undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/11720475,31966904,30549344" target="_blank" rel="noopener noreferrer">11720475, 31966904, 30549344</a>', 'Notes': '1) we examined TP53 and its downstream genes p21 BAX and BCL-2 in ovarian tumour tissues and have evaluated the results in relation to clinico-pathological parameters, clinical outcome and response to platinum-based chemotherapy. 2) BAX expression was found to be associated with both progression-free (RHR 0.44, P = 0.05) and overall survival (RHR 0.42, P = 0.03). 3) MiR-181a directly targets BAX: cisplatin resistant prostate cancer cells exhibit upregulated miR-181a and downregulated BAX expression. 4) co-transfection of BAX significantly attenuated the cisplatin resistance mediated by miR-181a overexpression in PC3 cells. 5) 127 samples including adjacent normal, primary tumor, and resistance to chemoradiation therapy (RCRT) samples from oral squamous cell carcinoma (OSCC) patients: Frequent progressive decrease of Bax expression with infrequent promoter methylation, polymorphisms G(-248)A, and mutations was observed in OSCC progression/resistance. 6) by targeting Akt pathway, induction of Bax-dependent cell death was observed and this was further enhanced with nimbolide treatment in SCC9/SCC4-CisR cells.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNCHANGED', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BAX" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27113" target="_blank" rel="noopener noreferrer">27113</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BXH1" target="_blank" rel="noopener noreferrer">Q9BXH1</a>', 'HUGO Gene symbol': 'BBC3', 'Protein name': 'p53 upregulated modulator of apoptosis', 'Function': 'Promotes partial unfolding of BCL2L1 and dissociation of BCL2L1 from p53/TP53. Regulates ER stress-induced neuronal apoptosis. Also a transcriptional target of p53. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21863213%2C%2033034274%5Buid%5D" target="_blank" rel="noopener noreferrer">21863213, 33034274</a>', 'Notes': '1) Induction of PUMA by cisplatin was abolished in p53-deficient SKOV3 cells. 2) Elevated expression of PUMA-induced apoptosis and sensitized A2780s and SKOV3 ovarian cancer cells to cisplatin. 3) the combination of PUMA and low-dose cisplatin, significantly suppressed xenograft tumor growth in vivo through enhanced induction of apoptosis compared with treatment with PUMA or cisplatin alone. 4) PUMA chemosensitized intrinsically resistant SKOV3 cells to cisplatin through downregulation of Bcl-xL and Mcl-1. 5) NIPBL Modulates Cisplatin Sensitivity Through Upregulation of PUMA in Esophageal Squamous Cell Carcinoma Cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BBC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/586" target="_blank" rel="noopener noreferrer">586</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P54687" target="_blank" rel="noopener noreferrer">P54687</a>', 'HUGO Gene symbol': 'BCAT1', 'Protein name': 'Branched-chain-amino-acid aminotransferase, cytosolic. ', 'Function': 'Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27246112%5Buid%5D" target="_blank" rel="noopener noreferrer">27246112</a>', 'Notes': '1) Expression of BCAT1 was up-regulated in HCC tissues and induced chemoresistance to cisplatin in HCC cells. 2) Branched-chain aminotransferases (BCATs) have a catabolic function, catalyzing the transamination of all three BCAAs to the corresponding branched-chain a-ketoacids and glutamate.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/596" target="_blank" rel="noopener noreferrer">596</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10415" target="_blank" rel="noopener noreferrer">P10415</a>', 'HUGO Gene symbol': 'BCL2', 'Protein name': 'B-cell lymphoma 2 / Protein Phosphatase 1, Regulatory Subunit 50', 'Function': 'Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/19240170,16009487,10615232" target="_blank" rel="noopener noreferrer">19240170, 16009487, 10615232</a>', 'Notes': '1) In squamous cell carcinoma of the head and neck (HNSCC) cell lines, high endogenous Bcl-2 expression was associated with increased cisplatin resistance, 2) experimental overexpression of Bcl-2 promoted cisplatin resistance. 3) In oropharyngeal squamous cell carcinoma (OPSCC) patients, tumors positive for Bcl-2 before treatment had greater risk of treatment failure (hazard ratio, 5.99; 95% confidence interval, 1.73−20.8;\xa0P\xa0= 0.0014) under platinum-based chemoradiation. 4) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. 5) Expression of bcl-2, p53 and MDM-2 was assessed by immunohistochemical staining of tumour tissues collected at initial surgery prior to treatment with CDDP-based chemotherapy. Among 66 patients with advanced ovarian cancer with measurable tumour following surgery and evaluable for response to chemotherapy, 42, 45 and 56% were positive for bcl-2, p53 and MDM-2, respectively. 6) Significantly fewer tumours of patients who had a complete response to chemotherapy (CR) showed positivity for bcl-2 (2/20) than for p53 (6/20) and MDM-2 (8/20, P < 0.001). 7) There was an inverse correlation between bcl-2 staining and initial response to chemotherapy, especially in serous and endometrial adenocarcinomas. 8) In patients with stage III-IV, serous or endometrioid adenocarcinomas, significantly poorer survival was seen for those with bcl-2 positive tumours than those with negative bcl-2 staining (P = 0.0064). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/597" target="_blank" rel="noopener noreferrer">597</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16548" target="_blank" rel="noopener noreferrer">Q16548</a>', 'HUGO Gene symbol': 'BCL2A1', 'Protein name': 'Bcl-2-related protein A1', 'Function': 'Retards apoptosis induced by IL-3 deprivation; response to hemopoietic cells to external signals and in maintaining endothelial survival during infection; inhibits apoptosis induced by serum starvation in the mammary epithelial cell line HC11.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31003775%2C%2024277158%5Buid%5D" target="_blank" rel="noopener noreferrer">31003775, 24277158</a>', 'Notes': '1) prenylated Rab acceptor 1 (RABAC1 or PRA1) inhibits the anti-apoptotic activity of BCL2A1. 2) When apoptosis was induced by cisplatin, the anti-apoptotic activity of BCL2A1 was blocked by RABAC1 expression. 3) Two days after cisplatin, significant increases were observed in five proapoptotic genes: Bik, Bid, Bok, Trp53p2, and Card6 and a significant decrease in one antiapoptotic gene Bcl2a1. In contrast, Nol3, an antiapoptotic gene, showed a significant increase in expression. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/598" target="_blank" rel="noopener noreferrer">598</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q07817" target="_blank" rel="noopener noreferrer">Q07817</a>', 'HUGO Gene symbol': 'BCL2L1', 'Protein name': 'Bcl-2-like protein 1', 'Function': 'Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/26401016,17275076,31262032,17848273" target="_blank" rel="noopener noreferrer">26401016, 17275076, 31262032, 17848273</a>', 'Notes': '1) In 18.4% of GC cases (19/103), amplification of the antiapoptotic gene BCL2L1 was observed, and 2) subsequently a BCL2L1 inhibitor was shown to markedly decrease cell viability in BCL2L1-amplified cell lines and in similarly altered patient-derived GC xenografts, especially when combined with other chemotherapeutic agents, including cisplatin. 3) Cisplatin-induced down-regulation of Bcl-xL was strictly associated with apoptosis and absence of recurrence in in ovarian carcinoma cells. 4) Expression of Bcl-xS to impede anti-apoptotic activity of Bcl-xL highly sensitized SKOV3 resistant cells to cisplatin-induced apoptosis, and delayed recurrence. 5) cisplatin-resistant UC cells (T24/R) upregulated the antiapoptotic factor, B-cell lymphoma-extra large (Bcl-xL). 6) Knockdown of Bcl-xL by siRNA resensitized cisplatin-resistant cells to the cisplatin cytotoxic effect. 7) HNSCC cell lines selected for cisplatin resistance had wild-type p53 and high levels of Bcl-xL. 8) Patients whose tumors expressed low levels of p53 and Bcl-xL enjoyed the best organ preservation and disease-free survival whereas patients whose tumors expressed low levels of p53 and high levels of Bcl-xL had the worst outcome. ', 'Up / down in Pt-resistant cells': 'UNCHANGED', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2L1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10018" target="_blank" rel="noopener noreferrer">10018</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43521" target="_blank" rel="noopener noreferrer">O43521</a>', 'HUGO Gene symbol': 'BCL2L11', 'Protein name': 'Bcl-2-like protein 11 / BCL2‐interacting mediator', 'Function': 'Binds and inhibits Bcl-2 and induces apoptosis and anoikis;\xa0a member of the BH3‐only death activator family and a key determinant of cell fate upon cytokine withdrawal.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21561860%2C%2022924699%5Buid%5D" target="_blank" rel="noopener noreferrer">21561860, 22924699</a>', 'Notes': '1) treatment of ovarian cancer cells with cisplatin caused Bim phosphorylation and subsequent degradation. 2) its degradation is associated with cisplatin resistance. 3) cisplatin treatment caused the activation of ERK, which correlated with Bim phosphorylation and degradation. 4) By inhibiting ERK phosphorylation, Bim phosphorylation and degradation were blocked. 5) Bim was phosphorylated and degraded in cisplatin-resistant OV433 cells but not in the parental OV433 cells. 6) inhibition of Bim degradation by the proteasome inhibitor MG132 sensitized resistant OV433 cells to cisplatin-induced death.\xa0', 'Up / down in Pt-resistant cells': 'DOWN/PHOS', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2L11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/599" target="_blank" rel="noopener noreferrer">599</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92843" target="_blank" rel="noopener noreferrer">Q92843</a>', 'HUGO Gene symbol': 'BCL2L2', 'Protein name': 'Bcl-2-like protein 2', 'Function': 'Promotes survival. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30019389%5Buid%5D" target="_blank" rel="noopener noreferrer">30019389</a>', 'Notes': '1) MiR‐335‐5P was lowly expressed in cisplatin-resistant ovarian cancer A2780/DDP cells. 2) Overexpression of miR‐335‐5p suppressed BCL2L2 expression in A2780 and A2780/DDP cells. 3) MiR‐335‐5p suppressed cell viability and enhanced cell apoptosis of A2780/DDP cells through downregulating BCL2L2. 4) MiR‐335‐5p reduced the DDP‐resistance and inhibited the growth of A2780/DDP cells in vivo', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BCL2L2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8678" target="_blank" rel="noopener noreferrer">8678</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14457" target="_blank" rel="noopener noreferrer">Q14457</a>', 'HUGO Gene symbol': 'BECN1', 'Protein name': 'Beclin-1', 'Function': '1) a central role in autophagy 2) core subunit of the PI3K complex 3) PI3KC3-C1 is involved in initiation of autophagosomes and PI3KC3-C2 in maturation of autophagosomes and endocytosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29512762%2C%2029399172%2C%2026458502%5Buid%5D" target="_blank" rel="noopener noreferrer">29512762, 29399172, 26458502</a>', 'Notes': '1) Cisplatin induced autophagy by upregulating the mRNA and protein expression levels of autophagy protein (Atg)5 and Beclin 1. 2) knockdown of Atg5 and Beclin 1 by small interfering RNA transfection impaired cisplatin‑induced activation of autophagic responses, increased caspase‑3 cleavage and inhibited cell viability. 3) Amongst 141 ovarian carcinoma samples, the loss of BECN1, LC3, and HMGB-1 expression was identified in 59 (41.8%), 35 (24.8%), and 66 (46.8%) samples, respectively. 4) negative expression of Beclin 1 was associated with a shorter progression-free survival in comparison to positive Beclin 1 expression in OCCC who received cytoreductive surgery, followed by a standard platinum-based chemotherapy regimen (P=0.027, log-rank test). 5) Beclin 1-negative tumors were no more resistant to primary adjuvant chemotherapy than were Beclin 1-positive tumors (50.0 vs. 66.7%, P=0.937). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BECN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27018" target="_blank" rel="noopener noreferrer">27018</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00994" target="_blank" rel="noopener noreferrer">Q00994</a>', 'HUGO Gene symbol': 'BEX3', 'Protein name': 'Brain‐expressed X‐linked 3', 'Function': 'CD271‐associated protein, may be a signaling adapter molecule involved in p75NTR-mediated apoptosis induced by NGF.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28083995%5Buid%5D" target="_blank" rel="noopener noreferrer">28083995</a>', 'Notes': '1) BEX3 expression was inducible in response to cisplatin treatment. 2) significant upregulation of BEX3 was observed in cisplatin‐resistant NPC cells. 3) BEX3 overexpression is important for the NPC cell to enrich the stemness features and acquire cisplatin‐resistant phenotype,\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BEX3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8553" target="_blank" rel="noopener noreferrer">8553</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14503" target="_blank" rel="noopener noreferrer">O14503</a>', 'HUGO Gene symbol': 'BHLHE40', 'Protein name': 'Basic helix-loop-helix transcription factor E40', 'Function': 'associated with the regulation of apoptosis, cell proliferation, and circadian rhythms, as well as malignancy in various cancers', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25876658%2C%2023423709%5Buid%5D" target="_blank" rel="noopener noreferrer">25876658, 23423709</a>', 'Notes': '1) DEC1 expression was up-regulated in CDDP-treated esophageal cancer TE 10 cells. 2) DEC1 knockdown by siRNA in TE 10 decreased CDDP-induced apoptosis. 3) DEC1 overexpression promoted CDDP-induced apoptosis. 4) In 118 archived tissues, the positive rate of DEC1 was reduced in human lung cancer samples (36/118, 30.5 %) compared with adjacent normal lung tissues (106/118, 89.8 %), as measured by immunohistochemical staining. 5) Loss of DEC1 was correlated with poor differentiation (p\u2009=\u20090.005) and high p-TNM stage (p\u2009=\u20090.002). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BHLHE40" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/637" target="_blank" rel="noopener noreferrer">637</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P55957" target="_blank" rel="noopener noreferrer">P55957</a>', 'HUGO Gene symbol': 'BID', 'Protein name': 'BH3-interacting domain death agonist', 'Function': 'The major proteolytic product p15 BID allows the release of cytochrome c (By similarity). Isoform 1, isoform 2 and isoform 4 induce ICE-like proteases and apoptosis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/29182622,32024383" target="_blank" rel="noopener noreferrer">29182622, 32024383</a>', 'Notes': '1) RNAi-mediated silencing of Bid or Bak in Bax-deficient human prostate cancer DU 145 cells suppressed the cisplatin drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling.\xa02) There is increasing evidence that mitochondrial priming correlates with cisplatin response in various cancers. Notably, Bim and Bid, two of the proapoptotic BH3-only proteins, are recognized as the most effective inducers of mitochondrial priming in OC. 3) Overexpression of truncated Bid from adenovirus (Ad-tBid), mito-primed cells displayed more sensitivity to cisplatin both in vitro and ex vivo. 4) a combined cisplatin plus Ad-tBid therapy markedly inhibited tumor growth in a subcutaneous xenotransplanted tumor model. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BID" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/638" target="_blank" rel="noopener noreferrer">638</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13323" target="_blank" rel="noopener noreferrer">Q13323</a>', 'HUGO Gene symbol': 'BIK', 'Protein name': 'Bcl-2-interacting killer', 'Function': 'Accelerates programmed cell death. Association to the apoptosis repressors Bcl-X(L), BHRF1, Bcl-2 or its adenovirus homolog E1B 19k protein suppresses this death-promoting activity.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30176890%5Buid%5D" target="_blank" rel="noopener noreferrer">30176890</a>', 'Notes': '1) KLF4 was induced by cisplatin in prostate cancer cells and that the increase in KLF4 promoted cell apoptosis. 2) KLF4 directly bound to the promoter of BIK, facilitating its transcription. 3) the gene encoding KLF4 was a direct target of miR-32-5p. The downregulation of miR-32-5p in response to cisplatin treatment promoted KLF4 expression, which resulted in a increase in the chemosensitivity of prostate cancer.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/274" target="_blank" rel="noopener noreferrer">274</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00499" target="_blank" rel="noopener noreferrer">O00499</a>', 'HUGO Gene symbol': 'BIN1', 'Protein name': 'Myc box-dependent-interacting protein 1', 'Function': 'A member of the BIN/ amphiphysin/ Rvs (BAR) family of proteins. A MYC-interacting protein with features of a tumor suppressor. Activates a caspase-independent apoptotic process. interacts with and attenuates the two major cell-cycle–promoting transcription factors, MYC and E2F1 and slows cell-cycle progression', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21447800%2C%2030733337%2C%2022778941%5Buid%5D" target="_blank" rel="noopener noreferrer">21447800, 30733337, 22778941</a>', 'Notes': '1) BIN1 overexpression enhances sensitivity to cisplatin, regardless of the status of TP53; knockdown of BIN1 confers cisplatin resistance. 2) Inhibition of c-MYC by BIN1 constitutes a mechanism whereby BIN1 increases cisplatin sensitivity; c-MYC also bind and sequest BIN1.\xa03) BIN1 bound to the automodification domain of and suppressed the catalytic activity of PARP1; PARP1 also suppresses BIN1 activity. 3) overexpressed c-MYC repressed BIN1 expression  thereby released PARP1 activity, which results in increased DNA repair activity and allows cancer cells to acquire cisplatin resistance. 4) BIN1 prevented E2F1 from transcriptionally activating the human ATM promoter.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/329" target="_blank" rel="noopener noreferrer">329</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13490" target="_blank" rel="noopener noreferrer">Q13490</a>', 'HUGO Gene symbol': 'BIRC2', 'Protein name': 'Baculoviral IAP repeat-containing protein 2', 'Function': 'Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling. \xa0Multi-functional protein which regulates caspases and apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> NF-kB signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29769618%2C%2011145600%2C%2022669575%2C%2028804784%5Buid%5D" target="_blank" rel="noopener noreferrer">29769618, 11145600, 22669575, 28804784</a>', 'Notes': '1) Genetic and pharmacological inhibition of XIAP, BIRC2, and BIRC3 is sufficient to restore cisplatin-induced apoptosis in ovarian cancer cells in the presence of COL11A1 in ovarian cancer cells and xenograft mouse models, respectively. 2) AT-406, which induces cIAP1 degradation, enhances the carboplatin-induced ovarian cancer cell death and increases survival of the experimental mice. 4) High levels of cIAP1 and 2 were detected in up to 50% of high-grade serous and non-high-grade serous platinum-resistant carcinomas. 5) cIAP proteins are effectively degraded with the drug birinapant. In platinum-resistant tumors with ≥22.4 ng of cIAP per 20 μg of tumor lysate, the combination of birinapant with carboplatin was effective in eliminating the cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; UNCHANGED in R', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIRC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/330" target="_blank" rel="noopener noreferrer">330</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13489" target="_blank" rel="noopener noreferrer">Q13489</a>', 'HUGO Gene symbol': 'BIRC3', 'Protein name': 'Baculoviral IAP repeat-containing protein 3', 'Function': 'Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling. \xa0Multi-functional protein which regulates caspases and apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> NF-kB signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/29769618,26291056" target="_blank" rel="noopener noreferrer">29769618, 26291056</a>', 'Notes': '1) Genetic and pharmacological inhibition of XIAP, BIRC2, and BIRC3 is sufficient to restore cisplatin-induced apoptosis in ovarian cancer cells in the presence of COL11A1 in ovarian cancer cells and xenograft mouse models, respectively. 2) the components of COL11A1- integrin α1β1/DDR2- Src-PI3K/Akt-NF-kB-IAP signaling pathway serve as poor prognosis markers in ovarian cancer patients. 3) In vitro, (5Z)-7-oxozeaenol significantly reduced BIRC3 expression in FLO-1 and KYAE-1 cells. Exposure to chemotherapeutic agents or radiotherapy plus (5Z)-7-oxozeaenol resulted in a strong synergistic antiapoptotic effect. 4) In oesophageal cancer patients, median expression of BIRC3 was significantly (P<0.0001) higher in adenocarcinoma than in the more sensitive squamous cell carcinoma subtype. 5) The BIRC3 expression significantly discriminated patients with sensitive or resistant adenocarcinoma against docetaxel, cisplatin, 5-fluorouracil, and concurrent radiotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; UNCHANGED in R', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIRC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/332" target="_blank" rel="noopener noreferrer">332</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15392" target="_blank" rel="noopener noreferrer">O15392</a>', 'HUGO Gene symbol': 'BIRC5', 'Protein name': 'Baculoviral IAP repeat-containing protein 5', 'Function': 'Component of a chromosome passage protein complex (CPC) essential for chromosome alignment and segregation; dual roles in promoting cell proliferation and preventing apoptosis ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23229441%2C%2020514400%2C%2027384994%2C%2023358177%2C%2011241318%5Buid%5D" target="_blank" rel="noopener noreferrer">23229441, 20514400, 27384994, 23358177, 11241318</a>', 'Notes': '1) knockdown of SVV enhanced cisplatin-induced cell apoptosis and inhibited the invasive potential in ovarian cancer A2780/CP cells.\xa02) CDDP induced survivin expression, which was blocked by siRNA in rat hepatoma cell line K-251. 3) PI3K inhibitor LY294002 also attenuated survivin expression induced by CDDP. 4) Of 1,065 gastric carcinoma samples, higher expression of BIRC5 were predictive for poor OS. 6) Positive survivin expression was also associated with platinum resistance in EOC patients. 7) Fourteen patients with advanced esophageal cancer had received platinum-based chemotherapy prior to surgery. The survivin expression in the cancer tissue in patients who achieved a partial response (PR) was significantly lower than that in patients with no change (NC) and in patients with progressive disease. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIRC5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79444" target="_blank" rel="noopener noreferrer">79444</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96CA5" target="_blank" rel="noopener noreferrer">Q96CA5</a>', 'HUGO Gene symbol': 'BIRC7', 'Protein name': 'Baculoviral IAP repeat-containing protein 7', 'Function': 'Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23188704%5Buid%5D" target="_blank" rel="noopener noreferrer">23188704</a>', 'Notes': '1) in four colon cancer cell lines (HCT116, RKO, KM12C, and SW620), different response to cisplatin was related to endogenous Livin expression level. 2) the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. 3) Livin remained in the cytoplasm after treatment with cisplatin, the elevated expression of Livin was enhanced at the mRNA level. 4) The PI3K inhibitor LY294002 inhibited both the phosphorylation of mTOR and upregulation of Livin. 5) The stable overexpression of Livin inhibited the activation of caspase-3 and led to resistance to cisplatin, while the knockdown of Livin by siRNA rendered colon cancer cells more sensitive to cisplatin.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BIRC7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/641" target="_blank" rel="noopener noreferrer">641</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P54132" target="_blank" rel="noopener noreferrer">P54132</a>', 'HUGO Gene symbol': 'BLM', 'Protein name': 'Bloom syndrome protein', 'Function': "ATP-dependent DNA helicase that unwinds single- and double-stranded DNA in a 3'-5' direction", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29452344%5Buid%5D" target="_blank" rel="noopener noreferrer">29452344</a>', 'Notes': '1) The average expression levels of\xa0BLM\xa0and\xa0FANCI\xa0were significantly higher in the carboplatin-sensitive ovarian cancers (P\u2009=\u20090.026 and\xa0P\u2009=\u20090.036, respectively). 2) The knockdown of either BLM or FANCI by siRNA resulted in greater resistance to cisplatin but no significant effect on sensitivity to paclitaxel. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BLM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/648" target="_blank" rel="noopener noreferrer">648</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35226" target="_blank" rel="noopener noreferrer">P35226</a>', 'HUGO Gene symbol': 'BMI1', 'Protein name': 'Polycomb complex protein', 'Function': 'Stem cell factor; component of a Polycomb group (PcG) multiprotein PRC1-like complex, catalyzes K119 mono-ubiquitination of histone H2A, which contributes to gene silencing ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> CSC<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29685168%2C%2026294655%2C%2021445297%5Buid%5D" target="_blank" rel="noopener noreferrer">29685168, 26294655, 21445297</a>', 'Notes': '1) Silencing BMI1 could reduce cell growth and metastasis, promote cell apoptosis, and enhance the platinum sensitivity of EOC cells. 2) BMI1 might alter extracellular matrix structure and angiogenesis of tumor cells through regulating Focal adhesion and PI3K/AKT pathways. 3) Patients with Bmi-1-positive localized tumors had a much lower 5-year disease-free survival and overall survival. 4) silencing Bmi-1 reduces intracellular GSH levels and thereby sensitizes chemoresistant ovarian cancer cells to cisplatin; activates the DNA damage response pathway, caspases and cleaves PARP. 5) In an in vivo orthotopic mouse model of chemoresistant ovarian cancer, knockdown of Bmi-1 by nanoliposomal delivery significantly inhibits tumor growth; While cisplatin monotherapy was inactive, combination of Bmi-1 silencing along with cisplatin almost completely abrogated ovarian tumor growth. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BMI1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/652" target="_blank" rel="noopener noreferrer">652</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12644" target="_blank" rel="noopener noreferrer">P12644</a>', 'HUGO Gene symbol': 'BMP4', 'Protein name': 'Bone morphogenetic protein 4', 'Function': 'Induces cartilage and bone formation. Also acts in mesoderm induction, tooth development, limb formation and fracture repair;\xa0regulates cancer progression by promoting EMT and angiogenesis in certain kinds of cancer cells (18663362)', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22535375%2C%2021674241%5Buid%5D" target="_blank" rel="noopener noreferrer">22535375, 21674241</a>', 'Notes': '1) Epigenomic analysis identified BMP4 as an epigenetically regulated gene highly expressed in cisplatin-resistant lines. 2) BMP4 is necessary and sufficient for the expression of several prooncogenic traits, likely mediated through stimulation of EMT. 3) In primary tumours, BMP4 promoter methylation levels were inversely correlated with BMP4 expression, and patients with high BMP4-expressing GC tumors exhibited significantly worse prognosis. 4) targeted genetic inhibition of BMP4 caused significant sensitisation of GC cells to cisplatin. 5) In carcinoma samples taken before and after platinum-based neoadjuvant chemotherapy from 28 patients with advanced, high-grade serous ovarian carcinoma, strong expression of BMP-4 before chemotherapy was an independent prognostic factor of longer progression-free time (p = 0.002) and overall survival (p = 0.02). ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BMP4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/657" target="_blank" rel="noopener noreferrer">657</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P36894" target="_blank" rel="noopener noreferrer">P36894</a>', 'HUGO Gene symbol': 'BMPR1A', 'Protein name': 'Bone morphogenetic protein receptor type-1A', 'Function': 'On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases - TGF-B signaling. ', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26235139%5Buid%5D" target="_blank" rel="noopener noreferrer">26235139</a>', 'Notes': '1) BMP ligands are amplified in human ovarian cancers. 2) BMP receptor expression correlates with poor progression-free-survival (PFS). 2) active BMP signaling has been observed in human ovarian cancer tissue. 4) ovarian cancer cell lines have active BMP signaling in a cell autonomous fashion. 5) Inhibition of BMP signaling with a small molecule receptor kinase antagonist is effective at reducing ovarian tumor sphere growth. 6) BMP inhibition can enhance sensitivity to Cisplatin treatment and regulates gene expression involved in platinum resistance in ovarian cancer.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BMPR1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/664" target="_blank" rel="noopener noreferrer">664</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12983" target="_blank" rel="noopener noreferrer">Q12983</a>', 'HUGO Gene symbol': 'BNIP3', 'Protein name': 'BCL2/adenovirus E1B 19 kDa protein-interacting protein 3', 'Function': 'A mitochondrial protein that contains a BH3 domain and acts as a pro-apoptotic factor. The encoded protein interacts with anti-apoptotic proteins, including the E1B 19 kDa protein and Bcl2. This gene is silenced in tumors by DNA methylation', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26201611%2C%2033202209%2C%2032412667%5Buid%5D" target="_blank" rel="noopener noreferrer">26201611, 33202209, 32412667</a>', 'Notes': '1) BNIP3 and BNIP3L abundance was markedly increased by cisplatin or hypoxia. 2) The suppressed expression of BNIP3 caused inhibition of oxygen consumption and stimulated production of the mitochondrial ROS; 3) cytochrome c release in the cells with BNIP3 knockout and knockdown was higher than in the wild-type (WT) upon apoptosis stimulation by cisplatin. 4) Analysis of the SubG1 population by flow cytometry confirmed the elevated level of apoptosis in the BNIP3 knockout cells. 5) Pretreatment with the antioxidant Trolox did not affect cell death, indicating that it was independent on reactive oxygen species. 6) BNIP3 knockdown with siRNA in ovarian cancer cell lines A2780 and OVCAR4 significantly reduced cisplatin cytotoxicity in these two cell lines and alleviated cisplatin-induced apoptosis. 7) Gene Expression Omnibus and The Cancer Genome Atlas with ovarian cancer: higher BNIP3 level was correlated with poorer overall survival and progression-free survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BNIP3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/666" target="_blank" rel="noopener noreferrer">666</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UMX3" target="_blank" rel="noopener noreferrer">Q9UMX3</a>', 'HUGO Gene symbol': 'BOK', 'Protein name': 'Bcl-2-related ovarian killer protein', 'Function': 'Pro-apoptotic protein. In response to ER stress through BAX/BAK1 and PERK-mediated UPR', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29985192%5Buid%5D" target="_blank" rel="noopener noreferrer">29985192</a>', 'Notes': '1) BOK was frequently downregulated in Testicular Cancer (TC) tissues compared with paratumor tissues. 2)BOK overexpression inhibited TC cell proliferation and invasion. 3) BOK knockdown promoted TC cell proliferation and invasion. 4) Surprisingly, either BOK overexpression or knockdown rendered TC cells resistant to Cisplatin (DDP). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BOK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/672" target="_blank" rel="noopener noreferrer">672</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P38398" target="_blank" rel="noopener noreferrer">P38398</a>', 'HUGO Gene symbol': 'BRCA1', 'Protein name': 'Breast cancer type 1 susceptibility protein', 'Function': "E3 ubiquitin-protein ligase ( 'Lys-6'-linked polyubiquitin). The BRCA1-BARD1 heterodimer coordinates DNA damage repair, checkpoint, ubiquitination and transcriptional regulation to maintain genomic stability. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to  HRR via its direct interaction with PALB2,  through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. ", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/DNA replication<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15547178%2C%2017956347%2C%2018413725%2C%2020940403%2C%2022253870%2C%2024168967%5Buid%5D" target="_blank" rel="noopener noreferrer">15547178, 17956347, 18413725, 20940403, 22253870, 24168967</a>', 'Notes': '1) BRCA1 interact with the Pol II holoenzyme complex and p53 and c-Myc and triger transcriptional changes linked to cell cycle checkpoint and apoptosis. 2) ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance. 3) nine recurrent BRCA1-mutated ovarian cancers previously treated with platinum compounds, including five with acquired platinum resistance, one with primary platinum resistance, and three with platinum sensitivity. 4) Four of the six recurrent platinum-resistant tumors had developed secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 protein, 5) none of the three platinum-sensitive recurrent tumors developed BRCA1 sequence alterations. 6) The BRCA1 locus product protein BRCA1-IRIS is overexpressed in several cisplatin-resistant ovarian cancer cell lines, 7) overexpression of BRCA1-IRIS triggers expression of the antiapoptotic protein survivin; negative modulation of phosphatidylinositol 3-kinase (PI3K) signaling or AKT silencing reduced survivin expression. 8) silencing BRCA1-IRIS in ovarian cancer cell lines derepressed PTEN expression along with the antiapoptotic AKT targets FOXO1 and FOXO3a, suppressing survivin expression. 9) Cisplatin (≤50 μmol/L) exposure was sufficient to activate expression of the BRCA1-IRIS-AKT-survivin cascade in HOSE cells, whereas under similar conditions cisplatin failed to induce apoptosis in ovarian cancer cell lines expressing this regulatory cascade. 10) High PARP, FANCD2 and BRCA1 expressions were significantly correlated with each other; 11) Of all patients, 9% recurred within the first year. Among early recurring patients, 41% had high levels of PARP, FANCD2 and P53, compared to 19.5% of patients without early recurrence (p\u200a=\u200a0.04). Women with high levels of PARP, FANCD2 and/or P53 had first year cumulative cancer incidence of 17% compared with 7% for the other groups (P\u200a=\u200a0.03). 12) In serous ovarian cancer, higher levels of miR-9 were inversely correlated with BRCA1 expression (Spearman rank correlation: R (2) = 0.379; P = .003). 13) Patients with higher levels of miR-9 had better chemotherapy response, platinum sensitivity, and longer progression-free survival (PFS) (high vs low miR-9 expression: median PFS = 26.4 months, 95% CI = 13.8 to 39.0 months vs median PFS = 15.4 months, 95% CI = 6.8 to 23.9 months, P = .01).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/675" target="_blank" rel="noopener noreferrer">675</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51587" target="_blank" rel="noopener noreferrer">P51587</a>', 'HUGO Gene symbol': 'BRCA2', 'Protein name': 'Breast cancer type 2 susceptibility protein', 'Function': 'Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Part of a PALB2-scaffolded HR complex. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication<br><br> DDR/FA<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18264087%2C%2022711857%2C%2020877358%2C%2029066501%5Buid%5D" target="_blank" rel="noopener noreferrer">18264087, 22711857, 20877358, 29066501</a>', 'Notes': '1) ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance. 2) acquired resistance to cisplatin in BRCA2-mutated tumors can be mediated by secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading frame. 3) Germ-line mutations of BRCA1 or BRCA2 were found in 14.1% of patients overall, including 16.6% of serous cancer patients (high-gradeserous, 17.1%); [corrected] 44% had no reported family history of breast or ovarian cancer. 4) Patients carrying germ-line mutations had improved rates of progression-free and overall survival. 5) In the relapse setting, patients carrying mutations more frequently responded to both platin- and nonplatin-based regimens than mutation-negative patients, even in patients with early relapse after primary treatment. 6) Mutation-negative patients who responded to multiple cycles of platin-based treatment were more likely to carry somatic BRCA1/2 mutations. 7) The xenograft from a woman carrying a germline BRCA2 mutationwas also highly sensitive to radiotherapy and cisplatin-based treatments. 8) platinum-resistant cancer had a higher percentage of high BRCA2 level (87.5% vs 43.6%, P\u2009=\u20090.001), 9) patients with a low BRCA2 level in cancer tissues had longer progression-free survival (with a median time of 28.0 vs 12.0 months, P\u2009<\u20090.001) and platinum-free duration (with a median time of 19.0 vs 5.0 months, P\u2009<\u20090.001) compared with those with a high BRCA2 level. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/65980" target="_blank" rel="noopener noreferrer">65980</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H8M2" target="_blank" rel="noopener noreferrer">Q9H8M2</a>', 'HUGO Gene symbol': 'BRD9', 'Protein name': 'Bromodomain-containing protein 9', 'Function': 'Plays a role in chromatin remodeling and regulation of transcription (22464331, 26365797). Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Immune response<br><br> MYC signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28714904%2C%2032457312%5Buid%5D" target="_blank" rel="noopener noreferrer">28714904, 32457312</a>', 'Notes': "1) Combined treatment of doxorubicin or carboplatin with I-BRD9 resulted in additive to synergistic inhibitory effects on cell proliferation.\xa02) following DNA damage, the bromodomain of BRD9 binds acetylated K515 on RAD54 and facilitates RAD54's interaction with RAD51, which is essential for HR. 3) BRD9 is overexpressed in ovarian cancer and depleting BRD9 sensitizes cancer cells to olaparib and cisplatin. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRD9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/83990" target="_blank" rel="noopener noreferrer">83990</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BX63" target="_blank" rel="noopener noreferrer">Q9BX63</a>', 'HUGO Gene symbol': 'BRIP1', 'Protein name': 'Fanconi anemia group J / BRCA1-interacting protein 1', 'Function': "DNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination.", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26680099%5Buid%5D" target="_blank" rel="noopener noreferrer">26680099</a>', 'Notes': "1)\xa0ectopic expression of BRIP1 could remarkably enhance the antitumor activity of cisplatin, as demonstrated by decreased cell viability, colony formation and tumour xenografts' weight. 2) BRIP1 promoted cisplatin-mediated cell apoptosis and suppressed tumour angiogenesis. 3) BRIP1 expression was observed to be reduced in squamous cancer tissue and adenocarcinoma compared with normal cervix tissue, 4) there were significant correlations between the reduction in BRIP1 expression and unfavorable variables. ", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/682" target="_blank" rel="noopener noreferrer">682</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35613" target="_blank" rel="noopener noreferrer">P35613</a>', 'HUGO Gene symbol': 'BSG', 'Protein name': 'basigin or Emmprin', 'Function': 'a type I glycoprotein (immunoglobulin superfamily), stimulates adjacent fibroblasts or tumor cells to produce MMPs; develop chemoresistance by mediating activation of PI3K and MAPK (27608940); CD147-ICD binds to a panel of promoter elements including NFkB', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> NF-kB signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28056551%2C%2017671123%2C%2028703811%5Buid%5D" target="_blank" rel="noopener noreferrer">28056551, 17671123, 28703811</a>', 'Notes': '1) hepatitis B X-interacting protein up-regulated CD147 at the protein expression and transcriptional levels. 2) Emmprin and survivin proteins were identified as strong independent prognostic factors for response and survival after cisplatin-containing chemotherapy in patients with advanced bladder cancer. 3) cholesterol depletion inhibits the endocytosis of CD147; but that the constitutive shedding of CD147 mediated by ADAM10 is enhanced. 4) HAb 18 (a specific antibody targeting CD147) inhibits CD147 shedding and reduces sequential CD147-ICD (intracellular domain of CD147). 5) overexprssion of CD147-ICD enhances autophagy. 6) the combination of HAb 18 and cisplatin exhibited marked antitumor efficiency (liver cancer).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BSG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/708" target="_blank" rel="noopener noreferrer">708</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q07021" target="_blank" rel="noopener noreferrer">Q07021</a>', 'HUGO Gene symbol': 'C1QBP', 'Protein name': 'Complement component 1 Q subcomponent-binding protein', 'Function': '1) promotes oxidative phosphorylation; positively regulates PDH activity. 2) Promotes HR by stabilizing MRE11 and activating MRN Complex (31353207). 3) predominantly localized in the mitochondria (23692256); interacts with  ARF to promote mitochondria apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR/HR<br><br> Hypoxia signaling<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22771308%2C%2016544101%2C%2023692256%5Buid%5D" target="_blank" rel="noopener noreferrer">22771308, 16544101, 23692256</a>', 'Notes': '1) HABP1 over-expression was correlated to histological-differentiation, residual-tumor-size, serum CA-125 levels and International Federation of Gynecology and Obstetrics (FIGO) stage. 2) Multivariate analyses demonstrated that increased expression of HABP1 was associated with cisplatin resistance. 3) HABP1 low-expression resulted in an increased five-year OS and PFS. 4) Cox proportional hazards test identified that high expression of HABP1 led to increased risk for stage III/IV serous ovarian cancer via poor OS and PFS. This was similar for cisplatin resistant patients. 5) a two-fold increase in total intracellular HABP1 expression at 24 h of cisplatin treatment in Hela cells; a reduction in apoptotic cell population in cisplatin treated HeLa cells with disrupted HABP1. 6) siRNA-mediated p32 knockdown resulted in enhanced cell death in cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=C1QBP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/790" target="_blank" rel="noopener noreferrer">790</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27708" target="_blank" rel="noopener noreferrer">P27708</a>', 'HUGO Gene symbol': 'CAD', 'Protein name': 'CAD protein', 'Function': 'This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER<br><br> DDR/nucleotide synthesis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30038717%5Buid%5D" target="_blank" rel="noopener noreferrer">30038717</a>', 'Notes': '1) the prognostic complementarity between de novo pyrimidine synthesis and nucleotide excision repair expression in a total of 570 bladder urothelial carcinoma patients. 2) the\xa0de novo\xa0pyrimidine synthesis gene CAD is associated with poor survival (P = 0.008) and is co-altered with the nucleotide excision repair gene POLD2.\xa03) Expression of each gene was associated with cisplatin-based therapy resistance, and accordingly, CADhighPOLD2high patients were associated with worse survival than CADhighPOLD2low and CADlowPOLD2high patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/817" target="_blank" rel="noopener noreferrer">817</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13557" target="_blank" rel="noopener noreferrer">Q13557</a>', 'HUGO Gene symbol': 'CAMK2D', 'Protein name': 'Calcium/calmodulin dependent protein kinase IIδ', 'Function': 'the regulation of Ca2+\xa0homeostasis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca2+\xa0influx\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Calcium signaling<br><br> Detox<br><br> Hypoxia signaling<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30127991%5Buid%5D" target="_blank" rel="noopener noreferrer">30127991</a>', 'Notes': '1) CAMK2D and SMARCA2 were identified as exhibiting increased expression in cisplatin-resistant cells. 2) Overexpression of either SMARCA2 or CAMK2D led to a significant increase in the survival rates of A2780 and SKVO3 cells following cisplatin treatment. 3) An increased mRNA level of CAMK2D was detected in samples with shorter RFS rates. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAMK2D" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/823" target="_blank" rel="noopener noreferrer">823</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07384" target="_blank" rel="noopener noreferrer">P07384</a>', 'HUGO Gene symbol': 'CAPN1', 'Protein name': 'Calpain-1 catalytic subunit', 'Function': 'Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28089626%5Buid%5D" target="_blank" rel="noopener noreferrer">28089626</a>', 'Notes': '1) Cisplatin induced endoplasmic reticulum stress, indicated by an increase in calcium staining. 2) calpain 1 inhibition by both specific siRNA and exogenous inhibitor (calpeptin) attenuated cisplatin-induced apoptosis in these cells. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAPN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/826" target="_blank" rel="noopener noreferrer">826</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04632" target="_blank" rel="noopener noreferrer">P04632</a>', 'HUGO Gene symbol': 'CAPNS1', 'Protein name': 'Calcium-activated neutral proteinase', 'Function': 'Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction; ubiquitous protease with potential involvement in apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18214855%2C%2028089626%2C%2030448882%2C%2027994509%5Buid%5D" target="_blank" rel="noopener noreferrer">18214855, 28089626, 30448882, 27994509</a>', 'Notes': '1) After cisplatin treatment, calpain was activated, resulting in Bid cleavage at 4-5 hr, followed by Bid translocation and cytochrome c release, leading to cell death in living human lung adenocarcinoma cells. 2) cisplatin induced ER stress, indicated by an increase in calcium staining and protein expression of Grp78 and calmodulin, followed by cleavage of α-fodrin and caspase-12 and, eventually, apoptosis. 3) calpain 1 inhibition by both specific small interfering RNA and exogenous inhibitor (calpeptin) attenuated cisplatin-induced apoptosis in these cells. 4) MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAPNS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/29775" target="_blank" rel="noopener noreferrer">29775</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BWT7" target="_blank" rel="noopener noreferrer">Q9BWT7</a>', 'HUGO Gene symbol': 'CARD10', 'Protein name': 'Caspase recruitment domain-containing protein 10', 'Function': 'Activates NF-kappa-B via BCL10 and IKK.', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24833094%5Buid%5D" target="_blank" rel="noopener noreferrer">24833094</a>', 'Notes': '1) CARMA3 overexpression shown in 52 of 101 ovarian cancer specimens. 2) CARMA3 overexpression positively correlated with tumor histology and advanced FIGO stage. 3) CARMA3 depletion in ovarian cancer cell lines A2780 and HO8910 inhibited ovarian cancer cell proliferation and blocked cell cycle progression. 4) CARMA3 depletion also sensitized ovarian cancer cells to cisplatin-induced cytotoxicity. 5) Western blot showed that CARMA3 depletion downregulated cyclin D1, cyclin E, and Bcl-2 levels. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CARD10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/100506742" target="_blank" rel="noopener noreferrer">100506742</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6UXS9" target="_blank" rel="noopener noreferrer">Q6UXS9</a>', 'HUGO Gene symbol': 'CASP12', 'Protein name': 'Inactive caspase-12', 'Function': 'No protease activity; endoplasmic reticulum (ER)-specific caspase; reduces activation of NFkB', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ER stress response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15901768%5Buid%5D" target="_blank" rel="noopener noreferrer">15901768</a>', 'Notes': '1) Pig kidney LLC-PK1 cells that were transfected with anti-caspase 12 antibody significantly attenuated cisplatin-induced apoptosis.\xa02) the interaction of cisplatin with the ER cytochrome P450 leads to activation of procaspase 12, resulting in apoptosis. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP12" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23581" target="_blank" rel="noopener noreferrer">23581</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31944" target="_blank" rel="noopener noreferrer">P31944</a>', 'HUGO Gene symbol': 'CASP14', 'Protein name': 'Caspase-14', 'Function': 'Non-apoptotic caspase involved in epidermal differentiation. Binds to AIF and interferes with AIF nuclear translocation', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21567094%5Buid%5D" target="_blank" rel="noopener noreferrer">21567094</a>', 'Notes': '1) Casp-14 overexpression correlated with tumor stage, cell differentiation and lymphovascular involvement. 2) ectopic expression of casp-14 decreased cisplatin-mediated cell killing. 3) silencing of casp-14 expression increased cisplatin sensitivity. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP14" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/835" target="_blank" rel="noopener noreferrer">835</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42575" target="_blank" rel="noopener noreferrer">P42575</a>', 'HUGO Gene symbol': 'CASP2', 'Protein name': 'Caspase-2', 'Function': 'Involved in the activation cascade of caspases responsible for apoptosis execution.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11703590%2C%2030816202%2C%209787143%5Buid%5D" target="_blank" rel="noopener noreferrer">11703590, 30816202, 9787143</a>', 'Notes': '1) overexpression of miR-494 promoted the proliferation and colony formation of NSCLC cells and reduced their sensitivity to cisplatin-induced apoptosis. 2) caspase-2 (CASP2) is a functional target of miR-494, and the expression of CASP2 is inversely associated with miR-494\xa0in vitro. 3) miR-494 promoted the proliferation and colony formation of NSCLC cells and reduced their sensitivity to cisplatin-induced apoptosis by targeting CASP2.\xa04) Although uncleaved caspase 2 level per se had no prognostic significance for AML, the interactive effect of high levels of both uncleaved caspase 2 and 3 denoted very poor survival (P < .001) and had the largest effect of all prognostic variables (P < .001; estimated relative risk, 2.49; 95% confidence interval, 1.59 to 3. 90). ', 'Up / down in Pt-resistant cells': 'UNCLEAVED', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/836" target="_blank" rel="noopener noreferrer">836</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42574" target="_blank" rel="noopener noreferrer">P42574</a>', 'HUGO Gene symbol': 'CASP3', 'Protein name': 'Caspase-3', 'Function': 'The downstream apoptosis executioner caspase-3 cleaves many substrates including DNA repair enzyme PARP.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11703590%2C%2027384994%2C%209787143%5Buid%5D" target="_blank" rel="noopener noreferrer">11703590, 27384994, 9787143</a>', 'Notes': '1) The activation of initiator caspases-8, -9 and -2, and executioner caspase-3 began after eight hours of cisplatin treatment, thereafter markedly increased in a time and dose-dependent manner. 2) Inhibition of caspase-3 by over expressing cowpox virus p35 protein or alternatively by the peptide inhibitor DEVD-CHO provided marked protection against cell death and partial protection against DNA damage. 3) Of 1,065 gastric carcinoma samples, high expression of CASP3 (HR = 0.5, p = 6E-14) correlated to longer OS. 4) When the effect of each uncleaved caspase was considered individually, a high level of uncleaved caspase 3 (P = .04), but not of caspase 2 (P = .16), was associated with decreased survival. ', 'Up / down in Pt-resistant cells': 'DOWN/UNCLEAVED', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/837" target="_blank" rel="noopener noreferrer">837</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49662" target="_blank" rel="noopener noreferrer">P49662</a>', 'HUGO Gene symbol': 'CASP4', 'Protein name': 'Caspase-4', 'Function': 'Essential effector of NLRP3 inflammasome-dependent CASP1 activation and IL1B and IL18 secretion in response to non-canonical activators, such as UVB radiation, cholera enterotoxin subunit B and cytosolic LPS', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ER stress response<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18842681%2C%2016357177%5Buid%5D" target="_blank" rel="noopener noreferrer">18842681, 16357177</a>', 'Notes': '1)\xa0activation of the unfolded protein response (UPR) is involved in resistance of melanoma cells to cisplatin, 2) this is associated with glucose-regulated protein 78 (GRP78)-mediated inhibition of activation of caspase-4 and -7. 3) The UPR was constitutively activated in cultured melanoma cell lines and fresh melanoma isolates as evidenced by elevated expression levels of the GRP78 protein and the active form of x-box-binding protein 1 messenger RNA. 4) Treatment with CDDP further increased the levels, indicative of induction of endoplasmic reticulum stress and activation of the UPR by the drugs. 5) Inhibition of GRP78 by siRNA-sensitized melanoma cells to CDDP. 6) This was associated with enhanced caspase-4 and -7 activation as siRNA knockdown of the caspases blocked induction of apoptosis. 7) overexpression of GRP78 attenuated activation of caspase-4 and -7 and induction of apoptosis by the drugs. 8) CDDP induced activation of caspase-4 and -7 appeared to be mediated by calpain activity in that it was blocked by the calpain inhibitors calpeptin and PD150606 even when GRP78 was inhibited by siRNA.\xa09) A peptide inhibitor or siRNA-mediated silencing of caspase-4 attenuated cell death, confirming that ER stress played an important role in cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/839" target="_blank" rel="noopener noreferrer">839</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P55212" target="_blank" rel="noopener noreferrer">P55212</a>', 'HUGO Gene symbol': 'CASP6', 'Protein name': 'Caspase-6', 'Function': 'Involved in the activation cascade of caspases responsible for apoptosis execution. Cleaves PARP in vitro, as well as lamins.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18064040%5Buid%5D" target="_blank" rel="noopener noreferrer">18064040</a>', 'Notes': '1) The executioner caspase-6 and -7 were identified as transcriptional targets of p53 in cisplatin injury. 2) Treatment of p53 (-/-) cells with cisplatin did not induce caspase-6 and -7 expression and subsequent activation. 3) In caspase-3 (-/-) cells, inhibition of caspase-6 and -7 activations markedly prevented cisplatin-induced cell death. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/840" target="_blank" rel="noopener noreferrer">840</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P55210" target="_blank" rel="noopener noreferrer">P55210</a>', 'HUGO Gene symbol': 'CASP7', 'Protein name': 'Caspase-7', 'Function': "Activation cascade of caspases. Cleaves and activates SREBPs; cleaves PARP at a '216-Asp-|-Gly-217' bond. ", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18064040%2C%2022986525%5Buid%5D" target="_blank" rel="noopener noreferrer">18064040, 22986525</a>', 'Notes': '1) The executioner caspase-6 and -7 were identified as transcriptional targets of p53 in cisplatin injury. 2) Treatment of p53 (-/-) cells with cisplatin did not induce caspase-6 and -7 expression and subsequent activation. 3) In caspase-3 (-/-) cells, inhibition of caspase-6 and -7 activations markedly prevented cisplatin-induced cell death. 4) caspase-7 is down-regulated in primary prostate tumors and metastatic lesions across multiple datasets and is by itself associated with disease recurrence and disease-specific survival. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/841" target="_blank" rel="noopener noreferrer">841</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14790" target="_blank" rel="noopener noreferrer">Q14790</a>', 'HUGO Gene symbol': 'CASP8', 'Protein name': 'Caspase-8', 'Function': 'Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21487429%2C%2014695141%5Buid%5D" target="_blank" rel="noopener noreferrer">21487429, 14695141</a>', 'Notes': '1) CDDP-resistant ovarian cancer CP70 cells expressed less caspase 8 protein, whereas mRNA levels were similar compared with A2780. 2) Pre-exposure of particularly CP70 to cisplatin resulted in strongly elevated caspase 8 protein and mRNA levels. 3) Cisplatin-induced caspase 8 protein levels were essential for the rhTRAIL-sensitising effect as demonstrated using caspase 8 small-interfering RNA (siRNA) and caspase-8 overexpressing constructs. 4) Weak expression of caspase-8 was an independent significant prognostic factor for unfavorable progression-free survival outcome of medulloblastoma (MB) and was more predictive than standard clinical factors. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/842" target="_blank" rel="noopener noreferrer">842</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P55211" target="_blank" rel="noopener noreferrer">P55211</a>', 'HUGO Gene symbol': 'CASP9', 'Protein name': 'Caspase-9', 'Function': 'Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Promotes DNA damage-induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12543167%2C%2010680594%2C%2027935869%5Buid%5D" target="_blank" rel="noopener noreferrer">12543167, 10680594, 27935869</a>', 'Notes': '1) Following cisplatin treatment, protelyzed Casp9 subunits were detected in head and neck squamous cell carcinoma (HNSCCs) HSC-2 cells, but not detected in HSC-2CR. 2) Using a direct enzymatic assay measuring cleavage of the synthetic peptide substrate (LEHD-AFC), Casp9 activity in cisplatin-treated HSC-2CR was less than that in cisplatin-treated HSC-2.\xa03) the use of a specific inhibitor of Casp-9 almost completely blocked cisplatin-induced apoptosis. 4) The active cleaved form of caspase9 (caspase 9s) was detected in PEO1 cells but not in PEO4 cells, and this was elevated in the presence of cisplatin. ', 'Up / down in Pt-resistant cells': 'UNCLEAVED', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP/CLEAVED', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CASP9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/857" target="_blank" rel="noopener noreferrer">857</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q03135" target="_blank" rel="noopener noreferrer">Q03135</a>', 'HUGO Gene symbol': 'CAV1', 'Protein name': 'Caveolin-1', 'Function': 'scaffolding protein within caveolar membranes; regulates CTNNB1-mediated Wnt pathway. Negatively regulates TGFB1-mediated activation of SMAD2/3 by mediating the internalization of TGFBR1 from membrane rafts leading to its subsequent degradation ', 'Putative_mechanism_associated_with_Pt_resistance': 'Notch signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26503358%5Buid%5D" target="_blank" rel="noopener noreferrer">26503358</a>', 'Notes': '1) the mRNA and protein expression levels of Cav-1 were significantly higher in ovarian caner cell lines SKOV3/DDP and A2780/DDP than in SKOV3 and A2780, respectively. 2) Knockdown of Cav-1 significantly decreased the IC50 value in cisplatin-resistant cells. 3) knockdown of Cav-1 could significantly enhance cisplatin induced cell apoptosis. 4) knockdown of Cav-1 significantly downregulate the protein expression level of Notch-1, p-Akt and p-NF-κB p65 in cisplatin-resistant ovarian cancer cells. 4) Overexpression of Cav-1 upregulated the IC50 value, but under the effect of Notch-1 siRNA or LY294002 or PDTC, the IC50 value was markedly decreased.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAV1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/112464" target="_blank" rel="noopener noreferrer">112464</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q969G5" target="_blank" rel="noopener noreferrer">Q969G5</a>', 'HUGO Gene symbol': 'CAVIN3', 'Protein name': 'Caveolae-associated protein 3 / Protein kinase C delta-binding protein', 'Function': 'Required for the formation of caveolae in smooth muscle. Regulates the circadian clock; activates the mTOR signaling pathway (32352004); interacts with PP1-α and the product functions in cell apoptosis (31332168); ROR1-Cavin3 interaction is a necessity for caveola-dependent endocytosis and prosurvival signaling on the cell surface (30894682)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32945503%5Buid%5D" target="_blank" rel="noopener noreferrer">32945503</a>', 'Notes': '1) a significantly lower expression level of PRKCDBP was expressed in the A549/DDP cell line and LAD tissues than that in A549 cells and adjacent cancer tissues. 2) while the DNMT1 mRNA level was remarkably increased and the promoter of PRKCDBP was hypermethylated in the A549/DDP cell line. 3) When PRKCDBP was overexpressed, the DNMT1 mRNA level was markedly decreased, the rate of proliferation, IC50 of cisplatin, G2/M phase and S phase cells were obviously reduced, while G0/G1 phase cells, apoptosis distinctly increased, but migration ability did not significantly change. 4) TNF‑α overexpression resulted in an increase of PRKCDBP mRNA level, while TNF‑α siRNA led to PRKCDBP mRNA level distinctly reduced. 7) Overexpression of DNMT1 improved IC50 in A549 cells.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CAVIN3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/875" target="_blank" rel="noopener noreferrer">875</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35520" target="_blank" rel="noopener noreferrer">P35520</a>', 'HUGO Gene symbol': 'CBS', 'Protein name': 'Cystathionine beta-synthase', 'Function': 'Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30458366%2C%2024236104%5Buid%5D" target="_blank" rel="noopener noreferrer">30458366, 24236104</a>', 'Notes': '1) Cystathionine β-synthase (CBS) is overexpressed in ovarian cancer tissues and is itself associated with cisplatin resistance. 2) Treatment with exogenous carbon monoxide (CO), a known inhibitor of CBS, as well as and lentiviral-mediated silencing, mitigate cisplatin resistance in ovarian cancer cells by attenuation of GSH and MT levels. 3) Cisplatin-resistant cells, treated with both cisplatin and CO, exhibited significantly lower cell viability versus those treated with cisplatin alone. 4) the effects of CO in circumventing chemotherapeutic drug resistance is at least in part mediated by the inactivation of endogenous CBS. 5) The in vitro effects of CBS silencing can be reversed by exogenous supplementation with the GSH and H2S producing chemical Na2S. 6) Silencing CBS in a cisplatin resistant orthotopic model in vivo by siRNA inhibits tumor growth, reduces nodule formation and sensitizes ovarian cancer cells to cisplatin. 7) CBS also regulates bioenergetics of ovarian cancer cells by regulating mitochondrial ROS production, oxygen consumption and ATP generation. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CBS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26112" target="_blank" rel="noopener noreferrer">26112</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/A6NI79" target="_blank" rel="noopener noreferrer">A6NI79</a>', 'HUGO Gene symbol': 'CCDC69', 'Protein name': 'Coiled-coil domain-containing protein 69', 'Function': 'Required for the localization of AURKB and PLK1 to the spindle midzone; a regulator for DNA replication (16441230); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29254192%2C%2030651135%5Buid%5D" target="_blank" rel="noopener noreferrer">29254192, 30651135</a>', 'Notes': '1) CCDC69 expression was significantly elevated in the cisplatin-resistant A2780cis cells than the cisplatin-sensitive A2780 cells. 2) stable CCDC69 knockout A2780cis and SKOV3 cells were more sensitive to cisplatin than their corresponding wildtype cells. 3) inhibition of CCDC69 expression abrogated the G1 and G2/M arrest. 4) exposure to cisplatin after depletion of CCDC69 increased mitochondrial injury and upregulated p53 acetylation. 5) the cisplatin induced cytotoxicity is related to reduced c-Myc protein expression. 6) CCDC69 expression was significantly higher in cisplatin-sensitive groups compared with chemo-resistant groups from TCGA database. 7) High CCDC69 expression was associated longer survival. 8) CCDC69 overexpressing 293 and A2780 cells with wildtype p53 and contributes to cisplatin sensitivity following treatment with cisplatin.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCDC69" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6347" target="_blank" rel="noopener noreferrer">6347</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13500" target="_blank" rel="noopener noreferrer">P13500</a>', 'HUGO Gene symbol': 'CCL2', 'Protein name': 'C-C motif chemokine 2', 'Function': 'Regulates migration and infiltration of monocytes/macrophages which then become TAMs (Tumor Associated Macrophages) in the tumor microenvironment. ', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24816187%2C%2026629063%5Buid%5D" target="_blank" rel="noopener noreferrer">24816187, 26629063</a>', 'Notes': '1) Elevated CCL2 expression was found in three non‐MDR paclitaxel resistant ovarian cancer lines ES‐2/TP, MES‐OV/TP and OVCAR‐3/TP, compared to parental cells. 2) Mice xenografted with these cells were treated with the anti‐human CCL2 antibody CNTO 888 and the anti‐mouse MCP‐1 antibody C1142, with and without paclitaxel or carboplatin: an additive effect of CCL2 blockade on the efficacy of paclitaxel and carboplatin. 3) This therapeutic effect was largely due to inhibition of mouse stromal CCL2. 4) a low expression of CCL2 was associated with better outcome in breast cancer patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCL2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6370" target="_blank" rel="noopener noreferrer">6370</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15444" target="_blank" rel="noopener noreferrer">O15444</a>', 'HUGO Gene symbol': 'CCL25', 'Protein name': 'C-C motif chemokine 25', 'Function': 'Binds to CCR9.\xa0Potentially involved in T-cell development. CCR9 signalling facilitates immature T cell survival through 1) PI3K/Akt signaling; 2) FAK phosphorylation via FAK-Akt signaling. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20565782%2C%2025296976%5Buid%5D" target="_blank" rel="noopener noreferrer">20565782, 25296976</a>', 'Notes': '1) CCL25-CCR9 interactions in OvCa cells increased anti-apoptotic signaling cascades in OvCa cells, which rescued cells from cisplatin-induced cell death. 2) CCL25-CCR9 interactions mediated Akt, activation as well as GSK-3β and FKHR phosphorylation in a PI3K-dependent and FAK-independent fashion. 3) Expression of CCR9 and CCL25 was significantly higher (p < 0.0001) in NSCLC tissues and serum respectively. 4) expression of both CCR9 and CCL25 was significantly higher in adenocarcinomas (ACs) compared to squamous cell carcinomas (SCCs) (p = 0.04, and p < 0.0001). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCL25" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6352" target="_blank" rel="noopener noreferrer">6352</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13501" target="_blank" rel="noopener noreferrer">P13501</a>', 'HUGO Gene symbol': 'CCL5', 'Protein name': 'C-C motif chemokine 5', 'Function': 'Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26983899%5Buid%5D" target="_blank" rel="noopener noreferrer">26983899</a>', 'Notes': '1) the cisplatin-induced CCL5 secretion derived from cancer-associated fibroblasts (CAFs) promoted ovarian cancer cell resistance to cisplatin. 2) Via a cytokine chip assay, a spectrum of secreted proteins that were derived from the CAFs were induced by cisplatin. 3) Among these, CCL5 significantly attenuated the cytotoxic effect of cisplatin chemotherapy in vitro and in vivo. 4) CCL5 expression was also detected in 62 serous ovarian cancer patient tissue specimens using IHC: chemotherapy resistant patients displayed higher expression of CCL5 than the chemo-sensitive patients (P<0.05). 5) CCL5 notably increased STAT3 and Akt phosphorylation levels in ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCL5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3491" target="_blank" rel="noopener noreferrer">3491</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00622" target="_blank" rel="noopener noreferrer">O00622</a>', 'HUGO Gene symbol': 'CCN1', 'Protein name': 'Cysteine-rich 61', 'Function': 'A member of the connective tissue growth factor CCN family, facilitates angiogenesis by interacting with integrins. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18800188%2C%2011751417%5Buid%5D" target="_blank" rel="noopener noreferrer">18800188, 11751417</a>', 'Notes': '1) overexpressed or inhibited CYR61\xa0expression\xa0in human cervical cancer cells (HeLa cells): CYR61 prevents cisplatin-induced apoptosis by inhibiting caspase-3 activity in HeLa cells.\xa02) Overexpression of CTGF, WISP-1, CYR61, and NOVH was found in 55 (24 of 44), 46 (20 of 44), 39 (17 of 44), and 11% (5 of 44) primary breast tumors, respectively. 3) significant associations were found between CYR61 expression and stage, tumor size, lymph node, age, and estrogen receptor expression. 4) Among the 20 cases of paired normal and tumour tissues, Cyr61 expression was associated with statistically significant colorectal cancer-specific mortality (p\u2009=\u20090.029). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1490" target="_blank" rel="noopener noreferrer">1490</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29279" target="_blank" rel="noopener noreferrer">P29279</a>', 'HUGO Gene symbol': 'CCN2', 'Protein name': 'CCN family member 2', 'Function': 'Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates cellular migration, adhesion, proliferation, ECM formation, and regulation of tumorigenesis; interacts with integrin to regulate a number of biological functions (20376786)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24637722%5Buid%5D" target="_blank" rel="noopener noreferrer">24637722</a>', 'Notes': '1) CCN2 was upregulated in human osteosarcoma cells after treatment with cisplatin. 2) overexpression of CCN2 increased the resistance to cisplatin-mediated cell apoptosis. 3) reduction of CCN2 by CCN2 shRNA promoted the chemotherapeutic effect of cisplatin. 4) CCN2 provided resistance to cisplatin-induced apoptosis through upregulation of Bcl-xL and survivin. 5) Knockdown of Bcl-xL or survivin removed the CCN2-mediated resistance to apoptosis induced by cisplatin. 6) CCN2 also promoted FAK, MEK, and ERK survival signaling pathways to enhance tumor survival during cisplatin treatment. 7) In a mouse xenograft model, overexpression of CCN2 promoted resistance to cisplatin. However, knockdown of CCN2 increased the therapeutic effect of cisplatin.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCN2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/890" target="_blank" rel="noopener noreferrer">890</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P20248" target="_blank" rel="noopener noreferrer">P20248</a>', 'HUGO Gene symbol': 'CCNA2', 'Protein name': 'Cyclin-A2', 'Function': 'Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29207607%2C%2019583808%5Buid%5D" target="_blank" rel="noopener noreferrer">29207607, 19583808</a>', 'Notes': '1) loss of cyclin A2 causes high rates of double-strand breaks (DSB) in MCF-7 and MDA-MB-231 cells. 2) The increased DSB was due to defective HR-mediated repair of the breaks, resulting from reduced\xa0MRE11\xa0and RAD51 proteins. 3) Cyclin A2 mediates\xa0MRE11\xa0abundance through its\xa0MRE11\xa0mRNA binding property and RAD51 abundance through inhibition of proteasome degradation of RAD51. 4) cyclin A2 depletion hypersensitized the cells to DNA damaging agents, such as\xa0cisplatin\xa0and melphalan.\xa05) overexpression of cyclin A2 is an indicator of a poor prognosis of various malignancies including endometrial carcinoma. 6) The expression of cyclin A2 protein was increased in advanced-stage and chemotherapy-refractory stage endometrial carcinomas compared with that in early-stage tumours. 7) The expression levels of cyclin A2 in endometrial carcinoma cell lines correlated positively with the IC(50) for cisplatin. Endometrial carcinoma HHUA cells that overexpressed cyclin A2 showed increased resistance to cisplatin in vitro and in vivo, 8) via the activation of a survival pathway, the inositol-3 phosphate kinase (PI3K) cascade. 5) An Akt-binding protein, periplakin, is a novel target of cyclin A2.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCNA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/595" target="_blank" rel="noopener noreferrer">595</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P24385" target="_blank" rel="noopener noreferrer">P24385</a>', 'HUGO Gene symbol': 'CCND1', 'Protein name': 'G1/S-specific cyclin-D1', 'Function': 'Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20395447%5Buid%5D" target="_blank" rel="noopener noreferrer">20395447</a>', 'Notes': '1) CCND1 was the most significantly differentially expressed gene when comparing the parental and CDDP-resistant testicular germ cell tumor cells. 2) CCND1 was also found to be dramatically overexpressed both in induced and intrinsically resistant samples of ovarian and prostate cancer. 3) combined CCND1 knockdown using small-interfering RNA and cisplatin treatment inhibited cell growth in vitro significantly more effectively than any of these single treatments. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCND1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/898" target="_blank" rel="noopener noreferrer">898</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P24864" target="_blank" rel="noopener noreferrer">P24864</a>', 'HUGO Gene symbol': 'CCNE1', 'Protein name': 'G1/S-specific cyclin-E1', 'Function': 'Essential for the control of the cell cycle at the G1/S (start) transition. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21103391%2C%2016572426%5Buid%5D" target="_blank" rel="noopener noreferrer">21103391, 16572426</a>', 'Notes': '1) Genomic amplification of 19q12 occurs in several cancer types including ovarian cancer where it is associated with primary treatment failure. 2) We systematically attenuated expression of genes within the minimally defined 19q12 region in ovarian cell lines using siRNA to identify driver oncogene(s) within the amplicon.\xa03) Knockdown of CCNE1 resulted in G1/S phase arrest, reduced cell viability and apoptosis only in amplification-carrying cells. 4) Although CCNE1 knockdown increased cisplatin resistance in short-term assays, clonogenic survival was inhibited after treatment. 5) Significant differences in Ccne1 and Ran expression were observed in a comparison of low malignant potential and grade 1 tumor samples (p<0.01). 6) irrespective of the grade, Ccne1, Ran, Cdc20 and Cks1 showed significant differences of expression in association with the clinical stage of disease. 7) While high level of Ccne1 have previously been associated with poor outcomes, here we found that high level of either Ran or Cdc20 appear to be more tightly associated with a poor prognosis (p<0.001, 0.03, respectively). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCNE1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10983" target="_blank" rel="noopener noreferrer">10983</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14094" target="_blank" rel="noopener noreferrer">Q14094</a>', 'HUGO Gene symbol': 'CCNI', 'Protein name': 'Cyclin I', 'Function': 'Cyclin I has a cyclin box motif; oscillates during the cell cycle; involved in cell survival, angiogenesis, and cell differentiation; interacts with CDK5 (23907122); Cyclin I and p35 determine the subcellular distribution of Cdk5 (25500740).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26698249%5Buid%5D" target="_blank" rel="noopener noreferrer">26698249</a>', 'Notes': '1) high level of cyclin I was associated with cisplatin resistance in CC. 2) cyclin I protein becomes highly expressed in human CC patients resistant to cisplatin chemotherapy. 3) Stable overexpressed cyclin I promotes Hela cell resistance to higher concentrations of cisplatin. 4) upregulated level of cyclin I increased tumor cells growth in vitro and enhanced tumor resistance to cisplatin in vivo. 5) cyclin I upregulated the expression of cyclin-dependent kinase 5 (Cdk5) promoting cisplatin resistance by preventing apoptosis in CC cell line. 6) the cyclin I overexpressed Hela cell lines produce increased sensitivity to cisplatin treatment through knockdown of Cdk5 protein with siRNA.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCNI" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10803" target="_blank" rel="noopener noreferrer">10803</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51686" target="_blank" rel="noopener noreferrer">P51686</a>', 'HUGO Gene symbol': 'CCR9', 'Protein name': 'C-C chemokine receptor type 9', 'Function': 'Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20565782%2C%2021637913%5Buid%5D" target="_blank" rel="noopener noreferrer">20565782, 21637913</a>', 'Notes': '1) CCL25-CCR9 interactions in OvCa cells increased anti-apoptotic signaling cascades in OvCa cells, which rescued cells from cisplatin-induced cell death. 2) CCL25-CCR9 interactions mediated Akt, activation as well as GSK-3β and FKHR phosphorylation in a PI3K-dependent and FAK-independent fashion. 3) significantly higher (p<0.001) expression of CCR9 and CCL25 in serous adenocarcinoma followed by serous papillary cystadenoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, cystadenoma, mucinous boderline adenocarcinoma, clear cell carcinoma, granulosa cell tumor, dysgerminoma, transitional cell carcinoma, Brenner tumor, yolk sac tumor, adenocarcinoma and fibroma cases, compared to non-neoplastic ovarian tissue. 4) Similar to tissue expression, CCR9 was also significantly expressed by the ovarian cancer cell lines (OVCAR-3 and SK-OV-3) in comparison to normal adult ovarian epithelial cell. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCR9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/100133941" target="_blank" rel="noopener noreferrer">100133941</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25063" target="_blank" rel="noopener noreferrer">P25063</a>', 'HUGO Gene symbol': 'CD24', 'Protein name': 'Cluster of differentiation (CD) 24', 'Function': 'A small, heavily glycosylated mucin-like cell surface protein, the molecule functionally enhances the metastatic potential of cancer cells', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28440503%2C%2027276062%5Buid%5D" target="_blank" rel="noopener noreferrer">28440503, 27276062</a>', 'Notes': '1) CD24 was expressed in 70.1% of primary ovarian carcinoma tissues, which were obtained from 174 patients, 2) the expression of CD24 was an independent predictor of survival in patients with ovarian cancer who received 6-course conventional TC (paclitaxel and carboplatin) therapies. 3) CD24 induces the EMT phenomenon, which is involved in cell invasion, the highly proliferative phenotype, colony formation and which is associated with cisplatin resistance and the properties of CSCs, via the activation of PI3K/Akt, NF-κB and ERK in Caov-3 cisplatin-resistant cell lines. 4) CD24 expression level appears to be a significant molecular phenotype of cisplatin-resistant residual cells in laryngeal carcinoma lines. 5) CD24 expression level directly affects cisplatin sensitivity and affects the expression of critical apoptotic, stem and drug resistance genes. 6) A relatively small retrospective patient tumor analysis suggests that CD24 high tumors go on to show an unfavorable response to cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD24" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/29126" target="_blank" rel="noopener noreferrer">29126</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NZQ7" target="_blank" rel="noopener noreferrer">Q9NZQ7</a>', 'HUGO Gene symbol': 'CD274', 'Protein name': 'Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1', 'Function': 'Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32024543%2C%2025597412%2C%2030808674%5Buid%5D" target="_blank" rel="noopener noreferrer">32024543, 25597412, 30808674</a>', 'Notes': '1) PD-L1 expression was significantly increased in A549/CDDP, MCF7/ADR and HepG2/ADR cells and was attributed mainly to enhanced JNK/c-Jun signaling activation. 2) Mechanistically, decreased COP1 increased c-Jun accumulation, which subsequently inhibited HDAC3 expression and thereby enhanced histone H3 acetylation of the PD-L1 promoter. 3)  PD-L1 expression could be inhibited by JNK/c-Jun inhibition or HDAC3 overexpression in vivo, which could largely reverse inhibited CD3+\xa0T cell proliferation in vitro. 4) PD-L1 expression was significantly increased in the cisplatin-resistant clinical NSCLC samples and positively correlated with c-Jun expression but negatively correlated with HDAC3 expression. 5) PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK/STAT3 signaling pathway in bladder cancer to regulate glucose metabolism and cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD274" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/958" target="_blank" rel="noopener noreferrer">958</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25942" target="_blank" rel="noopener noreferrer">P25942</a>', 'HUGO Gene symbol': 'CD40', 'Protein name': 'Tumor necrosis factor receptor superfamily member 5', 'Function': 'Receptor for CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate macrophages and B cells. Also expressed on the surfaces of a variety of malignant cells.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27044825%2C%2022010829%2C%2024885116%5Buid%5D" target="_blank" rel="noopener noreferrer">27044825, 22010829, 24885116</a>', 'Notes': '1) sCD40L showed a significant dose-dependence inhibitory effect on the proliferation of ovarian cancer cell lines. 2) sCD40L in combination with cisplatin could sensitized SKOV3/DDP cells to cisplatin treatment and reversed the drug resistance of SKOV3/DDP cells. 3) Activation of CD40 by rsCD40L induces two phases of autocrine TNF-α: the rapid early phase involving p38 MAP kinase and the robust and persistent late phase through enhanced tnf-α gene transcription. 4) Blocking TNF-α with either a specific TNFR1 siRNA or a neutralizing anti-TNF-α antibody dramatically attenuated the potentiation effect of rsCD40L on cisplatin-induced cancer cell death. 5) Positive CD40 mutant expression suggests a poorer prognosis of gastric cancer cases.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD40" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/959" target="_blank" rel="noopener noreferrer">959</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29965" target="_blank" rel="noopener noreferrer">P29965</a>', 'HUGO Gene symbol': 'CD40LG', 'Protein name': 'CD40 ligand', 'Function': 'Cytokine that binds to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production.\xa0A member of the TNF superfamily.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27044825%2C%2022010829%2C%2024885116%5Buid%5D" target="_blank" rel="noopener noreferrer">27044825, 22010829, 24885116</a>', 'Notes': 'Same as CD40', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD40LG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/960" target="_blank" rel="noopener noreferrer">960</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16070" target="_blank" rel="noopener noreferrer">P16070</a>', 'HUGO Gene symbol': 'CD44', 'Protein name': 'CD44 antigen', 'Function': 'Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22498306,29385995,31953176" target="_blank" rel="noopener noreferrer">22498306, 29385995, 31953176</a>', 'Notes': "1) miR-199a targets CD44 via an miR-199a-binding site in the 3'-UTR; CD44 mRNA and protein expression was significantly decreased in miR-199a-transfected ovarian CICs. 3) miR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin, pacitaxel, and adriamycin, and reduced mRNA expression of the multidrug resistance gene ABCG2. 4) xenograft experiments confirmed that miR-199a suppressed the growth of xenograft tumors formed by ovarian CICs in vivo. 5) the CD44 variant isoform CD44v9 positivity was an independent risk factor of cancer-specific survival (P = 0.024, hazard ratio = 5.16) in urothelial cancer patients who had recurrence and/or metastasis and received cisplatin-based chemotherapy. 6) The expression of CD44v8-10 and xCT was stronger in urothelial cancer cisplatin-resistant T24PR cells than in T24 cells. The amount of intracellular glutathione was significantly higher in T24PR cells than in T24 cells, and intracellular ROS production by cisplatin was lower in T24PR cells than in T24 cells. 7) the knockdown of CD44v8-10 by siRNA led to the recovery of cisplatin sensitivity in T24PR cells. 8) increased expression of CD44 in the cut margin of recurrent HNSCC patients were associated with poor prognosis. 9) inhibition of CD44 by using 1,2,3,4 tetrahydroisoquinoline (THIQ) modulates the expression of Wnt/ β-catenin signaling proteins and further silencing of β-catenin also decreases the expression of CD44. 10) inhibition of CD44 chemosensitizes cisplatin-resistant HNSCC cells towards cisplatin. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD44" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1604" target="_blank" rel="noopener noreferrer">1604</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08174" target="_blank" rel="noopener noreferrer">P08174</a>', 'HUGO Gene symbol': 'CD55', 'Protein name': 'Complement decay-accelerating factor', 'Function': 'A glycoprotein involved in the regulation of the complement cascade.\xa0Binding to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28838952%5Buid%5D" target="_blank" rel="noopener noreferrer">28838952</a>', 'Notes': "1) CD55 was highly expressed in endometrioid ovarian and uterine CSCs and cisplatin-resistant cells. 2) Patients with high tumor CD55 expression at diagnosis had significantly worse progression-free survival compared with patients with low CD55 levels (hazard ratio 4.7, confidence interval 1.5–14.6, P = 0.003). 3) Upon CD55 inhibition, the core pluripotency transcription factors' (NANOG, SOX2, and OCT4) expression was inhibited at the RNA and protein levels. 4) CD55-silenced CSCs from cisplatin-naive cells lines (A2780, TOV112D) and Mouse experiment cells (EEC-4) had significantly higher sensitivity to cisplatin and lower survival rates at cisplatin doses from 2.5 to 50 µM, compared with nontargeted control cells. 5) CD55 inhibition led to increased sensitivity to cisplatin in cisplatin-resistant CP70 and HEC1a cell lines. 6) Mice with CD55-silenced CSCs were more sensitive to cisplatin as compared with tumors originating from nontargeted CSC controls. 7) an increase in NANOG and SOX2 mRNA levels was observed upon CD55 overexpression. 8) CD55-overexpressing non-CSCs had significantly higher rates of survival and lower levels of caspase 3/7 activity upon cisplatin treatment compared with non-CSCs transduced with empty vector. 9) non-CSCs transduced with CD55 demonstrated active ROR2 and LCK signaling through LIME, these pathways were not induced in non-CSCs with TM-CD55. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD55" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/925" target="_blank" rel="noopener noreferrer">925</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01732" target="_blank" rel="noopener noreferrer">P01732</a>', 'HUGO Gene symbol': 'CD8A', 'Protein name': 'T-cell surface glycoprotein CD8 alpha chain', 'Function': 'serves as a\xa0co-receptor\xa0for the\xa0T cell receptor\xa0(TCR). Like the TCR, CD8 binds to a\xa0major histocompatibility complex\xa0(MHC) molecule, but is specific for the\xa0class I MHC\xa0protein. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM/stroma<br><br> Immune response<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27133165%5Buid%5D" target="_blank" rel="noopener noreferrer">27133165</a>', 'Notes': '1) Effector T cells and fibroblasts are major components in the tumor microenvironment. 2) the interaction between effector T cells and fibroblasts play a role in platinum-based chemoresistance and modulate chemotherapeutic response in patients with ovarian cancer. 3) fibroblasts diminish cisplatin accumulation in ovarian cancer cells by releasing GSH and cysteine. 4) stromal fibroblasts predict platinum-based therapeutic response and patient survival. 5) Intraepithelial and stromal CD8+ T cells correlate with improved survival in ovarian cancer. 6) CD8+ T cells can abolish fibroblast-mediated platinum resistance via IFNγ. 7) CD8+ T cells alter the metabolism of cystine and GSH in fibroblasts. 8) CD8+ T cell-derived IFNγ activates GGT and promotes extracellular GSH degradation and diminishes fibroblast cysteine generation through downregulation of system xc− cysteine and glutamate antiporter. 9) IFNγ-activated STAT1 binds to specific promoter region of xCT and rapidly inhibits xCT gene transcription through JAK-STAT1 signaling in fibroblasts but not in tumor cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': '', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD8A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/926" target="_blank" rel="noopener noreferrer">926</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10966" target="_blank" rel="noopener noreferrer">P10966</a>', 'HUGO Gene symbol': 'CD8B', 'Protein name': 'T-cell surface glycoprotein CD8 beta chain', 'Function': 'AS CD8A', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM/stroma<br><br> Immune response<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27133165%5Buid%5D" target="_blank" rel="noopener noreferrer">27133165</a>', 'Notes': 'AS CD8A', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': '', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD8B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11140" target="_blank" rel="noopener noreferrer">11140</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16543" target="_blank" rel="noopener noreferrer">Q16543</a>', 'HUGO Gene symbol': 'CDC37', 'Protein name': 'Hsp90 co-chaperone Cdc37', 'Function': 'Co-chaperone that binds to numerous kinases and promotes their interaction with the Hsp90 complex, resulting in stabilization and promotion of their activity. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18931700%2C%2029331417%20%5Buid%5D" target="_blank" rel="noopener noreferrer">18931700, 29331417¬†</a>', 'Notes': '1) silencing of CDC37 in human colon cancer cells diminished association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT.\xa02) Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by inhibition of the G1/S-phase transition. 3) Knockdown of FOSL1 and CDC37 in RIP3-KD cells induced cell death induced by different cisplatin concentrations. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDC37" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/998" target="_blank" rel="noopener noreferrer">998</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P60953" target="_blank" rel="noopener noreferrer">P60953</a>', 'HUGO Gene symbol': 'CDC42', 'Protein name': 'Cell division control protein 42 homolog', 'Function': 'Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Involved in epithelial cell polarization processes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25432132%2C%2020930109%5Buid%5D" target="_blank" rel="noopener noreferrer">25432132, 20930109</a>', 'Notes': '1) Direct regulation of miR-25 on its target gene, CDC42: The expression of miR-25 in NSCLC cells or human tissues was significantly higher than that in normal lung cells or adjacent non-cancerous tissues. 2)Downregulation of miR-25 markedly inhibited A549 cell proliferation, induced G1 cell cycle arrest, increased cisplatin sensitivity, and suppressed the growth of caner cell xenograft in vivo. 3) CDC42 was confirmed to be the directly regulated by miR-25 in A549 cells. Upregulation of CDC42 in A549 cells rescued the inhibitory effect on proliferation and the G1 cell cycle arrest induced by miR-25 downregulation.4) CTR2 regulates the transport of cDDP in part through control of the rate of macropinocytosis via activation of Rac1 and cdc42. \xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDC42" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8317" target="_blank" rel="noopener noreferrer">8317</a>', 'Uniprot_link': '<a href="http://www.uniprot.org/uniprot/O00311" target="_blank" rel="noopener noreferrer">O00311</a>', 'HUGO Gene symbol': 'CDC7', 'Protein name': 'Cell division cycle 7-related protein kinase', 'Function': 'Seems to phosphorylate critical substrates that regulate the G1/S phase transition and/or DNA replication', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30293817%2C%2026966728%2C%2025255219%2C%2029713760%5Buid%5D" target="_blank" rel="noopener noreferrer">30293817, 26966728, 25255219, 29713760</a>', 'Notes': '1) Cdc7 inhibitor dequalinium chloride and clofoctol sensitize the effect of platinum compounds and radiation due to synergistic effect. 2) A total of 18 significantly upregulated genes were detected in cisplatin resistant BC cell line T24R2, including PRKAR2A, PRKAR2B, CYCS, BCL2, BIRC3, DFFB, CASP6, CDK6, CCNE1, STEAP3, MCM7, ORC2, ORC5, ANAPC1, and ANAPC7, CDC7, CDC27, and SKP1. 3) miR-630 was highly expressed in A549 and NIH3T3 cells where CDC7 was downregulated, but lower in H1299, MCF7, MDA-MB-231, HeLa and 2BS cells where CDC7 was upregulated. 4) the induction of miR-630 occurred commonly in a variety of human cancer and immortalized cells in response to genotoxic agents. 5) downregulation of CDC7 by miR-630 was associated with cisplatin (CIS)-induced inhibitory proliferation in A549 cells. 6) There was a synergistic effect between CDC7 inhibitor XL413 and DNA-damaging agents (e.g. cisplatin and 5-fluorouracil) on OSCC in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDC7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64866" target="_blank" rel="noopener noreferrer">64866</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H5V8" target="_blank" rel="noopener noreferrer">Q9H5V8</a>', 'HUGO Gene symbol': 'CDCP1', 'Protein name': 'CUB-domain-containing protein 1', 'Function': 'a transmembrane glycoprotein that is widely expressed in epithelial cells as both full-length 135\u2009kDa and proteolytically processed 70\u2009kDa forms', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25893298%5Buid%5D" target="_blank" rel="noopener noreferrer">25893298</a>', 'Notes': '1) Disruption of CDCP1 via silencing and antibody-mediated inhibition markedly reduce the ability of TOV21G OCC cells to form intraperitoneal tumors and induce accumulation of ascites in mice. 2) CDCP1 effects are mediated via a novel mechanism of protein kinase B (Akt) activation. 3) CDCP1 is functionally important in OCC, with its expression elevated in 90% of 198 OCC tumors and increased CDCP1 expression correlating with poor patient disease-free and overall survival. 4) CDCP1 is largely restricted to the surface of malignant cells where it is accessible to therapeutic antibodies. 5) antibody-mediated blockade of CDCP1 in vivo significantly increased the anti-tumor efficacy of carboplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDCP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/999" target="_blank" rel="noopener noreferrer">999</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12830" target="_blank" rel="noopener noreferrer">P12830</a>', 'HUGO Gene symbol': 'CDH1', 'Protein name': 'Cadherin-1', 'Function': 'E-cadherin is a major component of tubular adherent proteins that maintain intercellular contacts and cell polarity in epithelial tissue. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29581579%2C%2030653577%2C%2015102685%5Buid%5D" target="_blank" rel="noopener noreferrer">29581579, 30653577, 15102685</a>', 'Notes': '1) Epithelial mesenchymal transition (EMT) and cancer stem cells (CSC) have been associated with resistance to chemotherapy. 2) Cisplatin reduced E-cadherin expression both in mouse kidney and proximal tubular epithelial cell lines (mTECs). 3) cisplatin-resistant ovarian cell line A2780cis cells differ from their cisplatin-sensitive counterparts in the CDH1 methylation. Methylation in A2780cis cells is elevated compared to A2780. 4) CDH1 promoter hypermethylation was found in 40 of 73 cases (54%), and it was significantly associated with worse prognosis of gastric cancer patients. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDH1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1000" target="_blank" rel="noopener noreferrer">1000</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P19022" target="_blank" rel="noopener noreferrer">P19022</a>', 'HUGO Gene symbol': 'CDH2', 'Protein name': 'Cadherin-2', 'Function': 'Calcium-dependent cell adhesion protein', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21618587%2C%2019190132%2C%2029731893%5Buid%5D" target="_blank" rel="noopener noreferrer">21618587, 19190132, 29731893</a>', 'Notes': '1) cisplatin-induced transition of EMT in residual cancer cells correlated with reduced E-cadherin, and increased N-cadherin and vimentin expression. 2) Expression of N-cadherin is preserved in cisplatin-resistant GCT\xa0cells, pointing to an important physiological role in cell survival. 3) N-cadherin-downregulation results in a significant decrease of proliferation, migration, and invasion and stimulates apoptosis in cisplatin-naive and resistant GCT cell lines.\xa04) Low expression of CDH2 (N-cadherin) correspond to high brain metastasis-free at 2 years after diagnosis in patients with more advanced lung cancer. 5) These results were confirmed by immunohistochemical detection of N-cadherin in independent cohort of primary NSCLC. 6) Patients with low CDH2 expression had an improved prognosis and benefited from temozolomide therapy in glioblastoma. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNCHANGED', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDH2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51755" target="_blank" rel="noopener noreferrer">51755</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NYV4" target="_blank" rel="noopener noreferrer">Q9NYV4</a>', 'HUGO Gene symbol': 'CDK12', 'Protein name': 'Cyclin-dependent kinase 12', 'Function': 'Phosphorylates CTD of RNA polymerase II,  regulating transcription elongation. Regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24554720%5Buid%5D" target="_blank" rel="noopener noreferrer">24554720</a>', 'Notes': '1) the recurrent somatic CDK12 mutations identified in ovarian cancers impair the catalytic activity of this kinase, which is involved in the transcription of a subset of genes, including BRCA1 and other DNA repair genes. 2) disabling CDK12 function in ovarian cancer cells reduces BRCA1 levels, disrupts HR repair, and sensitizes these cells to the cross-linking agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888). 3) these findings suggest that many CDK12 mutations are an unrecognized cause of HR defects in ovarian cancers.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK12" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1017" target="_blank" rel="noopener noreferrer">1017</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P24941" target="_blank" rel="noopener noreferrer">P24941</a>', 'HUGO Gene symbol': 'CDK2', 'Protein name': 'Cyclin-dependent kinase 2', 'Function': 'Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25557169%2C%2011585414%20%5Buid%5D" target="_blank" rel="noopener noreferrer">25557169, 11585414¬†</a>', 'Notes': '1) BRCA1 and BRCA2 are also known E2F targets and overexpressed in CCNE1-amplified HGSOC. 2) Inhibition of CDK1/2 by SNS032 or dinaciclib resulted in downregulation of BRCA1 and chemosensitization specifically in cyclin E1-driven cells. 3) p27kip1 expression was reduced in ovarian carcinomas in contrast to benign and borderline tumors. 4) The expression of cyclin E and cdk2 gradually increased from benign to borderline to malignant tumors. 5) patients with p27kip1 expression had a high overall survival rate. 6) Patients with cyclin E overexpression had a low overall survival rate. 7) When the combination of these proteins was analyzed, patients with the p27kip1 (−)/cyclin E (++)/cdk2 (++) phenotype were significantly associated with the poorest overall survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1019" target="_blank" rel="noopener noreferrer">1019</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11802" target="_blank" rel="noopener noreferrer">P11802</a>', 'HUGO Gene symbol': 'CDK4', 'Protein name': 'Cyclin-dependent kinase 4', 'Function': 'Phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29666673%2C%2021477379%5Buid%5D" target="_blank" rel="noopener noreferrer">29666673, 21477379</a>', 'Notes': '1) roniciclib (BAY1000394), a potent pan-CDK inhibitor, displays promising anti-neoplastic activity as a single agent and potentiates cisplatin lethality in preclinical nasopharyngeal carcinoma (NPC) models.\xa02) The expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). 3) Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. 4) Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. 5) Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. 6) suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1020" target="_blank" rel="noopener noreferrer">1020</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00535" target="_blank" rel="noopener noreferrer">Q00535</a>', 'HUGO Gene symbol': 'CDK5', 'Protein name': 'Cyclin-dependent kinase 5', 'Function': 'Regulates neuronal development and neuronal survival, migration and differentiation, etc; EGF-activated EGFR leads to the activation of CDK5 and increased proliferation in EOC, thyroid carcinoma, and melanoma cells (24091658). Some Cdk5 substrates include FAK, STAT3, AKT, Rb etc. (31910742)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> ECM signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26698249%2C%2030621723%5Buid%5D" target="_blank" rel="noopener noreferrer">26698249, 30621723</a>', 'Notes': '1) high level of cyclin I was associated with cisplatin resistance in CC. 2) cyclin I protein becomes highly expressed in human CC patients resistant to cisplatin chemotherapy. 3) Stable overexpressed cyclin I promotes Hela cell resistance to higher concentrations of cisplatin. 4) upregulated level of cyclin I increased tumor cells growth in vitro and enhanced tumor resistance to cisplatin in vivo. 5) cyclin I upregulated the expression of Cdk5 promoting cisplatin resistance by preventing apoptosis in CC cell line. 6) the cyclin I overexpressed Hela cell lines produce increased sensitivity to cisplatin treatment through knockdown of Cdk5 protein with siRNA.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1022" target="_blank" rel="noopener noreferrer">1022</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P50613" target="_blank" rel="noopener noreferrer">P50613</a>', 'HUGO Gene symbol': 'CDK7', 'Protein name': 'CDK-activating kinase (CAK)', 'Function': 'Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25411854%2C%2028455421%5Buid%5D" target="_blank" rel="noopener noreferrer">25411854, 28455421</a>', 'Notes': '1) CDK7 has been identified as a differentially expressed gene that is highly correlated with endometrial carcinoma. 2) the half maximal inhibitory concentration of cisplatin was reduced from 45.12 µg/ml to 3.200 µg/ml following the inhibition of CDK7 expression levels, indicating a significantly increased cytotoxicity in the treated cells (P<0.05) in the HEC-1-A endometrial carcinoma cell line. 3) High CDK7 protein expression was associated with poor prognosis of breast cancer within the RATHER TNBC cohort (n = 109) and the METABRIC TNBC cohort (n = 203). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDK7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1026" target="_blank" rel="noopener noreferrer">1026</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P38936" target="_blank" rel="noopener noreferrer">P38936</a>', 'HUGO Gene symbol': 'CDKN1A', 'Protein name': 'Cyclin-dependent kinase inhibitor 1', 'Function': 'May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage.\xa0Inhibits the kinase activity of the cyclin D-CDK4 complex; promotes its kinase activity towards RB1. Binds and inhibits PCNA, leading to blockade of DNA synthesis and inhibition of cell proliferation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21933447%2C%2020811155%2C%2011078909%5Buid%5D" target="_blank" rel="noopener noreferrer">21933447, 20811155, 11078909</a>', 'Notes': '1) p21 predominantly localizes to the cytoplasm in platinum-resistant ovarian cancer cell line C13* compared to its parental OV2008. Persistent exposure to low dose cisplatin in OV2008 leads to p21 translocation from nuclear to cytoplasm. 2) Knockdown of cytoplasmic p21 by siRNA in C13* notably increased cisplatin-induced apoptosis. Inhibition of p21 translocation into the cytoplasm by Akt2 shRNA significantly increased cisplatin-induced apoptosis, 3) Induction of p21 translocation into the cytoplasm by transfection of constitutively active Akt2 in OV2008 enhanced the resistance to cisplatin. 4) cytoplasmic p21 was negatively correlated with the response to cisplatin based treatment. 5) The transfection of p21(cip1/waf1) cDNA into SKOV3 and OVCAR3 ovarian cancer cells led to reduction of tumor cell growth, enhanced susceptibility to cisplatin-induced apoptosis, and abolition of recurrency after cisplatin exposure. ', 'Up / down in Pt-resistant cells': 'localizes to the cytoplasm', 'Up / down to promote Pt-resistance': 'DOWN/UP/cytoplasm', 'Up / down after Pt-treatment': 'localizes to the cytoplasm', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1027" target="_blank" rel="noopener noreferrer">1027</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46527" target="_blank" rel="noopener noreferrer">P46527</a>', 'HUGO Gene symbol': 'CDKN1B', 'Protein name': 'Cyclin-dependent kinase inhibitor 1B', 'Function': 'Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27314502%2C%2011585414%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27314502, 11585414¬†</a>', 'Notes': '1) chemoresistant cell lines using paclitaxel (TAX),\xa0cisplatin\xa0(DDP) and carboplatin (CBP) in SKOV3 ovarian\xa0cancer\xa0cells. 2) the\xa0expression\xa0levels\xa0of p27 were dramatically downregulated in chemoresistant cells. 3) the methylation of DDP‑resistant cells was significantly higher compared with SKOV3 cells. 4) demethylation by\xa05-aza restored p27 expression in DDP-resistant cells, and increased their sensitivity to DDP. 5) the overexpression of p27 arrested the cell cycle in S phase and promoted an apoptotic response to DDP. 6) p27kip1 expression was reduced in ovarian carcinomas in contrast to benign and borderline tumors. 7) The expression of cyclin E and cdk2 gradually increased from benign to borderline to malignant tumors. 8) patients with p27kip1 expression had a high overall survival rate. 9) Patients with cyclin E overexpression had a low overall survival rate. 7) When the combination of these proteins was analyzed, patients with the p27kip1 (−)/cyclin E (++)/cdk2 (++) phenotype were significantly associated with the poorest overall survival. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1028" target="_blank" rel="noopener noreferrer">1028</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49918" target="_blank" rel="noopener noreferrer">P49918</a>', 'HUGO Gene symbol': 'CDKN1C', 'Protein name': 'Cyclin-dependent kinase inhibitor 1C', 'Function': 'Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to a lesser extent, of the mitotic cyclin B-CDC2.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22289679%2C%2019239430%5Buid%5D" target="_blank" rel="noopener noreferrer">22289679, 19239430</a>', 'Notes': '1) p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo. 2) Micro-array analysis of our own series of novel paclitaxel- and platinum-resistant EOC cell lines has revealed that several such genes are down-regulated in isogenic paclitaxel-resistant cell lines, including Wee1 and p57Kip2. 3) Surprisingly, patients exhibiting p57KIP2 promoter methylation survived longer than patients without p57KIP2 DNA methylation. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN1C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1029" target="_blank" rel="noopener noreferrer">1029</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42771" target="_blank" rel="noopener noreferrer">P42771</a>', 'HUGO Gene symbol': 'CDKN2A', 'Protein name': 'Cyclin-dependent kinase inhibitor 2A', 'Function': 'Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25263447%2C%209036870%2C%2018196872%2C%2025663864%2C%2017611411%5Buid%5D" target="_blank" rel="noopener noreferrer">25263447, 9036870, 18196872, 25663864, 17611411</a>', 'Notes': '1) the overexpression of a p53-positive regulator, p14ARF, inhibited MDM2-mediated p53 degradation and led to the imbalance of p53 turnover that promoted the formation of p53 aggregates. 2) the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment in vitro and in vivo. 3) Increased expression of P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. 4) NSCLC cells with elevated p16 exhibited enhanced sensitivities to low concentration cisplatin treatment. 5) Knockdown of P16INK4A in cervical carcinoma SiHa cells promoted apoptosis following treatment with DDP. 6) P14ARF sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1031" target="_blank" rel="noopener noreferrer">1031</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42773" target="_blank" rel="noopener noreferrer">P42773</a>', 'HUGO Gene symbol': 'CDKN2C', 'Protein name': 'Cyclin-dependent kinase 4 inhibitor C', 'Function': '1) INK4 family members of CDKI, interact only with CDK4/6 and inhibit the G1/S transition. 2) Tumor suppressor gene, also involved in DNA damage response and apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21494915%5Buid%5D" target="_blank" rel="noopener noreferrer">21494915</a>', 'Notes': '1) P18 protects against cisplatin-induced renal cell injury. 2) Overexpression of p18 arrested cell cycle progression in the G1 phase and inhibited proliferation. 3) p18 overexpression did not affect cisplatin-induced necrosis, but it reduced the percentage of apoptotic cells significantly. 4) The severity of ER Stress (ERS) induced by cisplatin was also decreased by p18 overexpression. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN2C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1051" target="_blank" rel="noopener noreferrer">1051</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17676" target="_blank" rel="noopener noreferrer">P17676</a>', 'HUGO Gene symbol': 'CEBPB', 'Protein name': 'CCAAT/enhancer-binding protein beta, C/EBP beta', 'Function': 'Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26087191%2C%2029748013%5Buid%5D" target="_blank" rel="noopener noreferrer">26087191, 29748013</a>', 'Notes': "1) Chemoresistant EOC cells expressed higher COL11A1 and c/EBPβ than chemosensitive cells. 2) COL11A1 or c/EBPβ downregulation suppressed chemoresistance. 3) COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel. 4) The c/EBPβ binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression. 5) LIP was degraded by constitutive ubiquitination in primary MPM cells derived from patients poorly responsive to cisplatin. 6) LIP ubiquitination was directly correlated with cisplatin chemosensitivity and was associated with patients' survival after chemotherapy. 7) Overexpression of LIP restored cisplatin's pro-apoptotic effect by activating CHOP/TRB3/caspase 3 axis and up-regulating calreticulin. 8) Proteasome inhibitor carfilzomib and lysosome inhibitor chloroquine prevented LIP degradation. 13) The triple combination of carfilzomib, chloroquine and cisplatin increased ER stress-triggered apoptosis and immunogenic cell death in patients' samples, and reduced tumor growth in cisplatin-resistant MPM preclinical models.", 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CEBPB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8837" target="_blank" rel="noopener noreferrer">8837</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15519" target="_blank" rel="noopener noreferrer">O15519</a>', 'HUGO Gene symbol': 'CFLAR', 'Protein name': 'Cellular FLICE-like inhibitory protein, c-FLIP', 'Function': 'Inhibitor of TNFRSF6/FAS mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23313194%2C%2023167276%5Buid%5D" target="_blank" rel="noopener noreferrer">23313194, 23167276</a>', 'Notes': '1) Complete cisplatin mediated suppression of c-FLIP expression in CDDP-sensitive T24 cells but no change in resistant T24R2 cells after cisplatin treatment. 2) Suppression of c-FLIP expression in T24R2 cells by siRNA rendered these cells significantly more sensitive to cisplatin treatment than untransfected T24R2 cells (bladder cancer cells). 3) In univariate analyses of CFLAR mRNA expression in adult AML patients, those individuals with higher than median mRNA expression of the long splice form CFLAR(L) (but not the short splice form) had significantly lower 3 year overall survival (P = 0·04) compared to those with low expression. ', 'Up / down in Pt-resistant cells': 'UP/long spliced form', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; UNCHANGED in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CFLAR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1108" target="_blank" rel="noopener noreferrer">1108</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14839" target="_blank" rel="noopener noreferrer">Q14839</a>', 'HUGO Gene symbol': 'CHD4', 'Protein name': 'Chromodomain-helicase-DNA-binding protein 4', 'Function': 'Component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin by deacetylating histones', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25737278%2C%2027443740%5Buid%5D" target="_blank" rel="noopener noreferrer">25737278, 27443740</a>', 'Notes': "1) PARPi resistance (D'Andrea) AACR presentation;  2) loss of the nucleosome remodeling factor CHD4 confers cisplatin resistance. 3) BRCA2 mutant ovarian cancers with reduced CHD4 expression significantly correlate with shorter progression-free survival and shorter overall survival. 4) The loss of Pax transactivation-domain interacting protein (PTIP), PARP1, and Chromodomain Helicase DNA Binding Protein 4 (CHD4) in a BRCA2 deficient background was associated to resistance to cisplatin and PARP inhibitors, not due to the re-acquisition of a functional HR, but to an increased protection of replication forks. ", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CHD4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1111" target="_blank" rel="noopener noreferrer">1111</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14757" target="_blank" rel="noopener noreferrer">O14757</a>', 'HUGO Gene symbol': 'CHEK1', 'Protein name': 'Serine/threonine-protein kinase Chk1', 'Function': 'Required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to DNA damage; binds to and phosphorylates CDC25A, CDC25B and CDC25C; also phosphorylates NEK6, RAD51, TP53,  FANCE, TLK1 ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22537224%2C%2030771522%5Buid%5D" target="_blank" rel="noopener noreferrer">22537224, 30771522</a>', 'Notes': '1) geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors (UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient OC ells when compared to FA-deficient cells. 2) Inhibition of Chk1 synergized with cisplatin to induce mitotic cell death in the p53-deficeint SCLC cells. 3) The effect was regulated in part through activation of caspase 2 and downregulation of E2F transcription factor 1 (E2F1). 4) Chk1 inhibitors prexasertib and AZD7762 enhanced cisplatin antitumor activity and overcame cisplatin resistance in SCLC preclinical models in vitro an in vivo. 5) higher expression of Chk1 was associated with poorer overall survival of patients with SCLC.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CHEK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11200" target="_blank" rel="noopener noreferrer">11200</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O96017" target="_blank" rel="noopener noreferrer">O96017</a>', 'HUGO Gene symbol': 'CHEK2', 'Protein name': 'Serine/threonine-protein kinase Chk2', 'Function': 'Required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to DSB; phosphorylates CDC25A, CDC25B and CDC25C, NEK6, BRCA2, FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24657486%2C%2018162465%2C%2022312557%2C%2017940507%5Buid%5D" target="_blank" rel="noopener noreferrer">24657486, 18162465, 22312557, 17940507</a>', 'Notes': '1) In two well-defined ovarian cancer patient groups with the largest contrast in treatment response, high expression of Chk2 was related to good response (OR=0.132; P=0.014). 2) Chk2 depletion abrogated the cisplatin-induced S-phase cell cycle arrest and caused increased resistance to cisplatin in long-term clonogenic survival assays. 3) Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. 4) Chk2 activation at Thr68 phosphorylation is regulated by p53 in response to cisplatin treatment in wt p53-contain cells, but not in p53-deficient cells, of human ovarian cancer. 5) Using a Chk2 inhibitor to block this cellular pathway greatly enhanced the efficacy of cisplatin in cancer chemotherapy. 6) pretherapeutic biopsies from 94 oesophageal squamous cell carcinomas in patients who underwent neoadjuvant chemoradiotherapy (RCTx: 45 Gy plus cisplatin and 5-fluorouracil) and subsequent oesophagectomy: Expression of proteins involved in DNA repair and/or cell-cycle regulation, that is p53, p53 (phosphorylated at Ser15), EGFR, ATM protein kinase (phosphorylated at Ser1981) and checkpoint kinase 2 (CHK2) (phosphorylated at Thr68) was correlated with the response to RCTx and with overall survival. Tumours that were positive for CHK2 expression more frequently showed clinically determined regression after RCTx (69.4%) than tumours that were negative for CHK2 expression (32.1%; P=0.0011). ', 'Up / down in Pt-resistant cells': 'DOWN/DEPHOS', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CHEK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25978" target="_blank" rel="noopener noreferrer">25978</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UQN3" target="_blank" rel="noopener noreferrer">Q9UQN3</a>', 'HUGO Gene symbol': 'CHMP2B', 'Protein name': 'Charged multivesicular body protein 2b', 'Function': 'Core component of the endosomal sorting required for transport complex III (ESCRT-III)/regulated exocytosis\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27322682%5Buid%5D" target="_blank" rel="noopener noreferrer">27322682</a>', 'Notes': '1) the expression of vimentin was downregulated in drug-resistant ovarian cancer cell lines A2780-DR and HO-8910 as compared to their respective control cells. 2) Silencing of CHMP2B and PDZK1 in both A2780-DR and HO-8910 cells led to decreased cellular cisplatin accumulation. 2) The vimentin (VIM) downregulation increased CHMP2B and PDZK1 expression. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CHMP2B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1147" target="_blank" rel="noopener noreferrer">1147</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15111" target="_blank" rel="noopener noreferrer">O15111</a>', 'HUGO Gene symbol': 'CHUK', 'Protein name': 'conserved helix-loop-helix ubiquitous kinase / Inhibitor of nuclear factor kappa-B kinase subunit beta', 'Function': 'IKK-α and IKK-β phosphorylate the IκB proteins, marking them for degradation via\xa0ubiquitination\xa0and allowing NF-κB transcription factors to go into the nucleus', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18560356%2C%2029950928%2C%2017785555%5Buid%5D" target="_blank" rel="noopener noreferrer">18560356, 29950928, 17785555</a>', 'Notes': '1) Protein expression of ETS1 and IKKα were significantly up-regulated in 231/DDP cells. 2) Both Notch-1 and IKKalpha knockdown sensitize CaSki cells to cisplatin-induced apoptosis to equivalent extents.\xa03) IKKalpha was expressed in the nucleus of basal cells of normal oral epithelium, but not or marginally detected in 32.8% of carcinomas. 4) The immunoreactivity was significantly decreased in less differentiated carcinomas (P < 0.05) and correlated to long-term survival of patients (P < 0.01) with an independent prognostic value (P < 0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CHUK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57650" target="_blank" rel="noopener noreferrer">57650</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TCG1" target="_blank" rel="noopener noreferrer">Q8TCG1</a>', 'HUGO Gene symbol': 'CIP2A', 'Protein name': 'cancerous inhibitor of protein phosphatase 2A', 'Function': 'directly interacts with c-myc, inhibits PP2A activity towards c-myc ser62 to prevent c-myc degradation;\xa0increases P-Akt by negatively regulating Akt related PP2A activity (20729919); facilitates the EMT process via RAS/ERK pathway (25458953); participates in the Wnt/β-catenin pathway (25015035).', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> MYC signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30106121%2C%2029103022%2C%2030410608%2C%2026629248%5Buid%5D" target="_blank" rel="noopener noreferrer">30106121, 29103022, 30410608, 26629248</a>', 'Notes': '1) CIP2A knockdown enhanced DDP sensitivity. 2) CIP2A depletion accelerated the process of DNA damage caused by DDP treatment. 3) CIP2A suppression increased the cytotoxicity of DDP, which resulted in a decrease in the subcutaneous tumor growth in a xenograft mouse model.4) CIP2A has higher expression in DDP-resistant GC patients. 5) DDP-resistant GC patients with high CIP2A expression presented with poorer overall survival rates than those with low CIP2A expression. 6) CIP2A knockdown in DDP-resistant GC cells resulted in attenuated proliferative abilities and increased apoptosis level. 7) CIP2A depletion sensitizes DDP-resistant cells to DDP and CIP2A overexpression antagonizes DDP-sensitive cells to DDP. 8) CIP2A influences the expression of multidrug resistance-related proteins in GC cells. 9) CIP2A promoted epithelial-mesenchymal transformation (EMT) and chemoresistance to cisplatin in RCC cells. 10) Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin. 11) CIP2A overexpression increases DDP resistance in SKOV3 cells via pAKT activity. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN/UNPHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CIP2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9076" target="_blank" rel="noopener noreferrer">9076</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95832" target="_blank" rel="noopener noreferrer">O95832</a>', 'HUGO Gene symbol': 'CLDN1', 'Protein name': 'Claudin-1', 'Function': 'Claudins function as major constituents of the tight junction complexes', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28614291%2C%2032754286%5Buid%5D" target="_blank" rel="noopener noreferrer">28614291, 32754286</a>', 'Notes': '1) expression of CLDN1 in NSCLC is up-regulated and it is correlated with clinicopathological features. 2) CLDN1 expression in A549/CDDP cells is up-regulated at both transcriptional and translational levels. 3) Reduced CLDN1 expression decreases the CDDP resistance, proliferation, migration, and invasion. 4) CLDN1 activates autophagy through up-regulation of ULK1 phosphorylation and promotes drug resistance of NSCLC cells to CDDP. 5) CLDN1 repressed cancer progression via a feedback loop of the CLDN1-EPHB6-ERK1/2-SLUG axis, which repressed metastasis, drug resistance, and cancer stemness; Combined treatment with cisplatin and trichostatin A or vorinostat (facilitating CLDN1 expression) had a synergistic effect on Lung cancer-cell death (A549). 6) Upregulation of CLDN1 and RUNX3 predict a positive chemotherapeutic response and clinical outcome for patients with lung adenocarcinoma', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLDN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1365" target="_blank" rel="noopener noreferrer">1365</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15551" target="_blank" rel="noopener noreferrer">O15551</a>', 'HUGO Gene symbol': 'CLDN3', 'Protein name': 'Claudin-3', 'Function': 'tight junction protein; interacts with PDZ domain-containing proteins such as ZO proteins which serve as adapters for other proteins involved in cell signaling; interactors include PTEN, plays a role in proliferation, differentiation, and motility (11283726); related to EMT and WNT pathway (29511369);  ', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Platinum uptake<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23053666%2C%2024482188%2C%2017647191%5Buid%5D" target="_blank" rel="noopener noreferrer">23053666, 24482188, 17647191</a>', 'Notes': '1) Knockdown of CLDN3 or CLDN4 rendered human ovarian carcinoma 2008 cells resistant to cDDP in both in vitro culture and in vivo xenograft model. 2) The net accumulation of platinum (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and CLDN4KD cells. 3) The endogenous mRNA levels of copper influx transporter CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP. 4) Reexpression of an shRNAi-resistant CLDN3 or CLDN4 up-regulated CTR1 levels, reversed the cDDP resistance, and enhanced TJ formation in the knockdown cells. 5) Baseline copper (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and CLDN4KD cells. 6) shCLDN3 knockdown combined with low-dose cisplatin demonstrates apparent synergistic antitumor activity in OC. 7) Claudin-3 depletion decreased the formation rates of spheres and tumors and increased cisplatin sensitivity in NSCLC. 8) Ovarian serous adenocarcinoma patients with high CLDN3 expression had substantially shorter survival. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLDN3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1364" target="_blank" rel="noopener noreferrer">1364</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14493" target="_blank" rel="noopener noreferrer">O14493</a>', 'HUGO Gene symbol': 'CLDN4', 'Protein name': 'Claudin-4', 'Function': 'AS in CLDN3. Reduction of claudin-4 in cancer cells facilitates the detachment of single cells from the cellular network and promotes invasion in a similar manner to E-cadherin (12668723).', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Platinum uptake<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23053666%2C%2023599806%2C%2021508375%5Buid%5D" target="_blank" rel="noopener noreferrer">23053666, 23599806, 21508375</a>', 'Notes': '1) AS in CLDN3. 2) Suppression of claudin-4 resulted in a significant increase of cisplatin sensitivity and cellular accumulation of fluorescence-labeled cisplatin. 3) Claudin-4 expression was significantly greater in ovarian cancer tissue from chemoresistant patients compared to chemosensitive patients. The overall survival was significantly shorter for claudin-4-positive than claudin-4-negative cases.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLDN4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1366" target="_blank" rel="noopener noreferrer">1366</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95471" target="_blank" rel="noopener noreferrer">O95471</a>', 'HUGO Gene symbol': 'CLDN7', 'Protein name': 'Claudin-7', 'Function': 'Plays a major role in tight junction-specific obliteration of the intercellular space; associated with EpCAM to promote EMT (25514462): EpIC released from EpCAM acts as a cotranscription factor in cooperation with β-catenin to upregulate vimentin, Snail, Slug and downregulate E-cadherin. ', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21134740%5Buid%5D" target="_blank" rel="noopener noreferrer">21134740</a>', 'Notes': '1) CLDN-7 transcripts in EOCs were significantly up-regulated compared with normal ovarian tissues (P<0.001). 2) High CLDN-7 expression in primary tumour correlated with shorter progression-free survival (PFS) of the patients (P=0.005) and poor sensitivity to platinum-based chemotherapy (P=0.024). 3) CLDN-7 was highly expressed in 2774 and HeyA8 human ovarian cancer cells and inhibition of CLDN-7 by its siRNA significantly enhanced the sensitivity of 2774 and HeyA8 cells to cisplatin treatment', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLDN7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1192" target="_blank" rel="noopener noreferrer">1192</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00299" target="_blank" rel="noopener noreferrer">O00299</a>', 'HUGO Gene symbol': 'CLIC1', 'Protein name': 'Chloride intracellular channel protein 1', 'Function': 'overexpressed in activated macrophages; a homologous protein of GST superfamily; response of oxidative stress by acting as sensor and effector; regulates stabilization of cell membrane potential, transepithelial transport, maintenance of intracellular pH, and regulation of cell volume; regulation of integrin family proteins (29669336).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> ECM signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27825122%2C%2029805518%5Buid%5D" target="_blank" rel="noopener noreferrer">27825122, 29805518</a>', 'Notes': '1) The expression levels of CLIC1 and LGALS3BP in epithelial ovarian cancer tissues were significantly higher than those in normal ovary tissues. 2) The knockdown of CLIC1 in A2780 cell line showed an increased sensitivity to hydrogen peroxide and cisplatin. 3) mRNA and protein levels of CLIC1 was significantly higher in higher-grade tumors than in low-grade tumors. 4) overexpression of CLIC1 was associated with cisplatin resistance (P<0.001). 5) CLIC1 expression was an independent factor that predicted shorter progression-free survival (P=0.006) and overall survival for patients with epithelial ovarian cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLIC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1201" target="_blank" rel="noopener noreferrer">1201</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13286" target="_blank" rel="noopener noreferrer">Q13286</a>', 'HUGO Gene symbol': 'CLN3', 'Protein name': 'Battenin', 'Function': 'membrane protein involved in microtubule-dependent, anterograde transport of late endosomes and lysosomes', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux<br><br> vesicle trafficking', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26299671%5Buid%5D" target="_blank" rel="noopener noreferrer">26299671</a>', 'Notes': '1) CLN3 depletion markedly reduced the half maximum inhibitory concentration in the human ovarian cancer cisplatin‑resistant and carboplatin‑resistant sublines, A2780/DDP and A2780/CBP cells. ', 'Up / down in Pt-resistant cells': 'UNCHANGED', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLN3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9575" target="_blank" rel="noopener noreferrer">9575</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15516" target="_blank" rel="noopener noreferrer">O15516</a>', 'HUGO Gene symbol': 'CLOCK', 'Protein name': 'circadian regulator Clock', 'Function': 'Transcriptional activator, forms a core component of the circadian clock, activates the expression of ATF4', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17297441%2C%2025485508%20%5Buid%5D" target="_blank" rel="noopener noreferrer">17297441, 25485508¬†</a>', 'Notes': '1) Clock is overexpressed in cisplatin-resistant cells. 2) Clock expression significantly correlates with cisplatin sensitivity. 3) Clock activate ATF4 expression through E-box elements. 4) the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide.\xa05) Higher expression of several clock genes (e.g., CLOCK, PER1, PER2, PER3, CRY2, NPAS2 and RORC) in breast cancer patients was found to be associated with longer MFS in univariate Cox regression analyses (HR<1 and FDR-adjusted P < 0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLOCK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/81037" target="_blank" rel="noopener noreferrer">81037</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96KA5" target="_blank" rel="noopener noreferrer">Q96KA5</a>', 'HUGO Gene symbol': 'CLPTM1L', 'Protein name': 'Cleft Lip and Palate Transmembrane Protein 1-Like', 'Function': 'up-regulated transcript in a cisplatin resistant ovarian tumor cell line; coactivator of the transcription factor Erβ, (downstream target: CDC25A, c-Jun, and BCL2); induces ER-β signaling (32943060)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Hormone receptor signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22675468%5Buid%5D" target="_blank" rel="noopener noreferrer">22675468</a>', 'Notes': '1) CLPTM1L has been identified as an overexpressed protein in human ovarian tumor cell lines that are resistant to cisplatin. 2) Upon loss of CLPTM1L accumulation in lung tumor cells, cisplatin and camptothecin induced apoptosis were increased in direct proportion to the level of CLPTM1L knockdown. 3) CLPTM1L protects from genotoxic stress induced apoptosis through regulation of Bcl-xL. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLPTM1L" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1191" target="_blank" rel="noopener noreferrer">1191</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10909" target="_blank" rel="noopener noreferrer">P10909</a>', 'HUGO Gene symbol': 'CLU', 'Protein name': 'Clusterin, Isoform 1 ', 'Function': 'extracellular chaperone; intracellular form translocated from ER to cytosol under stress, leading to the inhibition of apoptosis through the activation of Akt, NF-kB, YB-1, and HSF-1 (33160989); inhibits apoptosis through suppressing BAX-dp release of cytochrome c and interaction with HSPA5', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Autophagy<br><br> NF-kB signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24943969%2C%2020497247%2C%2033160989%5Buid%5D" target="_blank" rel="noopener noreferrer">24943969, 20497247, 33160989</a>', 'Notes': '1) DDP-induced secreted clusterin (sCLU) activation, which involved induction of pAkt and pERK1/2 activation that confer DDP resistance in immunocompromised mice.\xa02) sCLU silencing increased the sensitivity of lung cancer A549DDP cells to DDP in vivo. 3) sCLU overexpression decreased the chemosensitivity of A549 cells to DDP in vivo. 4) The expression level of clusterin did not correlate with age, gender, grade or stage. However, its expression was significantly associated with a decrease in disease-free survival (P < 0.05) in colorectal carcinomas. 5) sCLU overexpression promoted autophagy through AMPK/Akt/mTOR signaling pathway. 6) sCLU interact with ULK1.  7) high CLU expression is associated with therapy resistance in cancer and we demonstrated that sCLU-mediated mitophagy was revealed to inhibit cell death by cisplatin in Oral cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CLU" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1301" target="_blank" rel="noopener noreferrer">1301</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12107" target="_blank" rel="noopener noreferrer">P12107</a>', 'HUGO Gene symbol': 'COL11A1', 'Protein name': 'Collagen type XI alpha 1', 'Function': 'May play an important role in fibrillogenesis by controlling lateral growth of collagen II fibrils.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28815582%2C%2029769618%2C%2026087191%2C%2032312965%5Buid%5D" target="_blank" rel="noopener noreferrer">28815582, 29769618, 26087191, 32312965</a>', 'Notes': '1) COL11A1 and TWIST1 were among the most highly upregulated genes in chemoresistant tumors. 2) COL11A1 promotes ovarian cancer progression and is associated with chemoresistance to cisplatin and paclitaxel in ovarian cancer cells. 3) COL11A1-mediated NFkB activation, via transcriptional activation of IKKβ, promoted TWIST1, Mcl-1, and GAS6 expression, which were associated with chemoresistance and anti-apoptosis in ovarian cancer cells. 4) In resistant cells, Akt and PDK1 were highly expressed; 5) anticancer drugs enhanced binding activity between COL11A1 and PDK1 and attenuated PDK1 ubiquitination and degradation. 6) chemosensitive cells showed decreased activity of COL11A1 binding to PDK1 and increased PDK1 ubiquitination, which were reversed by COL11A1 overexpression. 7) Analysis of 104 EOC patients showed that high COL11A1 mRNA levels are significantly associated with poor chemoresponse and clinical outcome.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COL11A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1277" target="_blank" rel="noopener noreferrer">1277</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02452" target="_blank" rel="noopener noreferrer">P02452</a>', 'HUGO Gene symbol': 'COL1A1', 'Protein name': 'Collagen alpha-1(I) chain', 'Function': 'Type I collagen is a member of group I collagen (fibrillar forming collagen).', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27853186%2C%2033287446%2C%2029906404%5Buid%5D" target="_blank" rel="noopener noreferrer">27853186, 33287446, 29906404</a>', 'Notes': '1) multicellular tumor spheroids (MCTS):  hepatic stellate cells (HSCs) in MCTS significantly increased the compactness of spheroids and exhibited strong resistance to sorafenib and cisplatin relative to other types of stromal cells. 2) Increased COL1A1 expression was apparent in activated HSCs but not in fibroblasts or vascular endothelial cells in MCTS. 3) losartan, which can inhibit collagen I synthesis, attenuated the compactness of spheroids and increased the therapeutic efficacy of anticancer therapies in MCTS. 4) W1 cisplatin-resistant ovarian cancer cell binding to COL1 upregulates integrin-associated signals via FAK/PRAS40/mTOR. 5) mTOR appears as key for resistance, its blockade reversed COL1 effects on W1 cell resistance completely. 5) COL1 binding via DDR1 activates the MAPK pathway, of which JNK1/2 appears critical for COL1-mediated cisplatin resistance. 6) JNK1/2 inhibition inverts COL1 effects in W1CR cells, whereas intrinsic cisplatin resistance remained unaffected. 7) In patients with breast cancer, cellular expression of COL1A1 was associated with ER/PR expression and metastasis status. The increased COL1A1 level was associated with poor survival, especially in patients with ER+ breast cancer. 8) Patients with a high-level of COL1A1 showed better cisplatin-based chemotherapy response.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COL1A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1281" target="_blank" rel="noopener noreferrer">1281</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02461" target="_blank" rel="noopener noreferrer">P02461</a>', 'HUGO Gene symbol': 'COL3A1', 'Protein name': 'Collagen alpha-1(III) chain', 'Function': 'Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27390605%2C%2029050298%5Buid%5D" target="_blank" rel="noopener noreferrer">27390605, 29050298</a>', 'Notes': '1) very high expression levels of COL3A1 protein, and the presence of extracellular COL3A1 in the CDDP-resistant ovarian cancer W1TR cell line. 2) The cells mainly responsible for the extracellular COL3A1 production are aldehyde dehydrogenase-1A1 (ALDH1A1) positive cells.\xa03) highly-expressed COL3A1 was closely correlated with local recurrence and Human bladder cancer (BCa) stage. 4) BCa patients with higher expression of COL3A1 had a significantly shorter overall survival time and disease free survival time.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COL3A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1293" target="_blank" rel="noopener noreferrer">1293</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12111" target="_blank" rel="noopener noreferrer">P12111</a>', 'HUGO Gene symbol': 'COL6A3', 'Protein name': 'Collagen alpha-3(VI) chain', 'Function': 'Collagen VI acts as a cell-binding protein.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12726863%5Buid%5D" target="_blank" rel="noopener noreferrer">12726863</a>', 'Notes': '1) Serial analysis of gene expression (SAGE) profiling of cisplatin-resistant and sensitive cells revealed that many ECM genes were elevated in cisplatin-resistant ovarian cancer cells including COL6A3. 2) cultivation of cisplatin-sensitive cells in the presence of collagen VI protein promoted resistance in vitro. 3) Staining of ovarian tumors with collagen VI antibodies confirmed collagen VI expression in vivo and suggested reorganization of the extracellular matrix in the vicinity of the tumor. 4) the presence of collagen VI correlated with tumor grade, an ovarian cancer prognostic factor. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COL6A3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10063" target="_blank" rel="noopener noreferrer">10063</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14061" target="_blank" rel="noopener noreferrer">Q14061</a>', 'HUGO Gene symbol': 'COX17', 'Protein name': 'Cytochrome c oxidase copper chaperone', 'Function': 'Copper metallochaperone essential for the assembly of the mitochondrial respiratory chain complex IV (CIV), also known as cytochrome c oxidase', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24473407%5Buid%5D" target="_blank" rel="noopener noreferrer">24473407</a>', 'Notes': 'Cisplatin Binds to Human Copper Chaperone Cox17: The Mechanistic Implication of Drug Delivery to Mitochondria', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COX17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1347" target="_blank" rel="noopener noreferrer">1347</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14406" target="_blank" rel="noopener noreferrer">P14406</a>', 'HUGO Gene symbol': 'COX7A2', 'Protein name': 'Cytochrome c oxidase subunit 7A2', 'Function': 'Cytochrome c oxidase catalyzes the reduction of oxygen to water. Electrons originating from reduced cytochrome c in the intermembrane space (IMS) are transferred via the dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 to the active site in subunit 1', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23592244%5Buid%5D" target="_blank" rel="noopener noreferrer">23592244</a>', 'Notes': '1) clinical response to cisplatin correlated with pre-existing defects in the mitochondrial respiratory chain complexes of esophageal adenocarcinoma cancer cells, caused by loss of specific cytochrome c oxidase (COX) subunits. 2) Knockdown of a COX protein altered chemosensitivity in vitro, increasing the propensity of cancer cells to undergo cell death following cisplatin treatment. 3) In an independent validation, patients with reduced COX protein expression prior to treatment exhibited favourable clinical outcomes to chemotherapy, whereas tumors with unchanged COX expression were chemoresistant. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=COX7A2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1376" target="_blank" rel="noopener noreferrer">1376</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P23786" target="_blank" rel="noopener noreferrer">P23786</a>', 'HUGO Gene symbol': 'CPT2', 'Protein name': 'Carnitine O-palmitoyltransferase 2, mitochondrial', 'Function': 'Reconverts acylcarnitines back into the respective acyl-CoA esters that can then undergo beta-oxidation, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29872321%2C%2022951905%5Buid%5D" target="_blank" rel="noopener noreferrer">29872321, 22951905</a>', 'Notes': '1) we have identified CPT2 which is the rate-limiting enzyme of fatty acid oxidation, downregulated in HCC and was significantly associated with tumor histological differentiation and venous invasion. 2) knockdown of CPT2 remarkably enhanced the tumorigenic activity and metastatic potential of hepatoma cells. 3) CPT2 silencing induced chemoresistance to cisplatin. 4) low expression of CPT2 promoted cancer cell lipogenesis via upregulation of stearoyl-CoA desaturase-1, the key enzyme involved in the synthesis of monounsaturated fatty acids, at both mRNA and protein levels in hepatoma cell line.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CPT2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1385" target="_blank" rel="noopener noreferrer">1385</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16220" target="_blank" rel="noopener noreferrer">P16220</a>', 'HUGO Gene symbol': 'CREB1', 'Protein name': 'Cyclic AMP-responsive element-binding protein 1', 'Function': 'Phosphorylation-dependent transcription factor (Phosphorylated by PKA, CaMKIV, p70S6K, and RSK2); binds to cAMP response element (CRE); critical for cell cycle and survival (15837624). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30093630%2C%2030069985%2C%2025825983%5Buid%5D" target="_blank" rel="noopener noreferrer">30093630, 30069985, 25825983</a>', 'Notes': '1) suppression of SETD2 or CREB1 conferred cisplatin resistance through inhibition of H3K36me3 and ERK activation in NSCLC cells. 2) SETD2 and CREB1 contribute to cisplatin cytotoxicity via regulation of the ERK signaling pathway. 3) PDE4 inhibitor roflumilast activated the cAMP/PKA/CREB pathway and upregulated the mitochondrial ferritin (FtMt) level in OVCAR3 and SKOV3 cells. 4) Roflumilast enhanced DDP sensitivity and reversed the DDP resistance of ovarian cancer cells via activation of cAMP/PKA/CREB pathway and upregulation of the downstream FtMt expression. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CREB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1410" target="_blank" rel="noopener noreferrer">1410</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02511" target="_blank" rel="noopener noreferrer">P02511</a>', 'HUGO Gene symbol': 'CRYAB', 'Protein name': 'Alpha-crystallin B chain', 'Function': 'contribute to the transparency and refractive index of the lens. Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions; a recognized anti-apoptotic protein (31239701); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27194715%2C%2025337251%5Buid%5D" target="_blank" rel="noopener noreferrer">27194715, 25337251</a>', 'Notes': '1) induction of Hsf1 and the small heat shock protein crystallin-αB (CryAB) during cisplatin nephrotoxicity in mice. 2) cisplatin induced Hsf1 and CryAB in a cultured renal proximal tubular cells (RPTCs). 3) Transfection or restoration of Hsf1 into Hsf1 knockdown cells suppressed cisplatin-induced apoptosis, 4) Hsf1 knockdown increased Bax translocation to mitochondria and cytochrome c release into the cytosol. 5) In RPTCs, Hsf1 knockdown led to a specific downregulation of CryAB. 6) Transfection of CryAB into Hsf1 knockdown cells diminished their sensitivity to cisplatin-induced apoptosis.\xa07) CRYAB expression in the mRNA and protein levels was significantly higher in colorectal cancer (CRC) tissues (P < 0.05 and P = 0.014, respectively). 8) The expression of CRYAB protein in CRC was significantly associated with distant metastasis (P = 0.040) and overall survival (P = 0.003). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CRYAB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1435" target="_blank" rel="noopener noreferrer">1435</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09603" target="_blank" rel="noopener noreferrer">P09603</a>', 'HUGO Gene symbol': 'CSF1', 'Protein name': 'Macrophage colony-stimulating factor 1', 'Function': 'Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29372560%2C%2022005523%5Buid%5D" target="_blank" rel="noopener noreferrer">29372560, 22005523</a>', 'Notes': '1) colony-stimulating-factor-1 receptor (CSF-1R) was upregulated in cisplatin-resistant SK-OV-3 and CaoV-3 cells. 2) parental SK-OV-3 and CaoV-3 cells were more resistant to cisplatin after CSF-1R overexpression, 3) CSF-1R knockdown in SK-OV-3 and CaoV-3 cells promoted cisplatin sensitivity. 4) CSF-1R significantly promoted active AKT and ERK1/2 signalling pathways in cisplatin-resistant cells. 5) a combination of cisplatin and CSF-1R inhibitor effectively inhibited tumour growth in xenografts. 6) Down-regulation of miR-130b in ovarian cancer was associated with FIGO III-IV clinical stages and poorer histological differentiation. 7) Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1436" target="_blank" rel="noopener noreferrer">1436</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07333" target="_blank" rel="noopener noreferrer">P07333</a>', 'HUGO Gene symbol': 'CSF1R', 'Protein name': 'Macrophage colony-stimulating factor 1 receptor', 'Function': 'Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29372560%2C%2022005523%5Buid%5D" target="_blank" rel="noopener noreferrer">29372560, 22005523</a>', 'Notes': 'As in CSF1', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSF1R" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1495" target="_blank" rel="noopener noreferrer">1495</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35221" target="_blank" rel="noopener noreferrer">P35221</a>', 'HUGO Gene symbol': 'CTNNA1', 'Protein name': 'Catenin alpha-1 / alphaE-catenin ', 'Function': 'A component of Beta-catenin, e-cadherin complex. Its function correlates to CDH1. ', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24973089%2C%208205352%2C%2027229528%5Buid%5D" target="_blank" rel="noopener noreferrer">24973089, 8205352, 27229528</a>', 'Notes': '1) knockdown of α(E)-catenin in tubular epithelial cells resulted in a significant loss of viability after cisplatin challenge. 2) the expression of α(E)-catenin was further decreased after cisplatin treatment. 3) In all E-cad(+) tumours, the frequency of lymph node and liver metastasis was higher in alpha-cat(-) tumours than in alpha-cat(+) tumours in human gastric cancer.\xa04) compared with their parental CDDP-sensitive lines, the expressions of mesenchymal markers (vimentin, fibronectin and N-cadherin) increased significantly and the expressions of epithelial markers (E-cadherin, α-catenin and β-catenin) decreased dramatically in A549-res and NCI-H520-res cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CTNNA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1499" target="_blank" rel="noopener noreferrer">1499</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35222" target="_blank" rel="noopener noreferrer">P35222</a>', 'HUGO Gene symbol': 'CTNNB1', 'Protein name': 'Catenin beta-1', 'Function': 'Key downstream component of the canonical Wnt signaling, involved in cell adhesion and transcription of proteins that promote development and EMT', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27384994%2C%2026860078%2C%2025214561%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27384994, 26860078, 25214561¬†</a>', 'Notes': '1) β-catenin and B-cell lymphoma-extra large (Bcl-xl) were significantly upregulated in Lung cancer A549/CDDP cells compared with A549/WT cells.\xa02) β-catenin activator LiCl reduced the sensitivity of A549/WT cells to cisplatin. 3) β-catenin upregulates the expression of the anti-apoptotic protein Bcl-xl. 4) silencing of β-catenin with siRNA decreased the mRNA and protein expression of Bcl-xl, and sensitized A549/WT cells to cisplatin. 5) High expression levels of CTNNB1, MYC, and CCND1 were associated with poorer overall survival in low-grade Endometrioid endometrial carcinoma (EEC) tumors.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CTNNB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79004" target="_blank" rel="noopener noreferrer">79004</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H467" target="_blank" rel="noopener noreferrer">Q9H467</a>', 'HUGO Gene symbol': 'CUEDC2', 'Protein name': 'moderately conserved ubiquitin-binding domain of about 40 amino acids / CUE domain-containing protein 2', 'Function': 'critical roles in cell cycle, inflammation and tumorigenesis. Phosphorylated by Cdk1 and promotes the release of APC/C from checkpoint inhibition. Interacts with IkB kinase α (IKKα) and IKKβ and has an inhibitory role in the activation of NFκB', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Immune response<br><br> NF-kB signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31205536%5Buid%5D" target="_blank" rel="noopener noreferrer">31205536</a>', 'Notes': '1) overexpression of CUEDC2 might be a promising biomarker to evaluate the progression and to predict likely relapse of serous ovarian carcinoma. 2) higher expression of CUEDC2 was associated with higher resistance to cisplatin. 3) The overall survival (OS) and disease-free survival time (DFS) of patients with cisplatin resistant was shorter than that of those with cisplatin sensitive, respectively, and the cisplatin sensitivity was independent predictor of a shorter OS time and DFS time. 4) Knockdown of CUEDC2 by siRNA enhanced the cisplatin sensitivity of serous ovarian carcinoma cells in SKOV3 cell lines. 5) the phosphorylation of p38 MAPK were obviously increased after CUEDC2 knockdown, while p38 MAPK signaling contributes to cell growth and cell apoptosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CUEDC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8452" target="_blank" rel="noopener noreferrer">8452</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13618" target="_blank" rel="noopener noreferrer">Q13618</a>', 'HUGO Gene symbol': 'CUL3', 'Protein name': 'Cullin-3', 'Function': 'Core component of multiple cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins such as KEAP1. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23939375%2C%2031548347%5Buid%5D" target="_blank" rel="noopener noreferrer">23939375, 31548347</a>', 'Notes': '1) Cisplatin-induced cytotoxicity was augmented by depletion of CUL3, and antagonized by siCUL1 in both ES2 and SKOV3 ovarian cancer cells.\xa02) Patients with metastatic NSCLC with mutations in KEAP1, NFE2L2, or CUL3 have shorter TTF and OS after first-line platinum doublet chemotherapy compared with matched controls. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CUL3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8451" target="_blank" rel="noopener noreferrer">8451</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13619" target="_blank" rel="noopener noreferrer">Q13619</a>', 'HUGO Gene symbol': 'CUL4A', 'Protein name': 'Cullin-4A', 'Function': 'Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28095394%2C%2030562757%5Buid%5D" target="_blank" rel="noopener noreferrer">28095394, 30562757</a>', 'Notes': '1) Activation of the cullin 4a-containing E3 ubiquitin ligase complex CRL leads to ubiquitylation of several key NER proteins such as XPC itself to initiate removal of the DNA lesion.\xa02) Transient knockdown of CUL4A sensitised parental HCT116 cells towards cisplatin. 3) CUL4A and TP53 protein expression was significantly higher in cancerous tissues compared to normal tissues. 4) Significant correlation between CUL4A and TP53 expression was observed. 5) CUL4A expression was an independent prognostic factor for overall survival (OS) and disease-free survival (DFS). 6) patients with tumors that had both CUL4A overexpression and mutant TP53 protein accumulation relapsed and died within a significantly short period after surgery (P < 0.001). 7) patients with both CUL4A+ and TP53+ positive tumors had extremely poor OS and DFS. 8) Knockdown of CUL4A by a siRNA significantly suppressed the progression of EMT, proliferation, migration, and invasion of colon cancer cells in vitro and tumor growth in vivo. 9) ZEB1 silencing blocked CUL4A-driven these processes. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CUL4A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/50624" target="_blank" rel="noopener noreferrer">50624</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86UP6" target="_blank" rel="noopener noreferrer">Q86UP6</a>', 'HUGO Gene symbol': 'CUZD1', 'Protein name': 'CUB and zona pellucida-like domain-containing protein 1', 'Function': 'CUZD1 antiserum inhibits cell attachment and proliferation of ovarian cancer cells so may be involved in these processes. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16862170%5Buid%5D" target="_blank" rel="noopener noreferrer">16862170</a>', 'Notes': '1) the expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) after treatment with several chemotherapeutic drugs. 2) this suppression in HuUO-44 expression was also correlated to the cisplatin sensitivity in two other ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose-dependent manner. 3) HuUO-44 RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced by cisplatin (P<0.01). 4) overexpression of HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (P<0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CUZD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3627" target="_blank" rel="noopener noreferrer">3627</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02778" target="_blank" rel="noopener noreferrer">P02778</a>', 'HUGO Gene symbol': 'CXCL10', 'Protein name': 'C-X-C motif chemokine 10 / interferon gamma-induced protein-10', 'Function': 'Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26336986%5Buid%5D" target="_blank" rel="noopener noreferrer">26336986</a>', 'Notes': '1) In rat liver transplantation model, significant up-regulation of IP10 associated with multidrug resistant genes was found in small-for-size liver graft. 2) high expression of circulating IP10 was significant correlated with tumor recurrence in HCC patients underwent LDLT. 3) Overexpression of IP10 promoted HCC cell proliferation and tumor growth under cisplatin treatment by activation of ATF6/Grp78 signaling. 4) IP10 neutralizing antibody sensitized cisplatin treatment in nude mice. 5) The overexpression of IP10, which induced by liver graft injury, may lead to cisplatin resistance via ATF6/Grp78 ER stress signaling pathway. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CXCL10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6387" target="_blank" rel="noopener noreferrer">6387</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48061" target="_blank" rel="noopener noreferrer">P48061</a>', 'HUGO Gene symbol': 'CXCL12', 'Protein name': 'Stromal cell-derived factor 1', 'Function': 'Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28721072%5Buid%5D" target="_blank" rel="noopener noreferrer">28721072</a>', 'Notes': '1) CXCL12 blocks cisplatin-induced apoptosis in A549. 2) CXCR4 contributes to CXCL12-mediated anti-apoptosis by activating JAK2/STAT3 pathway in NSCLC cells. 3) CXCL12 expression significantly correlated with tumor classification, lymph node metastasis, stage, and tumor size (P<0.05), and the expression of p-STAT3 was significantly associated with lymph node metastasis (P<0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CXCL12" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3576" target="_blank" rel="noopener noreferrer">3576</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10145" target="_blank" rel="noopener noreferrer">P10145</a>', 'HUGO Gene symbol': 'CXCL8', 'Protein name': 'Interleukin-8', 'Function': 'Pro-inflammatory chemokine that is principally a chemoattractant and activator of neutrophils during an immune response; also has cell growth, angiogenic and motogenic effects in different types of malignancies ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26267317,15087251" target="_blank" rel="noopener noreferrer">26267317, 15087251¬†</a>', 'Notes': '1) Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive and reversed platinum resistance in resistant cell lines, 2) IL-8 receptor antagonist treatment also enhanced platinum sensitivity. 3) Nuclear localisation of IL-8RA was only detected in platinum resistant tumours. 4) All cell lines show expression of IL-8 with a rapid transcriptional induction of IL-8 following platinum exposure. 5) high expression of IL-8 is significantly correlated with poor prognosis in ovarian cancer patients receiving platinum-based combination chemotherapy. ', 'Up / down in Pt-resistant cells': 'UNCHANGED/nuclear localization of IL8RA', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CXCL8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7852" target="_blank" rel="noopener noreferrer">7852</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61073" target="_blank" rel="noopener noreferrer">P61073</a>', 'HUGO Gene symbol': 'CXCR4', 'Protein name': 'C-X-C chemokine receptor type 4', 'Function': 'Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27922681%5Buid%5D" target="_blank" rel="noopener noreferrer">27922681</a>', 'Notes': '1) CXCR4\xa0was significantly highly expressed in cisplatin-resistant NSCLC patients and the A549/DDP\xa0cell\xa0line.\xa02) CXCR4 inhibition by siRNA reversed chemoresistance and decreased tumor cell proliferation. 3) overexpression of CXCR4 in NSCLC promotes cisplatin resistance via CXCR4-mediated CYP1B1 upregulation. 4) The expression levels of stromal cell-derived factor (SDF)-1, CXCR4, matrix metalloproteinase (MMP) 2, and MMP9 mRNA and protein levels were significantly reduced in CDDP-treated cells compared to untreated ovarian CICs. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CXCR4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1545" target="_blank" rel="noopener noreferrer">1545</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16678" target="_blank" rel="noopener noreferrer">Q16678</a>', 'HUGO Gene symbol': 'CYP1B1', 'Protein name': 'Cytochrome P450 1B1', 'Function': 'A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroid hormones and vitamins; uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27922681%2C%2024408020%5Buid%5D" target="_blank" rel="noopener noreferrer">27922681, 24408020</a>', 'Notes': '1) Increasing evidence has shown that many cytotoxic drugs are metabolized by cytochrome p450 (CYP) enzymes. 2) Bioinformatics analysis showed that the expression of CYP1B1 had a positive correlation with CXCR4, 3) CYP1B1 mRNA and protein level were significantly downregulated as a result of CXCR4 knockdown. 4) the CYP1B1 silencing significantly decreased CXCR4 expression levels and cisplatin resistance. 5) CYP1B1 overexpression is associated with poor survival and cisplatin resistance in NSCLC. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CYP1B1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1571" target="_blank" rel="noopener noreferrer">1571</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05181" target="_blank" rel="noopener noreferrer">P05181</a>', 'HUGO Gene symbol': 'CYP2E1', 'Protein name': 'cytochrome P450 2E1', 'Function': 'High concentration in ER. A cytochrome P450 monooxygenase involved in the metabolism of fatty acids. Hydroxylates fatty acids specifically at the omega-1 position displaying the highest catalytic activity for saturated fatty acids ', 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response<br><br> Metabolism/Lipid<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16251482%2C%2012675844%2C%2015239125%5Buid%5D" target="_blank" rel="noopener noreferrer">16251482, 12675844, 15239125</a>', 'Notes': '1) cisplatin-treated cells overexpressing CYP2E1 produce a significant increase in oxidative stress compared to cells that do not express this enzyme, finally causing liver damage. 2) CYP2E1 is responsible for contributing to cisplatin-induced acute renal failure, since CYP2E1-depleted mice maintained a preserved kidney function compared to those with normal enzyme expression. 3) CYP2E1 revealed low level of expression in 70% of the tumor tissues at both mRNA and protein levels. 4) The low expression of CYP2E1 was significantly correlated with the aggressive tumor phenotype, including poor differentiation status (by the Edmondson grading system) (p=0.038), absence of tumor capsule (p=0.030) and younger age of the hepatocellular carcinoma (HCC) patients (p=0.002). 5) CYP2E1 expression level and pTNM stage were independent prognostic factors for disease-free survival. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CYP2E1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51339" target="_blank" rel="noopener noreferrer">51339</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NYF0" target="_blank" rel="noopener noreferrer">Q9NYF0</a>', 'HUGO Gene symbol': 'DACT1', 'Protein name': 'Dapper1 Antagonist of Catenin-1 ', 'Function': 'canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family proteins', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28839145%5Buid%5D" target="_blank" rel="noopener noreferrer">28839145</a>', 'Notes': '1) all tested EOC cell lines and primary EOC tissues, especially type I EOC, were observed to have significantly lower DACT1 expression than normal controls. 2) Overexpression of DACT1 (3AO-DACT1) results in slower growth and formed smaller tumours in nude mice compared to 3AO-NC. 3) 3AO-DACT1 had lower levels of key mediators of canonical Wnt signalling, Dvl2 and β-catenin, GSK-3β with phosphorylated Ser9, and the Wnt/β-catenin target genes, with significantly lower nuclear β-catenin levels. 4) 3AO-DACT which contained higher levels of lipidated LC3 (LC3-II) and Beclin1, but lower levels of p62/SQSTM1, were more sensitive to cis-platinum. 5) chloroquine, an autophagy inhibitor,  partially rescued its cis-platinum sensitivity. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DACT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1612" target="_blank" rel="noopener noreferrer">1612</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P53355" target="_blank" rel="noopener noreferrer">P53355</a>', 'HUGO Gene symbol': 'DAPK1', 'Protein name': 'Death-associated protein kinase 1', 'Function': 'calmodulin dependent kinase, positive mediator of g-IFN induced programmed cell death', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20048748%5Buid%5D" target="_blank" rel="noopener noreferrer">20048748</a>', 'Notes': '1) TSA induced apoptosis in both A549 cells and A549/CDDP cells. 2) TSA enhanced the sensitivity of A549/CDDP cells to cisplatin, along with concomitant DAPK up-regulation. 3) When DAPK was over-expressed, A549/CDDP cells became sensitive to cisplatin and the cytotoxicity of TSA could be increased. 4) the cytotoxicity of TSA could be alleviated by inhibition of DAPK activity by the expression of a recombinant C-terminal fragment of DAPK or RNA interference.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DAPK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1613" target="_blank" rel="noopener noreferrer">1613</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43293" target="_blank" rel="noopener noreferrer">O43293</a>', 'HUGO Gene symbol': 'DAPK3', 'Protein name': 'Death-associated protein kinase 3', 'Function': 'Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21775533%5Buid%5D" target="_blank" rel="noopener noreferrer">21775533</a>', 'Notes': '1) Among 157 successfully genotyped SNPs, 9 and 10 SNPs were top SNPs associated with OS for patients with NSCLC and SCLC, respectively, although they were not significant after adjusting for multiple testing. 2) Fifteen genes, including 7 located within 200 kb up or downstream of the 4 top SNPs and 8 genes for which expression was correlated with 3 SNPs in LCLs were selected for siRNA screening. 3) Knockdown of DAPK3 and METTL6, for which expression levels were correlated with the rs11169748 and rs2440915 SNPs, significantly decreased cisplatin sensitivity in lung cancer cells.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DAPK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1616" target="_blank" rel="noopener noreferrer">1616</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UER7" target="_blank" rel="noopener noreferrer">Q9UER7</a>', 'HUGO Gene symbol': 'DAXX', 'Protein name': 'Death domain-associated protein 6', 'Function': '1) Transcription corepressor known to repress transcriptional potential of several sumoylated transcription factors.\xa02)  MDM2-DAXX-USP7 complex prevents MDM2 self-ubiquitination and enhances the intrinsic E3 ligase activity of MDM2 towards TP53, thereby promoting TP53 ubiquitination and subsequent proteasomal degradation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'p53 signaling<br><br> TGF-β signaling<br><br> Transcription<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29906705%5Buid%5D" target="_blank" rel="noopener noreferrer">29906705</a>', 'Notes': '1) Adenovirus E1B 55-kilodalton (E1B-55K) mediated DAXX degradation represents a potential mechanism by which E1B-55K sensitizes cancer cells to chemotherapy. 2) Ovarian cancer cells with E1B-55K expression were more sensitive to cisplatin than cells without E1B-55K expression. 3) In vivo C13* xenograft studies showed that the combination of cisplatin and E1B-55K was markedly more effective to slow tumor growth and to confer prolonged survival of tumor-bearing mice than either cisplatin or E1B-55K alone. 4) the expression levels of DAXX in OV2008 and A2780 fell in a dose-dependent manner, but it was increased in cisplatin-resistant C13* and A2780-DDP cells after cisplatin treatment. 5) Knockdown of DAXX enhanced the sensitivity to cisplatin both in OV2008 and C13* cells, while overexpression of DAXX restored the cisplatin resistance phenotype in OV2008 cells. 6) DAXX expression in ovarian cancer tissues was related to the response to chemotherapy and prognosis in ovarian cancer patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; INCREASED in R', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DAXX" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9937" target="_blank" rel="noopener noreferrer">9937</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6PJP8" target="_blank" rel="noopener noreferrer">Q6PJP8</a>', 'HUGO Gene symbol': 'DCLRE1A', 'Protein name': 'DNA cross-link repair 1A protein', 'Function': 'May be required for DNA interstrand cross-link repair. Also required for checkpoint mediated cell cycle arrest in early prophase in response to mitotic spindle poisons.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29048400%2C%2015572677%5Buid%5D" target="_blank" rel="noopener noreferrer">29048400, 15572677</a>', 'Notes': '1) Overexpressed in adaptive cisplatin resistance ovarian cancer stem cell line A2780. 2) SNM1A- and SNM1B-deficient cells were sensitive to cisplatin but not to X-rays. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DCLRE1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64858" target="_blank" rel="noopener noreferrer">64858</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H816" target="_blank" rel="noopener noreferrer">Q9H816</a>', 'HUGO Gene symbol': 'DCLRE1B', 'Protein name': "5' exonuclease Apollo", 'Function': "5'-3' exonuclease that plays a central role in telomere maintenance. Also functions within the Fanconi anemia pathway in response to DNA interstrand crosslinks", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> DDR/HR<br><br> DDR/telomere', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28430596%5Buid%5D" target="_blank" rel="noopener noreferrer">28430596</a>', 'Notes': 'Depletion of hSNM1B/Apollo renders human cells hypersensitive towards ICL-inducing agents, resulting in reduced survival rates after treatment with MMC and cisplatin in DT40 cells and Hela cells', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DCLRE1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64421" target="_blank" rel="noopener noreferrer">64421</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96SD1" target="_blank" rel="noopener noreferrer">Q96SD1</a>', 'HUGO Gene symbol': 'DCLRE1C', 'Protein name': 'Protein artemis', 'Function': 'Functions within the Fanconi anemia pathway in response to DNA interstrand crosslinks, functions  in a complex with DNAPK in the non homologous end joining (NHEJ) pathway to form coding and signal joints respectively.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21785230%5Buid%5D" target="_blank" rel="noopener noreferrer">21785230</a>', 'Notes': 'The Artemis-deficient cells were not as sensitive as the XRCC4-deficient cells, except to cisplatin and mitomycin C.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DCLRE1C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1642" target="_blank" rel="noopener noreferrer">1642</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16531" target="_blank" rel="noopener noreferrer">Q16531</a>', 'HUGO Gene symbol': 'DDB1', 'Protein name': 'DNA damage-binding protein 1', 'Function': 'Binds to DDB2 to form the UV-DDB complex, which may recognize UV-induced DNA damage and recruit proteins for NER.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> CSC<br><br> DDR/NER<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24249678%5Buid%5D" target="_blank" rel="noopener noreferrer">24249678</a>', 'Notes': '1) DDB1 and DDB2 cooperate to repress Bcl-2 transcription.\xa02) As DDB2', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DDB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1643" target="_blank" rel="noopener noreferrer">1643</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92466" target="_blank" rel="noopener noreferrer">Q92466</a>', 'HUGO Gene symbol': 'DDB2', 'Protein name': 'DNA damage-binding protein 2', 'Function': '1) DNA repair factor in NER.\xa02) New functions beyond DNA repair: inhibiting Bcl-2 and p21; blocking EMT; regulating NF-κB activity (23774208); mediating premature senescence. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> CSC<br><br> DDR/NER<br><br> EMT<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20013802%2C%2024574518%5Buid%5D" target="_blank" rel="noopener noreferrer">20013802, 24574518</a>', 'Notes': '1) DDB2 is not required for the repair of cisplatin-induced DNA damage, but can be induced by cisplatin treatment. 2) DDB2-deficient noncancer cells exhibit enhanced resistance to cell growth inhibition and apoptosis induced by cisplatin than cells with fully restored DDB2 function. 3) DDB2 expression in cisplatin-resistant ovarian cancer cell line CP70 and MCP2 was lower than their cisplatin-sensitive parental A2780 cells. 4) Overexpression of DDB2 sensitized CP70 cells to cisplatin-induced cytotoxicity and apoptosis via activation of the caspase pathway and downregulation of antiapoptotic Bcl-2 protein. 5) Overexpressing DDB2 in human ovarian cancer cells suppressed its capability to recapitulate tumors in athymic nude mice. 6) DDB2 is able to reduce the cancer stem cell (CSC) population characterized with high aldehyde dehydrogenase activity in ovarian cancer cells, probably through disrupting the self-renewal capacity of CSCs. 7) Low DDB2 expression correlates with poor outcomes among patients with ovarian cancer', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DDB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/220042" target="_blank" rel="noopener noreferrer">220042</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IXT1" target="_blank" rel="noopener noreferrer">Q8IXT1</a>', 'HUGO Gene symbol': 'DDIAS', 'Protein name': 'DNA damage-induced apoptosis suppressor protein\xa0/ Nitric oxide-inducible gene protein', 'Function': 'May be an anti-apoptotic protein involved in DNA repair or cell survival.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26493727%5Buid%5D" target="_blank" rel="noopener noreferrer">26493727</a>', 'Notes': '1) NFATc1 or DDIAS inhibition clearly enhanced apoptosis induced by cisplatin in lung cancer NCI-H1703 and A549 cells. 2) DDIAS overexpression rescued NCI-H1703 cells from cisplatin-mediated cell death and caspase-3/7 activation. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DDIAS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1649" target="_blank" rel="noopener noreferrer">1649</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35638" target="_blank" rel="noopener noreferrer">P35638</a>', 'HUGO Gene symbol': 'DDIT3', 'Protein name': 'DNA damage-inducible transcript 3 protein', 'Function': 'Multifunctional transcription factor in ER stress response;\xa0plays an essential role in apoptotic execution pathways triggered by ER stress', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ER stress response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29702190%5Buid%5D" target="_blank" rel="noopener noreferrer">29702190</a>', 'Notes': '1) CHOP expression in tumor tissues form 69 lung cancer patients: deficient CHOP expression is associated with poor prognosis. 2) Cisplatin-resistant lung cancer cells exhibited lower expression of CHOP compared to that in sensitive lung cancer cells, 3) silencing or augmenting CHOP expression enhanced or impaired cisplatin resistance. 4) CHOP is directly associated with the regulation of autophagy or apoptosis-regulatory genes including LC3-II, death receptor 5 (DR5), and telomere repeat-binding factor 3. 5) CHOP was identified as a target of miR-146a, and increased miR-146a expression in lung cancer cells was suggested to be responsible for CHOP mRNA down-regulation. 6) animal models confirmed that abnormally expressed miR-146a in lung cancer cells does not affect growth, but rather alters chemotherapy sensitivity. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DDIT3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/780" target="_blank" rel="noopener noreferrer">780</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q08345" target="_blank" rel="noopener noreferrer">Q08345</a>', 'HUGO Gene symbol': 'DDR1', 'Protein name': 'Epithelial discoidin domain-containing receptor 1', 'Function': '1) Tyrosine kinase that functions as a cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix. 2) interacts with α2β1 integrin receptors and activates cell signaling pathways, which increased the expression of mesenchymal markers. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28743276%5Buid%5D" target="_blank" rel="noopener noreferrer">28743276</a>', 'Notes': "1) Both the mRNA and protein of DDR1 were aberrantly overexpressed in ovarian cancer tissues compared with the normal control. 2) high expression of DDR1 was statistically associated with lymph node metastasis, TNM stage and distant metastasis (P < 0.05) but not with age and differentiation (P > 0.05)  3) the 3-year overall survival (OS) rate of the group with DDR1 high expression was significantly lower than that of the group with DDR1 low expression (41.67% vs 74.55%, P = 0.0091). 4) a negative correlation between DDR1 and a tumor suppressor miRNA, miR-199a-3p, was observed in ovarian cancer tissues. 5) miR-199a-3p decreased the expression of DDR1 via targeting the 3'UTR of DDR1 mRNA. 6) miR-199a-3p inhibitor enhanced the cisplatin resistance of SKOV3 cells. 7) knockdown of DDR1 by siRNA significantly increased the sensitivity of SKOV3 and HO-8910 cells to cisplatin treatment and reverse the cisplatin resistance induced by miR-199a-3p inhibor. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DDR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79139" target="_blank" rel="noopener noreferrer">79139</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BUN8" target="_blank" rel="noopener noreferrer">Q9BUN8</a>', 'HUGO Gene symbol': 'DERL1', 'Protein name': 'Derlin-1', 'Function': 'Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28178653%5Buid%5D" target="_blank" rel="noopener noreferrer">28178653</a>', 'Notes': '1) Derlin-1 was upregulated in 38.6% (58/150) cases of cancer samples. The rate of Derlin-1 overexpression was higher in muscle invasive bladder cancer (MIBC) than non-muscle invasive bladder cancer (NMIBC) (p=0.0079). 2) Derlin-1 was a predicting factor for poor patient prognosis. 3) Knockdown of Derlin-1 inhibited while its overexpression facilitated cell invasion and colony formation. 4) Derlin-1 overexpression induced\xa0cisplatin\xa0resistance while its depletion sensitized cancer cells to\xa0cisplatin. 5) Derlin-1 activated AKT phosphorylation and upregulated Bcl-2 expression. 6) Blockage of AKT signaling by LY294005 abolished the effects of Derlin-1 on Bcl-2 and\xa0cisplatin\xa0resistance. 7) Derlin-1 interacted with p110α subunit of PI3K. 8) Derlin-1 depletion downregulated and its overexpression upregulated cell MMP-2/9 expression and ERK phosphorylation. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DERL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1719" target="_blank" rel="noopener noreferrer">1719</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00374" target="_blank" rel="noopener noreferrer">P00374</a>', 'HUGO Gene symbol': 'DHFR', 'Protein name': 'Dihydrofolate reductase', 'Function': 'Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/amino acid<br><br> Metabolism/One carbon', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19446547%2C%2023903781%2C%2026887775%5Buid%5D" target="_blank" rel="noopener noreferrer">19446547, 23903781, 26887775</a>', 'Notes': '1) Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. 2) berberine suppresses the growth of cDDP-resistant cells more than the sensitive counterparts, by interfering with the expression of folate cycle enzymes, dihydrofolate reductase (DHFR) and thymidylate synthase (TS). 3) Overexpression of DHFR gene result in cDDP-resistance in ovarian cancer SKOV3 cell line. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DHFR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/81624" target="_blank" rel="noopener noreferrer">81624</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NSV4" target="_blank" rel="noopener noreferrer">Q9NSV4</a>', 'HUGO Gene symbol': 'DIAPH3', 'Protein name': 'Diaphanous (mDia)-related formin-2', 'Function': 'Formin proteins are key regulators of F-actin and microtubule cytoskeletal dynamics. mDia formins (mDia1-3) are Rho GTPase effectors. mDia proteins regulate F-actin networks critical for maintaining the integrity of multi-cellular epithelial structures.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26898799%2C%2029856124%5Buid%5D" target="_blank" rel="noopener noreferrer">26898799, 29856124</a>', 'Notes': '1) critical role for mammalian Diaphanous (mDia)-related formin-2 in maintaining EOC spheroid structure. 2) Combining either cisplatin or taxol with SMIFH2 did not significantly enhance the effects of either drug alone in ES2 monolayers, while Skov3 monolayers treated with taxol or cisplatin and SMIFH2 showed significant additive inhibition of viability.  3) Combining mDia functional inhibition in 2D and 3D EOC spheroid models with standard chemotherapeutics used in EOC therapy is a more effective therapeutic strategy. 4) In muscle‐invasive bladder cancer (MIBC), the expression of DIAPH3, EMR2, MMP1, STX12, and UHMK1 was found to be significantly associated with response to Gem/Cisplatin. 5) High expression of DIAPH3, LMAN1, PPP2R5E, and UHMK1 and low HLA‐E expression were significantly associated with shorter recurrence‐free survival (P = .002, P = .006, P = .008, P = .002, and P = .009). 6) high DIAPH3, HLA‐E, and LMAN1 expression was significantly associated with shorter overall survival (P = .043, P = 0.018, and P = .014), and high PPP2R5E and UHMK1 expression showed a trend toward association with shorter overall survival in MIBC (P = .052 and P = .078).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': '3D-cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DIAPH3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23405" target="_blank" rel="noopener noreferrer">23405</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UPY3" target="_blank" rel="noopener noreferrer">Q9UPY3</a>', 'HUGO Gene symbol': 'DICER1', 'Protein name': 'Endoribonuclease Dicer', 'Function': 'RNase III family, processes micro (mi)-RNA precursors into mature miRNAs', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30221734%2C%2015723655%2C%2019092150%5Buid%5D" target="_blank" rel="noopener noreferrer">30221734, 15723655, 19092150</a>', 'Notes': '1) Dicer was expressed at low levels in cisplatin‑resistant A2780 cells when compared with parental cells. 2) knocking down Dicer using shRNA decreased the sensitivity of A2780 and CAOV3 cells to cisplatin. 3) downregulating Dicer significantly inhibited cisplatin‑induced apoptosis in ovarian cancer cells, and decreased the levels of proteins involved in apoptosis signaling pathways, including P73, P63, P53, caspase‑9 and caspase‑3. 4) logistic regression analysis demonstrated that the higher incidence of reduced Dicer expression in poorly differentiated tumors remained significant even after correction for other parameters (P = 0.02). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DICER1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9077" target="_blank" rel="noopener noreferrer">9077</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95661" target="_blank" rel="noopener noreferrer">O95661</a>', 'HUGO Gene symbol': 'DIRAS3', 'Protein name': 'GTP-binding protein Di-Ras3', 'Function': 'ras superfamily; associated with growth suppression/tumor supressor; regulates autophagy in certain cancer cells by regulating the autophagosome initiation complex. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26247722%5Buid%5D" target="_blank" rel="noopener noreferrer">26247722</a>', 'Notes': '1) ARHI (DIRAS3) is downregulated in 60% of ovarian cancers and associated with shortened progression-free survival. 2) In cell culture, re-expression of ARHI induces autophagy and ovarian cancer cell death within 72\u2009h. 3) In xenografts, re-expression of ARHI arrests cell growth and induces autophagy, but does not kill engrafted cancer cells.  When ARHI levels are reduced after 6 weeks, dormancy is broken and xenografts grow promptly. 4) Re-expression of ARHI enhanced the cytotoxic effect of cisplatin in cell culture, increasing caspase-3 activation and PARP cleavage by inhibiting ERK and HER2 activity and downregulating XIAP and Bcl-2. 5) In xenografts, treatment with cisplatin significantly slowed the outgrowth of dormant autophagic cells after reduction of ARHI. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DIRAS3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22943" target="_blank" rel="noopener noreferrer">22943</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94907" target="_blank" rel="noopener noreferrer">O94907</a>', 'HUGO Gene symbol': 'DKK1', 'Protein name': 'dickkopf WNT signaling pathway inhibitor 1', 'Function': '1) secreted proteins characterized by two cysteine-rich domains that mediate protein-protein interactions. 2) binds to the LRP6 co-receptor and inhibits beta-catenin-dependent Wnt signaling. ', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26353782%2C%2019303159%5Buid%5D" target="_blank" rel="noopener noreferrer">26353782, 19303159</a>', 'Notes': '1) global gene expression profiles of NSCLC clones surviving a pulse treatment with cisplatin was analysed, and DKK1 is among the top deregulated genes by microarray and were validated by q-RT-PCR. 2) Knockdown of DKK1 by siRNA sensitized for cisplatin in two different NSCLC cell lines and in ovarian A2780 cells, but not in the A2780 cis subline made resistant to cisplatin by chronic exposure, suggesting a role of DKK1 in intrinsic but not acquired platinum refractoriness. 3) The cisplatin sensitization from NSCLC were validated also in ovarian cancer cells. 4) The expression level of DKK1 was associated with the staining pattern of beta-catenin in hepatocellular carcinomas (HCC) cell lines, 5) DKK1 overexpression correlated with beta-catenin cytoplasmic/nuclear accumulation in clinical HCC samples (P=0.011, correlation coefficient=0.144). 6) High DKK1 expression predicted unfavorable prognosis in HCC patients, especially in early stage patients and those with normal AFP levels.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DKK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27122" target="_blank" rel="noopener noreferrer">27122</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBP4" target="_blank" rel="noopener noreferrer">Q9UBP4</a>', 'HUGO Gene symbol': 'DKK3', 'Protein name': 'Dickkopf-related protein 3', 'Function': 'Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26093488%5Buid%5D" target="_blank" rel="noopener noreferrer">26093488</a>', 'Notes': '1) DKK3 was overexpressed (>2-fold) in 75.8% (72/95) of esophageal adenocarcinomas. 2) Stable transfection of DKK3 significantly increased proliferation (P\xa0<\xa0.05) and Matrigel invasion (P\xa0<\xa0.001). 3) Levels of\xa0SMAD4, a key mediator of the transforming growth factor-ß pathway, increased after activin treatment of OE33/DKK3, and siSMAD4 significantly decreased Matrigel invasion, suggesting that DKK3 acts through the transforming growth factor-β pathway. 4) OE33/DKK3 cells increased endothelial tube formation and were significantly more resistant to 5-fluorouracil and\xa0cisplatin, and DKK3 expression was significantly higher in chemoresistant esophageal adenocarcinomas (P\xa0<\xa0.005). 5) In NOD/SCIDγ mice, OE33/DKK3 cells resulted in tumors at all sites (8/8), whereas vector cells grew in only 1 of 8 sites. Nodal metastases were also significantly increased in patients with esophageal adenocarcinomas highly overexpressing DKK3, 28 of 32 (88%) versus 42 of 63 (68%) (P\xa0<\xa0.05).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DKK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1786" target="_blank" rel="noopener noreferrer">1786</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26358" target="_blank" rel="noopener noreferrer">P26358</a>', 'HUGO Gene symbol': 'DNMT1', 'Protein name': 'DNA methyltransferase 1', 'Function': 'major enzyme responsible for maintaining methylation patterns following DNA replication and shows a preference for hemi-methylated DNA.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Oncogene signaling/EGFR<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28222434,26351843,23318422,28791708,33222246,21458988" target="_blank" rel="noopener noreferrer">28222434, 26351843, 23318422, 28791708, 33222246, 21458988</a>', 'Notes': '1) miR-30a-5p and miR-30c-5p dramatically decreased in cisplatin-resistant CP70 cells due to overexpressed-DNMT1 induced aberrant methylation. 2) miR-30a/c-5p in turn directly inhibited DNMT1. 3) Forced expression of miR-30a/c-5p or knocking down of DNMT1 promoted cisplatin susceptibility and partially reversed epithelial-mesenchymal transition (EMT) in CP70 cells. 4) ectopic expression of DNMT1 induced cisplatin resistance and partial EMT in cisplatin-sensitive ovarian cancer A2780 cells. 5) Acute cisplatin treatment induces an EGFR mediated increase in DNMT activity. 6) Cisplatin resistant cells also showed increased DNMT activity and global methylation. 7) nude mice injected intraperitoneally with SKOV3/DDP cells transfected with DNNT-targeting miR-152 mimics exhibited upregulated cisplatin sensitivity in vivo. 8) In vivo administration of DNMT1-containing exosomes exacerbated xenograft progression and reduced overall survival significantly. 9) Dual targeting of G9a and DNMT1 with epigenetic small molecule inhibitors such as CM272 markedly reduced cholangiocarcinoma CCA cells proliferation and synergized with Cisplatin. 10) Patients of gastric cancer with low DNMT1 expression demonstrated a significantly better histopathological/clinical response (P=0.03/P=0.008) and OS (P(log-rank)=0.001). 11) In vitro, knockdown of DNMT1 caused an increased chemosensitivity towards cisplatin. 12) Combined treatment with cisplatin and DAC showed a synergistic effect leading to increased cytotoxicity in the cisplatin-resistant cell line AGS.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DNMT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9046" target="_blank" rel="noopener noreferrer">9046</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60496" target="_blank" rel="noopener noreferrer">O60496</a>', 'HUGO Gene symbol': 'DOK2', 'Protein name': 'Docking protein 2', 'Function': 'enzymatically inert adaptor or scaffolding protein; reduces cell activation induced by  IL-4, as well as other cytokines (negative feedback loop) (24963146); modulating Bcr-Abl signaling.  recruitment of DOK2 to EGFR mediates inhibition of downstream activation of RAS (24255704)', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23684582%5Buid%5D" target="_blank" rel="noopener noreferrer">23684582</a>', 'Notes': '1) DOK2 is among the 296 genes that were methylated and transcriptionally repressed in platinum resistant patients. 2) DOK2 is among the 19 genes that when suppressed altered the chemoresistance of the cells in culture. 3) The loss of DOK2 decreased the level of apoptosis in response to carboplatin. 4) in cells with reduced DOK2, the level of anoikis was decreased. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DOK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55332" target="_blank" rel="noopener noreferrer">55332</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8N682" target="_blank" rel="noopener noreferrer">Q8N682</a>', 'HUGO Gene symbol': 'DRAM1', 'Protein name': 'DNA damage regulated autophagy modulator 1', 'Function': 'regulated by p53; a lysosomal membrane protein that is required for the induction of autophagy. Decreased transcriptional expression of this gene is associated with various tumors.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Autophagy<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28545442%2C%2026146406%2C%2017397945%5Buid%5D" target="_blank" rel="noopener noreferrer">28545442, 26146406, 17397945</a>', 'Notes': '1) Cisplatin-induced cell death in Cisplatin-sensitive ovarian cancer cells (A2780) was mediated by p53-induced apoptosis acompanied by expresson of damage-regulated autophagy modulator (DRAM). 2) In Cisplatin-resistant cells, decreased\xa0DRAM\xa0expression (p\xa0<\xa00.01) hindered p21-mediated cell death and contributed to cisplatin resistance.\xa03) N-myc and STAT interactor (NMI) expressing breast cancer cells showed autophagic vacuoles and LC3 processing; NMI expression increased the cisplatin sensitivity of the breast cancer cells. 4) DRAM1 is regulated by NMI and NMI sensitizes breast cancer cells to cisplatin treatment through DRAM1 dependent autophagy. 5) p53 siRNA prevented cisplatin-mediated up-regulation of FLJ11259/DRAM in NT2/D1 cells. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DRAM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1828" target="_blank" rel="noopener noreferrer">1828</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q02413" target="_blank" rel="noopener noreferrer">Q02413</a>', 'HUGO Gene symbol': 'DSG1', 'Protein name': 'Desmoglein-1', 'Function': 'Component of intercellular desmosome junctions. Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22333708%5Buid%5D" target="_blank" rel="noopener noreferrer">22333708</a>', 'Notes': '1) Univariate analyses identified, among others, negative membranous DSG1 staining (P=0.009), negative cytoplasmic DSC1 staining (P=0.012) and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.004) to be associated with improved cancer-specific survival (CSS). 2) On multivariate analyses positive DSG1 (membranous)+DSC1 (cytoplasmic) staining (HR 6.95,\xa0P=0.044), large tumour size and lymph node metastases (HR 6.44,\xa0P=0.004) and radiation without chemotherapy (HR 6.73\xa0P=0.004) were associated with worse CSS. 3) On univariate analysis, improved disease-free survival was associated with negative membranous staining of DSG1 (P=0.047), and negative DSG1 (membranous)+negative DSC1 (cytoplasmic) staining (P=0.025), among others.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DSG1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/90527" target="_blank" rel="noopener noreferrer">90527</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q1HG43" target="_blank" rel="noopener noreferrer">Q1HG43</a>', 'HUGO Gene symbol': 'DUOXA1', 'Protein name': 'Dual oxidase maturation factor 1', 'Function': 'Dual oxidases DUOX1 and DUOX2 are NADPH oxidases which are involved in hydrogen peroxide production necessary for thyroid hormonogenesis. They form a heterodimer with specific maturation factors DUOXA1 and DUOXA2, respectively, which is essential for the maturation and function of the DUOX enzyme complexes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30166592%2C%2029704517%5Buid%5D" target="_blank" rel="noopener noreferrer">30166592, 29704517</a>', 'Notes': '1) A total of 7 ROS-related genes upregulated in cisplatin-resistant ovarian cancer IGROV1 CR cells when compared to sensitive GROV1 cells. Among these genes, the expression level change of DUOXA1 is the most significant upregulated. 2) resulting in elevated ROS level sustains the activation of ATR-Chk1 pathway, leading to resistance to cisplatin in ovarian cancer cells. 3) using qHTCS we identified two Chk1 inhibitors (PF-477736 and AZD7762) that re-sensitize resistant cells to cisplatin. 4) Blocking this novel pathway by inhibiting ROS, DUOXA1, ATR or Chk1 effectively overcomes cisplatin resistance in vitro and in vivo. 5) the clinical studies also confirm the activation of ATR and DOUXA1 in ovarian cancer patients, and elevated DOUXA1 or ATR-Chk1 pathway correlates with poor prognosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DUOXA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1843" target="_blank" rel="noopener noreferrer">1843</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28562" target="_blank" rel="noopener noreferrer">P28562</a>', 'HUGO Gene symbol': 'DUSP1', 'Protein name': 'Dual specificity protein phosphatase 1', 'Function': "Dual specificity phosphatase that dephosphorylates MAP kinase MAPK1/ERK2 on both 'Thr-183' and 'Tyr-185'", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18089824%2C%2026581245%5Buid%5D" target="_blank" rel="noopener noreferrer">18089824, 26581245</a>', 'Notes': '1) in the human ovarian cancer cell lines, cisplatin induces MKP-1 through ERK2-mediated phosphorylation. 2) inhibition of ERK2 activity by inhibitor U0126 or by si RNA decreases MKP-1 induction, leading to an increase in cisplatin-induced cell death. 3) MKP-1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistance. 4) MKP-1 downregulation suppresses PARP-1 and PAR protein expression and cisplatin resistance. 6) MKP-1 suppresses MAPK activities to maintain PARP-1 and PAR levels. 7) JNK is the protein that is responsible for suppressing PARP-1 expression. 8) analysis of TCGA data showed that increased DUSP1 expression was associated with decreased overall (P= 0.049) and progression-free (P= 0.0005) survival in ovarian cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DUSP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1848" target="_blank" rel="noopener noreferrer">1848</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16828" target="_blank" rel="noopener noreferrer">Q16828</a>', 'HUGO Gene symbol': 'DUSP6', 'Protein name': 'Dual specificity protein phosphatase 6', 'Function': 'Dual specificity protein phosphatase 6. Inactivates MAP kinases. Has a specificity for the ERK family ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18632752%5Buid%5D" target="_blank" rel="noopener noreferrer">18632752</a>', 'Notes': '1) MKP3 is underexpressed in ovarian cancer. 2) Both cispaltin-resistant A2780cp and C13* cell lines had relatively low expression protein levels of MKP3. 3) MKP3, a negative regulator of ERK1/2, lost its expression particularly in the protein level, was significantly correlated with high ERK1/2 activity in primary human ovarian cancer cells. 4) the loss of MKP3 protein was associated with high intracellular ROS accumulation such as hydrogen peroxide. 5) shRNA knock down of MKP3 resulted in increased ERK1/2 activity, cell proliferation rate, anchorage-independent growth ability and resistance to cisplatin in ovarian cancer cells. 6) enforced expression of MKP3 in MKP3-deficient ovarian cancer cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice. 7) the enforced expression of MKP3 succeeded to sensitize ovarian cancer cells to cisplatin-induced apoptosis in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DUSP6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1856" target="_blank" rel="noopener noreferrer">1856</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14641" target="_blank" rel="noopener noreferrer">O14641</a>', 'HUGO Gene symbol': 'DVL2', 'Protein name': 'Segment polarity protein dishevelled homolog', 'Function': 'Wnt signal transduction pathways. Participates both in canonical and non-canonical Wnt signaling by binding to the cytoplasmic C-terminus of frizzled family members and transducing the Wnt signal to down-stream effectors.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27432651%5Buid%5D" target="_blank" rel="noopener noreferrer">27432651</a>', 'Notes': '1) DVL2 was over-expressed in cisplatin-resistant human lung cancer cells A549/CDDP compared to the parental A549 cells. 2) Inhibition of DVL2 by its inhibitor (3289-8625) or shDVL2 resensitized A549/CDDP cells to cisplatin. 3) over-expression of DVL2 in A549 cells increased the protein levels of BCRP, MRP4, and Survivin, which are known to be associated with chemoresistance, 4) inhibition of DVL2 in A549/CDDP cells decreased these protein levels, and reduced the accumulation and nuclear translocation of β-catenin. 5) shβ-catenin abolished the DVL2-induced the expression of BCRP, MRP4, and Survivin. 6) GSK3β/β-catenin signals were aberrantly activated by DVL2, and inactivation of GSK3β reversed the shDVL2-induced down-regulation of β-catenin.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DVL2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1857" target="_blank" rel="noopener noreferrer">1857</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92997" target="_blank" rel="noopener noreferrer">Q92997</a>', 'HUGO Gene symbol': 'DVL3', 'Protein name': 'Segment polarity protein dishevelled homolog DVL-3', 'Function': 'Involved in the signal transduction pathway mediated by multiple Wnt genes.', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18225596%2C%2020572159%5Buid%5D" target="_blank" rel="noopener noreferrer">18225596, 20572159</a>', 'Notes': '1) Dvl stealth RNAi down-regulated the expression of Dvl-3 in mesothelioma cells and Dvl stealth RNAi and cisplatin in combination suppressed cell growth synergistically. 2) both protein and mRNA of Dvl-1 and Dvl-3 are overexpressed in NSCLC in a manner related to poor prognosis. Dvl-1 may affect the biological behavior of lung cancer cells mainly through beta-catenin (canonical Wnt pathway), while Dvl-3 mainly through p38 and JNK pathway (noncanonical Wnt pathway).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DVL3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8655" target="_blank" rel="noopener noreferrer">8655</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P63167" target="_blank" rel="noopener noreferrer">P63167</a>', 'HUGO Gene symbol': 'DYNLL1', 'Protein name': 'Dynein light chain 1, cytoplasmic', 'Function': 'non-catalytic accessory components of the cytoplasmic dynein 1 complex; inhibitor of DNA end resection', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30464262%2C%2030559443%5Buid%5D" target="_blank" rel="noopener noreferrer">30464262, 30559443</a>', 'Notes': '1) DYNLL1 was among the top-ranked factors that cause resistance in both the olaparib and platinum screen. 2) The loss of\xa0DYNLL1\xa0enables\xa0DNA\xa0end\xa0resection\xa0and restores homologous recombination in BRCA1-mutant\xa0cells, thereby inducing resistance to platinum drugs and inhibitors of poly(ADP-ribose) polymerase. 3) Low expression of DYNLL1 significantly correlates with worse PFS of BRCA1-mutant patients with HGSOC from TCGA dataset. 4) no such correlation was observed with the PFS of BRCA-proficient patients with HGSOC. 5) In\xa0cells,\xa0DYNLL1\xa0limits nucleolytic degradation of\xa0DNA\xa0ends by associating with the\xa0DNA\xa0end-resection\xa0machinery (MRN complex, BLM helicase and DNA2 endonuclease). 6) In vitro,\xa0DYNLL1\xa0binds\xa0directly to\xa0MRE11\xa0to\xa0limit\xa0its\xa0end-resection\xa0activity.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DYNLL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8445" target="_blank" rel="noopener noreferrer">8445</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92630" target="_blank" rel="noopener noreferrer">Q92630</a>', 'HUGO Gene symbol': 'DYRK2', 'Protein name': 'Dual specificity tyrosine-phosphorylation-regulated kinase 2', 'Function': "1) downstream of ATM and phospho p53/TP53 at 'Ser-46' to induce apoptosis upon DNA damage.\xa02) initiates the degradation of several proteins via ubiquitination. ", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> CSC<br><br> EMT<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25712377%5Buid%5D" target="_blank" rel="noopener noreferrer">25712377</a>', 'Notes': '1) DYRK2 protein expression was posttranslationally reduced in cisplatin-resistant SA cell lines. 2) Knockdown of DYRK2 in Mouse experiment resulted in mesenchymal phenotype and tumor resistance to cisplatin. 3) Immunohistochemistry demonstrated that DYRK2 expression inversely correlated with Snail expression. 4) reduced expression of DYRK2 was associated with shorter overall survival in SA. 5) DYRK2 may inhibit EMT through Snail degradation in ovarian SA ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DYRK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1869" target="_blank" rel="noopener noreferrer">1869</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01094" target="_blank" rel="noopener noreferrer">Q01094</a>', 'HUGO Gene symbol': 'E2F1', 'Protein name': 'Transcription factor E2F1', 'Function': 'binds DNA cooperatively with DP proteins through the E2 recognition site of genes whose products are involved in cell cycle regulation or in DNA replication. E2F1 binds RB1 preferentially in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17200349%2C%2025139024%5Buid%5D" target="_blank" rel="noopener noreferrer">17200349, 25139024</a>', 'Notes': '1) Survival analyses showed low expression of E2F1 or E2F2 to be significantly associated with favorable disease-free and overall survival (E2F1, P = 0.039 and 0.047, respectively; E2F2, P = 0.009 and 0.006, respectively). 2) high expression of inhibiting E2F4 or E2F7 predicted favorable disease-free and overall survival (E2F4, P = 0.047 and 0.042, respectively; E2F7, P = 0.048 and 0.042, respectively). 3) A high E2F2 to E2F4 ratio was the most valuable prognostic variable for disease-free survival in multivariate analysis (hazard ratio, 6.494; P = 0.002). 4) Ovarian tumors considered platinum resistant were associated with lower E2F4 and E2F7 expression (P = 0.012 and 0.009, respectively) compared with platinum-sensitive tumors. 5) ratios of E2F1 or E2F2 to E2F7 were the most favorable variables in predicting platinum resistance. 6) miR-136 directly targets E2F1. 7) the low-level expression of miR-136 is significantly associated with a more aggressive and/or poor prognostic phenotype of patients with gliomas. 7) Both gain- and loss-of-function experiments showed that miR-136 expression can reverse cisplatin resistance and enhance the response to cisplatin treatment. 8) Depletion of E2F1 recapitulated the tumor-suppressive functions of miR-136, whereas re-expression of E2F1 attenuated the function of miR-136 in glioma cells. 9) miR-136 is inversely correlated with E2F1 expression in human glioma samples. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=E2F1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1870" target="_blank" rel="noopener noreferrer">1870</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14209" target="_blank" rel="noopener noreferrer">Q14209</a>', 'HUGO Gene symbol': 'E2F2', 'Protein name': 'Transcription factor E2F2', 'Function': 'The DRTF1/E2F complex target genes involved in cell cycle regulation or in DNA replication to control cell-cycle progression from G1 to S phase. E2F2 binds specifically to RB1 in a cell-cycle dependent manner.', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17200349%2C%2026458859%5Buid%5D" target="_blank" rel="noopener noreferrer">17200349, 26458859</a>', 'Notes': "1) miR-26a was downregulated in cisplatin-resistant gastric cancer SGC-7901/DDP cells compared with SGC-7901 cells. 2) miR-26a has target sites in the 3'-UTR of NRAS and E2F2. 3) knockdown of NRAS or E2F2 sensitize GC cells to cisplatin. 3) As E2F1. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=E2F2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1874" target="_blank" rel="noopener noreferrer">1874</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16254" target="_blank" rel="noopener noreferrer">Q16254</a>', 'HUGO Gene symbol': 'E2F4', 'Protein name': 'Transcription factor E2F4', 'Function': 'Transcription activator found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication; binds with high affinity to RBL1 and RBL2.', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17200349%2C%2015611646%5Buid%5D" target="_blank" rel="noopener noreferrer">17200349, 15611646</a>', 'Notes': '1) As E2F1. 2) E2F4 levels are diminished following treatment with cyclin dependent kinase inhibitors (flavopiridol, roscovitine and BMS-387032) or with DNA damaging drugs (cisplatin and VP16). In contrast, each of these drugs induced E2F1. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=E2F4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/144455" target="_blank" rel="noopener noreferrer">144455</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96AV8" target="_blank" rel="noopener noreferrer">Q96AV8</a>', 'HUGO Gene symbol': 'E2F7', 'Protein name': 'atypical E2F family members ', 'Function': 'transcription repressor whose levels are induced by DNA damage. Its repression targets include CDC6 and MCM2—as well as HR proteins, including RAD51 and BRCA1. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17200349%2C%2030032296%5Buid%5D" target="_blank" rel="noopener noreferrer">17200349, 30032296</a>', 'Notes': '1) Tumors considered platinum resistant were associated with lower E2F4 and E2F7 expression (P = 0.012 and 0.009, respectively) compared with platinum-sensitive tumors. 2) down-regulation of E2F7 may contribute to mechanisms underlying platinum resistance, and calculation of ratios of proliferation-promoting E2F1 to E2F7 could serve as a putative predictor of platinum resistance. 3) BRCA2-deficient cells are less sensitive to PARP inhibitor and cisplatin treatment after E2F7 depletion. 4) the mechanism underlying this activity involves increased expression of RAD51, a target for E2F7-mediated transcriptional repression. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=E2F7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1909" target="_blank" rel="noopener noreferrer">1909</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25101" target="_blank" rel="noopener noreferrer">P25101</a>', 'HUGO Gene symbol': 'EDNRA', 'Protein name': 'Endothelin-1 receptor', 'Function': 'important role in tumor cell migration, metastasis, and proliferation', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23192269%2C%2014519635%5Buid%5D" target="_blank" rel="noopener noreferrer">23192269, 14519635</a>', 'Notes': '1) Ninety percent of malignant ovarian tumors express endothelin receptors. 2) ETRA inhibition in combination with chemotherapy reduced the formation of tumor spheres. 3) when used in combination with chemotherapy, ETRA inhibition specifically reduced tumor growth in cell lines with CD133+ cancer stem cells. 4) Elevated expression of ET-1, ET(A)R, and ET(B)R was more common in breast carcinomas of patients with lower disease-free survival time and overall survival. 6) a statistically significant correlation was observed between ET(A)R expression and reduced disease-free survival time (P = 0.041). 7) the prognostic impact of ET(A)R expression was shown to be more pronounced in the subgroup of patients with a putative favorable prognosis according to classic prognostic factors. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EDNRA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1950" target="_blank" rel="noopener noreferrer">1950</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01133" target="_blank" rel="noopener noreferrer">P01133</a>', 'HUGO Gene symbol': 'EGF', 'Protein name': 'Pro-epidermal growth factor', 'Function': 'stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Hypoxia signaling<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11391854%5Buid%5D" target="_blank" rel="noopener noreferrer">11391854</a>', 'Notes': '1) As EGFR. 2) EGF enhances cisplatin-induced cell death by activating an apoptotic pathway that is independent of caspase 3. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EGF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1956" target="_blank" rel="noopener noreferrer">1956</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00533" target="_blank" rel="noopener noreferrer">P00533</a>', 'HUGO Gene symbol': 'EGFR', 'Protein name': 'Epidermal growth factor receptor', 'Function': 'Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26351843%2C%2027384994%2C%2011597399%5Buid%5D" target="_blank" rel="noopener noreferrer">26351843, 27384994, 11597399</a>', 'Notes': '1) Acute cisplatin treatment activates the EGFR and downstream signaling pathways, and induces an EGFR mediated increase in DNMT activity. 2) Cisplatin resistant cells also showed increased DNMT activity and global methylation. 3) EGFR inhibition during repeated cisplatin treatments generated cells that were more sensitive to cisplatin and did not develop increases in DNA methylation or DNMT activity compared to controls. 4) Of 1,065 gastric carcinoma samples, higher expression of EGFR (HR = 1.86,\xa0p\xa0= 8.5E-11) were predictive for poor OS. 5) The EGFR was found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers. In these cancers, increased EGFR expression was associated with reduced recurrence-free or overall survival rates in 70% (52/74) of studies. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EGFR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54583" target="_blank" rel="noopener noreferrer">54583</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9GZT9" target="_blank" rel="noopener noreferrer">Q9GZT9</a>', 'HUGO Gene symbol': 'EGLN1', 'Protein name': 'Egl nine homolog 1 / Hypoxia-inducible factor prolyl hydroxylase 2', 'Function': 'Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31285371%5Buid%5D" target="_blank" rel="noopener noreferrer">31285371</a>', 'Notes': '1)\xa0PHD2 was shown to be a direct substrate of\xa0ERK; Phosphorylation of\xa0PHD2\xa0by\xa0ERK\xa0prevents its binding to HIF1α, thus inhibiting HIF1α hydroxylation and degradation-increasing HIF1α stability. 2) ERK/PHD2\xa0signaling in Platinum resistant ovarian cancer (PROC) cells is dependent on TGFβ1, promoting\xa0platinum\xa0resistance\xa0by stabilizing HIF1α. Inhibition of TGFβ1 by SB431542,\xa0ERK\xa0by selumetinib, or HIF1α by YC-1 efficiently overcame platinum resistance\xa0both\xa0in vitro\xa0and\xa0in vivo. 3) Activation of the\xa0ERK/PHD2/HIF1α axis in patients with PROC, correlating highly with poor prognoses for patients.', 'Up / down in Pt-resistant cells': 'PHOS', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EGLN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/112399" target="_blank" rel="noopener noreferrer">112399</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H6Z9" target="_blank" rel="noopener noreferrer">Q9H6Z9</a>', 'HUGO Gene symbol': 'EGLN3', 'Protein name': 'Prolyl hydroxylase EGLN3 / egl-9 family hypoxia inducible factor 3', 'Function': 'Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4 and HIF1A', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31375625%5Buid%5D" target="_blank" rel="noopener noreferrer">31375625</a>', 'Notes': '1) BIM-EL, a proapoptotic BH3-only protein, is hydroxylated by EglN3 and subsequently bound by VHL. 2) VHL mutants fail to bind hydroxylated BIM-EL, regardless of whether they have the ability to bind hydroxylated HIFα or not. 3) VHL binding inhibits BIM-EL phosphorylation by ERK on serine 69. This causes BIM-EL to escape from proteasomal degradation, allowing it to enhance EglN3-induced apoptosis. 4) BIM-EL was rapidly degraded in cells lacking wild-type VHL or in which EglN3 was inactivated genetically or by lack of oxygen, leading to enhanced cell survival and chemotherapy resistance. 5)\xa0Combination therapy using ERK inhibitors, however, resensitizes VHL- and EglN3-deficient cells that are otherwise cisplatin-resistant.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EGLN3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1958" target="_blank" rel="noopener noreferrer">1958</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18146" target="_blank" rel="noopener noreferrer">P18146</a>', 'HUGO Gene symbol': 'EGR1', 'Protein name': 'early growth response 1', 'Function': 'transcription activator of its target genes including TNF, TP53, RB1, and BAX that are involved in the cell death pathway upon radiation or chemotherapy; a MAPK-regulated gene involved in promoting apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Autophagy<br><br> DDR/NER<br><br> Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25650716%5Buid%5D" target="_blank" rel="noopener noreferrer">25650716</a>', 'Notes': '1) MIR152 expression was dramatically downregulated in the cisplatin-resistant cell lines A2780/CP70, SKOV3/DDP compared with their respective parental cells, 2) and in ovarian cancer tissues associated with cisplatin-resistance. 3) Overexpression of MIR152 sensitized cisplatin-resistant ovarian cancer cells by reducing cisplatin-induced autophagy. 4) A mouse subcutaneous xenograft tumor model using A2780/CP70 cells with overexpressing MIR152 was established and displayed decreased tumor growth in response to cisplatin. 5) ATG14 is a functional target of MIR152. 6) EGR1 regulated the MIR152 gene at the transcriptional level. 7) Ectopic expression of EGR1 enhanced efficacy of chemotherapy in A2780/CP70 cells. 8) Both EGR1 and MIR152 expression levels were significantly lower in ovarian cancer tissues with high levels of ERCC1, a marker for cisplatin-resistance. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EGR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10938" target="_blank" rel="noopener noreferrer">10938</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H4M9" target="_blank" rel="noopener noreferrer">Q9H4M9</a>', 'HUGO Gene symbol': 'EHD1', 'Protein name': 'EH domain-containing protein 1', 'Function': 'ATP- and membrane-binding protein that controls membrane reorganization/tubulation upon ATP hydrolysis. In vitro causes vesiculation of endocytic membranes', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27411790%5Buid%5D" target="_blank" rel="noopener noreferrer">27411790</a>', 'Notes': '1) The immunohistochemistry assay showed that adjuvant chemotherapy-treated NSCLC patients expressing EHD1 exhibited reduced OS compared with patients who did not express EHD1 (P\u2009=\u20090.01). 2) EHD1 gene was upregulated in CDDP- resistant NSCLC cells. 3) the IC50 value of EHD1 knockdown cells was at least 5.2-fold lower than that of the control cells. 4) the total platinum level was lower in A549-EHD1 cells than in control cells, and the concentration of CDDP was higher in the EHD1 knockdown cells than in the A549/DDP control cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EHD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9451" target="_blank" rel="noopener noreferrer">9451</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NZJ5" target="_blank" rel="noopener noreferrer">Q9NZJ5</a>', 'HUGO Gene symbol': 'EIF2AK3', 'Protein name': 'Eukaryotic translation initiation factor 2-alpha kinase 3', 'Function': "Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response<br><br> Platinum efflux<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29039478%2C%2028499449%20%5Buid%5D" target="_blank" rel="noopener noreferrer">29039478, 28499449¬†</a>', 'Notes': '1) reduction of eIF2α phosphorylation by PERK knockdown enhanced cisplatin-induced p53 activation and apoptosis. (in HK-2 human renal proximal tubular cells) 2) ER stress-resistant cells were cross-resistant to multiple chemotherapeutic drugs: such multidrug resistance (MDR) was due to the overexpression of the plasma-membrane transporter MDR related protein 1 (MRP1). 3) Gene profiling analysis unveiled that cells with acquired resistance to ER stress and chemotherapy share higher expression of the UPR sensor protein kinase PERK, which mediated Nrf2-driven transcription of MRP1. 4) Disrupting PERK/Nrf2 axis reversed at the same time resistance to ER stress and chemotherapy. 5) The inducible silencing of PERK reduced tumor growth and restored chemosensitivity in resistant tumor xenografts.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF2AK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1965" target="_blank" rel="noopener noreferrer">1965</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05198" target="_blank" rel="noopener noreferrer">P05198</a>', 'HUGO Gene symbol': 'EIF2S1', 'Protein name': 'Eukaryotic translation initiation factor 2 subunit 1', 'Function': 'Functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S pre-initiation complex.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> ER stress response<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23570372%5Buid%5D" target="_blank" rel="noopener noreferrer">23570372</a>', 'Notes': '1) the phosphorylation of eIF2α suppresses cisplatin-induced A549 cell apoptosis. 2) Cisplatin induced eIF2α phosphorylation through protein kinase RNA. 3) phospho-eIF2α inhibited cisplatin-induced A549 cells apoptosis, at least in part, by suppressing the p38 pathway. 4) analysis of tissue microarrays information demonstrated that phospho-eIF2α predicted a poor prognosis in patients with NSCLC.\xa0', 'Up / down in Pt-resistant cells': 'PHOS', 'Up / down to promote Pt-resistance': 'PHOS', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF2S1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8661" target="_blank" rel="noopener noreferrer">8661</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14152" target="_blank" rel="noopener noreferrer">Q14152</a>', 'HUGO Gene symbol': 'EIF3A', 'Protein name': 'Eukaryotic translation initiation factor 3 subunit A', 'Function': 'The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21625209%2C%2026213845%2C%2021610145%5Buid%5D" target="_blank" rel="noopener noreferrer">21625209, 26213845, 21610145</a>', 'Notes': "1) CDDP-sensitive sub-clone S16 isolated from an nasopharyngeal carcinoma cell line CNE-2 has increased eIF3a expression. 2) Knocking down its expression in S16 cells increased cellular resistance to CDDP. 3) eIF3a down-regulates translation of the NER proteins XPA, XPC, RAD23B and RPA32. 4) Overexpression and knockdown of eIF3a increased and decreased the cellular response to cisplatin in ovarian cancer A2780/DDP and A2780 cells, respectively. 4) eIF3a improves ovarian cancer patients' response to DDP-based chemotherapy via down regulating XPC and p27(Kip1). 5) eIF3a expression associates with response of lung cancer patients to platinum-based chemotherapy. 6) eIF3a knockdown or overexpression, respectively, increased and decreased the cellular resistance to cisplatin and anthrocycline anticancer drugs.", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF3A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8666" target="_blank" rel="noopener noreferrer">8666</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75821" target="_blank" rel="noopener noreferrer">O75821</a>', 'HUGO Gene symbol': 'EIF3G', 'Protein name': 'Eukaryotic translation initiation factor 3 subunit G', 'Function': 'core subunit of the eIF3 complex; it is also involved in caspase-mediated apoptosis, and is upregulated in multidrug-resistant cancer cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24080033%2C%2026935993%5Buid%5D" target="_blank" rel="noopener noreferrer">24080033, 26935993</a>', 'Notes': '1) The activation of caspases by cisplatin in T24 cells induces the cleavage of eIF3g. 2) The cleaved N-terminus was translocated to the nucleus, activating caspase-3, and that it also showed a strong DNase activity. 3) CDDP induce release of AIF from mitochondria. 4) eIF3g is one of the cytosolic targets that interacts with mature AIF, 5) the AIF’s cellular functions of the inhibition of protein synthesis during apoptosis.', 'Up / down in Pt-resistant cells': 'CLEAVED TO ACTIVATE APOPTOSIS', 'Up / down to promote Pt-resistance': 'CLEAVED TO ACTIVATE APOPTOSIS', 'Up / down after Pt-treatment': 'CLEAVED/ACTIVATED', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF3G" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1977" target="_blank" rel="noopener noreferrer">1977</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06730" target="_blank" rel="noopener noreferrer">P06730</a>', 'HUGO Gene symbol': 'EIF4E', 'Protein name': 'Eukaryotic translation initiation factor 4 subunit E', 'Function': 'Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Hypoxia signaling<br><br> Oncogene signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18327707%2C%2027588477%2C%2028417568%2C%2031512056%5Buid%5D" target="_blank" rel="noopener noreferrer">18327707, 27588477, 28417568, 31512056</a>', 'Notes': '1) Overexpression of eIF4E decreased the efficacy of\xa0cisplatin-induced\xa0cell growth inhibition in ESCC cell line and xenograft model. 2) eIF4E knockdown by shRNA increased\xa0cisplatin-induced\xa0cytotoxicity in ESCC cell lines, and enhanced chemosensitivity to cisplatin in xenograft tumor models. 3) eIF4E expression was increased significantly in clinical ESCC tissues and and ESCC cell lines and its expression level was correlated with lymph node metastasis, TNM stage, as well as overall and disease-free survival of ESCC. 4) AURKA promotes acquired and de novo resistance to cisplatin in in vitro and in vivo gastric cancer cell models. 5) AURKA mediates phosphorylation of eIF4E to promote protein translation of pro-oncogenic downstream effectors such as c-MYC and HDM2. 6) the positive correlative over-expression was seen between eIF4E and Snail in NPC tissues. 7) In NPC cells, eIF4E knockdown significantly reduced Snail mRNA and protein levels, attenuated the invasive ability of the cells, and sensitized the cells to cisplatin. 8) enforced the expression of eIF4E significantly increased Snail mRNA and protein levels, and promoted the invasive ability in NPC cells. 9) Under the condition of the high eIF4E expression, Snail knockdown significantly increased E-cad mRNA level and weaken the invasive ability of NPC cells. 10) eIF4E directly bound Snail mRNA for translation initiation displayed by the RIP assay. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF4E" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1978" target="_blank" rel="noopener noreferrer">1978</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13541" target="_blank" rel="noopener noreferrer">Q13541</a>', 'HUGO Gene symbol': 'EIF4EBP1', 'Protein name': 'EIF4E binding protein', 'Function': 'Phosphorylation of 4E-BP1 releases translation initiation factor eIF4E, allowing for the initiation of CAP-dependent protein synthesis to drive the selective translation of specific oncogenic mRNAs encoding proteins responsible for survival factors (survivin, Mcl1, XIAP), tumor angiogenesis (VEGF-A, FGF2) and the DDR (BRCA1, 53BP1, γH2AX, others), among other pathways. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> mTOR signaling<br><br> Oncogene signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25976336%2C%2027196780%2C%2025658620%5Buid%5D" target="_blank" rel="noopener noreferrer">25976336, 27196780, 25658620</a>', 'Notes': '1) The levels of phosphorylated mTOR (p-mTOR), p70S6K, and 4E-BP1 were significantly increased in cisplatin-reistant A2780cis ovarian cancer cells compared to A2780 cells. 2) Platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition. 3) Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.  4) Animals with platinum-resistant OVCAR-3 tumors treated with carboplatin plus mTORC1/2 inhibition had significantly longer median survival and strikingly reduced metastasis compared with animals treated with carboplatin plus everolimus, which inhibits only mTORC1. 5) Reduced tumor growth, metastasis, and increased survival by mTORC1/2 inhibition with carboplatin treatment was associated with reduced AKT-activating phosphorylation and increased 4E-BP1 hypophosphorylation (activation). 6) EIF4EBP1 protein is notably upregulated in 8 HCC tissues (randomly selected from the 40 HCCs) and is significantly increased in another 88 paraffin-embedded HCCs (53%, 47/88). 7) EIF4EBP1 protein expression in HCC tissues is significantly correlated with serum AFP (P = 0.003) and marginally significantly associated with pathological grade (P = 0.085), tumor number (P = 0.084), tumor embolus (P = 0.084) and capsulation (P = 0.073). 8) Patients with higher EIF4EBP1 protein expression have a much worse 5-year overall survival (40.3% vs 73.6%) and 5-year disease-free survival (33.0% vs 49.0%) than those with low expression. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'DOWN/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF4EBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1982" target="_blank" rel="noopener noreferrer">1982</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78344" target="_blank" rel="noopener noreferrer">P78344</a>', 'HUGO Gene symbol': 'EIF4G2', 'Protein name': 'Eukaryotic translation initiation factor 4 gamma 2', 'Function': 'Appears to play a role in the switch from cap-dependent to IRES-mediated translation during mitosis, apoptosis and viral infection. Cleaved by some caspases and viral proteases.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28117895%2C%209819442%2C%2022555068%2C%2011175261%5Buid%5D" target="_blank" rel="noopener noreferrer">28117895, 9819442, 22555068, 11175261</a>', 'Notes': "1) miR-379 expression is significantly downregulated in chemoresistant nonsmall cell lung cancer (NSCLC) tissues and cells. 2) Manipulation of miR-379 levels could alter the in vitro and in vivo cisplatin (CDDP) resistance in lung cancer (LCa) cells. 3) miR-379 potentiated LCa chemosensitivity via modulation of CDDP-induced apoptosis by directly targeting the EIF4G2 3'UTR. 4) we observed an inverse correlation between miR-379 and EIF4G2 expression in LCa tissues from patients with CDDP-based chemotherapy.\xa05) Treatment of HeLa cells with the apoptosis inducers cisplatin and etoposide resulted in cleavage of eIF4G, and the extent of its cleavage correlated with the onset and extent of observed inhibition of cellular translation. 6) In renal tubular cells, overexpression of DAP5/p97 and DAP5/p86 increased the translation of Bcl-2 and reduced the extent of cisplatin-induced apoptosis. 7) siRNA knockdown of DAP5 decreased the translation of Bcl-2 and increased the degree of apoptosis. 8) DAP5 expression was positively regulated by the PI3K/Akt/mTOR signaling pathway.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EIF4G2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/146956" target="_blank" rel="noopener noreferrer">146956</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96AY2" target="_blank" rel="noopener noreferrer">Q96AY2</a>', 'HUGO Gene symbol': 'EME1', 'Protein name': 'Crossover junction endonuclease EME1', 'Function': 'Interacts with MUS81 to form a DNA structure-specific endonuclease', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26573761%2C%2026679694%2C%2019267403%5Buid%5D" target="_blank" rel="noopener noreferrer">26573761, 26679694, 19267403</a>', 'Notes': '1) Haploinsufficiency of Eme1 led to hypersensitivity to cisplatin in the colon cancer cell line HCT116.\xa02) Although ERCC1, Rad51 and Mus81 protein levels correlated with cisplatin sensitivity to some extent, the clearest correlation was observed with Eme1. 3) Survivin overexpression, frequently found in breast cancers and others, is associated with poor prognosis. Clinically, EME1, RAD51, EXO1, BLM expressions correlate with that of BIRC5 (coding for Survivin) and are of prognostic value. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EME1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/56946" target="_blank" rel="noopener noreferrer">56946</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q7Z589" target="_blank" rel="noopener noreferrer">Q7Z589</a>', 'HUGO Gene symbol': 'EMSY', 'Protein name': 'BRCA2-interacting transcriptional repressor EMSY', 'Function': 'Regulator which is able to repress transcription.  Its interaction with BRCA2, when over-expressed, would lead to impairment of BRCA2 functions (21735447).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29707144%5Buid%5D" target="_blank" rel="noopener noreferrer">29707144</a>', 'Notes': '1) EMSY is amplified and overexpressed in various sporadic cancers. 2) In 134 frozen OvCa samples, clinical relevance of changes in\xa0EMSY\xa0mRNA expression and DNA sequence was evaluated in two subgroups treated with either taxane/platinum (TP, n=102) or platinum/cyclophosphamide (PC, n=32). 3) High\xa0EMSY\xa0expression negatively affected overall survival (OS), disease-free survival (DFS) and sensitivity to treatment (PS) in the TP-treated subgroup (p-values: 0.001, 0.002 and 0.010, respectively).\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EMSY" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2018" target="_blank" rel="noopener noreferrer">2018</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q04743" target="_blank" rel="noopener noreferrer">Q04743</a>', 'HUGO Gene symbol': 'EMX2', 'Protein name': 'Homeobox protein EMX2', 'Function': 'Transcription factor, linked to the WNT signaling pathway during embryonic patterning (20697358); inhibits the AKT/mTOR/S6K signaling pathway and decreases EMT (31432154);', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26132438%5Buid%5D" target="_blank" rel="noopener noreferrer">26132438</a>', 'Notes': '1) EMX2 expression was down-regulated in lung SCC tissue samples compared to their matched adjacent normal tissues. 2) Positive EMX2 expression was significantly associated with improved overall survival in stage I lung SCC patients, and in stage II/IIIA lung SCC patients receiving adjuvant chemotherapy. 3) EMX2 expression was also associated with expression of EMT markers in both lung SCC cell lines and tissue samples. 4) Knock-down of EMX2 expression in lung SCC cells promoted chemo-resistance and cell migration.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EMX2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2022" target="_blank" rel="noopener noreferrer">2022</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17813" target="_blank" rel="noopener noreferrer">P17813</a>', 'HUGO Gene symbol': 'ENG', 'Protein name': 'Endoglin', 'Function': 'Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis; a regulatory component of the transforming growth factor‐β (TGF‐β) receptor complex and modulates cellular responses to TGF‐β ', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23147994%2C%2028944897%5Buid%5D" target="_blank" rel="noopener noreferrer">23147994, 28944897</a>', 'Notes': '1) Endoglin (CD105) is a membranous protein overexpressed in tumor-associated endothelial cells, chemoresistant populations of ovarian cancer cells, and potentially stem cells.\xa02) Endoglin inhibition increased apoptosis, increased cisplatin sensitivity and downregulates expression of numerous DNA repair genes, including BARD1, H2AFX, NBN, NTHL1, and SIRT1. BARD1, 3) Endoglin inhibition was induced by platinum exposure. 4) In vivo, anti-endoglin treatment decreased tumor weight in both ES2 and HeyA8MDR models when compared to control (35-41% reduction, p<0.05). 5) Endoglin inhibition with carboplatin was associated with even greater inhibitory effect when compared to control (58-62% reduction, p<0.001). 6) The overall response rate to Neoadjuvant chemotherapy (NAC) of these 34 patients was 67.6%.  Increased expression of endoglin in primary breast tumors prior to NAC correlated with improved response in primary tumors (P=0.019) or in primary tumors and regional lymph nodes (P=0.014). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ENG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2023" target="_blank" rel="noopener noreferrer">2023</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06733" target="_blank" rel="noopener noreferrer">P06733</a>', 'HUGO Gene symbol': 'ENO1', 'Protein name': 'Alpha-enolase', 'Function': 'Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25951350,30301274,28548950" target="_blank" rel="noopener noreferrer">25951350, 30301274, 28548950</a>', 'Notes': '1) ENO1 silencing significantly reduced cell glycolysis, proliferation, migration, and invasion and mediated inactivation of PI3K/AKT signaling. 2) Knocking down ENO1 could significantly enhance the sensitivity of endometrial carcinoma (EC) cells to\xa0cisplatin\xa0(DDP) and markedly inhibited the growth of EC xenografts in vivo. 3) EC patients with higher ENO1 expression had a markedly shorter overall survival than patients with low ENO1 expression.\xa04) granulin A (GRN A), an anticancer peptide, is able to interact with ENO1 and inhibit the growth of HCC in vitro. 5) the combination of cisplatin and GRN A displayed potent synergistic effect for the inhibitory effect on HCC. 6) Overexpression of ENO1 diminished the synergistic effect of GRN A and cisplatin in HCC cells. 7) An in vivo study confirmed that the combined use of the two drugs displayed more potent antitumor activity compared to mice treated with cisplatin and GRN A alone. 8) the increased expression of ENO1 in cisplatin-resistant gastric cancer cells. 9) Depletion of ENO1 by siRNA significantly reduced glycolysis and reversed drug resistance. 10) the elevated levels of ENO1 proteins were associated with the shorter overall survival of gastric cancer patients. 11) the increased expression of ENO1 was found in cisplatin-resistant gastric cancer cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ENO1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5168" target="_blank" rel="noopener noreferrer">5168</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13822" target="_blank" rel="noopener noreferrer">Q13822</a>', 'HUGO Gene symbol': 'ENPP2', 'Protein name': 'Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 / autotaxin', 'Function': 'secreted enzyme (by adipocytes) functions as a lysophospholipase D to generate the lipid survival factors lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20100569%2C%2011593532%5Buid%5D" target="_blank" rel="noopener noreferrer">20100569, 11593532</a>', 'Notes': '1) ENPP2 was identified as a candidate gene causing drug resistance to carboplatin or paclitaxel. 2) siRNA directed to ENPP2 resulted in earlier apoptosis following treatment with carboplatin. 2-carbacyclic phosphatidic acid (ccPA 16:1), a small molecule inhibitor of autotaxin, also accelerated apoptosis induced by carboplatin. 3) Stable ectopic expression of autotaxin in OVCAR-3 cells led to a delay in apoptosis. 4) When serum was withdrawn to remove exogenous LPA, ccPA caused a pronounced potentiation of apoptosis induced by carboplatin in cells expressing autotaxin. 5) The mean expression level of ATX gene in HCC samples was higher than that in normal liver tissues. 6) Intrahepatic metastasis, vascular invasion and poor differentiation were more frequently noted in HCC patients with high ATX expression than in patients with low ATX expression.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ENPP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2033" target="_blank" rel="noopener noreferrer">2033</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q09472" target="_blank" rel="noopener noreferrer">Q09472</a>', 'HUGO Gene symbol': 'EP300', 'Protein name': 'Histone acetyltransferase p300', 'Function': 'Chromatin remodeling. Also acetylates non-histone targets: ALX1, HDAC1, PRMT1 or SIRT2; indirectly increases activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> p53 signaling<br><br> PKA signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28341962%2C%2020210796%2C%2021310163%5Buid%5D" target="_blank" rel="noopener noreferrer">28341962, 20210796, 21310163</a>', 'Notes': '1) In bladder cancer cells, experimental downregulation of EP300 also leads to doxorubicin and cisplatin resistance. 2) Knockdown of Foxo3a-associated acetyltransferase p300 promoted cancer-cell growth and cisplatin resistance. 3) Levels of the histone acetyltransferase (HAT), p300, were decreased due to a consistent cisplatin post-treatment. 4) Immuno histochemical analysis demonstrated that EP300 expression was low in metaplastic breast cancer, a rare, but aggressive form of the disease with poor prognosis that is characterized by morphological and physiological features of EMT.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EP300" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4072" target="_blank" rel="noopener noreferrer">4072</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16422" target="_blank" rel="noopener noreferrer">P16422</a>', 'HUGO Gene symbol': 'EPCAM', 'Protein name': 'Epithelial cell adhesion molecule', 'Function': 'Cell surface expression of CSC-like markers. The intracellular domain (EpICD) is released into the cytoplasm to form a complex with the FHL2, β-catenin, and Lef-1 to activate WNT signaling; the extracellular domain (EpEX) is released into the area surrounding the cell to activate RTK signaling (e.g. EGFR)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Oncogene signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20301390%2C%2021618587%2C%2028574829%5Buid%5D" target="_blank" rel="noopener noreferrer">20301390, 21618587, 28574829</a>', 'Notes': '1) ovarian cancers containing high levels of EpCAM have a significantly much lower probability of achieving overall responsive rates after first-line chemotherapy. 2) subpopulation of EpCAM-positive ovarian cancer cells shows a significantly higher viability compared with EpCAM-negative cells in response to cisplatin treatment by preventing chemotherapy-induced apoptosis, which is regulated by EpCAM-Bcl-2 axis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EPCAM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1969" target="_blank" rel="noopener noreferrer">1969</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29317" target="_blank" rel="noopener noreferrer">P29317</a>', 'HUGO Gene symbol': 'EPHA2', 'Protein name': 'Ephrin type-A receptor 2', 'Function': 'Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32417448%2C%2032115889%2C%2027653549%5Buid%5D" target="_blank" rel="noopener noreferrer">32417448, 32115889, 27653549</a>', 'Notes': '1) progranulin, and not ephrin-A1, the canonical ligand for EphA2, is the predominant EphA2 ligand in bladder cancer. 2) Progranulin evoked Akt- and Erk1/2-mediated EphA2 phosphorylation at Ser897, which could drive bladder tumorigenesis. 3) EphA2 depletion severely blunted progranulin-dependent motility and anchorage-independent growth, and sensitized bladder cancer cells to cisplatin treatment. 4) liprin-α1 as a novel progranulin-dependent EphA2 interacting protein and establishing its critical role in cell motility.\xa05) inhibition or knockdown of RSK1/2 prevented oncogenic EphA2-S897 phosphorylation and EphA2-GPRC5A co-regulation, leading to downregulation of EphA2. 6) In combination with platinum, RSK inhibitors effectively sensitized even the most platinum-resistant EphA2high , GPRC5Ahigh cells. 6) Overexpression of EPHA2 has been observed in multiple cancers and reported to be associated with poor prognosis. 7) anti-EPHA2 monoclonal antibody (mAb), DS-8895a in combination with cisplatin showed better efficacy than each of the monotherapies did in the human gastric cancer model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EPHA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2064" target="_blank" rel="noopener noreferrer">2064</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04626" target="_blank" rel="noopener noreferrer">P04626</a>', 'HUGO Gene symbol': 'ERBB2', 'Protein name': 'Receptor tyrosine-protein kinase erbB-2', 'Function': 'Part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16112085%2C%2023274876%2C%2014679128%2C%2028989055%2C%2019575783%2C%2018337622%5Buid%5D" target="_blank" rel="noopener noreferrer">16112085, 23274876, 14679128, 28989055, 19575783, 18337622</a>', 'Notes': '1) 111 patients with ovarian cancer treated with cisplatin and paclitaxel: a role for polymorphism in the outcome of ovarian cancer patients - patients carrying the valine homozygotic genotype present a lower overall survival - the G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. 2) human ovarian serous adenocarcinoma cells, TU-OS-4 overexpressing EGFR, and HER2, and phosphorylated HER2 protein is resistant to both cisplatin and paclitaxel. 3) Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2, be effective in inhibiting growth of TU-OS-4 cells, additive to cisplatin. 4) Lapatinib combined with carboplatin also significantly inhibits serous ovarian carcinoma growth compared with each drug alone in a xenograft mouse model. 5) Only HER-2 overexpression in OC patients was significantly associated with shorter progression-free survival and overall survival after platinum based chemotherapy. 6) Non-small cell lung cancer patients with high expression of HER2 exhibited resistance to cisplatin-based chemotherapies that are the standard treatment for this disease. 7) HER-2 expression was significantly associated with cisplatin sensitivity (p = 0.0089) in head and neck squamous cell carcinoma (HNSCC). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERBB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2065" target="_blank" rel="noopener noreferrer">2065</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21860" target="_blank" rel="noopener noreferrer">P21860</a>', 'HUGO Gene symbol': 'ERBB3', 'Protein name': 'Receptor tyrosine-protein kinase erbB-3', 'Function': 'cell surface receptor binds to neuregulin-1 (NRG1), which increases Y-P and promotes its association with PI3K', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18803287%2C%2022841590%2C%2030621788%5Buid%5D" target="_blank" rel="noopener noreferrer">18803287, 22841590, 30621788</a>', 'Notes': '1) Sensitivity to gefitinib correlated with overexpression and constitutive phosphorylation of HER2 and HER3 in chemoresistant glioma and ovarian cancer  cell lines. 2) treatment of cells with cisplatin resulted in activation of the HER3 receptor. 3) The increase in HER3 phosphorylation was detected in well-established ovarian cancer cell lines which originate from patients previously treated with these chemotherapeutic drugs. 4) ErbB1 and ErbB3 co-overexpression is accompanied with the poor prognosis and can be used efficiently in targeted therapy of gastric cancer patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERBB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2066" target="_blank" rel="noopener noreferrer">2066</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15303" target="_blank" rel="noopener noreferrer">Q15303</a>', 'HUGO Gene symbol': 'ERBB4', 'Protein name': 'Receptor tyrosine-protein kinase erbB-4', 'Function': 'cell surface receptor binds to not only neuregulins but also betacellulin, heparin-binding EGF, and epiregulin. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28178720%2C%2011280782%5Buid%5D" target="_blank" rel="noopener noreferrer">28178720, 11280782</a>', 'Notes': '1) High-level ERBB4 expression was observed at a significantly higher frequency in ovarian serous carcinoma compared with normal control tissue. 2) Among tumor specimens, ERBB4 expression was significantly higher for those with incomplete response (IR) to platinum based chemotherapy compared with complete response (CR) (P = .033). 3) OS was inversely correlated with ERBB4 expression levels. Median rates of OS were 18, 22, and 58 months among high-, intermediate-, and low-expression tumors, respectively. 4) ERBB4 expression by IHC may correlate with chemotherapy-resistant ovarian serous carcinoma and shortened OS. 5) cell lines (PE04 and PE06), resistant to cisplatin possessed markedly higher levels of erbB4 than in the initial cell line (PE01). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERBB4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2067" target="_blank" rel="noopener noreferrer">2067</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07992" target="_blank" rel="noopener noreferrer">P07992</a>', 'HUGO Gene symbol': 'ERCC1', 'Protein name': 'DNA excision repair protein ERCC-1', 'Function': "Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL).\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20944091%2C%2012915808%2C%2025941922%5Buid%5D" target="_blank" rel="noopener noreferrer">20944091, 12915808, 25941922</a>', 'Notes': '1) Of 1,065 gastric carcinoma samples, higher expression of ERCC1 (HR = 1.36, p = 0.0012) were predictive for poor OS. 2) overexpression of ERCC1 and other NER enzymes during ovarian cancer chemotherapy with cisplatin appears to be implicated in the formation of cellular and clinical drug resistance. 3) baseline ERCC1 mRNA overexpression has been related to poor response and survival in cisplatin-treated NSCLC patients. 4) Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2068" target="_blank" rel="noopener noreferrer">2068</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18074" target="_blank" rel="noopener noreferrer">P18074</a>', 'HUGO Gene symbol': 'ERCC2', 'Protein name': 'General transcription and DNA repair factor IIH helicase subunit XPD', 'Function': "ATP-dependent 5'-3' DNA helicase, component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA. ", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%20%2027449101%2C%2025096233%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215,¬† 27449101, 25096233</a>', 'Notes': '1) miR-770-5p expression was reduced in platinum-resistant patients. 2) Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted the response to cisplatin treatment and survival among OVC patients. 3) Overexpression of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin treatment. 4) ERCC2, a target gene of miR-770-5p, was negatively regulated by miR-770-5p. 5) siRNA-mediated silencing of ERCC2 reversed the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. 6) A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. 7) pretreatment tumor and germline DNA from 50 patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy (25 pT0/pTis "responders," 25 pT2+ "nonresponders") to identify somatic mutations that occurred preferentially in responders: ERCC2 was the only significantly mutated gene enriched in the cisplatin responders compared with nonresponders (q < 0.01). 8) Expression of representative ERCC2 mutants in an ERCC2-deficient cell line failed to rescue cisplatin and UV sensitivity. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2071" target="_blank" rel="noopener noreferrer">2071</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P19447" target="_blank" rel="noopener noreferrer">P19447</a>', 'HUGO Gene symbol': 'ERCC3', 'Protein name': 'General transcription and DNA repair factor IIH helicase subunit XPB', 'Function': "ATP-dependent 3'-5' DNA helicase, component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%2011516928%2C%2015882455%2C%2025069034%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215, 11516928, 15882455, 25069034</a>', 'Notes': '1) cells\xa0defective in ERCC1 are more sensitive than\xa0cells\xa0defective in ERCC3 with regard to cisplatin-induced reproductive cell death. 2) ERCC1 and ERCC3 mutants showed a higher frequency of apoptosis and, to a lesser degree, necrosis compared to\xa0repair\xa0proficient\xa0cells. 3) ERCC3 (XPB), ERCC4 (XPF), and ERCC5 (XPG) RE levels were significantly lower in the melanoma cell lines than in the melanocyte cell line 24 hours after cisplatin treatment. 4) All lung cancer patients (n = 161) received cisplatin or carboplatin plus a third-generation drug: in stage III patients, response was significantly associated with SNPs in ERCC1 and in ERCC3 genes.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2072" target="_blank" rel="noopener noreferrer">2072</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92889" target="_blank" rel="noopener noreferrer">Q92889</a>', 'HUGO Gene symbol': 'ERCC4', 'Protein name': 'DNA repair endonuclease XPF', 'Function': 'Catalytic component of a structure-specific DNA repair endonuclease responsible for the 5-prime incision during DNA repair. Involved in homologous recombination that assists in removing interstrand cross-links.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%2020418188%2C%2029247747%2C%2021737503%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215, 20418188, 29247747, 21737503</a>', 'Notes': '1) The repair of both types of cisplatin-DNA lesions was decreased with downregulation of XPF, ERCC1 or both XPF-ERCC1; The ICL-induced DSBs persist in the absence of XPF-ERCC1. 2) A double knockdown of XPF-ERCC1 displays the greatest level of cellular cytotoxicity when compared with XPF or ERCC1 alone. 3) Tumors with NER alterations were associated with improved overall survival (OS) and progression-free survival (PFS). 4) two NER mutations (ERCC6-Q524* and ERCC4-A583T), identified in the two most platinum-sensitive tumors, were functionally associated with platinum sensitivity in vitro. 5) RCC3 (XPB), ERCC4 (XPF), and ERCC5 (XPG) RE levels were significantly lower in the melanoma cell lines than in the melanocyte cell line 24 hours after cisplatin treatment. 6) Expression level of XPF in HNSCC tumors correlates with clinical response to platinum-based chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2073" target="_blank" rel="noopener noreferrer">2073</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28715" target="_blank" rel="noopener noreferrer">P28715</a>', 'HUGO Gene symbol': 'ERCC5', 'Protein name': 'DNA repair protein complementing XP-G cells', 'Function': "Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3' incision in DNA nucleotide excision repair (NER). Acts as a cofactor for a DNA glycosylase that removes oxidized pyrimidines from DNA.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%2026338418%2C%2033469680%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215, 26338418, 33469680</a>', 'Notes': "1) a\xa0common\xa0polymorphic variant in the\xa0ERCC5\xa05' untranslated region (UTR) generates\xa0upstream\xa0ORF\xa0(uORF) that affects both the background expression of this protein and its ability to be synthesized following exposure to agents that cause bulky adduct DNA damage. 2) Individuals that harbor uORF1 have a marked resistance to\xa0platinum-based\xa0agents, illustrated by the significantly reduced progression-free survival of pediatric ependymoma patients treated with such compounds. 3) inhibition of DNA-PKcs restores sensitivity to\xa0platinum-based\xa0compounds by preventing uORF1-dependent\xa0ERCC5\xa0expression.\xa04) the A allele and GA‑AA genotype of rs11069498 of ERCC5 were related to the response to platinum based chemotherapy in lung cancer patients. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2074" target="_blank" rel="noopener noreferrer">2074</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q03468" target="_blank" rel="noopener noreferrer">Q03468</a>', 'HUGO Gene symbol': 'ERCC6', 'Protein name': 'DNA excision repair protein ERCC-6', 'Function': 'Essential factor involved in transcription-coupled nucleotide excision repair which allows RNA polymerase II-blocking lesions to be rapidly removed from the transcribed strand of active genes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%2025634215%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215, 25634215</a>', 'Notes': '1) two NER mutations (ERCC6-Q524* and ERCC4-A583T), identified in the two most platinum-sensitive epithelial ovarian cancer (EOC) tumors, were functionally associated with platinum sensitivity\xa0in vitro. 2) Expression of wild-type ERCC6 rescued cisplatin sensitivity of ERCC6-deficient cells, whereas complementation with mutant ERCC6-Q524* did not impact cisplatin sensitivity.\xa03) Tumors with NER alterations were associated with improved overall survival (OS) and progression-free survival (PFS), compared with patients without NER alterations or BRCA1/2 mutations. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1161" target="_blank" rel="noopener noreferrer">1161</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13216" target="_blank" rel="noopener noreferrer">Q13216</a>', 'HUGO Gene symbol': 'ERCC8', 'Protein name': 'DNA excision repair protein ERCC-8', 'Function': 'Substrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29247747%2C%2030417012%2C%2012208738%5Buid%5D" target="_blank" rel="noopener noreferrer">29247747, 30417012, 12208738</a>', 'Notes': '1)\xa0Of updated gene expression data and survival information of 1656 ovarian cancer patients, high expression of ERCC1 and ERCC8 mRNA was related to a worse overall survival among ovarian cancer patients, especially in late stage and poor differentiation serous ovarian patients.\xa02) High ERCC8 mRNA expression indicated a worse OS for all GC patients. defects in the NER pathway (XPA, ERCC2, ERCC4, ERCC5, ERCC6 and ERCC8) result in hypersensitivity to platinating agents, and restoration of NER integrity correlates with rescue of the cisplatin sensitivity of these cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERCC8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2081" target="_blank" rel="noopener noreferrer">2081</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75460" target="_blank" rel="noopener noreferrer">O75460</a>', 'HUGO Gene symbol': 'ERN1', 'Protein name': 'Serine/threonine-protein kinase/endoribonuclease IRE1', 'Function': 'key sensor for the endoplasmic reticulum unfolded protein response (UPR)', 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27322083%2C%2030248920%5Buid%5D" target="_blank" rel="noopener noreferrer">27322083, 30248920</a>', 'Notes': '1) ER stress-mediated apoptosis occurred in sphere-forming cells by the cisplatin+IRE1α inhibitor (IRE1i) treatment. 2) IRE1i, synergistic with cisplatin, up-regulated elF2α phosphorylation, 3) this was followed by the induction of CHOP in sphere-forming cells.\xa04) In breast cancer, UPR signalling promotes a malignant phenotype and can confer tumours with resistance to widely used therapies.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2113" target="_blank" rel="noopener noreferrer">2113</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14921" target="_blank" rel="noopener noreferrer">P14921</a>', 'HUGO Gene symbol': 'ETS1', 'Protein name': 'Protein C-ets-1', 'Function': 'Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> EMT<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15252143%2C%2029950928%2C%20%2029974077%2C%2011066046%5Buid%5D" target="_blank" rel="noopener noreferrer">15252143, 29950928,¬† 29974077, 11066046</a>', 'Notes': '1) Ets-1 is a transcription factor for metallothioneins. 2) overexpress Ets-1 show similar or greater resistance to cisplatin. 3) ETS1 is associated with cisplatin resistance through IKKα/NF-κB pathway in TNBC cell line MDA-MB-231. 4) Increased ABC transporters were induced by the activation of NF-κB pathway in 231/DDP cells. 5) Protein expression of ETS1 and IKKα were significantly up-regulated in 231/DDP cells. 6) Inhibition of ETS1 expression enhances chemo-sensitivity to DDP and reversed the activation of NF-κB pathway in 231/DDP cells and subcutaneous transplantation tumor in vivo. 7) Association between ETS1 and the core IKKα promoter. 8) c‐Ets1 was strongly expressed in the head portion of papillary carcinoma tissues that invaded the stroma. 9) c‐Ets1 expression was associated significantly with histologic grade (P < 0.005), the presence of invasion to greater than one‐half myometrium (P < 0.001), surgical stage (P < 0.005), and vascular involvement (P = 0.009).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ETS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9156" target="_blank" rel="noopener noreferrer">9156</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UQ84" target="_blank" rel="noopener noreferrer">Q9UQ84</a>', 'HUGO Gene symbol': 'EXO1', 'Protein name': 'Exodeoxyribonuclease 1', 'Function': 'MMR, HR', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24824601%2C%2024147022%5Buid%5D" target="_blank" rel="noopener noreferrer">24824601, 24147022</a>', 'Notes': '1) FOXM1 facilitates DNA repair through regulating direct transcriptional target EXO1 to protect ovarian cancer cells from cisplatin-mediated apoptosis. 2) Attenuating FOXM1 and EXO1 expression by siRNA, augments the chemotherapy efficacy against ovarian cancer. 3) 1635 breast tumor samples were analyzed for gene expression. Seven candidate genes in chromosome 1q including EXO1 are consistently over expressed in breast tumors, specifically in high grade and aggressive breast tumors with poor clinical outcome. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EXO1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2146" target="_blank" rel="noopener noreferrer">2146</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15910" target="_blank" rel="noopener noreferrer">Q15910</a>', 'HUGO Gene symbol': 'EZH2', 'Protein name': 'Histone-lysine N-methyltransferase EZH2', 'Function': 'Methyltransferase-mediated pathway regulating replication for restart. Knockdown results in fork stabilization and PARPi resistance.', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Platinum uptake<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20686362%2C%2027610467%2C%2016330673%2C%2030166592%2C%2029630768%5Buid%5D" target="_blank" rel="noopener noreferrer">20686362, 27610467, 16330673, 30166592, 29630768</a>', 'Notes': '1) EZH2 was overexpressed in cisplatin-resistant ovarian cancer cells compared with cisplatin-sensitive cells 2) interfering with EZH2 expression can inhibit SKOV3/DDP cell autophagy and reverse resistance to cisplatin. 3) EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses. 4) seven pairs of samples from ovarian cancer patients who were given platinum-based chemotherapy with recurrent tumor, 71.43% (5 out of 7) and 83.33% (6 out of 7) patients have elevated c-Myc and EZH2 expression levels after tumor recurrence. 5) Measurements of EZH2 in 84 ovarian cancer patients suggested that patients with high EZH2 levels tend to have poor responses to cisplatin. 6) The EZH2 level progressively increased in cells receiving repeated cisplatin exposure. 7) Downregulation of EZH2 not only sensitized cellular reactions to cisplatin and increased cellular platinum accumulation when cells were exposed to both cisplatin and BODIPY‐Pt (a fluorescent cisplatin complex) but also protected copper transporter 1, a high‐affinity copper transporter closely related to cisplatin resistance, from cisplatin‐induced proteasomal degradation. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EZH2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7430" target="_blank" rel="noopener noreferrer">7430</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15311" target="_blank" rel="noopener noreferrer">P15311</a>', 'HUGO Gene symbol': 'EZR', 'Protein name': 'Ezrin', 'Function': 'Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> EMT<br><br> NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29391894%5Buid%5D" target="_blank" rel="noopener noreferrer">29391894</a>', 'Notes': "1) the protein expression levels in\xa0PAK5\xa0and Ezrin in SOSP-9607/CDDP were significantly higher than those in SOSP-9607 (P<0.01). 2) The results of immunohistochemistry showed that the expression quantities of\xa0PAK5\xa0and Ezrin in osteosarcoma tissues were significantly higher than those in para-tumor tissues (P<0.01). 3) Pearson's correlation analysis showed that expression of\xa0PAK5\xa0and Ezrin was positively correlated (r=0.197, P=0.023). 4) The osteosarcoma resistance is closely related to the expression levels of\xa0PAK5\xa0and Ezrin genes.\xa0", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EZR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/80233" target="_blank" rel="noopener noreferrer">80233</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q0VG06" target="_blank" rel="noopener noreferrer">Q0VG06</a>', 'HUGO Gene symbol': 'FAAP100', 'Protein name': 'Fanconi anemia core complex-associated protein 100', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17396147%5Buid%5D" target="_blank" rel="noopener noreferrer">17396147</a>', 'Notes': 'FAAP100-null Hela cells are extremely sensitive to DNA crosslinking drugs cisplatin and MMC', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAAP100" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/91442" target="_blank" rel="noopener noreferrer">91442</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BTP7" target="_blank" rel="noopener noreferrer">Q9BTP7</a>', 'HUGO Gene symbol': 'FAAP24', 'Protein name': 'Fanconi anemia core complex-associated protein 24', 'Function': 'Plays a role in DNA repair through recruitment of the FA core complex to damaged DNA. Regulates FANCD2 monoubiquitination upon DNA damage.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23333308%5Buid%5D" target="_blank" rel="noopener noreferrer">23333308</a>', 'Notes': 'FANCM−/−FAAP24−/−\xa0double mutant exhibited markedly increased sensitivity to cisplatin compared to the single mutants\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAAP24" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8772" target="_blank" rel="noopener noreferrer">8772</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13158" target="_blank" rel="noopener noreferrer">Q13158</a>', 'HUGO Gene symbol': 'FADD', 'Protein name': 'FAS-associated death domain protein', 'Function': 'Apoptotic adaptor molecule that recruits caspase-8 or caspase-10 to the activated Fas (CD95) or TNFR-1 receptors.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10397248%2C%2017975136%2C%2016109772%0a%5Buid%5D" target="_blank" rel="noopener noreferrer">10397248, 17975136, 16109772</a>', 'Notes': '1) Ovarian cancer cell line A2780 cells demonstrated increased FADD\xa0expression\xa0in response to cisplatin treatment.\xa02) the basal level of FADD expression is greater in the A2780 cells compared to both CDDP-resistant CP70 and C30 cells. 3) a decrease in FADD expression was observed in the CP70 and C30 cells following CDDP treatment. 4) Analysis of 167 laryngeal carcinomas showed that increased expression of FADD (P = 0.007) and Ser194 phosphorylated FADD (P = 0.011) were associated with a worse disease-specific survival. 5) FADD was recently reported to be involved in cell cycle regulation. 6) cell culture studies demonstrated that overexpression of p-FADD leads to an increase in NF-κB activity. 7) increased levels of FADD transcripts were significantly correlated with overexpression of cyclins D1 (P < 0.01) and B1 (P < 0.01). ', 'Up / down in Pt-resistant cells': 'DOWN/UP/PHOS', 'Up / down to promote Pt-resistance': 'DOWN/UP/PHOS', 'Up / down after Pt-treatment': 'UP in S; DOWN in R', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FADD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23201" target="_blank" rel="noopener noreferrer">23201</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92567" target="_blank" rel="noopener noreferrer">Q92567</a>', 'HUGO Gene symbol': 'FAM168A', 'Protein name': 'Tongue cancer resistance-associated protein 1', 'Function': 'Protects cells from induced-DNA damage and apoptosis. Acts, at least in part, through PI3K/AKT/NFKB signaling pathway and by preventing POLB degradation. Decreases POLB ubiquitation and stabilizes its protein levels', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28454268%2C%2028859669%5Buid%5D" target="_blank" rel="noopener noreferrer">28454268, 28859669</a>', 'Notes': '1) TCRP1 expression is associated with resistance to DDP in lung and ovarian cancer cells with acquired platinum resistance.  2) Knockdown of TCRP1 resensitized the cells to the platinum-based agents. 3) A positive correlation exists between TCRP1 expression and primary resistance to platinum in lung cancer cells. 4) miR-493 is silenced in resistant lung cancer cell due to the aberrant DNA methylation. 5) Enforced expression of miR-493 in lung cancer cells promotes chemotherapy sensitivity to cisplatin through impairing the DNA damage repair and increasing the cells apoptosis in vitro and in vivo. 6) TCRP1 is a direct functional target of miR-493. 7) Ectopic expression of TCRP1 attenuated increased apoptosis in miR-493-overexpressing lung cancer cells upon cisplatin treatment. 8) miR-493 level is negatively correlated with TCRP1 expression in lung cancer patients. 9) TCRP1 expression were correlated with poor survival.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAM168A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/222584" target="_blank" rel="noopener noreferrer">222584</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5T0W9" target="_blank" rel="noopener noreferrer">Q5T0W9</a>', 'HUGO Gene symbol': 'FAM83B', 'Protein name': 'Protein FAM83B', 'Function': 'Probable proto-oncogene that functions in the epidermal growth factor receptor/EGFR signaling pathway. May activate both EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=33423038%5Buid%5D" target="_blank" rel="noopener noreferrer">33423038</a>', 'Notes': '1) ovarian cancer patients with low FAM83B levels had shorter survival time, tissues with cisplatin resistance also had low FAM83B levels. 2) FAM83B overexpression inhibits cisplatin resistance showed in increased ovarian cancer cell proliferation and growth rate, and reduced apoptosis rate, while FAM83B knockdown promotes cisplatin resistance. 3) FAM83B interacted with APC to inhibit Wnt pathway activity, causing ovarian cancer cisplatin resistance. 4) FAM83B levels were negative with Wnt pathway activity in clinic samples, confirming FAM83B inhibited Wnt pathway activity.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAM83B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22909" target="_blank" rel="noopener noreferrer">22909</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y2M0" target="_blank" rel="noopener noreferrer">Q9Y2M0</a>', 'HUGO Gene symbol': 'FAN1', 'Protein name': 'Fanconi-associated nuclease 1', 'Function': 'Fanconi anemia. Nuclease required for the repair of DNA interstrand cross-links (ICL) recruited at sites of DNA damage by monoubiquitinated FANCD2. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21115814%2C%2027026368%2C%2020603016%5Buid%5D" target="_blank" rel="noopener noreferrer">21115814, 27026368, 20603016</a>', 'Notes': '1) the depletion of FANCD2/FANCI-associated nuclease, KIAA1018/FAN1,  sensitizes human cells to MMC and cisplatin.\xa02) chicken DT40 B cells, in which the FAN1 locus was disrupted by gene targeting. FAN1-null cells are highly sensitive to cisplatin and MMC, but not to ionizing or UV radiation, methyl methanesulfonate, or camptothecin. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2175" target="_blank" rel="noopener noreferrer">2175</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15360" target="_blank" rel="noopener noreferrer">O15360</a>', 'HUGO Gene symbol': 'FANCA', 'Protein name': 'Fanconia anemia group A protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28864460%2C%2024486548%5Buid%5D" target="_blank" rel="noopener noreferrer">28864460, 24486548</a>', 'Notes': "1) The germline S1088F\xa0FANCA\xa0variant in combination with\xa0FANCA\xa0LOH was deleterious for FANCA function and contributed to the patient's exceptional response to\xa0cisplatin. 2) miR-503 regulates cell apoptosis, and thus modulates the resistance of non-small cell lung cancer cells (NSCLC) to cisplatin. 3) the expression of miR-503 was significantly decreased in NSCLC tissues due to increased methylated promoter; miR-503 targets FANCA and represses its expression at the transcriptional level. 4) Up-regulation of FANCA was inversely associated with the hypermethylation of miR-503 in NSCLC tissues (P = 0.009). 5) the expression of miR-503 was decreased in the cisplatin-resistant non-small cell lung cancer cells, A549/cis, compared with the parental A549 cells. 6) Long-term cisplatin exposure promotes methylation of miR-503 gene in human NSCLC Cells. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2187" target="_blank" rel="noopener noreferrer">2187</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NB91" target="_blank" rel="noopener noreferrer">Q8NB91</a>', 'HUGO Gene symbol': 'FANCB', 'Protein name': 'Fanconia anemia group B protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27626685%5Buid%5D" target="_blank" rel="noopener noreferrer">27626685</a>', 'Notes': '1) Altogether, 25 genes were significantly differentially expressed between tumors exhibiting Pathologic complete response (pCR) and non-pCR, and these genes were downregulated in the pCR group compared to the non-pCR group. A difference in expression level greater than 1.5-fold was detected for nine genes:\xa0MGMT,\xa0ERCC4,\xa0FANCB,\xa0UBA1,\xa0XRCC5,\xa0XPA,\xa0XPC,\xa0PARP3, and\xa0RPA1.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2176" target="_blank" rel="noopener noreferrer">2176</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00597" target="_blank" rel="noopener noreferrer">Q00597</a>', 'HUGO Gene symbol': 'FANCC', 'Protein name': 'Fanconia anemia group C protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23838005%5Buid%5D" target="_blank" rel="noopener noreferrer">23838005</a>', 'Notes': '1) Cells transformed by JAK2 V617F mutant exhibited resistance to anti-cancer drugs such as cisplatin (CDDP), mitomycin C (MMC) and bleomycin (BLM).\xa02) the expression of FANCC was significantly induced by JAK2 V617F mutant through activation of STAT5. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2177" target="_blank" rel="noopener noreferrer">2177</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BXW9" target="_blank" rel="noopener noreferrer">Q9BXW9</a>', 'HUGO Gene symbol': 'FANCD2', 'Protein name': 'Fanconia anemia group D2 protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26385482%2C%2016648566%2C%2022253870%5Buid%5D" target="_blank" rel="noopener noreferrer">26385482, 16648566, 22253870</a>', 'Notes': '1) Using siRNA knockdown of FANCF, FANCL, or FANCD2 inhibited function of the FA/BRCA pathway in A549, A549/DDP and SK-MES-1 cells, and potentiated sensitivity of the three cells to cisplatin. 2) curcumin, a compound that is generally regarded as safe, inhibits the monoubiquitination of the FANCD2 protein as predicted by the screen and consequently sensitizes ovarian and breast tumor cell lines to cisplatin through apoptotic cell death. 3) Ovarian cancer patients with concomitantly high levels of PARP, FANCD2 and P53 protein expression are at increased risk of early ovarian cancer recurrence and platinum resistance.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2178" target="_blank" rel="noopener noreferrer">2178</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9HB96" target="_blank" rel="noopener noreferrer">Q9HB96</a>', 'HUGO Gene symbol': 'FANCE', 'Protein name': 'Fanconi anemia group E protein', 'Function': 'As part of the Fanconi anemia (FA) complex. Required for the nuclear accumulation of FANCC and provides a critical bridge between the FA complex and FANCD2', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24451376%5Buid%5D" target="_blank" rel="noopener noreferrer">24451376</a>', 'Notes': 'The FANCE mutant that specifically disrupts the FANCE-FANCD2 interaction conferred cellular sensitivity to a similar degree as FANCE null cells, suggesting the significance of the FANCE-FANCD2 interaction in promoting cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCE" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2188" target="_blank" rel="noopener noreferrer">2188</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NPI8" target="_blank" rel="noopener noreferrer">Q9NPI8</a>', 'HUGO Gene symbol': 'FANCF', 'Protein name': 'Fanconia anemia group F protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26385482%2C%2012692539%5Buid%5D" target="_blank" rel="noopener noreferrer">26385482, 12692539</a>', 'Notes': '1) Using siRNA knockdown of FANCF, FANCL, or FANCD2 inhibited function of the FA/BRCA pathway in A549, A549/DDP and SK-MES-1 cells, and potentiated sensitivity of the three cells to cisplatin. 2) FANCF inactivation in ovarian tumors resulted from methylation of its CpG island, and acquired cisplatin resistance (C13 cells) correlated with demethylation of FANCF. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2189" target="_blank" rel="noopener noreferrer">2189</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15287" target="_blank" rel="noopener noreferrer">O15287</a>', 'HUGO Gene symbol': 'FANCG', 'Protein name': 'Fanconi anemia group G protein', 'Function': 'operates in a postreplication repair or a cell cycle checkpoint function; ICL repair; the maintenance of normal chromosome stability.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12861027%5Buid%5D" target="_blank" rel="noopener noreferrer">12861027</a>', 'Notes': '1) FANCG-deficient DT40 cells resemble mammalian fancg mutants in that they are sensitive to killing by cisplatin and mitomycin C (MMC). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55215" target="_blank" rel="noopener noreferrer">55215</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NVI1" target="_blank" rel="noopener noreferrer">Q9NVI1</a>', 'HUGO Gene symbol': 'FANCI', 'Protein name': 'Fanconia anemia group I protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29452344%5Buid%5D" target="_blank" rel="noopener noreferrer">29452344</a>', 'Notes': '1) The average expression levels of\xa0BLM\xa0and\xa0FANCI\xa0were significantly higher in the carboplatin-sensitive ovarian cancers. 2) The knockdown of either BLM or FANCI by siRNA resulted in greater resistance to cisplatin but no significant effect on sensitivity to paclitaxel. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCI" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55120" target="_blank" rel="noopener noreferrer">55120</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NW38" target="_blank" rel="noopener noreferrer">Q9NW38</a>', 'HUGO Gene symbol': 'FANCL', 'Protein name': 'E3 ubiquitin-protein ligase FANCL', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26385482%2C%2017106252%5Buid%5D" target="_blank" rel="noopener noreferrer">26385482, 17106252</a>', 'Notes': '1) Using siRNA knockdown of FANCF, FANCL, or FANCD2 inhibited function of the FA/BRCA pathway in A549, A549/DDP and SK-MES-1 cells, and potentiated sensitivity of the three cells to cisplatin. 2) the Calu-6 lung cancer cell line carries a defective FA-BRCA pathway and detected substantially reduced expression of FANCL.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57697" target="_blank" rel="noopener noreferrer">57697</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IYD8" target="_blank" rel="noopener noreferrer">Q8IYD8</a>', 'HUGO Gene symbol': 'FANCM', 'Protein name': 'Fanconia anemia group M protein', 'Function': 'Fanconi anemia', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24708616%5Buid%5D" target="_blank" rel="noopener noreferrer">24708616</a>', 'Notes': 'Increased expression of FANCM, FANCL, UBE2T and RAD18 mRNA was observed in non-complete responders (NCR) compared to CR cervical tumor samples. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FANCM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2191" target="_blank" rel="noopener noreferrer">2191</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12884" target="_blank" rel="noopener noreferrer">Q12884</a>', 'HUGO Gene symbol': 'FAP', 'Protein name': 'Fibroblast Activation Protein Alpha / Prolyl endopeptidase FAP', 'Function': 'Cell surface glycoprotein serine protease that participates in ECM degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth, on substrates such as alpha-2-antiplasmin SERPINF2 and SPRY2. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25331442%5Buid%5D" target="_blank" rel="noopener noreferrer">25331442</a>', 'Notes': '1) Of 338 EOC tissues, FAP immunoexpression by tumor stroma was a significant predictive factor for platinum resistance (p\xa0=\u20090.0154). 2) In survival analysis of days to recurrence, FAP stoma (+) was associated with shorter recurrence than those with FAP (-) stroma (p\u2009=\u20090.0247). 3) In 21.8\xa0% of tumors, FAP protein was expressed by the tumor epithelium, and FAP mRNA was more highly expressed in tumors (n\u2009=\u2009489) than in normal tissues (n\u2009=\u20098) (p\u2009=\u20093.88\u2009×\u200910(-4)). 4) In vitro, addition of FAP to EOC cells induced a 10-12\xa0% increase in cell viability both in the presence and absence of cisplatin. 5) siRNA silencing of FAP resulted in ~10\xa0% reduction in EOC cell proliferation. 6) FAP expression in EOC is associated with poorer clinical outcomes.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/355" target="_blank" rel="noopener noreferrer">355</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25445" target="_blank" rel="noopener noreferrer">P25445</a>', 'HUGO Gene symbol': 'FAS', 'Protein name': 'Tumor necrosis factor receptor superfamily member 6', 'Function': 'Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17308072%2C%2016091761%2C%2016821621%2C%2032628088%5Buid%5D" target="_blank" rel="noopener noreferrer">17308072, 16091761, 16821621, 32628088</a>', 'Notes': '1) pretreatment of ovarian cancer OVCAR3 cells with clinically relevant cisplatin concentrations significantly improved receptor-dependent apoptotic signaling by up-modulating CD95 (FAS) receptor expression and increasing death-inducing signaling complex formation efficiency. 2) The synergy of cisplatin pretreatment and CD95 triggering in inducing cell death was also shown in p53mu tumor cells derived from ascitic fluid of advanced-stage EOC patients. 3) Of 123 urothelial cancer (UC), less frequent Fas expression was significantly associated with a higher pathological grade, a more advanced stage and poorer prognosis (P=0.010). 4) Baseline sFas increased with the number of previous chemotherapy lines (p =0.008). 5) During pharmacokinetics, the median sFas response was correlated to 5-Fluorouracil or cisplatin concentrations. 6) inherited abnormalities in apoptosis pathway, related to FAS c.-671A > G and FASL c.-844 C > T single nucleotide variants, can alter toxicity and survival of tobacco- and alcohol-related head and neck squamous cell carcinoma patients homogeneously treated with cisplatin chemoradiation.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/356" target="_blank" rel="noopener noreferrer">356</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48023" target="_blank" rel="noopener noreferrer">P48023</a>', 'HUGO Gene symbol': 'FASLG', 'Protein name': 'Tumor necrosis factor ligand superfamily member 6', 'Function': 'Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31225740%2C%2012815464%2C%2031978067%2C%2032628088%5Buid%5D" target="_blank" rel="noopener noreferrer">31225740, 12815464, 31978067, 32628088</a>', 'Notes': '1) miR-21-5p targeted FASLG and suppressed the sensitivity of HCC cells to DDP treatment. 2) cisplatin sensitivity of testicular germ cell tumor cells is dependent on the activation of the CD95 death pathway. 3) loss of cisplatin-induced activation of this CD95 signaling pathway may result in resistance to cisplatin. 4) The expression of Fas ligand (FasL) was lower in cisplatin-resistant LC cells than that in NC cells. 5) inherited abnormalities in apoptosis pathway, related to FAS c.-671A > G and FASL c.-844 C > T single nucleotide variants, can alter toxicity and survival of tobacco- and alcohol-related head and neck squamous cell carcinoma patients homogeneously treated with cisplatin chemoradiation.  ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FASLG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2194" target="_blank" rel="noopener noreferrer">2194</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49327" target="_blank" rel="noopener noreferrer">P49327</a>', 'HUGO Gene symbol': 'FASN', 'Protein name': 'Fatty acid synthase', 'Function': 'Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20508725%5Buid%5D" target="_blank" rel="noopener noreferrer">20508725</a>', 'Notes': '1) the FASN transcript level in SKOV3 cells was significantly reduced by N130 induction or by NAC1 knockdown. 2) Immunohistochemistry showed that NAC1 and FASN immunointensities in ovarian serous carcinoma tissues had a highly significant correlation (P < .0001). 3) Recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (P < .001). 4) an FASN staining score of >1 in serous carcinomas was associated with a worse overall survival time (P < .01). 5) C93, a new FASN inhibitor, induced massive apoptosis in carboplatin/paclitaxel resistant ovarian cancer cells. 6) NAC1 is essential for FASN expression in ovarian serous carcinomas and the expression of FASN significantly correlates with tumor recurrence and disease aggressiveness. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FASN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2195" target="_blank" rel="noopener noreferrer">2195</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14517" target="_blank" rel="noopener noreferrer">Q14517</a>', 'HUGO Gene symbol': 'FAT1', 'Protein name': 'Protocadherin Fat 1\xa0(Cadherin family member 7', 'Function': 'Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Redox/Glutathione<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31783581%5Buid%5D" target="_blank" rel="noopener noreferrer">31783581</a>', 'Notes': '1) In-silica analyses indicate FAT1 mutations are frequent and drive head-neck SCC, with enhanced expression defining high-risk population and poor prognosis. 2) shFAT1 suppressed PCNA and upregulated BAX/BCL2 ratio in SAS and HSC-3 cells. 3) compared with wild-type cells, shFAT1 concomitantly impaired HSC-3 cell migration, invasion, and clonogenicity. 4) over-expressed FAT1 characterized cisplatin-resistance (CispR), 5) shFAT1 synchronously re-sensitized CispR cells to cisplatin, enhanced glutathione (GSH)/GSH synthetase (GSS)-mediated oxidative stress and deregulated LRP5/WNT2 signaling.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2197" target="_blank" rel="noopener noreferrer">2197</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35544" target="_blank" rel="noopener noreferrer">P35544</a>', 'HUGO Gene symbol': 'FAU', 'Protein name': '40S ribosomal protein S30', 'Function': 'Fau modifies apoptosis-controller Bcl-G, which is also a key target for candidate oncoprotein maternal embryonic leucine zipper kinase (MELK).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19830698%2C%2019671159%5Buid%5D" target="_blank" rel="noopener noreferrer">19830698, 19671159</a>', 'Notes': '1) the expression of FAU was reduced in the A2780cis (cisplatin resistant subclone of A2780) cell line compared with the A2780 ovarian cancer cell line. 2) Downregulation of FAU in the A2780 cell line by siRNAs (siRNAs) to FAU resulted in a significant increase in resistance to carboplatin-induced cell death. 3) Overexpressing FAU was associated with increased sensitivity to carboplatin-induced apoptosis. 4) A significant reduction in the expression of FAU was seen in the malignant compared with normal ovarian samples (Kruskal-Wallis P = 0.0261).  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAU" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/114907" target="_blank" rel="noopener noreferrer">114907</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q969P5" target="_blank" rel="noopener noreferrer">Q969P5</a>', 'HUGO Gene symbol': 'FBXO32', 'Protein name': 'F-box only protein 32', 'Function': '1) a member of the F-box protein family and constitutes one of the four subunits of the ubiquitin protein ligase complex; 2) a novel apoptosis regulator; 3) TGF-β/SMAD target gene', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20065949%5Buid%5D" target="_blank" rel="noopener noreferrer">20065949</a>', 'Notes': '1) Expression of FBXO32 was observed in the normal ovarian surface epithelium, but not in ovarian cancer cell lines. 2) FBXO32 methylation was observed in ovarian cancer cell lines displaying constitutive TGF-beta/SMAD4 signaling. 3) epigenetic drug treatment restored FBXO32 expression in ovarian cancer cell lines regardless of FBXO32 methylation status. 4) In advanced-stage ovarian tumors, a significant (29.3%; P<0.05) methylation frequency of FBXO32 was observed and the association between FBXO32 methylation and shorter progression-free survival was significant. 5) Reexpression of FBXO32 markedly reduced proliferation of a platinum-resistant ovarian cancer cell line both in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FBXO32" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2237" target="_blank" rel="noopener noreferrer">2237</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P39748" target="_blank" rel="noopener noreferrer">P39748</a>', 'HUGO Gene symbol': 'FEN1', 'Protein name': 'Flap endonuclease 1', 'Function': "Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER<br><br> DDR/FA<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26718738%2C%2024880630%5Buid%5D" target="_blank" rel="noopener noreferrer">26718738, 24880630</a>', 'Notes': '1) the expression of FEN1 was significantly induced by CDDP in a dose‑ and time‑dependent manner.\xa02) The targeting of FEN1 in gastric cancer SGC‑7901 cells, in combination with CDDP treatment, significantly inhibited their proliferation and effectively increased their apoptotic rate. 3) FEN1 protein expression was evaluated in 568 oestrogen receptor (ER) negative breast cancers, 894 ER positive breast cancers and 156 ovarian epithelial cancers. 4) FEN1 mRNA overexpression is associated with poor breast cancer specific survival in univariate (p = 4.4 × 10(-16)) and multivariate analysis (p = 9.19 × 10(-7)). 5) In ER positive as well as in ER negative tumours, FEN1 protein overexpression is associated with poor survival in univariate and multivariate analysis (ps < 0.01). 6) In ovarian epithelial cancers, similarly, FEN1 overexpression is associated with high grade, high stage and poor survival (ps < 0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FEN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2246" target="_blank" rel="noopener noreferrer">2246</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05230" target="_blank" rel="noopener noreferrer">P05230</a>', 'HUGO Gene symbol': 'FGF1', 'Protein name': 'fibroblast growth factor 1', 'Function': 'Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling<br><br> Oncogene signaling/FGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22990650%5Buid%5D" target="_blank" rel="noopener noreferrer">22990650</a>', 'Notes': '1) Nine genes, including FGF1 and FGFR2 were differentially expressed in serous and nonserous tumours. 2) MDM2 and ERBB2 expression was increased in platinum-sensitive patients. 3) FGF1, FGFR2 and PDRFRB expression significantly inversely influenced progression-free survival. 4) Stable FGF1 gene knockdown in platinum-resistant A2780DPP cells re-sensitised cells to both cisplatin and carboplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2247" target="_blank" rel="noopener noreferrer">2247</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09038" target="_blank" rel="noopener noreferrer">P09038</a>', 'HUGO Gene symbol': 'FGF2', 'Protein name': 'Fibroblast growth factor 2', 'Function': 'Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/FGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21625473%5Buid%5D" target="_blank" rel="noopener noreferrer">21625473</a>', 'Notes': '1) the Janus kinase TYK2 is phosphorylated downstream of FGF-2 signaling and required for the full phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. 2) TYK2 is necessary for the induction of key anti-apoptotic proteins, such as BCL-2 and myeloid cell leukemia sequence (MCL) 1, and for the promotion of cell survival upon FGF-2. 3) Silencing JAK1, JAK2 or TYK2 using RNA interference (RNAi) inhibits FGF2-mediated proliferation and results in the sensitization of tumor cells to chemotherapy-induced killing. 4) These effects are independent of activation of signal transducer and activator of transcription (STAT) 1, STAT3 and STAT5A/B, the normal targets of JAK signaling. Instead, 5) TYK2 associates with the other kinases previously implicated in FGF-2-mediated drug resistance.\xa0', 'Up / down in Pt-resistant cells': 'Stroma UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2263" target="_blank" rel="noopener noreferrer">2263</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21802" target="_blank" rel="noopener noreferrer">P21802</a>', 'HUGO Gene symbol': 'FGFR2', 'Protein name': 'Fibroblast growth factor receptor 2,', 'Function': 'Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling<br><br> Oncogene signaling/FGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23027129%5Buid%5D" target="_blank" rel="noopener noreferrer">23027129</a>', 'Notes': '1) In a loss-of-function kinome-wide RNA interference screen to identify genes that cause cisplatin sensitization, FGFR2 as an important determinant of cisplatin resistance. 2) Pharmacological inhibition of FGFR2 confirmed the importance of this kinase in NB chemoresistance. Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLXL. 3) FGFR2 was shown to activate protein kinase C-δ to induce BCL2 expression. 3) FGFR2, as well as the ligand fibroblast growth factor-2, were consistently expressed in primary NB and NB cell lines, indicating the presence of an autocrine loop. 4) FGFR2 correlates with MYCN amplification and with advanced stage disease, demonstrating the clinical relevance of FGFR2 in NB.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGFR2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2271" target="_blank" rel="noopener noreferrer">2271</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07954" target="_blank" rel="noopener noreferrer">P07954</a>', 'HUGO Gene symbol': 'FH', 'Protein name': 'Fumarate hydratase, mitochondrial', 'Function': 'Tumor suppressor. TCA cycle. Hydrates fumarate to form malate. Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer (HLRCC). ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Hypoxia signaling<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16098467%2C%2017418408%2C%2019470762%2C%2022534668%2C%2030013182%2C%2031138787%5Buid%5D" target="_blank" rel="noopener noreferrer">16098467, 17418408, 19470762, 22534668, 30013182, 31138787</a>', 'Notes': '1) Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer (HLRCC). 2) Stabilization of HIF1 and upregulated transcription of HIF target genes in HLRCC tumor samples and in FH siRNA-treated cells. 3) fumarate and succinate both suppress the homologous recombination (HR) required for the resolution of DNA double-strand breaks (DSBs). 4) HLRCC and SDH PGL/PCC as familial DNA repair deficiency syndromes. 5) Compared with A549, the expression of fumarate hydratase, were decreased in A549/DDP. 6) FH was the most significant gene which induced by CDDP treatment. and the suppression of FH could enhance the cytotoxicity of CDDP. 7) Miconazole Nitrate (MN) could inhibit FH activity and enhance the effect of CDDP in vitro and in vivo. 8) The FH expression, which was higher in GC tissues than in noncancerous tissues, was negatively associated with the prognosis of patients. 9) In metastatic clear cell renal cell carcinoma (mccRCC) patients, low FH expression in primary tumors is associated with longer PFS during any first-line or TKI treatment, and also with better OS. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2316" target="_blank" rel="noopener noreferrer">2316</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21333" target="_blank" rel="noopener noreferrer">P21333</a>', 'HUGO Gene symbol': 'FLNA', 'Protein name': 'Filamin-A', 'Function': 'crosslinks actin filaments into orthogonal networks in cortical cytoplasm; interacts with DNA damage response proteins BRCA1 and BRCA2 (22051193)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22051193%5Buid%5D" target="_blank" rel="noopener noreferrer">22051193</a>', 'Notes': '1) reduction of filamin-A sensitizes cancer cells to chemotherapy reagents bleomycin and\xa0cisplatin, delays the repair of not only DSBs but also single strand breaks (SSBs) and interstrand crosslinks (ICLs), and increases chromosome breaks. 2) By treating a panel of human melanoma cell lines with variable filamin-A expression, we observed a correlation between expression level of filamin-A protein and drug IC(50). 3) Inhibition of the expression of filamin-A confers an increased sensitivity to bleomycin and\xa0cisplatin\xa0treatment in a mouse xenograft tumor model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLNA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2324" target="_blank" rel="noopener noreferrer">2324</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35916" target="_blank" rel="noopener noreferrer">P35916</a>', 'HUGO Gene symbol': 'FLT4', 'Protein name': 'vascular endothelial growth factor receptor 3, ', 'Function': 'primary receptor for VEGF-C/VEGF-D secreted by Tumor-associated macrophages (TAMs) ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling/VEGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24862760%2C%2026148594%2C%2027699040%5Buid%5D" target="_blank" rel="noopener noreferrer">24862760, 26148594, 27699040</a>', 'Notes': '1) VEGFR3 inhibition in ovarian cancer cells is associated with decreased levels of both BRCA1 and BRCA2.\xa02) VEGFR3 inhibition–mediated down-regulation of BRCA gene expression reversed chemotherapy resistance and restored chemosensitivity in resistant cell lines in which a BRCA2 mutation had reverted to wild type. (ovarian cancer ascites) 3) The protein and mRNA expression levels of survivin, MMP-2, VEGF-C, and VEGFR-3 in the cisplatin group and the combined treatment group were lower than that in the control group (P < 0.05). 4) Patients who responded to paclitaxel-ifosfamide-cisplatin chemotherapy expressed significantly higher VEGFR-1 and VEGFR-3 mean values compared with non-responders (P<0.001). ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2335" target="_blank" rel="noopener noreferrer">2335</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02751" target="_blank" rel="noopener noreferrer">P02751</a>', 'HUGO Gene symbol': 'FN1', 'Protein name': 'Fibronectin', 'Function': 'Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/27465871,31904865,29257300,27207836" target="_blank" rel="noopener noreferrer">27465871, 31904865, 29257300, 27207836</a>', 'Notes': '1) The differentially express level of FN1, SERPINA1 and ORM1 between platinum-sensitive (PTS) and platinum-resistant (PTR) ovarian cancer patient play a essential role in measuring subtle changes in response to platinum-based chemotherapy and may be involved in biological processes of platinum resistance. 2) Upregulation of FN1 on ovarian cancer‐associated mesothelial cells may induce platinum‐resistance via activating Akt signaling in ovarian cancer cells. 3) Dexamethasone significantly increased the levels of intracellular and secreted FN in melanoma cell lines by increasing glucocorticoid receptor‑mediated FN protein stability. 4) Extracellular FN significantly enhanced melanoma cell adhesion and survival in the presence of cisplatin, whereas partially blocking extracellular FN signaling with a CD44 antibody significantly reduced FN‑enhanced adhesion and survival. 5) FN1 was more highly expressed in NSCLC A549/DDP than in A549 cells, and significantly upregulated by cisplatin treatment in H1299 cells. 6) Knockdown of FN1 reduced the IC50 value of cisplatin, inhibited cell migration and promoted apoptosis. 7) FN1 and integrin-β1 protein directly interacted with each other both in A549 and A549/DDP cells. 8) FN1 silencing suppressed the Wnt/β-catenin signaling pathway, and this effect was dampened by integrin-β1-blocking antibody. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2348" target="_blank" rel="noopener noreferrer">2348</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15328" target="_blank" rel="noopener noreferrer">P15328</a>', 'HUGO Gene symbol': 'FOLR1', 'Protein name': 'Folate receptor alpha', 'Function': 'Binds to folate and reduces folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29433550%5Buid%5D" target="_blank" rel="noopener noreferrer">29433550</a>', 'Notes': '1) FOLR1 protein expression was lowest in normal ovarian tissue, higher in benign ovarian tumors, and highest in malignant tumors. 2) FOLR1 expression was decreased in platinum drug-resistant ovarian tumors compared to sensitive tumors. Consistent with this, FOLR1 expression in tumors progressing (PR) following cisplatin treatment was lower than levels in tumors with complete response (CR). 3) SKOV3 cells with FOLR1 overexpression were the most sensitive to cisplatin treatment. 4) Cisplatin also induced S phase arrest in a concentration-dependent manner. Apoptosis and S phase proportion were significantly altered by FOLR1 overexpression. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOLR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2350" target="_blank" rel="noopener noreferrer">2350</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14207" target="_blank" rel="noopener noreferrer">P14207</a>', 'HUGO Gene symbol': 'FOLR2', 'Protein name': 'Folate receptor beta', 'Function': 'Binds to folate and reduces folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/amino acid<br><br> Metabolism/One carbon', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21571862%5Buid%5D" target="_blank" rel="noopener noreferrer">21571862</a>', 'Notes': '1) Our analysis identified 4 genes, HDAC4, STAT1, FOLR2, and PIK3R1 as overexpressed in clinically resistant cells, each of which also significantly potentiated cisplatin response when knocked down by siRNA.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOLR2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2353" target="_blank" rel="noopener noreferrer">2353</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01100" target="_blank" rel="noopener noreferrer">P01100</a>', 'HUGO Gene symbol': 'FOS', 'Protein name': 'Proto-oncogene c-Fos', 'Function': 'Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11916245%2C%2018854825%2C%202113532%2C%201660142%2C%2010644041%5Buid%5D" target="_blank" rel="noopener noreferrer">11916245, 18854825, 2113532, 1660142, 10644041</a>', 'Notes': '1) A dominant negative that inhibits AP-1 DNA binding, named AdA-FOS: Overexpressing AdA-FOS resulted in a significant decrease in cell viability of cisplatin-resistant ovarian cancer KB85 and A2780/CP70 cells at drug doses normally not lethal to the cell.  2) Treatment with Cyclosporin A (CSA) sensitized ovarian cancer A2780DDP cells to cisplatin; CSA suppresses cisplatin-induced c-fos gene expression. 4) Knock down of c-fos with fos ribozyme resulted in decreased c-fos gene expression, concomitant with reduced expression of thymidylate (dTMP) synthase, DNA polymerase b, topoisomerase I, and metallothionein as well as reduced cisplatin reistance. 5) Of 101 patients, reduced c-Fos expression was independently associated with unfavourable progression-free survival as well as overall survival in platinum-based chemotherapy. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP in R                                    ', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2354" target="_blank" rel="noopener noreferrer">2354</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P53539" target="_blank" rel="noopener noreferrer">P53539</a>', 'HUGO Gene symbol': 'FOSB', 'Protein name': 'Protein fosB', 'Function': 'a member of the AP-1 transcription complex family of proteins', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27633497%2C%2014734480%5Buid%5D" target="_blank" rel="noopener noreferrer">27633497, 14734480</a>', 'Notes': '1) FOSB expression was significantly decreased in gastric cancer cases. 2) Downregulated expression of FOSB was correlated with poor differentiation, lymph node metastasis and advanced TNM stage. 3) low FOSB expression exhibited a significant correlation with poor prognosis for GC patients. 4) Overexpression of FOSB significantly suppressed cell proliferation, clone formation and migration in GC cell lines. 5) silencing of FOSB expression in GC cells promoted proliferation, clone formation and migration.\xa06) The Fos gene family members, FOS and FOSB, showed up-regulation in two of three cisplatin-resistant gastric cancer cells', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOSB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8061" target="_blank" rel="noopener noreferrer">8061</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15407" target="_blank" rel="noopener noreferrer">P15407</a>', 'HUGO Gene symbol': 'FOSL1', 'Protein name': 'Fos-related antigen 1', 'Function': 'a member of the AP-1 transcription complex family of proteins', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16061661%2C%2028220783%5Buid%5D" target="_blank" rel="noopener noreferrer">16061661, 28220783</a>', 'Notes': '1) Microarray analysis revealed 51 genes whose mRNA increased by at least 2-fold in PE01CDDP cells relative to PE01 (including FRA1, ETV4, MCM2, AXL, MT3, TRAP1, and FANCG), 2) siRNA inhibition of FRA1, TCP1, and MCM2 expression was associated with reduced growth and FRA1 inhibition with enhanced cisplatin sensitivity. 3) High FOSL1 expression identifies mutant KRAS lung and pancreatic cancer patients with the worst survival outcome. Furthermore, FOSL1 genetic inhibition is detrimental to both KRAS-driven tumour types.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOSL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2303" target="_blank" rel="noopener noreferrer">2303</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99958" target="_blank" rel="noopener noreferrer">Q99958</a>', 'HUGO Gene symbol': 'FOXC2', 'Protein name': 'Forkhead box protein C2', 'Function': 'Forkhead box (Fox) transcription factors family; the formation of special mesenchymal tissues', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27336949%5Buid%5D" target="_blank" rel="noopener noreferrer">27336949</a>', 'Notes': '1) The relative expression level of FOXC2 mRNA in CDDP-resistant ovarian cancer tissues was higher than that in CDDP-sensitive tissues. 2) the expression of FOXC2 mRNA and protein in CDDP-resistant ovarian cancer cell line (SKOV3/CDDP) cell line was higher than that in its parental cell line (SOKV3). 3) shRNA-mediated FOXC2 knockdown significantly increased the in vitro and in vivo sensitivity of SKOV3/CDDP cells to CDDP by enhancing apoptosis, 4) upregulation of FOXC2 significantly decreased the in vitro and in vivo sensitivity of SKOV3 cells to CDDP by reducing apoptosis. 5) FOXC2 activates the Akt and MAPK signaling pathways, and then induced the decreased expression of Bcl-2 protein and the increased expression of Bax and cleaved caspase-3 proteins.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2305" target="_blank" rel="noopener noreferrer">2305</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q08050" target="_blank" rel="noopener noreferrer">Q08050</a>', 'HUGO Gene symbol': 'FOXM1', 'Protein name': 'Forkhead box protein M1', 'Function': 'Transcriptional factor regulating the expression of cell cycle genes essential for DNA replication and mitosis', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24824601%5Buid%5D" target="_blank" rel="noopener noreferrer">24824601</a>', 'Notes': '1) FOXM1 expression was up-regulated in cisplatin resistant ovarian cancer tissues and cells. 2) FOXM1 facilitates DNA repair through regulating direct transcriptional target EXO1 to protect ovarian cancer cells from cisplatin-mediated apoptosis. 3) Attenuating FOXM1 and EXO1 expression by small interfering RNA, augments the chemotherapy efficacy against ovarian cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2308" target="_blank" rel="noopener noreferrer">2308</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12778" target="_blank" rel="noopener noreferrer">Q12778</a>', 'HUGO Gene symbol': 'FOXO1', 'Protein name': 'Forkhead box protein O1', 'Function': 'involved in diverse intracellular signaling pathways and regulates cell-cycle arrest, apoptosis, DNA damage repair, and detoxification of reactive oxygen species by regulating specific gene settings; FOXO is known to be a direct phosphorylation (inhibitory) target of the protein kinase Akt', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Apoptotic signaling<br><br> Cell cycle<br><br> Oncogene signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24576622%2C%2024202965%2C%2028664915%5Buid%5D" target="_blank" rel="noopener noreferrer">24576622, 24202965, 28664915</a>', 'Notes': '1) cisplatin or oxaliplatin in combination with the MEK1/2 inhibitor CI-1040 resulted in a synergistic effect on platinum-sensitive ovarian cancer cells. 2) The drug combinations were additive in platinum-resistant cells exhibiting increased phospho-ERK1/2, down-regulation of apoptosis-related factors (BAX, PUMA, FOXO1). 3) FOXO1 knockdown in sensitive cells reduced the efficacy of the combination treatment. 4) Cisplatin treatment induced FOXO1 expression and activation in both gastric cancer cell lines. 5) FOXO1 overexpression increased the CDDP resistance without changes in cell growth, 6) FOXO1 silencing enhanced CDDP cytotoxicity. 7) Both constitutive and CDDP-induced FOXO1 activations were accompanied by an increase in p110α and pAkt expression. 8) Akt inhibition by LY294002 treatment restored the CDDP cytotoxicity that was suppressed by FOXO1 overexpression. 9) Advanced EOC tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin-paclitaxel resistance.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXO1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2309" target="_blank" rel="noopener noreferrer">2309</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43524" target="_blank" rel="noopener noreferrer">O43524</a>', 'HUGO Gene symbol': 'FOXO3', 'Protein name': 'Forkhead box protein O3 / The\xa0Forkhead\xa0family\xa0transcription\xa0factor\xa0FKHRL1', 'Function': 'an inducer of apoptosis in its unphosphorylated form by binding to Fas', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Apoptotic signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24814195%2C%2029716743%2C%2020210796%2C%2019160093%2C%2028664915%2C%2026857210%5Buid%5D" target="_blank" rel="noopener noreferrer">24814195, 29716743, 20210796, 19160093, 28664915, 26857210</a>', 'Notes': '1) Foxo3a knockdown increased cell proliferation and resistance to cisplatin. 2) mithramycin stimulated Foxo3a expression through reactive oxygen species production and sensitized cells to cisplatin, which was abolished by Foxo3a knockdown. 3) the acetylation status of Foxo3a was decreased in response to cisplatin treatment and was lower in cisplatin-resistant cells. 4) Low expression of Foxo3a is Associated with Poor Prognosis in Ovarian Cancer Patients. 5) Advanced tumours with low relative activation of the metabolic signature and increased FOXO1 T24/FOXO3 T32 phosphorylation (P=0.041) were associated with carboplatin–paclitaxel resistance. 5) FoxO3 directs the basal transcription of Kelch-like ECH-associated protein 1 (Keap1). 6) FoxO3 depletion resulted in Keap1 down-regulation, thereby activating Nrf2 signaling. 7)FoxO3 silencing led to decreased ros production, therefore protecting cells from oxidative stress-induced killing in an Nrf2-dependent manner.8) FoxO3 deficiency strongly potentiated tumor formation in nude mice and rendered cholangiocarcinoma xenografts resistant to cisplatin-induced cell death by activating Nrf2. 9)clinical cholangiocarcinoma samples displayed FoxO3-Keap1 down-regulation and Nrf2 hyperactivation.', 'Up / down in Pt-resistant cells': 'DOWN/PHOS/LOW-ACETYL', 'Up / down to promote Pt-resistance': 'DOWN/PHOS', 'Up / down after Pt-treatment': 'UP in S/UNCHANGED in R/DEACETYL/DEPHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXO3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27086" target="_blank" rel="noopener noreferrer">27086</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H334" target="_blank" rel="noopener noreferrer">Q9H334</a>', 'HUGO Gene symbol': 'FOXP1', 'Protein name': 'The winged helix transcription factor Forkhead box P1', 'Function': 'Transcriptional repressor, regulates development of B cells; represses expression of IL-7 receptor α-chain (IL-7Rα), phosphorylation of MEK and ERK (21532575); suppresses the antitumor function of interleukin 21 (IL-21) (26500140); ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Immune response<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25502083%2C%2025895457%2C%2026654944%5Buid%5D" target="_blank" rel="noopener noreferrer">25502083, 25895457, 26654944</a>', 'Notes': '1) The relative expression of FOXP1 and GARS was significantly lower in cisplatin-resistant RMG-I-H, COC1/DDP, HO8910/PM than RMG-I-C, COC1, HO8910 ovarian cancer cells, respectively. 2) Low-expression level of FOXP1 was validated at the protein level by immunohistochemistry in paraffin embedded ovarian tissues. 3) In 58 drug-sensitive samples and 34 drug-resistant samples showed a significant decrease of FOXP1 expression in the resistant group. 4) Low nuclear FOXP1 expression was associated with chemotherapy resistance and short survival time of patients with ovarian cancer. 5) Knockdown of FOXP1 expression in A2780 or SKOV3 ovarian cancer cells decreased spheroid formation, expression of stemness-related genes and epithelial to mesenchymal transition-related genes, cell migration, and resistance to Paclitaxel or Cisplatin treatment, 6) overexpression of FOXP1 did the opposite. 7) overexpression of FOXP1 increased promoter activity of ABCG2, OCT4, NANOG, and SOX2, among which the increases in ABCG2, OCT4, and SOX2 promoter activity were dependent on the presence of FOXP1-binding site. 8) In xenotransplantation of A2780 ovarian cancer cells into nude mice, knockdown of FOXP1 expression significantly decreased tumor size. These results strongly suggest FOXP1 functions as an oncogene by promoting cancer stem cell-like characteristics in ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'DOWN/UP/CYTOPLASTIC', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11167" target="_blank" rel="noopener noreferrer">11167</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12841" target="_blank" rel="noopener noreferrer">Q12841</a>', 'HUGO Gene symbol': 'FSTL1', 'Protein name': 'Follistatin-related protein 1', 'Function': 'May modulate the action of some growth factors on cell proliferation and differentiation. Binds heparin', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28883005%5Buid%5D" target="_blank" rel="noopener noreferrer">28883005</a>', 'Notes': '1) FSTL1 is overexpressed in ESCCs, where it correlates with poor overall survival. 2) Genetic amplification of FSTL1 or chromosome 3q, where it is located, occurred frequently in ESCC. 3) Elevating FSTL1 levels by various means was sufficient to drive ESCC cell proliferation, clonogenicity, migration, invasion, self-renewal, and\xa0cisplatin\xa0resistance\xa0in vitro\xa0and tumorigenicity and distant metastasis\xa0in vivo.\xa04) Conversely, FSTL1 attenuation by shRNA or neutralizing antibody elicited the opposite effects in ESCC cells. 5) FSTL1 drives ESCC oncogenesis and metastasis through various pathways, with deregulation of NFκB and BMP signaling figuring prominently. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FSTL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8880" target="_blank" rel="noopener noreferrer">8880</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96AE4" target="_blank" rel="noopener noreferrer">Q96AE4</a>', 'HUGO Gene symbol': 'FUBP1', 'Protein name': 'Far upstream element (FUSE) binding protein 1', 'Function': 'Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. ', 'Putative_mechanism_associated_with_Pt_resistance': 'MYC signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29113212%5Buid%5D" target="_blank" rel="noopener noreferrer">29113212</a>', 'Notes': '1) the expression of FBP1 was significantly higher in EOC tissues than in normal epithelial ovarian or in epithelial ovarian adenoma tissue. 2) FBP1 expression was significantly correlated with the grade of epithelial ovarian cancer. 3) Carboplatin inhibited the expression of FBP1 in epithelial ovarian cancer cells. 4) FBP1 knockdown increases the sensitivity of ovarian cancer cells to carboplatin. 5) the expression of β-catenin and MMP-9 were lower in FBP1 knockdown cells compared with control EOC cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FUBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8325" target="_blank" rel="noopener noreferrer">8325</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H461" target="_blank" rel="noopener noreferrer">Q9H461</a>', 'HUGO Gene symbol': 'FZD8', 'Protein name': 'Frizzled-8', 'Function': 'Receptor for Wnt proteins. Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalosomes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23445611%2C%2028368389%5Buid%5D" target="_blank" rel="noopener noreferrer">23445611, 28368389</a>', 'Notes': '1) Treatment with cisplatin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in TNBC cell lines resulted in increased FZD8 expression in residual tumors of xenograft models. 2) Inhibition of FZD8 by siRNA in the presence of cisplatin plus TRAIL reduced β-catenin and survivin levels and increased apoptosis in vitro and in vivo. 3) c-Myc overexpression has been linked to FZD8 overexpression in TNBC cell lines, associating c-Myc-driven transcription to chemoresistance and TNBC CSC survival.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FZD8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2539" target="_blank" rel="noopener noreferrer">2539</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11413" target="_blank" rel="noopener noreferrer">P11413</a>', 'HUGO Gene symbol': 'G6PD', 'Protein name': 'Glucose-6-phosphate 1-dehydrogenase', 'Function': 'Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/PPP<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/26337086,31814893" target="_blank" rel="noopener noreferrer">26337086, 31814893</a>', 'Notes': '1) cisplatin-resistant ovarian cancer C13 cells not only present an increased glucose-uptake and consumption, 2) but also exhibit increased expression and enzymatic activity of the Pentose Phosphate pathway (PPP) enzyme Glucose-6-Phosphate Dehydrogenase (G6PDH). 3) cisplatin-resistant cells are more sensitive to G6PDH inhibition.\xa04)  blocking the TGFβ1-FOXM1-HMGA1-G6PD axis by knocking down FOXM1, HMGA1, or G6PD individually impaired TGFβ1-induced cisplatin resistance in lung cancer H1299 and H226 cells. 5) silencing FOXM1, HMGA1, or G6PD prevented TGFβ1 from eliminating ROS in cisplatin-treated cells. 6) immunohistochemical analysis in 216 NSCLC patients was performed: positive correlations among the expression levels of FOXM1, HMGA1, and G6PD in NSCLC tissues; Kaplan-Meier analysis showed that OS was worse among patients with high FOXM1, HMGA1, or G6PD staining than among those with low staining. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=G6PD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2551" target="_blank" rel="noopener noreferrer">2551</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q06546" target="_blank" rel="noopener noreferrer">Q06546</a>', 'HUGO Gene symbol': 'GABPA', 'Protein name': 'GA-binding protein alpha chain, GABP subunit alpha', 'Function': 'Transcription factor capable of interacting with purine rich repeats (GA repeats).\xa0ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> CSC<br><br> Metabolism/OXPHOS<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31802036%5Buid%5D" target="_blank" rel="noopener noreferrer">31802036</a>', 'Notes': '1) we unexpectedly observed that GABPA ablation inhibited TERT expression, but robustly increased proliferation, stem, and invasive phenotypes and cisplatin resistance in bladder BC cells, while its overexpression exhibited opposite effects, and inhibited in vivo metastasizing in a xenograft transplant model.\xa02) The overall survival (OS) was significantly longer in patients with high-GABPA expression. 3) the gene expression levels of NRF1, GA-binding protein transcription factor‑α (GABPA), TFAM and TFB1M were higher in the OC SKOV3/DDP cells than in the SKOV3 cells. 4) Downstream targets FoxA1 and GATA3 induce CDKN1A and CDKN1B expression transcriptionally. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GABPA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1647" target="_blank" rel="noopener noreferrer">1647</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P24522" target="_blank" rel="noopener noreferrer">P24522</a>', 'HUGO Gene symbol': 'GADD45A', 'Protein name': 'Growth arrest and DNA damage-inducible protein GADD45 alpha', 'Function': 'A regulator of p38 MAPKs, affects PCNA interaction with some CDKs; stimulates DNA excision repair', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Cell cycle<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=8950993%2C%2015837757%5Buid%5D" target="_blank" rel="noopener noreferrer">8950993, 15837757</a>', 'Notes': '1) Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. 2) Of FFPE samples of 61 Gastric Cancerpatients who received a 5-fluorouracil (5-FU)– and cisplatin-based chemotherapy, high DPD levels were more frequently found in nonresponding patients and were associated with worse survival. 3) GADD45A and Thymidine Phosphorylase (TP) levels showed weak associations with response, but GADD45A expression correlated with survival. There was no association with response for TS expression, but tumors with a high TS level were associated with worse survival. The combination of GADD45A and TP revealed the strongest predictive effect. High expression values of TP and/or GADD45A were exclusively found in nonresponding patients (P = 0.002) and were associated with a significantly poorer survival (P = 0.04).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GADD45A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/90480" target="_blank" rel="noopener noreferrer">90480</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TAE8" target="_blank" rel="noopener noreferrer">Q8TAE8</a>', 'HUGO Gene symbol': 'GADD45GIP1', 'Protein name': 'Growth arrest and DNA damage-inducible proteins-interacting protein 1', 'Function': '1) Acts as a negative regulator of G1 to S cell cycle phase progression by inhibiting cyclin-dependent kinases.\xa02) May play a role in mitochondrial protein synthesis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28599472%5Buid%5D" target="_blank" rel="noopener noreferrer">28599472</a>', 'Notes': '1) NAC1 expression was markedly negatively associated with growth arrest and DNA-damage-inducible 45γ-interacting protein 1 (GADD45GIP1) expression in ovarian cancer. 2) Increased NAC1 expression or decreased GADD45GIP1 expression was significantly associated with decreased progression-free survival (P=0.0041). 3) knockdown of NAC1 by RNAi significantly increased GADD45GIP1 expression and cisplatin cytotoxicity in SKOV3 cells. 4) Overexpression of NAC1 in TOV-21G cells increased the resistance to cisplatin. 5) NAC1-dependent suppression of senescence, mediated through GADD45GIP1, serves an important role in promoting cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GADD45GIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2621" target="_blank" rel="noopener noreferrer">2621</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14393" target="_blank" rel="noopener noreferrer">Q14393</a>', 'HUGO Gene symbol': 'GAS6', 'Protein name': 'Growth arrest-specific protein 6', 'Function': 'Ligand for tyrosine-protein kinase receptors TYRO3, AXL, and MER (TAM) whose signaling is implicated in full and sustained platelet activation and other cell growth and survival, cell adhesion and cell migration. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27876874%5Buid%5D" target="_blank" rel="noopener noreferrer">27876874</a>', 'Notes': '1) TWIST1 expression resulted in upregulation of GAS6 and L1CAM. 2) Knockdown studies of these genes demonstrated that loss of GAS6 or L1CAM sensitized cells to cisplatin. 3) a new lncRNA GAS6-AS1 (GAS6 antisense RNA 1), whose expression was downregulated in tumor tissues in 50 patients with non-small cell lung cancer (NSCLC) (P < 0.001). 4) decreased GAS6-AS1 expression was negatively correlated with lymph node metastasis (P = 0.032) and advanced tumor node metastasis stage (P = 0.003). 5) GAS6-AS1 expression served as an independent predictor for overall survival (P = 0.036). 6) GAS6-AS1 level was inversely correlated with GAS6 (growth-arrest-specific gene6) mRNA level (Pearson’s correlation −0.620). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GAS6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2729" target="_blank" rel="noopener noreferrer">2729</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48506" target="_blank" rel="noopener noreferrer">P48506</a>', 'HUGO Gene symbol': 'GCLC', 'Protein name': 'Glutamate--cysteine ligase catalytic subunit', 'Function': 'the first rate-limiting enzyme of glutathione synthesis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=7488097%2C%2029474642%2C%2027133165%5Buid%5D" target="_blank" rel="noopener noreferrer">7488097, 29474642, 27133165</a>', 'Notes': '1) γ-Glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance in human small-cell lung cancer cell line, SBC-3. 2) Of patients (n\u2009=\u200922) with advanced lung adenocarcinoma, high expression of GCLC was a risk factor for poorer post-recurrence survival after cisplatin-based chemotherapy (hazard ratio, 6.26; 95% confidence interval, 1.37–28.7; P = 0.018). 3) shGCLC downregulated the protein expression of GCLC, decreased intracellular GSH level, and promoted cisplatin-induced apoptosis.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GCLC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2730" target="_blank" rel="noopener noreferrer">2730</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48507" target="_blank" rel="noopener noreferrer">P48507</a>', 'HUGO Gene symbol': 'GCLM', 'Protein name': 'Glutamate--cysteine ligase regulatory subunit', 'Function': 'This protein is involved in step\xa01\xa0of the subpathway that synthesizes glutathione from L-cysteine and L-glutamate.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14532974%2C%2026356271%2C%2016012725%5Buid%5D" target="_blank" rel="noopener noreferrer">14532974, 26356271, 16012725</a>', 'Notes': '1) We inhibited each subunit of GCL mRNA using a specific ribozyme (M-Rz and C-Rz) in the pulmonary adenocarcinoma cell line A549. 2) CDDP-resistance was more effectively ameliorated when GCLM rather than GCLC was inhibited. GCLM is a potentially more effective pharmacologic target for ameliorating CDDP-resistance in non-small cell lung cancer than GCLC. 3) The endogenous expression levels of Nrf2 as well as its target genes including GCLC, GCLM, HO-1, NQO1 and MRP1 were much higher in A549/DDP cells than those of A549 cells and the susceptibility of A549/DDP cells to cisplatin was partially restored by silencing Nrf2. 4) We examined the gene expression of GCLM and GCLC in four human SCLC xenografts: the overexpression of GCLM is correlated with CDDP-resistance in SCLC xenografts in vivo.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GCLM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9518" target="_blank" rel="noopener noreferrer">9518</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99988" target="_blank" rel="noopener noreferrer">Q99988</a>', 'HUGO Gene symbol': 'GDF15', 'Protein name': 'Growth differentiation factor 15', 'Function': 'a member of TGF-b/bone morphogenetic protein (BMP) super family; a stress-responsive cytokine; may act as a metabolic regulator, increase insulin sensitivity, regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses\xa0(26273671). ', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Oncogene signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29580231%2C%2025490861%2C%2026018318%5Buid%5D" target="_blank" rel="noopener noreferrer">29580231, 25490861, 26018318</a>', 'Notes': '1) Increasing levels of serum GDF15 was significantly associated with FIGO stage and lymphonodus metastasis. 2) The chemo-resistant EOC patients (median, 1225.0 pg/mL) showed significantly higher GDF15 than chemo-sensitive patients (median, 824.2 pg/mL; P\u2009=\u20090.013). 3) Highly expressed GDF15 was an independent negative prognostic indicator in the PFS (P\u2009=\u20090.026) of the 122 EOC cases in the multivariate analysis. 4) knockdown of GDF15 in cisplatin-resistant A2780cis in vivo resulted in enhanced subcutaneous tumor growth in mice but increased sensitivity to carboplatin treatment. 5) GDF15 may contribute to carboplatin resistance by suppressing tumor growth through p27. 6) Twist knockdown significantly decreased GDF15 expression, cell invasion, matrix metalloproteinase‑2 expression/activity and the IC50 values of cisplatin, which was completely reversed by overexpression of GDF15. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GDF15" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2674" target="_blank" rel="noopener noreferrer">2674</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P56159" target="_blank" rel="noopener noreferrer">P56159</a>', 'HUGO Gene symbol': 'GFRA1', 'Protein name': 'GDNF family receptor α 1', 'Function': 'Receptor for GDNF. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor tyrosine kinase to promote a spectrum of endocrine neoplasias. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Autophagy<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27754745%2C%2025575823%2C%2030040982%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27754745, 25575823, 30040982¬†</a>', 'Notes': '1) GFRA1 contributes to the development of cisplatin-induced chemoresistance in osteosarcoma by facilitating autophagy via SRC-AMP-activated protein kinase (AMPK) signaling. 2) high expression of sialyltransferase ST3GAL1 was associated with poor clinical outcome in patients with late stage breast cancer and high expression of both ST3GAL1 and GFRA1 adversely impacted outcome in those with high grade tumors.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GFRA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79893" target="_blank" rel="noopener noreferrer">79893</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H3C7" target="_blank" rel="noopener noreferrer">Q9H3C7</a>', 'HUGO Gene symbol': 'GGNBP2', 'Protein name': 'Gametogenetin-binding protein 2', 'Function': "May be involved in spermatogenesis. GGNBP2 may function as a corepressor to inhibit ERa's transcriptional activity and consequently inhibits tumorigenic potential of breast cancer cells; inhibition of IL-6/STAT3 signaling activation (30450530); ", 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24842157%5Buid%5D" target="_blank" rel="noopener noreferrer">24842157</a>', 'Notes': '1) RNASET2 and GGNBP2 mRNA levels were significantly lower in A2780-CBP (carboplatin-resistant) and A2780-DDP (cisplatin-resistant) ovarian cancer cells than in the parental A2780 cells 2) and were downregulated in drug-resistant ovarian cancer tissues compared with their drug-sensitive counterparts. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GGNBP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2678" target="_blank" rel="noopener noreferrer">2678</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P19440" target="_blank" rel="noopener noreferrer">P19440</a>', 'HUGO Gene symbol': 'GGT1', 'Protein name': 'Glutathione hydrolase 1 proenzyme', 'Function': 'Cleaves the gamma-glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and other gamma-glutamyl compounds.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12123741%2C%2024664430%5Buid%5D" target="_blank" rel="noopener noreferrer">12123741, 24664430</a>', 'Notes': '1) cisplatin treatment of HeLa cells was accompanied by an early 3-fold induction of GGT synthesis. 2) Both cell lines showed comparable intracellular GSH levels and cisplatin resistance when cultured in high (250 microM) or low (50 microM) cysteine-containing medium. 3) When 50 microM of GSH were included in the low-cysteine culture medium only HeLa-GGT cells partially recovered their intracellular GSH and exhibited an increased resistance to cisplatin. 4) Cisplatin treatment also inhibited GGT-dependent production of reactive oxygen species, a process depending on the availability of cysteinylglycine produced during GSH catabolism. 5) cisplatin forms adducts with cysteinylglycine 10 times more rapidly than with GSH, and that these adducts were formed only in the extracellular medium of HeLa GGT cells. 6) Low GGT activity resulted in high cisplatin sensitivity, as observed in RPTEC-SV40 cells or after siRNA mediated knock-down of GGT in RPTEC/TERT1 cells that have high GGT activity.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GGT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2697" target="_blank" rel="noopener noreferrer">2697</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17302" target="_blank" rel="noopener noreferrer">P17302</a>', 'HUGO Gene symbol': 'GJA1', 'Protein name': 'Gap junction alpha-1\xa0', 'Function': 'A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, a direct connection from cell to cell to transfer molecules such as ions, cyclic AMP, cyclic GMP, phosphoinositides, nucleotides, amino acids, or glutathione; cytotoxicity in neighboring untreated bystander cells through gap junctions (GJs) (15069205); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> bystander effect<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17072341%2C%2030279363%2C%2019056535%2C%2029495625%5Buid%5D" target="_blank" rel="noopener noreferrer">17072341, 30279363, 19056535, 29495625</a>', 'Notes': '1) GJA1 (encoding connexin 43 (Cx43)) and TWIST1, which are highly upregulated in cisplatin-resistant cells. 2) paradoxically, inhibition of Cx43 function in high expressing cells led to an increase in drug resistance - Ga-p junction inhibitor, α-GA treatment of ACRP cells, led to a significant increase in cisplatin resistance. 3) cisplatin toxicity can also be mediated by functional gap junction intercellular communication (GJIC) (Bystander Effect) - cisplatin cytotoxicity is mediated by cellular density (gap junction intercellular communication (GJIC)). 4) At high or gap junction forming density, this effect is ablated when GJA1 or Connexin 43 (Cx43) is targeted, leading to cisplatin resistance. 5) reduced expression of both connexin 43 and E-cadherin significantly correlated to poor differentiation, advanced TNM stage, and lymph note metastasis of NSCLCs. 6) Connexin 43 and E-cadherin expression significantly correlated with each other. Over-expression of connexin 43 significantly induced E-cadherin expression. 7) Better survival was associated with a high expression of Cx43 in unstratified and luminal tumors but with a low expression in Her2e subtype. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GJA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2735" target="_blank" rel="noopener noreferrer">2735</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08151" target="_blank" rel="noopener noreferrer">P08151</a>', 'HUGO Gene symbol': 'GLI1', 'Protein name': 'GLI family zinc finger 1', 'Function': 'transcriptional activator. Regulates normal development; mediates SHH signaling ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hedgehog signaling<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24366538%2C%2029552194%2C%2023423781%5Buid%5D" target="_blank" rel="noopener noreferrer">24366538, 29552194, 23423781</a>', 'Notes': '1) The Hedgehog pathway is molecularly linked to increased resistance to cisplatin and increased repair of platinum-DNA damage, through C-JUN. 2) GLI1, which has five known isoforms, is a positive transcriptional regulator in Hedgehog. 3) only one of five isoforms of GLI1 may be responsible for the Hedgehog link with C-JUN and thus, increased platinum-DNA adduct repair. 4) significant differences were also revealed in the expression levels of SMO (P=0.013) and GLI1 (P=0.0005) between the platinum drug-sensitive and drug-resistant groups. 5) The overexpression of SMO and GLI1 was further confirmed in the cisplatin-resistant ovarian cancer cell line A2780/DDP. 6) Inhibition of Gli1 expression decreases ABCB1 and ABCG2 gene expression levels and enhances the response of ovarian cancer cells to certain chemotherapeutic drugs. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GLI1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2736" target="_blank" rel="noopener noreferrer">2736</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10070" target="_blank" rel="noopener noreferrer">P10070</a>', 'HUGO Gene symbol': 'GLI2', 'Protein name': 'GLI family zinc finger 2', 'Function': 'transcription regulator in the hedgehog (Hh) pathway; transcriptional activator or transcriptional repressor (By similarity). Requires STK36 for full transcriptional activator activity. Required for normal embryonic development', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hedgehog signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31697978%2C%2022142828%5Buid%5D" target="_blank" rel="noopener noreferrer">31697978, 22142828</a>', 'Notes': '1) MiR-182-5p was down-regulated in cisplatin-resistant Lung Adenocarcinoma cells and directly targeted GLI2. 2) Interference with miR-182-5p or GLI2 silencing resulted in modulation of cell proliferation, clonogenic potential, and cisplatin-sensitivity. 3) Analysis of stem cell genes upregulated in recurrent high-grade ovarian adenocarcinomas tumors reveals both primary mediators of the hedgehog pathway (GLI1,2) to be increased after chemotherapy. 4) A2780cp20 cells were found to express GLI1 2.05-fold higher and GLI2 1.40-fold higher (p<0.001) than their parental line (A2780ip2), suggesting these hedgehog pathway members may be involved in mediating platinum resistance. 5) increased sensitivity to cisplatin was observed in both A2780cp20 and ES2 cell lines after knockdown of Gli2, but not Gli1. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GLI2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2744" target="_blank" rel="noopener noreferrer">2744</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94925" target="_blank" rel="noopener noreferrer">O94925</a>', 'HUGO Gene symbol': 'GLS', 'Protein name': 'Glutaminase kidney isoform, mitochondrial', 'Function': 'Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glutaminolysis<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27191653%2C%2029633308%5Buid%5D" target="_blank" rel="noopener noreferrer">27191653, 29633308</a>', 'Notes': 'As GLS2', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GLS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27165" target="_blank" rel="noopener noreferrer">27165</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UI32" target="_blank" rel="noopener noreferrer">Q9UI32</a>', 'HUGO Gene symbol': 'GLS2', 'Protein name': 'Glutaminase liver isoform, mitochondrial', 'Function': 'Plays an important role in the regulation of glutamine catabolism. Promotes mitochondrial respiration and increases ATP generation in cells by catalyzing the synthesis of glutamate and alpha-ketoglutarate. Increases cellular anti-oxidant function via NADH and glutathione production.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glutaminolysis<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27191653%2C%2029633308%5Buid%5D" target="_blank" rel="noopener noreferrer">27191653, 29633308</a>', 'Notes': '1) increasing c-Myc expression in both sensitive cell lines after 24 and 48hr cisplatin treatment (2uM). 2) c-Myc expression is upregulated in platinum resistant compared to sensitive ovarian cancer cell lines. 3) In platinum-sensitive ovarian cancer cell lines the metabolism of both, glucose and glutamine was initially up-regulated in response to platinum treatment. 4) Platinum resistant cells were approximately 4-times more sensitive to glutamine deprivation compared to sensitive cells, with an upregulated expression of glutamine transporter ASCT2 and glutaminase. 5) This resulted in a higher oxygen consumption rate compared to platinum-sensitive cell lines reflecting the increased dependency of glutamine utilization through the tricarboxylic acid cycle. 6) The important role of glutamine metabolism was confirmed by stable overexpression of glutaminase, which conferred platinum resistance. 7) shRNA knockdown of glutaminase in platinum resistant cells resulted in re-sensitization to platinum treatment. 8) combining the glutaminase inhibitor BPTES with platinum synergistically inhibited platinum sensitive and resistant ovarian cancers in vitro.  9) c-Myc is the upstream regulator increasing the dependency of platinum resistant ovarian cancer cell lines on glutamine metabolism via the TCA cycle and in the regulation of oxidative phosphorylation. 10) A significant correlation between higher levels of glutaminase gene expression and reduced progression free and overall survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GLS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84572" target="_blank" rel="noopener noreferrer">84572</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UJJ9" target="_blank" rel="noopener noreferrer">Q9UJJ9</a>', 'HUGO Gene symbol': 'GNPTG', 'Protein name': 'N-acetylglucosamine-1-phosphotransferase subunit gamma', 'Function': 'Initial step of the biosynthesis of N-glycans', 'Putative_mechanism_associated_with_Pt_resistance': 'Glycosylation<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20005867%5Buid%5D" target="_blank" rel="noopener noreferrer">20005867</a>', 'Notes': '1) The cross-resistance to cisplatin is due to increased expression and altered N-linked glycosylation of MRP1 or MRP4. 2) Pre-treatment with tunicamycin, which inhibits the biosynthesis of N-linked oligosaccharides, results in Pt-resistance in sensitive cells and increased the electrophoretic mobility of MRP1 and MRP4, reproducing the association between decreased glycosylation of MRP1 and MRP4 and decreased Pt accumulation observed in the resistant Ovarian IGROV-1/OHP cells. 3) The observed N-glycosylation defect of Pt-resistant cells was linked to reduced levels of N-acetylglucosamine-1-phosphotransferase (GNPTG) and mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5).  ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GNPTG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64083" target="_blank" rel="noopener noreferrer">64083</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H4A6" target="_blank" rel="noopener noreferrer">Q9H4A6</a>', 'HUGO Gene symbol': 'GOLPH3', 'Protein name': 'Golgi phosphoprotein 3', 'Function': 'Phosphatidylinositol-4-phosphate-binding protein that links Golgi membranes to the cytoskeleton and may participate in the tensile force required for vesicle budding from the Golgi.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30015866%2C%2024458516%5Buid%5D" target="_blank" rel="noopener noreferrer">30015866, 24458516</a>', 'Notes': '1) Colorectal HT29 cells were resistant to 10\xa0µM\xa0cisplatin\xa0treatment, whereas the expression of GOLPH3, P-glycoprotein, phosphorylated extracellular signal-regulated kinase (pERK)1/2 and β-catenin protein was significantly upregulated compared with the control group. 2) With\xa0cisplatin\xa0treatment, silencing GOLPH3 gene expression downregulated the expression of these proteins, reduced\xa0cell\xa0proliferation and tumorigenicity, induced apoptosis and reversed the\xa0resistance\xa0of HT29 cells to\xa0cisplatin. 3) the change in pERK1/2 and β-catenin expression demonstrated that the mechanism of GOLPH3 overexpression involved in cisplatin resistance was associated\xa0with activation of the mitogen-activated protein kinase/ERK and Wnt/β‑catenin signaling pathways in HT29 cells. 4) The tumorigenicity experiment in nude mice also demonstrated that silencing GOLPH3 expression increased the sensitivity of HT29 cells to\xa0cisplatin\xa0in\xa0vivo.\xa05) GOLPH3 is overexpressed in colorectal cancer tissues and promotes the proliferation of colon cancer cells. 6) GOLPH3 was associated with poor prognosis in colorectal cancer. 7) Ovarian cancer patients with low dispersed cytoplasmic GOLPH3 expression had significantly longer overall survival than patients with high dispersed cytoplasmic expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GOLPH3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55204" target="_blank" rel="noopener noreferrer">55204</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H4A5" target="_blank" rel="noopener noreferrer">Q9H4A5</a>', 'HUGO Gene symbol': 'GOLPH3L', 'Protein name': 'Golgi phosphoprotein 3-like', 'Function': 'Phosphatidylinositol-4-phosphate-binding protein that may antagonize the action of GOLPH3 which is required for the process of vesicle budding at the Golgi and anterograde transport to the plasma membrane', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28978336%5Buid%5D" target="_blank" rel="noopener noreferrer">28978336</a>', 'Notes': '1) The expression of GOLPH3L was markedly upregulated in ovarian cancer cell lines and tissues, 2) high GOLPH3L expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. 3) GOLPH3L overexpression confers CDDP resistance on ovarian cancer cells; 4) inhibition of GOLPH3L sensitized ovarian cancer cell lines to CDDP cytotoxicity both in vitro and in vivo. 5) GOLPH3L upregulated the levels of nuclear p65 and phosphorylated inhibitor of nuclear factor Kappa-B kinase-β and IκBα, thereby activating canonical nuclear factor-κB (NF-κB) signaling.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GOLPH3L" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/65056" target="_blank" rel="noopener noreferrer">65056</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86WP2" target="_blank" rel="noopener noreferrer">Q86WP2</a>', 'HUGO Gene symbol': 'GPBP1', 'Protein name': 'Vasculin', 'Function': 'Functions as a GC-rich promoter-specific transactivating transcription factor.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29669295%5Buid%5D" target="_blank" rel="noopener noreferrer">29669295</a>', 'Notes': '1) GPBP1 knockdown resulted in the upregulation of distinct and canonical HR factors such as BRCA1 and RAD51B in response to BMN673. 2) GPBP1 Loss Causes PARP and Platinum Resistance by Regulating the Expression of Factors Involved in HR in MCF10A cells. 3) In the TCGA ovarian cohort, survival analysis indicated that GPBP1 loss was associated with poor outcome and resistance to platinum therapy. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9052" target="_blank" rel="noopener noreferrer">9052</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NFJ5" target="_blank" rel="noopener noreferrer">Q8NFJ5</a>', 'HUGO Gene symbol': 'GPRC5A', 'Protein name': 'Retinoic acid-induced protein 3', 'Function': 'Orphan receptor; retinoic acid-inducible;  interaction between retinoid and G-protein signaling pathways; as an interactor of EphA2 and β1‐integrin (27715394); mediates the hypoxia-induced adaptive response (30143543)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Hippo signaling<br><br> Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32115889%5Buid%5D" target="_blank" rel="noopener noreferrer">32115889</a>', 'Notes': '1) Using high-grade serous ovarian cancer (HGSC) patient material and cell lines: robust cisplatin and carboplatin-induced ERK1/2-RSK1/2-EphA2-GPRC5A signaling switch associated with cancer cell intrinsic and acquired chemoresistance. 2) inhibition or knockdown of RSK1/2 prevented oncogenic EphA2-S897 phosphorylation and EphA2-GPRC5A co-regulation, leading to downregulation of EphA2. 3) In combination with platinum, RSK inhibitors effectively sensitized even the most platinum-resistant EphA2high\xa0, GPRC5Ahigh\xa0cells. 4) In HGSC patient tumors, GPRC5A was expressed exclusively in cancer cells and associated with chemotherapy resistance and poor survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPRC5A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2878" target="_blank" rel="noopener noreferrer">2878</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P22352" target="_blank" rel="noopener noreferrer">P22352</a>', 'HUGO Gene symbol': 'GPX3', 'Protein name': 'Glutathione peroxidase 3 ', 'Function': 'a key component of cellular antioxidant regulation, protects cells and enzymes from oxidative damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, by glutathione.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22017790%2C%2027918237%5Buid%5D" target="_blank" rel="noopener noreferrer">22017790, 27918237</a>', 'Notes': '1) Serum levels of GPX3 were found to be significantly lower in patients than controls (p = 1 × 10-2). 2) this was found to be dependent on the stage of papillary serous ovarian cancer. 3) GPX3 promoter region methylation in approximately one third of colorectal cancer (CRC) samples. 4) GPX3 methylation leads to reduced GPX3 expression and increased oxaliplatin and cisplatin sensitivity. 5) in cell lines with high baseline levels of GPX3 expression or with the ability to increase GPX3 expression, platinum resistance is increased. 6) GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPX3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2879" target="_blank" rel="noopener noreferrer">2879</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P36969" target="_blank" rel="noopener noreferrer">P36969</a>', 'HUGO Gene symbol': 'GPX4', 'Protein name': 'Phospholipid hydroperoxide glutathione peroxidase', 'Function': 'Essential antioxidant peroxidase that directly reduces phospholipid hydroperoxide even if they are incorporated in membranes and lipoproteins. Can also reduce fatty acid hydroperoxide, cholesterol hydroperoxide and thymine hydroperoxide.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31556117%5Buid%5D" target="_blank" rel="noopener noreferrer">31556117</a>', 'Notes': '1) GPX4 was higher expressed in cancer tissues than normal and was negatively associated with prognosis of patients. 2) at upstream of GPX4 there was low DNA methylation sites and enhanced level of H3K4me3 and H3K27ac, indicating that high level of GPX4 in cancer may resulted from epigenetic regulation. 3) GPX4 may potentially be involved in translation of protein, mitochondrial respiratory chain complex I assembly, electron transport oxidative phosphorylation, nonalcoholic fatty liver disease, and metabolic pathways. 4) GPX4 inhibited ferroptosis in cancer cells, the inhibition of GPX4 via RSL3 could enhance the anticancer effect of cisplatin in vitro and in vivo.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPX4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9687" target="_blank" rel="noopener noreferrer">9687</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q4ZG55" target="_blank" rel="noopener noreferrer">Q4ZG55</a>', 'HUGO Gene symbol': 'GREB1', 'Protein name': 'Protein GREB1', 'Function': 'May play a role in estrogen-stimulated cell proliferation. GREB1, along with CCND1 and MYC, are common transcription targets for E2 (17β-estradiol)-mediated proliferative responses, via ESR1 engagement', 'Putative_mechanism_associated_with_Pt_resistance': 'Hormone receptor signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30056367%2C%2033192515%5Buid%5D" target="_blank" rel="noopener noreferrer">30056367, 33192515</a>', 'Notes': '1) the development of platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated. 2) GREB1 Expression Defines Platinum Sensitivity and Correlates with Longer PFS in Ovarian Cancer. 3) GREB1 mRNA level was downregulated in cisplatin-resistant A2780cis compared to A2780 parental cells. 4) from GDSC-Lung Adenocarcinoma cell lines and the cohorts TCGA-LUAD and Local-LUAD, we found only one gene (GREB1) with mutations related to decreased CDDP sensitivity as well as worse overall survival (OS) and progression-free survival (PFS). 5) The GREB1-mutant (GREB1-MT) group had a higher frequency of gene mutations. Additionally, gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA) suggested reduced accumulation of intracellular drugs in the GREB1-MT group, in addition to increased drug efflux and enhanced DNA damage repair and intracellular detoxification. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GREB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26585" target="_blank" rel="noopener noreferrer">26585</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60565" target="_blank" rel="noopener noreferrer">O60565</a>', 'HUGO Gene symbol': 'GREM1', 'Protein name': 'Gremlin-1', 'Function': 'Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a  bone morphogenetic protein (BMP) antagonist ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17003113%2C%2029968778%5Buid%5D" target="_blank" rel="noopener noreferrer">17003113, 29968778</a>', 'Notes': '1) BMPs and their antagonists are known to play a crucial role in stem and progenitor\xa0cellbiology as regulators of the balance between expansion and differentiation. 2) GREMLIN\xa01\xa0expression in the stroma of human BCC tumors but not in normal skin in vivo. 3) BMP 2 and 4 are\xa0expressed\xa0by BCC\xa0cells. Ex vivo, BMP inhibits, and\xa0Gremlin\xa01\xa0promotes,\xa0proliferation\xa0of cultured BCC\xa0cells. 4) GREMLIN\xa01\xa0is\xa0expressed\xa0by\xa0stromal\xa0cells\xa0in many carcinomas but not in the corresponding normal tissue counterparts that we examined.\xa05) Cisplatin had at least an additive efect in the reduction of JL-1 and H2052 mesothelioma cell proliferation when combined with pirfenidone, which down-regulate GREM1 expression. 6) two studies using non-small cell lung cancer (NSCLC) xenograf mouse models suggested also that pirfenidone alone did not signifcantly reduce tumor proliferation. However, combining pirfenidone with a platin chemotherapy compound resulted in a signifcant decrease in tumor growth. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GREM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2932" target="_blank" rel="noopener noreferrer">2932</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49841" target="_blank" rel="noopener noreferrer">P49841</a>', 'HUGO Gene symbol': 'GSK3B', 'Protein name': 'Glycogen synthase kinase-3 beta', 'Function': 'a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17671694%5Buid%5D" target="_blank" rel="noopener noreferrer">17671694</a>', 'Notes': '1) We compared the expression/phosphorylation of GSK-3beta between the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. The expression levels of total GSK-3beta and pGSK-3beta-tyr-216 were similar in these cells; however, CP70 cells had a much higher expression of pGSK-3beta-ser-9 than A2780 cells. 2) Lithium chloride, which is a GSK-3beta inhibitor and stimulates pGSK-3beta-ser-9, significantly increased the IC50 of cisplatin and counteracted cisplatin-induced apoptosis of A2780 and CP70 cells. 3) In contrast, overexpression of a constitutively active S9A GSK-3beta mutant increased the sensitivity of CP70 cells to cisplatin and significantly enhanced cisplatin-mediated apoptosis. 4) It is suggested that the cisplatin-resistance of CP70 cells is mediated by stabilizing p53. We demonstrated that GSK-3beta negatively regulated the expression of p53.\xa0', 'Up / down in Pt-resistant cells': 'PHOS', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSK3B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2934" target="_blank" rel="noopener noreferrer">2934</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06396" target="_blank" rel="noopener noreferrer">P06396</a>', 'HUGO Gene symbol': 'GSN', 'Protein name': 'Gelsolin', 'Function': 'Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25246592%5Buid%5D" target="_blank" rel="noopener noreferrer">25246592</a>', 'Notes': '1) CDDP-induced GSN down-regulation is associated with its cleavage and apoptosis. 2) C-terminal GSN fragment (C-GSN) sensitized chemoresistant cells to CDDP, intact GSN and its N-terminal fragment (N-GSN) attenuated this response. 3) GSN silencing also facilitated CDDP-induced apoptosis in chemoresistant cells. 4)  intact GSN (I-GSN) was prosurvival in the presence of CDDP through a FLICE-like inhibitory protein (FLIP)-Itch interaction. 5)  In resistant cells, GSN was highly expressed and CDDP failed to abolish the I-GSN-FLIP-Itch interaction, resulting in the dysregulation of the downstream responses. 6) GSN overexpression was significantly associated with more aggressive behavior and more cancer deaths in ovarian serous adenocarcinoma patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2936" target="_blank" rel="noopener noreferrer">2936</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00390" target="_blank" rel="noopener noreferrer">P00390</a>', 'HUGO Gene symbol': 'GSR', 'Protein name': 'Glutathione reductase, mitochondrial', 'Function': 'Maintains high levels of reduced glutathione in the cytosol.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22792399%2C%2030364292%5Buid%5D" target="_blank" rel="noopener noreferrer">22792399, 30364292</a>', 'Notes': '1) Cisplatin resistance in IGROVCDDP cells is multifactorial and is mediated in part by the glutathione pathway and decreased accumulation of drug. Total cellular glutathione was not increased. 2) However, the enzyme activity of GSR and GGT1 were up-regulated. 3) High GSR and HCP5 expression level were correlated with poor survival of Small cell lung cancer (SCLC)  patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2937" target="_blank" rel="noopener noreferrer">2937</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48637" target="_blank" rel="noopener noreferrer">P48637</a>', 'HUGO Gene symbol': 'GSS', 'Protein name': 'Glutathione synthetase', 'Function': 'catalyzes the second step of glutathione biosynthesis, which is the ATP-dependent conversion of gamma-L-glutamyl-L-cysteine to glutathione. Defects in this gene are a cause of glutathione synthetase deficiency', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31783581%2C%2028219206%5Buid%5D" target="_blank" rel="noopener noreferrer">31783581, 28219206</a>', 'Notes': '1) over-expressed FAT1 characterized cisplatin-resistance (CispR), shFAT1 synchronously re-sensitized CispR cells to cisplatin, enhanced glutathione (GSH)/GSH synthetase (GSS)-mediated oxidative stress and deregulated LRP5/WNT2 signaling. 2) GSS genetic polymorphism rs725521 plays an important role in the response to platinum-based chemotherapy, while rs7265992 and rs725521 have important effect on the prognosis of SCLC patients. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2938" target="_blank" rel="noopener noreferrer">2938</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08263" target="_blank" rel="noopener noreferrer">P08263</a>', 'HUGO Gene symbol': 'GSTA1', 'Protein name': 'Glutathione S-transferase A1', 'Function': 'Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21150160,30431119,2898306" target="_blank" rel="noopener noreferrer">21150160, 30431119, 2898306¬†</a>', 'Notes': '1) Knockdown of GSTA1, which was up-regulated in CDDP-resistant ovarian cancer cells, by GSTA1 siRNA restored cisplatin sensitivity in NOY1-CR cells. 2) GSTA1 silencing enhanced DDP cytotoxicity in SGC7901/DDP cells by 6‑fold, in A549/DDP cells by 5‑fold and in SKOV3/DDP cells by 2‑fold.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/373156" target="_blank" rel="noopener noreferrer">373156</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y2Q3" target="_blank" rel="noopener noreferrer">Q9Y2Q3</a>', 'HUGO Gene symbol': 'GSTK1', 'Protein name': 'Glutathione S-transferase kappa 1', 'Function': 'The enzyme can also prevent ER stress and ER stress induced adiponectin down-regulation, which implies that GSTK1 assists the ER’s functions.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23330092%2C%2029845423%5Buid%5D" target="_blank" rel="noopener noreferrer">23330092, 29845423</a>', 'Notes': '1) increased hGSTK1 gene expression was detected only in resistant erythroleukemia K562/CDDP and mammary adenocarcinoma MCF-7/CDDP cells. 2) A prognostication model using expression levels of G6PD and 9 related genes (PSMA2, PSMB8, SHFM1, GSS, GSTK1, MGST2, POLD3, MSH2, MSH6) could independently predict LGG patient survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2944" target="_blank" rel="noopener noreferrer">2944</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09488" target="_blank" rel="noopener noreferrer">P09488</a>', 'HUGO Gene symbol': 'GSTM1', 'Protein name': 'Glutathione S-transferase Mu 1', 'Function': 'Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29285301%2C%202898306%2C%2022085405%5Buid%5D" target="_blank" rel="noopener noreferrer">29285301, 2898306, 22085405</a>', 'Notes': '1) Of 170 untreated metastatic breast cancer patient, the null genotypes of GSTT1 and GSTM1 were significantly correlated to poor OS compared with the present genotypes, respectively. 2) Inhibition of GSTM1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells, consistent with siRNA-mediated knockdown of GSTM1 gene. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2948" target="_blank" rel="noopener noreferrer">2948</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q03013" target="_blank" rel="noopener noreferrer">Q03013</a>', 'HUGO Gene symbol': 'GSTM4', 'Protein name': 'Glutathione S-transferase Mu 4', 'Function': 'Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20200426%5Buid%5D" target="_blank" rel="noopener noreferrer">20200426</a>', 'Notes': '1) We observed suggestive associations between lung cancer survival and GSTT1 copy number, and GSTA5, GSTM4, and ABCC4 SNPs, adjusted for covariates (P = 0.018, 0.002, and 0.002, respectively) or not (P = 0.005, 0.011, and 0.002). 2) One hundred lymphoblastoid cell lines were then treated with cisplatin, and IC(50) values were significantly associated with the GSTM4 SNP (P = 0.019). 4) GSTM4, GSTT1, and ABCC4 overexpression significantly decreased cisplatin sensitivity in lung cancer and HEK293T cell lines.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTM4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2950" target="_blank" rel="noopener noreferrer">2950</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09211" target="_blank" rel="noopener noreferrer">P09211</a>', 'HUGO Gene symbol': 'GSTP1', 'Protein name': 'Glutathione S-transferase Pi', 'Function': 'Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9850649%2C%202898306%2C%2014678959%5Buid%5D" target="_blank" rel="noopener noreferrer">9850649, 2898306, 14678959</a>', 'Notes': '1) Of 87 surgically resected specimens, 55 (63.2%) were GST pi positive. 2) Twenty-five of 28 patients (89.3%) who showed no response to chemotherapy had GST pi-positive tumor cells. 3) The predictive value of positive GST pi staining for drug resistance was 75.8% (25/33). 4) adenovirus-mediated Ad.GST-CD ::upp/5-FC directed by GSTP1 promoter (to shut down GSTP1) is an effective approach to overcome cisplatin-resistant ovarian cancer. 5) GST-pi amplification was detected in 7 of 10 cell lines. Five were relatively cisplatin resistant, and 2 were relatively cisplatin sensitive (mean IC(50), 11.2 and 2.75 microM). 6) In 10 tumor specimens, 4 had no amplification of GST-pi. All 4 had a complete response to neoadjuvant chemotherapy; of the 2 patients showing GST-pi amplification: neither responded to chemotherapy, and both died of disease <9 months from diagnosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2952" target="_blank" rel="noopener noreferrer">2952</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30711" target="_blank" rel="noopener noreferrer">P30711</a>', 'HUGO Gene symbol': 'GSTT1', 'Protein name': 'Glutathione S-transferase theta-1', 'Function': 'Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25648141%2C%202898306%2C%2020200426%5Buid%5D" target="_blank" rel="noopener noreferrer">25648141, 2898306, 20200426</a>', 'Notes': '1) As GSTM1. 2) We observed suggestive associations between lung cancer survival and GSTT1 copy number, and GSTA5, GSTM4, and ABCC4 SNPs, adjusted for covariates (P = 0.018, 0.002, and 0.002, respectively) or not (P = 0.005, 0.011, and 0.002). 3) GSTM4, GSTT1, and ABCC4 overexpression significantly decreased cisplatin sensitivity in lung cancer and HEK293T cell lines.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GSTT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3014" target="_blank" rel="noopener noreferrer">3014</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16104" target="_blank" rel="noopener noreferrer">P16104</a>', 'HUGO Gene symbol': 'H2AX', 'Protein name': 'Variant histone H2A', 'Function': 'Variant histone H2A. Plays a central role in transcription regulation, DNA repair. Required for checkpoint response to IR; and for DSB repair when modified by C-terminal phosphorylation.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26138778%5Buid%5D" target="_blank" rel="noopener noreferrer">26138778</a>', 'Notes': '1) In the drug-resistant derivative cell lines there was overall a significant increase in the number and persistence of both γ-H2AX and Rad51 foci in the nuclei of cells over a 72-hour period, when compared to the non-resistant parental cell lines (ANOVA p < 0.0001).\xa0(Pt-resistant ovarian cancer cell line (A2780cis(R) vs sensitive A2780 parental). 2) A high p-H2AX expression in CRC tissues was associated with tumor stage and perineurial invasion. 3) a high p-H2AX expression was associated with poor DMFS and OS. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=H2AX" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9563" target="_blank" rel="noopener noreferrer">9563</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95479" target="_blank" rel="noopener noreferrer">O95479</a>', 'HUGO Gene symbol': 'H6PD', 'Protein name': 'GDH/6PGL endoplasmic bifunctional protein', 'Function': 'Oxidizes glucose-6-phosphate and glucose, as well as other hexose-6-phosphates.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/PPP<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26337086%5Buid%5D" target="_blank" rel="noopener noreferrer">26337086</a>', 'Notes': '1) cisplatin-resistant ovarian cancer cells (C13), are characterized by reduced mitochondrial activity and higher glucose-dependency when compared to the cisplatin-sensitive counterpart. 2) C13 cells not only present an increased glucose-uptake and consumption, but also exhibit increased expression and enzymatic activity of the Pentose Phosphate pathway (PPP) enzyme Glucose-6-Phosphate Dehydrogenase (G6PDH).  3) cisplatin-resistant cells are more sensitive to G6PDH inhibition. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=H6PD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1839" target="_blank" rel="noopener noreferrer">1839</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99075" target="_blank" rel="noopener noreferrer">Q99075</a>', 'HUGO Gene symbol': 'HBEGF', 'Protein name': 'Heparin-binding epidermal growth factor-like growth factor', 'Function': 'Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22609777%2C%2025115341%2C%2030285805%5Buid%5D" target="_blank" rel="noopener noreferrer">22609777, 25115341, 30285805</a>', 'Notes': '1) HB-EGF was over-expressed in a paclitaxel-resistant human ovarian carcinoma cell line (A2780/Taxol) and a cisplatin-resistant cell line (A2780/CDDP), as well as the xenograft mouse tissue samples with these cells. 2) HBEGF inhibitor CRM197 significantly induced anti-proliferative activity in a dose-dependent manner with the cell-cycle arrest at the G0/G1 phase and enhanced apoptosis in A2780/Taxol and A2780/CDDP cells. 3) CRM197 significantly suppressed the growth of drug-resistant ovarian cancer xenografts in vivo (p<0.001). 4) CRM197 markedly downregulates the expression of excision repair cross-complementing group 1 (P = 0.002) and DNA repair capacity in A2780/CDDP tumor (P < 0.001). 5) Public databases provided evidence linking high expression of BHLHE40 and HBEGF to poor prognosis of triple-negative breast cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HBEGF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54985" target="_blank" rel="noopener noreferrer">54985</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NWW0" target="_blank" rel="noopener noreferrer">Q9NWW0</a>', 'HUGO Gene symbol': 'HCFC1R1', 'Protein name': 'Host cell factor C1 regulator 1', 'Function': 'Regulates HCFC1 activity by modulating its subcellular localization.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28039608%5Buid%5D" target="_blank" rel="noopener noreferrer">28039608</a>', 'Notes': '1) HPIP is highly expressed in high-grade primary ovarian tumors. 2) HPIP promotes the migration, invasion and EMT in OAW42 cells and induces EMT in these cells via activation of the PI3K/AKT pathway. 3) HPIP expression confers cisplatin resistance to SKOV3 cells after prolonged exposure 4) its subsequent knockdown decreases the viability of these cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HCFC1R1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3065" target="_blank" rel="noopener noreferrer">3065</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13547" target="_blank" rel="noopener noreferrer">Q13547</a>', 'HUGO Gene symbol': 'HDAC1', 'Protein name': 'Histone deacetylase 1', 'Function': 'Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'MYC signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24475290%2C%2029456726%2C%2029561664%2C%2030071534%5Buid%5D" target="_blank" rel="noopener noreferrer">24475290, 29456726, 29561664, 30071534</a>', 'Notes': '1) Knockdown of HDAC1 or DNMT1 expression, and pharmacological inhibition of DNMT or HDAC enzymatic activity, significantly increases RGS10 expression and cisplatin-mediated cell death. 2) DNMT1 knock down also decreases HDAC1 binding to the RGS10 promoter in chemoresistant cells, suggesting HDAC1 recruitment to RGS10 promoters requires DNMT1 activity. 3) Overexpression of HDAC1 was detected in the nucleus of all cases with mucinous carcinoma (MUC) followed by clear cell carcinoma (CCC) (80%), Serous carcinoma (SEC) (73%), and endometrioid carcinoma (EMC) (53%). 4) The comparison between prior to and following chemotherapy revealed a nuclear expression increase in HDAC1 (76% vs. 92%; P=0.03). 5) HDAC1 nuclear expression adversely affected overall survival in SEC (P=0.02) and EMC (P=0.03). 6) miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. 7) The overexpression of HDAC1 decreased cisplatin sensitivity and promoted proliferation in OC cells. 8) In cisplatin-resistant A2780CDDP cells, HDAC1 knockdown by siRNA suppressed cell proliferation, and increased apoptosis and chemosensitivity by downregulating c-Myc and upregulating miR-34a. In cisplatin-sensitive A2780 cells, HDAC1 knockdown did not affect cell proliferation and apoptosis. 9) targeting HDAC1 inhibited A2780CDDP-induced xenograft tumor growth but not A2780-induced xenograft tumor growth. Targeting HDAC1 sensitized both A2780- and A2780CDDP-induced xenograft tumors to cisplatin treatment.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HDAC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8841" target="_blank" rel="noopener noreferrer">8841</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15379" target="_blank" rel="noopener noreferrer">O15379</a>', 'HUGO Gene symbol': 'HDAC3', 'Protein name': 'Histone deacetylase 3', 'Function': 'Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4), and some other non-histone substrates.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32024543%5Buid%5D" target="_blank" rel="noopener noreferrer">32024543</a>', 'Notes': '1) PD-L1 expression was significantly increased in A549/CDDP, MCF7/ADR and HepG2/ADR cells and was attributed mainly to enhanced JNK/c-Jun signaling activation. 2) Mechanistically, decreased COP1 increased c-Jun accumulation, which subsequently inhibited HDAC3 expression and thereby enhanced histone H3 acetylation of the PD-L1 promoter. 3)  PD-L1 expression could be inhibited by JNK/c-Jun inhibition or HDAC3 overexpression in vivo, which could largely reverse inhibited CD3+\xa0T cell proliferation in vitro. 4) PD-L1 expression was significantly increased in the cisplatin-resistant clinical NSCLC samples and positively correlated with c-Jun expression but negatively correlated with HDAC3 expression.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HDAC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9759" target="_blank" rel="noopener noreferrer">9759</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P56524" target="_blank" rel="noopener noreferrer">P56524</a>', 'HUGO Gene symbol': 'HDAC4', 'Protein name': 'Histone deacetylase 4', 'Function': 'Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21571862%5Buid%5D" target="_blank" rel="noopener noreferrer">21571862</a>', 'Notes': '1) Transcriptional analysis of a matched ovarian cell line series  (PEO1/PEO4/PEO6, PEA1/PEA2, PEO14/PEO23) identified 91 up- and 126 downregulated genes common to acquired resistance. 2) Significantly enhanced apoptotic response to platinum treatment in resistant cells was observed following knockdown of HDAC4, FOLR2, PIK3R1, or STAT1 (P < 0.05). 3) Analysis of 16 paired tumor biopsies taken before and after development of clinical platinum resistance showed significantly increased HDAC4 expression in resistant tumors [n = 7 of 16 (44%); P = 0.04]. 4) clinical selection of HDAC4-overexpressing tumor cells upon exposure to chemotherapy promotes STAT1 deacetylation and cancer cell survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HDAC4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79654" target="_blank" rel="noopener noreferrer">79654</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5T447" target="_blank" rel="noopener noreferrer">Q5T447</a>', 'HUGO Gene symbol': 'HECTD3', 'Protein name': 'E3 ubiquitin-protein ligase HECTD3', 'Function': 'A novel member of the HECT (homologous to E6-AP carboxyl terminus) domain family of E3s. Mediates ubiquitination of TRIOBP faciliting cell cycle progression.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28989055%5Buid%5D" target="_blank" rel="noopener noreferrer">28989055</a>', 'Notes': '1) HECTD3 depletion promotes carboplatin-induced apoptosis in both an ovarian cancer cell model and a xenograft mouse model. 2) high HECTD3 expression is significantly associated with poor platinum response and prognosis in ovarian cancer patients. 3) HER2 can up-regulate HECTD3 expression through activating STAT3. 4) HER2 inhibitors, such as lapatinib, down-regulate HECTD3 expression and thus promote the chemosensitivity of ovarian cancer cells to carboplatin. 5) Lapatinib combined with carboplatin also significantly inhibits serous ovarian carcinoma growth compared with each drug alone in a xenograft mouse model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HECTD3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/113510" target="_blank" rel="noopener noreferrer">113510</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TDG4" target="_blank" rel="noopener noreferrer">Q8TDG4</a>', 'HUGO Gene symbol': 'HELQ', 'Protein name': 'Helicase POLQ-like', 'Function': "Single-stranded DNA-dependent ATPase and 5' to 3' DNA helicase. Involved in the repair of DNA cross-links and double-strand break (DSB) resistance.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29572031%5Buid%5D" target="_blank" rel="noopener noreferrer">29572031</a>', 'Notes': '1) HELQ expression associates with response of EOC patients to platinum-based chemotherapy and their overall survival (OS), disease free survival (DFS). 2) HELQ overexpression or knockdown, respectively, increased and decreased the cellular resistance to cisplatin, DNA repair activity, and expression of DNA repair proteins of Nucleotide excision repair (NER) pathway.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HELQ" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23462" target="_blank" rel="noopener noreferrer">23462</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y5J3" target="_blank" rel="noopener noreferrer">Q9Y5J3</a>', 'HUGO Gene symbol': 'HEY1', 'Protein name': 'Hairy/enhancer-of-split related with YRPW motif protein 1', 'Function': 'Transcriptional repressor which binds preferentially to the canonical E box sequence. Downstream effector of Notch signaling required for cardiovascular development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29146722%5Buid%5D" target="_blank" rel="noopener noreferrer">29146722</a>', 'Notes': '1) HEY1\xa0is specifically upregulated in HNSCC compared with normal tissues in the TCGA data set.\xa02) NOTCH4\xa0is more significantly related to\xa0HEY1\xa0activation in HNSCC in comparison with other\xa0NOTCH\xa0receptors.\xa03) NOTCH4\xa0promotes cell proliferation,\xa0cisplatin\xa0resistance, inhibition of apoptosis, and cell-cycle dysregulation. 4) NOTCH4\xa0and\xa0HEY1\xa0upregulation resulted in decreased\xa0E-cadherin\xa0expression and increased\xa0Vimentin,\xa0Fibronectin, TWIST1, and\xa0SOX2\xa0expression.\xa0NOTCH4\xa0and\xa0HEY1\xa0expression was associated with an EMT phenotype as well as increased invasion and cell migration.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HEY1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3082" target="_blank" rel="noopener noreferrer">3082</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14210" target="_blank" rel="noopener noreferrer">P14210</a>', 'HUGO Gene symbol': 'HGF', 'Protein name': 'hepatocyte growth factor', 'Function': 'Secreted by mesenchymal cells, acts on cells of mainly epithelial origin; functions in angiogenesis, tumorigenesis, and tissue regeneration; secretion in the tumor microenvironment contributes to the innate and acquired resistance to RAF inhibitors.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/HGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14996735%2C%2025351134%5Buid%5D" target="_blank" rel="noopener noreferrer">14996735, 25351134</a>', 'Notes': '1) hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) 2) this effect is mediated by the p38 mitogen-activated protein kinase. 3) In nonovarian cancer cell models, as expected, HGF provides protection from drug-induced apoptosis. 4) HGF expression was associated with tumor‑node‑metastasis (TNM) clinical stage, histological grade, lymph node metastasis and prognosis (P<0.05). 5) The efficiency of chemotherapy in HGF negative patients (90%) was significantly higher (P<0.05) compared with HGF positive patients (68.75%).', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HGF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3090" target="_blank" rel="noopener noreferrer">3090</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14526" target="_blank" rel="noopener noreferrer">Q14526</a>', 'HUGO Gene symbol': 'HIC1', 'Protein name': 'Hypermethylated in cancer 1 protein / HIC ZBTB transcriptional repressor 1', 'Function': 'Transcriptional repressor involved in down-regulation of SIRT1 and thereby is involved in regulation of p53/TP53-dependent apoptotic DNA-damage responses.\xa0Regulation of SIRT1 transcription in response to nutrient deprivation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15149548%5Buid%5D" target="_blank" rel="noopener noreferrer">15149548</a>', 'Notes': '1) 22 gene promoters for hypermethylation in 70 differentiated nonseminoma germ cell tumors (NSGCTs) derived from 60 patients; the frequency of promoter hypermethylation of individual genes differed between cisplatin-sensitive and resistant tumors.\xa0RASSF1A\xa0(52% in resistant vs. 28% in sensitive) and\xa0HIC1\xa0(47% in resistant vs. 24% in sensitive) genes showed higher frequency of promoter hypermethylation in resistant tumors. 2) hypermethylation of RASSF1A, HIC1, and APC genes was higher in the treated tumors, with highly resistant (C2/C3) tumors exhibiting the highest incidence', 'Up / down in Pt-resistant cells': 'DOWN/methylated promoter', 'Up / down to promote Pt-resistance': 'DOWN/methylated promoter', 'Up / down after Pt-treatment': 'DOWN/methylated promoter', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HIC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3091" target="_blank" rel="noopener noreferrer">3091</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16665" target="_blank" rel="noopener noreferrer">Q16665</a>', 'HUGO Gene symbol': 'HIF1A', 'Protein name': 'Hypoxia-inducible factor 1-alpha', 'Function': 'Functions as a master transcriptional regulator of the adaptive response to hypoxia.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/11927290,11410504,21737664,32939054,27593081" target="_blank" rel="noopener noreferrer">11927290, 11410504, 21737664, 32939054, 27593081</a>', 'Notes': '1) HIF-1α overexpression in biopsies of brain, breast, cervical, esophageal, oropharyngeal and ovarian cancers is correlated with treatment failure and mortality.\xa02) Exposure of NSCLC SPCA1 and A549 cells to 0.5% O2 significantly increased resistance to cisplatin and doxorubicin. 3) Hypoxia-induced resistance to cisplatin and doxorubicin were reversed in SPCA1/HIF-1alpha(-) and A549/HIF-1alpha(-) cells. 4) The combination of HIF-1alpha protein overexpression with nonfunctional p53 indicates a dismal prognosis in EOC patients. 5) HIF-1α expression was significantly correlated with initial response to CRT (p=0.0027): esophageal cancer patients with high HIF-1α expression had significantly poorer local control (LC) (5-year LC: 42.7%) than those with low expression (5-year LC: 72.5%; p=0.0322). 6) Patients with high HIF-1α expression also had significantly lower recurrence-free survival (RFS) compared to those with low HIF-1α expression. 7) High HIF1α expression is a predictor of poor clinical response to CRT in HPV-negative LA-HNSCC patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HIF1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/28996" target="_blank" rel="noopener noreferrer">28996</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H2X6" target="_blank" rel="noopener noreferrer">Q9H2X6</a>', 'HUGO Gene symbol': 'HIPK2', 'Protein name': 'Homeodomain-interacting protein kinase 2', 'Function': 'phosphorylates p53 at Ser46 for specific activation of proapoptotic target genes, including p53AIP1, PIG3, Bax, Noxa, and KILLER/DR5 and contributes to the regulation of p53-induced apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18395248%2C%2024846322%5Buid%5D" target="_blank" rel="noopener noreferrer">18395248, 24846322</a>', 'Notes': '1) HIPK2 was expressed differently in sensitive versus chemoresistant cells in response to different chemotherapeutic drugs (i.e., cisplatin and adriamycin), though the p53Ser46 apoptotic pathway was not defective in chemoresistant ovarian cancer 2008C13 cells. 2) OC 2008C13 cells were resistant to cisplatin but sensitive to adriamycin-induced apoptosis through activation of the HIPK2/p53Ser46 pathway. 3) HIPK2 knock-down inhibited the adriamycin-induced apoptosis in 2008C13 cells. 4) Exogenous HIPK2 triggered apoptosis in chemoresistant cells, associated with induction of p53Ser46-target gene AIP1. 5) HIPK2 mRNA and protein levels are significantly decreased in cisplatin-resistant bladder cancer cell in vivo and in vitro. 6) Downregulation of HIPK2 increases the cell viability in a dose- and time-dependent manner during cisplatin treatment, whereas overexpression of HIPK2 reduces the cell viability. 7) HIPK2 overexpression partially overcomes cisplatin resistance in RT4-CisR cell. 8) Wip1 (wild-type p53-induced phosphatase 1) expression is upregulated in RT4-CisR cell compared with RT4 cell, and HIPK2 negatively regulates Wip1 expression in bladder cancer cell. 9) HIPK2 and Wip1 expression is also negatively correlated after cisplatin-based combination chemotherapy in vivo. 10) overexpression of HIPK2 sensitizes chemoresistant bladder cancer cell to cisplatin by regulating Wip1 expression. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HIPK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3099" target="_blank" rel="noopener noreferrer">3099</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52789" target="_blank" rel="noopener noreferrer">P52789</a>', 'HUGO Gene symbol': 'HK2', 'Protein name': 'Hexokinase-2', 'Function': 'In vertebrates there are four major glucose-phosphorylating isoenzymes, designated hexokinase I, II, III and IV (glucokinase).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> Autophagy<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29247711,19770592,31560931" target="_blank" rel="noopener noreferrer">29247711, 19770592, 31560931</a>', 'Notes': '1) Increased HK2 levels were detected in drug-resistant human ovarian cancer cells and tissues. 2) Cisplatin downregulated HK2 in cisplatin-sensitive but not in resistant ovarian cancer cells. 3) HK2 knockdown sensitized resistant ovarian cancer cells to cisplatin-induced cell death and apoptosis. 4) HK2 overexpression in cisplatin-sensitive cells induced cisplatin resistance. 5) HK2 overexpression enhanced cisplatin-induced ERK1/2 phosphorylation and autophagy while HK2 knockdown showed the opposite effects. 6) Blocking the MEK/ERK pathway using the MEK inhibitor U0126 prevented cisplatin-induced autophagy enhanced by HK2 overexpression. 7) HK2 knockdown sensitized resistance ovarian tumor xenografts to cisplatin in vivo. 8) In cancer cells, the majority of hexokinase II is localized to the mitochondria through interaction with VDAC. 9) disruption in the binding of hexokinase II to the mitochondria markedly potentiates the onset of caspase-2 induced mitochondrial damage, thus resulting in a synergistic induction of cisplatin induced cytotoxicity. 10) The high levels of HXKII induced by hypoxia conferred cisplatin resistance in all tested B-cell lymphoma cell lines. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; UNCHANGED in R', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3146" target="_blank" rel="noopener noreferrer">3146</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09429" target="_blank" rel="noopener noreferrer">P09429</a>', 'HUGO Gene symbol': 'HMGB1', 'Protein name': 'High mobility group protein B1', 'Function': 'Multifunctional redox sensitive protein. Binds to DNA to promote the assembly of proteins with a specific DNA target site; involved in replication, transcription, DNA repair etc.\xa0Promotes autophagy by disrupting the interaction between Beclin-1 and its negative regulator Bcl-2 by competitively binding to Beclin-1', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> DDR/BER<br><br> DDR/NER<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26397184%2C%2029844838%20%5Buid%5D" target="_blank" rel="noopener noreferrer">26397184, 29844838¬†</a>', 'Notes': '1) Anticancer agents including doxorubicin, cisplatin and etoposide each induced HMGB1 upregulation, promoted cytosolic HMGB1 translocation and the elevation of autophagic activity in human NB cells. 2) RNAi -mediated knockdown of HMGB1 restored the chemosensitivity of NB cells. 3) HMGB1 promoted the proliferative activity and invasive potential of NB cells. 4) HMGB1 enhanced drug resistance by inducing Beclin-1-mediated autophagy. 5) HMGB1 facilitated autophagic progression and reduced oxidative stress induced by doxorubicin. 6) positive expression levels of HMGB1, BRCA1 and P62 in ovarian carcinoma tissue were all higher than in para-carcinoma normal tissues (P<0.05). 7) 38 out of 60 ovarian cancer patients were drug resistant and 22 patients were sensitive to the therapy. the positive expression of HMGB1, BRCA1 and P62 was associated with the platinum resistance of ovarian cancer patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HMGB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3148" target="_blank" rel="noopener noreferrer">3148</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26583" target="_blank" rel="noopener noreferrer">P26583</a>', 'HUGO Gene symbol': 'HMGB2', 'Protein name': 'High mobility group protein B2', 'Function': 'Multifunctional protein with various roles in different cellular compartments. May act in a redox sensitive manner. In the nucleus is an abundant chromatin-associated non-histone protein involved in transcription, chromatin remodeling and V(D)J recombination and probably other processes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> DDR/BER<br><br> DDR/NER<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25327479%2C%2020851854%5Buid%5D" target="_blank" rel="noopener noreferrer">25327479, 20851854</a>', 'Notes': '1) siRNA-mediated silencing of HMGB2 increased the sensitivity of the HNSCC cell lines to cisplatin and 5-FU.\xa02) HMGB2 overexpression was significantly correlated with shorter overall survival time, both at mRNA and protein level. 3) HMGB2 knockdown by siRNAs decreased cell proliferation, and overexpression of HMGB2 by expression vectors diminished cisplatin- and etoposide-induced cell death.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HMGB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3156" target="_blank" rel="noopener noreferrer">3156</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04035" target="_blank" rel="noopener noreferrer">P04035</a>', 'HUGO Gene symbol': 'HMGCR', 'Protein name': '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'Function': 'In the first committed step of the mevalonate pathway, HMG-CoA reductase (HMGCR) converts HMG-CoA to mevalonic acid. The products of the mevalonate pathway include sterol isoprenoids such as cholesterol, and non-sterol isoprenoids such as dolichol, heme-A, isopentenyl, and ubiquinone', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Metabolism/Lipid', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29466876%5Buid%5D" target="_blank" rel="noopener noreferrer">29466876</a>', 'Notes': '1) Three targets of SREBP2, namely LDLR, FDFT1, and HMGCR were increased in ovarian cancer A2780-resistant cell lines and were found elevated in live cells after cisplatin treatment via qPCR. 2) RNAi of SREBP2 in A2780 cell line resulted in a decrease of cell viability after cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HMGCR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3162" target="_blank" rel="noopener noreferrer">3162</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09601" target="_blank" rel="noopener noreferrer">P09601</a>', 'HUGO Gene symbol': 'HMOX1', 'Protein name': 'Heme\xa0oxygenase-1', 'Function': 'Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Modulates cytokine production, cell proliferation, and apoptosis (excess of free heme sensitizes cells to undergo apoptosis)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hypoxia signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16678019%2C%2028808929%5Buid%5D" target="_blank" rel="noopener noreferrer">16678019, 28808929</a>', 'Notes': '1) Ectopic expression of pcDNA3-HO-1 and siRNA of HO-1 further revealed the\xa0protective\xa0role of HO-1 against cisplatin in auditory HEI-OC1 cells. 2) Among the catabolic metabolites of HO-1, both carbon monoxide (CO) and bilirubin were directly involved in the protective role of HO-1 against cisplatin through inhibition of reactive oxygen species generation. 3) the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. 4) Patients with high expression of HO-1 exhibited an unfavorable prognosis after treatment with cisplatin+paclitaxel. 5) In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of EMT related Vimentin, Zeb-1, anti-apoptotic Bcl-2, and the decreased expressions of Keratin) and Bax. 6) after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HMOX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6928" target="_blank" rel="noopener noreferrer">6928</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35680" target="_blank" rel="noopener noreferrer">P35680</a>', 'HUGO Gene symbol': 'HNF1B', 'Protein name': 'Hepatocyte nuclear factor 1-beta / HNF1 homeobox B', 'Function': 'Transcription factor of genes in normal mesodermal and endodermal developments; directly suppresses SMAD6 expression (33174391)', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> TGF-β signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24968817%2C%2025952785%5Buid%5D" target="_blank" rel="noopener noreferrer">24968817, 25952785</a>', 'Notes': '1) the mRNA expression of HNF1B in 586\xa0ovarian serous cystadenocarcinomas and in platinum-resistant A2780 epithelial ovarian cancer cells was significantly decreased. 2) Ovarian clear cell carcinoma is a distinct subtype of epithelial ovarian cancer, characterized by an association with endometriosis, glycogen accumulation and resistance to chemotherapy. Key driver events, including ARID1A mutations and HNF1B overexpression, have been recently identified. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HNF1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3209" target="_blank" rel="noopener noreferrer">3209</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31271" target="_blank" rel="noopener noreferrer">P31271</a>', 'HUGO Gene symbol': 'HOXA13', 'Protein name': 'Homeobox protein Hox-A13', 'Function': 'Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Transcription<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29757528%5Buid%5D" target="_blank" rel="noopener noreferrer">29757528</a>', 'Notes': '1) The median survival of patients with high\xa0HOXA13\xa0expression was significantly shorter than those with low expression (P\u2009=\u20090.027).\xa02) HOXA13\xa0was associated with worse tumor regression grade (P\u2009=\u20090.009). 3) Low\xa0HOXA13\xa0expressed cells decreased the half‐maximal inhibitory concentration of cisplatin (P\u2009<\u20090.05), increased cisplatin‐induced apoptosis (P\u2009<\u20090.05), and decreased EMT (P\u2009<\u20090.05) compared with high\xa0HOXA13\xa0expressed cells. 4) In low\xa0HOXA13\xa0expressed cells, cleaved caspase‐3 and cleaved PARP expression induced by cisplatin increased, while expression of E‐cadherin and Snail protein, markers of EMT, was upregulated and downregulated, respectively. 5) EMT decreased in low\xa0HOXA13expressed cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXA13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3201" target="_blank" rel="noopener noreferrer">3201</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00056" target="_blank" rel="noopener noreferrer">Q00056</a>', 'HUGO Gene symbol': 'HOXA4', 'Protein name': 'Homeobox protein Hox-A4', 'Function': "Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds to sites in the 5'-flanking sequence of its coding region with various affinities.", 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Immune response<br><br> Redox<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29402501%2C%2030501603%5Buid%5D" target="_blank" rel="noopener noreferrer">29402501, 30501603</a>', 'Notes': '1) Of 23 HOX genes tested in the training cohort, HOXA4 (HR=1.20, 95% CI=1.07-1.34, P=0.002) and HOXB3 (HR=1.09, 95% CI=1.01-1.17, P=0.027) overexpression were significantly associated with shorter PFS in multivariate analysis. 2) Based on the optimal cutoff of the HOXA4/HOXB3 risk score, median PFS was 16.9months (95% CI=14.6-21.2months) and not reached (>80months) for patients with high and low risk scores, respectively (HR=8.89, 95% CI=2.09-37.74, P<0.001). 3) In TCGA, the HOXA4/HOXB3 risk score was significantly associated with disease-free survival (HR=1.44, 95% CI=1.00-2.09, P=0.048). 4) HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05). 5) HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXA4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10481" target="_blank" rel="noopener noreferrer">10481</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92826" target="_blank" rel="noopener noreferrer">Q92826</a>', 'HUGO Gene symbol': 'HOXB13', 'Protein name': 'Homeobox protein Hox-B13', 'Function': 'Transcription factor which is part of a developmental regulatory system; binds preferentially to methylated DNA', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> NF-kB signaling<br><br> Oncogene signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31037158%5Buid%5D" target="_blank" rel="noopener noreferrer">31037158</a>', 'Notes': '1) High expression of HOXB13 observed in 17.8% of the lung adenocarcinoma patients in this study promoted cancer progression and predicted poor prognosis. 2) HOXB13 upregulated an array of metastasis- and drug-resistance-related genes, including ABCG1, EZH2, and Slug, by directly binding to their promoters. 3) Cisplatin induced HOXB13 expression in lung adenocarcinoma cells, and patient-derived xenografts and depletion of ABCG1 enhanced the sensitivity of lung adenocarcinoma cells to cisplatin therapy. 4) determining the combined expression of HOXB13 and its target genes can predict patient outcomes.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXB13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3213" target="_blank" rel="noopener noreferrer">3213</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14651" target="_blank" rel="noopener noreferrer">P14651</a>', 'HUGO Gene symbol': 'HOXB3', 'Protein name': 'Homeobox protein Hox-B3', 'Function': 'Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis; miR-375-HOXB3-CDCA3/DNMT3B regulatory pathway (29439669)', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Redox<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29402501%2C%2027186281%5Buid%5D" target="_blank" rel="noopener noreferrer">29402501, 27186281</a>', 'Notes': '1) Of 23 HOX genes tested in the training cohort, HOXA4 (HR=1.20, 95% CI=1.07-1.34, P=0.002) and HOXB3 (HR=1.09, 95% CI=1.01-1.17, P=0.027) overexpression were significantly associated with shorter PFS in multivariate analysis. 2) Based on the optimal cutoff of the HOXA4/HOXB3 risk score, median PFS was 16.9months (95% CI=14.6-21.2months) and not reached (>80months) for patients with high and low risk scores, respectively (HR=8.89, 95% CI=2.09-37.74, P<0.001). 3) In TCGA, the HOXA4/HOXB3 risk score was significantly associated with disease-free survival (HR=1.44, 95% CI=1.00-2.09, P=0.048). 4) HOXA4 or HOXB3 overexpression in ovarian cancer cells decreased sensitivity to cisplatin and attenuated the generation of cisplatin-induced ROS (P<0.05). 5) HOXB3 was directly bound by miR-375, and was negatively regulated by miR-375 in pancreatic cancer cells. 6) MiR-375 was upregulated in pancreatic tumors and pancreatic cancer cell lines. HOXB3 downregulation reversed the phenotype of miR-375 overexpression on cancer proliferation, migration and cisplatin chemosensitivity in pancreatic cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3214" target="_blank" rel="noopener noreferrer">3214</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17483" target="_blank" rel="noopener noreferrer">P17483</a>', 'HUGO Gene symbol': 'HOXB4', 'Protein name': 'Homeobox protein Hox-B4', 'Function': 'Sequence-specific transcription factor which is part of a developmental regulatory system\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Platinum efflux<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29660518%5Buid%5D" target="_blank" rel="noopener noreferrer">29660518</a>', 'Notes': '1) HOXB4 expressions at mRNA and protein levels were upregulated in Taxol-resistant ovarian cancer  A2780 (A2780/Taxol) and DDP-resistant SKOV-3 (SKOV-3/DDP) cells. 2) HOXB4 knockdown enhanced the cytotoxic effects of Taxol and DDP in A2780/Taxol and SKOV-3/DDP cells, respectively. 3) HOXB4 silencing suppressed the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway and reduced the expression of ABCB1, ABCC1 and ABCG2 in ovarian cancer cells. 4) PI3K inhibitor LY294002 or siRNA targeting Akt (si-Akt) treatment inhibited cell viability, decreased protein levels of ABCB1, ABCC1 and ABCG2, and increased LDH release in A2780/Taxol and SKOV-3/DDP cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXB4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3217" target="_blank" rel="noopener noreferrer">3217</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09629" target="_blank" rel="noopener noreferrer">P09629</a>', 'HUGO Gene symbol': 'HOXB7', 'Protein name': 'Homeobox protein Hox-B7', 'Function': 'Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NHEJ<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31568655%5Buid%5D" target="_blank" rel="noopener noreferrer">31568655</a>', 'Notes': '1) High expression of HOXB7 was associated with cisplatin resistance and worse chemotherapy efficacy. 2) HOXB7 knockdown reinforced cisplatin sensitivity. 3) HOXB7 interacts with Ku70, Ku80 and DNA‐PKcs. 4) HOXB7 knockdown was related to the downregulation of Ku70, Ku80 and DNA‐PKcs as well as arrested cell cycle in S phase. 5) HOXB7 inhibition by HXR9 had a synergistic effect to improve cisplatin sensitivity.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXB7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3234" target="_blank" rel="noopener noreferrer">3234</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13378" target="_blank" rel="noopener noreferrer">P13378</a>', 'HUGO Gene symbol': 'HOXD8', 'Protein name': 'Homeobox protein Hox-D8', 'Function': 'Sequence-specific transcription factor which is part of a developmental regulatory system\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Hypoxia signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30194340%5Buid%5D" target="_blank" rel="noopener noreferrer">30194340</a>', 'Notes': '1) HOXD8 mRNA and protein expression levels measured by reverse transcription polymerase chain reaction and ELISA, respectively, were significantly higher in ovarian cancer CDDP-resistant SKOV3-DDP and HO-8910PM than in their corresponding cell lines.  2) In 52 cases of different ovarian disease, the patients with recurrent and cisplatin-resistant ovarian cancer had higher expression levels of HOXD8 than patients with primary malignant tumours (p\u2009=\u20090.018, p\u2009=\u20090.001) or benign tumours (p\u2009=\u20090.001, p\u2009<\u20090.001). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HOXD8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/78995" target="_blank" rel="noopener noreferrer">78995</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8N3J3" target="_blank" rel="noopener noreferrer">Q8N3J3</a>', 'HUGO Gene symbol': 'HROB', 'Protein name': 'Homologous recombination OB-fold protein', 'Function': 'DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32528060%2C%2031467087%5Buid%5D" target="_blank" rel="noopener noreferrer">32528060, 31467087</a>', 'Notes': '1) loss of MCM8IP is associated with cellular sensitivity to cisplatin and PARP inhibition. 2) MCM8IP-deficient cells exhibit slower replication fork progression and increased fork stalling in response to cisplatin.\xa03) interactions of MCM8IP with RPA1 and MCM8-9 facilitate HR and replication fork progression and promote chemoresistance. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HROB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3297" target="_blank" rel="noopener noreferrer">3297</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00613" target="_blank" rel="noopener noreferrer">Q00613</a>', 'HUGO Gene symbol': 'HSF1', 'Protein name': 'Heat shock factor protein 1', 'Function': "stress-inducible and DNA-binding transcription factor that plays a central role in the transcriptional activation of the heat shock response (HSR), leading to the expression of a large class of molecular chaperones heat shock proteins (HSPs) that protect cells from cellular insults' damage", 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27194715%2C%2030131848%5Buid%5D" target="_blank" rel="noopener noreferrer">27194715, 30131848</a>', 'Notes': '1) induction of Hsf1 and the small heat shock protein crystallin-αB (CryAB) during cisplatin nephrotoxicity in mice. 2) cisplatin induced Hsf1 and CryAB in a cultured renal proximal tubular cells (RPTCs). 3) Transfection or restoration of Hsf1 into Hsf1 knockdown cells suppressed cisplatin-induced apoptosis, 4) Hsf1 knockdown increased Bax translocation to mitochondria and cytochrome c release into the cytosol. 5) In RPTCs, Hsf1 knockdown led to a specific downregulation of CryAB. 6) Transfection of CryAB into Hsf1 knockdown cells diminished their sensitivity to cisplatin-induced apoptosis.\xa07) from 478 prostate cancer patients with long term follow-up, increased nuclear HSF1 expression correlated with disease advancement and aggressiveness and was, independently from established clinicopathological variables, predictive of both early initiation of secondary therapy and poor disease-specific survival. 8) In a joint model with the clinical Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained a predictive factor of shortened disease-specific survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3320" target="_blank" rel="noopener noreferrer">3320</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07900" target="_blank" rel="noopener noreferrer">P07900</a>', 'HUGO Gene symbol': 'HSP90AA1', 'Protein name': 'Heat shock protein HSP 90-alpha', 'Function': 'Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction.', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23135731,33331136,21617238" target="_blank" rel="noopener noreferrer">23135731, 33331136, 21617238</a>', 'Notes': '1) HSP90AA1 RNAi inhibited the proliferation of ovarian cancer SKOV3 cell line and increased the apoptosis upon cisplatin treatment. 2) overexpression of HSP90AA1 decreased the chemosensitivity to cisplatin of SKOV3 cells and overexpression of HSP90AA1 could partially rescue the survival rate of SKOV3 cells which were treated with cisplatin. 3) three isogenic EOC models of acquired Pt resistance (TOV-112D, OVSAHO, and MDAH-2774). Using this approach, we identified several differentially expressed proteins in Pt-resistant (Pt-res) compared to parental cells and the chaperone HSP90 as a central hub of these protein networks. 4) up-regulation of HSP90 was observed in all Pt-res cells and heat-shock protein 90 alpha isoform knockout resensitizes Pt-res cells to cisplatin (CDDP) treatment. 5) pharmacological HSP90 inhibition using two different inhibitors 17AAG and ganetespib synergizes with CDDP in killing Pt-res cells in all tested models. 5) genetic or pharmacological HSP90 inhibition plus CDDP -induced apoptosis and increased DNA damage, particularly in Pt-res cells. 6) the antitumor activities of HSP90 inhibitors (HSP90i) were confirmed both ex vivo in primary cultures derived from Pt-res EOC patients ascites and in vivo in a xenograft model. 7) a decreased expression of Hsp16,2, Hsp90 and SOUL expression and an increased Bax/ Bcl-2 ratio correlates to the responding tumors of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSP90AA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3326" target="_blank" rel="noopener noreferrer">3326</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08238" target="_blank" rel="noopener noreferrer">P08238</a>', 'HUGO Gene symbol': 'HSP90AB1', 'Protein name': 'Heat shock protein HSP 90-beta', 'Function': 'As HSP90AA1', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27258564,31449053,31379752" target="_blank" rel="noopener noreferrer">27258564, 31449053, 31379752</a>', 'Notes': '1) HSP90AB1 is related to IDH mutation and the expressions of HSP90AB1 and TIMP1 can predict prognosis in astrocytic tumors.\xa02) interaction of hsp90B with MAST1 blocked ubiquitination of MAST1 at lysines 317 and 545 by the E3 ubiquitin ligase CHIP and prevented proteasomal degradation. 3) Expression of hsp90Β positively and CHIP negatively correlates with MAST1 protein level and cisplatin resistance in 76 tumor samples collected from head and neck squamous cell carcinoma (HNSCC) patients. 4) combined treatment with a hsp90 inhibitor and the MAST1 inhibitor lestaurtinib further abrogated MAST1 activity and consequently enhanced cisplatin-induced tumor growth arrest in a patient-derived xenograft model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSP90AB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3303" target="_blank" rel="noopener noreferrer">3303</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P0DMV8" target="_blank" rel="noopener noreferrer">P0DMV8</a>', 'HUGO Gene symbol': 'HSPA1A', 'Protein name': 'Heat shock 70 kDa protein 1A', 'Function': 'Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28237487,28466152,30066840,22281241,26947588" target="_blank" rel="noopener noreferrer">28237487, 28466152, 30066840, 22281241, 26947588</a>', 'Notes': '1) HSP70 inhibitor and cisplatin inhibit cervical cancer Hela cell proliferation in vitro and transplanted tumor growth synergistically. 2) siRNA knockdown of HSP70 enhances the antitumor effects of cisplatin in cultured human osteosarcoma cells. 2) overexpression of HSP70 decreased cisplatin‑induced gastric cancer HGC‑27 cell apoptosis. 3) Hsp70 is highly expressed in cisplatin-resistant cells. Hsp70 promotes chemoresistance, in part, by blocking Bax translocation to the mitochondria and mitochondrial protein release to cytosol in human ovarian cancer cells. 4) 2-DE accompanied by MALDI-TOF-MS was used to analyze ten cases of advanced cervical cancer patients receiving cisplatin-based NAC: the high-fold changes proteins of stathmin1, Hsp70 and PKM2 were validated by Western blot analysis. 5) Over-expression of Hsp70 inhibits the efficacy of cisplatin. Hsp70 inhibitor enhanced the sensitivity to cisplatin in both Hela and Hela/DDP cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSPA1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3304" target="_blank" rel="noopener noreferrer">3304</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P0DMV9" target="_blank" rel="noopener noreferrer">P0DMV9</a>', 'HUGO Gene symbol': 'HSPA1B', 'Protein name': 'Heat shock 70 kDa protein 1B', 'Function': 'Molecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the formation and dissociation of protein complexes. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28237487,28466152,30066840,22281241,26947588" target="_blank" rel="noopener noreferrer">28237487, 28466152, 30066840, 22281241, 26947588</a>', 'Notes': '1) HSP70 inhibitor and cisplatin inhibit cervical cancer Hela cell proliferation in vitro and transplanted tumor growth synergistically. 2) siRNA knockdown of HSP70 enhances the antitumor effects of cisplatin in cultured human osteosarcoma cells. 2) overexpression of HSP70 decreased cisplatin‑induced gastric cancer HGC‑27 cell apoptosis. 3) Hsp70 is highly expressed in cisplatin-resistant cells. Hsp70 promotes chemoresistance, in part, by blocking Bax translocation to the mitochondria and mitochondrial protein release to cytosol in human ovarian cancer cells. 4) 2-DE accompanied by MALDI-TOF-MS was used to analyze ten cases of advanced cervical cancer patients receiving cisplatin-based NAC: the high-fold changes proteins of stathmin1, Hsp70 and PKM2 were validated by Western blot analysis. 5) Over-expression of Hsp70 inhibits the efficacy of cisplatin. Hsp70 inhibitor enhanced the sensitivity to cisplatin in both Hela and Hela/DDP cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSPA1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3309" target="_blank" rel="noopener noreferrer">3309</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11021" target="_blank" rel="noopener noreferrer">P11021</a>', 'HUGO Gene symbol': 'HSPA5', 'Protein name': 'Glucose-regulated protein\xa078', 'Function': 'a major stress-inducible calcium-binding chaperone localized to the endoplasmic reticulum (ER), serves as a buffer against calcium efflux from the ER that could trigger the mitochondrial apoptotic program', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Chaperone<br><br> ER stress response<br><br> Oncogene signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24756776%2C%2029650944%5Buid%5D" target="_blank" rel="noopener noreferrer">24756776, 29650944</a>', 'Notes': '1) the chemotherapy-sensitive ovarian tumor sections showed weak staining for GRP78.\xa02) Cisplatin-sensitive A2780 cells with low GRP78 undergo senescence easilier than the cisplatin-resistant C13K cells following a dose-gradient cisplatin exposure. 3) Forced overexpression of GRP78 protected the cisplatin-sensitive A2780 cells from cisplatin-induced senescence through P53 and CDC2. 4) Knockdown of GRP78 rescued the senescence sensitivity of cisplatin-resistant C13K cells to cisplatin through P21 and CDC2. 5) Twisting of Ca2+ release from ER stores by GRP78 was associated with the sensitivity of cisplatin-induced senescence. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSPA5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3315" target="_blank" rel="noopener noreferrer">3315</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04792" target="_blank" rel="noopener noreferrer">P04792</a>', 'HUGO Gene symbol': 'HSPB1', 'Protein name': 'Heat shock protein beta-1', 'Function': 'Small heat shock protein;\xa0plays a role in stress resistance and actin organization', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21888831%2C%2029017331%2C%2032848724%2C%2016080521%2C%2011403922%2C%2026872057%5Buid%5D" target="_blank" rel="noopener noreferrer">21888831, 29017331, 32848724, 16080521, 11403922, 26872057</a>', 'Notes': '1) Hsp27 is involved in the cytoprotective role of the UPR in cisplatin-induced apoptosis. 2) Hsp27 inhibits cisplatin-induced HCC cell death through autophagy activation. 3) HSPB1 mRNA low expression was correlated to better overall survival (OS) for all NSCLC patients and better OS in lung adenocarcinoma (LUAD) patients, in different chemotherapy status. 4) genetic polymorphisms and the prognosis in lung cancer patients treated with platinum-based chemotherapy: the polymorphisms of HSPB1 rs2070804 and HSPA4 rs3088225 were significantly associated with lung cancer survival. 5) Hsp27-negative (p = 0.0057) and Hsp70-negative patients (p = 0.010) were all good responders. Hsp27 was the most reliable predictor of the effect of chemo-radiotherapy and radiotherapy among the four potential markers. 6) Compared with control cells, generate drug-resistant spheres (DRSPs) displayed increased CSC and anti-apoptotic properties, greater resistance to cisplatin, and overexpression of p-Hsp27 via activation of p38 MAPK signaling. 7) Knockdown of Hsp27 or p38 decreased cisplatin resistance and increased apoptosis in DRSPs. 8) Overexpression of p-Hsp27 was usually detected in advanced-stage patients with lung cancer and indicated short survival.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSPB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3329" target="_blank" rel="noopener noreferrer">3329</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10809" target="_blank" rel="noopener noreferrer">P10809</a>', 'HUGO Gene symbol': 'HSPD1', 'Protein name': '60 kDa heat shock protein, mitochondrial', 'Function': 'Chaperonin implicated in mitochondrial protein import and macromolecular assembly. Together with Hsp10, facilitates the correct folding of imported proteins. May also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21559731%2C%208100743%2C%2018372523%2C%2032124395%2C%2021340800%5Buid%5D" target="_blank" rel="noopener noreferrer">21559731, 8100743, 18372523, 32124395, 21340800</a>', 'Notes': '1) A correlation between the intrinsic level of HSP60 expression and cDDP resistance: using linear regression analysis both Head and Neck UMSCC5 and UMSCC10b cell lines demonstrated a high degree of correlation with coefficients of 0.91 and 0.90, respectively.\xa02) The expression of HSP60 in human ovarian carcinoma 2008 cells is induced by cisplatin treatment. 3) 2008/C13*5.25 DDP-resistant cells constitutively over-expressed hsp60 mRNA and protein. 4) Increased HSP60 mRNA expression is associated with cisplatin resistance in some in vitro models and with shorter survival among ovarian cancer patients. 6) Combination of the HSP60 antibody with docetaxel or cisplatin was significantly synergistic in both sensitive and chemoresistant EOC cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HSPD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27429" target="_blank" rel="noopener noreferrer">27429</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43464" target="_blank" rel="noopener noreferrer">O43464</a>', 'HUGO Gene symbol': 'HTRA2', 'Protein name': 'Serine protease HTRA2, mitochondrial', 'Function': 'In response to apoptotic stimuli, HtrA2 is released from the mitochondria into the cytosol, and promotes or induces cell death either by direct binding to and inhibition of BIRC proteins; also associated with cell invasion, by cleaving β-actin and decreasing the amount of filamentous actin (F-actin)\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29168038%5Buid%5D" target="_blank" rel="noopener noreferrer">29168038</a>', 'Notes': 'The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis: 1) repeated cisplatin treatment induced downregulation of HtrA2 protein expression, before and after cisplatin-based chemotherapy in SAC. 2) Progression-free survival and overall survival of SAC with low expression of HtrA2 were worse than those with high expression. 3) HtrA2 protein expression was lower in cisplatin-resistant KFr13 ovarian cancer cells than in the sensitivie KF28 cells. 4) downregulation of HtrA2 with siRNA in KF28 had not only cisplatin resistance, but also more invasive capacity. 5) Repeated treatment with cisplatin downregulated the HtrA2 protein, which led to cisplatin resistance and increased invasive capacity. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HTRA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3383" target="_blank" rel="noopener noreferrer">3383</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05362" target="_blank" rel="noopener noreferrer">P05362</a>', 'HUGO Gene symbol': 'ICAM1', 'Protein name': 'Intercellular adhesion molecule 1', 'Function': 'a cell surface glycoprotein which is typically expressed on endothelial cells and cells of the immune system. It binds to integrins of type CD11a/CD18, or CD11b/CD18 and is also exploited by Rhinovirus as a receptor.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23832872%2C%2018271937%5Buid%5D" target="_blank" rel="noopener noreferrer">23832872, 18271937</a>', 'Notes': '1) Induction of ICAM-1 expression (ranging from 3- to 228-fold on mRNA level and 1.7- to 108-fold on protein level) resulted in indications of decreased ovarian cancer cell growth and reduced cisplatin sensitivity. 2) Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ICAM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3397" target="_blank" rel="noopener noreferrer">3397</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P41134" target="_blank" rel="noopener noreferrer">P41134</a>', 'HUGO Gene symbol': 'ID1', 'Protein name': 'DNA-binding protein inhibitor ID-1', 'Function': 'Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors.  Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation.', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Cell cycle<br><br> Immune response<br><br> NF-kB signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32080166%5Buid%5D" target="_blank" rel="noopener noreferrer">32080166</a>', 'Notes': '1) ID1 induces high autophagy and confers cancer cell chemoresistance. 2) ID1 first activates the NF-κB signaling through facilitating the nuclear translocation of NF-κB p65, which strengthens the expression and secretion of IL-6 from cancer cells to subsequently activate STAT3 through the protein phosphorylation at Y705.  3) STAT3 functions to promote the transcription of the activating transcription factor 6 (ATF6), which induces endoplasmic reticulum stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin and paclitaxel treatment. 4) a significant correlation between the expression of ID1 and ATF6 in 1104 high grade serous ovarian cancer tissues, and that patients with the high expression of ID1 or ATF6 were resistant to platinum treatment and had the poor overall survival and progression-free survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ID1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3458" target="_blank" rel="noopener noreferrer">3458</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01579" target="_blank" rel="noopener noreferrer">P01579</a>', 'HUGO Gene symbol': 'IFNG', 'Protein name': 'Interferon gamma', 'Function': 'Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27133165%2C%207768637%2C%2010735496%2C%2026695443%5Buid%5D" target="_blank" rel="noopener noreferrer">27133165, 7768637, 10735496, 26695443</a>', 'Notes': '1) IFNg administration increased the therapeutic efficacy of cisplatin treatment as shown by reduced ovarian tumor volume. 2) Human ovarian carcinoma cells (2008 and its cisplatin-resistant sub-line 2008/C13*) were sensitized to cisplatin by treatment with human recombinant IFN gamma; produced no significant change in the uptake of CDDP; but a time-dependent decrease of cellular glutathione and total glutathione-S-transferase activity, principally the pi isoform. 3) the inclusion of IFN-gamm in the first-line platinum-based chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. 4) The analysis of residual tumour cells in chemo-responder PDX revealed a strong overexpression of IFN-inducible genes, induced early after Neoadjuvant chemotherapy (NAC) treatment and associated with increased STAT1 phosphorylation, DNA-damage and apoptosis. 5) No increase in IFN-inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy. 6) Overexpression of IFN-related genes was associated with human IFN-γ secretion by tumour cells.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IFNG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3479" target="_blank" rel="noopener noreferrer">3479</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05019" target="_blank" rel="noopener noreferrer">P05019</a>', 'HUGO Gene symbol': 'IGF1', 'Protein name': 'Insulin-like growth factor I', 'Function': 'The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity.', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> ECM signaling<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19318572%2C%2024727326%5Buid%5D" target="_blank" rel="noopener noreferrer">19318572, 24727326</a>', 'Notes': '1) A2780 ovarian cancer cells were treated by weekly cycles of cisplatin over a period of 6 months. 2) IGF-IR expression levels increased during treatment cycles and correlated with cisplatin resistance. 3) Purified IGF-I induced cisplatin resistance in diverse ovarian cancer cell lines, 4) small molecule inhibitors proved that IGF-IR and PI3K are essential for cisplatin resistance. 5) Ganitumab potently inhibited baseline and IGF-I-, IGF-II-, and insulin-induced IGF-IR and IGF-IR/insulin hybrid receptor signaling in vitro and in vivo. 6) Synergistic and additive drug interactions were seen for ganitumab and carboplatin or paclitaxel in vitro. 7) ganitumab significantly increased the efficacy of cisplatin in ovarian cancer xenograft models in vivo. 8) As IGF1R. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3480" target="_blank" rel="noopener noreferrer">3480</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08069" target="_blank" rel="noopener noreferrer">P08069</a>', 'HUGO Gene symbol': 'IGF1R', 'Protein name': 'Insulin-like growth factor 1 receptor', 'Function': 'Receptor tyrosine kinase binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> ECM signaling<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28545426%5Buid%5D" target="_blank" rel="noopener noreferrer">28545426</a>', 'Notes': '1) As IGF1. 2) IGF1 and IGF-1R staining was positive in 169 (80%) and 139 (66%) colorectal cancer cases, respectively. 3) Univariate and multivariate analyses showed significant correlation between expression of IGF-1 and tumor size (p=0.0024), and depth of invasion (p=0.0147). 3) IGF-1R was significantly correlated to tumor size and depth of invasion in univariate analysis, only tumor size (p=0.0658) had a strong association in multivariate analysis. .', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF1R" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3481" target="_blank" rel="noopener noreferrer">3481</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01344" target="_blank" rel="noopener noreferrer">P01344</a>', 'HUGO Gene symbol': 'IGF2', 'Protein name': 'Insulin-like growth factor II', 'Function': 'The insulin-like growth factors possess growth-promoting activity. Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=33061807%2C%2020443017%5Buid%5D" target="_blank" rel="noopener noreferrer">33061807, 20443017</a>', 'Notes': '1) lnc-MCEI knockdown significantly improved the chemosensitivity of ESCC to cisplatin (DDP) both in vivo and in vitro. 2) lnc-MCEI functioned as a competing endogenous RNA (ceRNA) via sponging miR-6759-5p and IGF2 was a target of miR-6759-5p. 3) IGF2 suppressed chemosensitivity of ESCC cells via PI3K/AKT pathway. 4) HNSCC cell line RPMI2650CR showed a 9.38-fold increased IC50  for CDDP in comparison with the parental cell line, RPMI2650: IGF2 was found to be one of the candidates for acquired CDDP-resistance. 5) The introduction of IGF2 into RPMI2650 caused CDDP resistance. 6) siRNA-mediated knockdown of IGF2 caused reduction of acquired CDDP-resistance in RPMI2650CR. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10642" target="_blank" rel="noopener noreferrer">10642</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NZI8" target="_blank" rel="noopener noreferrer">Q9NZI8</a>', 'HUGO Gene symbol': 'IGF2BP1', 'Protein name': 'growth factor 2 mRNA-binding protein 1', 'Function': 'RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). Regulates mRNAs such as PTEN, ACTB, MAPK4, MKI67, c-MYC, and CD44. Plays important roles in cell proliferation and growth of normal tissues and tumor tissues, as well as tumor cell adhesion, apoptosis, migration, and invasion. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Oncogene signaling<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28685895%2C%2029660014%5Buid%5D" target="_blank" rel="noopener noreferrer">28685895, 29660014</a>', 'Notes': '1) Ectopic expression of miR-708 sensitized SKOV3 and A2780 and SKOV3/DDP and A2780/DDP cells to cisplatin. 2)  Mechanistically, miR-708 downregulated the expression of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) and suppressed Akt phosphorylation. 3) Silencing of IGF2BP1 markedly blocked the phosphorylation of Akt. 4) Overexpression of IGF2BP1 restored cisplatin resistance and Akt phosphorylation in miR-708-overexpressing ovarian cancer cells. 5) In ovarian cancer, the enhanced expression of IGF2BP1 and most of its miRNA-controlled target mRNAs is associated with poor prognosis.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF2BP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10643" target="_blank" rel="noopener noreferrer">10643</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00425" target="_blank" rel="noopener noreferrer">O00425</a>', 'HUGO Gene symbol': 'IGF2BP3', 'Protein name': 'growth factor 2 mRNA-binding protein 3', 'Function': "RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling<br><br> Platinum uptake<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26158423%5Buid%5D" target="_blank" rel="noopener noreferrer">26158423</a>', 'Notes': '1) From 140 EOC patients, high expression of IMP3 or Lin28B was associated with poor survival, and women diagnosed at advanced stages with elevated IMP3 and Lin28B were at higher risk of developing chemoresistance. 2)High IMP3 levels combined with high Lin28B levels significantly correlated with the poorest 5-year survival rates. 3) Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, 4) of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake. 5) High expression of hCTR1 correlated with low expression of IMP3/Lin28B and better progression-free survival in advanced-stage EOC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF2BP3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3482" target="_blank" rel="noopener noreferrer">3482</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11717" target="_blank" rel="noopener noreferrer">P11717</a>', 'HUGO Gene symbol': 'IGF2R', 'Protein name': 'insulin like growth factor 2 receptor / Cation-independent mannose-6-phosphate receptor', 'Function': 'Mediates the transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes; binds IGF2', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25402559%5Buid%5D" target="_blank" rel="noopener noreferrer">25402559</a>', 'Notes': '1) Of all NSCLC patients, 204 had high IGF2R expression and 260 had low IGF2R expression. 2) the low IGF2R expression was closely associated with the chemotherapy response in NSCLC patients: Patients with low IGF2R expressions had a poorer prognosis than those with high IGF2R expressions. 3) IGF2R inhibition by si-RNA technique in NSCLC cell lines increased the proliferation, migration and invasion abilities, but reduced the apoptosis rate. 4)  IGF2R silencing significantly enhanced the chemo-resistance of NSCLC cell lines to cisplatin treatment.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IGF2R" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3551" target="_blank" rel="noopener noreferrer">3551</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14920" target="_blank" rel="noopener noreferrer">O14920</a>', 'HUGO Gene symbol': 'IKBKB', 'Protein name': 'Inhibitor of nuclear factor kappa-B kinase subunit beta', 'Function': 'Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damage or other cellular stresses', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24854552%2C%2032020377%5Buid%5D" target="_blank" rel="noopener noreferrer">24854552, 32020377</a>', 'Notes': '1) the expression of mRNA level of IKBKB gene in A549/DDP was significantly higher than that in lung cancer A549 cell line. 2) overexpression of IKBKB decreased the sensitivity to cisplain: the IC50 was increased 2.85 fold, the apoptosis rate was decreased 59%, the activity of NF-κB is greatly increased. 3) cisplatin-resistant HNSCC cells have a stronger ability to migrate and invade, as well as display higher IKKβ/NF-κB activity compared to their parental partners. 4) knockdown of IKKβ, but not NF-κB, dramatically impaired cell migration and invasion in these cells. 5) the IKKβ inhibitor, CmpdA, also inhibited cell migration and invasion. 6) cisplatin-resistant HNSCC expressed higher levels of N-Cadherin and IL-6, which were significantly inhibited by CmpdA. 7) CmpdA treatment dramatically abated cisplatin-resistant HNSCC cell metastasis to lungs in a mouse model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IKBKB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9641" target="_blank" rel="noopener noreferrer">9641</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14164" target="_blank" rel="noopener noreferrer">Q14164</a>', 'HUGO Gene symbol': 'IKBKE', 'Protein name': 'I-kappa-B kinase e', 'Function': 'Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19497997%5Buid%5D" target="_blank" rel="noopener noreferrer">19497997</a>', 'Notes': '1) Of 96 ovarian cancer specimens examined, 63 exhibited elevated levels of IKKepsilon. 2) alterations of IKKepsilon were associated with late-stage and high-grade tumors. 3) Overall survival in patients with elevated levels of IKKepsilon was significantly lower than patients whose tumors expressed normal levels of IKKepsilon. 4) both early and late-stage tumors that overexpressed IKKepsilon conferred a poor prognosis, as compared with those that did not possess elevated IKKepsilon levels. 5) overexpression of IKKepsilon rendered cells resistant to cisplatin, 6) knockdown of IKKepsilon overcame cisplatin resistance in both A2780CP and C13 cells.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IKBKE" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3589" target="_blank" rel="noopener noreferrer">3589</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P20809" target="_blank" rel="noopener noreferrer">P20809</a>', 'HUGO Gene symbol': 'IL11', 'Protein name': 'Interleukin-11', 'Function': 'Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29662190%5Buid%5D" target="_blank" rel="noopener noreferrer">29662190</a>', 'Notes': '1) platinum-resistant ovarian cancer elevated ROS levels sustain high level of IL-11 by stimulating FRA1-mediated IL-11 expression 2) increased IL-11 causes resistance to platinum drugs by constitutively activating JAK2-STAT5 via an autocrine mechanism. 3) Inhibition of JAK2 by LY2784544 or IL-11 by anti-IL-11 antibody overcomes the platinum resistance in vitro or in vivo. 4) clinic studies also confirm the activated IL-11-JAK2 pathway in platinum-resistant ovarian cancer patients, which highly correlates with poor prognosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3605" target="_blank" rel="noopener noreferrer">3605</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16552" target="_blank" rel="noopener noreferrer">Q16552</a>', 'HUGO Gene symbol': 'IL17A', 'Protein name': 'Interleukin-17A', 'Function': 'Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30655852%5Buid%5D" target="_blank" rel="noopener noreferrer">30655852</a>', 'Notes': '1) It has been suggested that IL-17 is key to promoting the development of resistance to DDP in several major types of cancer. 2) IL-17 was found to promote the viability of HCT116 colorectal cells treated with DDP, 3) blocking IL-17 signaling leading to HCT116 cell apoptosis. 4) IL-17 was also shown to regulate the expression of several apoptosis-related proteins, including phosphorylated-protein kinase B (p-Akt), apoptosis regulator BAX (Bax), apoptosis regulator Bcl-2 (Bcl-2) and serine/threonine-protein kinase mTOR (mTOR). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL17A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3552" target="_blank" rel="noopener noreferrer">3552</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01583" target="_blank" rel="noopener noreferrer">P01583</a>', 'HUGO Gene symbol': 'IL1A', 'Protein name': 'Interleukin-1 alpha', 'Function': 'Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=8938138%2C%2017096856%5Buid%5D" target="_blank" rel="noopener noreferrer">8938138, 17096856</a>', 'Notes': '1) ovarian carcinoma OVCAR-3 cells are resistant to clinically relevant concentrations of chemotherapeutic agents, including cisplatin. 2) Both carboplatin and IL-1alpha as single agents inhibited the growth of OVCAR-3 cells grown as xenograft in nude mice; 3) Treatment with IL-1alpha followed by carboplatin caused a significant delay in tumor growth, resulting in a significant enhancement (4-fold) of the anti-tumor effect of carboplatin. 4) Potentiation of the anti-tumor activity of carboplatin by IL-1alpha was due to a significant (3- to 4-fold) increase in the accumulation of total Pt in IL-1-treated tumor xenograft, resulting in a 2-fold increase in DNA-Pt adduct formation in these tumors. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3553" target="_blank" rel="noopener noreferrer">3553</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01584" target="_blank" rel="noopener noreferrer">P01584</a>', 'HUGO Gene symbol': 'IL1B', 'Protein name': 'Interleukin-1 beta', 'Function': 'Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30641908%5Buid%5D" target="_blank" rel="noopener noreferrer">30641908</a>', 'Notes': '1) interleukin 1β (IL-1β)-induced upregulation of genes was associated with cisplatin resistance in breast cancer cells. 2) IL-1β particularly upregulates the expression of the tumor protein 63 (TP63) isoform ΔNP63α, through the activation of the IL-1β/IL-1RI/β-catenin signaling pathway. 3) Upregulation of ΔNP63α leads to an increase in the expression of the cell survival factors epidermal growth factor receptor (EGFR) and phosphatase 1D (Wip1), and a decrease in the DNA damage sensor, ataxia-telangiectasia mutated (ATM). 4) The participation of these processes in the increase of resistance to cisplatin was confirmed by silencing\xa0TP63\xa0expression or by inhibition of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) activity in the IL-1β/IL-1RI/β-catenin signaling pathway.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/50616" target="_blank" rel="noopener noreferrer">50616</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9GZX6" target="_blank" rel="noopener noreferrer">Q9GZX6</a>', 'HUGO Gene symbol': 'IL22', 'Protein name': 'Interleukin-22', 'Function': 'Cytokine that contributes to the inflammatory response in vivo.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32010312%5Buid%5D" target="_blank" rel="noopener noreferrer">32010312</a>', 'Notes': '1) IL-22 expression was significantly increased in osteosarcoma tissues and cell lines compared with the adjacent normal tissues and the normal osteoblast hFOB1.19 cells. 2) IL-22 expression was higher in MG63/DDP cells compared with MG63 cells. 3) The IL-22 siRNA in MG63/DDP cells significantly decreased the IC50\xa0of DDP and decreased the cell viability of MG63/DDP cells. 4) IL-22 RNA interference decreased BCl-2 expression and phosphorylation of STAT3, induced apoptosis, and increased the expression of Bax and cleaved caspase-3. 5) The IL-22 overexpression plasmid had opposite effects to the observations in IL-22 siRNA-transfected MG63 cells.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL22" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11009" target="_blank" rel="noopener noreferrer">11009</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13007" target="_blank" rel="noopener noreferrer">Q13007</a>', 'HUGO Gene symbol': 'IL24', 'Protein name': 'Interleukin-24', 'Function': 'Has antiproliferative properties on melanoma cells and may contribute to terminal cell differentiation.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28942243%2C%2029048638%5Buid%5D" target="_blank" rel="noopener noreferrer">28942243, 29048638</a>', 'Notes': '1) ZBTB7A is increased in cisplatin-resistant osteosarcoma cells. 2) elevated ZBTB7A inhibits cisplatin-induced apoptosis by repressing IL24.\xa03) The cisplatin (DDP)-resistant lung carcinoma cell line A549/DDP was subjected to adenovirus-mediated transfection with the human IL-24 gene (Ad-hIL-24): Ad-hIL-24 significantly decreased the levels of p-AKT and P-gp, and effectively inhibited A549/DDP cell growth and a significantly increased rate of apoptosis, as well as G2/M-phase. 6) these effects were increased in cells treated with Ad-IL-24 combined with DDP when compared with those treated with Ad-hIL-24 or DDP alone. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL24" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64806" target="_blank" rel="noopener noreferrer">64806</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H293" target="_blank" rel="noopener noreferrer">Q9H293</a>', 'HUGO Gene symbol': 'IL25', 'Protein name': 'Interleukin-25', 'Function': 'Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8. Proinflammatory cytokine favoring Th2-type immune responses.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31044552%5Buid%5D" target="_blank" rel="noopener noreferrer">31044552</a>', 'Notes': '1) both IL-25 and MVP were elevated expressed in cisplatin-resistant lung adenocarcinoma cell line (A549/CDDP). 2) Silencing of IL-25 resulted in down-regulation of MVP expression and reduced cisplatin tolerance of A549/CDDP cells. 3) Overexpression of IL-25 resulted in increase of MVP expression and the cisplatin tolerance in A549 cells. 4) the extracellular IL-25 could stimulate the expression of MVP and activate the NF-κB signaling pathway. 5) IL-25 reduced the sensitivity of xenografts to chemotherapy.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL25" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3569" target="_blank" rel="noopener noreferrer">3569</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05231" target="_blank" rel="noopener noreferrer">P05231</a>', 'HUGO Gene symbol': 'IL6', 'Protein name': 'Interleukin-6', 'Function': 'Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27340780,29731768,20236757,27108527,26313152" target="_blank" rel="noopener noreferrer">27340780, 29731768, 20236757, 27108527, 26313152</a>', 'Notes': '1) The expression of IL-6 was higher in the CDDP-resistant osteosarcoma tissue samples as compared to the sensitive samples. 2) treatment of osteosarcoma Saos-2 cells with IL-6 inhibited cisplatin-induced apoptosis. 3) lockade of IL-6 in mesenchymal stem cells (MSCs) conditioned medium via specific neutralizing antibodies attenuated the protective effect of MSCs on Saos-2 tumor cells against cisplatin. 4) Analyzing tumorous mRNA expression data from 399 HNSCC patients revealed that high IL-6 expression predicted poor prognosis. Similar tendency was observed in platinum treated patients. 5) knockdown of IL-6 in human NSCLC cells (A549IL-6si and H157IL-6si) enhanced cisplatin cytotoxicity as compared to their parents (A549IL-6sc and H157IL-6sc). 6) Subcutaneous xenograft mouse models were developed using a pair of A549sc and A549IL-6si cells: Higher tumor regression was detected in the A549IL-6si xenografts compared to A549sc xenografts following cisplatin treatment. 7) Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells, but no increase was detected in A549IL-6si and H157IL-6si cells. 8) up regulation of these molecules by IL-6 may be through activation of IL-6 downstream signaling pathways like Akt, MAPK, Stat3, and Erk. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3570" target="_blank" rel="noopener noreferrer">3570</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08887" target="_blank" rel="noopener noreferrer">P08887</a>', 'HUGO Gene symbol': 'IL6R', 'Protein name': 'Interleukin-6 receptor subunit alpha', 'Function': 'Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitates an association with IL6ST.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28388577%5Buid%5D" target="_blank" rel="noopener noreferrer">28388577</a>', 'Notes': '1) interleukin-6 (IL-6) activates oncogenic STAT3, which directly repressed miR-204 via a conserved STAT3-binding site near the TRPM3 promoter region upstream of miR-204. 2) Repression of miR-204 was required for IL-6-induced cisplatin (cDDP) resistance in epithelial ovarian cancer (EOC) cells. 3) Conversely, IL-6 receptor (IL-6R) is a direct miR-204 target. 4) the resulting IL-6R/STAT3/miR-204 feedback loop was identified in patients with EOC, and its activity correlated with chemosensitivity. 5) exogenous miR-204 blocked this circuit and enhanced cDDP sensitivity both in vitro and in vivo by inactivating IL-6R/STAT3 signaling and subsequently decreasing the expression of anti-apoptotic proteins. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL6R" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3574" target="_blank" rel="noopener noreferrer">3574</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13232" target="_blank" rel="noopener noreferrer">P13232</a>', 'HUGO Gene symbol': 'IL7', 'Protein name': 'Interleukin-7', 'Function': 'Hematopoietic growth factor capable of stimulating the proliferation of lymphoid progenitors.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22415136%2C%2031599032%5Buid%5D" target="_blank" rel="noopener noreferrer">22415136, 31599032</a>', 'Notes': '1) glioma U251/CP2 cells gained two to three copies of C8orf70 and IL-7 genes. 2) IL-7 mRNA expression was studied in 12 glioma cell lines, and expression was positively correlated with the IC 50 of cisplatin. 3) IL-7 mRNA expression was also positively correlated with the IC 50 of cisplatin in 91 clinical glioma specimens. 4) treatment with recombinant human IL-7 (rhIL-7) enhanced cisplatin resistance and increased the relative growth rate of the glioma cells. 5) the apoptosis induced by cisplatin could be inhibited by IL-7. 5) IL-7R was increased in A549/DDP cells compared with A549 cells. The block of IL-7R reversed the inhibitory effects of IL-7 combined with cisplatin and decreased the numbers of apoptosis cells induced by treatment of IL-7 combined with cisplatin. 6) JAK3/STAT5 pathway was involved in enhancing role of cisplatin sensitivity of NSCLC cells by IL-7. 7) In vivo, cisplatin significantly inhibited tumour growth and IL-7 combined with cisplatin achieved the best therapeutic effect.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IL7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3611" target="_blank" rel="noopener noreferrer">3611</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13418" target="_blank" rel="noopener noreferrer">Q13418</a>', 'HUGO Gene symbol': 'ILK', 'Protein name': 'Integrin-linked protein kinase', 'Function': 'Receptor-proximal protein kinase regulating integrin-mediated signal transduction\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25760437%5Buid%5D" target="_blank" rel="noopener noreferrer">25760437</a>', 'Notes': '1) combined treatment with lentivirus-mediated ILK interference and\xa0cisplatin\xa0chemotherapy induced significantly more cell apoptosis than mono-chemotherapy or knockdown.\xa02) The increased cell apoptosis and proliferation inhibition were attributed to abnormal downstream protein expression of ILK, including phospho-glycogen synthase kinase 3β, p-AKT, activator protein-1, β-catenin, cyclin D1 and matrix metalloproteinase-9. ILK inhibition may suppress the proliferation of lung cancer cell A549 and increase A549 sensitivity to cisplatin. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ILK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3659" target="_blank" rel="noopener noreferrer">3659</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10914" target="_blank" rel="noopener noreferrer">P10914</a>', 'HUGO Gene symbol': 'IRF1', 'Protein name': 'interferon regulatory factor 1', 'Function': 'transcriptional regulator and tumor suppressor; activator of genes involved in both innate and acquired immune responses.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23079474%2C%20%2024995581%2C%2031078735%5Buid%5D" target="_blank" rel="noopener noreferrer">23079474,¬† 24995581, 31078735</a>', 'Notes': '1) The treatment of ovarian cancer cells with CDDP boosted the expression of IRF-1. 2) overexpressing IRF-1 suppressed the transformed phenotype of ovarian cancer cells and  associated with p21 induction irrespective of p53 proficiency. 3) IRF-1 silencing sensitized cells to the apoptotic death induced by CDDP and reduced the induction of p21 by CDDP. 4) After patinum drug treatment, HGSOC patients with low IRF1 had a 61% [95% CI: 42%–80%] probability of recurrence within the same 12-month time period. Patients in the high IRF1 group had only a 12.5% [95% CI: 2%–61%] probability of recurrence within the first 12 months following surgery. 5) IRF-1 reverses platinum resistance by downregulating the expression of P-glycoprotein in gastric cancer. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=IRF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3678" target="_blank" rel="noopener noreferrer">3678</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08648" target="_blank" rel="noopener noreferrer">P08648</a>', 'HUGO Gene symbol': 'ITGA5', 'Protein name': 'Integrin alpha-5/beta-1 (ITGA5:ITGB1) ', 'Function': 'A receptor for fibronectin and fibrinogen.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31911861,28328815,32534716,33110104" target="_blank" rel="noopener noreferrer">31911861, 28328815, 32534716, 33110104</a>', 'Notes': '1) the integrin α5 expression is remarkably upregulated in cisplatin resistant esophageal squamous cell carcinoma (Res) cells, and inhibition of α5 results in more apoptosis and endows the Res cells resensitize to cisplatin in vitro and in vivo. 2) the expression of BARD1 is significantly increased in Res cells, and silencing of BARD1 reverse the effects of α5 on cisplatin resistance. 3) the α5/FAK/PI3K/AKT signal axis is activated in Res cells, which mediates the increased expression of BARD1, as well as the cisplatin resistance and cell survival. 3) The expression of ITGA5 and ITGA6 in SKOV3/DDP2 and A2780/DDP cells of ovarian cancer was increased as compared to their DDP-sensitive parents. 4) Integrin αvβ6 not only played an important role in colony formation, but also protected cholangiocarcinoma cells from cisplatin-induced growth inhibition and apoptosis. 5) ERK/MAPK signaling pathway was involved in integrin αvβ6-mediated resistance of cholangiocarcinoma cells to cisplatin. 6) cholangiocarcinoma patients who were αvβ6-positive showed a significantly shorter overall survival period than those who were αvβ6-negative (p=0.004). 7) Integrin alpha V (ITGAV) expression is associated with shortened overall-survival in esophageal adenocarcinoma patients who received preoperative chemoradiation (5-Fluouracil, cisplatin, 40 Gy) or chemotherapy alone.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; data mining', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGA5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3655" target="_blank" rel="noopener noreferrer">3655</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P23229" target="_blank" rel="noopener noreferrer">P23229</a>', 'HUGO Gene symbol': 'ITGA6', 'Protein name': 'integrin subunit alpha 6', 'Function': 'The alpha 6 beta 4 integrin may promote tumorigenesis, while the alpha 6 beta 1 integrin may negatively regulate erbB2/HER2 signaling.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28328815%2C%2030930993%5Buid%5D" target="_blank" rel="noopener noreferrer">28328815, 30930993</a>', 'Notes': '1) The high expression of ITGA6 in 287 ovarian cancer patients of TCGA cohort was significantly associated with poorer progression-free survival. 2) ITGA6 is a central drug resistance gene, and that its expression was upregulated in cisplatin-resistant SKOV3 (SKOV3/DDP2), cisplatin-resistant A2780 (A2780/DDP) cells, and in 54 cases of drug-resistant tissues, as compared with in the controls. 3) ITGA6 was significantly associated with ovarian cancer and drug resistance. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGA6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3688" target="_blank" rel="noopener noreferrer">3688</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05556" target="_blank" rel="noopener noreferrer">P05556</a>', 'HUGO Gene symbol': 'ITGB1', 'Protein name': 'Integrin beta-1', 'Function': 'receptor for collagen; recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. also receptor for fibronectin.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27589736%2C%2019158362%5Buid%5D" target="_blank" rel="noopener noreferrer">27589736, 19158362</a>', 'Notes': '1) silencing of β1 integrin inhibited cell migration, invasion, and increased the sensitivity to cisplatin in TNBC cells. 2) activation of β1 integrin increased cell migration, invasion, and decreased the sensitivity to cisplatin. 3) silencing of β1 integrin abolished Focal adhesion kinese (FAK) mediated cell survival. 4) Overexpression of FAK could restore cisplatin-induced apoptosis in β1 integrin-depleted cells. 5) β1 integrin expression was also positively correlated with FAK (p\xa0= 0.031) in clinical tissue. 6) β1 integrin expression was significantly correlated with patient outcome.\xa07) Epithelial cells expressing either beta1 or beta3 integrins, in which p53 activity is suppressed, undergo G(2) arrest but show little apoptosis after treatment with cisplatin or other genotoxicants. 8) The apoptotic response is strongly enhanced by the c-Src[Y530F] oncogene in cells expressing beta1 integrins, whereas such sensitization is reduced when these cells are engineered to express beta3 integrins instead.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3693" target="_blank" rel="noopener noreferrer">3693</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18084" target="_blank" rel="noopener noreferrer">P18084</a>', 'HUGO Gene symbol': 'ITGB5', 'Protein name': 'Integrin beta-5', 'Function': 'It binds to an α subunit to form a heterodimeric integrin complex regulation of cell growth and motility. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27294003%2C%2029100351%5Buid%5D" target="_blank" rel="noopener noreferrer">27294003, 29100351</a>', 'Notes': '1) cisplatin suppressed glycolysis-related proteins expression, including glucose transporter 1 (GLUT1), glucose transporter 4 (GLUT4) and lactate dehydrogenase B (LDHB), through down-regulating integrin β5 (ITGB5)/focal adhesion kinase (FAK) signaling pathway.\xa02) ITGB5 overexpression rescued cisplatin-induced inhibition of cancer cell glycolysis, growth and proliferation. 3) expression of three of the family members, ITGA5, ITGB5 and ITGA2B, were significantly associated with the overall survival (OS) or relapse-free survival (RFS) of HBV-related HCC patients. 4) patients with lower expression of both ITGA5 and ITGB5 had the best OS and RFS (P = 0.017 and P = 0.002, respectively).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGB5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3694" target="_blank" rel="noopener noreferrer">3694</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18564" target="_blank" rel="noopener noreferrer">P18564</a>', 'HUGO Gene symbol': 'ITGB6', 'Protein name': 'integrin subunit beta 6', 'Function': 'Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30808674,32534716" target="_blank" rel="noopener noreferrer">30808674, 32534716</a>', 'Notes': '1) Retinoic acid-related orphan receptor C (RORC) bound the promoter region of PD-L1 and negatively regulated PD-L1 expression. 2) PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK signaling pathway. 3) RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis.\xa04) Integrin αvβ6 not only played an important role in colony formation, but also protected cholangiocarcinoma cells from cisplatin-induced growth inhibition and apoptosis. 5) ERK/MAPK signaling pathway was involved in integrin αvβ6-mediated resistance of cholangiocarcinoma cells to cisplatin. 6) cholangiocarcinoma patients who were αvβ6-positive showed a significantly shorter overall survival period than those who were αvβ6-negative (p=0.004). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGB6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3696" target="_blank" rel="noopener noreferrer">3696</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26012" target="_blank" rel="noopener noreferrer">P26012</a>', 'HUGO Gene symbol': 'ITGB8', 'Protein name': 'integrin\xa0β8', 'Function': 'This protein noncovalently binds to an alpha subunit to form a heterodimeric integrin complex.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29436681%5Buid%5D" target="_blank" rel="noopener noreferrer">29436681</a>', 'Notes': '1) miR-199a-3p was significantly downregulated in chemoresistant ovarian cancer tissues, 2) CDDP-resistant SKOV3/CDDP cells. 3) Restoration of miR-199a-3p in SKOV3/CDDP cells results in enhanced CDDP sensitivity, 4) miR-199a-3p inhibition resulted in the opposite effects. 5) ITGB8 was a direct target of miR-199a-3p. 6) overexpression of ITGB8 restored CDDP resistance inhibited by miR-199a-3p. 7) orthotopic ovarian cancer mouse model showed that miR‑199a-3p enhanced CDDP sensitivity of ovarian cancer in vivo. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITGB8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9452" target="_blank" rel="noopener noreferrer">9452</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43736" target="_blank" rel="noopener noreferrer">O43736</a>', 'HUGO Gene symbol': 'ITM2A', 'Protein name': 'Integral membrane protein 2A', 'Function': 'Involved in cell differentiation; inhibits cell growth in human breast cancer via enhancing autophagy induction (31438969); a transcriptional target of PKA-CREB, regulates autophagic flux via interaction with the vacuolar ATPase (25951193)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> lysosomes', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26691219%5Buid%5D" target="_blank" rel="noopener noreferrer">26691219</a>', 'Notes': '1) ITM2A was significantly downregulated in invasive carcinomas compared to normal, adenoma and borderline tumor tissues. 2) ITM2A loss occurred in 45.6% (41 of 90) of invasive carcinomas and was significantly associated with FIGO stage, type II tumors, suboptimal debulking operation, recurrence and chemoresistance. 3) ITM2A loss and higher FIGO stage were independent factors for poor prognosis. 5) Expression of ITM2A inhibited growth and induced G2/M cell cycle arrest by attenuating cdc2, cyclin B1, cdc25c and p-cdc2 (Thr 161). 6) In vitro and in vivo experiments showed that ITM2A expression significantly reduced the paclitaxel and carboplatin IC50 and tumor mass after paclitaxel treatment.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITM2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3708" target="_blank" rel="noopener noreferrer">3708</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14643" target="_blank" rel="noopener noreferrer">Q14643</a>', 'HUGO Gene symbol': 'ITPR1', 'Protein name': 'IP3 receptor isoform 1', 'Function': 'Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Calcium signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15608674%5Buid%5D" target="_blank" rel="noopener noreferrer">15608674</a>', 'Notes': '1) Using two pairs of parental and cisplatin-resistant bladder cancer cell lines, we found a markedly reduced expression of inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1), endoplasmic reticulum membrane protein, in cisplatin-resistant cells. 2) The suppression of IP3R1 expression using siRNA in parental cells prevented apoptosis and resulted in decreased sensitivity to cisplatin. 3) overexpression of IP3R1 in resistant cells induced apoptosis and increased sensitivity to cisplatin.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ITPR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/182" target="_blank" rel="noopener noreferrer">182</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78504" target="_blank" rel="noopener noreferrer">P78504</a>', 'HUGO Gene symbol': 'JAG1', 'Protein name': 'jagged-1 protein', 'Function': 'Ligand for multiple Notch receptors and involved in the mediation of Notch signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'Notch signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24659709%5Buid%5D" target="_blank" rel="noopener noreferrer">24659709</a>', 'Notes': '1) miR-199b-5p as significantly down-regulated in cisplatin-resistant ovarian cancer cells. 2) miR-199b-5p is clinically associated with advanced and poor survival ovarian cancers. 3) JAG1 was a primary target of miR-199b-5p. 4) Re-expression of miR-199b-5p and siRNA-mediated JAG1 knockdown or treatment with Notch specific inhibitor γ-secretase (GSI) attenuated JAG1-Notch1 signaling activity, thereby enhancing cisplatin-mediated cell cytotoxicity in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JAG1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3717" target="_blank" rel="noopener noreferrer">3717</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60674" target="_blank" rel="noopener noreferrer">O60674</a>', 'HUGO Gene symbol': 'JAK2', 'Protein name': 'Tyrosine-protein kinase JAK2', 'Function': 'Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications.\xa0 ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28721072%2C%2024782986%2C%2024764577%5Buid%5D" target="_blank" rel="noopener noreferrer">28721072, 24782986, 24764577</a>', 'Notes': '1) CXCR4 contributes to CXCL12-mediated anti-apoptosis by activating JAK2/STAT3 pathway in NSCLC cells. 2) in vitro treatment of OVCA 433 and HEY cell lines with cisplatin or paclitaxel resulted in the activation of the JAK2/STAT3 pathway. 3) Coupling of the stem cell marker CD44 with the embryonic stem cell marker Nanog has been shown to be associated with the activation of STAT3 in ovarian cancer cells. 4) High mRNA expression and gene amplification of PD-L1 were both significantly associated with high JAK2 expression (P<0.0001). 5) Of 223 archived breast tumors from 2,460 patients in 3 cohorts, increased JAK2 was associated with a decreasing risk of recurrence (multivariate p=0.003, n=223). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JAK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3725" target="_blank" rel="noopener noreferrer">3725</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05412" target="_blank" rel="noopener noreferrer">P05412</a>', 'HUGO Gene symbol': 'JUN', 'Protein name': 'Transcription factor AP-1', 'Function': 'Transcription factor that promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30439707,31949859,32341033" target="_blank" rel="noopener noreferrer">30439707, 31949859, 32341033</a>', 'Notes': "1) Expression of miR-139-5p was decreased in ovarian cancer SKOV3-R and A2780-R cells. Recovery of miR-139-5p increased the sensitivity of SKOV3-R and A2780-R cells to cisplatin treatment, inhibited the interaction of c-Jun and ATF2, and decreased Bcl-xl expression in SKOV3-R and A2780-R cells. 2) Expression of miR-139-5p promoted cisplatin-induced mitochondrial apoptosis through binding the 3' untranslated region of c-Jun mRNA.\xa03) c-Jun was up-regulated in the docetaxel/cisplatin/5-fluorouracil-insensitive group with P = 0.0008  in hypopharyngeal carcinoma. 4) platinum resistance was mediated by DGKA and its product, phosphatidic acid (PA),  in ovarian cancer: DGKA activates the transcription factor c-JUN and consequently enhances expression of a cell-cycle regulator, WEE1. 5) PA facilitates c-JUN N-terminal kinase recruitment to c-JUN and its nuclear localization, leading to c-JUN activation upon cisplatin exposure. 6) Pharmacologic inhibition of DGKA sensitized ovarian cancer cells to cisplatin treatment; 8) DGKA-c-JUN-WEE1 signaling positively correlated with platinum resistance in tumors derived from patients with ovarian cancer.", 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JUN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3726" target="_blank" rel="noopener noreferrer">3726</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17275" target="_blank" rel="noopener noreferrer">P17275</a>', 'HUGO Gene symbol': 'JUNB', 'Protein name': 'Transcription factor jun-B', 'Function': 'part of AP-1', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11916245%2C%2028358415%5Buid%5D" target="_blank" rel="noopener noreferrer">11916245, 28358415</a>', 'Notes': 'As JUN', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JUNB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3727" target="_blank" rel="noopener noreferrer">3727</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17535" target="_blank" rel="noopener noreferrer">P17535</a>', 'HUGO Gene symbol': 'JUND', 'Protein name': 'Transcription factor jun-D', 'Function': 'part of AP-1', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> Oncogene signaling/MAPK<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23942796%5Buid%5D" target="_blank" rel="noopener noreferrer">23942796</a>', 'Notes': "1) As JUN. 2) fresh-frozen tissues of 161 ovarian cancer patients. 3) A high pc-Jun (phosporylated c-Jun Ser63) expression was significantly associated with shorter progression-free survival (14 vs. 16 months, p = 0.017) and overall survival (25 vs. 41 months, p = 0.038). 4) In case of JunD, moderate protein levels were associated with a better prognosis, leading to longer progression-free and overall survival compared to weak or strong JunD expression (PFS in cases with weak/moderate/strong JunD expression: 14 vs. 19.5 vs. 16 months, p = 0.011; OAS: 32 vs. 42 vs. 35.5 months, p = 0.009). 5) Multivariate Cox regression analysis confirmed an independent and significant impact of pc-Jun and JunD on the patient's prognosis. ", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=JUND" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8850" target="_blank" rel="noopener noreferrer">8850</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92831" target="_blank" rel="noopener noreferrer">Q92831</a>', 'HUGO Gene symbol': 'KAT2B', 'Protein name': 'Histone acetyltransferase KAT2B', 'Function': 'p300/CBP-associated factor (PCAF); has significant histone acetyltransferase activity with core histones (H3 and H4), and also with nucleosome core particles. Also acetylates non-histone proteins, such as ACLY, PLK4, RRP9/U3-55K and TBX5. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> EMT<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20530585%2C%2020491776%5Buid%5D" target="_blank" rel="noopener noreferrer">20530585, 20491776</a>', 'Notes': '1) PCAF was also overexpressed in cisplatin-resistant cells and endowed an antiapoptotic phenotype through enhanced E2F1 expression. 2) PCAF-overexpressing cells showed enhanced expression of E2F1 and conferred cell resistance to chemotherapeutic agents. 3) Downregulation of PCAF decreased E2F1 expression and sensitized cells to chemotherapeutic agents. Moreover, knockdown of PCAF induced G(1) arrest and apoptosis.\xa04) PCAF, Twist1, and Y-box binding protein-1 (YB-1) expressions were elevated in cisplatin- and doxorubicin-resistant cancer cells. 5) PCAF manipulation modulated YB-1 transcription in a Twist1-dependent manner. 6) PCAF regulated the Twist1 intracellular localization and the Twist1 transcriptional activity through its acetylation function to the Twist1. 7) Suppression of PCAF expression reduced YB-1 expression in human urothelial cancer KK47 cells, and rendered KK47 cells sensitive to cisplatin and doxorubicin, but not to 5-fluorouracil. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KAT2B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10524" target="_blank" rel="noopener noreferrer">10524</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92993" target="_blank" rel="noopener noreferrer">Q92993</a>', 'HUGO Gene symbol': 'KAT5', 'Protein name': 'Histone acetyltransferase KAT5 ', 'Function': 'Catalytic subunit of the NuA4; acetylation of nucleosomal histones H4 and H2A; involved in growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair; also acetylates non-histone proteins, such as ATM, NR1D2, RAN, FOXP3, ULK1 and RUBCNL/Pacer; BMI1 interacts with a cluster of E-box elements on the MDR1 promoter and recruits TIP60 resulting in acetylation of histone H2A and H3 (27295567).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Platinum efflux<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28634400%2C%2026915295%2C%2018458078%5Buid%5D" target="_blank" rel="noopener noreferrer">28634400, 26915295, 18458078</a>', 'Notes': '1) the physical interaction between the TIP60 and FANCD2 proteins has been identified that is critical for ICL repair. 2) the chemoresistant nasopharyngeal carcinoma cells, derived from chronic treatment of cisplatin, show elevated expression of TIP60. 3) TIP60 binds to the promoters of FANCD2 and BRCA1 and promote the expression of FANCD2 and BRCA1. 4) cisplatin caused these Tip60-silenced normal MEC to accumulate γH2AX but did not increase their apoptosis. Indeed, siTip60 provided cells with modest protection against cisplatin-induced death, as confirmed by their lack of cleaved PARP. 5) Tip60 is overexpressed in cisplatin-resistant cells. 6) Knockdown of Tip60 expression rendered cells sensitive to cisplatin but not to oxaliplatin, vincristine, and etoposide. 7) Tip60 expression is significantly correlated with cisplatin sensitivity in human lung cancer cell lines. 8) the promoter region of the Tip60 gene contains several E boxes, and its expression was regulated by the E-box binding circadian transcription factor Clock. 9) Hyperacetylation of H3K14 and H4K16 was found in cisplatin-resistant cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KAT5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84148" target="_blank" rel="noopener noreferrer">84148</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H7Z6" target="_blank" rel="noopener noreferrer">Q9H7Z6</a>', 'HUGO Gene symbol': 'KAT8', 'Protein name': 'MYST family of Histone acetyltransferase KAT8', 'Function': "Histone acetyltransferase which may be involved in transcriptional activation; acetylation of nucleosomal histone H4; may influence the function of ATM; can also acetylate TP53/p53 at 'Lys-120'; KAT8 regulates G2/M cell cycle arrest through AKT/ERK-cyclin D1 signaling (23638218).", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Oncogene signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29298824%5Buid%5D" target="_blank" rel="noopener noreferrer">29298824</a>', 'Notes': '1) cells depleted of MOF and under replicative stress induced by\xa0cisplatin, hydroxyurea, or camptothecin have reduced survival, a higher frequency of S-phase-specific chromosome damage, and increased R-loop formation.\xa02)MOF interacted with PCNA and affected its ubiquitination and recruitment to the DNA damage site. 3) Depletion of MOF, therefore, compromised the DNA damage repair response as evidenced by decreased Mre11, RPA70, Rad51, and PCNA focus formation, reduced DNA end resection, and decreased CHK1 phosphorylation in cells after exposure to hydroxyurea or cisplatin. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KAT8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3778" target="_blank" rel="noopener noreferrer">3778</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12791" target="_blank" rel="noopener noreferrer">Q12791</a>', 'HUGO Gene symbol': 'KCNMA1', 'Protein name': 'potassium channel calcium activated large conductance subfamily M alpha, member 1 ', 'Function': 'a subunit of calcium-regulated big potassium (BK) channels, which are opened by changes in membrane electrical potential and/or by increases in concentration of intracellular calcium ion (Ca2+).', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26386726%5Buid%5D" target="_blank" rel="noopener noreferrer">26386726</a>', 'Notes': '1) miR-31 is increased, whilst KCNMA1 is reduced in resistant ovarian cells. 2) Over-expression of miR-31 increased CDDP-resistance, as did knockdown of KCNMA1 or inhibition of BK channels. 3) miR-31 represses KCNMA1 expression. 4) Comparing the levels of miR-31 and KCNMA1 to cisplatin resistance in the NCI60 panel or chemoresistance in cohorts of ovarian cancer tumours reveals correlations that support a role for these genes in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KCNMA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55818" target="_blank" rel="noopener noreferrer">55818</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y4C1" target="_blank" rel="noopener noreferrer">Q9Y4C1</a>', 'HUGO Gene symbol': 'KDM3A', 'Protein name': 'Lysine-specific demethylase 3A', 'Function': 'KDM3A employs two distinct mechanisms; one by demethylating histone (H3K9me2) and the other by targeting a non-histone protein, p53. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> CSC<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27694900%5Buid%5D" target="_blank" rel="noopener noreferrer">27694900</a>', 'Notes': '1) lysine demethylase KDM3A/JMJD1A, which specifically demethylates H3K9me2, is highly expressed in platinum-resistant ovarian cancer cells. 2) lysine demethylase KDM3A as a critical regulator of ovarian cancer stemness and cisplatin resistance by inducing the expressions of pluripotent molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2 (Bcl-2) respectively. 3) KDM3A induces ovarian cancer growth while antagonizing cellular senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21Waf1/Cip1. 4) demethylating p53. 5) KDM3A depletion inhibited the growth of subcutaneously implanted cisplatin-resistant human ovarian cancer cells in athymic nude mice. 6) KDM3A is abundantly expressed and positively correlated with Sox2 expression in human ovarian cancer tissues. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDM3A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5927" target="_blank" rel="noopener noreferrer">5927</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29375" target="_blank" rel="noopener noreferrer">P29375</a>', 'HUGO Gene symbol': 'KDM5A', 'Protein name': 'Lysine-specific demethylase 5A', 'Function': "Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code; regulates a translational program that controls p53 protein expression (30388705)", 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR<br><br> p53 signaling<br><br> Transcription/Epigenetics<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20371346%5Buid%5D" target="_blank" rel="noopener noreferrer">20371346</a>', 'Notes': '1) These human PC9 lung adenocarcinoma cells demonstrate >100-fold reduced CDDP sensitivity and maintain viability via engagement of IGF-1 receptor signaling and an altered chromatin state that requires the histone demethylase RBP2/KDM5A/Jarid1A. 2) This drug-tolerant phenotype is transiently acquired and relinquished at low frequency by individual cells within the population, implicating the dynamic regulation of phenotypic heterogeneity in drug tolerance. 3) The drug-tolerant subpopulation can be selectively ablated by treatment with IGF-1 receptor inhibitors or chromatin-modifying agents, potentially yielding a therapeutic opportunity. 4) Upregulated KDM5A in Drug Tolerance Polulations (DTPs) leads to reduced H3K4me3/2 and decreased the sensitivity of the population to cisplatin. 5) KDM5A silencing decreases the number of DTPs and increased the sensitivity of parental PC9 lung adenocarcinoma cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDM5A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3791" target="_blank" rel="noopener noreferrer">3791</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35968" target="_blank" rel="noopener noreferrer">P35968</a>', 'HUGO Gene symbol': 'KDR', 'Protein name': 'Vascular endothelial growth factor receptor 2', 'Function': 'Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/VEGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28383032%2C%2016697074%5Buid%5D" target="_blank" rel="noopener noreferrer">28383032, 16697074</a>', 'Notes': '1) expression of the VEGF family is higher in therapy-resistant EOC cells compared to sensitive ones. 2) Overexpression of VEGFR2 correlated with resistance to cisplatin. 3) combination with VEGFR2-inhibitor apatinib synergistically increased cisplatin sensitivity. 4) Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. 5) Patients with tumors expressing VEGF or KDR tended to have poorer outcomes, 6) VEGF expression and KDR expression were positively correlated. 7) Outcomes were poor in patients with tumors positive for both VEGF and VEGFRs. Multivariate analysis identified expression of both flt-1 and KDR and VEGF and KDR as possible independent prognostic factors.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9817" target="_blank" rel="noopener noreferrer">9817</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14145" target="_blank" rel="noopener noreferrer">Q14145</a>', 'HUGO Gene symbol': 'KEAP1', 'Protein name': 'Kelch-like ECH-associated protein 1', 'Function': 'a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/23045278,27601007,31548347" target="_blank" rel="noopener noreferrer">23045278, 27601007, 31548347</a>', 'Notes': '1) Overexpression of miR-141 resulted in enhanced resistance to cisplatin in ovarian cancer cell lines. 2) miR-141 levels were higher in non-serous ovarian tumors that did not respond well to therapy (platinum-free interval <6 months). 3) miR-141 directly targets KEAP1, 4) downregulation of KEAP1 induces cisplatin resistance. 5) overexpression of KEAP1 significantly enhanced cisplatin sensitivity. 6) the NF-κB pathway, which can be regulated by KEAP1, is activated upon miR-141 overexpression, and that inhibition of this pathway partially reverses miR-141-mediated cisplatin resistance. 7) gene expression data retrieved from TCGA consortium indicated that KEAP1 mutation significantly affects NRF2 signaling activity in patients with NSCLC. 8) Deletion of Keap1 in Trp53-null murine LUAD and LSCC resulted in increased clonogenic survival upon treatment with diverse cytotoxic chemotherapies. 9) In patients with NSCLC, median time to treatment failure (TTF) after first-line cisplatin chemotherapy for the KEAP1/NFE2L2/CUL3-mutant cohort was 2.8 months compared with 8.3 months in the control group (P < 0.0001). Median overall survival (OS) was 11.2 months in the KEAP1/NFE2L2/CUL3-mutant group and 36.8 months in the control group (P = 0.006).', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KEAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10112" target="_blank" rel="noopener noreferrer">10112</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95235" target="_blank" rel="noopener noreferrer">O95235</a>', 'HUGO Gene symbol': 'KIF20A', 'Protein name': 'Kinesin-like protein', 'Function': 'localized to the Golgi apparatus; microtubule-associated motor protein; functions in mitosis, migration, and intracellular transport; activates JAK/STAT3 (31841120)', 'Putative_mechanism_associated_with_Pt_resistance': 'Hedgehog signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30254487%5Buid%5D" target="_blank" rel="noopener noreferrer">30254487</a>', 'Notes': '1) KIF20A expression was obviously elevated at both mRNA and protein levels in EOC cell lines and clinical cancer tissues compared with normal ovarian epithelial cell and adjacent normal ovarian tissues. 2) KIF20A protein expression was highly correlated with International Federation of Gynecology and Obstetrics stage (P=0.008), lymph node metastasis (P=0.002), intraperitoneal metastasis (P<0.001), vital status at last follow-up (P<0.001), intraperitoneal recurrence (P=0.030), tumor recurrence (P=0.005), drug resistance (P=0.013), and ascites with tumor cells (P<0.001). 3) KIF20A overexpression was closely related to poorer overall survival and disease progression-free survival. Furthermore, Cox regression analysis revealed that KIF20A can act as an independent hazard indicator for predicting clinical outcomes in EOC patients. 4) KIF20A overexpression promoted invasion and metastasis of EOC cells and also confers resistance to cisplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KIF20A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3814" target="_blank" rel="noopener noreferrer">3814</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15726" target="_blank" rel="noopener noreferrer">Q15726</a>', 'HUGO Gene symbol': 'KISS1', 'Protein name': 'Metastasis-suppressor KiSS-1', 'Function': 'KiSS1-induced GPR54 signaling inhibits breast cancer cell migration and epithelial-mesenchymal transition via protein kinase D1 (24894166). Studies suggest a putative role in the regulation of events downstream of cell-matrix adhesion, perhaps involving cytoskeletal reorganization.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> NF-kB signaling<br><br> Oncogene signaling/PKC<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21383688%5Buid%5D" target="_blank" rel="noopener noreferrer">21383688</a>', 'Notes': '1) a significant suppression of KiSS1 mRNA and protein expression in the CDDP-resistant (CR) cells. 2) Genetic suppression of KiSS1 in CDDP-sensitive cell lines rendered them CR, an observation that was mechanistically linked to alterations in glutathione S-transferase-π expression and function. 3) loss of KiSS1 expression was associated with metastatic human HNSCC tumors compared with non-metastatic tumors. 4) Genetic reconstitution of KiSS1 in CR cells abrogated cellular migration and induced CDDP sensitivity. 5) significant improvement in survival of the mice bearing CR-KiSS1 tumors. 6) alterations in apoptotic pathways and CDDP metabolism contributed to KiSS1-associated chemotherapy sensitization.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KISS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3815" target="_blank" rel="noopener noreferrer">3815</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10721" target="_blank" rel="noopener noreferrer">P10721</a>', 'HUGO Gene symbol': 'KIT', 'Protein name': 'Mast/stem cell growth factor receptor Kit', 'Function': 'Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and regulates cell survival and proliferation, stem cell maintenance', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21787767%5Buid%5D" target="_blank" rel="noopener noreferrer">21787767</a>', 'Notes': '1) The Mouse experiment tumors that arose from purified CD117(+)Lineage(-) ovarian serous adenocarcinoma cells reproduced the original tumor heterogeneity and could be serially generated, demonstrating the ability to self-renew and to differentiate, two defining properties of stem cells. 2) immunohistochemistry analysis of 25 patients with advanced ovarian serous adenocarcinoma revealed positive immunostaining for CD117 in 40% (10 of 25) of patients. 3) CD117 expression was statistically correlated with resistance to conventional chemotherapy (P=0.027).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KIT" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9314" target="_blank" rel="noopener noreferrer">9314</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43474" target="_blank" rel="noopener noreferrer">O43474</a>', 'HUGO Gene symbol': 'KLF4', 'Protein name': 'Krueppel-like factor 4', 'Function': 'Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27296948%2C%2028108288%5Buid%5D" target="_blank" rel="noopener noreferrer">27296948, 28108288</a>', 'Notes': '1) KLF4 was significantly downregulated in cisplatin-resistant lung cancer A549 cells. 2) Forced KLF4 expression inhibited cell growth and induced apoptosis. 3) overexpression of KLF4 was able to inhibit cell migration and invasion, to inhibit the expression of Slug, Twist, and vimentin, and to increase the expression of E-cadherin and subsequent inhibition of the EMT process. 4) KLF4 expression was downregulated in ovarian cancer tissue compared to normal ovarian tissue, and low KLF4 expression correlated with high risk ovarian carcinoma and poor patient survival. 5) Enforced KLF4 expression by lentiviral transduction sensitized ovarian cancer cells to the effects of the chemotherapy drugs, paclitaxel and cisplatin. 6) Treatment of ovarian cancer cells with APTO-253, a small molecule inducer of KLF4, enhanced the efficacy of both chemotherapy drugs.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KLF4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/688" target="_blank" rel="noopener noreferrer">688</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13887" target="_blank" rel="noopener noreferrer">Q13887</a>', 'HUGO Gene symbol': 'KLF5', 'Protein name': 'Krueppel-like factor 5', 'Function': 'transcription factor, involved in cell proliferation and mediates cell survival and tumorigenesis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> CSC<br><br> DDR<br><br> EMT<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23869764%2C%2030900384%5Buid%5D" target="_blank" rel="noopener noreferrer">23869764, 30900384</a>', 'Notes': '1) KLF5 was highly expressed in the ovarian\xa0cancer\xa0cell\xa0line SKOV3 sphere cells, accompanied by elevated survivin expression. 2) Silencing KLF5 by siRNA in sphere cells down-regulated survivin expression, which also sensitized the sphere cells to apoptosis induced by chemotherapeutic drugs (cisplatin or paclitaxel). 3) KLF5 controlled survivin expression by directly binding the surivin promoter in the cells. 4) Breast cancer patients with higher KLF5 expression had shorter disease-free survival and overall survival time, whereas patients with lower KLF5 expression had better survival. 5) Knockdown of KLF5 promotes cisplatin‐induced cell apoptosis via regulating DNA damage checkpoint proteins in non‐small cell lung cancer. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KLF5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9757" target="_blank" rel="noopener noreferrer">9757</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UMN6" target="_blank" rel="noopener noreferrer">Q9UMN6</a>', 'HUGO Gene symbol': 'KMT2B', 'Protein name': 'Histone-lysine N-methyltransferase 2B', 'Function': 'Knockdown results in fork stabilization and PARPi resistance.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27443740%5Buid%5D" target="_blank" rel="noopener noreferrer">27443740</a>', 'Notes': '1) Brca2−/− Mll4−/− B- cells showed a partial rescue of chromosomal aberrations upon PARPi and cisplatin treatment when compared to Brca2−/− cells alone. 2) PTIP constitutively associate with PA1 and with MLL3/ MLL4 histone methyltransferases; deposition of MRE11 on newly synthesized or stalled chromatin correlates with the establishment of H3K4me1 and H3K4me3 at RFs. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KMT2B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/58508" target="_blank" rel="noopener noreferrer">58508</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NEZ4" target="_blank" rel="noopener noreferrer">Q8NEZ4</a>', 'HUGO Gene symbol': 'KMT2C', 'Protein name': 'methyltransferase-mediated pathway regulating replication for restart/mixed lineage leukemia 3', 'Function': "Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation.", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30665945%2C%2030108106%5Buid%5D" target="_blank" rel="noopener noreferrer">30665945, 30108106</a>', 'Notes': '1) downregulation of KMT2C in bladder cancer cells leads to extensive changes in the epigenetic status and the expression of DNA damage response and DNA repair genes. 2) cells with low KMT2C activity are deficient in homologous recombination‐mediated double‐strand break DNA repair. 3) these cells seem to rely heavily on PARP1/2 for DNA repair, and treatment with the PARP1/2 inhibitor olaparib leads to synthetic lethality, 4) KMT2C overexpression combined with 5-FU or cisplatin led to reductions in cell proliferation ranging from 40-45%. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KMT2C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3845" target="_blank" rel="noopener noreferrer">3845</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01116" target="_blank" rel="noopener noreferrer">P01116</a>', 'HUGO Gene symbol': 'KRAS', 'Protein name': 'GTPase KRas', 'Function': 'Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22139083%5Buid%5D" target="_blank" rel="noopener noreferrer">22139083</a>', 'Notes': '1) EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125) and platinum resistance (n=306). 2) Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio=1.67, 95% confidence interval: 1.09-2.57, P=0.019, n=279). 3) EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio=3.18, confidence interval: 1.31-7.72, P=0.0106, n=291). 4) direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. ', 'Up / down in Pt-resistant cells': 'VARIANT', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRAS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3848" target="_blank" rel="noopener noreferrer">3848</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04264" target="_blank" rel="noopener noreferrer">P04264</a>', 'HUGO Gene symbol': 'KRT1', 'Protein name': 'Keratin, type II cytoskeletal 1', 'Function': 'May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase 1 (RACK1).', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22348822%5Buid%5D" target="_blank" rel="noopener noreferrer">22348822</a>', 'Notes': '1) Keratin 1 (KRT1), cathepsin D (CTSD) and annexin a5 (ANXA5) were identified as three proteins showing higher expression in CNE2/cDDP compared to nasopharyngeal carcinoma cell line CNE2.\xa02) suppression of KRT1 expression by siRNA resulted in decreased MDR in siRNA-CNE2/cDDP cells. 3) upregulation of KRT1 could result in increased of drug resistance in NPC cell lines. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3858" target="_blank" rel="noopener noreferrer">3858</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13645" target="_blank" rel="noopener noreferrer">P13645</a>', 'HUGO Gene symbol': 'KRT10', 'Protein name': 'Keratin, type I cytoskeletal 10', 'Function': 'Plays a role in the establishment of the epidermal barrier on plantar skin; inhibits cell cycle (10082575); loss of KRT10 leads to MAPK (15482487)', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> ECM signaling<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24434152%2C%2026125866%5Buid%5D" target="_blank" rel="noopener noreferrer">24434152, 26125866</a>', 'Notes': '1) KRT10 was identified as a differently expressed protein in cisplatin-treated C13K/PTEN cells. 2) overexpression of KRT10 sensitizes the drug-resistant ovarian cancer cells C13K to cisplatin. 3) knockdown of KRT10 with siRNA blocked the proliferation inhibition effect of cisplatin on C13K/PTEN cells. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRT10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3875" target="_blank" rel="noopener noreferrer">3875</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05783" target="_blank" rel="noopener noreferrer">P05783</a>', 'HUGO Gene symbol': 'KRT18', 'Protein name': 'Keratin, type I cytoskeletal 18', 'Function': 'Involved in the uptake of thrombin-antithrombin complexes by hepatic cells (By similarity). When phosphorylated, plays a role in filament reorganization. Involved in the delivery of mutated CFTR to the plasma membrane. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23449973%2C%20%2022699783%5Buid%5D" target="_blank" rel="noopener noreferrer">23449973,¬† 22699783</a>', 'Notes': '1) K8/18 deletion increased cisplatin-induced apoptosis through increased Fas receptor membrane targeting and the tight junction protein claudin1. 2) K8/18 stable knockdown using shRNA increased collective migration and invasiveness of epithelial cancer cells without modulating EMT markers.\xa03) K8/18-depleted cells showed PI3K/Akt/NF-κB hyperactivation and increased MMP2 and MMP9 expression. 4) the up-regulation of KT18 is observed in a majority of breast carcinomas whereas its down-regulation also occurs at a less frequency. 5)KT18 down-regulation was associated with histologically poorly differentiated carcinomas than well differentiated carcinomas, also significantly associated with the loss of ER and PR, the prognostic markers of the breast cancer (P < 0.05), while not with HER2, tumor size, and lymph node metastasis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRT18" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3852" target="_blank" rel="noopener noreferrer">3852</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13647" target="_blank" rel="noopener noreferrer">P13647</a>', 'HUGO Gene symbol': 'KRT5', 'Protein name': 'Keratin, type II cytoskeletal 5', 'Function': 'There are two types of cytoskeletal and microfibrillar keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26495758%2C%2028147318%5Buid%5D" target="_blank" rel="noopener noreferrer">26495758, 28147318</a>', 'Notes': '1) CK5+ cells are less apoptotic following cisplatin treatment. 2) Of a cohort of high grade serous ovarian carcinomas at surgery (n = 117) and after neoadjuvant chemotherapy (n = 21), high KRT5 mRNA in stage III/IV serous ovarian cancers was significantly associated with reduced progression-free (HR 1.38, P < 0.0001) and overall survival (HR 1.28, P = 0.013) 3) high KRT6 mRNA was only associated with reduced progression-free survival (HR 1.2, P = 0.031). 4) Both high K5/6 (≥ 10%, HR 1.78 95% CI; 1.03−2.65, P = 0.017) and high K5 (≥ 10%, HR 1.90, 95% CI; 1.12−3.19, P = 0.017) were associated with an increased risk of disease recurrence. 5) KRT5 but not KRT6C mRNA expression was increased in chemotherapy resistant primary serous ovarian cancer cells compared to chemotherapy sensitive cells. 6) The proportion of serous ovarian carcinomas with high K5/6 or high K5 immunostaining was significantly increased following neoadjuvant chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRT5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3856" target="_blank" rel="noopener noreferrer">3856</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05787" target="_blank" rel="noopener noreferrer">P05787</a>', 'HUGO Gene symbol': 'KRT8', 'Protein name': 'Keratin, type II cytoskeletal 8', 'Function': 'Cytokeratin. Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23449973%2C%2029100303%5Buid%5D" target="_blank" rel="noopener noreferrer">23449973, 29100303</a>', 'Notes': '1) As KRT18. 2) KRT8 expression was upregulated in clear cell renal cell carcinoma (ccRCC) and vein tumor thrombi (VTTs). 3) KRT8 overexpression in ccRCC was significantly correlated with aggressive characteristics and was predictive of a poor prognosis in ccRCC patients. 4) KRT8 overexpression in renal cancer cell lines promoted cell migration and invasion. 5) KRT8 knockdown suppressed ccRCC metastasis both\xa0in vitro\xa0and\xa0in vivo. 6) KRT8 promoted ccRCC metastasis by increasing IL-11 expression, causing IL-11 autocrine induction, and triggering STAT3 signaling.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRT8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3897" target="_blank" rel="noopener noreferrer">3897</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P32004" target="_blank" rel="noopener noreferrer">P32004</a>', 'HUGO Gene symbol': 'L1CAM', 'Protein name': 'Neural cell adhesion molecule L1', 'Function': 'Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27876874%2C%2029152102%2C%2021097529%2C%2022088438%5Buid%5D" target="_blank" rel="noopener noreferrer">27876874, 29152102, 21097529, 22088438</a>', 'Notes': '1) TWIST1 expression resulted in upregulation of GAS6 and L1CAM. 2) Knockdown studies of these genes demonstrated that loss of GAS6 or L1CAM sensitized cells to cisplatin. 3) Positive L1CAM expression (≥10% of tumor cells) was associated with disease-free survival, validated using RNAseq TCGA data. 4) L1CAM expression was independently associated with locoregional recurrence-free survival (hazard ratio 2.62, 95% CI 1.33 - 5.17, P = 0.006), and strongly associated with percentage of vimentin expressing tumor cells (P = 0.003). 5) Expression of both L1CAM and vimentin indicated a subgroup with the highest risk of recurrence (hazard ratio 3.15, 95% CI 1.25 - 7.92, P = 0.015). 6) L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. 7) L1CAM promoted cell proliferation by mainly activating ERK signaling. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=L1CAM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10542" target="_blank" rel="noopener noreferrer">10542</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43504" target="_blank" rel="noopener noreferrer">O43504</a>', 'HUGO Gene symbol': 'LAMTOR5', 'Protein name': 'hepatitis B X-interacting protein', 'Function': 'As part of the Regulator complex it is involved in amino acid sensing and activation of mTORC1; when complexed to BIRC5, interferes with apoptosome assembly, preventing recruitment of pro-caspase-9 to oligomerized APAF1', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28056551%5Buid%5D" target="_blank" rel="noopener noreferrer">28056551</a>', 'Notes': '1) hepatitis B X-interacting protein was highly expressed in ovarian cancer of cisplatin-resistant tissues and cells. 2) knockdown of hepatitis B X-interacting protein significantly reduced cell viability in A2780/CP compared with cisplatin treatment alone. 3) Hepatitis B X-interacting protein and cisplatin cooperated to induce apoptosis and increase the expression of c-caspase 3 as well as the Bax/Bcl-2 ratio. 4) In vivo, depletion of hepatitis B X-interacting protein decreased the tumor volume and weight induced by cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LAMTOR5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9113" target="_blank" rel="noopener noreferrer">9113</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95835" target="_blank" rel="noopener noreferrer">O95835</a>', 'HUGO Gene symbol': 'LATS1', 'Protein name': 'large tumor suppressor 1 ', 'Function': 'Serine/threonine-protein kinase, negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29168038%2C%2022909338%5Buid%5D" target="_blank" rel="noopener noreferrer">29168038, 22909338</a>', 'Notes': '1) As HTRA2. This HtrA2-mediated cell death is enhanced by LATS1. 2) mRNA and protein of LATS1 expression is significantly downregulated in glioma compared with normal control brain tissues. 3) downregulation of HtrA2, but not of LATS1 by specific siRNA, increased cisplatin resistance and invasion. 4) Patients with lower LATS1 expression had a significantly shorter overall survival time than did patients with higher LATS1 expression. 5) Multivariate analysis suggested that the level of LATS1 expression was an independent prognostic indicator (p<0.001) for the survival of patients with glioma. 6) Forced expression of LATS1 in glioma U251 cells not only significantly suppressed cell growth, migration and invasion, but retarded cell cycle progression from G2/M to G1 in vitro. 7) overexpressed LATS1 markedly inhibited the expression level of cell cycle factor CCNA1.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'UNKNOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LATS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3932" target="_blank" rel="noopener noreferrer">3932</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06239" target="_blank" rel="noopener noreferrer">P06239</a>', 'HUGO Gene symbol': 'LCK', 'Protein name': 'Tyrosine-protein kinase Lck', 'Function': 'Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28838952%5Buid%5D" target="_blank" rel="noopener noreferrer">28838952</a>', 'Notes': '1) CSCs and cisplatin-resistant cells had higher levels of both pLCK (Y394) and LCK compared with their non-CSC and cisplatin-naive counterparts, respectively. 2) LCK and pLCK (Y394) were coprecipitated with CD55. 3) CSCs treated with 1 µM saracatinib (Fyn/LcK inhibitor) demonstrated significantly higher sensitivity to cisplatin compared with CSCs treated with cisplatin and DMSO. 4) Similarly, LCK-silenced CSCs demonstrated significantly higher sensitivity to cisplatin. 5) LCK overexpressing non-CSCs had significantly higher survival rates and lower caspase 3/7 activity levels compared with non-CSCs with empty vector transduction upon cisplatin treatment. 5) CD55 signals through LCK pathway to induce cisplatin resistance via increased expression of DNA repair genes (BRCA1, MLH1). ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LCK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3949" target="_blank" rel="noopener noreferrer">3949</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01130" target="_blank" rel="noopener noreferrer">P01130</a>', 'HUGO Gene symbol': 'LDLR', 'Protein name': 'Low-density lipoprotein receptor', 'Function': 'Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Oncogene signaling/FGF<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31815680%2C%2032543783%5Buid%5D" target="_blank" rel="noopener noreferrer">31815680, 32543783</a>', 'Notes': "1) LDLR expressions were positively associated with epithelial ovarian carcinomas (EOCs) platinum-based chemotherapy patients' disease prognosis. 2) knocked-down LDLR could sensitize while overexpressed LDLR could insensitize EOC cells to cisplatin. 3) the trans-omics approaches depicted an LDLR→LPC (Lyso-phosphatidylcholine)→FAM83B (phospholipase-related)→FGFRs (cisplatin sensitivity and phospholipase-related) regulatory axis. 4) the manipulation of LDLR expression in EOC cells was found to determine the efficacy of cisplatin therapy in terms of tumor suppression. 5) LDLR knockdown increased the number of platinum-DNA adducts and reduced the LD platinum amount. 6) lipid profiles of 22 carcinoma cells with differential cisplatin sensitivity (9 sensitive vs 13 insensitive) revealed low storage lipid levels in insensitive cells. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LDLR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3958" target="_blank" rel="noopener noreferrer">3958</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17931" target="_blank" rel="noopener noreferrer">P17931</a>', 'HUGO Gene symbol': 'LGALS3', 'Protein name': 'Galectin-3', 'Function': 'Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27626163%5Buid%5D" target="_blank" rel="noopener noreferrer">27626163</a>', 'Notes': '1) galectin-3 maintains ovarian CSCs by activating the Notch1 intracellular domain (NICD1). 2) The number and size of ovarian CSCs decreased in the absence of galectin-3, 3) overexpression of galectin-3 increased them. 4) Overexpression of galectin-3 increased the resistance for cisplatin and paclitaxel-induced cell death. 5) Silencing of galectin-3 decreased the migration and invasion of ovarian cancer cells, and overexpression of galectin-3 reversed these effects. 5) The Notch signaling pathway was strongly activated by galectin-3 overexpression in A2780 cells. 6) Silencing of galectin-3 reduced the levels of cleaved NICD1 and expression of the Notch target genes, Hes1 and Hey1. 7) Overexpression of galectin-3 induced NICD1 cleavage and increased expression of Hes1 and Hey1. as well as increased the nuclear translocation of NICD1. 8) Overexpression of galectin-3 increased tumor burden in A2780 ovarian cancer xenografted mice. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LGALS3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3980" target="_blank" rel="noopener noreferrer">3980</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49916" target="_blank" rel="noopener noreferrer">P49916</a>', 'HUGO Gene symbol': 'LIG3', 'Protein name': 'DNA ligase 3', 'Function': 'LIG3-XRCC1 complex is responsible for ligation steps of NER and DNA strand-break repair.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER<br><br> DDR/HR<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24533712%2C%2017643379%2C%2019053130%5Buid%5D" target="_blank" rel="noopener noreferrer">24533712, 17643379, 19053130</a>', 'Notes': 'X-ray repair cross-complementing gene I protein (XRCC1) in complex with DNA polymerase beta, DNA ligase III, and poly(ADP-ribose) polymerase is important in the base excision repair process. 1) SNPs in ERCC5, RAD52, MUTYH and LIG3 correlated with the occurrence of CDDP-induced severe neutropenia 2) XRCC1-Lig3 is indispensable for ligation of NER-induced breaks and repair of UV lesions in quiescent cells. 3) DNA ligase III binds to Pt-modified DNA. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LIG3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3981" target="_blank" rel="noopener noreferrer">3981</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49917" target="_blank" rel="noopener noreferrer">P49917</a>', 'HUGO Gene symbol': 'LIG4', 'Protein name': 'DNA ligase 4', 'Function': 'LIG4-XRCC4 complex is responsible for the NHEJ ligation step', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20487264%2C%2024722796%2C%2026134445%5Buid%5D" target="_blank" rel="noopener noreferrer">20487264, 24722796, 26134445</a>', 'Notes': '1) Lig4-⁄- cells are hypersensitive to cisplatin. 2) Kaplan-Meier analysis of all patients showed a significant association between the LIG4 Thr9Ile CC polymorphism and superior progression-free survival and overall survival duing platinum based drug treatment. 3) High LIG4 expression was also tightly related to early biochemical recurrence when all tumors (P<0.0001) or the subsets of ERG-negative (P=0.0004) or ERG-positive prostate cancers (P=0.006) were analyzed. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LIG4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79727" target="_blank" rel="noopener noreferrer">79727</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H9Z2" target="_blank" rel="noopener noreferrer">Q9H9Z2</a>', 'HUGO Gene symbol': 'LIN28A', 'Protein name': 'Protein lin-28 homolog A', 'Function': 'RNA-binding protein that inhibits processing of pre-let-7 miRNAs and regulates translation of mRNAs that control developmental timing, pluripotency and metabolism. an important marker gene of stemness in ovarian cancer stem cells. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> CSC<br><br> Oncogene signaling<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25318762%5Buid%5D" target="_blank" rel="noopener noreferrer">25318762</a>', 'Notes': '1) Terrin sensitize cisplatin-resistant ovarian cancer stem cells to cisplatin by suppressing the expression of LIN28. 2) High expression of LIN28A and PLK4 was detected at the advanced pathological stage. 3) PLK4 expression was positively correlated with LIN28A (r=0.555; P=0.039). 4) The median survival analysis of patients with EOC with LIN28A and PLK4 double positive expression was 14 months, compared with 30 months in single positive and 60 months in double negative patients by Kaplan‑Meier analysis (P<0.05), following cisplatin treatment. 5) The expressions of LIN28A and PLK4 was elevated in different EOC cell lines compared to with a normal ovarian cell line. 6) The 293T cells transfected with LIN28A plus a PLK4 plasmid were the fastest‑growing group. These results suggest that co‑expression of LIN28A and PLK4 may be associated with poor prognosis of EOC.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LIN28A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/389421" target="_blank" rel="noopener noreferrer">389421</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6ZN17" target="_blank" rel="noopener noreferrer">Q6ZN17</a>', 'HUGO Gene symbol': 'LIN28B', 'Protein name': 'Protein lin-28 homolog B', 'Function': 'Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequesters them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Oncogene signaling<br><br> Platinum uptake<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26158423%5Buid%5D" target="_blank" rel="noopener noreferrer">26158423</a>', 'Notes': '1) From 140 EOC patients, high expression of IMP3 or Lin28B was associated with poor survival, and women diagnosed at advanced stages with elevated IMP3 and Lin28B were at higher risk of developing chemoresistance. 2)High IMP3 levels combined with high Lin28B levels significantly correlated with the poorest 5-year survival rates. 3) Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, 4) of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake. 5) High expression of hCTR1 correlated with low expression of IMP3/Lin28B and better progression-free survival in advanced-stage EOC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LIN28B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8543" target="_blank" rel="noopener noreferrer">8543</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61968" target="_blank" rel="noopener noreferrer">P61968</a>', 'HUGO Gene symbol': 'LMO4', 'Protein name': 'LIM domain transcription factor LMO4', 'Function': 'transcriptional regulator. It controls pathways regulating cell survival and cell death', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25501662%5Buid%5D" target="_blank" rel="noopener noreferrer">25501662</a>', 'Notes': '1) cisplatin treatment nitrates Lmo4 and decreases Lmo4 expression in the cochlea.  2) A potential role of Jak/Stat transcriptional machinery in relaying the Lmo4 protein signaling in cisplatin-induced ototoxicity. 3) In NSCLC patients receiving induction chemotherapy with cisplatin plus gemcitabine,  LMO4 has high expression level of NSCLC cell lines and tumor tissues, and 4) correlated with a lower survival rate. 5) LMO4 can regulate the migration and invasion of NSCLC cells through the AKT/PI3K pathway.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LMO4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4012" target="_blank" rel="noopener noreferrer">4012</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UIQ6" target="_blank" rel="noopener noreferrer">Q9UIQ6</a>', 'HUGO Gene symbol': 'LNPEP', 'Protein name': 'Leucyl-cystinyl aminopeptidase, placental leucine aminopeptidase', 'Function': 'cell surface aminopeptidase. Degrades peptide hormones such as oxytocin, vasopressin and angiotensin III; resides in GLUT4 vesicles, migrates to the cell membrane to facilitate glucose uptake in response to insulin stimulation (17233921). \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15491750%5Buid%5D" target="_blank" rel="noopener noreferrer">15491750</a>', 'Notes': '1) In 15 of 17 endometrial carcinoma patients, P-LAP was positive. 2) Twelve of seventeen patients were evaluable for response. Among the eight patients strongly positive for P-LAP, only two patients (25%) showed PR.3) all four patients who were weakly positive for P-LAP showed either complete response (CR) or partial response (PR). 4) Compared to vector control cells, apoptotic effect by carboplatin treatment was clearly inhibited overexpressing P-LAP.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LNPEP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4035" target="_blank" rel="noopener noreferrer">4035</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q07954" target="_blank" rel="noopener noreferrer">Q07954</a>', 'HUGO Gene symbol': 'LRP1', 'Protein name': 'Prolow-density lipoprotein receptor-related protein 1', 'Function': 'Endocytic receptor involved in endocytosis. Modulates microglial polarization through Shc1/PI3K/Akt pathway (30703614). Involved in cellular lipid homeostasis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> endocytosis<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30089260%5Buid%5D" target="_blank" rel="noopener noreferrer">30089260</a>', 'Notes': '1) LRP1 mRNA Is Induced by p53-Activating Stresses such as cisplatin. 2) LRP1 protein is only upregulated in response to sub-lethal stress: lethal doses of Cisplatin do not induce LRP1 protein. 3) p53-activating stress inhibit LRP1 de novo translation through an miRNA-based translational repression mechanism. 4) LRP1 suppression is sufficient to induce cell death in cancer cells, suggesting that p53-mediated suppression of LRP1 in response to lethal stress contributes to a pro-death response. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LRP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/56262" target="_blank" rel="noopener noreferrer">56262</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IWT6" target="_blank" rel="noopener noreferrer">Q8IWT6</a>', 'HUGO Gene symbol': 'LRRC8A', 'Protein name': 'Volume-regulated anion channel subunit LRRC81', 'Function': 'A subunit of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26530471%2C%2030015914%5Buid%5D" target="_blank" rel="noopener noreferrer">26530471, 30015914</a>', 'Notes': '1) Under isotonic conditions, about 50% of cisplatin uptake depended on LRRC8A and LRRC8D.\xa02) LRRC8A disruption also suppressed drug-induced apoptosis independently from drug uptake, possibly by impairing VRAC-dependent apoptotic cell volume decrease. 2) LRRC8A was elevated in 60% of colorectal cancer patient tissues. 3) Colon cancer patients with high‑ expressed LRRC8A had a survival time of 54.9±5.5 months, shorter than that of patients with low‑expressed LRRC8A (77.1±3.7). 4) survival time (52.6±7.3 months) of patients with metastases in the lymph nodes was shorter than that of patients without positive lymph nodes (72.2±3.6); patients with positive lymph nodes and an elevated LRRC8A expression had the highest mortality rate (~80%). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LRRC8A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55144" target="_blank" rel="noopener noreferrer">55144</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q7L1W4" target="_blank" rel="noopener noreferrer">Q7L1W4</a>', 'HUGO Gene symbol': 'LRRC8D', 'Protein name': 'Volume-regulated anion channel subunit LRRC8D', 'Function': 'D subunit of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26530471%5Buid%5D" target="_blank" rel="noopener noreferrer">26530471</a>', 'Notes': '1) As LRRC8A. 2) we investigated the data derived from ovarian cancer patients that were recently published by Patch et al (2015). 3) Although the available data are derived from fewer patients, also in this analysis a low expression of LRRC8D, but not LRRC8A, correlated with a modest, but significant decrease in survival. 4)  LRRC8D might also affect platinum drug responses in cancer patients.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LRRC8D" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9208" target="_blank" rel="noopener noreferrer">9208</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q32MZ4" target="_blank" rel="noopener noreferrer">Q32MZ4</a>', 'HUGO Gene symbol': 'LRRFIP1', 'Protein name': 'Leucine-rich repeat flightless-interacting protein 1', 'Function': "Transcriptional repressor which preferentially binds to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may regulate expression of TNF, EGFR and PDGFA.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Platinum efflux<br><br> Transcription<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22571463%5Buid%5D" target="_blank" rel="noopener noreferrer">22571463</a>', 'Notes': '1) Increased expression of GCF2 was found in human\xa0cisplatin-resistant human epidermoid carcinoma cells, 2) overexpression in GCF2-transfected cells results in loss of\xa0RhoA\xa0expression and disruption of the actin/filamin network. 3) The GCF2 transfectants also showed reduced accumulation of\xa0cisplatin\xa0and increased resistance. 4) siRNA targeted to GCF2 reactivated\xa0RhoA\xa0expression, and restored the fine structure of actin microfilaments. MRP1 was also relocated to the cell surface. 6) siRNA targeted to\xa0RhoA\xa0increased resistance 3-fold in KB-3-1 and KB-CP.5 cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LRRFIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/56413" target="_blank" rel="noopener noreferrer">56413</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NPC1" target="_blank" rel="noopener noreferrer">Q9NPC1</a>', 'HUGO Gene symbol': 'LTB4R2', 'Protein name': 'Leukotriene B4 receptor 2', 'Function': 'Low-affinity receptor for leukotrienes including leukotriene B4. Mediates chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26597704%2C%2029898809%5Buid%5D" target="_blank" rel="noopener noreferrer">26597704, 29898809</a>', 'Notes': "1) BLT2 and its ligand leukotriene B4 were highly up-regulated in cisplatin-resistant SK-OV-3 ovarian cancer cells. 2) play critical roles in mediating the chemoresistance through the activation of signal transducer and activator of transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6). 3) BLT2 depletion with siRNA clearly abolished the chemoresistance to cisplatin in SK-OV-3 ovarian cancer cells and further increased cell sensitivity to cisplatin chemotherapy by down-regulating the 'STAT-3-IL-6' cascade. 4) Enlarged tumor formation due to the cisplatin resistance of SK-OV-3 cells in cisplatin-treated athymic mice was also substantially reduced by co-treatment with the BLT2 inhibitor in vivo. 5) in a group of 545 triple negative breast cancer patients with metastasis,  the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LTB4R2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51747" target="_blank" rel="noopener noreferrer">51747</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95232" target="_blank" rel="noopener noreferrer">O95232</a>', 'HUGO Gene symbol': 'LUC7L3', 'Protein name': 'cisplatin resistance-associated overexpressed protein', 'Function': 'May play a role in RNA splicing', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10631324%2C%2012565863%5Buid%5D" target="_blank" rel="noopener noreferrer">10631324, 12565863</a>', 'Notes': '1) cDNA fragments, expressed higher in cisplatin-resistant ACHN/CDDP cells than its host ACHN cells, were isolated by di¡erential display. (Human renal cancer cell line). 2) cisplatin affects RNA splicing by changing the subnuclear distribution of SR proteins including CROP.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UNKNOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=LUC7L3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/346389" target="_blank" rel="noopener noreferrer">346389</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6ZN28" target="_blank" rel="noopener noreferrer">Q6ZN28</a>', 'HUGO Gene symbol': 'MACC1', 'Protein name': 'Metastasis-associated in colon cancer protein 1', 'Function': 'Acts as a transcription activator for MET and as a key regulator of HGF-MET signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/HGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26681060%2C%2030515418%5Buid%5D" target="_blank" rel="noopener noreferrer">26681060, 30515418</a>', 'Notes': '1) MACC1 mRNA and protein expression levels in SKOV-3/DDP cells were 2.66 ± 0.54 and 1.95 ± 0.45 times those seen in SKOV-3 cells. 2) Cisplatin sensitivity of MACC1 knockdown group was much higher than that in the control and shVect groups. 3) p-ERK1/2 expression decreased significantly in the MACC1 knockdown cells. 4) MACC1 mRNA high expression was significantly associated with unfavorable overall survival (hazard ratio (HR) = 1.51 (95% confidence interval (CI): 1.21 – 1.88), P = 0.00025) and progression-free survival (HR = 1.53 (95% CI: 1.24 – 1.89), P = 5.8e-05) in EOC patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MACC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10459" target="_blank" rel="noopener noreferrer">10459</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UI95" target="_blank" rel="noopener noreferrer">Q9UI95</a>', 'HUGO Gene symbol': 'MAD2L2', 'Protein name': 'Mitotic spindle assembly checkpoint protein MAD2B', 'Function': 'Adapter protein able to interact with different proteins and involved in different biological processes. interaction between REV3L and REV1, mediating TLS\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24597627%5Buid%5D" target="_blank" rel="noopener noreferrer">24597627</a>', 'Notes': '1) Expression was detected in the majority of EOCs (92.0%) with especially high levels of expression frequently observed in CCCs (73.5%) compared with that of non-CCCs (53.4%). 2) Enhanced immunoreactivity to REV7 was associated with poor prognosis represented by reduced progression-free survival in advanced stage (stage II-IV). 3) Knockdown of REV7 in CCC cells decreased cell proliferation without affecting cell cycle distribution; the number of apoptotic cells and DNA damaged cells were increased after cisplatin treatment. 4) In a nude mouse tumor xenograft model, inoculated REV7-knockdown tumors showed significantly reduced tumor volumes after cisplatin treatment compared with those of the control group. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAD2L2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4097" target="_blank" rel="noopener noreferrer">4097</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15525" target="_blank" rel="noopener noreferrer">O15525</a>', 'HUGO Gene symbol': 'MAFG', 'Protein name': 'Transcription factor MafG', 'Function': 'the small Mafs behave as transcriptional repressors when they dimerize among themselves but serve as transcriptional activators by dimerizing with NFE2, NFE2L1 and NFE2L2; associated with detoxification in oxidative stress situations', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29158814%5Buid%5D" target="_blank" rel="noopener noreferrer">29158814</a>', 'Notes': '1) miR-7 presented specific methylation in resistant cell lines, and was associated with poorer prognosis in ovarian cancer patients. 2) the direct regulation of MAFG through miR-7. 3) MAFG overexpression resulted in an increase in the resistance to CDDP in ovarian cancer A2780S and H23S cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAFG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4118" target="_blank" rel="noopener noreferrer">4118</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21145" target="_blank" rel="noopener noreferrer">P21145</a>', 'HUGO Gene symbol': 'MAL', 'Protein name': 'Myelin and lymphocyte protein', 'Function': 'vesicular trafficking; involved in reorganisation of lipid rafts for signalling and/or intracellular transport (11739628); apical transport of proteins in polarized epithelial cells; myelin biogenesis and/or myelin function; T-cell differentiation.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15897565%2C%2028545541%5Buid%5D" target="_blank" rel="noopener noreferrer">15897565, 28545541</a>', 'Notes': '1) Patterns of genes were identified that distinguish short-term and long-term ovarian cancer survivors. The expression model developed for advanced stage disease classified all 11 early-stage ovarian cancers as long-term survivors. 2) The MAL gene, which has been shown to confer resistance to cancer therapy, was most highly overexpressed in short-term survivors (3-fold compared with long-term survivors, and 29-fold compared with early-stage cases). 3) MAL (T-cell differentiation protein) emerged as the most up-regulated gene in spheroids, compared to parent cell line. 4) In HGSOC patients, MAL was significantly overexpressed in platinum-resistant compared to platinum-sensitive patients and resulted as an independent prognostic marker of survival.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10892" target="_blank" rel="noopener noreferrer">10892</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UDY8" target="_blank" rel="noopener noreferrer">Q9UDY8</a>', 'HUGO Gene symbol': 'MALT1', 'Protein name': 'Mucosa-associated lymphoid tissue lymphoma translocation protein 1', 'Function': 'A caspase-like protease that enhances BCL10-induced activation of NF-kappa-B. Involved in nuclear export of BCL10. Binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23358872%5Buid%5D" target="_blank" rel="noopener noreferrer">23358872</a>', 'Notes': '1) HECTD3 depletion dramatically decreases the levels of MALT1 in MCF7 and HeLa cells treated with cisplatin, which is correlated to an increase in apoptosis. 2) Knockdown of MALT1 likewise increases cisplatin-induced apoptosis in these cancer cells. 4) HECTD3 over-expression leads to a decreased cisplatin-induced apoptosis, 5) overexpression of MALT1 partially rescues HECTD3 depletion-induced apoptosis. 6) HECTD3 promotes cell survival through stabilizing MALT1.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MALT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84557" target="_blank" rel="noopener noreferrer">84557</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H492" target="_blank" rel="noopener noreferrer">Q9H492</a>', 'HUGO Gene symbol': 'MAP1LC3A', 'Protein name': 'Microtubule-associated proteins 1A/1B light chain 3A', 'Function': 'Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28382796%5Buid%5D" target="_blank" rel="noopener noreferrer">28382796</a>', 'Notes': '1) High expression of autophagy-related protein, LC3A, was detected in 78 cases (78%) in all CCC cases. 2) The patients with high LC3A expression showed significantly lower response rate to primary chemotherapy (17% vs. 100%, p<0.010), 3) had worse progression-free survival (PFS) and overall survival (OS) compared with those with LC3A low expression. 4) Inhibition of autophagy protein LC3A using hydroxychloroquine (HCQ) increased sensitivity to cisplatin in CCC cells in vitro.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP1LC3A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/81631" target="_blank" rel="noopener noreferrer">81631</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9GZQ8" target="_blank" rel="noopener noreferrer">Q9GZQ8</a>', 'HUGO Gene symbol': 'MAP1LC3B', 'Protein name': 'Microtubule-associated proteins 1A/1B light chain 3B', 'Function': 'Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes).', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26553068" target="_blank" rel="noopener noreferrer">26553068</a>', 'Notes': '1) Hypoxic exposure (1 % O2) of A549 cell stimulated autophagic induction in cancer cells, shown by increase of LC3BI to LC3BII conversion and decrease of p62/sequestosome1. 2) Hypoxic exposure also induced resistance of cancer cells to cisplatin, 3) LC3B siRNA restored the sensitivity of cancer cells to chemotherapy. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP1LC3B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5604" target="_blank" rel="noopener noreferrer">5604</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q02750" target="_blank" rel="noopener noreferrer">Q02750</a>', 'HUGO Gene symbol': 'MAP2K1', 'Protein name': 'Dual specificity mitogen-activated protein kinase kinase 1', 'Function': 'Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25408231%5Buid%5D" target="_blank" rel="noopener noreferrer">25408231</a>', 'Notes': '1) All together 1,452 eligible patients were identified. 2) Based on the ROC analysis the eight most significant genes were JRK, CNOT8, RTF1, CCT3, NFAT2CIP, MEK1, FUBP1 and CSDE1. 3) Silencing of MEK1, CSDE1, CNOT8 and RTF1, and pharmacological inhibition of MEK1 caused significant sensitization to carboplatin in the cell lines. 4) Of the eight genes, JRK (p\u2009=\u20093.2E-05), MEK1 (p\u2009=\u20090.0078), FUBP1 (p\u2009=\u20090.014) and CNOT8 (p\u2009=\u20090.00022) also correlated to progression free survival. 5) The correlation between the best biomarker candidate MEK1 and survival was validated in two independent cohorts by qRT-PCR (n\u2009=\u200934, HR\u2009=\u20095.8, p\u2009=\u20090.003) and IHC (n\u2009=\u200959, HR\u2009=\u20094.3, p\u2009=\u20090.033).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP2K1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5606" target="_blank" rel="noopener noreferrer">5606</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46734" target="_blank" rel="noopener noreferrer">P46734</a>', 'HUGO Gene symbol': 'MAP2K3', 'Protein name': 'mitogen-activated protein kinase kinase 3', 'Function': 'Dual specificity kinase, activated by cytokines and environmental stress; activates the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9926932%2C%2017406030%5Buid%5D" target="_blank" rel="noopener noreferrer">9926932, 17406030</a>', 'Notes': '1) cisplatin (cDDP) activated MAP kinase kinase kinase\xa0ASK1\xa0and subsequent downstream subgroups of MAP kinase kinase, SEK1 (or MKK4) and MKK3/MKK6, which in turn activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK) and p38 MAP kinase prior to caspase family protease activation and the onset of\xa0apoptosis\xa0in human ovarian carcinoma (OVCAR-3) and human kidney (293T) cells. 2) When the cells were exposed to various dosages of cDDP, the activities of the kinases were enhanced in a dose-dependent manner. 3) MAP2K3 is a strong promoter of tumor invasion, progression and short survival in several human cancers. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP2K3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6416" target="_blank" rel="noopener noreferrer">6416</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P45985" target="_blank" rel="noopener noreferrer">P45985</a>', 'HUGO Gene symbol': 'MAP2K4', 'Protein name': 'mitogen-activated protein kinase kinase 4', 'Function': 'Dual specificity protein kinase of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9926932%2C%2028446401%5Buid%5D" target="_blank" rel="noopener noreferrer">9926932, 28446401</a>', 'Notes': '1) As MAP2K3. 2) The expression of MAP2K4 was significantly correlated with the pathological grades of breast cancer (P=0.011). 3) patients with a high expression of MAP2K4 had a shorter overall survival rate than those with low MAP2K4 expressions (P=0.009). 4) Multivariate analysis identified high expression of MAP2K4 as the independent predictor of a poor outcome of patients with breast cancer. 5) The expressions of MAP2K4 and ER were not significantly correlated, but ER-negative patients with a high MAP2K4 expressionshowed the shortest overall survival time.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP2K4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4214" target="_blank" rel="noopener noreferrer">4214</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13233" target="_blank" rel="noopener noreferrer">Q13233</a>', 'HUGO Gene symbol': 'MAP3K1', 'Protein name': 'Mitogen-activated protein kinase kinase kinase 1', 'Function': 'Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23678002%5Buid%5D" target="_blank" rel="noopener noreferrer">23678002</a>', 'Notes': '1) treatment with CDDP resulted in down-regulation of c-Jun expression via caspase-9-dependent cleavage of c-Jun at Asp-65 and MEKK1-mediated ubiquitylation and degradation of c-Jun in CDDP-sensitive cancer cells.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP3K1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4217" target="_blank" rel="noopener noreferrer">4217</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99683" target="_blank" rel="noopener noreferrer">Q99683</a>', 'HUGO Gene symbol': 'MAP3K5', 'Protein name': 'Mitogen-activated protein kinase kinase kinase 5', 'Function': 'Mediates signaling for differentiation and survival; apoptosis signaling through mitochondria-dependent caspase activation; innate immune response (ASK1).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Immune response<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9926932%5Buid%5D" target="_blank" rel="noopener noreferrer">9926932</a>', 'Notes': '1) Expression of catalytically inactive ASK1 mutant inhibits ASK1 activation and CDDP-induced apoptosis', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP3K5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6885" target="_blank" rel="noopener noreferrer">6885</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43318" target="_blank" rel="noopener noreferrer">O43318</a>', 'HUGO Gene symbol': 'MAP3K7', 'Protein name': 'TGF-β-activating kinase 1', 'Function': 'induced by TGF beta and morphogenetic protein (BMP); in response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of NFkB', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25277189%5Buid%5D" target="_blank" rel="noopener noreferrer">25277189</a>', 'Notes': '\xa01) increased TAK1 and NF-κB signaling activities are involved in aggressive ovarian cancer cells. 2) inhibition of TAK1 can sensitize ovarian cancer cells to cisplatin-induced cell apoptosis. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAP3K7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5594" target="_blank" rel="noopener noreferrer">5594</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28482" target="_blank" rel="noopener noreferrer">P28482</a>', 'HUGO Gene symbol': 'MAPK1', 'Protein name': 'Mitogen-activated protein kinase 1', 'Function': 'the MAPK/ERK cascade. signaling cascade initiated by activated KIT and KITLG/SCF. mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> DDR<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21996734%2C%2022584435%2C%2020651982%5Buid%5D" target="_blank" rel="noopener noreferrer">21996734, 22584435, 20651982</a>', 'Notes': '1) Cisplatin treatment caused a time-dependent increase in the ratio of p-ERK1/2:total ERK1/2. 2) ERK activation increased after 24-h treatment with cisplatin and attained a peak 3.5-fold increase at 48\u2009h. 3) Cisplatin induced a similar time-dependent ERCC1 increase. 4) A similar time-dependent increase in XPF levels was observed. 5) The MEK inhibitor efficiently prevented this cisplatin-induced increase in ERCC1 protein. 6) Cisplatin treatment combined with specific inhibitors to each MAPK pathway (c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38) resulted in decreased ATF3 induction at the protein level. MAPK pathway inhibition led to decreased ATF3 messenger RNA expression and reduced cytotoxic effects of cisplatin. 7) In a multivariate analysis, among patients with TNBC, those with ERK-2-overexpressing tumors had a lower overall survival rate than those with low ERK-2-expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19-6.41). 8) high pMAPK levels were associated with a significantly higher relapse-free survival rate (HR, 0.66; 95% CI, 0.46-0.95). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5600" target="_blank" rel="noopener noreferrer">5600</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15759" target="_blank" rel="noopener noreferrer">Q15759</a>', 'HUGO Gene symbol': 'MAPK11', 'Protein name': 'Mitogen-activated protein kinase 11', 'Function': 'one of the four p38 MAPKs', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12637505%2C%2017406030%2C%2015386344%5Buid%5D" target="_blank" rel="noopener noreferrer">12637505, 17406030, 15386344</a>', 'Notes': '1) Cisplatin induced activation of three MAPKs, JNK, p38, and ERK, in a cisplatin-sensitive human ovarian carcinoma cell line (2008) and its resistant subclone (2008C13). 2) The JNK and p38 pathways were activated differentially in response to cisplatin, with the cisplatin-sensitive cells showing prolonged activation (8–12 h) and the cisplatin-resistant cells showing only transient activation (1–3 h) of JNK and p38. 3) In the sensitive cells, inhibition of cisplatin-induced JNK and p38 activation blocked cisplatin-induced apoptosis; 4) persistent activation of JNK resulted in hyperphosphorylation of the c-Jun transcription factor, which in turn stimulated the transcription of an immediate downstream target, the death inducer Fas ligand (FasL).\xa05) As MAP2K3. ', 'Up / down in Pt-resistant cells': 'DOWN/DEPHOS', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'Long-term PHOS in S; short-term PHOS in R', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6300" target="_blank" rel="noopener noreferrer">6300</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P53778" target="_blank" rel="noopener noreferrer">P53778</a>', 'HUGO Gene symbol': 'MAPK12', 'Protein name': 'Mitogen-activated protein kinase 12', 'Function': 'one of the four p38 MAPKs', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12637505%2C%2019620494%2C%2015386344%5Buid%5D" target="_blank" rel="noopener noreferrer">12637505, 19620494, 15386344</a>', 'Notes': '1) As MAPK11. 2) At the end of the study, 89% of urothelial carcinoma patients with low MAPK12 and GSTM3 expressions had survived, 3) 0% of patients with normal or high MAPK12 and high ICAM1 expressions had survived. 4) Patients with low MAPK12 and normal or high GSTM3 expressions and those with normal or high MAPK12 and low or normal ICAM1 expressions had intermediate survival rates. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'Long-term PHOS in S; short-term PHOS in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK12" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5603" target="_blank" rel="noopener noreferrer">5603</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15264" target="_blank" rel="noopener noreferrer">O15264</a>', 'HUGO Gene symbol': 'MAPK13', 'Protein name': 'Mitogen-activated protein kinase 13', 'Function': 'one of the four p38 MAPKs', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12637505%2C%2015386344%5Buid%5D" target="_blank" rel="noopener noreferrer">12637505, 15386344</a>', 'Notes': '1) As MAPK11. ', 'Up / down in Pt-resistant cells': 'DOWN/DEPHOS', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'Long-term PHOS in S; short-term PHOS in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1432" target="_blank" rel="noopener noreferrer">1432</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16539" target="_blank" rel="noopener noreferrer">Q16539</a>', 'HUGO Gene symbol': 'MAPK14', 'Protein name': 'Mitogen-activated protein kinase 14', 'Function': 'one of the four p38 MAPKs', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12637505%2C%2029956791%2C%2015386344%5Buid%5D" target="_blank" rel="noopener noreferrer">12637505, 29956791, 15386344</a>', 'Notes': '1) As MAPK11. 2) a significant correlation between IL‑12Rβ2 and p38MAPK expression (r=0.415, P=0.0143). 3) positive IL‑12Rβ2 and p38MAPK expression was associated with increased OS compared with negative protein expression in NSCLC. 4) The Cox proportional hazard models revealed that IL‑12Rβ2 and p38MAPK predicted a long OS. ', 'Up / down in Pt-resistant cells': 'DOWN/DEPHOS', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'Long-term PHOS in S; short-term PHOS in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK14" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5595" target="_blank" rel="noopener noreferrer">5595</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27361" target="_blank" rel="noopener noreferrer">P27361</a>', 'HUGO Gene symbol': 'MAPK3', 'Protein name': 'Mitogen-activated protein kinase 3', 'Function': 'the MAPK/ERK cascade. signaling cascade initiated by activated KIT and KITLG/SCF. mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> DDR<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21996734%2C%2020651982%5Buid%5D" target="_blank" rel="noopener noreferrer">21996734, 20651982</a>', 'Notes': '1) As MAPK1. 2) Positive pAMPK, NUAK2, MAPK3/1, and PDK-1 expression was observed in 379 (61.0%), 257 (41.4%), 327 (52.7%), and 67 (10.8%) gastric cancer cases, respectively. 3) Multivariate survival analysis showed that the survival for the patients with negative expression of pAMPK was worse than for the patients with the weak to strong positive expression [disease free survival (DFS): hazard ratio (HR)=1.361, P=0.029), and 4) the negative expression of MAPK3/1 was also associated with a worse survival compared to the positive expression (DFS: HR=1.401, p=0.029). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5599" target="_blank" rel="noopener noreferrer">5599</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P45983" target="_blank" rel="noopener noreferrer">P45983</a>', 'HUGO Gene symbol': 'MAPK8', 'Protein name': 'Mitogen-activated protein kinase 8', 'Function': 'involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. Phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24865582%2C%2016105650%2C%2029423673%2C%2020651982%2C%2015386344%5Buid%5D" target="_blank" rel="noopener noreferrer">24865582, 16105650, 29423673, 20651982, 15386344</a>', 'Notes': '1) Blocking the JNK-1, the major activator of c-Jun phosphorylation, reduced the expression of pre-microRNA mir-21 and increased the expression of its well-known target gene, PDCD4 and sensitize CDDP-resistant ovarian cancer cells. 2) Cisplatin treatment combined with specific inhibitors to each MAPK pathway (c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38) resulted in decreased ATF3 induction at the protein level. MAPK pathway inhibition led to decreased ATF3 messenger RNA expression and reduced cytotoxic effects of cisplatin. 3) Inhibition of JNK activity by transfection with a dominant negative allele of JNK blocked CDDP-induced apoptosis significantly in A2780 cells. 4) Selective stimulation of the JNK pathway by lipofectamine-mediated delivery of recombinant JNK1 led to activation of c-Jun and decrease of extracellular H2O2, as well as apoptosis sensitization to CDDP in A2780/DDP cells. 5) Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5601" target="_blank" rel="noopener noreferrer">5601</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P45984" target="_blank" rel="noopener noreferrer">P45984</a>', 'HUGO Gene symbol': 'MAPK9', 'Protein name': 'Mitogen-activated protein kinase 9', 'Function': 'In the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> Oncogene signaling/MAPK<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23678002%2C%2023365645%2C%2015386344%20%5Buid%5D" target="_blank" rel="noopener noreferrer">23678002, 23365645, 15386344¬†</a>', 'Notes': '1) activation of JNK2 (but not JNK1) phosphorylated and up-regulated the expression of c-Jun in CDDP-resistant cells. 2) Activated c-Jun bound to the promoter regions of the MDR1 gene and promoted the expression of MDR1. 3) Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAPK9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22983" target="_blank" rel="noopener noreferrer">22983</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y2H9" target="_blank" rel="noopener noreferrer">Q9Y2H9</a>', 'HUGO Gene symbol': 'MAST1', 'Protein name': 'Microtubule-associated serine/threonine-protein kinase 1', 'Function': 'Appears to link the dystrophin/utrophin network with microtubule filaments via the syntrophins.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30033091%5Buid%5D" target="_blank" rel="noopener noreferrer">30033091</a>', 'Notes': '1) cisplatin but no other DNA-damaging agents inhibit the MAPK pathway by dissociating cRaf from MEK1, while MAST1 replaces cRaf to reactivate the MAPK pathway in a cRaf-independent manner. 2) MAST1 expression levels, both protein and mRNA, were upregulated in cisplatin-resistant (cisR) cells that were chronically exposed to cisplatin, compared with parental cells. 3) expression of MAST1, both initial and cisplatin-induced, contributes to platinum resistance and worse clinical outcome. 4) Targeting MAST1 with lestaurtinib, a recently identified MAST1 inhibitor, restores cisplatin sensitivity, leading to the synergistic attenuation of cancer cell proliferation and tumor growth in human cancer cells and patient-derived xenograft models. 5) In 97 HNSCC patient cases who received platinum-containing therapy or non-platinum-\nbased therapy such as radiation or surgery, Resistant group showed significantly higher MAST1 and phospho-\nMEK1 levels compared with the Sensitive group in both pre- and post-treatment tumor samples. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAST1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4154" target="_blank" rel="noopener noreferrer">4154</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NR56" target="_blank" rel="noopener noreferrer">Q9NR56</a>', 'HUGO Gene symbol': 'MBNL1', 'Protein name': 'Muscleblind-like protein 1', 'Function': 'Mediates pre-mRNA alternative splicing regulation. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31791583%5Buid%5D" target="_blank" rel="noopener noreferrer">31791583</a>', 'Notes': '1) MBNL1 might be involved in the occurrence and poor prognosis of cervical cancer, and 2) MBNL1 could regulate the resistance of HeLa cells to cisplatin via Nrf2. 3) MBNL1 upregulated the degradation of Nrf2 protein by increasing the mRNA stability of Cul3.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MBNL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4170" target="_blank" rel="noopener noreferrer">4170</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q07820" target="_blank" rel="noopener noreferrer">Q07820</a>', 'HUGO Gene symbol': 'MCL1', 'Protein name': 'Induced myeloid leukemia cell differentiation protein Mcl-1', 'Function': 'Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19634140%2C%2012036450%2C%2016361547%5Buid%5D" target="_blank" rel="noopener noreferrer">19634140, 12036450, 16361547</a>', 'Notes': '1) concomitant inhibition of both BCL-X(L) and MCL1 lead to massive apoptosis in absence of cisplatin, this multi-targeted RNAi approach being much more efficient than conventional chemotherapy. 2) in presence of a low concentration of cisplatin, the concomitant down-regulation of Bcl-X(L) and MCL-1 allowed a complete annihilation of ovarian tumour cells population thus avoiding subsequent recurrence in vitro in cell lines highly refractory to any type of conventional chemotherapy. 3) The expression levels of BAX and MCL-1 mRNA were significantly higher in ovarian cancers and in adenomas than in normal ovaries (P < 0.05). 4) low BAX mRNA expression and high MCL-1 mRNA expression significantly correlate with poor survival for patients with stage III ovarian carcinomas (BAX, P = 0.05; MCL-1, P = 0.02). 5) diffuse-positive expression of MCL-1 protein significantly correlates with advanced clinical stage, high histologic grade, and poor survival (stage, P < 0.01; grade, P = 0.01; survival, P = 0.01). 6) Mcl-1, VEGFR2, and 14-3-3sigma expression might predict primary response against radiotherapy and cisplatin-based chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MCL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84515" target="_blank" rel="noopener noreferrer">84515</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UJA3" target="_blank" rel="noopener noreferrer">Q9UJA3</a>', 'HUGO Gene symbol': 'MCM8', 'Protein name': 'DNA helicase MCM8', 'Function': 'Component of the MCM8-MCM9 complex, a complex involved in the repair of double-stranded DNA breaks (DBSs) and DNA interstrand cross-links (ICLs) by homologous recombination (HR)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30648820%2C%2023401855.%2026215093%5Buid%5D" target="_blank" rel="noopener noreferrer">30648820, 23401855, 26215093</a>', 'Notes': '1) knockout of\xa0MCM9 or knockdown of\xa0MCM8 selectively hypersensitized transformed cells to cisplatin and olaparib. 2) knocking out\xa0MCM9 increased the sensitivity of\xa0HCT116 xenograft tumors to cisplatin.\xa03) MCM8 and MCM9 proteins are rapidly recruited to DNA damage sites and promote RAD51 recruitment. 4) MCM8-9 is required for DNA resection by MRN (MRE11-RAD50-NBS1) at DSBs to generate ssDNA. MCM8-9 interacts with MRN and is required for the nuclease activity and stable association of MRN with DSBs. The ATPase motifs of MCM8-9 are required for recruitment of MRE11 to foci of DNA damage. 5) Homozygous deletion of the MCM9 found in various cancers sensitizes a cancer cell line to interstrand-crosslinking (ICL) agents. A cancer-derived point mutation or an SNP on MCM8 associated with premature ovarian failure (POF) diminishes the functional activity of MCM8. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MCM8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/254394" target="_blank" rel="noopener noreferrer">254394</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NXL9" target="_blank" rel="noopener noreferrer">Q9NXL9</a>', 'HUGO Gene symbol': 'MCM9', 'Protein name': 'DNA helicase MCM9', 'Function': 'Component of the MCM8-MCM9 complex, a complex involved in the repair of double-stranded DNA breaks (DBSs) and DNA interstrand cross-links (ICLs) by homologous recombination (HR)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30648820%2C%2023401855.%2026215093%5Buid%5D" target="_blank" rel="noopener noreferrer">30648820, 23401855, 26215093</a>', 'Notes': '1) knockout of\xa0MCM9 or knockdown of\xa0MCM8 selectively hypersensitized transformed cells to cisplatin and olaparib. 2) knocking out\xa0MCM9 increased the sensitivity of\xa0HCT116 xenograft tumors to cisplatin.\xa03) MCM8 and MCM9 proteins are rapidly recruited to DNA damage sites and promote RAD51 recruitment. 4) MCM8-9 is required for DNA resection by MRN (MRE11-RAD50-NBS1) at DSBs to generate ssDNA. MCM8-9 interacts with MRN and is required for the nuclease activity and stable association of MRN with DSBs. The ATPase motifs of MCM8-9 are required for recruitment of MRE11 to foci of DNA damage. 5) Homozygous deletion of the MCM9 found in various cancers sensitizes a cancer cell line to interstrand-crosslinking (ICL) agents. A cancer-derived point mutation or an SNP on MCM8 associated with premature ovarian failure (POF) diminishes the functional activity of MCM8. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MCM9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4193" target="_blank" rel="noopener noreferrer">4193</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00987" target="_blank" rel="noopener noreferrer">Q00987</a>', 'HUGO Gene symbol': 'MDM2', 'Protein name': 'E3 ubiquitin-protein ligase Mdm2', 'Function': 'mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27646943%2C%2026876197%2C%2015790436%5Buid%5D" target="_blank" rel="noopener noreferrer">27646943, 26876197, 15790436</a>', 'Notes': '1) cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two- to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. 2) Although reduced p53 stability in 2780CP/Cl-16 cells was associated with moderate cellular overexpression of MDM2 or MDM4 (<1.5-fold), their binding to p53 was substantially enhanced (five- to eightfold). 3) downregulation of MDM2 or MDM4 by small interfering RNA in either resistant cell line induced p53 and restored p21 transactivation at 37\u2009°C, as did cisplatin-induced DNA damage at 32.5\u2009°C that coincided with reduced p53-MDM4 binding and cisplatin resistance. 4) Fifty-four percent and 33% of cases stained positive for p53 and mdm2, respectively. 5) mdm2 expression predicted of chemosensitivity and it was related with higher grade but not with other clinicopathological variables. 6) Significantly poorer survival was seen for those with p53 (P < 0.05) or mdm2 (P < 0.01) positive tumors than those with negative p53 or mdm2 staining. 7) Coexpression of p53 and mdm2 was also related to poor outcome (P < 0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MDM2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4194" target="_blank" rel="noopener noreferrer">4194</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15151" target="_blank" rel="noopener noreferrer">O15151</a>', 'HUGO Gene symbol': 'MDM4', 'Protein name': 'Protein Mdm4', 'Function': 'Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions.', 'Putative_mechanism_associated_with_Pt_resistance': 'p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27646943%2C%2026876197%2C%2022937789%5Buid%5D" target="_blank" rel="noopener noreferrer">27646943, 26876197, 22937789</a>', 'Notes': '1) As MDM2. 2) FL‐MDM4 and S‐MDM4 overexpression are indicators of p53 aberrations in CLL patients, suggesting that those patients have a poor prognosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MDM4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9833" target="_blank" rel="noopener noreferrer">9833</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14680" target="_blank" rel="noopener noreferrer">Q14680</a>', 'HUGO Gene symbol': 'MELK', 'Protein name': 'Maternal embryonic leucine zipper kinase', 'Function': 'Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19830698%2C%2019671159%2C%2028214016%5Buid%5D" target="_blank" rel="noopener noreferrer">19830698, 19671159, 28214016</a>', 'Notes': '1) AS FAU. 2) Elevated MELK expression was correlated with histological grading (n=6 data sets, p<0.05) and poor progression-free survival (HR 5.73, p<0.01) in OC patients and elevated MELK expression in other cancers with disease-free survival (n=3495, HR 1.071, p<0.001). 3) Inhibition or depletion of MELK reduced cell proliferation and anchorage-dependent and -independent growth in various OC cell lines through a G2/M cell cycle arrest, eventually resulting in apoptosis. 4) OTSSP167 retained its cytotoxicity in Cisplatin- and Paclitaxel-resistant IGROV1 and TYK-nu OC cells and sensitized OVCAR8 cells to Carboplatin but not Paclitaxel.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MELK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4221" target="_blank" rel="noopener noreferrer">4221</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00255" target="_blank" rel="noopener noreferrer">O00255</a>', 'HUGO Gene symbol': 'MEN1', 'Protein name': 'Menin / Multiple endocrine neoplasia type 1', 'Function': "Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. ", 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21127195%5Buid%5D" target="_blank" rel="noopener noreferrer">21127195</a>', 'Notes': '1) Menin inhibits AKT1 mediated cell proliferation and anti-apoptosis effects against cisplatin. 2) Menin terminating AKT activity partially through blocking its translocation from the cytoplasm to the plasma membrane. 3) expression of HA-AKT1, but not expression of menin or coexpression of HA-AKT1 and menin, suppressed cisplatin-induced release of free nucleosomal DNA: menin can suppress AKT1-mediated cell proliferation and antiapoptotic effects.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MEN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4233" target="_blank" rel="noopener noreferrer">4233</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08581" target="_blank" rel="noopener noreferrer">P08581</a>', 'HUGO Gene symbol': 'MET', 'Protein name': 'Hepatocyte growth factor receptor', 'Function': 'Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/HGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27384994%2C%209215689%2C%2022820099%5Buid%5D" target="_blank" rel="noopener noreferrer">27384994, 9215689, 22820099</a>', 'Notes': '1) hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) 2) this effect is mediated by the p38 mitogen-activated protein kinase. 3) In nonovarian cancer cell models, as expected, HGF provides protection from drug-induced apoptosis. 4) patients with c-Met-high EOC showed significantly worse survival than those with c-Met-low tumor. 5) inhibition of c-Met activity by PHA-665752 or blockade of the interaction of autocrined HGF with c-Met with neutralizing anti-HGF antibody promoted cisplatin efficacy in osteosarcoma cells, 6) addition of recombinant human HGF (rh-HGF) counteracts cisplatin cytotoxicity. 7) inhibition of c-Met activity led to suppression of the PI3K-Akt pathway, thus enhancing cisplatin chemosensitivity. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MET" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/131965" target="_blank" rel="noopener noreferrer">131965</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TCB7" target="_blank" rel="noopener noreferrer">Q8TCB7</a>', 'HUGO Gene symbol': 'METTL6', 'Protein name': 'tRNA N(3)-methylcytidine methyltransferase METTL6', 'Function': 'S-adenosyl-L-methionine-dependent methyltransferase that mediates N3-methylcytidine modification of residue 32 of the tRNA anticodon loop of tRNA(Ser); regulates pluripotency and tumor cell growth (32923617)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21775533%5Buid%5D" target="_blank" rel="noopener noreferrer">21775533</a>', 'Notes': '1) Among 157 successfully genotyped SNPs, 9 and 10 SNPs were top SNPs associated with OS for patients with NSCLC and SCLC, respectively, although they were not significant after adjusting for multiple testing. 2) Fifteen genes, including 7 located within 200 kb up or downstream of the 4 top SNPs and 8 genes for which expression was correlated with 3 SNPs in LCLs were selected for siRNA screening. 3) Knockdown of DAPK3 and METTL6, for which expression levels were correlated with the rs11169748 and rs2440915 SNPs, significantly decreased cisplatin sensitivity in lung cancer cells.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=METTL6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4245" target="_blank" rel="noopener noreferrer">4245</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26572" target="_blank" rel="noopener noreferrer">P26572</a>', 'HUGO Gene symbol': 'MGAT1', 'Protein name': 'Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase', 'Function': 'Initiates complex N-linked carbohydrate formation. Essential for the conversion of high-mannose to hybrid and complex N-glycans.', 'Putative_mechanism_associated_with_Pt_resistance': 'Glycosylation<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20005867%5Buid%5D" target="_blank" rel="noopener noreferrer">20005867</a>', 'Notes': '1) This Pt-drug resistance feature was associated with increased expression and altered N-linked glycosylation of ATP binding cassette transporters MRP1 and MRP4. 2) Pre-treatment with tunicamycin, which inhibits the biosynthesis of N-linked oligosaccharides, results in Pt-resistance in sensitive cells and increased the electrophoretic mobility of MRP1 and MRP4, reproducing the association between decreased glycosylation of MRP1 and MRP4 and decreased Pt accumulation observed in the resistant Ovarian IGROV-1/OHP cells. 3) The observed N-glycosylation defect of Pt-resistant cells was linked to reduced levels of N-acetylglucosamine-1-phosphotransferase (GNPTG) and mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5).  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MGAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4249" target="_blank" rel="noopener noreferrer">4249</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q09328" target="_blank" rel="noopener noreferrer">Q09328</a>', 'HUGO Gene symbol': 'MGAT5', 'Protein name': 'Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A', 'Function': 'Catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharide', 'Putative_mechanism_associated_with_Pt_resistance': 'Glycosylation<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20005867%5Buid%5D" target="_blank" rel="noopener noreferrer">20005867</a>', 'Notes': '1) This Pt-drug resistance feature was associated with increased expression and altered N-linked glycosylation of ATP binding cassette transporters MRP1 and MRP4. 2) Pre-treatment with tunicamycin, which inhibits the biosynthesis of N-linked oligosaccharides, results in Pt-resistance in sensitive cells and increased the electrophoretic mobility of MRP1 and MRP4, reproducing the association between decreased glycosylation of MRP1 and MRP4 and decreased Pt accumulation observed in the resistant Ovarian IGROV-1/OHP cells. 3) The observed N-glycosylation defect of Pt-resistant cells was linked to reduced levels of N-acetylglucosamine-1-phosphotransferase (GNPTG) and mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (MGAT5).  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MGAT5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4255" target="_blank" rel="noopener noreferrer">4255</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16455" target="_blank" rel="noopener noreferrer">P16455</a>', 'HUGO Gene symbol': 'MGMT', 'Protein name': 'Methylated-DNA--protein-cysteine methyltransferase', 'Function': 'Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/direct repair', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25693518%5Buid%5D" target="_blank" rel="noopener noreferrer">25693518</a>', 'Notes': '1) MGMT-proficient cells were highly resistant to the cytotoxic effects of CDDP as compared to MGMT-deficient cells. 2) the platinum level of DNA after CDDP exposure was significantly lower in MGMT-proficient cells than in MGMT-deficient cells. 3) MGMT protected nasopharyngeal carcinoma (NPC) cells from CDDP-induced DNA damage by enhancing DNA repair capacity. 4) MGMT protein directly bound to CDDP-induced DNA damages. Subsequently, CDDP-bound MGMT protein became ubiquitinated and was degraded through ubiquitin-mediated proteasome system. 5) in a cohort of 83 NPC patients. NPC patients who received CDDP-based concurrent chemoradiotherapy (CCRT), with high MGMT expression level, exhibited shorter progression-free survival (PFS; p\u2009=\u20090.022) and overall survival (OS; p\u2009=\u20090.015), than patients with low MGMT expression level. Furthermore, high MGMT expression level remained to be an independent prognostic factor for worse PFS (p\u2009=\u20090.01, hazard ratio 2.23) and OS (p\u2009=\u20090.018, hazard ratio 2.14).\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MGMT" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10367" target="_blank" rel="noopener noreferrer">10367</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BPX6" target="_blank" rel="noopener noreferrer">Q9BPX6</a>', 'HUGO Gene symbol': 'MICU1', 'Protein name': 'Mitochondrial Calcium Uptake 1', 'Function': 'Depending on the concentration of calcium, MICU1 acts both as an activator or inhibitor of mitochondrial calcium uptake; drives aerobic glycolysis in ovarian cancer', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Calcium signaling<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28530221%5Buid%5D" target="_blank" rel="noopener noreferrer">28530221</a>', 'Notes': '1) MICU1/CBARA1 drives aerobic glycolysis in ovarian cancer. 2) Among 126 drug-resistant tumour tissues, almost three-quarters (n=92, 73%) of samples had a moderate to high expression of MICU1 with a 95% Clopper-Pears on exact confidence interval (64%, 81%). 3) MICU1 overexpression correlates with poor overall survival (OS). 4) Silencing MICU1 in vitro increases oxygen consumption, decreases lactate production, inhibits clonal growth, migration and invasion of ovarian cancer cells, 5) silencing in vivo inhibits tumour growth, increases cisplatin efficacy and OS. 6) silencing MICU1 activates pyruvate dehydrogenase (PDH) by stimulating the PDPhosphatase-phosphoPDH-PDH axis; Forced-expression of MICU1 in normal cells phenocopies the metabolic aberrations of malignant cells. 7) a significant correlation between MICU1 and pPDH (inactive form of PDH) expression with poor prognosis. 8) MICU1 is a negative regulator of mitochondrial Ca2+ uptake silencing of which causes mitochondrial Ca2+ overload. 9) PDH which is regulated by a Ca2+-dependent phosphatase, while α-ketoglutarate- and isocitrate-dehydrogenases are regulated by direct binding of Ca2+ to these enzymes', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MICU1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84299" target="_blank" rel="noopener noreferrer">84299</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BRT3" target="_blank" rel="noopener noreferrer">Q9BRT3</a>', 'HUGO Gene symbol': 'MIEN1', 'Protein name': 'Migration and invasion enhancer 1', 'Function': '1) Increases cell migration by inducing filopodia formation. 2) Regulates apoptosis through control of CASP3. 3) Involved in a redox-related process.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23880825%2C%2024997554%5Buid%5D" target="_blank" rel="noopener noreferrer">23880825, 24997554</a>', 'Notes': '1) C35 preferentially interacts with ΔNp73. 2) When C35 was co-expressed with ΔNp73, the level of apoptosis of ovarian cancer cells in response to cisplatin treatment was largely reduced. 3) The reduction of this response was due to the activation of AKT and an increase in NFκB activity. 4) ΔNp73 acts synergistically with C35 via their binding to induce tumour formation and to mediate chemotherapy resistance. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MIEN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4286" target="_blank" rel="noopener noreferrer">4286</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75030" target="_blank" rel="noopener noreferrer">O75030</a>', 'HUGO Gene symbol': 'MITF', 'Protein name': 'Microphthalmia-associated transcription factor', 'Function': 'Regulates the expression of genes with essential roles in cell differentiation, proliferation and survival. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> EMT<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19784067%2C%2023921446%5Buid%5D" target="_blank" rel="noopener noreferrer">19784067, 23921446</a>', 'Notes': '1) SWI/SNF chromatin remodeling enzyme BRG1 interacts with MITF to promote melanocyte differentiation. 2) Re-introduction of BRG1 in BRG1-deficient SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to\xa0cisplatin.\xa03) Downregulation of the single ATPase, BRM, in SK-MEL5 cells inhibited expression of both differentiation-specific and pro-proliferative MITF target genes and inhibited tumorigenicity in vitro. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MITF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4292" target="_blank" rel="noopener noreferrer">4292</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40692" target="_blank" rel="noopener noreferrer">P40692</a>', 'HUGO Gene symbol': 'MLH1', 'Protein name': 'DNA mismatch repair protein Mlh1', 'Function': 'Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative MMR; also involved in NHEJ (22451719)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MMR<br><br> DDR/MMR<br><br> DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9233776%2C%2030594176%2C%2032922493%2C%2015240532%5Buid%5D" target="_blank" rel="noopener noreferrer">9233776, 30594176, 32922493, 15240532</a>', 'Notes': '1) hMLH1 mRNA is decreased in independent cisplatin resistant derivatives of a human ovarian carcinoma cell line. 2) An increase in the proportion of ovarian tumours negative for the hMLH1 subunit is observed in samples taken at second look laparotomy after chemotherapy (36%: 4/11), compared to untreated tumours (10%: 4/39). 3) Over-expression of MLH1 in Ishikawa cells dramatically increased the sensitivity of cells to cisplatin and enhanced cell apoptosis. 4) knockdown of MLH1 yielded the opposite effects in vitro. 5) The level of MLH1 and MSH2 mRNA expression was lower in the recurrence (R) group compared to the no recurrence (NR) group in bladder cancer after cisplatin-based chemotherapy; therefore, PFS time was increased in the patients with MLH1 and MSH2 gene expression levels above the cutoff point. 6) plasma DNA of patients with EOC for methylation of the hMLH1 CpG island before carboplatin/taxoid chemotherapy and at relapse:  hMLH1 methylation is significantly associated with increased microsatellite instability in plasma DNA at relapse. Acquisition of hMLH1 methylation in plasma DNA at relapse predicts poor overall survival of patients, independent from time to progression and age. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MLH1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4311" target="_blank" rel="noopener noreferrer">4311</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08473" target="_blank" rel="noopener noreferrer">P08473</a>', 'HUGO Gene symbol': 'MME', 'Protein name': 'Neprilysin', 'Function': 'Thermolysin-like specificity, but is almost confined to acting on polypeptides of up to 30 amino acids', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29048400%5Buid%5D" target="_blank" rel="noopener noreferrer">29048400</a>', 'Notes': '1) cisplatin resistance was the property of only CD10−/ALDH− CSCs. 2) Molecular analysis indicated that cisplatin resistance is associated with inherent- and adaptive-specific drug efflux and DNA-damage repair mechanisms. 2) Clinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MME" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4319" target="_blank" rel="noopener noreferrer">4319</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09238" target="_blank" rel="noopener noreferrer">P09238</a>', 'HUGO Gene symbol': 'MMP10', 'Protein name': 'matrix metalloproteinase-10; Stromelysin-2', 'Function': 'Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27072580%5Buid%5D" target="_blank" rel="noopener noreferrer">27072580</a>', 'Notes': '1) MMP10 is expressed in CSCs/CICs of EOC. 2) a high expression level of MMP10 is a marker for poor prognosis and platinum resistance in multivariate analysis. 3) MMP10 gene overexpression experiments and MMP10 gene knockdown experiments using siRNAs revealed that MMP10 has a role in the maintenance of CSCs/CICs in EOC and resistance to platinum reagent. 4) MMP10 activate canonical Wnt signaling by inhibiting noncanonical Wnt signaling ligand Wnt5a. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4327" target="_blank" rel="noopener noreferrer">4327</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99542" target="_blank" rel="noopener noreferrer">Q99542</a>', 'HUGO Gene symbol': 'MMP19', 'Protein name': 'Matrix metalloproteinase-19', 'Function': 'Endopeptidase that degrades various components of the extracellular matrix; facilitates the invasion of glioma cells', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31406154%5Buid%5D" target="_blank" rel="noopener noreferrer">31406154</a>', 'Notes': '1) knockdown of MMP-19 significantly increased sensitivities of OC cell lines Skov3 and Cov362 to Carboplatin.\xa02) MMP-19 and MMP-20 high expression are related to at least some kind of anti-cancer drug resistances in OC patients.  3) high expressions of MMP-19 as well as MMP-20 predicted poor outcome, drug resistance and cancer invasion in OC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP19" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4313" target="_blank" rel="noopener noreferrer">4313</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08253" target="_blank" rel="noopener noreferrer">P08253</a>', 'HUGO Gene symbol': 'MMP2', 'Protein name': 'Ubiquitinous metalloproteinase ', 'Function': 'mediates the homeostasis of ECM and are up-regulated in almost every type of human cancer, involved in tissue remodeling, and cancer cell invasion and metastasis', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response<br><br> Oncogene signaling/EGF_FGF<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19874802%2C%2027384994%2C%2031157304%5Buid%5D" target="_blank" rel="noopener noreferrer">19874802, 27384994, 31157304</a>', 'Notes': '1) Anti-invasive properties of cisPt associated with decrease in MMP-2 activity;  Cells\xa0incubated with increasing cisPt concentrations showed dose- and time-dependent decrease of the MMP-2 protein and activity.\xa02) Of 1,065 gastric carcinoma samples, higher expression of MMP2 (HR = 1.78, p = 2.6E-09) were predictive for poor OS. 3) MMP2 knockdown significantly decreased the proliferation and increased the apoptosis of HepG2 and Huh7 cells. Co-treatment with si-MMP2 and cisplatin significantly increased the sensitivity of HepG2 and Huh7 cells to cisplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9313" target="_blank" rel="noopener noreferrer">9313</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60882" target="_blank" rel="noopener noreferrer">O60882</a>', 'HUGO Gene symbol': 'MMP20', 'Protein name': 'Matrix metalloproteinase-20', 'Function': 'Degrades amelogenin, the major protein component of the enamel matrix and two of the macromolecules characterizing the cartilage extracellular matrix', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31406154%5Buid%5D" target="_blank" rel="noopener noreferrer">31406154</a>', 'Notes': '1) knockdown of MMP-20 significantly increased sensitivities of OC cell line Cov362 to Carboplatin. 2) MMP-19 and MMP-20 high expression are related to at least some kind of anti-cancer drug resistances in OC patients. 3) high expressions of MMP-19 as well as MMP-20 predicted poor outcome, drug resistance and cancer invasion in OC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP20" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4316" target="_blank" rel="noopener noreferrer">4316</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09237" target="_blank" rel="noopener noreferrer">P09237</a>', 'HUGO Gene symbol': 'MMP7', 'Protein name': 'Matrilysin', 'Function': 'Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase; also known to cleave non-ECM proteins, such as E-cadherin and Fas ligand (FasL) (28239354)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=33396213%5Buid%5D" target="_blank" rel="noopener noreferrer">33396213</a>', 'Notes': '1) MMP-7 was shown to be involved in cisplatin resistance. 2) tissue and circulating MMP-7 levels were evaluated in 124 bladder cancer patients who received postoperative platinum-based chemotherapy. 3) Tissue MMP-7 levels were analyzed by immunohistochemistry in 72 formalin-fixed, paraffin-embedded chemo-naïve tumor samples, while MMP-7 serum concentrations were determined in 132 serum samples of an independent cohort of 52 patients. 4) MMP-7 tissue and serum levels were correlated with clinicopathological and follow-up data. MMP-7 gene expression was determined by RT-qPCR in 20 urothelial cancer cell lines and two non-malignant urothelial cell lines. 5) MMP-7 was overexpressed in RT-112 and T-24 cells by stable transfection, to assess its functional involvement in platinum sensitivity. 6) High MMP-7 tissue expression and pretreatment serum concentrations were independently associated with poor overall survival (tissue HR = 2.296, 95%CI = 1.235–4.268 and\xa0p\xa0= 0.009; serum HR = 2.743, 95%CI = 1.258–5.984 and\xa0p\xa0= 0.011).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4318" target="_blank" rel="noopener noreferrer">4318</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14780" target="_blank" rel="noopener noreferrer">P14780</a>', 'HUGO Gene symbol': 'MMP9', 'Protein name': 'matrix metalloproteinase-9', 'Function': 'degrading type IV collagen present in the basement membrane.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> Immune response<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23056490%2C%2018211683%2C%2023340649%2C%2024408020%5Buid%5D" target="_blank" rel="noopener noreferrer">23056490, 18211683, 23340649, 24408020</a>', 'Notes': '1) enhanced mRNA expression of CD44, MMP9 and Oct4 was observed in the separate adherent (AD) population of ChemoResistant (CR) ovarian cancer patients. 2)  Genes with a fold change >4, upregulated in recurrent compared to primary tumors included: Septin 6, ZNF218, S100A8, MMP9, FOXF1 and ILIR2. 3) Co-incubation of cisplatin and an MMP-9/MMP-2 inhibitor resulted in significantly greater cytotoxicity as compared to either treatment alone in a cisplatin resistant MMP-9 overexpressing cell line; A2780cis. 4) pre-incubating with MMP-9i prior to cisplatin further enhances the cytotoxic effect. 5) MMP9 mRNA and protein levels were significantly reduced in CDDP-treated cells compared to untreated ovarian CICs. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MMP9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4331" target="_blank" rel="noopener noreferrer">4331</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51948" target="_blank" rel="noopener noreferrer">P51948</a>', 'HUGO Gene symbol': 'MNAT1', 'Protein name': 'CDK-activating kinase assembly factor MAT1', 'Function': 'Stabilizes the cyclin H-CDK7 complex to form a functional CDK-activating kinase (CAK) enzymatic complex. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER<br><br> Oncogene signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30477538%2C%2010673506%2C%2033272245%5Buid%5D" target="_blank" rel="noopener noreferrer">30477538, 10673506, 33272245</a>', 'Notes': '1) MNAT1 expressions in CRC tissue samples were associated with CRC carcinogenesis and poor patient outcomes.\xa02) mediates p53 ubiquitin-degradation to promote colorectal cancer malignance. 3) TFIIH has a 6-subunit core and a 3-subunit kinase (CAK) which is composed of CDK7, Cyclin H and MAT1. TFIIH has roles both in basal transcription initiation and in DNA repair. 4) TFIIH plays a major role in NER, which is able to remove bulky lesions, such as cisplatin adducts. 5) MNAT1 was markedly over-expressed in OS tissue, highly MNAT1 expression was closely associated with bad clinical expectations. 6) MNAT1 silencing could weaken the invasion, migration and proliferation of OS cells in vitro, and inhibit OS tumor growth in vivo. 7) MNAT1 contributed to the progression of OS via the PI3K/Akt/mTOR pathway. 8) the MNAT1 was required in the regulation of OS chemo-sensitivity to cisplatin (DDP).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MNAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64112" target="_blank" rel="noopener noreferrer">64112</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96BY2" target="_blank" rel="noopener noreferrer">Q96BY2</a>', 'HUGO Gene symbol': 'MOAP1', 'Protein name': 'modulator of apoptosis 1', 'Function': 'stimulates activation of the pro-apoptotic Bcl-2 family protein Bax', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27721409%5Buid%5D" target="_blank" rel="noopener noreferrer">27721409</a>', 'Notes': '1) the HECT (homologous to the E6-AP carboxyl terminus) family E3 ubiquitin ligase, UBR5, as a novel ubiquitin ligase for MOAP-1. 2) UBR5 interacts physically with MOAP-1, ubiquitylates MOAP-1 in vitro and inhibits MOAP-1 stability in cultured cells. 3) Dyrk2 kinase, a reported UBR5 interactor, cooperates with UBR5 in mediating MOAP-1 ubiquitylation.4) cisplatin-resistant ovarian cancer cell lines exhibit lower levels of MOAP-1 accumulation than their sensitive counterparts upon cisplatin treatment, consistent with the previously reported role of MOAP-1 in modulating cisplatin-induced apoptosis. 5) UBR5 knockdown increased MOAP-1 expression, enhanced Bax activation and sensitized otherwise resistant cells to cisplatin-induced apoptosis. 6) UBR5 expression was higher in ovarian cancers from cisplatin-resistant patients than from cisplatin-responsive patients.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MOAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4361" target="_blank" rel="noopener noreferrer">4361</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49959" target="_blank" rel="noopener noreferrer">P49959</a>', 'HUGO Gene symbol': 'MRE11', 'Protein name': 'Double-strand break repair protein MRE11', 'Function': 'Knockdown results in fork stabilization and PARPi resistance', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27798884%2C%2024215868%5Buid%5D" target="_blank" rel="noopener noreferrer">27798884, 24215868</a>', 'Notes': "PARPi resistance (D'Andrea) AACR presentation. 1) The expression of MRN complex was significantly associated with clinical factors including poorer prognosis and negatively associated with the expression of DNA damage marker phosphorylated H2A histone family, member X (γH2AX) in the nucleus. 2) In the biopsy specimens, low expression of MRE11 correlated with good response to chemotherapy and surgical resection after down-staging by chemotherapy. 3) the expression levels of MRE11 and RAD50 were independent predictors of surgical resection after chemotherapy. 4) CRC cells harboring biallelic MRE11 mutations were more sensitive to LT-626 and stable overexpression or knock-down of MRE11 in cell lines correlated with sensitivity. Synergism was evident between LT-626 and cisplatin. 5) Sensitivity to cisplatin and the PARP inhibitor BMN-673 was correlated with HR status. BRCA1, BRCA2, MRE11 and PTEN loss of expression was investigated as a potential determinant of BMN-673 sensitivity.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MRE11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4436" target="_blank" rel="noopener noreferrer">4436</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P43246" target="_blank" rel="noopener noreferrer">P43246</a>', 'HUGO Gene symbol': 'MSH2', 'Protein name': 'DNA mismatch repair protein Msh2', 'Function': 'Mismatch repair, platinum pathway; forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MMR<br><br> DDR/MMR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21696631%2C%2015947132%2C%2026519826%5Buid%5D" target="_blank" rel="noopener noreferrer">21696631, 15947132, 26519826</a>', 'Notes': '1) cisplatin induced p53, XPC and XPA and suppressed MSH2 consistent with resistant phenotype. 2) MSH2 missense mutations that were identified in tumors or as polymorphic variations can cause increased cisplatin tolerance independent of an initial mutator phenotype. 3) Mismatch repair (MMR) deficiency gives rise to cisplatin resistance and can lead to poor prognosis in cancers. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSH2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4437" target="_blank" rel="noopener noreferrer">4437</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P20585" target="_blank" rel="noopener noreferrer">P20585</a>', 'HUGO Gene symbol': 'MSH3', 'Protein name': 'DNA mismatch repair protein Msh3', 'Function': 'Mismatch repair. Heterodimerizes with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair; plays an important role in repairing DNA double strand breaks, beyond its function in MMR (21285347)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> DDR/MMR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27578576%2C%2025966119%2C%2030038702%2C%2010470370%2C%2021285347%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27578576, 25966119, 30038702, 10470370, 21285347¬†</a>', 'Notes': '1) Silencing\xa0MSH3\xa0expression enhances\xa0cisplatin\xa0sensitivity of human tongue cancer cells. 2) shRNA knockdown of MSH3 sensitized cells to both cisplatin and oxaliplatin at clinically relevant doses. 3) MSH3-deficient cells maintained higher levels of phosphorylated histone H2AX and 53BP1 after oxaliplatin treatment in comparison with MSH3-proficient cells, suggesting that MSH3 plays an important role in repairing DNA double strand breaks (DSBs). 4) This role of MSH3 was further supported by our findings that MSH3-deficient cells were sensitive to olaparib, a poly(ADP-ribose) polymerase inhibitor. 5) A statistically significant association was observed between the polymorphism rs26279 (Ala1054Thr) and sensitivity to platinum-based chemotherapy (P = 0.014) in a total of 180 patients with advanced NSCLC. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSH3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4439" target="_blank" rel="noopener noreferrer">4439</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43196" target="_blank" rel="noopener noreferrer">O43196</a>', 'HUGO Gene symbol': 'MSH5', 'Protein name': 'MutS protein homolog 5', 'Function': 'Involved in meiotic recombination in association with MSH4.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> DDR/MMR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22401567%5Buid%5D" target="_blank" rel="noopener noreferrer">22401567</a>', 'Notes': '1) MSH5 undergoes cisplatin-elicited protein induction and tyrosine phosphorylation in kidney 293 cells and lung cancer A549 cells.\xa02) Silencing of MSH5 by RNAi or expression of hMSH5 phosphorylation-resistant mutant hMSH5Y742F elevates cisplatin-induced G2 arrest and renders cells susceptible to cisplatin toxicity at clinically relevant doses. 3) a possible role for hMSH5 in recombinational repair of cisplatin-triggered double-strand breaks (DSBs). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSH5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2956" target="_blank" rel="noopener noreferrer">2956</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52701" target="_blank" rel="noopener noreferrer">P52701</a>', 'HUGO Gene symbol': 'MSH6', 'Protein name': 'DNA mismatch repair protein Msh6', 'Function': 'Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA mismatches thereby initiating DNA repair. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MMR<br><br> DDR/MMR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19286655%2C%2026519826%2C%2029063235%5Buid%5D" target="_blank" rel="noopener noreferrer">19286655, 26519826, 29063235</a>', 'Notes': '1) MSH6-deficient cells were more tolerant of CDDP than MSH6-proficient cells (IC50\xa09.8 ± 2.4\xa0versus\xa06.1 ± 0.4,\xa0p\xa0< 0.05). 2) the MutSα (MSH2-MSH6) heterocomplex is required to maintain cisplatin sensitivity, whereas the Mutsβ complex has no effect. 3) These results can be correlated with the increased repair of cisplatin ICLs and ICL induced DNA double strand breaks (DSBs) in the resistant cells. 4) Among seven MMR genes, high mRNA levels of MSH6, MLH1 and PMS2 were significantly associated with a better overall survival for all ovarian cancer patients treated with platinum-based chemotherapy, especially in late-stage and poor-differentiated ovarian cancer patients. Increased MSH6 and PMS2 mRNA expression was correlated with a favorable overall survival in serous ovarian cancer patients.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSH6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10232" target="_blank" rel="noopener noreferrer">10232</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13421" target="_blank" rel="noopener noreferrer">Q13421</a>', 'HUGO Gene symbol': 'MSLN', 'Protein name': 'Mesothelin', 'Function': 'Membrane glycoprotein frequently over-expressed in various malignancies, may play a role in cellular adhesion; its cleavage product, Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro; promotes EMT (28288645)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24465798%5Buid%5D" target="_blank" rel="noopener noreferrer">24465798</a>', 'Notes': '1) MSLN-siRNA combined with cisplatin, triggered a marked increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting a sensitizing effect of siRNA towards cisplatin in malignant pleural mesothelioma.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSLN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4487" target="_blank" rel="noopener noreferrer">4487</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28360" target="_blank" rel="noopener noreferrer">P28360</a>', 'HUGO Gene symbol': 'MSX1', 'Protein name': 'Msh homeobox 1', 'Function': 'Transcriptional repressor, the homeodomain of Msx1 functions as a protein-protein interacting motif rather than a DNA-binding domain and is essential for stabilization, nuclear accumulation, and apoptotic function of wild-type p53 (15705871). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26763252%5Buid%5D" target="_blank" rel="noopener noreferrer">26763252</a>', 'Notes': '1) CpG sites at contiguous genomic locations within the MSX1 gene have significantly lower levels of methylation in independent cohorts of HGSOC patients, which recur by 6 months compared with after 12 months (P < 0.05, q < 0.05, n = 78), have poor RECIST response (P < 0.05, q < 0.05, n = 61), and are associated with PFS in an independent cohort (n = 146). 2) A decrease in methylation at these CpG sites correlates with decreased MSX1 gene expression. 3) MSX1 expression is associated with PFS (HR, 0.92; 95% CI, 0.85-0.99; P = 0.029; n = 309). 4) Cisplatin-resistant ovarian cancer cell lines have reduced MSX1 expression, 5) MSX1 overexpression leads to cisplatin sensitization, increased apoptosis, and increased cisplatin-induced p21 expression.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4489" target="_blank" rel="noopener noreferrer">4489</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04731" target="_blank" rel="noopener noreferrer">P04731</a>', 'HUGO Gene symbol': 'MT1A', 'Protein name': 'Metallothionein-1A', 'Function': 'Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=3175622%2C%209216861%2C%2029854276%2C%2024924344%5Buid%5D" target="_blank" rel="noopener noreferrer">3175622, 9216861, 29854276, 24924344</a>', 'Notes': '1) Tumor cell lines with acquired resistance to the antineoplastic agent cisplatin overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. 2) Human carcinoma cells that maintained high levels of metallothionein because of chronic exposure to heavy metals were resistant to cisplatin, melphalan, and chlorambucil. 3) Overexpression of MT in the tumor was found in 70.6% of the patients. 4) Among 43 patients treated with cisplatin, the 5-year survival rate was 56% for MT-negative and 26% for MT-positive patients (p = 0.0277). 5) SNPs in ABCC5, MT1A, and NQO1 were significantly associated with oxaliplatin drug response. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MT1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4502" target="_blank" rel="noopener noreferrer">4502</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02795" target="_blank" rel="noopener noreferrer">P02795</a>', 'HUGO Gene symbol': 'MT2A', 'Protein name': 'Metallothionein-2', 'Function': 'platinum pathway', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=3175622%2C%209216861%2C%2029854276%2C%2033122816%5Buid%5D" target="_blank" rel="noopener noreferrer">3175622, 9216861, 29854276, 33122816</a>', 'Notes': '1) Tumor cell lines with acquired resistance to the antineoplastic agent cisplatin overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. 2) Human carcinoma cells that maintained high levels of metallothionein because of chronic exposure to heavy metals were resistant to cisplatin, melphalan, and chlorambucil. 3) Overexpression of human metallothionein-IIA led to resistance to cisplatin, melphalan, and chlorambucil but not to 5-fluorouracil or vincristine.. 4) Overexpression of MT in the tumor was found in 70.6% of the patients. 5) Among 43 patients treated with cisplatin, the 5-year survival rate was 56% for MT-negative and 26% for MT-positive patients (p = 0.0277). 6) Knockdown of MT2A expression levels resulted in significantly induced apoptotic rates during cisplatin treatment in MPM cell lines. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MT2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4504" target="_blank" rel="noopener noreferrer">4504</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25713" target="_blank" rel="noopener noreferrer">P25713</a>', 'HUGO Gene symbol': 'MT3', 'Protein name': 'Metallothionein-3', 'Function': 'Binds heavy metals. Contains three zinc and three copper atoms per polypeptide chain and only a negligible amount of cadmium. Inhibits survival and neurite formation of cortical neurons in vitro.', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16061661%2C%2027623342%2C%2029808689%2C%2033750814%20%5Buid%5D" target="_blank" rel="noopener noreferrer">16061661, 27623342, 29808689, 33750814¬†</a>', 'Notes': '1) Microarray analysis revealed 51 genes whose mRNA increased by at least 2-fold in PE01CDDP cells relative to PE01 (including FRA1, ETV4, MCM2, AXL,\xa0MT3, TRAP1, and FANCG). 2) the differentiation of PC12 cells into neurons induced MT-3 expression, thereby resulting in intracellular Cu accumulation and cisplatin resistance. 3) overexpression of MT3 reduced sensitivity of MT-3 transfected cells to CDDP. 4) We confirmed the cisplatin-metallothionein complex formation using mass spectrometry. 5) Overexpression of hMT3 decreased the sensitivity of neuroblastoma UKF-NB-4 cells to cisplatin. 6) cisplatin-sensitive human UKF-NB-4 cells remodelled into cisplatin-resistant cells via high and constitutive hMT3 expression in an in vivo model using chick chorioallantoic membrane assay. 7) several biological pathways related to apoptosis, transport, proteasome, and cellular stress were involved in cisplatin-resistance in hMT3 overexpressing UKF-NB-4 cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MT3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4514" target="_blank" rel="noopener noreferrer">4514</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00414" target="_blank" rel="noopener noreferrer">P00414</a>', 'HUGO Gene symbol': 'MT-CO3', 'Protein name': 'Cytochrome c oxidase subunit 3', 'Function': 'Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31534516%5Buid%5D" target="_blank" rel="noopener noreferrer">31534516</a>', 'Notes': '1) Differential microarray analysis identified downregulation of mitomiR-5787 in Cal27-re cells. 2) The sensitivity of tongue squamous cell carcinoma (TSCC) cells to cisplatin was regulated by miR-5787: reduced expression of miR-5787 changed the balance of glucose metabolism by shifting it from oxidative phosphorylation to aerobic glycolysis. Xenograft experiments in BALB/c-nu mice further verified the\xa0in vitro\xa0results. 3) Reduced expression of miR-5787 contributes to chemoresistance in TSCC cells by inhibiting the translation of mitochondrial cytochrome c oxidase subunit 3 (MT-CO3). 4) The prognostic analysis of 126 TSCC patients showed that the patients with low expression of miR-5787 and/or MT-CO3 had poor cisplatin sensitivity and prognosis.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MT-CO3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/92140" target="_blank" rel="noopener noreferrer">92140</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86UE4" target="_blank" rel="noopener noreferrer">Q86UE4</a>', 'HUGO Gene symbol': 'MTDH', 'Protein name': 'astrocyte elevated gene-1', 'Function': 'Downregulates SLC1A2/EAAT2 promoter; activates NF-kappa-B\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22372608%2C%2025684730%5Buid%5D" target="_blank" rel="noopener noreferrer">22372608, 25684730</a>', 'Notes': '1) The frequency and intensity of immunohistochemical AEG-1 expression increased in a step-wise fashion from normal to chemosensitive to chemoresistant tissues. 2) AEG-1 expression level was correlated with lymph nodal metastasis, histological differentiation, residual tumour size and response to primary chemotherapy. 3) Five-year progression-free survival (PFS) and overall survival (OS) rates were lower in the high-expression group than that in the low-expression group. 4) AEG-1 overexpression was an independent but poor prognostic factor in the OS and PFS of these patients, as determined by multivariate Cox regression analysis. 5) Multivariate logistic regression analysis revealed that the presence of cisplatin-based chemoresistance was significantly associated with expression level of AEG-1 and the degree of residual disease (P = 0.0001 and P = 0.0027, respectively). 6) the suppression of MTDH expression increased cell sensitivity to cisplatin. 7) MTDH-associated phosphoinositide 3-kinase/Akt signaling pathways may be involved in mediating the biological behavior of prostate cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MTDH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2475" target="_blank" rel="noopener noreferrer">2475</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42345" target="_blank" rel="noopener noreferrer">P42345</a>', 'HUGO Gene symbol': 'MTOR', 'Protein name': 'Serine/threonine-protein kinase mTOR', 'Function': 'Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> mTOR signaling<br><br> Oncogene signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29061642%2C%2028422725%2C%2024818169%2C%2019690197%2C%2027196780%2C%2031785230%2C%20%5Buid%5D" target="_blank" rel="noopener noreferrer">29061642, 28422725, 24818169, 19690197, 27196780, 31785230,¬†</a>', 'Notes': '1) CDDP-resistant Head and Neck Cancer (SCCHN) cell line FaDu clones were also characterized by increased activity of the PI3K-AKT-mTOR pathway; the poor prognostic value of mTOR pathway upregulation was confirmed in the TCGA SCCHN cohort. 2) expression of miR-199a-3p was positively correlated with cisplatin sensitivity in cholangiocarcinoma cell lines; mTOR was the target gene of miR-199a-3p, and that miR-199a-3p mimics could inhibit expression of mTOR. 3) The growth of ESCC xenografts was synergisticly inhibited by mTOR siRNA combined with cisplatin. 4) Increased expression of phospho-mTOR was observed in cisplatin-resistant ovarian cancer RMG1-CR and KOC7C-CR cells, compared with the respective parental cells, the increase was associated with increased activation of AKT. RMG1-CR and KOC7C-CR cells showed greater sensitivity to RAD001 than did parental RMG1 and KOC7C cells, respectively, in vitro and in vivo. 5) platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, either by mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242. 6) Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins. 7) Animals with platinum-resistant OVCAR-3 tumors treated with carboplatin plus mTORC1/2 inhibition had significantly longer median survival and strikingly reduced metastasis compared with animals treated with carboplatin plus everolimus, which inhibits only mTORC1. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MTOR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4552" target="_blank" rel="noopener noreferrer">4552</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBK8" target="_blank" rel="noopener noreferrer">Q9UBK8</a>', 'HUGO Gene symbol': 'MTRR', 'Protein name': 'Methionine synthase reductase', 'Function': 'Controls the activity of MTR in the folate metabolism by transferring the methyl group of methyltetrahydrofolate to homocysteine via the methionine synthase.\xa0Folate is a key factor regulating the SAM available for DNA methylation', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Metabolism/One carbon<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26550452%5Buid%5D" target="_blank" rel="noopener noreferrer">26550452</a>', 'Notes': '1) MTRR expression increased orderly from normal tissues, benign ovarian tumor to OC tissue. 2) MTRR over-expression in OC tissue was correlated with pathologic type (P=0.005), grade (P=0.037), FIGO stage (P=0.001), organ metastasis (P=0.009) and platinum resistance (P=0.038). 3) MTRR silencing inhibited cell proliferation, cisplatin resistance and autophagy, and induced apoptosis of OC cells. 4) MTRR silencing also affected the caspase expression as well as mTOR signaling pathway. 5) the tumor volume in MTRR-suppressed SKOV3/DDP mice treated with cisplatin significantly decreased when compared with controls (P<0.05).\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MTRR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4582" target="_blank" rel="noopener noreferrer">4582</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15941" target="_blank" rel="noopener noreferrer">P15941</a>', 'HUGO Gene symbol': 'MUC1', 'Protein name': 'Mucin-1', 'Function': 'transmembrane\xa0mucin, may reduce cell–cell and cell–matrix adhesion, and the cytoplasmic domain of MUC1 interacts with a variety of molecules involved in tumor proliferation such as epidermal growth factor receptor, c-Src, β-catenin, and Grb2. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response<br><br> NF-kB signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14998492%2C%2012578901%5Buid%5D" target="_blank" rel="noopener noreferrer">14998492, 12578901</a>', 'Notes': '1) The MUC1 transforming protein is overexpressed by most human carcinomas.\xa02) The MUC1 C-terminal subunit (MUC1 C-ter) localizes to mitochondria in HCT116/MUC1 colon carcinoma cells and heregulin stimulates mitochondrial targeting of MUC1 C-ter. 3) MUC1 attenuates cisplatin-induced (1) release of mitochondrial apoptogenic factors, (2) activation of caspase-3, and (3) induction of apoptosis. 4) knockdown of MUC1 expression in A549 lung and ZR-75-1 breast carcinoma cells by MUC1siRNA was associated with increased sensitivity to genotoxic drugs in vitro and in vivo. 5) A significant association was found between a high expression of MUC1 and histological grade (P = 0.005) and also disease stage (P = 0.001).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/94025" target="_blank" rel="noopener noreferrer">94025</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8WXI7" target="_blank" rel="noopener noreferrer">Q8WXI7</a>', 'HUGO Gene symbol': 'MUC16', 'Protein name': 'Mucin-16', 'Function': 'provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces; mesothelin binding to MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation (23694968); suppresses apoptosis (21785467)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> EMT<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19747716%2C%2029552305%5Buid%5D" target="_blank" rel="noopener noreferrer">19747716, 29552305</a>', 'Notes': '1) Down-regulation of cell surface MUC16 decreases cisplatin IC(50) by 5-fold in NIH:OVCAR3 cells but does not affect paclitaxel IC(50). 2) Caspase-9 and caspase-3 activation also significantly augmented in cisplatin-treated NIH:OVCAR3 cells expressing the anti-MUC16 scFv. 3) Ectopic expression of MUC16 CTD has the opposite effect. Cisplatin sensitivity and caspases activation are decreased by the ectopic expression of MUC16 CTD in SKOV3 cells. 4) MUC16 overexpression had functional effects on the behavior of lung cancer cells, including increasing their resistance to cisplatin, promoting their growth, and enhancing their migration and invasion capabilities. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUC16" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/727897" target="_blank" rel="noopener noreferrer">727897</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9HC84" target="_blank" rel="noopener noreferrer">Q9HC84</a>', 'HUGO Gene symbol': 'MUC5B', 'Protein name': 'Mucin-5B', 'Function': 'a secreted mucin, contributes to the lubricating and viscoelastic properties of whole saliva and cervical mucus; Alteration in expression is a hallmark of numerous epithelial cancers and has often been correlated to bad prognosis of the tumor (28972071)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26984395%2C%20%2021136676%2C%2025733373%5Buid%5D" target="_blank" rel="noopener noreferrer">26984395,¬† 21136676, 25733373</a>', 'Notes': '1) Downregulation of MUC5B expression increases chemo-sensitivity of MCF-7 breast cancer cells to cisplatin.\xa02) MUC5b protein abundance is upregulated in cisplatin-reistance ovarian cancer cells A2780-CP. 3) MUC5B expression was significantly associated with poorer differentiation (P = 0.0303), higher pathological TNM stage (p = 0.0153) and poorer prognosis of Non-Small Cell Lung Cancer adenocarcinoma patients (P = 0.0017). 4) Multivariable analysis with Cox proportional hazards models confirmed that MUC5B expression increased the hazard of death after adjusting for other clinicopathological factors (HR = 2.66; 95%CI, 1.26–5.61). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUC5B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/80198" target="_blank" rel="noopener noreferrer">80198</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96NY9" target="_blank" rel="noopener noreferrer">Q96NY9</a>', 'HUGO Gene symbol': 'MUS81', 'Protein name': 'Crossover junction endonuclease MUS81', 'Function': "Interacts with EME1 and EME2 to form a DNA structure-specific endonuclease with substrate preference for branched DNA structures with a 5'-end at the branch nick.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27255997%2C%2028291626%5Buid%5D" target="_blank" rel="noopener noreferrer">27255997, 28291626</a>', 'Notes': "PARPi resistance (D'Andrea) AACR presentation. 1) inhibition of MUS81 expression induced cellular senescence and enhanced the antitumor effect of cisplatin in SOC cells. 2) Mus81 knockdown could significantly improve the chemosensitivity of colon cancer cells in vitro and in vivo, especially to CDDP. 3) Mus81 knockdown also induced S phase arrest and elevated apoptosis in CDDP treated HCT116 cells through activating CHK1/CDC25A/CDK2 and CHK1/p53/Bax pathways, while these effects could be counteracted by CHK1 inhibition. ", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUS81" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4595" target="_blank" rel="noopener noreferrer">4595</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UIF7" target="_blank" rel="noopener noreferrer">Q9UIF7</a>', 'HUGO Gene symbol': 'MUTYH', 'Protein name': 'Adenine DNA glycosylase', 'Function': 'Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR/BER<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26336131%2C%2023677513%2C%2031578574%20%5Buid%5D" target="_blank" rel="noopener noreferrer">26336131, 23677513, 31578574¬†</a>', 'Notes': '1) SiRNAs targeting ercc1, ercc2,\xa0mutyh, and pnkp significantly sensitized cells to chemotherapy toward CDDP or TMZ, increasing cell death by up to 25% in glioma cells.\xa02) Exposure of cells to cisplatin leads to a moderate overall accumulation of Myh1 protein. 3) MUTYH was significantly downregulated in the resistant esophageal squamous cell carcinoma EC109/CDDP cells compared with that noted in the parental cells. 4) Ectopic expression of MUTYH significantly enhanced the CDDP‑mediated inhibitory effect on resistant cell proliferation and induction of apoptosis, 5) silencing of MUTYH by siRNA in parental cells led to decreased sensitivity to CDDP. 6) CDDP‑resistant cells went through EMT driven by its master regulator Twist, and MUTYH overexpression significantly reduced the Twist expression level and reversed the phenotype of EMT. 7) increased ROS production in response to MUTYH overexpression. 8) Reduced ROS by using N‑acetylcysteine inhibited the degradation of Twist. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUTYH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9961" target="_blank" rel="noopener noreferrer">9961</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14764" target="_blank" rel="noopener noreferrer">Q14764</a>', 'HUGO Gene symbol': 'MVP', 'Protein name': 'Major vault protein', 'Function': 'Major vault protein. Vaults have been suggested to play a direct role in multidrug resistance (MDR) to anticancer drugs; Notch1 could promote the expression of MVP and activate the AKT pathway as well as EMT process (30336197).', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Notch signaling<br><br> Oncogene signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9535882,27756418,19900859,7585126,23525731,20082278" target="_blank" rel="noopener noreferrer">9535882, 27756418, 19900859, 7585126, 23525731, 20082278</a>', 'Notes': '1) It has been recently noted that various cancer cell lines containing markedly elevated levels of vault particles exhibit resistance to a broad spectrum of chemotherapeutic drugs \xa02) Increased MVP expression was observed in CIS-, PAC- and TOP-, but not in DOX-resistant cell lines. 3) The upregulation of MVP/LRP expression was noted in lung cancer and was correlated with poor response to chemotherapy. 4) Of the 25 patients evaluated for a correlation of LRP to 1-year recurrence, we correctly predicted the 1-year recurrence of 24 patients based solely on the presence of LRP in ascitic tumor cells. 5) P-gp and MRP2 were not expressed in malignant cells of ascites or omental metastases. 6) Malignant cells from ascites had higher expression of LRP and were found to be more resistant to carboplatin treatment than cells from omental metastasis by in vitro assay. 7) LRP expression in the malignant cells of ascites correlated with carboplatin resistance by in vitro assay and recurrence at 1\xa0year. 8) NSCLC patients of stage IIIA (p=0.011), N1 and N2 status (p=0.008), high expression of MRP1 (p=0.034) and LRP (p=0.018) were associated with shorter TFS after cisplatin-based chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MVP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4609" target="_blank" rel="noopener noreferrer">4609</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01106" target="_blank" rel="noopener noreferrer">P01106</a>', 'HUGO Gene symbol': 'MYC', 'Protein name': 'Myc proto-oncogene protein', 'Function': 'Transcription factor that activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> MYC signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20459793%2C%2026227489%2C%202113532%2C%2030166592%2C%2032319562%2C%2024583641%5Buid%5D" target="_blank" rel="noopener noreferrer">20459793, 26227489, 2113532, 30166592, 32319562, 24583641</a>', 'Notes': "1) Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. 2) the disease-free (DFS) and the overall (OS) survival were decreased in ovarian cancer patients with high c-MYC mRNA levels. 3) c-MYC protein levels were higher in cisplatin-resistant cells when compared with their cisplatin-sensitive counterparts. 4) Significant inhibition of cell growth and viability, cell-cycle arrest, and activation of apoptosis were observed upon siRNA-mediated c-MYC depletion. 5) the tamoxifen (TAM)‑resistant breast cancer cells were significantly more sensitive to cisplatin compared with the parent cells, and the silencing of c‑MYC expression desensitized the cells to cisplatin through the inhibition of the cell cycle. 6) An increased c‑MYC expression was observed in 28 pairs of primary and metastatic tumors from patients treated with TAM, and the clinical remission rate of cisplatin‑based chemotherapy was significantly higher compared with other chemotherapy‑based regimens in 122 patients with TAM resistant breast cancer. 7) c-Myc deletion completely abrogated the immediate wave of apoptosis following both ionizing irradiation and cisplatin treatment, recapitulating the phenotype of p53 deficiency in the intestine. 8) c-Myc-deficient intestinal enterocytes upregulate Mdm2, which targets p53 for degradation. ", 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN/UP (AS in GSL2)/UP in OC cells (IGROV1)', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MYC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4615" target="_blank" rel="noopener noreferrer">4615</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99836" target="_blank" rel="noopener noreferrer">Q99836</a>', 'HUGO Gene symbol': 'MYD88', 'Protein name': 'Myeloid differentiation primary response protein MyD88', 'Function': 'Adapter protein involved in the Toll-like receptor (TLR4) and IL-1 receptor signaling pathway in the innate immune response', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18176604%2C%2024977712%2C%2025308861%5Buid%5D" target="_blank" rel="noopener noreferrer">18176604, 24977712, 25308861</a>', 'Notes': '1) MyD88 positive EOCs have a functioning TLR4/MyD88 pathway and may represent an ovarian cancer stem cell (CSC) that is highly resistant to pro-apoptotic signaling and which can recruit leukocytes to actively promote a pro-inflammatory, pro-proliferative microenvironment. / MyD88 negative EOCs in contrast lack MyD88 and may represent more differentiated tumours that are less biologically aggressive. 2) Significant alterations in MyD88 mRNA expression were observed between chemosensitive and chemoresistant cells and tissue. 3) MyD88 mRNA was upregulated 4.9 fold in a cohort of non-responders compared to responders (p<0.05). Similarly, TLR4 mRNA was upregulated 3.4 fold in this cohort (p<0.05). All patients analysed here had advanced serous papillary adenocarcinomas and received carboplatin and paclitaxel as first line chemotherapy following optimal debulking surgery. 4) Knockdown of TLR4 in SKOV-3 ovarian cells recovered chemosensitivity. / Knockdown of MyD88 alone did not. 5) Down-regulation of the expression of MyD88 in SKOV3/DDP cells decreased the cisplatin resistance. 6) The increased expression of p-Akt, XIAP, and MRP1 in SKOV3/DDP cells after cisplatin treatment was also repressed by the downregulation of MyD88. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MYD88" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7593" target="_blank" rel="noopener noreferrer">7593</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28698" target="_blank" rel="noopener noreferrer">P28698</a>', 'HUGO Gene symbol': 'MZF1', 'Protein name': 'Myeloid zinc finger 1', 'Function': 'Regulates transcription from the PADI1 and CDH2 promoter', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> DDR/NER<br><br> EMT<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16426580%5Buid%5D" target="_blank" rel="noopener noreferrer">16426580</a>', 'Notes': '1) EMSA with MZF1 ZN1-4 consensus oligonucleotides suggests that the MZF1 N-terminal domain of zinc finger cluster may bind to the MZF1-like site of the ERCC1 promoter region. 2) MZF1 mRNA in A2780/CP70 cells decreased upon cisplatin exposure. 3) Overexpression of MZF1 repressed the ERCC1 promoter activity as determined in co-transfection assay. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MZF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/112939" target="_blank" rel="noopener noreferrer">112939</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96RE7" target="_blank" rel="noopener noreferrer">Q96RE7</a>', 'HUGO Gene symbol': 'NACC1', 'Protein name': 'Nucleus accumbens-associated protein 1', 'Function': 'an important transcriptional regulator in maintaining embryonic stem (ES) cell pluripotency; facilitating EMT (30373858)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> EMT<br><br> ER stress response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19305429%2C%2021743489%2C%2017130457%5Buid%5D" target="_blank" rel="noopener noreferrer">19305429, 21743489, 17130457</a>', 'Notes': '1) NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. 2) NAC-1 proteins negatively regulate the expression of Gadd45gip1 (Crif1). Turning off the Gadd45 pathway appears to be critical for cancer cell survival and to facilitate tumor growth under cellular stress.\xa03) NAC-1 protein, shows significantly higher expression in recurrent chemoresistant ovarian serous carcinomas than in primary untreated tumors. 4) Ectopic expression of NAC1 increased paclitaxel resistance. 5) knockdown of NAC1 or disruption of NAC1 homodimerization sensitized cancer cells to chemotherapeutic drugs. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NACC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79923" target="_blank" rel="noopener noreferrer">79923</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H9S0" target="_blank" rel="noopener noreferrer">Q9H9S0</a>', 'HUGO Gene symbol': 'NANOG', 'Protein name': 'Homeobox protein NANOG', 'Function': 'Transcription regulator involved in inner cell mass and embryonic stem (ES) cells proliferation and self-renewal.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21342274%2C%2027884977%2C%2027105520%2C%2032710593%5Buid%5D" target="_blank" rel="noopener noreferrer">21342274, 27884977, 27105520, 32710593</a>', 'Notes': '1) Cisplatin-resistant OC2 cells highly expressed the stemness markers (Nanog, Oct4, Bmi1, CD117, CD133, and ABCG2).\xa02) Up-regulation of Oct4 and Nanog expression was significantly observed in cisplatin-resistant patients with OSCC. 3) Susceptibility to cisplatin increased in SKOV-3 cells on down-regulating NANOG and reversible results were obtained in Moody cells post-overexpression of NANOG. 4) Nanog overexpression was associated with overall progression, cisplatin resistance, and invasion of oral squamous cell carcinoma (OSCC). 5) Nanog recruitment to c-Myc, Slug, E-cadherin, and Oct-4 gene promoter was observed. 6) Positive correlation of Nanog protein expression with c-Myc, Slug, cyclin D1, MMP-2/-9, and Oct-4 and negative correlation with E-cadherin gene expression were found. 7) Knockdown of Nanog and treatment of epicatechin-3-gallate reversed cisplatin resistance and diminished invasion/migration potential.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NANOG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4675" target="_blank" rel="noopener noreferrer">4675</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99457" target="_blank" rel="noopener noreferrer">Q99457</a>', 'HUGO Gene symbol': 'NAP1L3', 'Protein name': 'Nucleosome assembly protein 1-like 3', 'Function': 'histone chaperone', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32701410%5Buid%5D" target="_blank" rel="noopener noreferrer">32701410</a>', 'Notes': '1) NAP1L3 was significantly upregulated in tissues with cisplatin resistance compared with cisplatin-sensitive tissues. 2) Patients with high NAP1L3 levels had poor prognosis, suggesting that NAP1L3 might regulate ovarian cancer resistance. 3) cells with high NAP1L3 had high cisplatin resistance, whereas cells with low NAP1L3 had poor cisplatin resistance. 4) NAP1L3 overexpression significantly increased cisplatin resistance, whereas NAP1L3 knockdown significantly reduced cisplatin resistance. 5) NAP1L3 regulated TGF-β pathway. 6) NAP1L3 overexpression increased the phosphorylation and nuclear translocation of SMAD2 and SMAD3.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NAP1L3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9476" target="_blank" rel="noopener noreferrer">9476</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O96009" target="_blank" rel="noopener noreferrer">O96009</a>', 'HUGO Gene symbol': 'NAPSA', 'Protein name': 'Napsin A', 'Function': 'aspartic peptidase, anti-apoptotic protein that promotes resistance to cisplatin by degradation of the tumor suppressor p53, which is a regulator of the cyclin kinase inhibitors as p21 and p27', 'Putative_mechanism_associated_with_Pt_resistance': 'p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20361941%5Buid%5D" target="_blank" rel="noopener noreferrer">20361941</a>', 'Notes': '1) nine genes (NAPA, CITED2, CABIN1, ADM, HIST1H1A, EHD1, MARK2, PTPN21, and MVD), which were consistently upregulated in two cisplatin-resistant HeLa cell lines. 2) shRNA knockdown of NAPA was the most efficient treatment able to sensitize cells to cisplatin. 3) In a genome-wide screening for genes involved in chemo-resistance, NAPA was over-expressed in cisplatin-resistant cells. 4) The NAPA (protein) Napsin A was described to promote resistance to cisplatin by degradation of the tumor suppressor p53.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NAPSA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/89795" target="_blank" rel="noopener noreferrer">89795</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IVL0" target="_blank" rel="noopener noreferrer">Q8IVL0</a>', 'HUGO Gene symbol': 'NAV3', 'Protein name': 'Neuron navigator 3', 'Function': 'May regulate IL2 production by T-cells. May be involved in neuron regeneration; a microtubule plus-end tracking protein; NAV3 depletion trimmed microtubule growth, prolonged growth factor signaling, prevented apoptosis and enhanced random cell migration (25678558)', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25579119%5Buid%5D" target="_blank" rel="noopener noreferrer">25579119</a>', 'Notes': '1) NAV3 was a potential target of miR-21-3p. 2) knockdown of NAV3 increases resistance. 3) miR-21-3p is raised, while NAV3 is reduced, in ovarian tumours that are resistant to platinum treatment.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NAV3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4683" target="_blank" rel="noopener noreferrer">4683</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60934" target="_blank" rel="noopener noreferrer">O60934</a>', 'HUGO Gene symbol': 'NBN', 'Protein name': 'Nibrin', 'Function': 'Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30638177%5Buid%5D" target="_blank" rel="noopener noreferrer">30638177</a>', 'Notes': '1) downregulation of FoxM1 sensitized NPC cells to\xa0cisplatin\xa0and reduced the repair of\xa0cisplatin-induced DNA double-strand breaks via inhibition of the MRN (MRE11-RAD50-NBS1)-ATM axis, which might be related to the ability of FoxM1 to regulate NBS1. 2) enhanced sensitivity of FoxM1 knockdown cells could be reduced by overexpression of NBS1.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NBN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8202" target="_blank" rel="noopener noreferrer">8202</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y6Q9" target="_blank" rel="noopener noreferrer">Q9Y6Q9</a>', 'HUGO Gene symbol': 'NCOA3', 'Protein name': 'Steroid receptor coactivator protein 3', 'Function': 'Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion (21647249).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> ECM signaling<br><br> NF-kB signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23652306%5Buid%5D" target="_blank" rel="noopener noreferrer">23652306</a>', 'Notes': '1) Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent prognostic marker. 2) High expression of SRC3 identified patients who have a significantly poorer survival with single-agent carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NCOA3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51079" target="_blank" rel="noopener noreferrer">51079</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P0J0" target="_blank" rel="noopener noreferrer">Q9P0J0</a>', 'HUGO Gene symbol': 'NDUFA13', 'Protein name': 'NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 / Gene associated with retinoic and IFN-induced mortality 19 protein', 'Function': 'Accessory subunit of the mitochondrial Complex I. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30032449%5Buid%5D" target="_blank" rel="noopener noreferrer">30032449</a>', 'Notes': '1) Expression levels of GRIM19 were significantly down-regulated in recurrent BC specimens, and in experimentally induced CDDP-resistant BC cells. 2) overexpression of the exogenous GRIM19 potentiated CDDP sensitivity and suppressed the survival and invasion of BC cells in the presence of CDDP challenge. 3) the compromised CDDP chemosensitization induced by GRIM19 loss was at least partially attributed to the attenuation of Bcl-xL polyubiquitination and subsequent degradation, because (1) GRIM19 colocalized with Bcl-xL in the mitochondria of BC cells and (2) GRIM19 overexpression promoted the ubiquitination of Bcl-xL, and this event could be effectively reversed by pretreatment with inhibitors of p38-MAPK and JNK pathways. 4)inhibition of Bcl-xL rectified GRIM19 deficiency-caused CDDP resistance in BC cells. 5) BCL2L1 mRNA levels were negatively correlated with GRIM19 mRNA levels in CDDP-associated clinical BC tissues.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NDUFA13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4734" target="_blank" rel="noopener noreferrer">4734</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46934" target="_blank" rel="noopener noreferrer">P46934</a>', 'HUGO Gene symbol': 'NEDD4', 'Protein name': 'E3 ubiquitin-protein ligase NEDD4', 'Function': "Specifically ubiquitinates 'Lys-63' in target proteins. Involved in the pathway leading to the degradation of VEGFR-2/KDFR,  IGF1R, FGFR1, RAPGEF2 and PTEN at multiple sites, thus leading to receptor internalization and degradation. ", 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28379054%5Buid%5D" target="_blank" rel="noopener noreferrer">28379054</a>', 'Notes': '1) EMT is closely associated with DDP-induced drug resistance in nasopharyngeal carcinoma cells (NPC) cells, as DDP-resistant cells displayed morphological and molecular markers changes consistent with EMT. 2) an enhanced migration and invasion potential in DDP-resistant NPC cells. 3) Overexpression of NEDD4 was found in DDP-resistant NPC cells; upregulation of NEDD4 was observed to relate to EMT in DDP-resistant cells. 4) depletion of NEDD4 in resistant cells led to a partial reversion of EMT phenotypes to MET characteristics and DDP-sensitivity. 5) NEDD4 is largely involved in EMT features and chemoresistance of NPC cancer cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NEDD4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23327" target="_blank" rel="noopener noreferrer">23327</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96PU5" target="_blank" rel="noopener noreferrer">Q96PU5</a>', 'HUGO Gene symbol': 'NEDD4L', 'Protein name': 'E3 ubiquitin-protein ligase NEDD4-like', 'Function': 'E3 ubiquitin-protein ligase which inhibits TGF-beta signaling by triggering SMAD2 and TGFBR1 ubiquitination and proteasome-dependent degradation. Promotes ubiquitination and internalization of various plasma membrane channels', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26130719%2C%2021909941%5Buid%5D" target="_blank" rel="noopener noreferrer">26130719, 21909941</a>', 'Notes': '1) DDB2-mediated NEDD4L downregulation endowed a significant impact on ovarian cancer cell proliferation through TGF-β signal transduction.\xa02) Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NEDD4L" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4738" target="_blank" rel="noopener noreferrer">4738</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15843" target="_blank" rel="noopener noreferrer">Q15843</a>', 'HUGO Gene symbol': 'NEDD8', 'Protein name': 'Ubiquitin-like protein', 'Function': 'Attachment of NEDD8 to cullins activates their associated E3 ubiquitin ligase activity, which control the ubiquitination and degradation of many proteins with key roles (p27, cyclin E, c-Myc, CDT1, NRF-2, HIF1A)', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Oncogene signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23633453%2C%2028569775%5Buid%5D" target="_blank" rel="noopener noreferrer">23633453, 28569775</a>', 'Notes': '1) MLN4924 is a potent inhibitor of NEDDylation and provoked the stabilization of key NEDD8 substrates and regulators of cellular redox status. 2) MLN4924 significantly augmented the activity of cisplatin against cisplatin-resistant cells, suggesting that aberrant NEDDylation may contribute to drug resistance. 3) MLN4924 and cisplatin cooperated to induce DNA damage, oxidative stress, and increased expression of the BH3-only protein NBK/BIK. 4) Administration of MLN4924 to mice bearing ovarian tumor xenografts significantly increased the efficacy of cisplatin against both cisplatin-sensitive and -resistant tumors. 5) 197 NPC tissues revealed an elevated NEDD8 expression as an unfavorable independent factor in overall survival and disease-free survival rates. 6) shRNA Downregulation of NEDD8 enhanced the susceptibility of NPC cells to cisplatin and radiation. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NEDD8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/252969" target="_blank" rel="noopener noreferrer">252969</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q969S2" target="_blank" rel="noopener noreferrer">Q969S2</a>', 'HUGO Gene symbol': 'NEIL2', 'Protein name': 'Endonuclease 8-like 2', 'Function': 'DNA glycosylase activity towards 5-hydroxyuracil and other oxidized derivatives of cytosine with a preference for DNA bubbles.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32626527%5Buid%5D" target="_blank" rel="noopener noreferrer">32626527</a>', 'Notes': "1) After cisplatin-based chemotherapy, the Neil2 gene had the polymorphism (T/C) in rs8191670 and it is associated with the PFS of advanced NSCLC patients. 2) MiR-548a targets NEIL2 3'UTR to suppress its expression. Upregulation of NEIL2 expression or downregulation of miR-548a could reduce the sensitivity of NSCLC cells to cisplatin.", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NEIL2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79858" target="_blank" rel="noopener noreferrer">79858</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NG66" target="_blank" rel="noopener noreferrer">Q8NG66</a>', 'HUGO Gene symbol': 'NEK11', 'Protein name': 'NIMA (never in mitosis gene A)-related expressed kinase', 'Function': 'G2/M checkpoint response to DNA damage; controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24969318%2C%2026501353%5Buid%5D" target="_blank" rel="noopener noreferrer">24969318, 26501353</a>', 'Notes': '1) NEK11 mRNA was significantly downregulated in 586 cases of ovarian serous cystadenocarcinomas and cisplatin-resistant A2780 ovarian cancer cells. 2) depletion of Nek11 prevents the G2/M arrest induced by genotoxic agents and promotes p53-dependent apoptosis both in the presence and absence of DNA damage. 3) The Nek11 kinase is a potential mediator of the DNA damage response whose expression is upregulated in early stage colorectal cancers (CRCs).', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NEK11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10763" target="_blank" rel="noopener noreferrer">10763</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48681" target="_blank" rel="noopener noreferrer">P48681</a>', 'HUGO Gene symbol': 'NES', 'Protein name': 'Nestin', 'Function': 'intermediate filament protein required for survival, renewal and mitogen-stimulated proliferation of neural progenitor cells. CSC marker; Cdk5-mediated nestin phosphorylation releases a pool of soluble nestin; binds to Keap1 to protect Nrf2 (31695040)', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> CSC<br><br> EMT<br><br> Oncogene signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22296500%5Buid%5D" target="_blank" rel="noopener noreferrer">22296500</a>', 'Notes': '1) CD133 and nestin were defined to be positive in 35.0% and 32.5% of the serous ovarian carcinoma tissues, respectively. It was observed that overexpression of nestin but not CD133 was associated with the cisplatin-based chemotherapy resistance and shorter overall survival of the patients, and nestin was found to be an independent prognostic factor. 2) positive nestin expression also correlated to increased expression of EGFR and VEGF, and elevated MVD in tumors. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NES" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4763" target="_blank" rel="noopener noreferrer">4763</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21359" target="_blank" rel="noopener noreferrer">P21359</a>', 'HUGO Gene symbol': 'NF1', 'Protein name': 'Neurofibromin', 'Function': 'Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29203787%2C%2030543142%5Buid%5D" target="_blank" rel="noopener noreferrer">29203787, 30543142</a>', 'Notes': '1) Brca1, Pten and\xa0Nf1, all of which are frequently mutated or deleted in HGSOC. 2) deletion of either Pten or Nf1 expression significantly accelerated tumor growth compared to p53 loss alone. 3) NF1-knockdown ovarian cells showed resistance to cisplatin-induced apoptosis. 4) NF1 regulated MCL1 expression at protein level. 5) miR-142-5p was regulated by NF1 via its promoter and targeted MCL1. Consistently, miR-142-5p mimic and si-MCL1 can attenuate the antiapoptotic effect of NF1 knockdown.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4771" target="_blank" rel="noopener noreferrer">4771</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35240" target="_blank" rel="noopener noreferrer">P35240</a>', 'HUGO Gene symbol': 'NF2', 'Protein name': 'Merlin', 'Function': 'Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27378628%5Buid%5D" target="_blank" rel="noopener noreferrer">27378628</a>', 'Notes': '1) Cohort 1 was comprised of 145 patients with malignant pleural mesothelioma intended to be treated with chemotherapy (CTX) followed by extrapleural pneumonectomy (EPP), thus both pre- and post-CTX tissues were available. Cohort 2 was comprised of 59 patients treated with EPP followed by intraoperative hyperthermic cisplatin and/or adjuvant CTX and/or radiotherapy: Kaplan-Meier survival curves revealed a significant association between low cytoplasmic Merlin expression in pre-induction CTX tissues of cohort 1 with shorter FFR (p = 0.02) and OS (p = 0.03). The same tendency was observed in the chemotherapy naïve tissues obtained during EPP of cohort 2. Low nuclear Merlin expression in post-CTX tissues (available from cohort 1 only) was associated with shorter FFR (p = 0.04) and OS (p = 0.05). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4780" target="_blank" rel="noopener noreferrer">4780</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16236" target="_blank" rel="noopener noreferrer">Q16236</a>', 'HUGO Gene symbol': 'NFE2L2', 'Protein name': 'Nuclear factor erythroid 2-related factor 2', 'Function': 'transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux<br><br> Redox<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28112439%2C%2024837013%5Buid%5D" target="_blank" rel="noopener noreferrer">28112439, 24837013</a>', 'Notes': '1) NRF2 plays a key role in mediating cisplatin resistance in ovarian cancer. 2) The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin-induced apoptosis compared to its control cell line; whereas 3) the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. 4) Bladder cancer cell lines showed variable Nrf2 expression. Nrf2 expression was greater in RT112-CP cisplatin-resistant cells compared with that in parental RT112 cells. 5) Nrf2 overexpression was associated with increased antioxidant response element reporter construct activity, increased Nrf2 target gene expression (MT proteins and glutathione reductase). 6) NRF2 depletion partially restored cisplatin sensitivity. 7) Expression of Nrf2 in bladder cancer following radical cystectomy was associated with unfavorable overall (median = 0.65 vs. 2.11 y, P = 0.045), bladder cancer-specific, and recurrence-free survival in those patients who also received neoadjuvant cisplatin-based chemotherapy but not in those treated with cystectomy alone.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NFE2L2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4790" target="_blank" rel="noopener noreferrer">4790</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P19838" target="_blank" rel="noopener noreferrer">P19838</a>', 'HUGO Gene symbol': 'NFKB1', 'Protein name': 'Nuclear factor NF-kappa-B p105 subunit', 'Function': 'NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes ', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18667446%2C%2029813121%5Buid%5D" target="_blank" rel="noopener noreferrer">18667446, 29813121</a>', 'Notes': '1) not only TG2 knockdown but also a TG2 enzymatic inhibitor (KCC009) sensitized SKOV3 cells to cisplatin. 2) NF-kappaB activity is decreased and the level of the inhibitory subunit I kappaB alpha is increased in ovarian cancer cells with diminished levels of TG2 or treated with KCC009. 3) Overexpression of the constitutively active p65 subunit of NF-kappaB, but not constitutively active Akt, rescued cells with diminished TG2 expression from cisplatin-induced apoptosis. 4) A total of 1159 patients from 7 eligible studies comparing prognostic significance of NF-κB expression levels in NSCLC: higher NF-κB expression was associated with shorter overall survival (OS) of NSCLC patients (HR = 2.78, 95% CI = 1.51–5.12, P = 0.001). Moreover, NF-κB expression was closely associated with tumor stage (HR = 0.32, 95% CI = 0.18–0.57, P<0.0001), lymph node metastasis (HR = 0.56, 95% CI = 0.38–0.83, P = 0.004) and 5-year OS for NSCLC patients ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NFKB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4791" target="_blank" rel="noopener noreferrer">4791</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00653" target="_blank" rel="noopener noreferrer">Q00653</a>', 'HUGO Gene symbol': 'NFKB2', 'Protein name': 'Nuclear factor NF-kappa-B p100 subunit', 'Function': 'the endpoint of a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis.', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24554706%2C%2016260623%5Buid%5D" target="_blank" rel="noopener noreferrer">24554706, 16260623</a>', 'Notes': 'mutp53 (e.g. R175H) induces NFKB2 expression to activate prosurvival NFκB signaling. The gene NF-κB2 is a prominent member of NF-kB group, whose overexpression in H1299 cells also leads to chemoresistance.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NFKB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4811" target="_blank" rel="noopener noreferrer">4811</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14543" target="_blank" rel="noopener noreferrer">P14543</a>', 'HUGO Gene symbol': 'NID1', 'Protein name': 'Nidogen-1', 'Function': 'Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Nidogens are linkers connecting collagen IV and laminin networks; binds to integrin α3β1 (1527019)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28416770%5Buid%5D" target="_blank" rel="noopener noreferrer">28416770</a>', 'Notes': '1) NID1 was a mesenchymal associated gene 2) its high expression was significantly correlated with shorter overall survival of ovarian cancer patients. 3) The ectopic expression of NID1 in OVCAR-3 cells revealed a epithelial-mesenchymal transition (EMT) phenotype accompanied by enhancement of motility, invasiveness and cisplatin resistance, 4) the knockdown of NID1 was sufficient to convert HEY cells into epithelial phenotype with decreased capability of motility, invasiveness and cisplatin resistance. 5) Mechanistic studies disclosed that NID1 activated ERK/MAPK signaling pathway to promote EMT. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NID1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26257" target="_blank" rel="noopener noreferrer">26257</a>', 'Uniprot_link': 'O15522', 'HUGO Gene symbol': 'NKX2-8', 'Protein name': 'NK2 homeobox 8', 'Function': 'homeobox-containing developmental regulator; promotes angiogenesis and activates NF-κB in esophageal cancer (23604637); overexpressed in some lung cancers and is linked to poor patient survival, possibly due to its resistance to cisplatin.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Metabolism/OXPHOS<br><br> NF-kB signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31047858%5Buid%5D" target="_blank" rel="noopener noreferrer">31047858</a>', 'Notes': "1) NKX2–8\xa0deletion was correlated with the overall and relapse-free survival of EOC patients. 2) NKX2–8 inhibited the FAO pathway by epigenetically suppressing multiple key components of the FAO cascade, including CPT1A and CPT2. 3) Loss of\xa0NKX2–8\xa0resulted in reprogramming of FA metabolism of EOC cells in an adipose microenvironment and leading to platinum resistance. 4) Importantly, pharmacological inhibition of FAO pathway using Perhexiline significantly counteracted\xa0NKX2–8\xa0deletion-induced chemoresistance and enhanced platinum's therapeutic efficacy in EOC.", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NKX2-8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4842" target="_blank" rel="noopener noreferrer">4842</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29475" target="_blank" rel="noopener noreferrer">P29475</a>', 'HUGO Gene symbol': 'NOS1', 'Protein name': 'Nitric oxide synthase, brain', 'Function': 'Produces nitric oxide (NO) which is a messenger molecule; typically, eNOS and nNOS produce NO at low or physiological levels, which plays important roles in the normal regulation of the cardiovascular and neural systems. NOS2-derived NO may induce apoptosis in cancer cells, while the lower concentration of NO typically generated by NOS1 may inhibit apoptosis and promote chemoresistance. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/VEGF<br><br> Platinum efflux<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18506185%2C%2030675218%2C%2029517684%2C%2031153640%5Buid%5D" target="_blank" rel="noopener noreferrer">18506185, 30675218, 29517684, 31153640</a>', 'Notes': '1) Basal iNOS levels were higher in OV2008 cells than in C13* cells. 2) Cisplatin upregulated iNOS, but dramatically reduced eNOS and nNOS, in OV2008 cells only. 3) cisplatin failed to upregulate iNOS and downregulate eNOS/nNOS in cisplatin-resistant C13* cells. 4) The NO donor S-nitroso-N-acetylpenicillamine (SNAP) increased p53 protein levels and enhanced cisplatin-induced apoptosis in C13* cells in a p53-dependent manner. 5) Specific iNOS inhibitor 1400W partially blocked cisplatin-induced apoptosis in OV2008 cells. 6) In cisplatin-resistant C13* cells, blocking all NOSs with NG-amino-L-arginine dramatically changed these cells from cisplatin-resistant to cisplatin-sensitive, greatly potentiating cisplatin-induced apoptosis.  7) eNOS/nNOS contributes (in a p53-independent manner) to chemoresistance by suppressing CDDP-induced apoptosis in isogenic CDDP-resistant cells. 8) The positive expression of NOS1 in cancer cells is an independent negative predictor of PFS and OS in patients with stage I–IIIA NSCLC after curative resection. 9) Mitochondrial NOS1 suppresses apoptosis in colon cancer cells through increasing SIRT3 activity. 10) overexpression of NOS1 could upregulate ABCG2 expression, and expression of ABCG2 was inhibited by NOS1 selective inhibitor (N-PLA). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4843" target="_blank" rel="noopener noreferrer">4843</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35228" target="_blank" rel="noopener noreferrer">P35228</a>', 'HUGO Gene symbol': 'NOS2', 'Protein name': 'Nitric oxide synthase, inducible', 'Function': 'Produces nitric oxide (NO) which is a messenger molecule; iNOS typically produces toxicity-associated NO\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling/PKG<br><br> p53 signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18506185%5Buid%5D" target="_blank" rel="noopener noreferrer">18506185</a>', 'Notes': 'As NOS1, iNOS contributes to CDDP-induced apoptosis in CDDP-sensitive cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP in S; DOWN in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4846" target="_blank" rel="noopener noreferrer">4846</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29474" target="_blank" rel="noopener noreferrer">P29474</a>', 'HUGO Gene symbol': 'NOS3', 'Protein name': 'Nitric oxide synthase, endothelial', 'Function': 'Produces nitric oxide (NO) which is a messenger molecule\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/VEGF<br><br> Platinum efflux<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18506185%2C%2029512753%5Buid%5D" target="_blank" rel="noopener noreferrer">18506185, 29512753</a>', 'Notes': '1) As NOS1,  eNOS/nNOS contributes (in a p53-independent manner) to chemoresistance by suppressing CDDP-induced apoptosis in isogenic CDDP-resistant cells. 2) Specific inhibitors of NOS3 reduced the IC50 of MCF‑7/MDR cells in response to various anticancer drugs, including adriamycin, cisplatin and 5‑fluorouracil. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOS3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4851" target="_blank" rel="noopener noreferrer">4851</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46531" target="_blank" rel="noopener noreferrer">P46531</a>', 'HUGO Gene symbol': 'NOTCH1', 'Protein name': 'Neurogenic locus notch homolog protein 1', 'Function': 'Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Notch signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25179844%2C%2027626163%20%5Buid%5D" target="_blank" rel="noopener noreferrer">25179844, 27626163¬†</a>', 'Notes': '1) miR-449a were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP. 2) The overexpression of miR-449a increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells. 3) miR-449a functioned through suppressing NOTCH1 directly. 4) BALB/c nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-449a mimics exhibited enhanced cisplatin sensitivity in vivo. 5) galectin-3 maintains ovarian CSCs by activating the Notch1 intracellular domain (NICD1). 6) As in LGALS3. 7) Overexpression of galectin-3 increased tumor burden in A2780 ovarian cancer xenografted mice. 8) Increased expression of galectin-3 was detected in advanced stages, compared to stage 1 or 2 in ovarian cancer patients, ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOTCH1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4854" target="_blank" rel="noopener noreferrer">4854</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UM47" target="_blank" rel="noopener noreferrer">Q9UM47</a>', 'HUGO Gene symbol': 'NOTCH3', 'Protein name': 'Neurogenic locus notch homolog protein 3', 'Function': 'Functions as a receptor for membrane-bound ligands Jagged-1, Jagged-2 and Delta-1 to regulate cell-fate determination (15350543)', 'Putative_mechanism_associated_with_Pt_resistance': 'Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28416766%5Buid%5D" target="_blank" rel="noopener noreferrer">28416766</a>', 'Notes': '1) 59 urothelial cancer patients:\xa0Notch3\xa0was more highly expressed in human urothelial cancer tissues; Notch3\xa0overexpression being associated with poor clinical outcome.\xa02) Notch3\xa0knockdown rendered urothelial cancer cells more sensitive to\xa0cisplatin.\xa03) Notch3 overexpression correlated with shorter progression-free/overall survival in patients with advanced stage (stage III, IV) ovarian carcinoma treated with platinum and taxane. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOTCH3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79400" target="_blank" rel="noopener noreferrer">79400</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96PH1" target="_blank" rel="noopener noreferrer">Q96PH1</a>', 'HUGO Gene symbol': 'NOX5', 'Protein name': 'NADPH oxidase 5', 'Function': 'Calcium-dependent NADPH oxidase that generates superoxide.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Calcium signaling<br><br> Oncogene signaling/AKT<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30225719%2C%2031423287%5Buid%5D" target="_blank" rel="noopener noreferrer">30225719, 31423287</a>', 'Notes': '1) the development of CDDP resistance was accompanied by enhanced expression of the genes encoding the key antioxidant enzymes (SOD2, CAT, GPX1, and HO-1) and transcription factor Nrf2, as well as reduced expression of the gene encoding NOX5 isoform of NADPH oxidase in OC SKOV-3 cells.\xa02) The current study established a cisplatin-resistant human epithelial cancer cell line. Notably, differential upregulation of NADPH oxidase 5 (NOX5) was identified in this resistant cell line. 3) cisplatin treatment induced cancer cells to express NOX5. 4) cells that overexpressed NOX5 exhibited greater resistance to cisplatin via the activation of Akt. 5) Treatment with curcumin may suppress NOX5 expression in cancer cells and enhance sensitivity to cisplatin treatment. 6) In a xenograft model, a combined regimen of cisplatin with low-dose curcumin significantly reduced malignant tumor growth.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NOX5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4869" target="_blank" rel="noopener noreferrer">4869</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06748" target="_blank" rel="noopener noreferrer">P06748</a>', 'HUGO Gene symbol': 'NPM1', 'Protein name': 'Nucleophosmin', 'Function': 'Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24515769%5Buid%5D" target="_blank" rel="noopener noreferrer">24515769</a>', 'Notes': '1) APE1/Ref-1 and NPM1 showed a significant correlation in ovarian serous cancer. 2) Patients with a poorer outcome showed a significant overexpression of nuclear NPM1 protein. 3) A Cox proportional hazards multivariate regression model revealed NPM1 expression to be independently significant for overall survival in high-grade ovarian serous cancers after correcting for stage, age, cytoreduction completeness, and platinum resistance.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NPM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1728" target="_blank" rel="noopener noreferrer">1728</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15559" target="_blank" rel="noopener noreferrer">P15559</a>', 'HUGO Gene symbol': 'NQO1', 'Protein name': 'NAD(P)H dehydrogenase [quinone] 1', 'Function': 'platinum pathway/DT-diaphorase/detoxicating', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29865885%2C%2023831944%2C%2024533712%20%5Buid%5D" target="_blank" rel="noopener noreferrer">29865885, 23831944, 24533712¬†</a>', 'Notes': '1) NQO1 is a highly inducible (by NRF2) cytoprotective gene that regulates reactive oxygen species (ROS) generation; a cytoprotective two-electron-specific reductase that highly expresses in various cancer cells. 2) Dunnione protects against experimental cisplatin-induced nephrotoxicity by increasing NQO1 and NAD+ levels.\xa03) NQO1 protects cells against renal failure induced by cisplatin, and that this effect is mediated by decreased NOX activity via cellular NADPH/NADP modulation. 4) SNPs in TPMT and NQO1 were significantly associated with progression-free survival in 104 ovarian cancer patients receiving cisplatin-cyclophosphamide chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NQO1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8856" target="_blank" rel="noopener noreferrer">8856</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75469" target="_blank" rel="noopener noreferrer">O75469</a>', 'HUGO Gene symbol': 'NR1I2', 'Protein name': 'Pregnane X receptor', 'Function': 'a nuclear receptor and transcription factor activated by variety of endogenous and xenobiotic compounds. affects drug metabolism/efflux and drug-drug interaction by activating transcription of genes such as MDR1, P450 ect.  ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Platinum efflux<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27572875%5Buid%5D" target="_blank" rel="noopener noreferrer">27572875</a>', 'Notes': '1) PXR agonists, phthalate and pregnenolone had significant positive effects on MDR1 expression and PXR-mediated transcription though the MDR1 promoter were significantly increased in the presence of paclitaxel or cisplatin. 2) Downregulation of PXR suppressed the augmented MDR1 expression and PXR-mediated transcription by PXR ligands, and significantly enhanced cell growth inhibition and apoptosis in the presence of paclitaxel or cisplatin. 3) ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NR1I2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3164" target="_blank" rel="noopener noreferrer">3164</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P22736" target="_blank" rel="noopener noreferrer">P22736</a>', 'HUGO Gene symbol': 'NR4A1', 'Protein name': 'orphan nuclear receptor TR3 / transcritption factor', 'Function': 'acts concomitantly with NURR1 in regulating the expression of delayed-early genes during liver regeneration.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Apoptotic signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23720056%5Buid%5D" target="_blank" rel="noopener noreferrer">23720056</a>', 'Notes': '1) TR3 protein expression was elevated in stage I tumors, but downregulated in a significant subset of metastatic tumors. 2) TR3 expression was significantly lower in platinum-resistant tumors in patients with metastatic disease, 3) low TR3 staining was associated with poorer overall and progression-free survival. 4) Nucleus-to-cytoplasm translocation of TR3 was observed in cisplatin-sensitive (OVCAR8, OVCAR3, and A2780PAR) but not cisplatin-resistant (NCI/ADR-RES and A2780CP20) ovarian cancer cells. 5) clear overlap between TR3 and mitochondrial Hsp60 in cisplatin-treated cells, which was associated with cytochrome c release. 6) stable shRNA- or transient siRNA-mediated TR3 downregulation displayed substantial reduction in cisplatin effects on apoptotic markers and cell growth in vitro and in vivo. 7) the cisplatin-induced cytoplasmic TR3 translocation required for apoptosis induction was regulated by JNK activation and inhibition of Akt. 8) cisplatin resistance was partially overcome by ectopic TR3 overexpression and by treatment with the JNK activator anisomycin and Akt pathway inhibitor, wortmannin. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NR4A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4893" target="_blank" rel="noopener noreferrer">4893</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01111" target="_blank" rel="noopener noreferrer">P01111</a>', 'HUGO Gene symbol': 'NRAS', 'Protein name': 'GTPase NRas', 'Function': 'Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10604725%2C%2029495918%2C%202113532%5Buid%5D" target="_blank" rel="noopener noreferrer">10604725, 29495918, 2113532</a>', 'Notes': "1) miR-26a was downregulated in cisplatin-resistant SGC-7901/DDP cells compared with SGC-7901 cells. 2) miR-26a could improve the sensitivity of GC cells to cisplatin. 3) miR-26a has target sites in the 3'-UTR of NRAS and E2F2 and reduces the\xa0expression\xa0levels of NRAS and E2F2. 4) knockdown of NRAS or E2F2 sensitize GC cells to cisplatin. 5) MicroRNA-29a has been observed to be downregulated in human lung cancer tissues. 6) In human clinical specimens, NRAS proto-oncogene was highly expressed in human lung cancer tissues compared to normal tissues. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP in R                                    ', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NRAS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8828" target="_blank" rel="noopener noreferrer">8828</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60462" target="_blank" rel="noopener noreferrer">O60462</a>', 'HUGO Gene symbol': 'NRP2', 'Protein name': 'Neuropilin-2', 'Function': 'High affinity receptor for semaphorins 3C, 3F, VEGF-165 and VEGF-145 isoforms of VEGF, and the PLGF-2 isoform of PGF.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/VEGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31235595%2C%2032038994%5Buid%5D" target="_blank" rel="noopener noreferrer">31235595, 32038994</a>', 'Notes': '1) VEGF–NRP2 promote homologous recombination (HR) in BRCA1 wild-type TNBC cells by contributing to the expression and function of Rad51. 2) VEGF–NRP2 stimulates YAP/TAZ-dependent Rad51 expression and that Rad51 is a direct YAP/TAZ–TEAD transcriptional target. 3) VEGF–NRP2–YAP/TAZ signaling contributes to the resistance of TNBC cells to cisplatin. 4) Rad51 rescues the defects in DNA repair upon inhibition of either VEGF–NRP2 or YAP/TAZ.\xa05) Neuropilin-2 (NRP2) is a prognostic indicator for reduced survival in bladder cancer (BCa) patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NRP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4907" target="_blank" rel="noopener noreferrer">4907</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21589" target="_blank" rel="noopener noreferrer">P21589</a>', 'HUGO Gene symbol': 'NT5E', 'Protein name': "5'-nucleotidase", 'Function': 'Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26629888%5Buid%5D" target="_blank" rel="noopener noreferrer">26629888</a>', 'Notes': '1) NT5E mRNA levels were observed to be elevated in cells upon in vitro and in vivo acquisition of platinum resistance in ovarian cancer cells, 2) specific targeting of NT5E increased tumor cell sensitivity to platinum. 3) tumor NT5E levels were prognostic for outcomes in ovarian cancer 4) were elevated after treatment with platinum. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NT5E" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4913" target="_blank" rel="noopener noreferrer">4913</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78549" target="_blank" rel="noopener noreferrer">P78549</a>', 'HUGO Gene symbol': 'NTHL1', 'Protein name': 'Endonuclease III-like protein 1', 'Function': 'Bifunctional DNA N-glycosylase with associated apurinic/apyrimidinic (AP) lyase function that catalyzes the first step in base excision repair (BER), the primary repair pathway for the repair of oxidative DNA damage. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18307537%2C%2032125823%5Buid%5D" target="_blank" rel="noopener noreferrer">18307537, 32125823</a>', 'Notes': '1) YB-1 binds specifically to the auto-inhibitory domain of hNTH1, providing a mechanism by which YB-1 stimulates hNTH1 activity. 2) YB-1 strongly stimulates in vitro the activity of hNTH1 toward DNA duplex probes containing oxidized bases, lesions prone to be present in cisplatin treated cells. 3) an increase in YB-1/hNTH1 complex formation in the mammary adenocarcinoma MCF7 cell line treated with UV light and cisplatin. 4) antisense RNAs against either YB-1 or hNTH1 increased cellular sensitivity to UV and cisplatin. 5) siRNA against hNTH1 re-established cytotoxicity in otherwise cisplatin-resistant YB-1 overexpressing MCF7 cells.\xa06) the hNTH1-YB1 interface is a druggable target for the development of new therapeutic strategies for the treatment of cisplatin-resistant tumors. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'YB1 interaction', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTHL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4916" target="_blank" rel="noopener noreferrer">4916</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16288" target="_blank" rel="noopener noreferrer">Q16288</a>', 'HUGO Gene symbol': 'NTRK3', 'Protein name': 'NT-3 growth factor receptor', 'Function': 'Receptor tyrosine kinase involved in nervous system and probably heart development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28746220%5Buid%5D" target="_blank" rel="noopener noreferrer">28746220</a>', 'Notes': '1) Compared to platinum-resistant population, amplification of NTRK3 was more common in the platinum-sensitive population. 2) CNVs of NTRK3 were associated with platinum-sensitive and platinum-resistant recurrences. Amplification of NTRK3 perfectly predicted platinum-sensitive relapse of ovarian cancer. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTRK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4922" target="_blank" rel="noopener noreferrer">4922</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30990" target="_blank" rel="noopener noreferrer">P30990</a>', 'HUGO Gene symbol': 'NTS', 'Protein name': 'Neurotensin/neuromedin N', 'Function': 'a 13-amino acid peptide acting as a neurotransmitter in the central nervous system and local hormone in the gastrointestinal tract. activates NTSR1, NTSR2 (G-protein–coupled receptor and NTSR3 (gp95/sortilin) (sorting protein of Vps10p-domain)', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28790113%5Buid%5D" target="_blank" rel="noopener noreferrer">28790113</a>', 'Notes': '1) NTSR1 antagonist, SR48692 enhanced the response to carboplatin in ovarian cancer cells and experimental tumors - a major improvement of platinum-induced DNA damage and cell death, as well as a decrease in tumor growth. 2) The relationship of these results to clinical studies was made by the detection of NTS and NTSR1 in 72% and 74% of ovarian cancer, respectively. 3) in a large series of high-grade ovarian cancer, NTSR1 mRNA was shown to correlate with higher stages and platinum resistance.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4923" target="_blank" rel="noopener noreferrer">4923</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30989" target="_blank" rel="noopener noreferrer">P30989</a>', 'HUGO Gene symbol': 'NTSR1', 'Protein name': 'Neurotensin receptor type 1', 'Function': 'G-protein coupled receptor for the tridecapeptide neurotensin (NTS)', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/MAPK<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28790113%5Buid%5D" target="_blank" rel="noopener noreferrer">28790113</a>', 'Notes': 'As NTS', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTSR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23636" target="_blank" rel="noopener noreferrer">23636</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P37198" target="_blank" rel="noopener noreferrer">P37198</a>', 'HUGO Gene symbol': 'NUP62', 'Protein name': 'Nuclear pore glycoprotein p62', 'Function': 'nucleocytoplasmic transport; plays a role in mitotic cell cycle progression by regulating centrosome segregation; a subset of the FG-repeat–containing NUPs (including NUP62) function in transcriptional regulation at intranuclear sites distal to the NPC\xa0(22074739); ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22074739%5Buid%5D" target="_blank" rel="noopener noreferrer">22074739</a>', 'Notes': '1) partial knockdown of nucleoporin p62 (NUP62) by siRNA confers cisplatin resistance to cultured high-grade ovarian carcinoma cells. 2) Treatment with NUP62 siRNA and cisplatin leaves resistant cells in a state of dormancy; 3) some dormant cells can be induced to proliferate by transient induction of NUP62 expression from an ectopic expression construct. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NUP62" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84876" target="_blank" rel="noopener noreferrer">84876</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96D31" target="_blank" rel="noopener noreferrer">Q96D31</a>', 'HUGO Gene symbol': 'ORAI1', 'Protein name': 'Calcium release-activated calcium channel protein 1', 'Function': 'Ca2+\xa0release-activated Ca2+\xa0(CRAC) channel mediates Ca2+\xa0influx following depletion of intracellular Ca2+\xa0stores; CRAC channels are the main pathway for Ca2+ influx in T-cells and promote the immune response by activating NFAT', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Calcium signaling<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21364678%2C%2025015419%5Buid%5D" target="_blank" rel="noopener noreferrer">21364678, 25015419</a>', 'Notes': '1) Orai1 represents the major molecular component of endogenous store-operated Ca(2+) entry (SOCE) in human prostate cancer (PCa) cells, and constitutes the principal source of Ca(2+) influx used by the cell to trigger apoptosis. 2) The downregulation of Orai1, and consequently SOCE, protects the cells from diverse apoptosis-inducing pathways, such as those induced by thapsigargin (Tg), tumor necrosis factor α, and cisplatin/oxaliplatin. 3) the apoptosis resistance of androgen-independent PCa cells is associated with the downregulation of Orai1 expression as well as SOCE. 4) Orai1 rescue, following Orai1 transfection of steroid-deprived cells, re-established the store-operated channel current and restored the normal rate of apoptosis. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ORAI1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5034" target="_blank" rel="noopener noreferrer">5034</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07237" target="_blank" rel="noopener noreferrer">P07237</a>', 'HUGO Gene symbol': 'P4HB', 'Protein name': 'Protein disulfide-isomerase', 'Function': 'catalyzes the formation, breakage and rearrangement of disulfide bonds', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26364260%2C%2029207176%5Buid%5D" target="_blank" rel="noopener noreferrer">26364260, 29207176</a>', 'Notes': '1) PDIA1 knockdown led to increased cytotoxicity in resistant A2780cis cells. 2) Coincubation with propynoic acid carbamoyl methyl amide 31 (PACMA31), a PDIA1 inhibitor, resensitized A2780cis cells to cisplatin treatment; the combination of cisplatin and PACMA31 acts synergistically.  3) downregulation of P4HB and PDIA3 may contribute to improve the survival of patients who receive chemotherapy and radiotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=P4HB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5058" target="_blank" rel="noopener noreferrer">5058</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13153" target="_blank" rel="noopener noreferrer">Q13153</a>', 'HUGO Gene symbol': 'PAK1', 'Protein name': 'Serine/threonine-protein kinase PAK 1', 'Function': 'Protein kinase involved in intracellular signaling pathways downstream of integrins and receptor-type kinases that plays an important role in cytoskeleton dynamics, in cell adhesion, migration, proliferation, apoptosis, mitosis, and in vesicle-mediated transport processes', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27713506%2C%2028535002%2C%2010531298%5Buid%5D" target="_blank" rel="noopener noreferrer">27713506, 28535002, 10531298</a>', 'Notes': '1) PAK1 confers cisplatin resistance by increasing β-catenin expression through ERK/GSK3β signaling. 2) The increased β-catenin expression promotes sphere cell formation and expression of stemness markers and this β-catenin-induced stemness is responsible for PAK1-mediated cisplatin resistance. 3) We enrolled 87 NSCLC patients who had received cisplatin-based chemotherapy to confirm the association between PAK1 expression and response to chemotherapy and outcomes. 4) PAK1 expression, evaluated by immunohistochemistry, was positively correlated with pERK and β-catenin expression in lung tumors. 5) Patients with high-PAK1, high-pERK, and high-nuclear β-catenin tumors more frequently showed an unfavorable response to cisplatin-based chemotherapy when compared to their counterparts. Kaplan-Meier and Cox regression analysis also indicated a poorer overall survival (OS) and relapse free survival (RFS) in patients with high-PAK1, high-pERK, and high-nuclear β-catenin tumors. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57144" target="_blank" rel="noopener noreferrer">57144</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P286" target="_blank" rel="noopener noreferrer">Q9P286</a>', 'HUGO Gene symbol': 'PAK5', 'Protein name': 'P21-activated kinase 5', 'Function': 'Phosphorylates the proto-oncogene RAF1 and stimulates its kinase activity. Promotes cell survival by phosphorylating the BCL2 antagonist of cell death BAD. Phosphorylates CTNND1, probably to regulate cytoskeletal organization and cell morphology.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling/MAPK<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25560489%2C%2023877225%2C%2029391894%5Buid%5D" target="_blank" rel="noopener noreferrer">25560489, 23877225, 29391894</a>', 'Notes': "1) PAK5 markedly inhibited cisplatin-induced apoptosis and promoted cell proliferation in hepatocellular carcinoma cells. 2) overexpression of PAK5 contributed to cell cycle regulation. 2) PAK5 expression was increased with EOC progression through the adenoma to carcinoma sequence, with the highest expression level in invasive and metastatic EOCs. 3) the expression level of PAK5 was also found to increase in accordance with the development of EOC Federation International of Gynecology and Obstetrics stages (P = 0.038) and differentiation grades (P = 0.008). 4) those patients who recurred within 6 months after accepting tumor reductive surgery and the following carboplatin + paclitaxel chemotherapy had the highest PAK5 expression (P = 0.015). 5)  the protein expression levels in PAK5 and Ezrin in SOSP-9607/CDDP were significantly higher than those in SOSP-9607 (P<0.01). 6) IHC showed that the expression quantities of PAK5 and Ezrin in osteosarcoma tissues were significantly higher than those in para-tumor tissues (P<0.01). 7) Pearson's correlation analysis showed that expression of PAK5 and Ezrin was positively correlated (r=0.197, P=0.023). 8) The osteosarcoma resistance is closely related to the expression levels of PAK5 and Ezrin genes. . ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAK5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79728" target="_blank" rel="noopener noreferrer">79728</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86YC2" target="_blank" rel="noopener noreferrer">Q86YC2</a>', 'HUGO Gene symbol': 'PALB2', 'Protein name': 'Partner and localizer of BRCA2', 'Function': 'Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks. Strongly stimulates the DNA strand-invasion activity of RAD51, stabilizes the nucleoprotein filament against a disruptive BRC3-BRC4 polypeptide and helps RAD51 to overcome the suppressive effect of replication protein A (RPA)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30472259%2C%2029872499%5Buid%5D" target="_blank" rel="noopener noreferrer">30472259, 29872499</a>', 'Notes': '1) Among the 158 NSCLC patients evaluable for response, high\xa0PALB2\xa0mRNA expression was predictive of response to\xa0cisplatin-docetaxel. 2) Specifically, an objective response rate of 77% to\xa0cisplatin-docetaxel was observed for patients with high\xa0PALB2\xa0mRNA expression compared with a rate of only 23 % for those with low\xa0PALB2\xa0mRNA expression (p\xa0= 0.0448). 3) PALB2 mRNA expression negatively associated to xenografts response to a platinum based therapy. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PALB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23022" target="_blank" rel="noopener noreferrer">23022</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8WX93" target="_blank" rel="noopener noreferrer">Q8WX93</a>', 'HUGO Gene symbol': 'PALLD', 'Protein name': 'Palladin', 'Function': 'Component of actin-containing microfilaments that control cell shape, adhesion, and contraction; integral component of adherens junctions and plays a role in the localization of E-cadherin to the junctions ', 'Putative_mechanism_associated_with_Pt_resistance': 'actin cytoskeleton<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27641360%5Buid%5D" target="_blank" rel="noopener noreferrer">27641360</a>', 'Notes': '1) PALLD SNP as breast cancer metastasis functional variant: breast cancer metastasis can be prevented by miR-96 or miR-182 treatment. 2) miR-96/miR-182 downregulate Palladin protein levels, thereby reducing breast cancer cell migration and invasion.\xa03) Combined delivery of the miRNAs with a chemotherapy drug, cisplatin, enables significant primary tumour shrinkage and metastasis prevention in Mouse experiment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PALLD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9061" target="_blank" rel="noopener noreferrer">9061</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43252" target="_blank" rel="noopener noreferrer">O43252</a>', 'HUGO Gene symbol': 'PAPSS1', 'Protein name': "Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1", 'Function': 'Bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two steps in the sulfate activation pathway.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Detox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28790117%5Buid%5D" target="_blank" rel="noopener noreferrer">28790117</a>', 'Notes': '1)  a positive correlation between low PAPSS1 expression and increased cisplatin sensitivity in lung adenocarcinoma. 2) In vitro, the potentiation effect was greatest when A549 cells were serum-starved under hypoxic conditions. 3) When treated with low-dose cisplatin, PAPSS1-deficient A549 spheroids showed a 58% reduction in size compared with control cells. 4) In vivo, PAPSS1 suppression and low-dose cisplatin treatment inhibited proliferation of lung tumor cells in zebrafish xenografts and significantly delayed development of subcutaneous tumors in mice. 5) Clinical data suggest that NSCLC and ovarian cancer patients with low PAPSS1 expression survive longer following platinum-based chemotherapy.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAPSS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/152559" target="_blank" rel="noopener noreferrer">152559</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6TCH7" target="_blank" rel="noopener noreferrer">Q6TCH7</a>', 'HUGO Gene symbol': 'PAQR3', 'Protein name': 'Progestin and adipoQ receptor family member 3', 'Function': 'Functions as a spatial regulator of RAF1 kinase by sequestering it to the Golgi; demonstrated tumor suppressor effects via inhibition of Raf/MEK/ERK signaling (32021448); interacts with Nrf2 and Keap1 and promotes their association (27212020)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling/MAPK<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28473198%5Buid%5D" target="_blank" rel="noopener noreferrer">28473198</a>', 'Notes': '1) RAD23B\xa0was able to directly associate with PAQR3, a newly-discovered tumor suppressor implicated in many types of human cancers. 2) PAQR3 reduced the protein level of XPC, together with accelerated degradation and enhanced polyubiquitination of XPC. 3) PAQR3 reduces nucleic distribution of\xa0RAD23B\xa0by tethering it to the Golgi apparatus, thus diminishing the amount of\xa0RAD23B\xa0proteins available to interact with XPC in the nucleus. 4) The viability of gastric cancer cells upon treatment with chemotherapy drugs including etoposide,\xa0cisplatin\xa0and doxorubicin was reduced by PAQR3 overexpression, but enhanced by PAQR3 knockdown. 5) The degree of DNA damage induced by these drugs, as measured by immunoblotting with γ-H2AX, was elevated by PAQR3 overexpression and lessened by PAQR3 knockdown.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAQR3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8505" target="_blank" rel="noopener noreferrer">8505</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86W56" target="_blank" rel="noopener noreferrer">Q86W56</a>', 'HUGO Gene symbol': 'PARG', 'Protein name': 'Poly(ADP-ribose) glycohydrolase', 'Function': 'catalyzes the hydrolysis of the endo- and exo-glycosidic bonds within the PAR polymers. Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22785358%5Buid%5D" target="_blank" rel="noopener noreferrer">22785358</a>', 'Notes': '1) Combined treatment with PARG inhibitor TA and cisplatin was found to induce apoptosis and increase DNA damage in the cisplatin-resistant (SKOV-3 CDDP/R) and cisplatin-sensitive (SKOV-3) human ovarian carcinoma cell lines. 2) TA  increase the accumulation of poly(ADP-ribose) (pADPr), following the release of apoptosis-inducing factor, and the activation of caspase-3. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PARG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11315" target="_blank" rel="noopener noreferrer">11315</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99497" target="_blank" rel="noopener noreferrer">Q99497</a>', 'HUGO Gene symbol': 'PARK7', 'Protein name': 'Protein/nucleic acid deglycase DJ-1', 'Function': 'catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals; functions as a protein deglycase that repairs methylglyoxal- and glyoxal-glycated proteins; inhibits p53 by sequestering p53 from promoters (23149933)', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> p53 signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27170529%2C%2022526154%2C%2021747690%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27170529, 22526154, 21747690¬†</a>', 'Notes': '1) siRNA-mediated DJ-1 suppression dramatically impaired proliferation, viability, and migration of the employed ovarian cancer cells. 2) the combinatorial approach led to the most pronounced therapeutic response in all the studied cell lines, outperforming both siRNA-mediated DJ-1 knockdown and cisplatin treatment alone. 3) DJ-1 depletion decreases the activity of the Akt pathway; 4) enhances the activity of p53 tumor suppressor protein. 5) weakens the cellular defense mechanisms against inherited oxidative stress. 6) The serum level of DJ-1 was higher in pancreatic cancer patients than healthy controls, and it has the relationship with tumor differentiation in pancreatic cancer. 7) Down-regulation of DJ-1 enhanced gemcitabine-induced apoptosis in three pancreatic cancer cell lines. 8) over-expression of DJ-1 desensitized the MIA PaCa-2 to the induction of apoptosis by gemcitabine. high 9) expression level of DJ-1 was associated with cisplatin resistance and a predictor for poor prognosis in 67 locally advanced NSCLC patients.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PARK7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/142" target="_blank" rel="noopener noreferrer">142</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09874" target="_blank" rel="noopener noreferrer">P09874</a>', 'HUGO Gene symbol': 'PARP1', 'Protein name': 'Poly ADP-ribose polymerase 1', 'Function': 'Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28281524%2C%2028650468%20%5Buid%5D" target="_blank" rel="noopener noreferrer">28281524, 28650468¬†</a>', 'Notes': '1) miR-216b was significantly downregulated in cisplatin-resistant ovarian cancer cells. 2) miR-216b reduced cisplatin-resistant cell viability and promoted apoptosis. 3) mRNA level of poly(ADP-ribose) polymerase (PARP)-1 was significantly regulated by miR-216b. 4) improved cisplatin sensitivity induced by miR-216b was markedly reversed by PARP1 overexpression. 5) Tumor formation assay in nude mice further provided an evidence on the suppressive role of miR-216b in tumor growth. 6) MKP-1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resistance while its downregulation suppresses PARP-1 and PAR protein expression and cisplatin resistance. 7) acquired cisplatin-resistant ovarian cancer cells expressed high levels of MKP-1 and PARP-1 proteins, and that silencing MKP-1 or PARP-1 increased cisplatin sensitivity in resistant cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'CLEAVED', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PARP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10038" target="_blank" rel="noopener noreferrer">10038</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UGN5" target="_blank" rel="noopener noreferrer">Q9UGN5</a>', 'HUGO Gene symbol': 'PARP2', 'Protein name': 'Poly ADP-ribose polymerase 2', 'Function': 'Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20798217%5Buid%5D" target="_blank" rel="noopener noreferrer">20798217</a>', 'Notes': 'PARP knockdown sensitizes cells to gemcitabine and cisplatin', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PARP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5076" target="_blank" rel="noopener noreferrer">5076</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q02962" target="_blank" rel="noopener noreferrer">Q02962</a>', 'HUGO Gene symbol': 'PAX2', 'Protein name': 'Paired box protein Pax-2', 'Function': 'transcription factor, normally expressed in fetal kidney but downregulated at birth. functions to suppress programmed cell death during nephrogenesis', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16609680%2C%2018439754%5Buid%5D" target="_blank" rel="noopener noreferrer">16609680, 18439754</a>', 'Notes': '1) PAX2 expression confers resistance to cisplatin-induced apoptosis in normal kidney cells and fetal kidney explants. 2) Pax2 knockdown sensitized RCC cells to cisplatin-induced apoptosis, killing 50-60% of cisplatin-resistant ACHN and CAKI-1 cells. 3) ACHN cells stably transfected with shRNAs targeted against the PAX2 homeodomain are 3-6-fold more susceptible to cisplatin-induced caspase-3 activation than control ACHN cells line. 4) growth of subcutaneous ACHN/shPAX2 xenografts in nude mice is significantly more responsive to cisplatin therapy than control ACHN cell tumors. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAX2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22976" target="_blank" rel="noopener noreferrer">22976</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6ZW49" target="_blank" rel="noopener noreferrer">Q6ZW49</a>', 'HUGO Gene symbol': 'PAXIP1', 'Protein name': 'PAX-interacting protein 1', 'Function': 'methyltransferase-mediated pathway regulating replication for restart. Knockdown results in fork stabilization and PARPi resistance.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27443740%5Buid%5D" target="_blank" rel="noopener noreferrer">27443740</a>', 'Notes': '1) knocking out the PTIP gene from the BRCA2-mutated tumors in cells as well as in mice and treated them with the drugs cisplatin and PARPi; Loss of the PTIP protein protected the cells from the drugs by stabilizing replication forks.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PAXIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5087" target="_blank" rel="noopener noreferrer">5087</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40424" target="_blank" rel="noopener noreferrer">P40424</a>', 'HUGO Gene symbol': 'PBX1', 'Protein name': 'Pre-B-cell leukemia transcription factor 1', 'Function': 'Acts as a transcriptional activator of PF4 in complex with MEIS1', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27590741%5Buid%5D" target="_blank" rel="noopener noreferrer">27590741</a>', 'Notes': '1) High levels of PBX1 expression correlated with shorter survival in post-chemotherapy ovarian cancer patients. 2) In tumor cells with low endogenous levels of PBX1, its enforced expression promoted cancer stem cell-like phenotypes, including most notably an increase in resistance to platinum-based therapy. 3) silencing PBX1 in platinum-resistant cells that overexpressed PBX1 sensitized them to platinum treatment and reduced their stem-like properties. 4) PBX1 binds directly to promoters of genes involved in stem cell maintenance and the response to tissue injury. 5) the PBX1 binding motif at STAT3 promoter acted to positively regulate STAT3 transcription. 6) a STAT3/JAK2 inhibitor could potently sensitize platinum-resistant cells to carboplatin and suppress their growth in vivo ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PBX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57326" target="_blank" rel="noopener noreferrer">57326</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96AQ6" target="_blank" rel="noopener noreferrer">Q96AQ6</a>', 'HUGO Gene symbol': 'PBXIP1', 'Protein name': 'Pre-B-cell leukemia transcription factor-interacting protein 1', 'Function': 'Inhibits the binding of PBX1-HOX complex to DNA and blocks the transcriptional activity of E2A-PBX1.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28039608%5Buid%5D" target="_blank" rel="noopener noreferrer">28039608</a>', 'Notes': '1) HPIP is highly expressed in high-grade primary ovarian tumors. 2) HPIP promotes the migration, invasion and EMT in OAW42 cells and induces EMT in these cells via activation of the PI3K/AKT pathway. 3) The latter was found to lead to stabilization of the Snail protein and to repression of E-cadherin expression through inactivation of GSK-3β. 4) HPIP expression confers cisplatin resistance to SKOV3 cells after prolonged exposure 5) knockdown decreases the viability of these cells and increases apoptosis following cisplatin treatment.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PBXIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9768" target="_blank" rel="noopener noreferrer">9768</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15004" target="_blank" rel="noopener noreferrer">Q15004</a>', 'HUGO Gene symbol': 'PCLAF', 'Protein name': 'PCNA-associated factor', 'Function': 'A regulator of DNA repair during DNA replication. Following DNA damage, the interaction with PCNA is disrupted, facilitating the interaction between monoubiquitinated PCNA and the translesion DNA synthesis DNA polymerase eta (POLH) at stalled replisomes', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30129654%5Buid%5D" target="_blank" rel="noopener noreferrer">30129654</a>', 'Notes': '1)\xa0P15PAF\xa0(KIAA0101) was significantly upregulated in high-grade serous ovarian cancer (HGSOC) and that high KIAA0101 expression was associated with poor\xa0prognosis. 2) FOXM1 transcriptionally activated KIAA0101 to drive proliferation and metastasis of ovarian cancer cells. 3) KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit\xa0cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in\xa0cisplatin\xa0resistance. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PCLAF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5111" target="_blank" rel="noopener noreferrer">5111</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12004" target="_blank" rel="noopener noreferrer">P12004</a>', 'HUGO Gene symbol': 'PCNA', 'Protein name': 'Proliferating cell nuclear antigen', 'Function': "Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25253786%2C%2024474685%2C%2029721165%2C%209790789%5Buid%5D" target="_blank" rel="noopener noreferrer">25253786, 24474685, 29721165, 9790789</a>', 'Notes': '1) PCNA inhibitor PCNA-I1 induced DNA damage and apoptosis in both LNCaP and PC-3 cells and enhanced DNA damage and apoptosis triggered by cisplatin. 2) T2AA hinders interactions of pol η and REV1 with monoubiquitinated PCNA. 3) ICLs are repaired by mechanisms using translesion DNA synthesis that is regulated by monoubiquitinated PCNA. T2AA significantly delayed reactivation of a reporter plasmid containing an ICL. 4) T2AA significantly enhanced formation of DNA double strand breaks (DSBs) by cisplatin. 5) When cells were treated by cisplatin and T2AA, their clonogenic survival was significantly less than that of those treated by cisplatin only. 5) DTT-defective PcnaK164R lymphomas and breast cancers were compared to their DDT-proficient controls hypersensitive to the chemotherapeutic drug cisplatin (CsPt), both in vitro and in vivo. 6) Poor response to chemotherapy was significantly correlated with P-glycoprotein expression (P < 0.005) and low PCNA labeling (P < 0. 05), ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP/Ub', 'Up / down after Pt-treatment': 'Ub', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PCNA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27250" target="_blank" rel="noopener noreferrer">27250</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q53EL6" target="_blank" rel="noopener noreferrer">Q53EL6</a>', 'HUGO Gene symbol': 'PDCD4', 'Protein name': 'Programmed cell death 4', 'Function': 'Inhibits translation initiation and cap-dependent translation; down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription (16449643). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20735432%5Buid%5D" target="_blank" rel="noopener noreferrer">20735432</a>', 'Notes': '1) Overexpression of PDCD4 enhanced chemosensitivity in SKOV3 and CAOV3 cells with low levels of PDCD4, 2) knockdown of PDCD4 reduced chemosensitivity in OVCAR3 cells with high levels of PDCD4. 3) the combination of enforced PDCD4 expression with cisplatin treatment significantly suppressed ovarian tumor growth in a xenograft animal model. 4) The PDCD4 effect appears to be specific for cisplatin and carboplatin, not affecting cyclophosphamide, etoposide, or paclitaxel. 5) PDCD4 significantly increased cisplatin-induced cleavage of caspase-3 and caspase-8 in vitro and in vivo. 6) A specific caspase-8 inhibitor, Z-ITED-FMK, attenuated cisplatin-induced apoptosis in PDCD4-overexpressing ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDCD4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/80310" target="_blank" rel="noopener noreferrer">80310</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9GZP0" target="_blank" rel="noopener noreferrer">Q9GZP0</a>', 'HUGO Gene symbol': 'PDGFD', 'Protein name': 'Platelet-derived growth factor D', 'Function': 'Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29240605%5Buid%5D" target="_blank" rel="noopener noreferrer">29240605</a>', 'Notes': '1) High PDGF-D expression is positively correlated with International Federation of Gynecology and Obstetrics stage (P < 0.001), histologic grade (P < 0.001), lymph node metastasis (P = 0.022), and poor prognosis (P < 0.001). 2) Platelet-derived growth factor D in platinum-resistant cases is overexpressed compared with that in platinum-sensitive cases (P < 0.001). Obstetrics stage (P = 0.029) and PDGF-D overexpression (P < 0.001) are independently correlated with platinum resistance.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDGFD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5156" target="_blank" rel="noopener noreferrer">5156</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16234" target="_blank" rel="noopener noreferrer">P16234</a>', 'HUGO Gene symbol': 'PDGFRA', 'Protein name': 'Platelet-derived growth factor receptor alpha', 'Function': 'Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/PDGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22266184%5Buid%5D" target="_blank" rel="noopener noreferrer">22266184</a>', 'Notes': '1) Sunitinib synergizes the antitumor effect of cisplatin. 2) sunitinib treatment resulted in the down-regulation of ERCC1 expression via the modulation of\xa0PDGFRA\xa0expression in gastric cancer cells.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDGFRA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5159" target="_blank" rel="noopener noreferrer">5159</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09619" target="_blank" rel="noopener noreferrer">P09619</a>', 'HUGO Gene symbol': 'PDGFRB', 'Protein name': 'Platelet-derived growth factor receptor beta', 'Function': 'Tyrosine-protein kinase receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/PDGF', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16575905%2C%2029857117%2C%2024277456%5Buid%5D" target="_blank" rel="noopener noreferrer">16575905, 29857117, 24277456</a>', 'Notes': "1) PDGFRB inhibitor ST1571 sensitize cisplatin-resistant U87/Pt cells toward cisplatin. STI571 specifically inhibited PDGF-BB-, but not PDGF-AA- or stem cell factor-mediated signaling. 2) In serum-containing medium, STI571 decreased phospho-Akt in U87/Pt cells, but not in U87, while activating extracellular signal-regulated kinase (Erk) in both. 3) STI571 antiproliferative effects were partially reverted by constitutively active Akt. 4) Cotreatment with inhibitors of phosphatidylinositol 3'-kinase (PI3K) or mitogen-activated protein kinase kinase (MEK) resulted in enhanced growth inhibition in glioma cells. 5) combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDGFRB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2923" target="_blank" rel="noopener noreferrer">2923</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30101" target="_blank" rel="noopener noreferrer">P30101</a>', 'HUGO Gene symbol': 'PDIA3', 'Protein name': 'Protein disulfide-isomerase A3', 'Function': 'Protein disulfide isomerases (PDIs) such as P4HB and PDIA3 act as molecular chaperones for reconstructing misfolded proteins, and are involved in endoplasmic reticulum stress and the unfolded protein response.', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone<br><br> Detox<br><br> ER stress response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29207176%2C%2026364260%2C%2024478030%5Buid%5D" target="_blank" rel="noopener noreferrer">29207176, 26364260, 24478030</a>', 'Notes': '1) expression levels of P4HB and PDIA3 were upregulated in glioma datasets. their increased expression was then validated in 99 glioma specimens compared with 11 non-tumor tissues. 2) High expression of P4HB and PDIA3 was significantly correlated with high Ki-67 and a high frequency of the TP53 mutation. 3) Kaplan-Meier survival curve and Cox regression analyses showed that glioma patients with high P4HB and PDIA3 expression had a poor survival outcome. 4) knockdown of PDIA3 suppressed cell proliferation, induced cell apoptosis, and decreased the migration of glioma cells. 5) downregulation of P4HB and PDIA3 may contribute to improve the survival of patients who receive chemotherapy and radiotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDIA3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5163" target="_blank" rel="noopener noreferrer">5163</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15118" target="_blank" rel="noopener noreferrer">Q15118</a>', 'HUGO Gene symbol': 'PDK1', 'Protein name': 'Pyruvate dehydrogenase kinase 1 ', 'Function': 'Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Metabolism/Glycolysis<br><br> Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30229902%5Buid%5D" target="_blank" rel="noopener noreferrer">30229902</a>', 'Notes': '1) Pyruvate dehydrogenase kinase 1 (PDK1) was upregulated in cisplatin-resistant ovarian cancer cells. 2) PDK1 knockdown in resistant cells led to increased sensitivity to cisplatin-induced cell death and apoptosis. 3) PDK1 downregulation also reversed the EMT and cell motility in cisplatin-resistant cells. 4) In a mouse xenograft model, tumors derived from PDK1-silenced ovarian cancer cells exhibited decreased tumor growth and EMT compared with control after the cisplatin treatment. 5) PDK1 overexpression led to increased phosphorylation of EGFR, 6) blocking EGFR kinase activity by erlotinib reversed cisplatin resistance induced by PDK1 overexpression. 7) in patients with ovarian cancer, higher PDK1 and p-EGFR levels were associated with chemoresistance. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5166" target="_blank" rel="noopener noreferrer">5166</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16654" target="_blank" rel="noopener noreferrer">Q16654</a>', 'HUGO Gene symbol': 'PDK4', 'Protein name': 'Pyruvate dehydrogenase kinase isozyme 4', 'Function': 'inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate.', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29907593%2C%2033221963%5Buid%5D" target="_blank" rel="noopener noreferrer">29907593, 33221963</a>', 'Notes': '1) Inhibition of PDK4 with dichloroacetate (DCA) resulted in increased PDH activity, reduced cell growth; siRNA knockdown of PDK4 inhibited bladder cancer cell proliferation. 2) Cotreatment of bladder cancer cells with cisplatin and DCA enhanced overall cell death\xa0in vitro.\xa03) Although daily treatment with 200 mg/kg DCA alone did not reduce tumor volumes in a xenograft model, combination treatment with cisplatin resulted in dramatically reduced tumor volumes as compared with either DCA or cisplatin alone. 4) PDK4 is the most up-regulated kinase in cisplatin-resistant cells. 5)  PDK4 upregulation to be directly linked with the acquisition of chemoresistance, driving enhanced tumor cell growth in vitro and in vivo. 6) PDK4 upregulation was detectable in patients with lung adenocarcinoma and that it was correlated with a poorer prognosis for these patients. 7) PDK4 was able to promote lung adenocarcinoma cell growth and cisplatin resistance at least in part via regulating endothelial PAS domain-containing protein 1 (EPAS1) expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDK4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5170" target="_blank" rel="noopener noreferrer">5170</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15530" target="_blank" rel="noopener noreferrer">O15530</a>', 'HUGO Gene symbol': 'PDPK1', 'Protein name': '3-phosphoinositide-dependent protein kinase 1', 'Function': 'Phosphorylates and activates a subgroup of the AGC family of protein kinases: (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 S6 kinase (RPS6KB1), p90 S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-kinase (PRKACA), PKC (PRKCD and PRKCZ), SGK1, SGK2 and SGK3, p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2).', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26087191%2C%2029064423%5Buid%5D" target="_blank" rel="noopener noreferrer">26087191, 29064423</a>', 'Notes': '1) In cisplatin resistant EOC cells, Akt and PDK1 were highly expressed. 2) COL11A1-PDK1 binding protects PDK1 from degradation, which is normally induced by paclitaxel and cisplatin, thus conferring resistance to cisplatin.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDPK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8566" target="_blank" rel="noopener noreferrer">8566</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00764" target="_blank" rel="noopener noreferrer">O00764</a>', 'HUGO Gene symbol': 'PDXK', 'Protein name': 'Pyridoxal kinase', 'Function': 'Required for synthesis of pyridoxal-5-phosphate from vitamin B6', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22854025%2C%2023287530%5Buid%5D" target="_blank" rel="noopener noreferrer">22854025, 23287530</a>', 'Notes': '1) By aggravating a bioenergetic catastrophe that involves the depleion of intracellular glutathione, vitamin B6 exacerbates cisplatin-mediated DNA damage, thus sensitizing a large panel of cancer cell lines to apoptosis. 2) vitamin B6 sensitizes cancer cells to apoptosis induction by distinct types of physical and chemical stress, including multiple chemotherapeutics. 3) This effect requires pyridoxal kinase (Mouse experimentK), the enzyme that generates the bioactive form of vitamin B6. 4) low Mouse experimentK expression levels were found to be associated with poor disease outcome in two independent cohorts of patients with NSCLC.\xa05) the siRNA-mediated downregulation of pyridoxal kinase (Mouse experimentK), the enzyme that generates the bioactive form of vitamin B6, protects NSCLC cells (as well as a large collection of human and murine malignant cells of distinct histological derivation) from the cytotoxic effects of CDDP. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDXK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57026" target="_blank" rel="noopener noreferrer">57026</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96GD0" target="_blank" rel="noopener noreferrer">Q96GD0</a>', 'HUGO Gene symbol': 'PDXP', 'Protein name': 'Pyridoxal phosphate phosphatase', 'Function': "catalyzes the dephosphorylation of pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP)", 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22854025%2C%2023287530%5Buid%5D" target="_blank" rel="noopener noreferrer">22854025, 23287530</a>', 'Notes': 'AS Mouse experimentK. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDXP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5174" target="_blank" rel="noopener noreferrer">5174</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5T2W1" target="_blank" rel="noopener noreferrer">Q5T2W1</a>', 'HUGO Gene symbol': 'PDZK1', 'Protein name': 'Na(+)/H(+) exchange regulatory cofactor NHE-RF3', 'Function': 'A scaffold protein that connects plasma membrane proteins and regulatory components', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27322682%5Buid%5D" target="_blank" rel="noopener noreferrer">27322682</a>', 'Notes': 'Silencing of CHMP2B and PDZK1 in both A2780-DR and HO-8910 cells led to decreased cellular cisplatin accumulation', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDZK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8682" target="_blank" rel="noopener noreferrer">8682</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15121" target="_blank" rel="noopener noreferrer">Q15121</a>', 'HUGO Gene symbol': 'PEA15', 'Protein name': 'Astrocytic phosphoprotein PEA-15', 'Function': 'Blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. Inhibits RPS6KA3 activities by retaining it in the cytoplasm. Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity and apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Oncogene signaling/AKT<br><br> Oncogene signaling/MAPK', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32102425%2C%2030569123%2C%2023481023%5Buid%5D" target="_blank" rel="noopener noreferrer">32102425, 30569123, 23481023</a>', 'Notes': '1) overexpression of PEA-15AA (a non-phosphorylatable variant) sensitised OC SKOV-3 cells to cisplatin. 2) PEA‑15 was overexpressed in gastric cancer tissues and associated with tumor staging, differentiation, pathological types and the prognosis of patients. 3) PEA‑15 depletion inhibited cell proliferation by reducing cyclin D1 expression through the extracellular signal‑regulated kinase (ERK) pathway, resulting in cell cycle arrest at the G1 phase, and induced apoptosis by activating caspase‑8. 4) PEA‑15 depletion also enhanced the inhibitory effect of CDDP that caused cell cycle arrest at the S phase 5) and also enhanced the pro‑apoptotic activity of CDDP in vitro and in animal models of tumorigenesis and therapeutic effects. 6) PEA‑15 and its phosphorylated forms were overexpressed in CDDP‑resistant cells, which had higher levels of p‑AKT. Specific inhibition of AKT by MK2206 reduced the expression of p‑PEA‑15 at the Ser116 residue, resulting in sequential downregulation of p‑ERK1/2, cyclin D1 and caspase‑8 activation. 7) expression of PEA-15 resulted in significant protection from cell death induced by cytotoxic drugs (5-FU, cisplatin) in colorectal carcinomas. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PEA15" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8864" target="_blank" rel="noopener noreferrer">8864</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15055" target="_blank" rel="noopener noreferrer">O15055</a>', 'HUGO Gene symbol': 'PER2', 'Protein name': 'Period circadian protein homolog 2', 'Function': 'Transcriptional repressor which forms a core component of the circadian clock.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Immune response<br><br> Oncogene signaling/AKT<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=33244267%5Buid%5D" target="_blank" rel="noopener noreferrer">33244267</a>', 'Notes': '1) Compared with parental cells, SKOV3/DDP cells had dramatically decreased PER2 expression, possibly due to hypermethylation in the PER2 promoter. 2) PER2 overexpression significantly inhibited proliferation while promoting cisplatin-induced apoptosis in SKOV3 and SKOV3/DDP cells. 3) PER2-overexpressing SKOV3/DPP cells yielded significantly reduced tumor mass in cisplatin-treated mice compared with control cells. 4) PER2 overexpression remarkably reduced the protein amounts of PI3K, AKT, and MDR1 while increasing those of caspase 3 and E-cadherin in tumor tissues. 5) Knockdown of PER2 exhibited opposite effects. PER2 overexpression also reduced the serum levels of TNF-α and IL-6 in tumor-bearing mice before the initiation of cisplatin treatment.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PER2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5209" target="_blank" rel="noopener noreferrer">5209</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16875" target="_blank" rel="noopener noreferrer">Q16875</a>', 'HUGO Gene symbol': 'PFKFB3', 'Protein name': '6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3', 'Function': 'Synthesis and degradation of fructose 2,6-bisphosphate', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Hypoxia signaling<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29410405%2C%2030226266%5Buid%5D" target="_blank" rel="noopener noreferrer">29410405, 30226266</a>', 'Notes': '1) Enhanced glycolysis in cancer cells has been linked to cell protection from DNA damaging signals, cisplatin promotes glycolysis, which is suppressed by PFKFB3 deletion. 2) Inhibition of PFKFB3 sensitizes tumor to cisplatin treatment in a xenograft model. 3) cisplatin induces PFKFB3 acetylation, which accumulates PFKFB3 in the cytoplasm. which facilitates its phosphorylation by AMPK, leading to PFKFB3 activation and enhanced glycolysis. 4) PFK158 plus CarBoPt treatments lead to significantly enhanced antitumor activity in a gynecologic cancer mouse model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP/acetylation', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PFKFB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5226" target="_blank" rel="noopener noreferrer">5226</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52209" target="_blank" rel="noopener noreferrer">P52209</a>', 'HUGO Gene symbol': 'PGD', 'Protein name': '6-phosphogluconate dehydrogenase', 'Function': 'Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO2, with concomitant reduction of NADP to NADPH - oxidative pentose phosphate pathway ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/PPP<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28713273%5Buid%5D" target="_blank" rel="noopener noreferrer">28713273</a>', 'Notes': '1) cisplatin-resistant cancer cells (C13∗ and A549DDP), had higher levels of 6PGD compared to their cisplatin-sensitive counterparts (OV2008 and A549). 2) ovarian and lung cancer patients with higher 6PGD levels have worse survival outcomes relative to patients with lower 6PGD expression. 3) the upregulation of 6PGD in cisplatin-resistant cells was due to the decreased expression of miR-206 and miR-613, which we found to target this enzyme. 4) suppressing 6PGD using shRNA, inhibitor or miR-206/miR-613, either as single agents or in combination, could sensitize cisplatin-resistant cancer cells to cisplatin treatment and thereby improving the therapeutic efficacy of cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PGD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5230" target="_blank" rel="noopener noreferrer">5230</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00558" target="_blank" rel="noopener noreferrer">P00558</a>', 'HUGO Gene symbol': 'PGK1', 'Protein name': 'Phosphoglycerate kinase 1', 'Function': 'Glycolytic enzyme via the reversible conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate; acts as a polymerase alpha cofactor protein in lagging strand DNA replication.', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone<br><br> DDR<br><br> Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30925862,23060548,29199648" target="_blank" rel="noopener noreferrer">30925862, 23060548, 29199648</a>', 'Notes': '1) PGK1 expression is elevated in tumor tissues of endometrial cancer, and high PGK1 levels are associated with clinical stages and metastasis. 2) Knockdown of PGK1 inhibits proliferation of endometrial cancer cells, and enhances the inhibitory effect of cisplatin on cell viability. 3) knockdown of PGK1 down-regulates the expression of DNA repair-related proteins, methylation-related enzymes, and total cellular methylation level. 4) PGK1 interact directly with HSP90 and exhibit pro-tumor effects by modulating the ATPase activity of HSP90. 5) siRNA knockdown of PGK1 significantly reduced cell growth and sensitized chemoresistant ovarian cells to cisplatin. 6) The osteosarcoma-sensitive tissue was analyzed using 2-DE and MS: cisplatin-resistant and cisplatin-sensitive osteosarcoma tissues were obtained. Five significantly differentially expressed proteins were identified, including ALDOA and PGK1.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PGK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10857" target="_blank" rel="noopener noreferrer">10857</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00264" target="_blank" rel="noopener noreferrer">O00264</a>', 'HUGO Gene symbol': 'PGRMC1', 'Protein name': 'Progesterone receptor membrane component-1 ', 'Function': 'PGRMC1 enhances autophagy, activates cytochrome p450, and invokes signaling pathways to promote cell survival and reduce the effect of drug treatments. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Hormone receptor signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19797399%2C%2028197632%5Buid%5D" target="_blank" rel="noopener noreferrer">19797399, 28197632</a>', 'Notes': "1) PGRMC1-deplete cells grew slower in vitro and did not show progesterone's (P4) antiapoptotic effect. 2) When transplanted into the peritoneum of athymic nude mice, parental dsRed-SKOV-3 cells developed numerous tumors. CDDP increased the percentage of apoptotic nuclei in typical clear cell tumors and P4 attenuated CDDP-induced apoptosis. 3) PGRMC1-deplete tumors developed in fewer mice; appeared smaller. These PGRMC1-deplete tumors were not responsive to CDDP's apoptotic effects. 4) The failure to respond to CDDP could be due to their poorly developed microvasculature system as judged by percentage of CD31-stained endothelial cells and/or their increased expression of ATP-binding cassette transporters, which are involved in drug resistance. 5) PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PGRMC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5245" target="_blank" rel="noopener noreferrer">5245</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35232" target="_blank" rel="noopener noreferrer">P35232</a>', 'HUGO Gene symbol': 'PHB', 'Protein name': 'Prohibitin', 'Function': 'Prohibitin inhibits DNA synthesis; associated with a block in the G0/G1 phase of the cell cycle and also with cell survival. PHB proteins act as a chaperone in the assembly of subunits of mitochondrial respiratory chain complexes (11852914)', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Chaperone<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20957754%2C%2018183577%2C%2028562344%2C%2025112877%5Buid%5D" target="_blank" rel="noopener noreferrer">20957754, 18183577, 28562344, 25112877</a>', 'Notes': '1) Phb1 is primarily associated with the mitochondria in ovarian cancer cells. 2) Over-expression of Phb1 by adenoviral Phb1 infection resulted in an increase in the percentage of ovarian cancer cells accumulating at G0/G1 phase of the cell cycle. 3) There is a significant decrease of PHB in tumor tissues from ovarian cancer patients who were resistant to platinum-based chemotherapies. 4) PHB accumulated in melanoma cell lines under stressing stimuli, such as cisplatin; 5) Prohibitin accumulated in the mitochondria of melanoma cells after cisplatin treatment and its de novo accumulation led to chemoresistance melanoma cell lines. 6) PHB knock-down sensitized melanoma cells to cisplatin treatment. 7) Prohibitin 1 (Phb1) dissociates from Opa1-Phb1 complex and binds phosphorylated p53 (serine 15) in response to CDDP in chemosensitive but not chemoresistant cervical cancer cells. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PHB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26227" target="_blank" rel="noopener noreferrer">26227</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43175" target="_blank" rel="noopener noreferrer">O43175</a>', 'HUGO Gene symbol': 'PHGDH', 'Protein name': 'D-3-phosphoglycerate dehydrogenase', 'Function': 'Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/amino acid<br><br> Redox<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32581546%2C%2032386122%2C%2025719555%2C%2033284994%5Buid%5D" target="_blank" rel="noopener noreferrer">32581546, 32386122, 25719555, 33284994</a>', 'Notes': '1) reduced concentrations of serine or inhibition of PHGDH hindered the toxicity and pro-apoptotic effects of cisplatin on gastric cancer cells. 2) the addition of serine could reverse the sensitivity of gastric cancer cells to cisplatin. 3) DNA damage was reduced by treatment with PHGDH inhibitor NCT-503 or CBR-5884. 4) Inhibition of serine metabolism induced a decrease in H3K4 tri-methylation, which was reversed by JIB-04 (inhibitor of H3K4 demethylase). 5) The tolerance of gastric cancer cells to cisplatin was relieved by JIB-04. 6) Through micrococcal nuclease experiments, we further found that inhibiting the activity of PHGDH strengthened chromatin tightness. 7) combined treatment using a PHGDH inhibitor and gemcitabine/cisplatin achieved synergistic tumor suppression compared to use of a single agent both in vitro as well as in vivo. 8) elevated PHGDH expression was found in cervical adenocarcinoma and was associated with tumor size and prognosis. 9) Knocking down PHGDH in HeLa cells significantly inhibited cell proliferation and increased cisplatin chemotherapy sensitivity. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PHGDH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5290" target="_blank" rel="noopener noreferrer">5290</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42336" target="_blank" rel="noopener noreferrer">P42336</a>', 'HUGO Gene symbol': 'PIK3CA', 'Protein name': 'Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform', 'Function': 'Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15790433%2C%2016275998%2C%2019701705%2C%2023266353%2C%2027489350%5Buid%5D" target="_blank" rel="noopener noreferrer">15790433, 16275998, 19701705, 23266353, 27489350</a>', 'Notes': '1) OVCAR-3/CDDP cells were 4.8-fold more resistant to cisplatin compared to OVCAR-3 cells following 72 h exposure to this drug. 2) Cisplatin inhibited Akt phosphorylation and activation in OVCAR-3 cells but not in OVCAR-3/CDDP cells. 3) The specific PI3K inhibitors LY294002 and wortmannin sensitized OVCAR-3/CDDP cells to cisplatin-induced apoptosis and decreased cell viability. 4) A low level of PTEN expression was strongly associated with amplified PIK3CA and PI3K/Akt activities in OVCAR-3/CDDP cells. 5) siRNA knockdown of PTEN and the expression of active p110alpha resulted in a blockade of apoptosis by cisplatin in OVCAR-3 cells. 6) LY294002 in combination with carboplatin was more effective in inhibiting ovarian cancer cell xenograft growth than either agent alone. 7) PIK3CA protein expression was assessed in a well-characterized series of early stage BC (n = 1,394) with long-term follow-up, using tissue microarrays and immunohistochemistry. 8) Patients with PIK3CA positive tumors had shorter BC specific and disease free survival, independent of other prognostic factors except grade. 9) PIK3CA mutation in patients with early stage (IB/II) cervical cancer was associated with poor survival after treatment with radiation and cisplatin, 10) PIK3CA-E545K (activating) mutation renders cervical cancer cells more resistant to cisplatin. 11) these phenotypes were reversed by the PI3K inhibitor GDC-0941. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3CA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5291" target="_blank" rel="noopener noreferrer">5291</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42338" target="_blank" rel="noopener noreferrer">P42338</a>', 'HUGO Gene symbol': 'PIK3CB', 'Protein name': 'Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform', 'Function': 'Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25884497%5Buid%5D" target="_blank" rel="noopener noreferrer">25884497</a>', 'Notes': '1) 717 splicing events affected by cisplatin, including 245 events involving cassette exons. 2) the cisplatin-induced splicing alterations required class I PI3Ks P110β but not components such as ATM, ATR and p53 that are involved in the DNA damage response. 3) The siRNA-mediated depletion of the splicing regulator SRSF4, but not SRSF6, expression abrogated many of the splicing alterations as well as cell death induced by cisplatin.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3CB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5294" target="_blank" rel="noopener noreferrer">5294</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48736" target="_blank" rel="noopener noreferrer">P48736</a>', 'HUGO Gene symbol': 'PIK3CG', 'Protein name': 'Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform', 'Function': 'Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 to generate PIP3. PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21652733%5Buid%5D" target="_blank" rel="noopener noreferrer">21652733</a>', 'Notes': '1) The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. 2) a set of 6 genes comprising ATR, LYK5, MPP2, PIK3CG, PIK4CA, and WNK4 were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. 3) overexpression of LYK5 and PIK3CG in tumor samples. 4) A pharmacological inhibitor of p110γ (encoded by PIK3CG) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3CG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5295" target="_blank" rel="noopener noreferrer">5295</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27986" target="_blank" rel="noopener noreferrer">P27986</a>', 'HUGO Gene symbol': 'PIK3R1', 'Protein name': 'Phosphatidylinositol 3-kinase regulatory subunit alpha', 'Function': 'Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane.\xa0Stabilizes the PI3K protein heterodimers. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29327155%2C%2021571862%5Buid%5D" target="_blank" rel="noopener noreferrer">29327155, 21571862</a>', 'Notes': '1) MiR-503 expression was significantly downregulated in cisplatin-resistant ovarian cancer cell line SKOV3/DDP compared with parental SKOV3. 2) Over-expression and knock-down of miR-503 partially regulated apoptotic activity and changed the cisplatin resistance of ovarian cancer cells. 3) miR-503 can directly target PI3K p85 and participates in the regulation of the PI3K/Akt signaling pathway. 4) miR-503 agomirs combined with cisplatin treatment significantly reduced the growth of tumors compared with cisplatin alone. 5) Our analysis identified 4 genes, HDAC4, STAT1, FOLR2, and\nPIK3R1 as overexpressed in clinically resistant cells, each of which also significantly potentiated cisplatin response when\nknocked down by siRNA.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3R1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5296" target="_blank" rel="noopener noreferrer">5296</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00459" target="_blank" rel="noopener noreferrer">O00459</a>', 'HUGO Gene symbol': 'PIK3R2', 'Protein name': 'Phosphatidylinositol 3-kinase regulatory subunit beta', 'Function': 'Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane.\xa0Stabilizes the PI3K protein heterodimers. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29327155%5Buid%5D" target="_blank" rel="noopener noreferrer">29327155</a>', 'Notes': 'As PI3KR1', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3R2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5292" target="_blank" rel="noopener noreferrer">5292</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11309" target="_blank" rel="noopener noreferrer">P11309</a>', 'HUGO Gene symbol': 'PIM1', 'Protein name': 'Serine/threonine-protein kinase pim-1', 'Function': 'Involved in cell survival and cell proliferation and thus provides a selective advantage in tumorigenesis.\xa0Involved in the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> MYC signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25342548%2C%2030349298%20%5Buid%5D" target="_blank" rel="noopener noreferrer">25342548, 30349298¬†</a>', 'Notes': "1) Pim-1 was upregulated in 66.2% of the lung tumor tissues and its expression was significantly related to advanced stage (P\u2009=\u20090.019) and lymph node metastasis (P\u2009=\u20090.026). 2) Reduced Pim-1 expression suppressed NSCLC cell growth, cell cycle progression and migration in vitro. 3) Pim-1 was a novel target of miR-486-5p determined by luciferase report assay, and ectopic miR-486-5p expression in cancer cells reduced Pim-1 expression. 4) eukaryotic translation initiation factor 4E (eIF4E) controlled the synthesis of Pim-1 in NSCLC cells, and its expression was positively associated with that of Pim-1 in NSCLC tissue specimens (r\u2009=\u20090.504, p\u2009<\u20090.001). 5) The downregulated miR-486-5p and upregulated eIF4E in NSCLC cells led to the overexpression of Pim-1 by relieving the inhibitory effect of the 3'-UTR or 5'-UTR of Pim-1 mRNA, 6) Pim-1 knockdown sensitized NSCLC cells to cisplatin. 7) Pim1 was also overexpressed in Ovarian Cancer and correlated with poor overall survival by bioinformatics analysis.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11040" target="_blank" rel="noopener noreferrer">11040</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P1W9" target="_blank" rel="noopener noreferrer">Q9P1W9</a>', 'HUGO Gene symbol': 'PIM2', 'Protein name': 'Serine/threonine-protein kinae pim-2 ', 'Function': 'Involved in cell survival and cell proliferation.\xa0Involved in the regulation of MYC transcriptional activity, cell cycle progression, cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> MYC signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25099161%5Buid%5D" target="_blank" rel="noopener noreferrer">25099161</a>', 'Notes': '1) All three PIM kinases were found expressed in a panel of 10 ovarian cancer cell lines, with the oncogenic PIM2 being the most commonly induced by cisplatin. 2) Targeting PIM2 kinase by either biochemical inhibitors or RNA interference impaired cell growth, decreased cisplatin-triggered BAD phosphorylation, and sensitized ovarian cancer cells to drug-induced apoptosis. 3) Overexpression of PIM2 triggered anchorage-independent growth and resulted in increased BAD phosphorylation and cell resistance to DNA damaging agents. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIM2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/65018" target="_blank" rel="noopener noreferrer">65018</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BXM7" target="_blank" rel="noopener noreferrer">Q9BXM7</a>', 'HUGO Gene symbol': 'PINK1', 'Protein name': 'PTEN induced kinase 1', 'Function': 'Protects against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30385753%2C%2028259921%20%5Buid%5D" target="_blank" rel="noopener noreferrer">30385753, 28259921¬†</a>', 'Notes': '1) PINK1 and Parkin were increased in kidney tissues during cisplatin treatment of mice. 2) In PINK1 or Parkin gene knockout mouse models, both basal and cisplatin-induced mitophagy in kidneys were defective. 3) PINK1 and Parkin knockout mice showed more severe renal functional loss, tissue damage, and apoptosis during cisplatin treatment. 4) The results suggest that PINK1/Parkin-mediated mitophagy is activated in cisplatin nephrotoxicity and has a protective role against kidney injury. 5) high PINK1 expression in NSCLC tumor tissues and cell lines. 6) PINK1 expression was associated with a more invasive tumor phenotype and poor prognosis. 7) in vitro studies using upregulation and knockdown of PINK1 confirmed that PINK1 promoted cell proliferation of NSCLC, which might be through as the NF-κB pathway. 8) downregulation of PINK1 enhanced cisplatin (CDDP)-induced NSCLC cell apoptosis.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PINK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55124" target="_blank" rel="noopener noreferrer">55124</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TC59" target="_blank" rel="noopener noreferrer">Q8TC59</a>', 'HUGO Gene symbol': 'PIWIL2', 'Protein name': 'Piwi-like protein 2', 'Function': 'Endoribonuclease that plays a central role during spermatogenesis', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21310163%2C%2022110608%5Buid%5D" target="_blank" rel="noopener noreferrer">21310163, 22110608</a>', 'Notes': '1) cisplatin induces chromatin relaxation in PIWIL2 (Mili)-Wild type (WT) mouse embryonic fibroblasts (MEFs), but not in Mili-knockout (KO) MEFs. 2) Mili is required for maintaining the euchromatic marks in MEFs upon cisplatin treatment. In addition, Mili-KO MEFs exhibited a significant deficiency in repairing cisplatin-induced DNA damage and displayed higher sensitivity to cisplatin. 3) Piwil2 was also enhanced in two completely different cisplatin-resistant ovarian cancer cell lines. 4) knockdown of Piwil2 expression in these two cell lines also resulted in their enhanced sensitivity to cisplatin and decreased their efficiency for removing cisplatin-induced DNA intrastrand crosslinks (Pt-GG). 5) PIWIL2 Mediates DNA Repair through Relaxation of Chromatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIWIL2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5315" target="_blank" rel="noopener noreferrer">5315</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14618" target="_blank" rel="noopener noreferrer">P14618</a>', 'HUGO Gene symbol': 'PKM', 'Protein name': 'Pyruvate kinase PKM', 'Function': 'converts PEP to pyruvate; the ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production; in tumor cells, it tends to exist as dimer PKM2; acts as a protein kinase and phosphorylates proteins, including histones; and Bcl2 which prevents the subsequent degradation of Bcl2 (28035139). \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Metabolism/Glycolysis<br><br> Metabolism/PPP<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27492148%2C%2030443191%2C%2033456577%5Buid%5D" target="_blank" rel="noopener noreferrer">27492148, 30443191, 33456577</a>', 'Notes': '1) PKM2 was significantly upregulated in cervical cancer tissues after treatment with neoadjuvant chemotherapy (NACT). 2) Using paired tumor samples (pre- and post-chemotherapy) from 36 cervical cancer patients, the mTOR/HIF-1α/c-Myc/PKM2 signaling pathway was significantly downregulated in post-chemotherapy cervical cancer tissues. 3) High levels of\xa0mTOR, HIF-1α, c-Myc, and PKM2 were associated with a positive chemotherapy response in cervical cancer patients treated with\xa0cisplatin-based NACT. 4) PKM2 knockdown desensitized cervical cancer cells to\xa0cisplatin. 5) PKM2, a glycolytic enzyme for Warburg effect, is strongly upregulated in BC, and contributes to the cisplatin resistance in BC: the expression level of PKM2 is higher in cisplatin resistant BC cells and tumors. 6) Down-regulation of PKM2 by siRNA or inhibition of PKM2 by shikonin re-sensitized the cisplatin resistant T24 cells. 7) Shikonin and cisplatin together exhibit significantly greater killing effects than when used alone. 8) Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PKM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9373" target="_blank" rel="noopener noreferrer">9373</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y263" target="_blank" rel="noopener noreferrer">Q9Y263</a>', 'HUGO Gene symbol': 'PLAA', 'Protein name': 'Phospholipase A(2) (PLA(2))-activating protein ', 'Function': 'regulates eicosanoid production and participates in inflammatory responses.\xa0Involved in ubiquitin-mediated membrane proteins trafficking to late endosomes. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19258036%2C%2019276398%5Buid%5D" target="_blank" rel="noopener noreferrer">19258036, 19276398</a>', 'Notes': '1) Cisplatin-stimulated plaa(high) cells contained significantly higher levels of DNA fragmentation, caspase 3, 8 and 9 activities, PLA(2) enzyme activity, and cytochrome c leakage from mitochondria than did the cisplatin-stimulated plaa(low) cells. 2) siRNA against PLAA (siRNA-PLAA) reduced the levels of cisplatin-induced PLAA, DNA fragmentation, and PLA(2) activation, while promoting cell viability in both plaa(high) and plaa(low) cells.\xa03) Of 116 colorectal cancer (CRC) patients with PLA2-negative tumors living significantly longer (P\u2009=\u20090.025).', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLAA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5347" target="_blank" rel="noopener noreferrer">5347</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P53350" target="_blank" rel="noopener noreferrer">P53350</a>', 'HUGO Gene symbol': 'PLK1', 'Protein name': 'Polo-like kinase 1', 'Function': 'important throughout M phase:  centrosome maturation, spindle assembly, the removal of cohesins, the inactivation of anaphase-promoting complex for mitotic exit and cytokinesis;\xa0suppresses the DNA damage response by inactivating the ATR/Chk1 pathway and the ATM/Chk2 pathway (16934469)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Cell cycle<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27748936%2C%2029663364%2C%2030876762%2C%2030488440%5Buid%5D" target="_blank" rel="noopener noreferrer">27748936, 29663364, 30876762, 30488440</a>', 'Notes': '1) miR-100 was lower in cisplatin resistant cell line SKOV3/DDP than in cisplatin sensitive cell line SKOV3. 2) mTOR and PLK1 are targets of miR-100. 3) tumors derived from miR-100 mimic-transfected cells were more sensitive to cisplatin and had reduced expression of mTOR and PLK1. 4) cisplatin-resistant OC cells have anaphase promoting complex/cyclosome (APC/C) dysfunction thus increased spindle checkpoint activity and functional dependency on PLK1 for mitotic exit. 5) PLK1 inhibition decreased the survival of cisplatin-resistant cells in vitro and in vivo and exacerbated spindle checkpoint response in these cells. 6) Both protein expressions were found to correlate with chemoresistance in patients with OCCC. 7) the combination of PLK1 inhibitor BI2536 and DDP was synergistic in ESCC cells, which induced pyroptosis in ESCC cells at low doses. 8) BI2536 significantly induced DNA damage and impaired the DNA damage repair pathway in DDP-treated cells both in vitro and in vivo. 9) By downregulating the expression of PLK1, both BI2536 andsi-PLK1 enhanced SGC-7901/DDP sensitivity to DDP, suppressing the proliferation and autophagy in GC cells. PLK1 inhibition also resulted in the repression of  CDC25C and cyclin B1.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10769" target="_blank" rel="noopener noreferrer">10769</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NYY3" target="_blank" rel="noopener noreferrer">Q9NYY3</a>', 'HUGO Gene symbol': 'PLK2', 'Protein name': 'Polo-like kinase 2', 'Function': 'A transcriptional target of p53 and activates a G2-M checkpoint; PLK2 physically binds to and phosphorylates TAp73 (26625870)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22289679%2C%2032349184%2C%2021402713%5Buid%5D" target="_blank" rel="noopener noreferrer">22289679, 32349184, 21402713</a>', 'Notes': '1) The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. 2) the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy. 3) PLK2 inhibition in Mouse experiment-OS cells prohibited clone formation, as indicated by a clonogenic assay, and sensitized osteosarcoma (OS) cells to cisplatin (CDDP). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5366" target="_blank" rel="noopener noreferrer">5366</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13794" target="_blank" rel="noopener noreferrer">Q13794</a>', 'HUGO Gene symbol': 'PMAIP1', 'Protein name': 'Phorbol-12-myristate-13-acetate-induced protein 1', 'Function': 'Contributes to p53/TP53-dependent apoptosis after radiation exposure and chemotherapy. Promotes activation of caspases. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25143433%2C%2023302226%2C%2022509021%5Buid%5D" target="_blank" rel="noopener noreferrer">25143433, 23302226, 22509021</a>', 'Notes': "1) Cisplatin treatment elicited apoptosis, ATM phosphorylation, upregulation of p53, Noxa (PMAIP1), and PUMA (BBC3), and cleavage of caspase-9, -7, fodrin, and PARP-1 in MCF-7 cells. 2) High constitutive NOXA levels are central for hypersensitivity of embryonal carcinoma cells to cisplatin. 3) miR-155 binding sites in the 3' UTRs of the targets, Tspan14, Lpin1, and Pmaip1. 4) H. pylori-infected miR-155(-/-) BMMs were significantly more susceptible to cisplatin DNA damage-induced apoptosis than were wild-type BMMs. ", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PMAIP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6490" target="_blank" rel="noopener noreferrer">6490</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40967" target="_blank" rel="noopener noreferrer">P40967</a>', 'HUGO Gene symbol': 'PMEL', 'Protein name': 'Melanocyte protein PMEL / 100 kDa\xa0type I\xa0transmembrane glycoprotein ', 'Function': 'amyloidogenic protein that is expressed primarily in pigment cells of the skin and eye; undergoes proteolytic processing to generate fibrils in MVB\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23921446%2C%2026066081%5Buid%5D" target="_blank" rel="noopener noreferrer">23921446, 26066081</a>', 'Notes': '1) knockdown of gp100/PMEL sensitized the cells to both paclitaxel and\xa0cisplatin in the MNT-1 melanoma cell line.\xa02) Cisplatin exposure triggers ligand-independent EGF receptor (EGFR) endocytosis; Stress-internalized EGFR co-segregates with exogenously expressed pre-melanosomal markers OA1 and fibrillar PMEL, following early endosomal sorting by the actin polymerization-promoting WASH complex; 3) knockdown of gp100/PMEL sensitized the cells to both paclitaxel and cisplatin', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PMEL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5371" target="_blank" rel="noopener noreferrer">5371</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29590" target="_blank" rel="noopener noreferrer">P29590</a>', 'HUGO Gene symbol': 'PML', 'Protein name': 'promyelocytic leukemia', 'Function': 'Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9398618%2C%2028744813%2C%2030244973%5Buid%5D" target="_blank" rel="noopener noreferrer">9398618, 28744813, 30244973</a>', 'Notes': '1) cisplatin at 6 micrograms/ml caused more than 5-10 fold increases in PML protein in hela cells; the induction is a post-transcriptional event. 2) PML expression in p53 transduced cells were 5-10 fold higher than the control, indicating that the enhanced expression of PML is apparently dependent on the p53 pathway. 3) combining use of CDDP with CK2 siRNA or inhibitor is more efficient in suppressing NSCLC cancer cell growth and promoting apoptosis than use of CDDP alone; CK2 suppresses proapoptosis gene PML. 4) High-OXPHOS HGSOCs showed a stronger PML histologic score. 5) High-PML HScores were associated with better patient prognosis in HGSOC patients. 6) PML and PGC-1a silencing significantly reduced the chemosensitivity (toward Platinum) of high-OXPHOS OCCLs. 7) PML silencing in mouse models also significantly reduced chemosensitivity in vivo. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PML" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5395" target="_blank" rel="noopener noreferrer">5395</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P54278" target="_blank" rel="noopener noreferrer">P54278</a>', 'HUGO Gene symbol': 'PMS2', 'Protein name': 'Mismatch repair endonuclease PMS2', 'Function': 'Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MMR<br><br> DDR/MMR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26423401%2C%2021528244%2C%2012601175%5Buid%5D" target="_blank" rel="noopener noreferrer">26423401, 21528244, 12601175</a>', 'Notes': '1) The expression of PMS2 is inversely correlated with Akt activity in human ovarian cancer in EOC cell lines and tissues; the PMS2 expression was negatively correlated with primary tumor stage in human EOC tissues 2) Akt could directly bind to\xa0PMS2\xa0and cause degradation of\xa0PMS2\xa0in EOC cells. 3)\xa0PMS2 promotes cisplatin-induced apoptosis; and\xa0was required for\xa0cisplatin-induced apoptosis and cell cycle arrest in G2/M phase.\xa04) simple recognition of the cisplatin adduct by the MSH2/MSH6 heterodimer is not sufficient for full detector function, but that PMS2 is also required for the pro-apoptotic signal to be generated from this detector. 5) Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PMS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11284" target="_blank" rel="noopener noreferrer">11284</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96T60" target="_blank" rel="noopener noreferrer">Q96T60</a>', 'HUGO Gene symbol': 'PNKP', 'Protein name': 'Bifunctional polynucleotide phosphatase/kinase', 'Function': "part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways. PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER<br><br> DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26336131%2C%2019364127%5Buid%5D" target="_blank" rel="noopener noreferrer">26336131, 19364127</a>', 'Notes': '1) SiRNAs targeting\xa0pnkp\xa0significantly sensitized Gliomas cells to cDDP. 2) Photoaffinity labeling reveals nuclear proteins (including PNK) that uniquely recognize cisplatin-DNA interstrand cross-links.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PNKP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5420" target="_blank" rel="noopener noreferrer">5420</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00592" target="_blank" rel="noopener noreferrer">O00592</a>', 'HUGO Gene symbol': 'PODXL', 'Protein name': 'Podocalyxin', 'Function': 'anti-adhesive transmembrane sialomucin. Affects EZR-dependent signaling events, leading to increased activities of the MAPK and PI3K pathways in cancer cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25915207%5Buid%5D" target="_blank" rel="noopener noreferrer">25915207</a>', 'Notes': '1) Overexpression of PODXL is associated with increased aggressiveness of breast and prostate cancer cells. 2) Overexpression of PODXL enhances cisplatin chemoresistance in OTSCC cells. It can be supressed by BMI1 knockdown. 3) knockdown of PODXL decreased cisplatin resistance. It can be reversed by overexpression of BMI1. 4) Overexpression of PODXL in both cell lines markedly elevated the expression level of Bmi1', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PODXL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5423" target="_blank" rel="noopener noreferrer">5423</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06746" target="_blank" rel="noopener noreferrer">P06746</a>', 'HUGO Gene symbol': 'POLB', 'Protein name': 'DNA polymerase beta', 'Function': "Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/BER<br><br> DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28074003%2C%2021357694%2C%2025561897%5Buid%5D" target="_blank" rel="noopener noreferrer">28074003, 21357694, 25561897</a>', 'Notes': '1) POLB rs3136797 germline mutation encoding P242R DNA polymerase beta (Pol β) is associated with poor prognosis for lung cancer, specifically in response to treatment with cisplatin. 2) Pol β preferentially inserts the incorrect nucleotide initiating mismatch repair and cell death. 3) cells defective in BER display a cisplatin-specific resistant phenotype. 4) This was accompanied by enhanced repair of cisplatin interstrand cross-links (ICLs) and ICL-induced DNA double strand breaks, but not intrastrand adducts. 5) Blocking BER with MX as well as deficiency of Polβ and UNG conferred resistance to cisplatin treatment. Complementing Polβ in the knockdown cells restored cisplatin sensitivity, implicating the role of Polβ in cisplatin resistance. 6) The T889C mutation was detected in 18 (10.17%) of 177 GC patients. And the T889C mutation was associated with POLB overexpression, lymph nodes metastases and poor tumor differentiation. 7) patients with- the mutation had significantly shorter survival time than those without-, following postoperative chemotherapy. 8) cell lines with T889C mutation in POLB gene were more resistant to the treatment of 5-fluorouracil, cisplatin and epirubicin than those with wild type POLB. 9) Forced expression of POLB gene with T889C mutation resulted in enhanced cell proliferation, invasion and resistance to anticancer drugs, along with increased DNA repair capability. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5424" target="_blank" rel="noopener noreferrer">5424</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28340" target="_blank" rel="noopener noreferrer">P28340</a>', 'HUGO Gene symbol': 'POLD1', 'Protein name': 'DNA polymerase delta catalytic subunit', 'Function': 'As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30214636%2C%2030344713%2C%2030388038%20%5Buid%5D" target="_blank" rel="noopener noreferrer">30214636, 30344713, 30388038¬†</a>', 'Notes': '1) protein expression levels of POLD1 were significantly elevated in breast cancer tissues compared with those in adjacent normal tissues. 2) Increased expression of POLD1 was associated with poor DFS (P=0.033); with shorter DFS at early-stage (P=0.037), late-stage cases (P=0.023) and with the presence of triple-negative tumors (TNBC; P=0.049). 3) Multivariate analysis revealed that POLD1 may be used as an independent prognostic factor in patients with breast cancer.\xa04) POLD1 expression increased 1.54-fold in cisplatin-resistant T24R BC cells. 5) MDPL has been associated with heterozygous mutations in POLD1 gene resulting in loss of DNA polymerase δ activity. 6) A persistence of DNA damage after cisplatin exposure in MDPL patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5425" target="_blank" rel="noopener noreferrer">5425</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49005" target="_blank" rel="noopener noreferrer">P49005</a>', 'HUGO Gene symbol': 'POLD2', 'Protein name': 'DNA polymerase delta subunit 2', 'Function': 'Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30038717%2C%2024449906%5Buid%5D" target="_blank" rel="noopener noreferrer">30038717, 24449906</a>', 'Notes': '1) the prognostic complementarity between de novo pyrimidine synthesis and nucleotide excision repair expression in a total of 570 bladder urothelial carcinoma patients. 2) the\xa0de novo\xa0pyrimidine synthesis gene CAD is associated with poor survival (P = 0.008) and is co-altered with the nucleotide excision repair gene POLD2.\xa03) Expression of each gene was associated with cisplatin-based therapy resistance, and accordingly, CADhighPOLD2high patients were associated with worse survival than CADhighPOLD2low and CADlowPOLD2high patients. 4) The purified four-subunit Pol ζ4 (Rev3-Rev7-PolD2-PolD3) is much more efficient and more processive at bypassing a 1,2-intrastrand d(GpG)-cisplatin cross-link than the two-subunit Pol ζ2 (Rev3-Rev7). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10714" target="_blank" rel="noopener noreferrer">10714</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15054" target="_blank" rel="noopener noreferrer">Q15054</a>', 'HUGO Gene symbol': 'POLD3', 'Protein name': 'DNA polymerase delta subunit 3', 'Function': 'Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25190177%2C%2027806724%5Buid%5D" target="_blank" rel="noopener noreferrer">25190177, 27806724</a>', 'Notes': '1) Endogenous expression of the peptide resulted in an increase in genomic DNA damage. 2) CaPeptide induction combined with treatment of sublethal doses of cisplatin resulted in a marked increase in death of the cisplatin-resistant MDA-MB-231 cell line. 3) CaPeptide was found to interact with POLD3, one of the subunits of DNA polymerase delta necessary for binding to PCNA. 4) A set of 7 genes (DCLRE1A, EXO1, KIAA0101, KIN, PCNA, POLD3, POLD2) were included in the module 31. Kaplan-Meier plot demonstrated that higher gene expression in this module significantly associate the patients with shorter survivals. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLD3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54107" target="_blank" rel="noopener noreferrer">54107</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NRF9" target="_blank" rel="noopener noreferrer">Q9NRF9</a>', 'HUGO Gene symbol': 'POLE3', 'Protein name': 'DNA polymerase epsilon subunit 3', 'Function': 'Accessory component of the DNA polymerase epsilon complex. Forms a complex with CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29618620%2C%2018302766%5Buid%5D" target="_blank" rel="noopener noreferrer">29618620, 18302766</a>', 'Notes': '1) A clinical correlation between the presence of 9q32-q33.1 gains in cisplatin-refractory patients.\xa02) POLE3\xa0and\xa0AKNA were the only two genes deregulated in resistant tumors harboring the 9q32-q33.1 gain. 3) POLE3 was up-regulated (>1.5-fold) in OC spheroids following cisplatin exposure. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLE3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5429" target="_blank" rel="noopener noreferrer">5429</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y253" target="_blank" rel="noopener noreferrer">Q9Y253</a>', 'HUGO Gene symbol': 'POLH', 'Protein name': 'DNA polymerase eta', 'Function': 'Error-free DNA polymerase in translesion synthesis (TLS), where the normal high fidelity DNA polymerases cannot proceed and DNA synthesis stalls. Plays an important role in the repair of UV-induced pyrimidine dimers and confers resistance to ultraviolet light.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25831546%2C%2022529383%2C%2031064846%2C%2016267001%5Buid%5D" target="_blank" rel="noopener noreferrer">25831546, 22529383, 31064846, 16267001</a>', 'Notes': '1) an elevated expression of DNA polymerase η (Pol η) in ovarian CSCs isolated from both ovarian cancer cell lines and primary tumors, indicating that CSCs may have intrinsically enhanced translesion DNA synthesis (TLS). 2) Down-regulation of Pol η blocked cisplatin-induced CSC enrichment both in vitro and in vivo through the enhancement of cisplatin-induced apoptosis in CSCs, indicating that Pol η-mediated TLS contributes to the survival of CSCs upon cisplatin treatment. 3) A depletion of miR-93 in ovarian CSCs - Enforced expression of miR-93 in ovarian CSCs reduced Pol η expression and increased their sensitivity to cisplatin.\xa04)  high level of PolH is associated with cisplatin resistance in lung and bladder cancer. 5) loss of PolH markedly attenuates cisplatin resistance in both cisplatin-sensitive and cisplatin-resistant lung cancer cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51426" target="_blank" rel="noopener noreferrer">51426</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBT6" target="_blank" rel="noopener noreferrer">Q9UBT6</a>', 'HUGO Gene symbol': 'POLK', 'Protein name': 'DNA polymerase kappa', 'Function': 'DNA polymerase specifically involved in DNA repair. Plays an important role in translesion synthesis, where the normal high-fidelity DNA polymerases cannot proceed and DNA synthesis stalls.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28391554%2C%2029715472%5Buid%5D" target="_blank" rel="noopener noreferrer">28391554, 29715472</a>', 'Notes': '1) strong transcriptional upregulation of the translesion synthesis DNA polymerase kappa (Pol κ), while expression of other DNA polymerases remained unchanged after cisplatin treatment. 2) DNA Pol κ is involved in bypass synthesis of diverse DNA lesions and considered a vital player in cellular survival under injurious conditions. 3) Pol κ targeting siRNA diminished the cisplatin-induced nuclear Pol κ immunoreactivity in DRG neurons and decreased the extent of cisplatin-induced DNA repair synthesis, as reflected in reduced incorporation of thymidine analog into nuclear DNA. 4) Pol κ depletion exacerbated global transcriptional suppression induced by cisplatin in DRG neurons.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLK" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27434" target="_blank" rel="noopener noreferrer">27434</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NP87" target="_blank" rel="noopener noreferrer">Q9NP87</a>', 'HUGO Gene symbol': 'POLM', 'Protein name': 'DNA-directed DNA/RNA polymerase mu', 'Function': 'Gap-filling polymerase involved in repair of DNA double-strand breaks by non-homologous end joining (NHEJ). Participates in immunoglobulin (Ig) light chain gene rearrangement in V(D)J recombination.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=12578393%5Buid%5D" target="_blank" rel="noopener noreferrer">12578393</a>', 'Notes': '1) Pol\xa0mu\xa0bypassed CDDP adducts with an efficiency of 14-35% compared to chain elongation on undamaged DNA, which is second only to pol eta in terms of bypass efficiency. 2) The bypass of Pt-DNA adducts by pol\xa0mu\xa0was highly error-prone on all templates, resulting in 2, 3, and 4 nt deletions. 3) bypass of Pt-DNA adducts by pol\xa0mu\xa0may involve looping out the Pt-GG adduct to allow chain elongation downstream of the adduct. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/353497" target="_blank" rel="noopener noreferrer">353497</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q7Z5Q5" target="_blank" rel="noopener noreferrer">Q7Z5Q5</a>', 'HUGO Gene symbol': 'POLN', 'Protein name': 'DNA polymerase nu', 'Function': 'DNA polymerase with very low fidelity that catalyzes considerable misincorporation by inserting dTTP opposite a G template, and dGTP opposite a T template', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19908865%2C%2016787914%2C%2019995904%5Buid%5D" target="_blank" rel="noopener noreferrer">19908865, 16787914, 19995904</a>', 'Notes': '1) May play a role in TLS during interstrand cross-link (ICL) repair.2) A small-scale siRNA screen targeting human DNA polymerases, in HeLa cells for increased sensitivity to the cross-link-inducing drug cisplatin: Two hits were identified: REV1, and POLN. 3) physical and functional interaction of POLN with factors belonging to the Fanconi anemia pathway, and interacts and cooperates in DNA repair with the helicase HEL308. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10721" target="_blank" rel="noopener noreferrer">10721</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75417" target="_blank" rel="noopener noreferrer">O75417</a>', 'HUGO Gene symbol': 'POLQ', 'Protein name': 'DNA polymerase theta', 'Function': 'synthetic lethal relationship between the HR pathway and Polθ-mediated repair in EOCs', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27533083%5Buid%5D" target="_blank" rel="noopener noreferrer">27533083</a>', 'Notes': '1) expression of translesion synthesis (TLS) polymerase Q (POLQ) was significantly elevated by exposure of lung cancer cells A549/DR (a cisplatin-resistant A549 cell line) to cisplatin. 2) POLQ expression correlated inversely with HR activity. 3) Co-depletion of BRCA2 and POLQ by siRNA markedly increased sensitivity of A549/DR cells to cisplatin. 4) Similar results were observed in A549/DR cells co-depleted of BRCA2 and POLQ following BMN673 (a PARP inhibitor) treatment. 5) the sensitization effects to cisplatin and BMN673 in A549/DR cells by co-depleting BRCA2 and POLQ was stronger than those by co-depleting BRCA2 and other TLS factors including POLH, REV3, or REV1. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POLQ" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10631" target="_blank" rel="noopener noreferrer">10631</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15063" target="_blank" rel="noopener noreferrer">Q15063</a>', 'HUGO Gene symbol': 'POSTN', 'Protein name': 'Periostin', 'Function': 'A disulfide-linked secretory protein expressed in bone tissues as well as an ECM protein (12235007); supports the adhesion and migration ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> ECM/stroma<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26716408%5Buid%5D" target="_blank" rel="noopener noreferrer">26716408</a>', 'Notes': '1) periostin (POSTN) was overexpressed in cancer stroma in epithelial ovarian cancer (EOC) patients. 2) patients with high levels of stromal\xa0POSTN\xa0tend to have higher percentage of\xa0cisplatin\xa0resistance compared to those with low levels of stromal\xa0POSTN. 3)\xa0POSTN\xa0treatment can induce\xa0cisplatin\xa0resistant and activate AKT pathway in A2780 cells in vitro. 4) Inhibition of AKT activity by AKT inhibitor MK-2206 abolished\xa0POSTN-induced AKT activation and\xa0cisplatin\xa0resistance in vitro. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POSTN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5460" target="_blank" rel="noopener noreferrer">5460</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01860" target="_blank" rel="noopener noreferrer">Q01860</a>', 'HUGO Gene symbol': 'POU5F1', 'Protein name': 'POU domain, class 5, transcription factor 1', 'Function': "Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). A well‐known stem cell marker and functional role in mediating chemoresistance", 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24954502%2C%2023340171%2C%2020683952%2C%2021342274%5Buid%5D" target="_blank" rel="noopener noreferrer">24954502, 23340171, 20683952, 21342274</a>', 'Notes': '1) Overexpression of OCT4 enhanced the resistance of HCC cells to chemotherapeutic drugs by activating AKT signaling pathways.\xa02) Elevated OCT4 expression was observed in oxaliplatin‐resistant colorectal cancer (CRC) cell lines with CSC properties 3) OCT4 could activate Signal Transducer and Activator of Transcription 3 (STAT3) pathway, leading to an increase in antiapoptotic property of chemoresistant CRC cells. In head and neck cancer, forced OCT4 expression promoted the conversion of differentiated cells into CSC and conferred resistance to cisplatin. 4) Sphere-forming/self-renewal capability was increased in cisplatin-resistant oral squamous cell carcinoma OC2 cells. 5) Cisplatin-resistant OC2 cells highly expressed the stemness markers (Nanog, Oct4, Bmi1, CD117, CD133, and ABCG2). 6) cisplatin-resistant OC2 cells increased migration/invasion/clonogenicity ability. 6) up-regulation of Oct4 and Nanog expression was significantly observed in cisplatin-resistant patients with OSCC (**P < 0.01).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=POU5F1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10891" target="_blank" rel="noopener noreferrer">10891</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBK2" target="_blank" rel="noopener noreferrer">Q9UBK2</a>', 'HUGO Gene symbol': 'PPARGC1A', 'Protein name': 'Peroxisome proliferator-activated receptor gamma coactivator 1-alpha', 'Function': 'Transcriptional coactivator for steroid receptors and nuclear receptors. regulate key mitochondrial genes as well as genes inovled in glucose and FA metabolism in metabolic reprogramming in response to dietary availability. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29749474%2C%2029472690%2C%2030880247%5Buid%5D" target="_blank" rel="noopener noreferrer">29749474, 29472690, 30880247</a>', 'Notes': '1) the expression of PGC1α and level of mitochondrial biogenesis were higher in cisplatin-resistant OC cell line SKOV3/DDP compared with cisplatin-sensitive SKOV3 cells. 2) SKOV3/DDP cells upregulated the expression of PGC1α and maintained mitochondrial structural and functional integrity through mitochondrial biogenesis under cisplatin stress. 3) Inhibiting the expression of PGC1α using short hairpin RNA led to the downregulation of mitochondrial biogenesis and high levels of apoptosis in the SKOV3/DDP cells, and cisplatin resistance was reversed in the PGC1α-deficient SKOV3/DDP cells.\xa04) ZLN005 increases their PGC-1α mRNA levels and reduces CDDP sensitivity in a  dose-\ndependent manner. 5) In biopsy material of 3 patients, an increase in mitochondrial mass levels and a decrease in the GAPDH/MT-CO1 ratio after platinum-based treatment was observed, strongly suggesting a metabolic reprograming towards a more oxidative metabolism. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPARGC1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/133522" target="_blank" rel="noopener noreferrer">133522</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86YN6" target="_blank" rel="noopener noreferrer">Q86YN6</a>', 'HUGO Gene symbol': 'PPARGC1B', 'Protein name': 'Peroxisome proliferator-activated receptor gamma coactivator 1-beta, PGC-1-beta, PPAR-gamma coactivator 1-beta, PPARGC-1-beta\xa0', 'Function': 'Plays a role of stimulator of transcription factors and nuclear receptors activities. Activates transcriptional activity of estrogen receptor alpha, nuclear respiratory factor 1 (NRF1) and glucocorticoid receptor in the presence of glucocorticoids.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS<br><br> mitochondria/synthesis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22777349%5Buid%5D" target="_blank" rel="noopener noreferrer">22777349</a>', 'Notes': '1) the development of adaptive chemoresistance in the A549 non-small-cell lung cancer cell line to CDDP is associated with the hetero- to homoplasmic shift of a nonsynonymous mutation in MT-ND2, encoding the mitochondrial Complex-I subunit ND2. 2) The mutation resulted in a 50% reduction of the NADH:ubiquinone oxidoreductase activity of the complex, which was compensated by increased biogenesis of respiratory chain complexes. 3) The compensatory mitochondrial biogenesis was most likely mediated by the nuclear co-activators peroxisome proliferator-activated receptor gamma co-activator-1α (PGC-1α) and PGC-1β, both of which were significantly upregulated in the CDDP-resistant cells. 4) both transient and stable silencing of PGC-1β re-established the sensitivity of these cells to CDDP-induced apoptosis. 5) the PGC-1β-mediated CDDP resistance was independent of the mitochondrial effects of the co-activator.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPARGC1B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5493" target="_blank" rel="noopener noreferrer">5493</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60437" target="_blank" rel="noopener noreferrer">O60437</a>', 'HUGO Gene symbol': 'PPL', 'Protein name': 'Periplakin', 'Function': 'Component of the cornified envelope of keratinocytes. May link the cornified envelope to desmosomes and intermediate filaments. May act as a localization signal in PKB/AKT-mediated signaling.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19583808%5Buid%5D" target="_blank" rel="noopener noreferrer">19583808</a>', 'Notes': '1) overexpression of cyclin A2 is an indicator of a poor prognosis of various malignancies including endometrial carcinoma. 2) The expression of cyclin A2 protein was increased in advanced-stage and chemotherapy-refractory stage endometrial carcinomas compared with that in early-stage tumours. 3) The expression levels of cyclin A2 in endometrial carcinoma cell lines correlated positively with the IC(50) for cisplatin. Endometrial carcinoma HHUA cells that overexpressed cyclin A2 showed increased resistance to cisplatin in vitro and in vivo, 4) via the activation of a survival pathway, the inositol-3 phosphate kinase (PI3K) cascade. 5) An Akt-binding protein, periplakin, is a novel target of cyclin A2. 6) The cyclin A2-induced up-regulation of periplakin was mediated via direct binding of Sp1 to the promoter that was activated by cyclin A2 along with chromatin remodelling involving CBP/p300, 7) the siRNA-mediated silencing of periplakin suppressed the PI3K pathway.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8493" target="_blank" rel="noopener noreferrer">8493</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15297" target="_blank" rel="noopener noreferrer">O15297</a>', 'HUGO Gene symbol': 'PPM1D', 'Protein name': 'protein phosphatase magnesium-dependent 1 ', 'Function': 'deactivates both p53 and Chk1 through site-specific dephosphorylation', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21927021%2C%2025154814%5Buid%5D" target="_blank" rel="noopener noreferrer">21927021, 25154814</a>', 'Notes': '1) site-specific differences in phospho-Ser-Chk1 content is different between sensitive and resistant cells in response to CDDP; 2) PPM1D, but not ATM or ATR, is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; 3) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53. 4) CDDP induced PPM1D down-regulation in sensitive CECA cells; 5) CDDP induced PPM1D nuclear localization in resistant CECA cells, and nuclear exclusion in sensitive CECA cells and OVCA xenografts; 6) Over-expression of active Akt in sensitive CECA cells stabilized PPM1D content; 7) Inhibition of Akt activity in resistant OVCA cells leads to decreased PPM1D stability and CDDP-induced down-regulation in resistant CECA cells; 8) PPM1D is highly expressed in human ovarian tumor subtypes and in a tissue microarray panel of ovarian tumors. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPM1D" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5515" target="_blank" rel="noopener noreferrer">5515</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P67775" target="_blank" rel="noopener noreferrer">P67775</a>', 'HUGO Gene symbol': 'PPP2CA', 'Protein name': 'Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform', 'Function': 'PP2A is the major phosphatase for microtubule-associated proteins (MAPs).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23518861%5Buid%5D" target="_blank" rel="noopener noreferrer">23518861</a>', 'Notes': "1) The expression of PP2A catalytic subunit, (PP2Ac) was reduced in A2780/CDDP 2) in cisplatin-resistant patients' tissues compared with A2780 and cisplatin-sensitive patients. 3) Knocking down of PP2A promoted autophagy suppressed DDP-induced apoptosis and cell death. 4) overexpression of PP2Ac or reinduction of the activity of PP2A by FTY720 decreased autophagy but increased cell death induced by CDDP. 5) apoptosis suppressed by the knocking down of PP2Ac can be reversed by the administration of autophagy inhibitor 3-methyladenine. 6) The elevated accumulation of microtubule-associated protein 1 light chain 3-II (LC3II) and the decline of the autophagy substrate p62 were also observed in PP2Ac-small interfering RNA transfected cells. 7) overexpression of PP2Ac suppressed the accumulation of LC3II and restored p62.", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPP2CA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5520" target="_blank" rel="noopener noreferrer">5520</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P63151" target="_blank" rel="noopener noreferrer">P63151</a>', 'HUGO Gene symbol': 'PPP2R2A', 'Protein name': 'Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform', 'Function': 'The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment.', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23087057%2C%2026800397%2C%2031221814%5Buid%5D" target="_blank" rel="noopener noreferrer">23087057, 26800397, 31221814</a>', 'Notes': "1) loss-of-function screen that identifies the PP2A heterotrimeric serine/threonine phosphatases PPP2R2A, PPP2R2D, PPP2R5A, and PPP2R3C in double-strand break (DSB) repair. 2) PPP2R2A-containing complexes directly dephosphorylated ATM at S367, S1893, and S1981 to regulate its retention at DSB sites. 3) Increased miR-222 levels are associated with a poor prognosis in patients with bladder cancer. 4) miR-222 activated the Akt/mTOR pathway and inhibited cisplatin-induced autophagy in bladder cancer cells by directly targeting protein phosphatase 2A subunit B (PPP2R2A). 5) Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin. 6) miR-221 directly targets PPP2R2A in osteosarcoma by binding to the 3'-UTR of the PPP2R2A mRNA; Restoration of PPP2R2A in miR-221-overexpressing OS cells recovers the cisplatin sensitivity of OS cells. ", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PPP2R2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10935" target="_blank" rel="noopener noreferrer">10935</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P30048" target="_blank" rel="noopener noreferrer">P30048</a>', 'HUGO Gene symbol': 'PRDX3', 'Protein name': 'Thioredoxin-dependent peroxide reductase, mitochondrial', 'Function': 'Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23503975%2C%2023564483%5Buid%5D" target="_blank" rel="noopener noreferrer">23503975, 23564483</a>', 'Notes': '1) the aberrant expression of PRDX3 in ovarian cancer may be a factor responsible for its progression. 2) siRNA downregulation of PRDX3 decreased the growth of the SKOV3 cells in vitro and in vivo. 3) silencing of PRDX3 triggered cisplatin‑mediated apoptosis in the ovarian cancer cells, which may act through suppression of the NF‑κB signaling pathway. 4) The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. 5) The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. 6) PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRDX3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5562" target="_blank" rel="noopener noreferrer">5562</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13131" target="_blank" rel="noopener noreferrer">Q13131</a>', 'HUGO Gene symbol': 'PRKAA1', 'Protein name': 'Catalytic subunit-1 of AMP-activated protein kinase (AMPK)', 'Function': 'an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22955258%2C%2020196784%5Buid%5D" target="_blank" rel="noopener noreferrer">22955258, 20196784</a>', 'Notes': '1) A low expression of pAMPK was found to be correlated with better RFS in patients with resected gastric cancer treated with adjuvant cisplatin-based chemotherapy. 2) siRNA-mediated AMPK down-regulation and AMPK inhibitor compound C increased cisplatin-induced tumour cell death (human U251 glioma line). 3) The ability of cisplatin to trigger autophagy was reduced by small interfering RNA (siRNA)-mediated AMPK silencing. ', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKAA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5563" target="_blank" rel="noopener noreferrer">5563</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P54646" target="_blank" rel="noopener noreferrer">P54646</a>', 'HUGO Gene symbol': 'PRKAA2', 'Protein name': 'AMP-activated protein kinase catalytic subunit alpha-2', 'Function': 'Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Metabolism/Glycolysis<br><br> Metabolism/OXPHOS<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29212260%2C%2022728651%2C%2020196784%5Buid%5D" target="_blank" rel="noopener noreferrer">29212260, 22728651, 20196784</a>', 'Notes': '1) AMP kinase subunit α2 (AMPKα2) transcripts and protein expression increased in Pt-resistant lung cancer H1299 cells. 2) Under-expression of AMPK-α2 was significantly correlated with a poorer tumor differentiation classified according to Edmonson’s grading and a poorer disease-free survival rate. 3) ectopic expression of AMPK enhanced the acetylation and stability of p53 in HCC cells. 4) The p53 deacetylase, SIRT1, was phosphorylated and inactivated by AMPK at Thr344, promoting p53 acetylation and apoptosis of HCC cells. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKAA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5564" target="_blank" rel="noopener noreferrer">5564</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y478" target="_blank" rel="noopener noreferrer">Q9Y478</a>', 'HUGO Gene symbol': 'PRKAB1', 'Protein name': 'Non-catalytic B1 subunit of AMP-activated protein kinase (AMPK)', 'Function': 'Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20722101%5Buid%5D" target="_blank" rel="noopener noreferrer">20722101</a>', 'Notes': 'knockdown of ATR, CHK1 and PRKAB1 led to potentiation of cisplatin response in SKOV3 ovarian cancer cells.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKAB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5565" target="_blank" rel="noopener noreferrer">5565</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43741" target="_blank" rel="noopener noreferrer">O43741</a>', 'HUGO Gene symbol': 'PRKAB2', 'Protein name': 'Non-catalytic B2 subunit of AMP-activated protein kinase (AMPK)', 'Function': 'Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22955258%2C%2020196784%5Buid%5D" target="_blank" rel="noopener noreferrer">22955258, 20196784</a>', 'Notes': '1) 40 patients treated with cisplatin-based adjuvant chemotherapy were included in the pAMPK-positive group, while 33 patients were included in the pAMPK-negative group. 2) In a multivariate analysis adjusted for age, sex, Lauren classification, and stage, the pAMPK-negative group was significantly associated with improved RFS (Hazard ratio\xa0=\xa00.459, 95\xa0% CI 0.109-0.711, P\xa0=\xa00.043).', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKAB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5573" target="_blank" rel="noopener noreferrer">5573</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10644" target="_blank" rel="noopener noreferrer">P10644</a>', 'HUGO Gene symbol': 'PRKAR1A', 'Protein name': 'cAMP-dependent protein kinase type I-alpha regulatory subunit', 'Function': 'Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.', 'Putative_mechanism_associated_with_Pt_resistance': 'PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=8853907%2C%2026543233%5Buid%5D" target="_blank" rel="noopener noreferrer">8853907, 26543233</a>', 'Notes': '1) mutants of the Chinese hamster ovary (CHO) and the mouse adrenocortical carcinoma Y1 cells harboring a defective regulatory subunit (RI) of the cAMP-dependent protein kinase (PKA) exhibited increased resistance to cisplatin. 2)\xa0These mutants are cross-resistant to other DNA-damaging chemotherapeutic agents, including bleomycin and melphalan. 3) wild-type CHO cells transfected with and overexpressing the yeast phosphodiesterase gene or a dominant mutant Rl alpha subunit gene also displayed similar increased resistance to cisplatin. 4) mutants with altered catalytic (C) subunits showed a sensitivity to cisplatin similar to the wild-type cells. 5) The Rl subunit mutants showed increased binding of nuclear factor(s) to the damaged DNA. 6) enhanced capacity for repair of DNA lesions in the PKA mutants. 7) rs767649 (A > T) located in miR-155 regulation region. 8) rs767649 exhibited the significant associations with the risk (adjusted OR = 1.12, 95% CI = 1.01–1.24, P = 0.031) and prognosis of NSCLC. 9) rs767649 variant allele could increase the transcriptional activity of miR-155, which in turn facilitated tumor growth and metastasis by inhibiting HBP1, TJP1, SMAD5 and PRKAR1A expression.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKAR1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5578" target="_blank" rel="noopener noreferrer">5578</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17252" target="_blank" rel="noopener noreferrer">P17252</a>', 'HUGO Gene symbol': 'PRKCA', 'Protein name': 'Protein kinase C alpha type', 'Function': 'PKC isoforms in malignant transformation and proliferation, and in the regulation of the phosphatidylinositol 3′-kinase/Akt and MEK/extracellular signal-regulated kinase pathways\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/PKC<br><br> Oncogene signaling/PKC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26300055%2C%2027554045%2C%2016166454%2C%207635571%2C%2020654585%2C%2019117992%5Buid%5D" target="_blank" rel="noopener noreferrer">26300055, 27554045, 16166454, 7635571, 20654585, 19117992</a>', 'Notes': '1) Cisplatin\xa0also provoked the generation of reactive oxygen species (ROS) by NADPH oxidase. ROS increment was responsible for the\xa0PKC-α activation that provoked EGFR transactivation and consequential phosphorylation of ERK1/2. 2) The inhibition of this pathway at various level (PKC-α, EGFR or ERK1/2) increased\xa0cisplatin-induced cytotoxicity.\xa03) MiR-483-3p was found up-regulated in 4 platinum resistant. 4) miR-483-3p over-expression reduced cell growth and conferred mild levels of cisplatin resistance in IGROV-1 cells. 5) Predicted targets of miR-483-3p included PRKCA, previously reported to be associated to platinum-resistance in ovarian carcinoma. 6) cisplatin sensitivity of IGROV-1 cells decreased upon molecular /pharmacological inhibition of PKC-alpha. 7) Knockdown of PKCdelta by small interfering RNA inhibited cisplatin-induced apoptosis but knockdown of PKCalpha enhanced cisplatin-induced cell death. 8) The abundance of PKC alpha decreased significantly in 2008/C13*5.25 cells, whereas the amount of PKC epsilon increased moderately in the resistant variant, with no alteration in PKC zeta content. 9) Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. 10) protein kinase Calpha-mediated Bcl-2 stabilization. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKCA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5579" target="_blank" rel="noopener noreferrer">5579</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05771" target="_blank" rel="noopener noreferrer">P05771</a>', 'HUGO Gene symbol': 'PRKCB', 'Protein name': 'Protein kinase C beta type', 'Function': 'Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in regulation of the B-cell receptor, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/PKC<br><br> Oncogene signaling/PKC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28246354%2C%2016508638%2C%208930400%2C%2018765998%5Buid%5D" target="_blank" rel="noopener noreferrer">28246354, 16508638, 8930400, 18765998</a>', 'Notes': '1) Protein kinase C β inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin. 2) RNA interference (RNAi) and in vitro phosphorylation studies revealed that PKC isoforms alpha, beta, delta, epsilon, zeta specifically involved in telomerase regulation, and the phosphorylation target was on hTERT. 3) A decrease in cPKC alpha and-beta and an increase in nPKC delta were associated with the cDDP-resistant phenotype. 4) There was a trend toward lower overall survival among malignant pleural mesothelioma patients expressing above-median PKCbeta1 (P=0.064), but not PKCbeta2. 5) Treatment of MPM cell lines with PKC beta inhibitor enzastaurin revealed an IC50 of 5 micromol/l, and strong synergism was observed when combined with cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKCB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5580" target="_blank" rel="noopener noreferrer">5580</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q05655" target="_blank" rel="noopener noreferrer">Q05655</a>', 'HUGO Gene symbol': 'PRKCD', 'Protein name': 'Protein kinase C delta type', 'Function': 'Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent, contrasting roles: promoting DNA damage-induced apoptosis; but anti-apoptotic cytokine receptor-initiated cell death: tumor suppression as well as survival of several cancers,', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/PKC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25017423%2C%2016166454%2C%2026300055%5Buid%5D" target="_blank" rel="noopener noreferrer">25017423, 16166454, 26300055</a>', 'Notes': '1) overexpression of miR-224-5p in ovarian cancer patients is associated with platinum-based chemoresistance in vivo as well as as well as in 4 human ovarian cancer cell lines (C13/OV2008; A2780CP/A2780S) in vitro. 2) PRKCD gene as one of the targets of miR-224-5p in mediating the primary chemoresistance of ovarian cancer patients. 3) reciprocal expression of miR-224-5p and PRKCD by quantitative analysis in complete response and incomplete response patients in vivo, and 2 pairs of cisplatin resistance and sensitive cell lines in vitro, after either miR-224-5p overexpression or knockdown transfection. 4) miR-224-5p and PRKCD can serve as novel predictors and prognostic biomarkers for ovarian papillary serous carcinoma (OPSC) patient response to overall disease-specific survival.  5) Knockdown of PKCdelta by small interfering RNA inhibited cisplatin-induced apoptosis but knockdown of PKCalpha enhanced cisplatin-induced cell death. 6) Cisplatin\xa0activated full-length\xa0PKC-δ and generated a\xa0PKC-δ fragment.\xa07) PKC-δ inhibition (by\xa0PKC-δ-siRNA) decreased ZL55 cell apoptosis. 8) Full-length\xa0PKC-δ translocated to the nucleus and activated caspase-3 expression, whereas\xa0PKC-δ fragment preferentially localized to mitochondria.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKCD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5591" target="_blank" rel="noopener noreferrer">5591</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78527" target="_blank" rel="noopener noreferrer">P78527</a>', 'HUGO Gene symbol': 'PRKDC', 'Protein name': 'DNA-dependent protein kinase catalytic subunit', 'Function': 'Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR<br><br> DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27499034%2C%2026108997%2C%2012464596%5Buid%5D" target="_blank" rel="noopener noreferrer">27499034, 26108997, 12464596</a>', 'Notes': '1) CD133+ osteosarcoma cell line MG‑63 cells were more resistant to cisplatin than CD133‑ MG‑63 cells, DNA‑PKcs and P‑gp were expressed at higher levels in the CD133+ MG‑63 cells compared with those levels in the CD133‑ MG‑63 cells. 2) Down-regulation of DNA-PKcs produced higher sensitivity of MG63 cells to DDP or VP16 through increasing apoptosis and causing cell cycle arrest in the G1 phase. 3) A significant correlation was found between the expression of DNA-PKcs and the effect of CRT in esophageal cancer: the high-DNA-PKcs expression group showed greater therapeutic sensitivity than the low-expression group. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKDC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5592" target="_blank" rel="noopener noreferrer">5592</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13976" target="_blank" rel="noopener noreferrer">Q13976</a>', 'HUGO Gene symbol': 'PRKG1', 'Protein name': 'Cyclic GMP (cGMP)–dependent protein kinase', 'Function': 'key downstream protein kinase mediating many of the biological effects of nitric oxide (NO) and natriuretic peptides in the cardiovascular system. Activates PKA/CREB, hippo signaling (22740515, 27179930); inhibits apopotic signaling through inactivation of ceramide synthesis (29896202)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hippo signaling<br><br> Oncogene signaling/MAPK<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18506185%2C%2020371672%2C%2022740515%2C%2029288364%5Buid%5D" target="_blank" rel="noopener noreferrer">18506185, 20371672, 22740515, 29288364</a>', 'Notes': '1) As NOS1: the NO/cGMP/PKG signaling pathway plays a key role in protecting human ovarian cancer cells against both spontaneous and cisplatin-induced apoptosis. 2) Basal activity of NO/cGMP/PKG signaling pathway protects against spontaneous apoptosis and confers resistance to cisplatin in ovarian cancer cells. 3) an important role of Src/PKG-Ialpha interaction in promoting DNA synthesis/cell proliferation in human ovarian cancer cells. 4) Combined treatment of PKG inhibitor DT-2 and cisplatin increased apoptosis, showing a synergistic effect. 5) the PKG-Iα kinase activity is necessary for maintaining higher levels of CREB phosphorylation at ser133 and protein expression of c-IAP1, livin, survivin, and Mcl-1, in NSCLC cells. 6) Underexpression of three miRNAs (miRNA-21, miRNA-125b, and miRNA-224) was independently associated with the chemotherapy sensitivity of patients with lung adenocarcinoma: The MAPK, PI3K-Akt, Ras, and cGMP-PKG signaling pathways were considered to be most probably correlated with platinum resistance.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKG1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8575" target="_blank" rel="noopener noreferrer">8575</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75569" target="_blank" rel="noopener noreferrer">O75569</a>', 'HUGO Gene symbol': 'PRKRA', 'Protein name': 'Interferon-inducible double-stranded RNA-dependent protein kinase activator A', 'Function': 'A dsRNA-binding protein that impacts miRNA maturation through interactions with Dicer (23661684); activates EIF2AK2/PKR in the absence of dsRNA (11752660)', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30305341%5Buid%5D" target="_blank" rel="noopener noreferrer">30305341</a>', 'Notes': '1) In orthotopic mouse models of MOC, we observed a significant antitumor effect of PRKRA siRNA plus oxaliplatin. 2) expression of miR-515-3p was regulated by PACT-Dicer interaction, and miR-515-3p increased the sensitivity of MOC to oxaliplatin. Mechanistically, miR-515-3p regulated chemosensitivity, in part, by targeting AXL. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRKRA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8842" target="_blank" rel="noopener noreferrer">8842</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43490" target="_blank" rel="noopener noreferrer">O43490</a>', 'HUGO Gene symbol': 'PROM1', 'Protein name': 'Prominin-1', 'Function': 'cell surface marker,  identifies cancer-initiating cells in a number of other malignancies, plays a role in cell differentiation, proliferation and apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> Notch signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18836486%2C%2023135908%2C%2032483269%5Buid%5D" target="_blank" rel="noopener noreferrer">18836486, 23135908, 32483269</a>', 'Notes': '1) CD133+ ovarian cancer cells generate both CD133+ and CD133- daughter cells, whereas CD133- cells divide symmetrically. 2) CD133+ cells exhibit enhanced resistance to platinum-based therapy. 3) Sorted CD133+ ovarian cancer cells also form more aggressive tumor xenografts at a lower inoculum than their CD133- progeny. 4) Epigenetic changes may be integral to the behavior of cancer progenitor cells and their progeny: CD133 transcription is controlled by both histone modifications and promoter methylation. 5) Sorted CD133- ovarian cancer cells treated with DNA methyltransferase and histone deacetylase inhibitors show a synergistic increase in cell surface CD133 expression; DNA methylation at the ovarian tissue active P2 promoter is inversely correlated with CD133 transcription. 6) promoter methylation increases in CD133- progeny of CD133+ cells, with CD133+ cells retaining a less methylated or unmethylated state. 7) CD133(+) cells were significantly increased in the relapsed tumors in three of six patients with lung cancer who have received cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PROM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54458" target="_blank" rel="noopener noreferrer">54458</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NZ81" target="_blank" rel="noopener noreferrer">Q9NZ81</a>', 'HUGO Gene symbol': 'PRR13', 'Protein name': 'Proline-rich protein 13 / taxol resistance gene 1', 'Function': 'impedes taxane-induced apoptosis in tumor cells by transcriptionally down-regulating thrombospondin-1 (TSP-1)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27779244%2C%2029805561%2C%2030650069%5Buid%5D" target="_blank" rel="noopener noreferrer">27779244, 29805561, 30650069</a>', 'Notes': '1) High TXR1 expression was associated with decreased PFS (P<0.001) and OS (P<0.001). 2) Multivariate analysis demonstrated that high PRR13/low THBS1 expression was an independent factor for decreased PFS (hazards ratio: 1.94; 95% confidence interval (CI): 1.48-2.92; P=0.008) and OS (hazard ratio: 3.89; 95% CI: 2.16-6.87; P<0.001). 3) The level of TXR1 expression was significantly higher in cisplatin-resistant specimens than that in cisplatin-sensitive specimens. 4) TXR1 expression was elevated in a cisplatin-resistance subline (SGC-7901/DDP). 5) Overexpression of TXR1 induced cisplatin resistance in SGC-7901 cells. 6) Downregulation of TXR1 reversed the drug resistance caused by elevation of TXR1 expression in SGC-7901/DDP cells. 7) Animal experiments proved the effect of TXR1 in inducing cisplatin resistance in vivo. 8) TXR1 regulated cisplatin resistance via apoptosis. 9) Txr1 promoted autophagy through modulation of MEK/ERK signaling. Deficiency of autophagy induced by Txr1 can sensitize drug-resistant cells to Oxaliplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRR13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5644" target="_blank" rel="noopener noreferrer">5644</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07477" target="_blank" rel="noopener noreferrer">P07477</a>', 'HUGO Gene symbol': 'PRSS1', 'Protein name': 'Trypsin-1', 'Function': 'Cationic trypsinogen 1. trypsin activates protease-activated receptor-2 (PAR-2); leading to ERK pathway (16691544, 20947888); degrading ECM upon activation', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling/MAPK<br><br> proteasome', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22379635%2C%2015015601%2C%2033585454%5Buid%5D" target="_blank" rel="noopener noreferrer">22379635, 15015601, 33585454</a>', 'Notes': '1) The 24-hour treatment of trypsin inhibitor MsTI in the cell culture medium decreased the clonogenic survival of MCF7 and HeLa cells in a dose-dependent manner and enhanced cisplatin-induced cytotoxicity. 2) The presence of MsTI during the entire incubation period reduced the D37 of cisplatin by 40% in both the cell lines. 3) PRSS1 expression levels in platinum-resistant samples (tissue/cell) were significantly higher than in samples sensitive to platinum. 4) knockdown of PRSS1 reduced the resistance of ovarian cancer cells to cisplatin. 5) overexpression of PRSS1 increased the resistance to cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRSS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5699" target="_blank" rel="noopener noreferrer">5699</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40306" target="_blank" rel="noopener noreferrer">P40306</a>', 'HUGO Gene symbol': 'PSMB10', 'Protein name': 'Proteasome subunit beta type-10', 'Function': 'The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'proteasome', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23165153%5Buid%5D" target="_blank" rel="noopener noreferrer">23165153</a>', 'Notes': '1) The resistant\xa0cells\xa0also showed an enhancement in proteolytic activity of proteasome accompanied by overexpression of its catalytic subunits (PSMβ9 and PSMβ10). 2) Pretreatment of the resistant\xa0cells\xa0with a potent proteasome inhibitor Z-Leu-Leu-Leu-al augmented the CDDP sensitization elicited by the AKR inhibitors.\xa0(human colon HCT15 cells)', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PSMB10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5698" target="_blank" rel="noopener noreferrer">5698</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28065" target="_blank" rel="noopener noreferrer">P28065</a>', 'HUGO Gene symbol': 'PSMB9', 'Protein name': 'Proteasome subunit beta type-9', 'Function': ' As PSMB10', 'Putative_mechanism_associated_with_Pt_resistance': 'proteasome', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23165153%5Buid%5D" target="_blank" rel="noopener noreferrer">23165153</a>', 'Notes': '1) As PSMB10', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PSMB9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5724" target="_blank" rel="noopener noreferrer">5724</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25105" target="_blank" rel="noopener noreferrer">P25105</a>', 'HUGO Gene symbol': 'PTAFR', 'Protein name': 'Platelet-activating factor receptor', 'Function': 'a chemotactic phospholipid mediator that possesses potent inflammatory activity; promotes ovarian cancer cell proliferation and invasion; activates PKA, FAK and JAK2 (14617636)', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24921917%5Buid%5D" target="_blank" rel="noopener noreferrer">24921917</a>', 'Notes': '1) Cisplatin induced increased PAFR expression in two ovarian cancer cell lines. 2) The upregulation of PAFR by CDDP correlated with the time-dependent accumulation of NF-κB and HIF-1α in the nucleus. 3) The inhibition of PAFR sensitised the ovarian cancer cells to CDDP. 4) The PI3K and ERK pathways lie downstream of activated PAFR in CDDP-treated cells and their inhibition enhanced CDDP sensitivity. 5) co-treatment with a PAFR antagonist (Ginkgolide B) and CDDP markedly reduced tumour growth in an in vivo model of ovarian cancer.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTAFR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5727" target="_blank" rel="noopener noreferrer">5727</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13635" target="_blank" rel="noopener noreferrer">Q13635</a>', 'HUGO Gene symbol': 'PTCH1', 'Protein name': 'Protein patched homolog 1', 'Function': "Acts as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). Associates with the smoothened protein (SMO) to transduce the hedgehog's proteins signal.", 'Putative_mechanism_associated_with_Pt_resistance': 'Hedgehog signaling<br><br> PKA signaling<br><br> Platinum efflux<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30110910%5Buid%5D" target="_blank" rel="noopener noreferrer">30110910</a>', 'Notes': '1) the Hedgehog receptor Ptch1, which is over-expressed in many recurrent and metastatic cancers, is a multidrug transporter and 2) it contributes to the efflux of chemotherapeutic agents. 3) Ptch1 uses the proton motive force to efflux drugs, in contrast to ABC transporters, which use ATP hydrolysis. 4) the “reversed pH gradient” that characterizes cancer cells, allows Ptch1 to function as an efflux pump specifically in cancer cells.  5) in mice where combining Ptch1 inhibitors with doxorubicin prevented the development of xenografted adrenocortical carcinoma tumors more efficiently than doxorubicin alone, and without obvious undesirable side effects.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTCH1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5728" target="_blank" rel="noopener noreferrer">5728</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P60484" target="_blank" rel="noopener noreferrer">P60484</a>', 'HUGO Gene symbol': 'PTEN', 'Protein name': 'Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase\xa0', 'Function': 'Tumor suppressor. Dual-specificity protein phosphatase; also a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from PIP3, PIP2, PI3-P and IP4', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24434152%2C%2028910982%2C%2019150122%5Buid%5D" target="_blank" rel="noopener noreferrer">24434152, 28910982, 19150122</a>', 'Notes': '1) Overexpression of PTEN reverses cisplatin-resistance in ovarian cancer cell line C13K. 2) there was a directly interaction between KRT10 and PTEN. 3) KRT10 is a downstream molecule of PTEN which improves cisplatin-resistance of ovarian cancer. 4) the conditioned media from cisplatin-resistant OSCC cells enhanced the chemoresistance of parental OSCC cell. 5) Exosomes derived from cisplatin-resistant OSCC cells transferred miR-21 to OSCC parental cells and induced cisplatin resistance by targeting PTEN and PDCD4 and decrease the DNA damage signaling in response to cisplatin. 6) the roles of cisplatin-resistant OSCC cells-derived exosomes in vivo were confirmed by subcutaneous xenograft mouse model. 7) Retrospectively collected paraffin blocks from 151 epithelial ovarian cancer patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed: Reduced expression of PTEN was found in 104 of the 151 cases (68.9%), and PTEN expression (p=0.009) were significant predictors for disease-free survival (DFS). The median DFS of patients with reduced PTEN expression was 20 months (range, 3-71 months), whereas that of patients with normal PTEN expression was 53 months (range, 2-81 months). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTEN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5733" target="_blank" rel="noopener noreferrer">5733</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P43115" target="_blank" rel="noopener noreferrer">P43115</a>', 'HUGO Gene symbol': 'PTGER3', 'Protein name': 'Prostaglandin E2 receptor EP3 subtype', 'Function': 'Receptor for prostaglandin E2 (PGE2). The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium; an important mediator of immune regulation, epithelial cell growth and invasion', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling<br><br> Platinum efflux<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30655206%5Buid%5D" target="_blank" rel="noopener noreferrer">30655206</a>', 'Notes': '1) An association between higher tumoral expression of PTGER3 and shorter patient survival in the ovarian cancer dataset of TCGA. 2) PTGER3 mRNA and protein levels were higher in cisplatin-resistant ovarian cancer cells than in their cisplatin-sensitive counterparts. 3) Silencing of PTGER3 via siRNA in cancer cells was associated with decreased cell growth and less invasiveness, as well as cell-cycle arrest and increased apoptosis, mediated through the Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. 4) siRNA-mediated silencing of PTGER3 combined with cisplatin resulted in robust antitumor effects in cisplatin-resistant ovarian cancer models. 5) Long-lasting PTGER3 silencing restores OC sensitivity to cisplatin in vivo. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTGER3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5743" target="_blank" rel="noopener noreferrer">5743</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35354" target="_blank" rel="noopener noreferrer">P35354</a>', 'HUGO Gene symbol': 'PTGS2', 'Protein name': 'Prostaglandin G/H synthase 2 / cyclooxygenase-2 ', 'Function': 'Converts arachidonate to prostaglandin H2 (hormone PGH2), a committed step in prostanoid synthesis. PTGS2 is responsible for production of inflammatory prostaglandins.', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling<br><br> Platinum efflux<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16831230%5Buid%5D" target="_blank" rel="noopener noreferrer">16831230</a>', 'Notes': '1) In the overall series, COX-2 positivity was found in a statistically significant higher percentage of not responding cases than in patients responding to chemotherapy (n = 15/21; 71.4% versus n = 17/47; 36.1%; p value = 0.0072). 2) A higher percentage of COX-2 positivity was found in patients unresponsive (n = 11/13; 84.6%) versus patients responsive to platinum-based chemotherapy (n = 9/26; 34.6%). 3) In cases administered platinum/paclitaxel, COX-2 positivity was found in 4 out of 8 (50%) of un responsive versus 8 out of 21 (38.1%) of responsive cases. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTGS2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5747" target="_blank" rel="noopener noreferrer">5747</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q05397" target="_blank" rel="noopener noreferrer">Q05397</a>', 'HUGO Gene symbol': 'PTK2', 'Protein name': 'Focal adhesion kinase 1', 'Function': 'Non-receptor protein-tyrosine kinase that regulates cell migration, adhesion, cell cycle progression, cell proliferation and apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31478830%2C%2027294003%2C%2028103122%2C%2023307041%5Buid%5D" target="_blank" rel="noopener noreferrer">31478830, 27294003, 28103122, 23307041</a>', 'Notes': '1) Sustained FAK Y397 phosphorylation (pY397) observed in neoadjuvant chemotherapy-resistant ovarian tumor patients.\xa02) Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. 3) PTK2 inhibition-induced sustained levels of ATG3 were able to sensitize cancer cells to DNA-damaging agents such as cisplatin. 4) High FAK alone or combined with low JWA expression significantly correlated with worse overall survival (OS) in gastric cancer patients under adjuvant fluorouracil-leucovorin-oxaliplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5774" target="_blank" rel="noopener noreferrer">5774</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26045" target="_blank" rel="noopener noreferrer">P26045</a>', 'HUGO Gene symbol': 'PTPN3', 'Protein name': 'Tyrosine-protein phosphatase non-receptor type 3', 'Function': 'May act at junctions between the membrane and the cytoskeleton. Possesses tyrosine phosphatase activity.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/EGFR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27833130%5Buid%5D" target="_blank" rel="noopener noreferrer">27833130</a>', 'Notes': '1) PTPN3 gene expression was substantially increased in both cisplatin and doxorubicin-resistant ovarian cancer cells. 2) Silencing of PTPN3 restored sensitivity to cisplatin and doxorubicin in resistant ovarian cancer cells. 3) Down-regulation of PTPN3 also inhibited cell cycle progression, migration, stemness in vitro and the tumorigenicity of resistant ovarian cancer cells in vivo. 4) the expression of PTPN3 was found to be regulated by miR-199 in resistant ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTPN3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5829" target="_blank" rel="noopener noreferrer">5829</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P49023" target="_blank" rel="noopener noreferrer">P49023</a>', 'HUGO Gene symbol': 'PXN', 'Protein name': 'Paxillin', 'Function': 'Cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion).', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24096476%5Buid%5D" target="_blank" rel="noopener noreferrer">24096476</a>', 'Notes': '1) cisplatin resistance was dependent on PXN expression: PXN overexpression in TL-13 and TL-10 cells increased resistance; PXN knockdown in H23 and CL1-5 cells decreased resistance. 2) the phosphorylation of PXN at Y118 and Y31 via the Src pathway was responsible for cisplatin resistance; ERK activation was also dependent on this PXN phosphorylation; Bcl-2 transcription was upregulated by phosphorylated PXN-mediated ERK activation via increased binding of phosphorylated CREB to the Bcl-2 promoter. 3) xenograft tumors induced by TL-13-overexpressing cells were successfully suppressed by cisplatin combined with Src or ERK inhibitor compared with treatment of cisplatin, Src inhibitor or ERK inhibitor alone. 4) A positive correlation of phosphorylated PXN with phosphorylated ERK and Bcl-2 was observed in lung tumors from NSCLC patients. 5) Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors.\xa0', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PXN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/22931" target="_blank" rel="noopener noreferrer">22931</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NP72" target="_blank" rel="noopener noreferrer">Q9NP72</a>', 'HUGO Gene symbol': 'RAB18', 'Protein name': 'Ras-related protein Rab-18', 'Function': 'Required for the localization of ZFYVE1 to lipid droplets and for its function in mediating the formation of endoplasmic reticulum-lipid droplets (ER-LD) contacts. Plays a role in apical endocytosis/recycling', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32494165%2C%2030464528%5Buid%5D" target="_blank" rel="noopener noreferrer">32494165, 30464528</a>', 'Notes': '1) Rab18 was upregulated in 45/112 (40.2%) cases of HNSCC tissues, which correlated with advanced T classification, positive nodal metastasis and tumor node metastasis (TNM) stage. 2) Rab18 was elevated in human HNSCC tissues and correlated with poor patient survival. 3) Rab18 overexpression increased growth rate, colony numbers, cell cycle progression and invading ability in FaDu cells. 4) Rab18 downregulated cisplatin-induced apoptosis and upregulated the mitochondrial membrane potential (Δψm). 5) Rab18 overexpression induced epithelial-to-mesenchymal transition, with downregulation of E-cadherin and upregulation of N-cadherin, Vimentin and Twist. 6) Rab18 overexpression also upregulated Survivin protein and Rab18 knockdown showed the opposite effects on these proteins. 7) Treatment of STAT3 inhibitor, SH-4-54, inhibited cell invasion, increased E-cadherin and downregulated N-cadherin, Twist and \ufeffSurvivin. SH-4-54 also abolished the effects of BCAT1 on these proteins, as well as cell invasion.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAB18" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57111" target="_blank" rel="noopener noreferrer">57111</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P57735" target="_blank" rel="noopener noreferrer">P57735</a>', 'HUGO Gene symbol': 'RAB25', 'Protein name': 'Ras-related protein Rab-25', 'Function': 'a small GTPase of the Rab11 subfamily involved in endosomal recycling and trafficking pathways; involved in the regulation of cell survival. Promotes invasive migration of cells in which it functions to localize and maintain integrin alpha-V/beta-1 at the tips of extending pseudopodia', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26967059%2C%2028400705%5Buid%5D" target="_blank" rel="noopener noreferrer">26967059, 28400705</a>', 'Notes': '1) Rab25 regulates HIF-1α protein expression in an oxygen independent manner in a panel of ovarian cancer cell lines. 2) Regulation of HIF-1α protein expression by Rab25 did not require transcriptional upregulation, but was dependent on de novo protein synthesis through the Erbb2/ERK1/2 and p70S6K/mTOR pathways. 3) Rab25 expression induced HIF-1 transcriptional activity, increased cisplatin resistance, and conferred intraperitoneal growth to the A2780 cell line in immunocompromised mice. 4) RAB25 mRNA and protein expression in prostate cancer (PCa) tissues were both significantly higher (both P < 0.001). 5) High Rab25 immunoreactive score (IRS)  was significantly associated with high Gleason score (P = 0.02) and distant metastasis (P = 0.01). 6) PCa patients with high Rab25 IRS had shorter overall and biochemical recurrence-free survivals than those with low Rab25 IRS (both P < 0.001). ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAB25" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5878" target="_blank" rel="noopener noreferrer">5878</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51148" target="_blank" rel="noopener noreferrer">P51148</a>', 'HUGO Gene symbol': 'RAB5C', 'Protein name': 'Ras-related protein Rab-5C', 'Function': 'Protein transport. Probably involved in vesicular traffic; binding of cisplatin to the\nN-terminus of Ctr1 is followed by internalization which therefore represents the means for cisplatin uptake. ', 'Putative_mechanism_associated_with_Pt_resistance': 'endocytosis<br><br> Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25096996%5Buid%5D" target="_blank" rel="noopener noreferrer">25096996</a>', 'Notes': '1) Quantitative proteomic analysis identified 340 differentially expressed proteins between OC A2780 and A2780-DR cells, which involve in diverse cellular processes, including metabolic process, cellular component biogenesis, cellular processes, and stress responses. 2) Expression levels of Ras-related proteins Rab 5C and Rab 11B in A2780-DR cells were lower than those in A2780 cells. 3) (sh)RNA knockdown of Rab 5C in A2780 cells resulted in markedly increased resistance to cisplatin 4) overexpression of Rab 5C in A2780-DR cells increases sensitivity to cisplatin, demonstrating that Rab 5C-dependent endocytosis plays an important role in cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAB5C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7879" target="_blank" rel="noopener noreferrer">7879</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51149" target="_blank" rel="noopener noreferrer">P51149</a>', 'HUGO Gene symbol': 'RAB7A', 'Protein name': 'Ras-related protein Rab-7a', 'Function': 'Key regulator in endo-lysosomal trafficking. Governs early-to-late endosomal maturation, microtubule minus-end as well as plus-end directed endosomal migration and positioning, and endosome-lysosome transport through different protein-protein interaction cascades.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29636548%2C%2030626032%5Buid%5D" target="_blank" rel="noopener noreferrer">29636548, 30626032</a>', 'Notes': '1) The hypoxic microenvironment promotes the release of exosomes determining the acquisition of a more aggressive phenotype and resistance to cisplatin. 2) In hypoxic conditions, ovarian cancer cells, STAT3 upregulate RAB27 (a RAB protein controlling late endosome docking with the plasma membrane) and downregulate RAB7. 3) a significant increase in the number of exosomes released in sera of cisplatin-resistant compared to drug sensitive patients: the analysis of cisplatin in exosomes has revelated that hypoxia impacts on the exosomal-mediated efflux of cisplatin from ovarian cancer cells. 4) down-regulation of RAB7A characterizes the chemoresistant phenotype, and that RAB7A depletion increases CDDP-resistance while RAB7A overexpression decreases it. 5) increased production of extracellular vesicles is modulated by RAB7A expression levels and correlates with reduction of CDDP intracellular accumulation. 6) RAB7A expression in pre-chemotherapy cancer tissues may predict platinum response in EOC. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAB7A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4218" target="_blank" rel="noopener noreferrer">4218</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61006" target="_blank" rel="noopener noreferrer">P61006</a>', 'HUGO Gene symbol': 'RAB8A', 'Protein name': 'Ras-related protein Rab-8A (small GTPase)', 'Function': 'a marker of recycling endosomes, key regulators of intracellular membrane trafficking; the translocation of TMEM205 may allow the exocytosis of platinum containing vesicles (12698203)', 'Putative_mechanism_associated_with_Pt_resistance': 'endocytosis<br><br> exocytosis<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21969054%5Buid%5D" target="_blank" rel="noopener noreferrer">21969054</a>', 'Notes': '1) Expression of RAB8 was markedly elevated in human cisplatin-resistant cells. 2) TMEM205 was co-localized with RAB8. 3) Dual transfectants with over-expression of both TMEM205 and RAB8 were found to be up to 4-fold more resistant to cisplatin, 4) cells transfected with RAB8 alone were ~2-fold more resistant.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAB8A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5879" target="_blank" rel="noopener noreferrer">5879</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40792" target="_blank" rel="noopener noreferrer">P40792</a>', 'HUGO Gene symbol': 'RAC1', 'Protein name': 'Ras-related protein Rac1', 'Function': 'Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neuron adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31314174%2C%2020930109%2C%2032193458%5Buid%5D" target="_blank" rel="noopener noreferrer">31314174, 20930109, 32193458</a>', 'Notes': '1) higher levels of RAC1 expression were associated with poorer prognosis in ESCC patients. 2) Enhanced RAC1 expression increased cell proliferation, migration, and chemoresistance\xa0in\xa0vitro. 3) Combination therapy using RAC1 inhibitor EHop‐016 and cisplatin significantly promoted cell viability inhibition, G2/M phase cycle arrest, and apoptosis. 4) Mechanistically, glycolysis was significantly downregulated in the RAC1 inhibitor monotherapy group and the combination group via inhibiting AKT/FOXO3a signaling. 5) The silencing of RAC1 inhibited AKT/FOXO3a signaling and cell glycolysis while the upregulation of RAC1 produced an opposite effect. 6) In murine xenograft models, the tumor volume and the expression of glycolytic enzymes were significantly reduced in combination therapy when compared to each monotherapy group.\xa07) CTR2 regulates the transport of cDDP in part through control of the rate of macropinocytosis via activation of Rac1 and cdc42. 7) Rac1 activates aldolase A and ERK signaling which up-regulates glycolysis and especially the non-oxidative pentose phosphate pathway (PPP). This leads to increased nucleotides metabolism which protects breast cancer cells from chemotherapeutic-induced DNA damage. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5887" target="_blank" rel="noopener noreferrer">5887</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P54727" target="_blank" rel="noopener noreferrer">P54727</a>', 'HUGO Gene symbol': 'RAD23B', 'Protein name': 'Ubiquitin receptor RAD23b', 'Function': 'May be involved in nucleotide excision repair', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20028083%2C%2028473198%5Buid%5D" target="_blank" rel="noopener noreferrer">20028083, 28473198</a>', 'Notes': '1) XPC-Rad23B binds cisplatin-damaged DNA; contacts with both strands of the DNA duplex and spans the DNA adduct. 2) Subcellular distribution of RAD23B controls XPC degradation and DNA damage repair in response to chemotherapy drugs. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD23B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10111" target="_blank" rel="noopener noreferrer">10111</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92878" target="_blank" rel="noopener noreferrer">Q92878</a>', 'HUGO Gene symbol': 'RAD50', 'Protein name': 'DNA repair protein RAD50', 'Function': 'Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19487811%5Buid%5D" target="_blank" rel="noopener noreferrer">19487811</a>', 'Notes': '1) A combination of\xa0cisplatin\xa0and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a corresponding increase in DNA damage and telomere shortening. 2) In\xa0cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy caused dramatic tumor regression with increased apoptosis.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD50" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5888" target="_blank" rel="noopener noreferrer">5888</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q06609" target="_blank" rel="noopener noreferrer">Q06609</a>', 'HUGO Gene symbol': 'RAD51', 'Protein name': 'DNA repair protein RAD51 homolog 1', 'Function': 'Plays an important role in homologous strand exchange through HR. Binds to single and double-stranded DNA and exhibits DNA-dependent ATPase activity. Catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29620223%2C%2031640742%2C%2026138778%2C%2026369335%5Buid%5D" target="_blank" rel="noopener noreferrer">29620223, 31640742, 26138778, 26369335</a>', 'Notes': '1) Resveratrol decreases Rad51 expression and sensitizes\xa0cisplatin‑resistant MCF‑7 breast cancer cells. 2) Cisplatin combined with metformin decreased cell viability and metastatic effect more than cisplatin alone in TNBC cells. 3) Metformin suppressed cisplatin-mediated RAD51 upregulation by decreasing RAD51 protein stability and increasing its ubiquitination. 4) cisplatin increased RAD51 expression in an ERK-dependent manner. 5)Overexpression of RAD51 blocked the metformin-induced inhibition of cell migration and invasion, 6) RAD51 knockdown enhanced cisplatin activity. 7) the combination of metformin and cisplatin exhibited a synergistic anticancer effect in an orthotopic murine model of 4T1 breast cancer in vivo. 8) miR-506 expression was closely associated with progression-free survival and overall survival in two independent patient cohorts totaling 598 epithelial ovarian cancer cases. 9) miR-506 could augment the response to cisplatin and olaparib through targeting RAD51 and suppressing homologous recombination in a panel of ovarian cancer cell lines. 10) Systemic delivery of miR-506 in an orthotopic ovarian cancer mouse model significantly augmented the cisplatin response, thus recapitulating the clinical observation. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD51" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5890" target="_blank" rel="noopener noreferrer">5890</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15315" target="_blank" rel="noopener noreferrer">O15315</a>', 'HUGO Gene symbol': 'RAD51B', 'Protein name': 'DNA repair protein RAD51 homolog 2', 'Function': 'Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25368520%2C%2015126333%20%5Buid%5D" target="_blank" rel="noopener noreferrer">25368520, 15126333¬†</a>', 'Notes': '1) RAD51B-depleted breast cancer cells have increased sensitivity to DNA damage/cisplatin, reduced efficiency of HR, and altered cell cycle checkpoint responses.\xa02) the recombinase RAD51 and, in vertabrates, five RAD51 paralogs. The paralogs form two complexes in solution, a XRCC3/RAD51C heterodimer and a RAD51B/RAD51C/RAD51D/XRCC2 heterotetramer. 3) Mutation of any one of the five paralog genes prevents subnuclear assembly of recombinase at damaged sites and renders cells 30-100 fold sensitive to DNA cross-linking drugs. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD51B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5889" target="_blank" rel="noopener noreferrer">5889</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43502" target="_blank" rel="noopener noreferrer">O43502</a>', 'HUGO Gene symbol': 'RAD51C', 'Protein name': 'DNA repair protein RAD51 homolog 3', 'Function': 'Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15126333%2C%2027465554%5Buid%5D" target="_blank" rel="noopener noreferrer">15126333, 27465554</a>', 'Notes': '1) the recombinase RAD51 and, in vertabrates, five RAD51 paralogs. The paralogs form two complexes in solution, a XRCC3/RAD51C heterodimer and a RAD51B/RAD51C/RAD51D/XRCC2 heterotetramer. 2) Mutation of any one of the five paralog genes prevents subnuclear assembly of recombinase at damaged sites and renders cells 30-100 fold sensitive to DNA cross-linking drugs. 3) Rad51c expression was detected using immunohistochemistry and was higher in NSCLC patient samples than in adjacent normal tissues. 4) Kaplan-Meier analysis revealed that high Rad51c expression was an independent predictor of short overall survival (OS) and disease-free survival (DFS) in NSCLC patients receiving chemotherapy and/or radiotherapy. 5) Rad51c knockdown increased the killing effect of ionizing radiation (IR) and enhanced cisplatin-induced apoptotic cells in NSCLC cells by disrupting the repair of cisplatin- and IR-induced DNA damage. 6) ectopic expression of Rad51c dramatically enhanced NSCLC cell resistance to cisplatin and radiotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD51C" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5892" target="_blank" rel="noopener noreferrer">5892</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75771" target="_blank" rel="noopener noreferrer">O75771</a>', 'HUGO Gene symbol': 'RAD51D', 'Protein name': 'DNA repair protein RAD51 homolog 4', 'Function': 'Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15126333%2C%2019347880%5Buid%5D" target="_blank" rel="noopener noreferrer">15126333, 19347880</a>', 'Notes': '1) the recombinase RAD51 and, in vertabrates, five RAD51 paralogs. The paralogs form two complexes in solution, a XRCC3/RAD51C heterodimer and a RAD51B/RAD51C/RAD51D/XRCC2 heterotetramer. 2) Mutation of any one of the five paralog genes prevents subnuclear assembly of recombinase at damaged sites and renders cells 30-100 fold sensitive to DNA cross-linking drugs. 3) the Rad51d (E233G) genetic variant confers increased cisplatin resistance and cell growth phenotypes in human breast carcinoma cell lines with a mutant p53 gene (BT20 and T47D) but not with a wild-type p53 gene (MCF-7). 4) Treatment with a p53 specific inhibitor, pifithrin alpha, restored this resistant phenotype in the MCF-7 cell line. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD51D" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5893" target="_blank" rel="noopener noreferrer">5893</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P43351" target="_blank" rel="noopener noreferrer">P43351</a>', 'HUGO Gene symbol': 'RAD52', 'Protein name': 'DNA repair protein RAD52 homolog', 'Function': 'Plays a central role in genetic recombination and DNA repair by promoting the annealing of complementary single-stranded DNA and by stimulation of the RAD51 recombinase.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=9774659%2C%2018473729%2C%2021779174%2C%2031381562%2C%2027531263%5Buid%5D" target="_blank" rel="noopener noreferrer">9774659, 18473729, 21779174, 31381562, 27531263</a>', 'Notes': "1) RAD52(-/-) cells were not hypersensitive to DNA damages induced by gamma-irradiation, methyl methanesulfonate, or cisplatin. 2) In the absence of BRCA2, the cell is more dependent on residual repair via Rad52, which makes Rad52 a target for therapy in BRCA-deficient tumors. 3) combined disruption of RAD52 and POLQ causes at least additive hypersensitivity to cisplatin, and a synthetic reduction in replication fork restart velocity: RAD52 is particularly important for repair using ≥ 50 nt repeat sequences that flank the DSB. 4) rs10774474 SNP which located in the 5'-flanking region of RAD52 was significantly associated with platinum-based chemotherapy response of of small cell lung cancer (SCLC).", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD52" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8438" target="_blank" rel="noopener noreferrer">8438</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92698" target="_blank" rel="noopener noreferrer">Q92698</a>', 'HUGO Gene symbol': 'RAD54L', 'Protein name': 'DNA repair and recombination protein RAD54-like', 'Function': 'Plays an essential role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16520463%5Buid%5D" target="_blank" rel="noopener noreferrer">16520463</a>', 'Notes': 'Single nucleotide polymorphisms of RecQ1,\xa0RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer after treatment treated with neoadjuvant concurrent gemcitabine and radiotherapy with or without a component of induction gemcitabine/cisplatin.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAD54L" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55086" target="_blank" rel="noopener noreferrer">55086</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6NSI4" target="_blank" rel="noopener noreferrer">Q6NSI4</a>', 'HUGO Gene symbol': 'RADX', 'Protein name': 'RPA-related protein RADX', 'Function': 'Single-stranded DNA-binding protein recruited to replication forks to maintain genome stability', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/DNA replication', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28735897%5Buid%5D" target="_blank" rel="noopener noreferrer">28735897</a>', 'Notes': '1) RADX antagonizes RAD51 activity at forks, and restores fork protection to BRCA2-depleted cells, 2) siRNA depletion of RADX suppressed the HU, cisplatin, and camptothecin hypersensitivity of cells with reduced RAD51 expression. 3) In cancer cells lacking BRCA2, RADX deletion restores fork protection without restoring HDR. 4) RADX inactivation confers chemotherapy and PARP inhibitor resistance to cancer cells with reduced BRCA2/RAD51 pathway function. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RADX" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11186" target="_blank" rel="noopener noreferrer">11186</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NS23" target="_blank" rel="noopener noreferrer">Q9NS23</a>', 'HUGO Gene symbol': 'RASSF1', 'Protein name': 'Ras association domain-containing protein 1', 'Function': 'Potential tumor suppressor. Required for death receptor-dependent apoptosis. Mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation.\xa0A proapoptotic Ras effector and plays an important role in the apoptotic DNA damage response (DDR)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23147544%2C%2029368096%2C%2025368379%5Buid%5D" target="_blank" rel="noopener noreferrer">23147544, 29368096, 25368379</a>', 'Notes': '1) A total of 54 head and neck squamous cell carcinoma patients were treated with frontline systemic chemotherapy composed of docetaxel (60 mg/m(2)) and cisplatin (65 mg/m(2)), every 3 weeks for up to 6 cycles. The expression levels of ERCC1 and RASSF1A were evaluated in the available 36 prechemotherapy samples. 2) The status of low ERCC1 and high RASSF1A expression was an independent favorable prognostic factor for OS in multivariate analysis (p = 0.043; hazard ratio, 7.224; 95% CI, 1.060-49.217). 3) Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. 4) RASSF1A forms a DNA damage-regulated complex with the key DNA repair protein xeroderma pigmentosum A (XPA). XPA requires RASSF1A to exert full repair activity, and RASSF1A-deficient cells exhibit an impaired ability to repair DNA during cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RASSF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5925" target="_blank" rel="noopener noreferrer">5925</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P06400" target="_blank" rel="noopener noreferrer">P06400</a>', 'HUGO Gene symbol': 'RB1', 'Protein name': 'Retinoblastoma-associated protein', 'Function': 'Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20428827%2C%2026238431.%2011336696%5Buid%5D" target="_blank" rel="noopener noreferrer">20428827, 26238431, 11336696</a>', 'Notes': '1) miR-106 and miR-150 were down-regulated while their target genes (RB1 and P53, respectively) were up-regulated after cisplatin treatment.\xa02) cisplatin induces K562 cells to apoptosis by reducing miR-106 which up-regulates RB1 or by inhibiting miR-150 which increases P53 expression. 3) In the discovery set, alteration in one or more of the three DNA repair genes ATM, RB1, and FANCC predicted pathologic response to CDDP (p<0.001; 87% sensitivity, 100% specificity) and better overall survival (p=0.007) for Muscle-invasive Bladder Cancer (MIBC) patient. 4) This test remained predictive for pathologic response in the validation set (p=0.033), with a trend towards better overall survival (p=0.055). ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5932" target="_blank" rel="noopener noreferrer">5932</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99708" target="_blank" rel="noopener noreferrer">Q99708</a>', 'HUGO Gene symbol': 'RBBP8', 'Protein name': 'DNA endonuclease RBBP8', 'Function': 'Endonuclease that cooperates with the MRE11-RAD50-NBN (MRN) complex in DNA-end resection', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26713604%2C%2029445424%5Buid%5D" target="_blank" rel="noopener noreferrer">26713604, 29445424</a>', 'Notes': '1) RBBP8, known to encode the endonuclease CtIP, as a novel susceptibility gene whose functional loss increases sensitivity towards PARP1 inhibition similar to\xa0BRCA1\xa0inactivation as recently demonstrated in a mice xenograft model of breast cancer.\xa02) RBBP1 methylation may predict significantly higher response rates to cisplatin treatment in breast and ovarian cancer patients.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; TCGA data analysis', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RBBP8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84991" target="_blank" rel="noopener noreferrer">84991</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96I25" target="_blank" rel="noopener noreferrer">Q96I25</a>', 'HUGO Gene symbol': 'RBM17', 'Protein name': 'Splicing factor 45KD / RNA-binding motif protein 17', 'Function': 'regulates alternative splicing; SPF45 activation via MAP kinases may connect extracellular stimuli to alternative splicing events that may impact cancer.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR<br><br> Oncogene signaling/MAPK<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16061639%2C%2029286307%5Buid%5D" target="_blank" rel="noopener noreferrer">16061639, 29286307</a>', 'Notes': '1) SPF45 overexpression conferred 3- to 21-fold resistance to carboplatin, vinorelbine, doxorubicin, etoposide, mitoxantrone, and vincristine in A2780 ovarian carcinoma cells. 2) Knockdown of SPF45 in parental A2780 cells using a hammerhead ribozyme sensitized A2780 cells to etoposide. 3) the selective estrogen receptor (ER) modulators tamoxifen and LY117018 (a raloxifene analogue) partially reversed SPF45-mediated drug resistance to mitoxantrone in A2780-SPF45 cells. 4) Quantitative PCR showed that ERbeta but not ERalpha was expressed in A2780 transfectants. 5) Coimmunoprecipitation experiments suggest that SPF45 and ERbeta physically interact in vivo. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RBM17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5935" target="_blank" rel="noopener noreferrer">5935</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P98179" target="_blank" rel="noopener noreferrer">P98179</a>', 'HUGO Gene symbol': 'RBM3', 'Protein name': 'RNA-binding protein 3', 'Function': 'Cold-inducible mRNA binding protein that enhances global protein synthesis at both physiological and mild hypothermic temperatures. Reduces the relative abundance of microRNAs when overexpressed.', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20727170%5Buid%5D" target="_blank" rel="noopener noreferrer">20727170</a>', 'Notes': '1) Increased RBM3 mRNA expression was associated with a prolonged RFS (HR = 0.64, 95% CI = 0.47-0.86, p = 0.003) and OS (HR = 0.64, 95% CI = 0.44-0.95, p = 0.024) in Cohort I. 2) Multivariate analysis confirmed that RBM3 mRNA expression was an independent predictor of a prolonged RFS, (HR = 0.61, 95% CI = 0.44-0.84, p = 0.003) and OS (HR = 0.62, 95% CI = 0.41-0.95; p = 0.028) in Cohort I. 3) In Cohort II, RBM3 protein expression was associated with a prolonged OS (HR = 0.53, 95% CI = 0.35-0.79, p = 0.002) confirmed by multivariate analysis (HR = 0.61, 95% CI = 0.40-0.92, p = 0.017). 4) RBM3 mRNA and protein expression levels were significantly higher in the cisplatin sensitive A2780 cell line compared to the cisplatin resistant A2780-Cp70 derivative. 5) siRNA-mediated silencing of RBM3 expression in the A2780 cells resulted in a decreased sensitivity to cisplatin as demonstrated by increased cell viability and reduced proportion of cells arrested in the G2/M-phase.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RBM3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27303" target="_blank" rel="noopener noreferrer">27303</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6XE24" target="_blank" rel="noopener noreferrer">Q6XE24</a>', 'HUGO Gene symbol': 'RBMS3', 'Protein name': 'RNA-binding motif, single-stranded-interacting protein 3', 'Function': 'The acetyltransferase CREB-binding protein (CBP) is essential for Wnt/β-catenin signaling–mediated chemoresistance via diverse mechanisms ', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30279231%5Buid%5D" target="_blank" rel="noopener noreferrer">30279231</a>', 'Notes': '1) Loss of RBMS3 in EOC was correlated with the overall and relapse-free survival. 2) Genetic ablation of RBMS3 significantly enhanced, whereas restoration of RBMS3 reduced, the chemoresistance ability of EOC cells both in vitro and in vivo. 3) RBMS3 inhibited β-catenin/CBP signaling through directly associating with and stabilizing multiple negative regulators, including DKK3, AXIN1, BACH1, and NFAT5, via competitively preventing the miR-126-5p-mediated repression of these transcripts. 4) cotherapy of CBP/β-catenin antagonist PRI-724 induced sensitization of RBMS3-deleted EOC to platinum therapy.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RBMS3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5965" target="_blank" rel="noopener noreferrer">5965</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46063" target="_blank" rel="noopener noreferrer">P46063</a>', 'HUGO Gene symbol': 'RECQL', 'Protein name': 'ATP-dependent DNA helicase Q1', 'Function': 'DNA helicase that may play a role in the repair of DNA that is damaged by ultraviolet light or other mutagens. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16978399%2C%2025538733%2C%2021571861%2C%2024688722%2C%2016227411%5Buid%5D" target="_blank" rel="noopener noreferrer">16978399, 25538733, 21571861, 24688722, 16227411</a>', 'Notes': '1) over-expression of\xa0RECQL, a DNA helicase involved in various types of DNA repair including mismatch, nucleotide excision and direct repair, was increased in our cisplatin-resistant oral squamous cell carcinoma cells. 2) Increased expression of RECQL4 mRNA was associated with reduced OS, DMFS, and RFS in all breast cancers, and with reduced OS in patients with luminal A, HER2-positive, ER-positive, and PR-positive breast cancer. 3) cell growth was significantly inhibited in vitro by silencing RECQ1 in hypopharyngeal carcinoma cells and the combination treatment of RECQ1 siRNA and cis-platinum (II) diammine dichloride significantly augmented the in vivo anticancer effects of the drug. 4) cisplatin and related platinum drugs induce inter-strand cross links in DNA that impair progression of replication forks and RECQ1 helicase functions are important to restore productive DNA replication. 5) RECQ1 expression was found to be elevated in ovarian cancer cells that were sensitive to carboplatin as compared to those which were carboplatin-resistant', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RECQL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9401" target="_blank" rel="noopener noreferrer">9401</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94761" target="_blank" rel="noopener noreferrer">O94761</a>', 'HUGO Gene symbol': 'RECQL4', 'Protein name': 'ATP-dependent DNA helicase Q4', 'Function': 'DNA helicase', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27013200%5Buid%5D" target="_blank" rel="noopener noreferrer">27013200</a>', 'Notes': '1) significant increases in RECQL4 mRNA or protein in >70% of three independent sets of human gastric cancer specimens examined, relative to normal gastric tissues. 2) high RECQL4 expression in primary tumors correlated well with poor survival and gastric cancer lines with high RECQL4 expression displayed increased resistance to\xa0cisplatin\xa0treatment. 3) a novel role for RECQL4 in transcriptional regulation of the multidrug resistance gene MDR1, through a physical interaction with the transcription factor YB1. 4) ectopic expression of RECQL4 in\xa0cisplatin-sensitive gastric cancer cells with low endogenous RECQL4 was sufficient to render them resistant to\xa0cisplatin, in a manner associated with YB1 elevation and MDR1 activation. 5) RECQL4 silencing in\xa0cisplatin-resistant gastric cancer cells with high endogenous RECQL4 suppressed YB1 phosphorylation, reduced MDR1 expression, and resensitized cells to\xa0cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RECQL4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5970" target="_blank" rel="noopener noreferrer">5970</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q04206" target="_blank" rel="noopener noreferrer">Q04206</a>', 'HUGO Gene symbol': 'RELA', 'Protein name': 'NF-kappaB p65', 'Function': 'NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Hypoxia signaling<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20585448%5Buid%5D" target="_blank" rel="noopener noreferrer">20585448</a>', 'Notes': '1) Comparing the proteomes of paired primary and recurrent post-chemotherapy ovarian high-grade serous carcinomas from nine ovarian cancer patients: more than half of the recurrent tumors expressed higher levels of several proteins including CP, FN1, SYK, CD97, AIF1, WNK1, SERPINA3, APOD, URP2, STAT5B and RELA (NF-kappaB p65). 2) Simultaneous knockdown of RELA and STAT5B was most effective in sensitizing tumor cells for carboplatin treatment. 3) the NF-kappaB inhibitor, BMS-345541, and the STAT5 inhibitor, Dasatinib, significantly enhanced cell sensitivity to carboplatin. 4) augmented Bcl-xL expression was detected in carboplatin-resistant cells. 5) Combined ectopic expression of RELA and STAT5B enhanced Bcl-xL promoter activity while treatment with BMS-345541 and Dasatinib decreased it. 6) Chromatin immunoprecipitation of the Bcl-X promoter region using a STAT5 antibody showed induction of RELA and STAT5 DNA-binding segments both in naïve cells treated with a high concentration of carboplatin as well as in carboplatin-resistant cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RELA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5971" target="_blank" rel="noopener noreferrer">5971</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01201" target="_blank" rel="noopener noreferrer">Q01201</a>', 'HUGO Gene symbol': 'RELB', 'Protein name': 'Transcription factor RelB', 'Function': 'NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Hypoxia signaling<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20564628%2C%2029921694%5Buid%5D" target="_blank" rel="noopener noreferrer">20564628, 29921694</a>', 'Notes': '1) Transcription factors p65 and RelB were coexpressed with IkappaB kinase alpha. 2) A significant association of p50 with poor overall survival was observed in a cohort of 33 patients who subsequently received combined paclitaxel, cisplatin, and cyclophosphamide. 3) TRAF3-deficient HPV+ tumors and cell lines exhibit increased expression of alternative NF-κB pathway components and transcription factors NF-κB2/RELB. Overexpression of TRAF3 inhibited NF-κB2/RELB expression, nuclear localization, and NF-κB reporter activity, as well as resistance to TNFα and cisplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RELB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5979" target="_blank" rel="noopener noreferrer">5979</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07949" target="_blank" rel="noopener noreferrer">P07949</a>', 'HUGO Gene symbol': 'RET', 'Protein name': 'Proto-oncogene tyrosine-protein kinase receptor Ret', 'Function': 'Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25795775%2C%2024276455%5Buid%5D" target="_blank" rel="noopener noreferrer">25795775, 24276455</a>', 'Notes': '1) Germ line missense mutations, which give rise to constitutively active oncogenic RET, were found to cause multiple endocrine neoplasia type 2, a dominant inherited cancer syndrome that affects neuroendocrine organs. 2) Knockdown of RET by shRNA in medullary thyroid cancer-derived cells stimulated expression of activating transcription factor 4 (ATF4), a master transcription factor for stress-induced apoptosis, through activation of its target proapoptotic genes NOXA and PUMA. RET knockdown also increased sensitivity to cisplatin-induced apoptosis.\xa03) RET physically interacted with and phosphorylated ATF4 at tyrosine and threonine residues. and inhibit the ATF4-dependent activation of the NOXA gene. 4) RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring the RET M918T activating mutation in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RET" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51455" target="_blank" rel="noopener noreferrer">51455</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBZ9" target="_blank" rel="noopener noreferrer">Q9UBZ9</a>', 'HUGO Gene symbol': 'REV1', 'Protein name': 'DNA repair protein REV1', 'Function': 'interacts with Y-type DNA polymerases (Pol) and Pol zeta to bypass many types of adducts that block the replicative DNA polymerases', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16495473%2C%2029864443%2C%2029598900%5Buid%5D" target="_blank" rel="noopener noreferrer">16495473, 29864443, 29598900</a>', 'Notes': '1) Overexpression of REV1 in ovarian carcinoma 2008 cells results in resistance to CDDP.  2) The hREV1-transfected sublines were 1.5- to 1.8-fold better than the parental 2008 cells at managing DDP adducts as assessed by their ability to express Renilla reniformis luciferase from a vector that had been extensively loaded with DDP adducts before transfection. 3) MLAF50 inhibited the interaction of REV1 UBM2 with ubiquitin and prevented chromatin localization of REV1 induced by cisplatin in U2OS cells. 4) In cells, one of the compound prevented recruitment of REV1 to PCNA foci on chromatin upon cisplatin treatment, delayed removal of UV-induced cyclopyrimidine dimers from nuclei, prevented UV-induced mutation of HPRT gene, and diminished clonogenic survival of cells that were challenged by cyclophosphamide or cisplatin. 5) To investigate if REV1 and REV3L polymorphisms influence survival of osteosarcoma patients treated with cisplatin-based chemotherapy: carriers of at least one polymorphic REV1 rs3087403 allele had significantly shorter EFS and overall survival (OS). Combination of REV1 rs3087403 and REV3L rs462779 polymorphisms was also significantly associated with shorter OS and shorter EFS. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=REV1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5980" target="_blank" rel="noopener noreferrer">5980</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60673" target="_blank" rel="noopener noreferrer">O60673</a>', 'HUGO Gene symbol': 'REV3L', 'Protein name': 'DNA polymerase zeta catalytic subunit', 'Function': "Catalytic subunit of the DNA polymerase zeta complex, an error-prone polymerase specialized in translesion DNA synthesis (TLS). Lacks an intrinsic 3'-5' exonuclease activity and thus has no proofreading function.", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/TLS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24956248%2C%2026165320%2C%2019289490%5Buid%5D" target="_blank" rel="noopener noreferrer">24956248, 26165320, 19289490</a>', 'Notes': '1) The influence of genetic variability in translesion polymerases\xa0REV1\xa0and REV3L on the outcome of\xa0cisplatin\xa0treatment in malignant mesothelioma patients:  REV3L rs465646, rs462779 and REV3L CCGG haplotype were significantly associated with longer overall survival (p = 0.007, p = 0.022 and p = 0.013, respectively). 2) cisplatin induced the expression of REV3L by recruiting Sp1 to its promoter. 3) Similar results were obtained when the ability of the cells to express luciferase from a platinated plasmid was measured. 4) REV3L overexpression or REV3L plus REV7L significantly enhanced the reporter activity. 5) shRNA-REV3L NSCLC H1299 cells reversed the effects. 6) a forced expression of REV3L conferred the resistance of H1299 cells to cisplatin, whereas the knockdown of REV3L sensitized cisplatin efficacy in H1299 cells. 7) A glioma cell model: upregulation of REV3L markedly attenuated cisplatin-induced apoptosis of the mitochondrial apoptotic pathway. 8) Downregulation of REV3L expression significantly enhanced the sensitivity of glioma cells to cisplatin. 8) REV3L may potentially contribute to gliomagenesis and play a crucial role in regulating cellular response to the DNA cross-linking agent cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=REV3L" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5981" target="_blank" rel="noopener noreferrer">5981</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35251" target="_blank" rel="noopener noreferrer">P35251</a>', 'HUGO Gene symbol': 'RFC1', 'Protein name': 'Replication factor C subunit 1', 'Function': 'The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins PCNA and activator 1.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11336696%2C%2019053130%5Buid%5D" target="_blank" rel="noopener noreferrer">11336696, 19053130</a>', 'Notes': '1) Wild-type Rb, but not LxCxE nonbinding Rb N757F mutant, promotes cell survival after cisplatin treatment and ionizing radiation. 2) RF-Cp145 enhanced survival of cisplatin and ionizing radiation-treated cells cotransfected with wild-type Rb but not LxCxE nonbinding Rb N757F mutant.\xa02) Proteins that bind to Platinum-Modified DNA identified by Photo-Affinity includes RFC1 and RFC2. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RFC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5982" target="_blank" rel="noopener noreferrer">5982</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35250" target="_blank" rel="noopener noreferrer">P35250</a>', 'HUGO Gene symbol': 'RFC2', 'Protein name': 'Replication factor C subunit 2', 'Function': 'The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19053130%5Buid%5D" target="_blank" rel="noopener noreferrer">19053130</a>', 'Notes': '1) Proteins that bind to Platinum-Modified DNA identified by Photo-Affinity includes RFC1 and RFC2. 2) RFC2 binds to damaged DNA downstream of damage recognition in the nucleotide excision repair pathway following excision of the damaged bases', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RFC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6001" target="_blank" rel="noopener noreferrer">6001</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43665" target="_blank" rel="noopener noreferrer">O43665</a>', 'HUGO Gene symbol': 'RGS10', 'Protein name': 'Regulator of G-protein signaling 10', 'Function': 'Regulates G protein-coupled receptor signaling cascades, such as CHRM2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21044322%2C%2024475290%5Buid%5D" target="_blank" rel="noopener noreferrer">21044322, 24475290</a>', 'Notes': '1) RGS2, RGS5, RGS10 and RGS17 transcripts are expressed at significantly lower levels in cells resistant to chemotherapy compared with parental, chemo-sensitive cells in gene expression datasets of multiple models of chemoresistance. 2) exposure of SKOV-3 cells to cytotoxic chemotherapy causes acute, persistent downregulation of RGS10 and RGS17 transcript expression. 3) Direct inhibition of RGS10 or RGS17 expression using siRNA knock-down significantly reduces chemotherapy-induced cell toxicity. 4) The effects of cisplatin, vincristine, and docetaxel are inhibited following RGS10 and RGS17 knock-down in cell viability assays and phosphatidyl serine externalization assays in SKOV-3 cells and MDR-HeyA8 cells. 5) AKT activation is higher following RGS10 knock-down 6) RGS 10 and RGS17 overexpression blocked LPA mediated activation of AKT, suggesting that RGS proteins may blunt AKT survival pathways. 7) The suppression of RGS10 is due to DNA hypermethylation and histone deacetylation. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RGS10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26575" target="_blank" rel="noopener noreferrer">26575</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UGC6" target="_blank" rel="noopener noreferrer">Q9UGC6</a>', 'HUGO Gene symbol': 'RGS17', 'Protein name': 'Regulator of G-protein signaling 17', 'Function': 'As Rgs10', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21044322%2C%2024475290%5Buid%5D" target="_blank" rel="noopener noreferrer">21044322, 24475290</a>', 'Notes': 'As Rgs10', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RGS17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/387" target="_blank" rel="noopener noreferrer">387</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61586" target="_blank" rel="noopener noreferrer">P61586</a>', 'HUGO Gene symbol': 'RHOA', 'Protein name': 'ras homolog family member A / Transforming protein RhoA', 'Function': 'Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Hippo signaling<br><br> Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22336585%2C%2023842948%2C%2026482039%2C%2025277379%2C%2020202822%20%5Buid%5D" target="_blank" rel="noopener noreferrer">22336585, 23842948, 26482039, 25277379, 20202822¬†</a>', 'Notes': '1) Rho/ROCK pathway inhibition by fasudil, an orally administered inhibitor of Rho kinases, enhanced cisplatin-induced growth inhibition and apoptosis in human ovarian cancer cell lines. 2) Fasudil inhibited hypoxia inducible factor (HIF)-1α protein expression. 3) Knockdown of RhoA, ROCK1 or ROCK2 also attenuated the expression of HIF-1α. 4) knockdown of HIF-1α using siRNA enhanced cisplatin-induced growth inhibition and apoptosis as did inhibition of the Rho/ROCK pathway by fasudil, the Rho/ROCK inhibitor Y27632, or by Rho/ROCK knockdown.\xa05) RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma. 6) Cisplatin treatment increased RhoA and ROCK activity accompanied by the reduced tyrosine phosphorylation of SHP2, which was reversed by LM11A-31. 7) phosphorylation of ezrin by ROCK via Fas receptor is involved in the early steps of cisplatin-induced apoptosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'Activity UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RHOA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57381" target="_blank" rel="noopener noreferrer">57381</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H4E5" target="_blank" rel="noopener noreferrer">Q9H4E5</a>', 'HUGO Gene symbol': 'RHOJ', 'Protein name': 'Rho-related GTP-binding protein / Ras-like protein family member 7B / Tc10-like GTP-binding protein)', 'Function': 'Plasma membrane-associated small GTPase specifically involved in angiogenesis', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22971344%5Buid%5D" target="_blank" rel="noopener noreferrer">22971344</a>', 'Notes': '1) In an unbiased genome-wide RNAi screen we identified RhoJ and its effector Pak1, as key modulators of melanoma cell sensitivity to DNA damage (including CDDP).\xa02) RhoJ activates Pak1 in response to drug-induced DNA damage, which then uncouples ATR from its downstream effectors, ultimately resulting in a blunted DNA damage response (DDR). 3) In addition, ATR suppression leads to the decreased phosphorylation of ATF2, and consequent increased expression of the melanocyte survival gene Sox10 resulting in a higher DDR threshold required to engage melanoma cell death. 4) In the setting of normal melanocyte behavior, this regulatory relationship may facilitate appropriate epidermal melanization in response to UV-induced DNA damage. 5) pathological pathway activation during oncogenic transformation produces a tumor that is intrinsically resistant to chemotherapy and has the propensity to accumulate additional mutations. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RHOJ" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55183" target="_blank" rel="noopener noreferrer">55183</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5UIP0" target="_blank" rel="noopener noreferrer">Q5UIP0</a>', 'HUGO Gene symbol': 'RIF1', 'Protein name': 'Telomere-associated protein', 'Function': 'Key regulator of TP53BP1 that plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage: acts by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29719287%5Buid%5D" target="_blank" rel="noopener noreferrer">29719287</a>', 'Notes': '1) RIF1 expression was significantly associated with the response of ovarian patients to platinum-based chemotherapy (P< 0.01). 2) In cohorts from online databases, high expression of RIF1 was associated with higher mortality of EOC patients based on platinum chemotherapy (P < 0.01). 3) RIF1 knockdown increased sensitivity to cisplatin in EOC in vitro and in vivo. 4) Deletion of RIF1 impaired the NER activity by inhibiting the NER proteins in ovarian cancer cells. 5) knockdown of RIF1 enhanced cisplatin-induced apoptosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RIF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8737" target="_blank" rel="noopener noreferrer">8737</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13546" target="_blank" rel="noopener noreferrer">Q13546</a>', 'HUGO Gene symbol': 'RIPK1', 'Protein name': 'Receptor-interacting serine/threonine-protein kinase 1', 'Function': 'transduces cell-death signals (programmed necrosis) following death receptors ligation. Conversely, the lysine (K) 63‐linked polyubiquitin chains serve as a docking site to mediate the formation of a complex upstream of NF‐κB that promotes the activation of pro‐survival signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28498503%2C%2024675421%5Buid%5D" target="_blank" rel="noopener noreferrer">28498503, 24675421</a>', 'Notes': '1) the activity of the NF-κB signaling pathway and K63-linked ubiquitination of RIP1 was higher in cisplatin-resistant ovarian (SKOV3/DDP) cells compared with parental cells. 2) deletion of the ZZ domain of p62 that interacts with RIP1 in SKOV3 cells markedly decreased K63-linked ubiquitination of RIP1 and inhibited the activation of the NF-κB signaling pathway. 3) loss of the ZZ domain from p62 led to poor proliferative capacity and high levels of apoptosis in SKOV3 cells and made them more sensitive to cisplatin treatment. 4) In lung cancer cells, knockdown of RIP1 substantially increased cisplatin-induced apoptotic cytotoxicity, which was associated with robust JNK activation. ', 'Up / down in Pt-resistant cells': 'Ub', 'Up / down to promote Pt-resistance': 'UP/Ub', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RIPK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11035" target="_blank" rel="noopener noreferrer">11035</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y572" target="_blank" rel="noopener noreferrer">Q9Y572</a>', 'HUGO Gene symbol': 'RIPK3', 'Protein name': 'Receptor-interacting serine/threonine-protein kinase 3', 'Function': 'Essential for necroptosis, a programmed cell death process in response to death-inducing TNF-alpha family members.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29331417%5Buid%5D" target="_blank" rel="noopener noreferrer">29331417</a>', 'Notes': '1) RIP3 is downregulated in esophageal squamous cell carcinoma (ESCC )and associated with poor clinical outcome and poor response to chemotherapy. 2) Loss of RIP3 expression confers a moderate amount of cisplatin resistance; re-expression of kinase-dead RIP3 also restored cisplatin sensitivity. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RIPK3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8635" target="_blank" rel="noopener noreferrer">8635</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00584" target="_blank" rel="noopener noreferrer">O00584</a>', 'HUGO Gene symbol': 'RNASET2', 'Protein name': 'Ribonuclease T2', 'Function': 'Has ribonuclease activity, with higher activity at acidic pH. Probably is involved in lysosomal degradation of ribosomal RNA, tumor suppressor genes', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24842157%2C%2011314033%5Buid%5D" target="_blank" rel="noopener noreferrer">24842157, 11314033</a>', 'Notes': '1) RNASET2 and GGNBP2 mRNA levels were significantly lower in A2780-CBP (carboplatin-resistant) and A2780-DDP (cisplatin-resistant) ovarian cancer cells than in the parental A2780 cells 2) were downregulated in drug-resistant ovarian cancer tissues compared with their drug-sensitive counterparts. 3) consistent with the expression profiles  retrieved from the Gene Expression Omnibus Profiles database. 4) Transfection of RNASET2 into ovarian tumor cell lines suppressed their tumorigenicity in nude mice and induced marked cell senescence during in vitro growth', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RNASET2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6045" target="_blank" rel="noopener noreferrer">6045</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99496" target="_blank" rel="noopener noreferrer">Q99496</a>', 'HUGO Gene symbol': 'RNF2', 'Protein name': 'E3 ubiquitin-protein ligase RING2', 'Function': 'Polycomb repressive complex 1 (PRC1) core member Ring1b/Rnf2, with ubiquitin E3 ligase activity towards histone H2A at lysine 119, is essential for early embryogenesis. Important for the transcription repression of various genes involved in development and diifferentiation', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/DNA replication<br><br> Oncogene signaling/MAPK<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29719173%5Buid%5D" target="_blank" rel="noopener noreferrer">29719173</a>', 'Notes': '1) ring finger protein 2 (RNF2) is highly expressed in OC cells.  2) the protein levels of RNF2, p-p38, and p-ERK significantly increased in cisplatin-resistant OC tissues (all P\u2009< 0.05), while the protein levels of p38 and ERK displayed no obvious difference (both P > 0.05).  3) RNF2 is the target gene of miR-139-5p. 4) MAPK activation and RNF2 were related to cisplatin resistance of OC. 5) miR-139-5p was downregulated in cisplatin-resistant OC tissues, 6) miR-139-5p overexpression could inhibit cell vitality, reduce cisplatin resistance, and promote apoptosis of OC cells. 7) miR-139-5p combined with MAPK inhibitors more obviously reduced cisplatin resistance of OC. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RNF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4919" target="_blank" rel="noopener noreferrer">4919</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01973" target="_blank" rel="noopener noreferrer">Q01973</a>', 'HUGO Gene symbol': 'ROR1', 'Protein name': 'Tyrosine-protein kinase transmembrane receptor ROR1, WNT receptor', 'Function': 'Has very low kinase activity in vitro. Receptor for ligand WNT5A which activates downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27239958%2C%2030907503%5Buid%5D" target="_blank" rel="noopener noreferrer">27239958, 30907503</a>', 'Notes': '1) ROR1 and ROR2 expression is increased in OC A2780-cis cells, alongside β-catenin-independent Wnt targets. 2) Knockdown of ROR1 and ROR2 significantly inhibited cell migration and invasion and simultaneous knockdown of ROR1 and ROR2 significantly sensitised cells to cisplatin, whilereas ROR overexpression in the parental cell line increased cell invasion.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ROR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4920" target="_blank" rel="noopener noreferrer">4920</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01974" target="_blank" rel="noopener noreferrer">Q01974</a>', 'HUGO Gene symbol': 'ROR2', 'Protein name': 'Tyrosine-protein kinase transmembrane receptor ROR2, WNT receptor', 'Function': 'early formation of chondrocytes; acts as a receptor for wnt ligand WNT5A which may result in the inhibition of WNT3A-mediated signaling (25029443).', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30056367%2C%2027239958%5Buid%5D" target="_blank" rel="noopener noreferrer">30056367, 27239958</a>', 'Notes': '1) Of patients with platinum-sensitive and -resistant ovarian cancer (total cohort \u202f=\u202f53), the development of platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated. 2) high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways. 3) Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ROR2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6097" target="_blank" rel="noopener noreferrer">6097</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51449" target="_blank" rel="noopener noreferrer">P51449</a>', 'HUGO Gene symbol': 'RORC', 'Protein name': 'Nuclear receptor ROR-gamma', 'Function': "Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of cellular differentiation, immunity, peripheral circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism", 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response<br><br> TGF-β signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30808674%5Buid%5D" target="_blank" rel="noopener noreferrer">30808674</a>', 'Notes': '1) Expression of RORC is lost in tumor tissues of bladder cancer patients. 2) Enhanced expression of RORC suppressed cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis\xa0in vitro\xa0and\xa0in vivo. 3) RORC bound the promoter region of programmed death ligand-1 (PD-L1) and negatively regulated PD-L1 expression. 4) PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK signaling pathway. 5) RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RORC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6117" target="_blank" rel="noopener noreferrer">6117</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27694" target="_blank" rel="noopener noreferrer">P27694</a>', 'HUGO Gene symbol': 'RPA1', 'Protein name': 'Replication protein A 70 kDa DNA-binding subunit', 'Function': 'As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and stabilizes single-stranded DNA intermediates, that form during DNA replication or upon DNA stress. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30072396%5Buid%5D" target="_blank" rel="noopener noreferrer">30072396</a>', 'Notes': '1) Our data revealed a striking correlation among these HGSOC cell lines between\xa0cisplatin sensitivity and the inability to efficiently repair DNA via NER, specifically during S phase. 2) Such defects in NER were attributable to RPA exhaustion arising from aberrant activation of DNA replication origins during replication stress. 3) Reduced RPA availability promoted\xa0Mre11-dependent degradation of nascent DNA at stalled RF in cell lines exhibiting elevated sensitivity to\xa0cisplatin. 4) Strikingly, defective S-phase NER, RF instability, and\xa0cisplatin\xa0sensitivity could all be rescued by ectopic overexpression of RPA. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6118" target="_blank" rel="noopener noreferrer">6118</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15927" target="_blank" rel="noopener noreferrer">P15927</a>', 'HUGO Gene symbol': 'RPA2', 'Protein name': 'Replication protein A 32 kDa subunit', 'Function': 'As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and stabilizes single-stranded DNA intermediates, that form during DNA replication or upon DNA stress.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18289945%2C%2019787780%5Buid%5D" target="_blank" rel="noopener noreferrer">18289945, 19787780</a>', 'Notes': '1) DNA polymerase eta (poleta)-deficient cells are more sensitive to both drugs than are normal cells. 2) In poleta-deficient cells, drug treatment leads to prolonged S-phase arrest, and increased phosphorylation of PIKK substrates Chk1, p95/Nbs1 and RPA2. 3) Cisplatin-induced DNA-PK-dependent hyperphosphorylation of RPA2 on serine 4/serine 8 occurs after recruitment of RPA to chromatin. 4) The absence of RPA2 hyperphosphorylation upon cisplatin correlated with a defect in cell-cycle progression and cell survival in HNSCC cells.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'PHOS', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25873" target="_blank" rel="noopener noreferrer">25873</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y3U8" target="_blank" rel="noopener noreferrer">Q9Y3U8</a>', 'HUGO Gene symbol': 'RPL36', 'Protein name': '60S ribosomal protein L36', 'Function': 'Component of the large ribosomal subunit; Alt-RPL36 downregulates the PI3K-AKT-mTOR signaling pathway by interacting with TMEM24 (33479206)', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16394183%5Buid%5D" target="_blank" rel="noopener noreferrer">16394183</a>', 'Notes': '1) Transfection of either the RPL36 cDNA or HSP10 cDNA conferred on KB-3-1 cells 2.5- to 3-fold resistance to cisplatin by clonogenic assays.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPL36" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6167" target="_blank" rel="noopener noreferrer">6167</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61927" target="_blank" rel="noopener noreferrer">P61927</a>', 'HUGO Gene symbol': 'RPL37', 'Protein name': '60S ribosomal protein L37', 'Function': 'Binds to the 23S rRNA. RPL37, RPS15, and RPS20 as RPs that can also bind Mdm2 and activate p53. (23874713)', 'Putative_mechanism_associated_with_Pt_resistance': 'p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20935493%5Buid%5D" target="_blank" rel="noopener noreferrer">20935493</a>', 'Notes': '1) depletion of L37 leads to cell cycle arrest in a L11- and p53-dependent manner. 2) some genotoxic insults, namely UV light and cisplatin, lead to proteasomal degradation of L37 in the nucleoplasm and to the ensuing L11-dependent stabilization of p53. 3) Ectopic L37 overexpression can attenuate the DNA damage response mediated by p53.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPL37" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6224" target="_blank" rel="noopener noreferrer">6224</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P60866" target="_blank" rel="noopener noreferrer">P60866</a>', 'HUGO Gene symbol': 'RPS20', 'Protein name': '40S ribosomal protein S20', 'Function': 'Promotes G1/S phase progression during cell cycle via upregulation of the levels of cyclin D1 and CDK4 and promotes cell survival in co-operation with GNL1 (30061673); plays a critical role in the regulation of ‘non-ribosomal function’ like modulating p53-MDM2 pathways', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> p53 signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16968546%2C%2021364753%2C%2026051182%2C%2023874713%5Buid%5D" target="_blank" rel="noopener noreferrer">16968546, 21364753, 26051182, 23874713</a>', 'Notes': '1) Chemotherapy for most patients (n = 50) consisted of repeated cycles of cisplatin and vincristine, with combinations of carboplatin, etoposide, cyclophosphamide and/or lomustine.  2) Gain of 8q is associated with worse overall survival, which is not entirely attributable to MYC amplification or overexpression. 3) By applying CGH results to gene expression analysis of medulloblastoma, three 8q-mapped genes are associated with overall survival in the larger group of 64 patients: eukaryotic translation elongation factor 1D (EEF1D), ribosomal protein L30 (RPL30), and ribosomal protein S20 (RPS20). 4) RPS20 belongs to the Acquired Resistance Signature (to cisplatin+Fluorouracil) whose expression is up-regulated in resistant gastric cancer patient samples.  5) RPL37, RPS15, and RPS20 as RPs that can also bind Mdm2 and activate p53. 6) For each RP, the mechanism of Mdm2 and p53 stabilization appears to be through inhibiting the E3 ubiquitin ligase activity of Mdm2; and they are each capable of inducing cell death and cell cycle arrest. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'Ub/UPR', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS20" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6191" target="_blank" rel="noopener noreferrer">6191</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P62701" target="_blank" rel="noopener noreferrer">P62701</a>', 'HUGO Gene symbol': 'RPS4X', 'Protein name': '40S ribosomal protein S4, X isoform', 'Function': 'Ribosomal protein S4 is encoded by more than one gene, namely this gene and ribosomal protein S4, Y-linked (RPS4Y). Physically associates with SLFN11 and blocks the mTOR signaling pathway\xa0(32292519)', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23800275%5Buid%5D" target="_blank" rel="noopener noreferrer">23800275</a>', 'Notes': '1) high expression of RPS4X was associated with a lower risk of death and later disease progression (HR\u2009=\u20090.713, P\u2009=\u20090.001 and HR\u2009=\u20090.761, P\u2009=\u20090.001, respectively) as compared to low expression of RPS4X. 2) YB-1 was not significantly associated with either recurrence or survival time in this cohort. 3) siRNA knockdown of RPS4X in two different ovarian cancer cell lines reduced their proliferative growth rate and increased their resistance to cisplatin.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS4X" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6195" target="_blank" rel="noopener noreferrer">6195</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15418" target="_blank" rel="noopener noreferrer">Q15418</a>', 'HUGO Gene symbol': 'RPS6KA1', 'Protein name': 'S6K-alpha-1 (p90)', 'Function': 'downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) and activates CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B, and modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1.', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Oncogene signaling/MAPK<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29642900%2C%2032667058%2C%2017508026%5Buid%5D" target="_blank" rel="noopener noreferrer">29642900, 32667058, 17508026</a>', 'Notes': '1) RSK1 and RSK2 activate pro-survival proteins Bcl-2 and Bcl-xL by post translational phosphorylation and 2) inactivation of the pro-apoptotic protein Bad, 3) enhancing its ability to bind 14-3-3 proteins and preventing its heterodimerization with the pro-survival proteins. 4) RSK1 and RSK2 also phosphorylate CREB leading to increased transcription of Bcl-2 and promote cell survival. 5) RSK1 directly inhibits caspase activity, promoting cell survival. 6) The combination of cisplatin and BI-D1870 (RSK inhibitor) potentiated the antimigration rate, the activation of caspases-3 and was associated with a significant decrease in RSK1 and ERK expression when compared to cisplatin alone. The combination of cisplatin and BI-D1870 also resulted in the inhibition of LC3 II to LC3 I expression when compared to BI-D1870. 7) Treatment of melanoma cell lines with cisplatin, a potent antitumor agent, increased the level of phosphorylated-ERK (P-ERK)1/2 and enhanced chemoresistance through activation of the cell survival protein 90-kDa ribosomal S6 kinase RSK1. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN/UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS6KA1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6197" target="_blank" rel="noopener noreferrer">6197</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51812" target="_blank" rel="noopener noreferrer">P51812</a>', 'HUGO Gene symbol': 'RPS6KA3', 'Protein name': 'Ribosomal protein S6 kinase alpha-3 (p90)', 'Function': 'downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) and activates CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B, and modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1.', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Oncogene signaling/MAPK<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23041051%5Buid%5D" target="_blank" rel="noopener noreferrer">23041051</a>', 'Notes': '1) whereas treatment with cisplatin did not alter the levels of RSK1 in response to cisplatin treatment, the structurally related RSK2 protein was downregulated in an ovarian cancer cell line (A2780). 2) knockdown of RSK2, in contrast to knockdown of RSK1, gave rise to enhanced cisplatin sensitivity in a cisplatin sensitive as well as a cisplatin-resistant A2780 cell line. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS6KA3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6198" target="_blank" rel="noopener noreferrer">6198</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P23443" target="_blank" rel="noopener noreferrer">P23443</a>', 'HUGO Gene symbol': 'RPS6KB1', 'Protein name': 'Ribosomal protein S6 kinase beta-1', 'Function': 'Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression.', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Oncogene signaling/MAPK<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18425342,21397856,31387554" target="_blank" rel="noopener noreferrer">18425342, 21397856, 31387554</a>', 'Notes': '1) The levels of phosphorylated p70S6K and its downstream target S6 but not total p70S6K or S6 were elevated in the H69 cells that acquired resistance to cisplatin (H69/CP) compared to parental small cell lung cancer H69 cells. 2) Cisplatin treatment resulted in the activation of p70S6K and downregulation of p70S6K enhanced cisplatin-induced apoptosis. 3) URI, a mitochondrial inhibitor of PP1γ, constitutively detains PP1γ in inactive complexes, and therefore sustains S6K1 survival signaling under growth factor-limiting conditions and mediates resistance of cells to cisplatin. 4) RAME was identified as a novel S6K1 inhibitor through blocking the interaction between S6K1 and mTOR: treatment of cervical cancer cells with RAME promoted autophagy and apoptosis, and greatly enhanced the anti-tumor effect of cisplatin in cisplatin-resistant cervical cancer cells.', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS6KB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6199" target="_blank" rel="noopener noreferrer">6199</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UBS0" target="_blank" rel="noopener noreferrer">Q9UBS0</a>', 'HUGO Gene symbol': 'RPS6KB2', 'Protein name': 'Ribosomal protein S6 kinase beta-2', 'Function': 'As RPS6KB1', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Oncogene signaling/MAPK<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18425342%2C%2021397856%5Buid%5D" target="_blank" rel="noopener noreferrer">18425342, 21397856</a>', 'Notes': 'As RPS6KB1', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS6KB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6201" target="_blank" rel="noopener noreferrer">6201</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P62081" target="_blank" rel="noopener noreferrer">P62081</a>', 'HUGO Gene symbol': 'RPS7', 'Protein name': '40S ribosomal protein S7', 'Function': 'Required for rRNA maturation', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling<br><br> Translation', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24244431%5Buid%5D" target="_blank" rel="noopener noreferrer">24244431</a>', 'Notes': '1) shRNA silencing of RPS7 promoted ovarian cancer cell proliferation, accelerated cell cycle progression, and slightly reduced cell apoptosis and response to\xa0cisplatin\xa0treatment. 2) Knockdown of RPS7 resulted in increased expression of P85α, P110α, and AKT2; the phosphorylated forms of MEK1/2 (Ser217/221), ERK1/2 (Thr202/Tyr204), JNK1/2 (Thr183/Tyr185), and P38 (Thr180/Tyr182) were consistently reduced after RPS7 was silenced. 3) Both the in vitro anchorage-independent colony formation and in vivo animal tumor formation capability of cells were enhanced after RPS7 was depleted; silencing of RPS7 enhanced ovarian cancer cell migration and invasion.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPS7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/3921" target="_blank" rel="noopener noreferrer">3921</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08865" target="_blank" rel="noopener noreferrer">P08865</a>', 'HUGO Gene symbol': 'RPSA', 'Protein name': '40S ribosomal protein SA / Laminin receptor protein', 'Function': 'Assembly and/or stability of the 40S ribosomal subunit. Also functions as a cell surface receptor for laminin: cell adhesion to the basement membrane and  signaling transduction pathways.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26293895%5Buid%5D" target="_blank" rel="noopener noreferrer">26293895</a>', 'Notes': '1) In colon cancer cells, knockdown of 67LR decreased the cell adhesion when laminins were applied. 2) 67LR knockdown increased the expression of Bax but inhibited the expression of Bcl-2. 3) 67LR knockdown significantly reduced the IC50 of 5-Fu and DDP from 6.33 and 9.75 to 3.02 and 4.41, respectively. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RPSA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6241" target="_blank" rel="noopener noreferrer">6241</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31350" target="_blank" rel="noopener noreferrer">P31350</a>', 'HUGO Gene symbol': 'RRM2', 'Protein name': 'Ribonucleoside-diphosphate reductase subunit M2', 'Function': 'Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19639316%2C%2023466567%5Buid%5D" target="_blank" rel="noopener noreferrer">19639316, 23466567</a>', 'Notes': "1) undifferentiated and clear cell carcinoma exhibited higher levels of hENT1, dCK, 5'NT, and RRM1 compared to serous ovarian tumors. 2) As of May 2009, the median follow-up was 32 months (range 10-80), and death of disease were observed in 17 cases (68.0%). 3) A statistically significant direct association of RRM2 expression levels and the relative risk of death was observed (Chi (2) = 8.18, P = 0.0043). 4) cases with high RRM2 expression had a shorter OS (median OS = 19 months) than cases with low RRM2 levels (median OS = 36 months) (P = 0.0506). 5) siRNA-mediated inhibition of RRM2 effectively induced G1/S-phase cell cycle arrest and increased drug (gemcitabine and cisplatin)-induced apoptotic fraction at 72 hours ( (96% ± 3.0)%) after transfection (P < 0.05).", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RRM2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/864" target="_blank" rel="noopener noreferrer">864</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13761" target="_blank" rel="noopener noreferrer">Q13761</a>', 'HUGO Gene symbol': 'RUNX3', 'Protein name': 'Runt-related transcription factor 3', 'Function': 'The RUNX family of transcription factors, RUNX1-3, are essential regulators of cell fate during development. Binds to enhancers and promoters of LCK, IL3 and GM-CSF. Upregulates CDKN1A promoter activity following TGF-beta stimulation', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26186909%5Buid%5D" target="_blank" rel="noopener noreferrer">26186909</a>', 'Notes': '1) The expression of RUNX3 was elevated in A2780cp cells compared to A2780s cells and 2) in EOC tissues from chemoresistant patients compared to those from chemosensitive patients. 3) Overexpression of RUNX3 rendered A2780s cells more resistant to carboplatin, 4) inhibition of RUNX3 increased sensitivity to carboplatin in A2780cp cells. 5) Inhibition of RUNX3 potentiated carboplatin-induced apoptosis in A2780cp cells. 5) Overexpression of RUNX3 increased cIAP2 expression in A2780s cells, 6) inhibition of RUNX3 decreased cIAP2 expression and potentiated carboplatin-induced decrease of cIAP2 in A2780cp cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RUNX3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6275" target="_blank" rel="noopener noreferrer">6275</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P26447" target="_blank" rel="noopener noreferrer">P26447</a>', 'HUGO Gene symbol': 'S100A4', 'Protein name': 'S100 calcium binding protein A4', 'Function': 'Involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25491625%5Buid%5D" target="_blank" rel="noopener noreferrer">25491625</a>', 'Notes': '1) resistance or insensitivity of Hep-2 cells to cisplatin might be associated with S100A4 and Slug expression. 2) Knockdown of S100A4 and Slug markedly enhanced the cisplatin-induced suppression of Hep-2 cell growth and increased apoptosis. 3) Knockdown of S100A4 may significantly reduce the levels of S100A4 mRNA, Slug mRNA and proteins, in cisplatin-treated Hep-2 cells. 4) Re-expression of Slug in S100A4 siRNA transfected Hep-2 cells restored the cisplatin resistance in the Hep-2 cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=S100A4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6278" target="_blank" rel="noopener noreferrer">6278</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31151" target="_blank" rel="noopener noreferrer">P31151</a>', 'HUGO Gene symbol': 'S100A7', 'Protein name': 'S100 calcium-binding protein A7 / psoriasin', 'Function': 'secreted by epithelial cells of the skin and is a key antimicrobial protein; regulates cell cycle\xa0progression and\xa0differentiation. High-molecular weight forms require transglutaminase activity (16778811)', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling<br><br> Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29485916%2C%2028051137%2C%2029956751%5Buid%5D" target="_blank" rel="noopener noreferrer">29485916, 28051137, 29956751</a>', 'Notes': "1) S100A7 was significantly overexpressed in human EOC tissue specimens and EOC cell lines Caov3 and SKOV3. 2) S100A7 knockdown cells demonstrated increased sensitivity to cisplatin. 3) miR-330-5p was shown to target the S100A7 3'UTR and to reduce EOC cell growth by inhibiting S100A7 expression. 4) mRNA expression of S100A7 was associated with poor survival of breast cancer patient. 5) higher levels of psoriasin expression were significantly associated a lack of response to neoadjuvant chemotherapy in patients with GC. 6) Psoriasin overexpression tended to decrease the sensitivity of GC cells to cisplatin, potentially by inhibiting apoptosis or increasing the S-phase population. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=S100A7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6280" target="_blank" rel="noopener noreferrer">6280</a>', 'Uniprot_link': 'P06702', 'HUGO Gene symbol': 'S100A9', 'Protein name': 'Calgranulin-B/ Calprotectin L1H subunit / Leukocyte L1 complex heavy chain / Migration inhibitory factor-related protein 14', 'Function': 'S100A9 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30288106%2C%2022487537%2C%2024631944%5Buid%5D" target="_blank" rel="noopener noreferrer">30288106, 22487537, 24631944</a>', 'Notes': '1) S100A9 overexpression could obviously increase the IC50 value of squamous cervical cancer SiHa cells to cisplatin and decrease the apoptosis rate induced by cisplatin. 2) Downregulation of S100A9 led to the opposite results. 3) In S100A9 overexpression SiHa cells, the expression level of Bcl-2, LRP, GST-π, p-AKT, p-ERK, p-FOXO1, and Nanog was significantly increased, while FOXO1 expression was decreased. The opposite results were observed in S100A9 knockdown SiHa cells. 4) Thirty-six squamous cervical cancer patients were identified as chemotherapy-response and 32 were non-response. 5) Protein expression in tumor cells: Exposure of tumor cells to chemotherapy results in a change of Annexin A2 and S100A expression (P<0.05). 6) Annexin A2, S100A8 and S100A9 protein expression correlates with tumor response to chemotherapy (P<0.05). 7) expression of S100A9 and EGFR closely associated chemoresistance, and that inhibition of S100A9 and EGFR may sensitize bladder tumor cells to the cisplatin-based chemotherapy.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=S100A9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6285" target="_blank" rel="noopener noreferrer">6285</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04271" target="_blank" rel="noopener noreferrer">P04271</a>', 'HUGO Gene symbol': 'S100B', 'Protein name': 'S100 calcium-binding protein B', 'Function': 'Binds to and initiates the activation of STK38; activating ERK1/2 and p53/TP53 signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> ECM signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27501952%2C%2029956807%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27501952, 29956807¬†</a>', 'Notes': '1) high expression of S100B in CD133+ OCSCs derived from ovarian cancer cell lines and primary tumors and in cisplatin‑resistant patient samples.  2) The S100B upregulation associated with more advanced tumor stages, poorer differentiation and poorer survival. 3) elevated S100B expression correlated with increased expression of stem cell markers including CD133, Nanog and Oct4. 4) S100B knockdown promoted the apoptosis of OCSCs after treatment with different concentrations of cisplatin. 5) S100B knockdown suppressed the in vitro self-renewal and 6) in vivo tumorigenicity of ovarian CSLCs and decreased their expression of stem cell markers. 7) The underlying mechanism of S100B‑mediated chemoresistance in OCSCs may be through p53 inhibition. 8) drug‑resistance genes, including MDR1 and MRP1, were involved in the process of S100B‑mediated OCSC chemoresistance. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=S100B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6303" target="_blank" rel="noopener noreferrer">6303</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21673" target="_blank" rel="noopener noreferrer">P21673</a>', 'HUGO Gene symbol': 'SAT1', 'Protein name': 'Diamine acetyltransferase 1', 'Function': 'catalyzes the acetylation of polyamines to produce H2O2 and 3-acetamidopropanal. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20031193%2C%2020443003%2C%2023903781%5Buid%5D" target="_blank" rel="noopener noreferrer">20031193, 20443003, 23903781</a>', 'Notes': '1) Quinoxaline pre-treatment synergistically increased SSAT expression, depleted polyamines, increased reactive oxygen species production, and produced synergistic tumor cell killing in both cell lines. 2) this combined therapy increased the chemosensitivity of cisplatin-resistant cells and cross-resistant to the polyamine analogues. On the contrary, some pre-treatment regimens of Spm analogues were antagonistic. 3) Both platinum agents induced SSAT mRNA in parental A2780 cells, but not in resistant cells. 4) berberine inhibits cellular growth by affecting polyamine metabolism, in particular through the upregulation of the key catabolic enzyme SSAT. 5) the sensitivity of resistant cells to cisplatin or to BESpm is reverted to the levels of sensitive cells by the co-treatment with berberine', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP in S; DOWN in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/60485" target="_blank" rel="noopener noreferrer">60485</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H4B6" target="_blank" rel="noopener noreferrer">Q9H4B6</a>', 'HUGO Gene symbol': 'SAV1', 'Protein name': 'protein salvador homolog 1', 'Function': 'Regulator of STK3/MST2 and STK4/MST1 in the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29393390%5Buid%5D" target="_blank" rel="noopener noreferrer">29393390</a>', 'Notes': '1) miR-149-5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. 2) the silencing of miR-149-5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin\xa0in vitro\xa0and\xa0in vivo. 3) the upregulation of miR-149-5p aggravated chemoresistance in ovarian cancer cells. 4) miR-149-5p directly targeted the core kinase components of the Hippo signaling pathway, MST1 and SAV1, resulting in the inactivation of TEAD transcription.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SAV1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/286205" target="_blank" rel="noopener noreferrer">286205</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8N9R8" target="_blank" rel="noopener noreferrer">Q8N9R8</a>', 'HUGO Gene symbol': 'SCAI', 'Protein name': 'Suppressor of cancer cell invasion protein', 'Function': 'Tumor suppressor which functions to suppress MRTFA-induced SRF transcriptional activity. May function in the RHOA-DIAPH1 signal transduction pathway and regulate cell migration through transcriptional regulation of ITGB1. Inhibition of RIF1 by SCAI allows BRCA1-mediated repair (28700933)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> DDR/NHEJ<br><br> ECM signaling<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31479922%5Buid%5D" target="_blank" rel="noopener noreferrer">31479922</a>', 'Notes': '1) Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression. 2) Cdr1as was downregulated in cisplatin-resistant OC patient tissues and cell lines. 3) Overexpression of Cdr1as inhibited cell proliferation and promoted the cisplatin-induced cell apoptosis in ovarian cancer cells. 4) repressed Cdr1as promoted the miR-1270 expression, and miR-1270 could bind to the predicted binding site of Cdr1as. 5) miR-1270  modulate the Suppressor of Cancer Cell Invasion (SCAI) expression. 6) SCAI mRNA were lower in cisplatin-resistant ovarian cancer tissues.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SCAI" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23513" target="_blank" rel="noopener noreferrer">23513</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14160" target="_blank" rel="noopener noreferrer">Q14160</a>', 'HUGO Gene symbol': 'SCRIB', 'Protein name': 'Protein scribble homolog', 'Function': 'Scaffold protein involved in different aspects of polarized cell differentiation regulating epithelial and neuronal morphogenesis and T-cell polarization. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31495720%5Buid%5D" target="_blank" rel="noopener noreferrer">31495720</a>', 'Notes': '1) Clinical analysis revealed that Scribble expression positively correlated with clinical outcomes and chemotherapeutic sensitivity in NSCLC patients. 2) Scribble protected Nox2 protein from proteasomal degradation. 3) Scribble knockdown induced cisplatin resistance by blocking Nox2/ROS and apoptosis in LRR domain-dependent manner. 4) low levels of Scribble correlated with high levels of PD-L1 via activation of\xa0Nrf2\xa0transcription in vivo and in vitro.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SCRIB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6390" target="_blank" rel="noopener noreferrer">6390</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21912" target="_blank" rel="noopener noreferrer">P21912</a>', 'HUGO Gene symbol': 'SDHB', 'Protein name': 'Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial', 'Function': 'Iron-sulfur protein (IP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30544766%2C%2027140478%2C%2030013182%5Buid%5D" target="_blank" rel="noopener noreferrer">30544766, 27140478, 30013182</a>', 'Notes': '1) cisplatin\xa0inhibits SDH, COX, and ATP synthase.\xa02) non-toxic doses of the mitochondrial Complex II inhibitor thenoyltrifluoroacetone (TTFA), which specifically inhibits the ubiquinone-binding site of succinate dehydrogenase (SDH), synergistically stimulated cell death, induced by harmless doses of cisplatin in a panel of chemoresistant neuroblastoma cell lines. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SDHB" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6391" target="_blank" rel="noopener noreferrer">6391</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99643" target="_blank" rel="noopener noreferrer">Q99643</a>', 'HUGO Gene symbol': 'SDHC', 'Protein name': 'Succinate dehydrogenase cytochrome b560 subunit, mitochondrial', 'Function': 'Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30544766%2C%2027140478%2C%2030013182%5Buid%5D" target="_blank" rel="noopener noreferrer">30544766, 27140478, 30013182</a>', 'Notes': '1) The hereditary leiomyomatosis and renal cell cancer (HLRCC) and succinate dehydrogenase-related hereditary paraganglioma and pheochromocytoma (SDH PGL/PCC) are linked to germline loss-of-function mutations in genes encoding the Krebs cycle enzymes fumarate hydratase and succinate dehydrogenase. 2)  fumarate and succinate both suppress HR, thus rendering tumor cells vulnerable to PARP inhibitors. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SDHC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6392" target="_blank" rel="noopener noreferrer">6392</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14521" target="_blank" rel="noopener noreferrer">O14521</a>', 'HUGO Gene symbol': 'SDHD', 'Protein name': 'Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial', 'Function': 'Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30544766%2C%2027140478%2C%2030013182%5Buid%5D" target="_blank" rel="noopener noreferrer">30544766, 27140478, 30013182</a>', 'Notes': 'Succinate dehydrogenase complex', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SDHD" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/29843" target="_blank" rel="noopener noreferrer">29843</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P0U3" target="_blank" rel="noopener noreferrer">Q9P0U3</a>', 'HUGO Gene symbol': 'SENP1', 'Protein name': 'Sentrin-specific protease 1', 'Function': 'Protease that catalyzes two essential functions in the SUMO pathway: maturation and deconjugation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26548925%2C%2023002208%5Buid%5D" target="_blank" rel="noopener noreferrer">26548925, 23002208</a>', 'Notes': '1) Hypoxia decreases sensitivity of SKOV3 cells to cisplatin. 2) SENP1 increased the protein levels of HIF-1α by deSUMOylation and weakened the sensitivity of hypoxic ovarian cancer cells to cisplatin. 3) Testicular germ cell tumors (TGCT) generally respond well to chemotherapy, but tumors that express low levels of the transcription factor OCT4 are associated with chemoresistance and poor prognosis. 4) hypoxia reduces OCT4 levels and increases the resistance of embryonal carcinoma (EC) cells to cisplatin and bleomycin. 5) the loss of OCT4 expression under hypoxia can be triggered by sumoylation, which was regulated by SUMO1 and the SUMO1 peptidase SENP1. 6) Under hypoxic conditions, overexpression of SUMO1gg (the active form of SUMO1) not only increased the level of sumoylated OCT4 (Su-OCT4), but also decreased the stability of OCT4 protein. 7) overexpression of SENP1 reduced the Su-OCT4 level induced by SUMO1gg overexpression, thereby maintaining OCT4 levels and enhancing chemosensitivity. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SENP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5055" target="_blank" rel="noopener noreferrer">5055</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05120" target="_blank" rel="noopener noreferrer">P05120</a>', 'HUGO Gene symbol': 'SERPINB2', 'Protein name': 'Plasminogen activator inhibitor 2', 'Function': 'Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23661500%5Buid%5D" target="_blank" rel="noopener noreferrer">23661500</a>', 'Notes': '1) SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two\xa0cisplatin\xa0resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. 2) Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant\xa0cisplatin-based chemotherapy (n\u2009=\u200967 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. 3) SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received\xa0cisplatin-based chemotherapy (P\u2009=\u20090.001, log rank test). 4) Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. 5) using chemical\xa0inhibitors\xa0of STAT3 activity (a downstream effecter of uPAR signaling pathway) showed that STAT3 suppression altered HNSCC cell line\xa0cisplatin\xa0sensitivity.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SERPINB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6317" target="_blank" rel="noopener noreferrer">6317</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29508" target="_blank" rel="noopener noreferrer">P29508</a>', 'HUGO Gene symbol': 'SERPINB3', 'Protein name': 'Serpin peptidase inhibitor, clade B, member 3 / squamous cell carcinoma antigen 1', 'Function': 'papain-like cysteine protease inhibitor to modulate the host immune response against tumor cells; an inhibitor of UV-induced apoptosis via suppression of the activity of JNK1, it confers resistance to drug-induced apoptosis by inhibiting lysosomal cathepsin proteases', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Metabolism/OXPHOS<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23185467%2C%2024810714%5Buid%5D" target="_blank" rel="noopener noreferrer">23185467, 24810714</a>', 'Notes': '1) In 136 chickens, EOC was found in 10 (7.4%). SERPINB3 mRNA was induced in cancerous, but not normal ovaries of chickens (P<0.01). 2) In 109 human patients with EOC, 15 (13.8%), 66 (60.6%) and 28 (25.7%) patients showed weak, moderate and strong expression of SERPINB3 protein, respectively. 3) Strong expression of SERPINB3 protein was a prognostic factor for platinum resistance (adjusted OR; odds ratio, 5.94; 95% Confidence Limits, 1.21-29.15), and for poor progression-free survival (PFS; adjusted HR; hazard ratio, 2.07; 95% CI; confidence interval, 1.03-4.41). 4) By blocking ROS generation at Complex I, SB3 abrogates PTP opening and cell death induced by platinum drugs in hepatoma HepG2 and HUH7 cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'chicken tissue; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SERPINB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5054" target="_blank" rel="noopener noreferrer">5054</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P05121" target="_blank" rel="noopener noreferrer">P05121</a>', 'HUGO Gene symbol': 'SERPINE1', 'Protein name': 'Serpin E1 /Plasminogen activator inhibitor 1', 'Function': 'Serine protease inhibitor. Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU).', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hypoxia signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28975405%5Buid%5D" target="_blank" rel="noopener noreferrer">28975405</a>', 'Notes': '1) SERPINE1 and SERPINE2 increased most dramatically under carboplatin treatment in A2780cp cells. 2) Carboplatin treatment could significantly increase the expression of SERPINE1 and induce the EMT process, with decreased expression of E-cadherin and increased expression of Vimentin, Snail and Twist. 3) Knockdown of SERPINE1, but not SERPINE2, in A2780cp cells could inhibit the EMT process. 4) hypomethylation in the promoter of SERPINE1 might result in the increased expression of SERPINE1 and subsequent EMT process in A2780cp cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SERPINE1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27244" target="_blank" rel="noopener noreferrer">27244</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y6P5" target="_blank" rel="noopener noreferrer">Q9Y6P5</a>', 'HUGO Gene symbol': 'SESN1', 'Protein name': 'Sestrin-1', 'Function': 'Sestrins are induced by the p53 and play a role in DDR and oxidative stress. The encoded protein mediates p53 inhibition of cell growth by activating AMPK, which inhibits mTOR. Also plays a critical role in antioxidant defense by regenerating overoxidized peroxiredoxins, and the expression of this gene is a potential marker for exposure to radiation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'mTOR signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30300027%5Buid%5D" target="_blank" rel="noopener noreferrer">30300027</a>', 'Notes': '1) SESN1 was induced by cisplatin treatment in human maxillary cancer cell line, IMC-3CR cells. 2) Suppression of SESN1 by RNAi induced apoptosis and reduced cell viability through enhancement of ROS after cisplatin treatment.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SESN1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/29072" target="_blank" rel="noopener noreferrer">29072</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BYW2" target="_blank" rel="noopener noreferrer">Q9BYW2</a>', 'HUGO Gene symbol': 'SETD2', 'Protein name': 'Histone-lysine N-methyltransferase', 'Function': "Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as a substrate; MSH6 interacts with the H3K36me3 mark (23622243)", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MMR<br><br> Transcription<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30093630%2C%2029842882%5Buid%5D" target="_blank" rel="noopener noreferrer">30093630, 29842882</a>', 'Notes': '1) SETD2 is frequently found to be mutated or deleted in a variety of human tumors. 2) SETD2-mediated trimethylation of H3K36 (H3K36me3) and CREB1 phosphorylation are critical for cellular sensitivity to cisplatin.\xa03) suppression of SETD2 or CREB1 and ectopic expression of mutant SETD2 conferred cisplatin resistance through inhibition of H3K36me3 and ERK activation in NSCLC cells. 4) SETD2 significantly enhanced cisplatin-induced apoptosis in osteosarcoma cells and inhibited cancer stem cell properties in OS cells. 5) SETD2 regulates Wnt/β-catenin signaling and its downstream gene c-myc, CD133 and cyclin D1. 6) SETD2 upregulates H3K36me3 modification in GSK3B loci and promotes its transcription, which lead to β-catenin degradation. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SETD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2810" target="_blank" rel="noopener noreferrer">2810</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P31947" target="_blank" rel="noopener noreferrer">P31947</a>', 'HUGO Gene symbol': 'SFN', 'Protein name': '14-3-3 protein sigma', 'Function': '14-3-3 protein sigma, when bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway. May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19528459%2C%2026346170%2C%2024185104%5Buid%5D" target="_blank" rel="noopener noreferrer">19528459, 26346170, 24185104</a>', 'Notes': '1) A 14-3-3sigma-dependent mechanism inhibits p53 activation in parental cells treated with a low cisplatin dose, thereby blocking p21 expression that is essential for senescence and consequently conferring to the parental cells a significant degree of resistance to cisplatin. 2) 14-3-3σ is highly expressed in HKESC-2R cells when compared to HKESC-2 cells. 3) Ectopic expression of 14-3-3σ increased cisplatin resistance in esophageal squamous cell carcinoma HKESC-2 cells, while its suppression sensitized SLMT-1 cells to cisplatin. 4) HMGB1 and XPA were found to be highly expressed in HKESC-2R cells with high 14-3-3σ expression. 5) Subsequent manipulation of 14-3-3σ by both overexpression and knockdown approaches concurrently altered the expression of HMGB1 and XPA. 6) 14-3-3σ, HMGB1, and XPA were preferentially expressed in cisplatin-resistant SLMT-1 cells when compared to those more sensitive to cisplatin. 7) In ESCC patients with poor response to cisplatin-based chemoradiation, their pre-treatment tumors expressed higher expression of HMGB1 than those with response to such treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SFN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6425" target="_blank" rel="noopener noreferrer">6425</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5T4F7" target="_blank" rel="noopener noreferrer">Q5T4F7</a>', 'HUGO Gene symbol': 'SFRP5', 'Protein name': 'secreted frizzled-related protein 5', 'Function': 'extracellular signaling molecules that antagonize Wnt signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18942711%2C%2019957335%5Buid%5D" target="_blank" rel="noopener noreferrer">18942711, 19957335</a>', 'Notes': '1) SFRP5 is downregulated frequently through promoter hypermethylation 2) this hypermethylation is associated with overall survival in ovarian cancer. 3) Restoration of the expression of SFRP5 attenuated Wnt signaling in ovarian cancer cells 4) suppressed cancer cell growth, invasion of cells and tumorigenicity in mice. These effects were independent of the canonical pathway. 5) The expression of SFRP5 inhibited epithelial-mesenchymal transition (EMT). 6) The restoration of SFRP5 downregulated AKT2 and sensitized ovarian cancer cells to chemotherapy. 7) These effects are consistent with the poor response to platinum-based chemotherapy in patients with methylation of SFRP5. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SFRP5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6446" target="_blank" rel="noopener noreferrer">6446</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00141" target="_blank" rel="noopener noreferrer">O00141</a>', 'HUGO Gene symbol': 'SGK1', 'Protein name': 'serum- and glucocorticoid-regulated kinase 1', 'Function': 'hormonal regulation of several ion channels and pumps; anti-apoptotic kinase: phosphorylates and inactivates the Foxo3a/FKRHL1; GSK3B which inhibits B-catenin; p53; IkB', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> NF-kB signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25485633%2C%2025219252%5Buid%5D" target="_blank" rel="noopener noreferrer">25485633, 25219252</a>', 'Notes': '1) SGK-1 inhibition suppresses tumor growth in Mouse experiment, 2) in combination with systemic cisplatin exceeds the effect of cisplatin alone. 3) Decreased expression of CD44 and HER 2 implies depletion of tumor stem cells, and less tumorigenicity.\xa04) elevated expression of GR induced by DEX up-regulates the expression of SGK-1; DEX inhibited apoptosis of SPC-A1 cells induced by CDDP. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SGK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6464" target="_blank" rel="noopener noreferrer">6464</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P29353" target="_blank" rel="noopener noreferrer">P29353</a>', 'HUGO Gene symbol': 'SHC1', 'Protein name': 'SHC-transforming protein 1', 'Function': 'Isoform\xa0p66Shc\xa0does not mediate Ras activation,\xa0acts as a downstream target of the tumor suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28678322%2C%2026431211%5Buid%5D" target="_blank" rel="noopener noreferrer">28678322, 26431211</a>', 'Notes': '1) A549/DDP cells presented remarkably higher expression of lncRNA TRPM2-AS than paired A549 cells. 2) re-sensitization to cisplatin was seen in A549/DDP cells after lncRNA TRPM2-AS knockdown. 3) the sensitivity of lncRNA TRPM2-AS-overexpressed A549 cells to cisplatin decreased obviously when compared with the control. 4) downregulated lncRNA TRPM2-AS induced cell apoptosis through activating the p53-p66shc pathway. 5) In HK2 cells, cisplatin exposure decreased the MnSOD and increased the expression of p53 and p66shc. 6) MnTBAP, a MnSOD mimic, blocked cisplatin-induced the generation of mtROS and cell injury. 7) P66shc and p53 siRNAs rendered renal cells resistant to cisplatin-induced mtROS production and cell death. 8) knockdown of p53 restored MnSOD and inhibiting p66shc.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SHC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79801" target="_blank" rel="noopener noreferrer">79801</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NEM2" target="_blank" rel="noopener noreferrer">Q8NEM2</a>', 'HUGO Gene symbol': 'SHCBP1', 'Protein name': 'SHC SH2 domain-binding protein 1', 'Function': 'May play a role in signaling pathways governing cellular proliferation, cell growth and differentiation. May be a component of a novel signaling pathway downstream of Shc.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31472149%5Buid%5D" target="_blank" rel="noopener noreferrer">31472149</a>', 'Notes': '1) SHCBP1\xa0was upregulated in lung cancer tissues and cells, patients with high\xa0SHCBP1\xa0had poor prognosis. 2) SHCBP1 overexpression promoted\xa0cisplatin\xa0resistance,\xa0migration\xa0and\xa0invasion.\xa03) SHCBP1\xa0knockdown inhibited\xa0cisplatin\xa0resistance,\xa0migration\xa0and\xa0invasion.\xa04) SHCBP1\xa0activated\xa0Wnt\xa0pathway, characterized by promoting β-catenin nuclear translocation. 5) Inhibition of\xa0Wnt\xa0pathway\xa0in\xa0SHCBP1\xa0overexpression cells reversed the effect of\xa0SHCBP1\xa0overexpression, confirming\xa0SHCBP1\xa0promoted lung cancer progression through\xa0activating\xa0Wnt\xa0pathway. 6) SHCBP1\xa0expression was positively corrected with\xa0Wnt\xa0pathway\xa0activity in lung cancer samples.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SHCBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23235" target="_blank" rel="noopener noreferrer">23235</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H0K1" target="_blank" rel="noopener noreferrer">Q9H0K1</a>', 'HUGO Gene symbol': 'SIK2', 'Protein name': 'salt inducible kinase 2', 'Function': "Phosphorylates 'Ser-794' of IRS1 in insulin-stimulated adipocytes, potentially modulating the efficiency of insulin signal transduction. Inhibits CREB activity by phosphorylating and repressing TORCs, the CREB-specific coactivators.", 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> PKA signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32458975%5Buid%5D" target="_blank" rel="noopener noreferrer">32458975</a>', 'Notes': '1) SIK2 was highly expressed in breast cancer tissues and cells compared with adjacent tissues and normal human breast epithelial cells, and it had higher diagnostic value for breast cancer. 2) Silencing SIK2 expression can inhibit proliferation and invasion of breast cancer cells and induce their apoptosis. 3) SIK2 knockdown inhibits glycolysis, reverses the resistance of drug-resistant cells to cisplatin, and inhibits PI3K/AKT/mTOR signaling pathway. 4) When LY294002 was used to inhibit PI3K/AKT/mTOR signaling pathway, the effect of pcDNA3.1-SIK2 on aerobic glycolysis of breast cancer cells could be reversed.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SIK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23411" target="_blank" rel="noopener noreferrer">23411</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96EB6" target="_blank" rel="noopener noreferrer">Q96EB6</a>', 'HUGO Gene symbol': 'SIRT1', 'Protein name': 'NAD-dependent protein deacetylase sirtuin-1', 'Function': 'longevity gene, induced by caloric restriction, regulates various cellular functions including DNA repair, cell survival and metabolism via the deacetylation of target proteins such as histone and p53', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> p53 signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26367491%2C%2021947960%5Buid%5D" target="_blank" rel="noopener noreferrer">26367491, 21947960</a>', 'Notes': '1) immunohistochemical expression of SIRT1 was significantly higher in endometrial carcinoma (108 cases) than in normal endometria (60 cases) (P<0.05), 2) its overexpression was associated with a shorter survival (P<0.05). 3) SIRT1 accelerated the proliferation of endometrial carcinoma cell lines (HHUA, HEC151, and HEC1B). 4) SIRT1 overexpression significantly enhanced the resistance for cisplatin and paclitaxel in HHUA cells. 5) the selective SIRT1 inhibitor (EX527) significantly suppressed the proliferation and cisplatin resistance of three endometrial carcinoma cell lines regardless of the p53 mutation status. 6) SIRT1 overexpression in HHUA cells accelerated tumor growth and cisplatin resistance in nude mice, 7) EX527 significantly suppressed the growth of tumors of HHUA and HEC1B cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SIRT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23410" target="_blank" rel="noopener noreferrer">23410</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NTG7" target="_blank" rel="noopener noreferrer">Q9NTG7</a>', 'HUGO Gene symbol': 'SIRT3', 'Protein name': 'NAD-dependent protein deacetylase sirtuin-3, mitochondrial', 'Function': 'plays a crucial role modulating ROS production and scavenging by regulating key proteins implicated in mitochondrial turnover and in antioxidant defenses.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27420645%5Buid%5D" target="_blank" rel="noopener noreferrer">27420645</a>', 'Notes': '1) When SIRT3 was silenced and combined with CDDP treatments, cell viability was highly decreased, and was accompanied by a significant increase in ROS production. 2) SIRT3 knockdown also affected PGC-1α and TFAM (mitochondrial biogenesis), and MnSOD and IDH2\xa0(antioxidant defenses) protein levels. 3) survival curves showed that higher SIRT3 expression is correlated to a poorer prognosis for patients with grade 3 breast cancer.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SIRT3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6495" target="_blank" rel="noopener noreferrer">6495</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15475" target="_blank" rel="noopener noreferrer">Q15475</a>', 'HUGO Gene symbol': 'SIX1', 'Protein name': 'Homeobox protein SIX1', 'Function': 'Transcription factor in regulation of cell proliferation, apoptosis and embryonic development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> EMT<br><br> TGF-β signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27987372%2C%2029113360%5Buid%5D" target="_blank" rel="noopener noreferrer">27987372, 29113360</a>', 'Notes': '1)\xa0SIX1 was aberrantly expressed in\xa0Esophageal squamous cell carcinoma (ESCCs).\xa02) SIX1\xa0cDNAtransfection induced overexpression of transforming growth factors (TGFB1\xa0and\xa0TGFB2) and its receptor (TGFBR2). 3) the\xa0SIX1‐transfectants highly expressed tumor basal cell markers such as\xa0NGFR,SOX2,ALDH1A1, and\xa0PDPN. 4) In two sets of 42 and 85\xa0ESCCpatients receiving surgery alone or neoadjuvant chemoradiotherapy followed by surgery, the cases with high\xa0SIX1\xa0mRNA\xa0and protein expression level significantly showed a poor prognosis. 5) miR-488 downregulated cell survival and increased apoptosis rate when treated with cisplatin and paclitaxel: Six1 is a target of miR-488. 6) a negative association between Six1 and miR-488 in ovarian cancer tissues. 7) Six1 plasmid reversed the effects of miR-488 on chemoresistance and apoptosis. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SIX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6573" target="_blank" rel="noopener noreferrer">6573</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P41440" target="_blank" rel="noopener noreferrer">P41440</a>', 'HUGO Gene symbol': 'SLC19A1', 'Protein name': 'Folate transporter 1 / Reduced folate carrier protein', 'Function': 'intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H+-pump.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/One carbon', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28138029%5Buid%5D" target="_blank" rel="noopener noreferrer">28138029</a>', 'Notes': 'As SLC46A1', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC19A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6510" target="_blank" rel="noopener noreferrer">6510</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15758" target="_blank" rel="noopener noreferrer">Q15758</a>', 'HUGO Gene symbol': 'SLC1A5', 'Protein name': 'Neutral amino acid transporter B(0)', 'Function': 'Sodium-dependent amino acids transporter that takes in all neutral amino acids, including glutamine, asparagine, and branched-chain and aromatic amino acids, and excludes methylated, anionic, and cationic amino acids', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27191653%2C%2020570523%5Buid%5D" target="_blank" rel="noopener noreferrer">27191653, 20570523</a>', 'Notes': '1) In platinum-sensitive ovarian cancer cell lines the metabolism of both, glucose and glutamine was initially up-regulated in response to platinum treatment. 2) platinum-resistant cells revealed a significant dependency on the presence of glutamine, 3) with an upregulated expression of glutamine transporter ASCT2 and glutaminase. 4) This resulted in a higher oxygen consumption rate compared to platinum-sensitive cell lines reflecting the increased dependency of glutamine utilization through the tricarboxylic acid cycle.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC1A5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6580" target="_blank" rel="noopener noreferrer">6580</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15245" target="_blank" rel="noopener noreferrer">O15245</a>', 'HUGO Gene symbol': 'SLC22A1', 'Protein name': 'Solute carrier family 22 member 1', 'Function': 'Translocates a broad array of organic cations with various structures and molecular weights including MPP, TEA, NMN, ASP, choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine, and metformin.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16914559%2C%2023053895%5Buid%5D" target="_blank" rel="noopener noreferrer">16914559, 23053895</a>', 'Notes': '1) cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K. 2) OCT1 silencing impaired cisplatin-mediated apoptosis of esophageal cancer cells. 2) The level of OCT1 mRNA in cisplatin-resistant cells was markedly reduced compared with parental cells. Promoter methylation of OCT1 was induced in cisplatin-resistant cells.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC22A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6582" target="_blank" rel="noopener noreferrer">6582</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15244" target="_blank" rel="noopener noreferrer">O15244</a>', 'HUGO Gene symbol': 'SLC22A2', 'Protein name': 'Solute carrier family 22 member 2', 'Function': 'Mediates the influx of agmatine, dopamine, noradrenaline, serotonin, choline, famotidine, ranitidine, histamine, creatinine, amantadine, memantine, acriflavine, amiloride, metformin, NMN, TEA, MPP, cimetidine, cisplatin and oxaliplatin.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16914559%2C%2018508032%2C%2024643204%5Buid%5D" target="_blank" rel="noopener noreferrer">16914559, 18508032, 24643204</a>', 'Notes': '1) cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K. 2) Oxaliplatin accumulation was related to hCTR1 and, at low concentration, ATP7A to DNA adducts formation while the retention was related to hCTR1, OCT2 and ATP7B. 3) The main polymorphisms on transporters OCT2, LRP, AQP2, AQP9 and TMEM205 genes were genotyped in 338 lung cancer patients. The rs195854 in genotypic model, rs896412 in genotypic and recessive models for all subjects showed significant association with chemotherapy response. In stratification analysis, TMEM205 rs896412, OCT2 rs1869641 and rs195854, AQP9 rs1516400 and AQP2 rs7314734 showed significant relation to chemotherapy response. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC22A2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6581" target="_blank" rel="noopener noreferrer">6581</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O75751" target="_blank" rel="noopener noreferrer">O75751</a>', 'HUGO Gene symbol': 'SLC22A3', 'Protein name': 'Solute carrier family 22 member 3', 'Function': 'Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16914559%2C%2029416650%5Buid%5D" target="_blank" rel="noopener noreferrer">16914559, 29416650</a>', 'Notes': '1) cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K. 2) Cisplatin resistant hepatoma cells showed a stably reduced cisplatin accumulation and a downregulation of OCT3. In contrast, OCT3 overexpression could reverse resistance.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC22A3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6576" target="_blank" rel="noopener noreferrer">6576</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P53007" target="_blank" rel="noopener noreferrer">P53007</a>', 'HUGO Gene symbol': 'SLC25A1', 'Protein name': 'mitochondrial citrate transporter', 'Function': 'promotes the efflux of tricarboxylic citrate to the cytoplasm in exchange for dicarboxylic cytosolic malate; a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs (29651165); promotes mitochondrial respiratory activity (29651165)', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Metabolism/OXPHOS<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24681808%2C%2029651165%5Buid%5D" target="_blank" rel="noopener noreferrer">24681808, 29651165</a>', 'Notes': '1) SLC25A1 (CIC) promotes tumorigenesis, while its inhibition blunts tumor growth. 2) several p53 mutants (but not wt) are directly recruited to the CIC promoter via a newly identified interaction with the transcription factor FOXO-1, resulting in induction of CIC transcription. 3) inhibition of CIC may improve survival rates and reduce chemo-resistance in tumors harboring p53 mutations. 4) carboplatin resistant tumors derived from patients or from cell lines display increased expression levels of CIC. 5) co-treatment with CIC inhibitors may re-sensitize certain resistant tumors to cisplatin or may permit achieving clinically effective tumor killing while employing more tolerable, less toxic doses of cisplatin. 6) elevated CIC levels predict poor survival outcome in tumors hallmarked by high frequency of p53 mutations. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; database; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC25A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11001" target="_blank" rel="noopener noreferrer">11001</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14975" target="_blank" rel="noopener noreferrer">O14975</a>', 'HUGO Gene symbol': 'SLC27A2', 'Protein name': 'Very long-chain acyl-CoA synthetase', 'Function': 'converts free long-chain fatty acids into fatty acyl-CoA esters, and thereby plays a key role in lipid biosynthesis and fatty acid degradation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Lipid<br><br> Platinum efflux<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30334452%2C%2026513225%5Buid%5D" target="_blank" rel="noopener noreferrer">30334452, 26513225</a>', 'Notes': '1) SLC27A2 down-regulation in primary ovarian cancer tissues correlates with chemo-resistance and poor patient survival in our patient cohort. 2) up-regulation of SLC27A2  sensitizes ovarian cancer cells to cisplatin in vitro and in vivo via apoptosis. 3)  miR-411 is the most strikingly over-expressed gene in response to ectopic expression of SLC27A2, 4) miR-411 under-expressed in recurrent ovarian cancer tissues. 5) Lower miR-411 expression contributes to ovarian cancer chemo-resistance in vitro and in vivo. 6) SLC27A2 directly binds specific sites in the miR-411 promoter region and is required for the transcriptional induction of miR-411. 7) The luciferase assays also confirm that miR-411 directly targets ABCG2 in ovarian cancer. 8) Reduced SLC27A2 correlated chemo-response and poor patient survival in lung cancer. 9) reduced SLC27A2 induced chemo-resistance in CD166+ LCSCs by negatively regulating Bmi1-ABCG2 signaling, and ABCG2 was a direct transcriptional target of Bmi1. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; cell line; clinical outcome; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC27A2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6513" target="_blank" rel="noopener noreferrer">6513</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11166" target="_blank" rel="noopener noreferrer">P11166</a>', 'HUGO Gene symbol': 'SLC2A1', 'Protein name': 'Solute carrier family 2, facilitated glucose transporter member 1 / Glucose transporter 1', 'Function': 'Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11571727%2C%2030861255%2C%2020870738%2C%2027294003%2C%2028222430%5Buid%5D" target="_blank" rel="noopener noreferrer">11571727, 30861255, 20870738, 27294003, 28222430</a>', 'Notes': '1) Ovarian carcinoma patients who experienced a complete clinical response to platinum-based chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative. 2) In multivariate analysis, high GLUT-1 expression levels were independent variables that maintained a significant association with response to chemotherapy. 3) Suppression of GLUT1 by siRNA or by BAY‐876, a GLUT1 inhibitor, enhanced cisplatin‐mediated inhibition of ESCC cell proliferation. 4) GLUT1 expression in pretreatment biopsy samples of esophageal squamous cell carcinoma (ESCC) was associated with the response to platinum‐based chemotherapy as well as the pathological tumor stage and histological response grade after esophagectomy. 5) cisplatin is reported to suppress glucose uptake: cisplatin suppressed glycolysis-related proteins expression, including GLUT1, GLUT4 and LDHB, through down-regulating ITGB5/FAK signaling in breast and cervical cancer cell lines. 6) Over-expression of miR-218 (targeting GLUT1) significantly reduced the rate of glucose uptake and total level of GSH and enhanced the chemo-sensitivity of bladder cancer to cisplatin. 7) Up-regulation of Glut1 could restore chemo-resistance in T24 and EJ cells. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC2A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/144195" target="_blank" rel="noopener noreferrer">144195</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TDB8" target="_blank" rel="noopener noreferrer">Q8TDB8</a>', 'HUGO Gene symbol': 'SLC2A14', 'Protein name': 'Solute carrier family 2, facilitated glucose transporter member 14', 'Function': 'Facilitative glucose transporter\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/Glycolysis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23462296%2C%2026773935%2C%2020870738%2C%2020678156%5Buid%5D" target="_blank" rel="noopener noreferrer">23462296, 26773935, 20870738, 20678156</a>', 'Notes': '1) six genes were significantly decreased in cisplatin-resistant ovarian cell lines: SLC2A14, SLC7A3, SLC7A8, SLC7A11, SLC16A14, SLC38A9.\xa02) cancerous epithelial cell take in larger amount of glucose. GLUT proteins, especially GLUT1, GLUT3, are expressed at higher levels in the malignant cell as are those not normally expressed in that tissue type. 3) Multiple genotoxic stimuli such as Adriamycin (ADR), etoposide (ETOP), cisplatin, UV, and γ-radiation resulted in a suppression of GLUT3 expression and glucose metabolism. 4) cisplatin-resistant cell lines did not show an early decrease in glucose uptake after cisplatin treatment. 5) Glut-3 was associated with higher UICC stage and inferior prognosis 6) See SLC2A1. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'UNKNOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC2A14" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1317" target="_blank" rel="noopener noreferrer">1317</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15431" target="_blank" rel="noopener noreferrer">O15431</a>', 'HUGO Gene symbol': 'SLC31A1', 'Protein name': 'High affinity copper uptake protein 1', 'Function': 'cisplatin uptake/transporter', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22491798%2C%2026158423%2C%2029630768%2C%2023010323%5Buid%5D" target="_blank" rel="noopener noreferrer">22491798, 26158423, 29630768, 23010323</a>', 'Notes': '1) Knockdown of IMP3 or Lin28B decreased cell proliferation, migration, and invasion, and increased the platinum sensitivity, but not taxol sensitivity, 2) of ovarian cancer cells through increased expression of hCTR1, a copper transporter involved in platinum uptake. 3) High expression of hCTR1 correlated with low expression of IMP3/Lin28B and better progression-free survival in advanced-stage EOC patients. 4) Downregulation of EZH2 increased cellular platinum accumulation by protecting CTR1 from cisplatin‐induced proteasomal degradation. 5) A2780cis cells showed decreased cisplatin accumulation and lower CTR1 expression compared to A2780 cells. 6) In both cell lines, CTR1 was localised near the nucleus; the steady-state localisation of the protein in perinuclear region appears to involve its continuous endocytosis from cell surface. 7) Co-localisation between CTR1 and a fluorescent cisplatin analogue labelled with carboxyfluorescein-diacetate could be observed in vesicular structures when continuous retrieval of the protein from cell membrane was inhibited. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC31A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/1318" target="_blank" rel="noopener noreferrer">1318</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15432" target="_blank" rel="noopener noreferrer">O15432</a>', 'HUGO Gene symbol': 'SLC31A2', 'Protein name': 'Probable low affinity copper uptake protein 2', 'Function': 'low affinity copper uptake protein 2', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19509135%2C%2020930109%2C%2023564780%5Buid%5D" target="_blank" rel="noopener noreferrer">19509135, 20930109, 23564780</a>', 'Notes': '1) knockdown of CTR2 increased whole-cell DDP uptake and\xa0DNA\xa0platination in both CTR1(+/+) and CTR1(-/-) cells and proportionately enhanced cytotoxicity while producing no effect on vesicular accumulation or efflux.\xa02) A significant positive correlation was found between CTR2 mRNA and protein levels and resistance to DDP in a panel of six ovarian carcinoma cell lines. 3) Knockdown of CTR2 was associated with activation of the Rac1 and cdc42 GTPases that control macropinocytosis but not activation of the phosphoinositide-3 kinase pathway. 4) CTR2 expression was increased in chemoresistant patients, but not significantly. However, the CTR2/CTR1 ratio was significantly increased in chemoresistant patients. 5) Cases with positive CTR2 expression or positive CTR2/CTR1 ratio had poor prognoses. When the CTR2 expression in ovarian cancer cells was suppressed, sensitivity to cisplatin was significantly increased.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC31A2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/55630" target="_blank" rel="noopener noreferrer">55630</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6P5W5" target="_blank" rel="noopener noreferrer">Q6P5W5</a>', 'HUGO Gene symbol': 'SLC39A4', 'Protein name': 'Zinc transporter ZIP4', 'Function': 'Plays an important role in cellular zinc homeostasis as a zinc transporter. Regulated in response to zinc availability', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28775359%5Buid%5D" target="_blank" rel="noopener noreferrer">28775359</a>', 'Notes': '1) SLC39A4 expression is significantly correlated with increased tumour size and regional lymph node spread, as well as shorter overall survival (OS) and disease-free survival (DFS). 2) SLC39A4 silencing by lentivirus-mediated shRNA blocked human lung cancer cell EMT and metastasis in vitro and in vivo, respectively. 3) SLC39A4 knockdown enhanced cancer cell sensitivity to cisplatin-induced death by inhibiting stemness in lung cancer cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC39A4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6520" target="_blank" rel="noopener noreferrer">6520</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08195" target="_blank" rel="noopener noreferrer">P08195</a>', 'HUGO Gene symbol': 'SLC3A2', 'Protein name': '4F2 cell-surface antigen heavy chain', 'Function': 'Required for the function of light chain amino-acid transporters. When associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine exchanger. It associates with integrins and mediates integrin-dependent signaling related to normal cell growth and tumorigenesis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> mTOR signaling<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30481785%5Buid%5D" target="_blank" rel="noopener noreferrer">30481785</a>', 'Notes': '1) ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. 2) Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, and decreased migration and invasion. 3) downregulation of ZEB1 decreased the volume and weight of implanted tumors. 4) SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. 5) Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, and decreased migration and invasion. 6) upregulation of SLC3A2 decreased the volume and weight of implanted tumors. 7) Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. 8) downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC3A2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/30061" target="_blank" rel="noopener noreferrer">30061</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NP59" target="_blank" rel="noopener noreferrer">Q9NP59</a>', 'HUGO Gene symbol': 'SLC40A1', 'Protein name': 'Solute carrier family 40 member 1 ', 'Function': 'May be involved in iron export from duodenal epithelial cell and also in transfer of iron between maternal and fetal circulation. Mediates iron efflux in the presence of a ferroxidase. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29212168%5Buid%5D" target="_blank" rel="noopener noreferrer">29212168</a>', 'Notes': '1) Elevated level of Nrf2 and reduced level of SLC40A1 were found in cisplatin-resistant ovarian cancer cells as compared with cisplatin-sensitive ovarian cancer cells. 2)  knockdown of Nrf2 leaded to increased expression of SLC40A1. 3) Nrf2 inhibited the transcription of SLC40A1. 4) Overexpression of SLC40A1 was able to reverse cisplatin resistance induced by Nrf2, 5) knockdown of SLC40A1 restored cisplatin resistance and increased iron concentration. 6) Desferal, an iron chelator overcome cisplatin resistance; works synergistically with brusatol, an Nrf2 inhibitor. 7) Iron overload induced by SLC40A1 knockdown resulted in cisplatin resistance in ovarian cancer. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC40A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/113235" target="_blank" rel="noopener noreferrer">113235</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96NT5" target="_blank" rel="noopener noreferrer">Q96NT5</a>', 'HUGO Gene symbol': 'SLC46A1', 'Protein name': 'Proton-coupled folate transporter', 'Function': 'exhibits an acidic pH optimum with high levels of transport activity at pHs characterizing the tumor microenvironment', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/amino acid<br><br> Metabolism/One carbon', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28138029%5Buid%5D" target="_blank" rel="noopener noreferrer">28138029</a>', 'Notes': 'Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates overcome cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC46A1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23657" target="_blank" rel="noopener noreferrer">23657</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UPY5" target="_blank" rel="noopener noreferrer">Q9UPY5</a>', 'HUGO Gene symbol': 'SLC7A11', 'Protein name': 'Cystine/glutamate transporter', 'Function': 'System xc cystine/glutamate antiporter is a membrane amino acid transporter that mediates the exchange of extracellular cystine and intracellular glutamate, which is a heterodimer composed of the 4F2 heavy chain (SLC3A2) and the light chain xCT', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux<br><br> Redox/Glutathione', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/24516043,27133165" target="_blank" rel="noopener noreferrer">24516043, 27133165</a>', 'Notes': '1) A panel of miRNAs were found to be dysregulated in\xa0cisplatin-resistant bladder cancer cells: miRNA-27a was found to target the cystine/glutamate exchanger\xa0SLC7A11\xa0and to contribute to\xa0cisplatin\xa0resistance through modulation of GSH biosynthesis. 2) In bladder cancer patients,\xa0SLC7A11\xa0expression was inversely related to miRNA-27a expression, and those tumors with high mRNA expression or high membrane staining for\xa0SLC7A11\xa0experienced poorer clinical outcomes. 3) Resistant cell lines were resensitized by restoring miRNA-27a expression or reducing\xa0SLC7A11\xa0activity with siRNA or with sulfasalazine. 4) GSH and cysteine released by fibroblasts contribute to platinum resistance; we mixed fibroblasts with OC cell line A2780 and inoculated subcutaneously into nude mice and treated the mice with cisplatin; knockdown of xCT expression in fibroblasts attenuated fibroblast-mediated cisplatin resistance in A2780. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC7A11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8140" target="_blank" rel="noopener noreferrer">8140</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01650" target="_blank" rel="noopener noreferrer">Q01650</a>', 'HUGO Gene symbol': 'SLC7A5', 'Protein name': 'Large neutral amino acids transporter small subunit 1', 'Function': 'The heterodimer with SLC3A2 functions as sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, L-DOPA, leucine, histidine, methionine and tryptophan', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/amino acid<br><br> mTOR signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19058911%2C%2028242177%5Buid%5D" target="_blank" rel="noopener noreferrer">19058911, 28242177</a>', 'Notes': '1) human head and neck cancer cell line, Hep-2, expresses both LAT1 and 4F2hc, another subunit of system L transporter. 2) BCH inhibited leucine uptake by the cells: Co-administration of cisplatin with BCH reduced the viability of the cells more than either agent alone. 3) BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC7A5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9368" target="_blank" rel="noopener noreferrer">9368</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14745" target="_blank" rel="noopener noreferrer">O14745</a>', 'HUGO Gene symbol': 'SLC9A3R1', 'Protein name': 'Na(+)/H(+) exchange regulatory cofactor NHE-RF1', 'Function': 'Scaffold protein that connects plasma membrane proteins with members of the ezrin/moesin/radixin family and thereby helps to link them to the actin cytoskeleton and to regulate their surface expression.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28085111%2C%2029867145%5Buid%5D" target="_blank" rel="noopener noreferrer">28085111, 29867145</a>', 'Notes': '1) Na⁺/H⁺ Exchanger Regulatory Factor 1 (NHERF1) was downregulated in cisplatin-resistant cells. 2) association of NHERF1 expression with disease-free survival of patients received cisplatin treatment. 3) NHERF1 overexpression inhibited proliferation and enhanced apoptosis in cisplatin-resistant HeLa cells, whereas NHERF1 knockdown had inverse effects. 4) NHERF1 significantly inhibited AKT and extracellular signal-regulated kinase (ERK) signaling pathways in cisplatin-resistant cells. 5) NHERF1 inhibition of cervical cancer cell proliferation through Wnt/β-catenin signaling was dependent on α-actinin-4 (ACTN4) expression. 6) A negative association between NHERF1 expression and levels of ACTN4 and β-catenin was found in mouse xenograft model and cervical cancer specimens. 7) Low levels of NHERF1 in cervical cancer specimens were found to associate with activation of cell proliferation and Wnt/β-catenin signaling by gene set enrichment analysis, and also were an independent predictive factor for worse prognosis of cervical cancer patients by Cox regression analysis. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLC9A3R1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/28234" target="_blank" rel="noopener noreferrer">28234</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NPD5" target="_blank" rel="noopener noreferrer">Q9NPD5</a>', 'HUGO Gene symbol': 'SLCO1B3', 'Protein name': 'Solute carrier organic anion transporter family member 1B3', 'Function': 'Mediates the Na+-independent uptake of organic anions, involved in the clearance of bile acids and organic anions from the liver. Of particular importance for hepatic drug elimination', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23757163%5Buid%5D" target="_blank" rel="noopener noreferrer">23757163</a>', 'Notes': '1) OATP1B3, but not OATP1B1, is abundantly expressed in multiple human solid tumors that include hepatocellular, lung, and ovarian carcinomas. 2) OATP1B3 gene expression in a panel of 60 human tumor cell lines was linked with sensitivity to multiple cytotoxic agents, including cisplatin, carboplatin, and oxaliplatin. 3) overexpression of OATP1B3 in mammalian cells increased cellular accumulation of platinum agents and decreased cell survival. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLCO1B3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/91607" target="_blank" rel="noopener noreferrer">91607</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q7Z7L1" target="_blank" rel="noopener noreferrer">Q7Z7L1</a>', 'HUGO Gene symbol': 'SLFN11', 'Protein name': 'Schlafen family member 11', 'Function': 'Inhibitor of DNA replication that promotes cell death in response to DNA damage. The SLNF11 C-terminal is constituted by a DNA/RNA helicase-like motif that has not been functionally characterized yet.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/DNA replication<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26625211%2C%2022927417%2C%2031128155%5Buid%5D" target="_blank" rel="noopener noreferrer">26625211, 22927417, 31128155</a>', 'Notes': '1) promoter CpG island hypermethylation-associated silencing of SLFN11 to be associated with increased resistance to platinum compounds. 2) silencing of SLFN11 gene expression increases resistance to cisplatin and carboplatin treatments. 3) the BRCA1 interacting DHX9 RNA helicase as a protein partner for SLFN11. 4) those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. 5) high SLFN11 expression independently predicts overall survival in a group of ovarian cancer patients treated with cisplatin-containing regimens. 6) SLFN11 irreversibly blocks replication in cells under replication stress, explaining why SLFN11-positive cells are markedly more efficiently killed by DNA-targeting drugs than SLFN11-negative cells. 7) SLFN11 is inactivated in ~50% of cancer cell lines and in a large fraction of tumors, 8) is linked with the native immune, interferon and T-cells responses, implying the translational relevance of measuring SLFN11 expression as a predictive biomarker of response and resistance in patients. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLFN11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/548593" target="_blank" rel="noopener noreferrer">548593</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BQ83" target="_blank" rel="noopener noreferrer">Q9BQ83</a>', 'HUGO Gene symbol': 'SLX1A', 'Protein name': 'Catalytic subunit of the SLX1-SLX4 structure-specific endonuclease ', 'Function': 'resolves DNA secondary structures generated during DNA repair and recombination.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24831703%2C%2024076221%5Buid%5D" target="_blank" rel="noopener noreferrer">24831703, 24076221</a>', 'Notes': '1) the single depletion of GEN1, MUS81, SLX4, or SLX1 led to a significant reduction in cisplatin-induced SCEs. 2) Consistent with the notion that efficient HJ resolution is required for faithful chromosome segregation, especially after treatment with cisplatin, we observed very high levels of mortality in both GM00637 and HeLa cells codepleted for GEN1 and either MUS81, SLX4, or SLX1 when compared with the single depletions', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLX1A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84464" target="_blank" rel="noopener noreferrer">84464</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8IY92" target="_blank" rel="noopener noreferrer">Q8IY92</a>', 'HUGO Gene symbol': 'SLX4', 'Protein name': 'Structure-specific endonuclease subunit SLX4', 'Function': 'several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21464321%2C%2030576517%2C%2019595721%5Buid%5D" target="_blank" rel="noopener noreferrer">21464321, 30576517, 19595721</a>', 'Notes': '1) ICL processing has been shown to also involve MUS81-EME1 and XPF-ERCC1, nucleases known to interact with SLX4, a docking protein that also can bind another nuclease, SLX1.\xa02) SLX4−/− cells expressing UBZ-deficient SLX4 were selectively sensitive to cisplatin, and that the UBZ domain was required for interaction of SLX4 with ubiquitylated FANCD2 and for its recruitment to DNA-damage foci generated by ICL-inducing agents. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SLX4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4089" target="_blank" rel="noopener noreferrer">4089</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13485" target="_blank" rel="noopener noreferrer">Q13485</a>', 'HUGO Gene symbol': 'SMAD4', 'Protein name': 'Mothers against decapentaplegic homolog 4', 'Function': 'In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. ', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28814088%2C%2022753594%2C%2020012971%2C%2026093488%5Buid%5D" target="_blank" rel="noopener noreferrer">28814088, 22753594, 20012971, 26093488</a>', 'Notes': '1) Cisplatin, norcantharidin and\xa0cisplatin\xa0plus norcantharidin significantly inhibited the proliferation of cells, significantly attenuated both the mRNA and protein expression of TGF-β1 and Smad7, and significantly up-regulated the mRNA and protein expression of\xa0Smad4. 2) DPC4/SMAD4 inactivation sensitized pancreatic cancer cells to cisplatin and irinotecan by 2- to 4-fold. 3) Esophagus tumors with total or subtotal regression, as determined by histopathological examination after neoadjuvant chemoradiotherapy, showed significantly higher levels of Smad4 mRNA expression than tumors with minor or no regression (P = 0.032). 4) Levels of SMAD4, a key mediator of the transforming growth factor-ß pathway, increased after activin treatment of OE33/DKK3, and siSMAD4 significantly decreased Matrigel invasion, suggesting that DKK3 acts through the transforming growth factor-β pathway. OE33/DKK3 cells increased endothelial tube formation and were significantly more resistant to 5-fluorouracil and cisplatin, ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMAD4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6595" target="_blank" rel="noopener noreferrer">6595</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51531" target="_blank" rel="noopener noreferrer">P51531</a>', 'HUGO Gene symbol': 'SMARCA2', 'Protein name': 'Probable global transcription activator SNF2L2', 'Function': 'Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22721696%2C%2030127991%5Buid%5D" target="_blank" rel="noopener noreferrer">22721696, 30127991</a>', 'Notes': '1) Downregulation of SWI/SNF chromatin remodeling factor subunits brg1 or brm modulates cisplatin cytotoxicity by impeding the repair of both intrastrand adducts and interstrand crosslinks (ICLs) 2) CAMK2D and SMARCA2 were identified as exhibiting increased expression in cisplatin-resistant cells. 3) Overexpression of either SMARCA2 or CAMK2D led to a significant increase in the survival rates of A2780 and SKVO3 cells following cisplatin treatment. 4) An increased mRNA level of CAMK2D was detected in samples with shorter RFS rates. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMARCA2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6597" target="_blank" rel="noopener noreferrer">6597</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51532" target="_blank" rel="noopener noreferrer">P51532</a>', 'HUGO Gene symbol': 'SMARCA4', 'Protein name': 'Transcription activator BRG1', 'Function': 'transcriptional activation and repression of select genes by chromatin remodeling, component of SWI/SNF chromatin remodeling complexes; involved in antioxidant and redox signaling (33014273)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling<br><br> Redox<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26671993,29515757,19784067" target="_blank" rel="noopener noreferrer">26671993, 29515757, 19784067</a>', 'Notes': '1) reduced expression of\xa0SMARCA4\xa0was associated with poor OS compared to high and intermediate expression (P<0.001 and P=0.009, respectively) in NSCLC patients under cisplatin-based chemotherapy. 2) In multivariate analysis, compared to low, high\xa0SMARCA4\xa0expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4–0.8, P=0.002). 3) SMARCA4 knockdown sensitizes pancreatic ductal epithelial cells to cisplatin. 4) Re-introduction of BRG1 in BRG1-deficient melanoma SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMARCA4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6605" target="_blank" rel="noopener noreferrer">6605</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q969G3" target="_blank" rel="noopener noreferrer">Q969G3</a>', 'HUGO Gene symbol': 'SMARCE1', 'Protein name': 'SWI / SNF-related, matrix-associated, and actin-dependent regulator of chromatin, subfamily e, member 1) ', 'Function': 'Component of SWI/SNF chromatin remodeling complexes involved in transcriptional activation and repression of genes; plays developmental and pathogenic roles (27149204) ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Hormone receptor signaling<br><br> Platinum efflux<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25611552%5Buid%5D" target="_blank" rel="noopener noreferrer">25611552</a>', 'Notes': '1) BAF57 expression was strongly correlated with sensitivities to cisplatin, doxorubicin, and 5-fluorouracil in 10 ovarian cancer cell lines. 2) In A2780 ovarian cancer cells, siRNA knockdown of BAF57 increased cell cycle arrest at G1 phase and the sensitivities to these anticancer agents. 3) cDNA microarray analysis of A2780 cells transfected with BAF57 siRNA showed that 134 genes were positively regulated by BAF57, including WHITE, ABCG2, BCRP. 4) knockdown of BAF57  results in decreased BCRP and ABCG2 gene expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMARCE1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6608" target="_blank" rel="noopener noreferrer">6608</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q99835" target="_blank" rel="noopener noreferrer">Q99835</a>', 'HUGO Gene symbol': 'SMO', 'Protein name': 'Smoothened', 'Function': 'G protein-coupled receptor that probably associates with the patched protein (PTCH) and initiates a signaling cascade leading to the activation and nuclear translocation of Gli which mediates transcription of genes controlling cell proliferation, differentiation and survival. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hedgehog signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29552194%2C%2027875522%5Buid%5D" target="_blank" rel="noopener noreferrer">29552194, 27875522</a>', 'Notes': '1) The expression of Hh signaling pathway components (SHH, SMO, PTCH, and GLI1) in 193 ovarian epithelial tumor specimens (including 147 malignant epithelial ovarian cancers, 30 borderline ovarian tumors, 16 benign ovarian epithelial tumors) and 11 normal ovarian epithelial tissues: significant differences were also revealed in the expression levels of SMO (P=0.013) and GLI1 (P=0.0005) between the platinum drug-sensitive and drug-resistant groups. 2) The overexpression of SMO and GLI1 was further confirmed in the cisplatin-resistant ovarian cancer cell line A2780/DDP by immunofluorescence, flow cytometry and western blotting. 3) Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMO" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6609" target="_blank" rel="noopener noreferrer">6609</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17405" target="_blank" rel="noopener noreferrer">P17405</a>', 'HUGO Gene symbol': 'SMPD1', 'Protein name': 'Acid Sphingomyelinase', 'Function': 'Converts sphingomyelin to ceramide', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/ceramide', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25846011%2C%2018679423%2C%2015150117%2C%2027107419%5Buid%5D" target="_blank" rel="noopener noreferrer">25846011, 18679423, 15150117, 27107419</a>', 'Notes': '1) Cisplatin treatment induced ovarian cell plasma membrane alterations accompanied by increased ASMase activity, leading to the upregulation of FAS, FASL and related pro-apoptotic BAX and PUMA genes. 2) Asm(-/-) mice were resistant to cisplatin and no apoptosis was observed in these organs after treatment. 3) Cells’ exposure to cisplatin induces a translocation of acidic sphingomyelinase (ASMase) to the extracellular surface of the plasma membrane, which induce a rapid increase of ceramide levels, triggering the redistribution of FAS, together with the adaptor molecule FADD and procaspase-8 to induce apoptosis. 4) Chemo-resistance to cisplatin is inversely proportional to A-SMase levels in melanoma cells and grafts. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMPD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64750" target="_blank" rel="noopener noreferrer">64750</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9HAU4" target="_blank" rel="noopener noreferrer">Q9HAU4</a>', 'HUGO Gene symbol': 'SMURF2', 'Protein name': 'E3 ubiquitin-protein ligase', 'Function': 'Forms a stable complex with the TGF-beta receptor-mediated phosphorylated SMAD2 and SMAD3. ', 'Putative_mechanism_associated_with_Pt_resistance': 'TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26716514%2C%2021750651%2C%2025149540%5Buid%5D" target="_blank" rel="noopener noreferrer">26716514, 21750651, 25149540</a>', 'Notes': ' 1) YAP1 ablation significantly improved sensitivities to cisplatin. 2) SMURF2, which can ubiquitinate, but stabilize EGFR by protecting it from c-Cbl-mediated degradation.\xa03) small interfering RNA (siRNA)-mediated knockdown of SMURF2 destabilized EGFR, induced an autophagic response and reduced the clonogenic survival of EGFR-expressing cancer cell lines. 4) Fucoidan decrease tumor growth by promoting Smurf2 and Smad7 to conjugate TGFRs, resulting in TGF degradation: synergistic effect of fucoidan combined with cisplatin. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SMURF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6615" target="_blank" rel="noopener noreferrer">6615</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95863" target="_blank" rel="noopener noreferrer">O95863</a>', 'HUGO Gene symbol': 'SNAI1', 'Protein name': 'Zinc finger protein SNAI1', 'Function': 'Involved in induction of the epithelial to mesenchymal transition (EMT), formation and maintenance of embryonic mesoderm, growth arrest, survival and cell migration. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22429801%2C%2020823140%5Buid%5D" target="_blank" rel="noopener noreferrer">22429801, 20823140</a>', 'Notes': '1) Morphological and phenotypic hallmarks of EMT were identified in the chemoresistant ovarian cancer cells. 2) Subsequent gene\xa0expression\xa0profiling revealed upregulation of EMT-related transcription factors including snail, slug, twist2 and zeb2.\xa03) By reducing expression of snail and slug, the mesenchymal phenotype was largely reversed and cells were resensitized to cisplatin. 4) The correlation between the expression of Snail and ERCC1 was confirmed in different cell lines, including HNSCC cells. 5) In HNSCC cell lines, overexpression of Snail in the low endogenous Snail/ERCC1 cell lines FaDu or CAL-27 increased ERCC1 expression, and hypoxia or overexpression of NBS1 also upregulated ERCC1. 6) Knockdown of Snail in the high endogenous Snail/ERCC1 cell line OECM-1 downregulated ERCC1 expression and attenuated cisplatin resistance. 7) suppression of ERCC1 in Snail- or NBS1-overexpressing HNSCC cells enhanced sensitivity to cisplatin. 8) Snail directly regulated ERCC1 transcription. 9) In patients with HNSCC, coexpression of Snail and ERCC1 correlated with cisplatin resistance and a poor prognosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SNAI1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6591" target="_blank" rel="noopener noreferrer">6591</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43623" target="_blank" rel="noopener noreferrer">O43623</a>', 'HUGO Gene symbol': 'SNAI2', 'Protein name': 'Zinc finger protein SNAI2', 'Function': 'Transcriptional repressor that modulates both activator-dependent and basal transcription. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32771963,25491625,22429801" target="_blank" rel="noopener noreferrer">32771963, 25491625, 22429801</a>', 'Notes': '1) Overexpression of slug promoted self-renewal of HNSCC cells via activation of sphere formation, the expression of stem cell markers, and induction of chemoresistance to cisplatin. 2) slug overexpression increased the migration and invasion of HNSCC cells in vitro and was mainly observed during the invasion in HNSCC xenograft mouse model. 3) slug expression knockdown abrogated their self-renewal capacity, stemness-associated gene expression, and cisplatin chemoresistance. 4) high levels of slug expression correlated with poor prognosis of patients with HNSCC. 5) Knockdown of S100A4 and Slug markedly enhanced the cisplatin-induced suppression of laryngeal carcinoma Hep-2 cell growth and increased apoptosis. 6) Knockdown of S100A4 may significantly reduce the levels of S100A4 mRNA, Slug mRNA and proteins, in cisplatin-treated Hep-2 cells. 7) Re-expression of Slug in S100A4 siRNA transfected Hep-2 cells restored the cisplatin resistance in the Hep-2 cells. 8) See in SNAI1 (22429801)', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SNAI2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6647" target="_blank" rel="noopener noreferrer">6647</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P00441" target="_blank" rel="noopener noreferrer">P00441</a>', 'HUGO Gene symbol': 'SOD1', 'Protein name': 'Superoxide dismutase [Cu-Zn]', 'Function': 'Destroys radicals which are normally produced within the cells and which are toxic to biological systems.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20682985%5Buid%5D" target="_blank" rel="noopener noreferrer">20682985</a>', 'Notes': '1) An enhanced cisplatin sensitivity was observed in the ovarian cancer A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6648" target="_blank" rel="noopener noreferrer">6648</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04179" target="_blank" rel="noopener noreferrer">P04179</a>', 'HUGO Gene symbol': 'SOD2', 'Protein name': 'Superoxide dismutase [Mn], mitochondrial', 'Function': 'Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31364751%2C%2030225719%2C%2025499851%5Buid%5D" target="_blank" rel="noopener noreferrer">31364751, 30225719, 25499851</a>', 'Notes': '1) a higher expression of SOD‑2 in human ESCC samples was associated with TNF‑α expression and poor overall survival in patients with ESCC. 2) the human ESCC cell line Eca‑109 was treated with TNF‑α in vitro. TNF‑α could upregulate SOD‑2 and induce cell proliferation in Eca109 cells, while blocking SOD‑2 using siRNA inhibited TNF‑α‑induced cell proliferation. 3) Upregulation of SOD‑2 by TNF‑α was inhibited by blocking the NF‑κB pathway. 4) TNF‑α could induce cisplatin resistance in Eca109 cells, while transfection with SOD‑2 siRNA could significantly increase the chemosensitivity of ESCC to cisplatin.\xa05) the development of drug resistance was accompanied by enhanced expression of the genes encoding the key antioxidant enzymes (SOD2, CAT, GPX1, and HO-1) and transcription factor Nrf2 in OC SKOV-3 cells. 6) the IC50 of cisplatin was positively correlated with MnSOD expression and its activity in a panel of lung adenocarcinoma cells. 7) an increase in Bcl-2 by MnSOD-mediated NF-κB activation confers greater cisplatin resistance than cIAP2, Bcl-xL, Mcl-1, and Snail. 8) MnSOD-mediated cisplatin resistance can be overcome by a Bcl-2 antagonist (ABT-199) or IKKβ inhibitor (curcumin) in cells and xenograft tumors. 9) MnSOD expression was positively correlated with nuclear p65 protein and Bcl-2 mRNA expression in tumors from patients with lung adenocarcinomas. It was more common for MnSOD-positive, nuclear p65-positive, or high Bcl-2 mRNA tumors to have an unfavorable response to cisplatin-based chemotherapy than their counterparts.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6656" target="_blank" rel="noopener noreferrer">6656</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00570" target="_blank" rel="noopener noreferrer">O00570</a>', 'HUGO Gene symbol': 'SOX1', 'Protein name': 'Transcription factor SOX-1', 'Function': 'transcription factor in the regulation of embryonic development and in the determination of the cell fate; interferes with Wnt/β-catenin signaling (22767186)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Transcription<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23994634%5Buid%5D" target="_blank" rel="noopener noreferrer">23994634</a>', 'Notes': '1) The level of SOX1 mRNA in cisplatin resistance cells was markedly reduced when compared to parental cells. 2) Promoter methylation of SOX1 was induced in cisplatin resistance cells. 3) SOX1 silencing enhanced the cisplatin-mediated autophagy in NSCLC. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6663" target="_blank" rel="noopener noreferrer">6663</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P56693" target="_blank" rel="noopener noreferrer">P56693</a>', 'HUGO Gene symbol': 'SOX10', 'Protein name': 'Transcription factor  SOX-10', 'Function': 'Transcription factor that plays a central role in developing and mature glia (By similarity).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> ECM signaling<br><br> EMT<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26951260%5Buid%5D" target="_blank" rel="noopener noreferrer">26951260</a>', 'Notes': '1) Malignant serous, mucinous, and endometrioid tumors were significantly more likely to express Sox10 than benign and borderline tumors. 2) Nuclear Sox10 staining was also associated with chemoresistance and shorter overall survival in ovarian adenocarcinomas, notably in high-grade serous adenocarcinoma. 3) Nuclear Sox10 expression is an independent indicator of poor prognosis in ovarian adenocarcinomas, notably in high-grade serous adenocarcinomas', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/64321" target="_blank" rel="noopener noreferrer">64321</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H6I2" target="_blank" rel="noopener noreferrer">Q9H6I2</a>', 'HUGO Gene symbol': 'SOX17', 'Protein name': 'Transcription factor SOX-17', 'Function': 'Modulates transcriptional regulation via WNT3A. Inhibits Wnt signaling. Promotes degradation of activated CTNNB1. Plays a key role in the regulation of embryonic development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30777052%5Buid%5D" target="_blank" rel="noopener noreferrer">30777052</a>', 'Notes': '1) High DNA methylation coincided with low mRNA and protein expression levels of SOX17 in pre-treatment endoscopic biopsy from ESCC patients with poor CCRT response. 2) SOX17 protein expression exhibited a good prediction performance in discriminating poor CCRT responders from good responder. 3) Overexpression of SOX17 sensitized KYSE510 radio-resistant cells to\xa0cisplatin, radiation or CCRT treatment in cell and xenograft models. 4) SOX17 transcriptionally down-regulated DNA repair and damage response-related genes including BRCA1, BRCA2, RAD51, KU80 DNAPK, p21, SIRT1, NFAT5 and\xa0REV3L\xa0in KYSE510 radio-resistant cells to achieve the sensitization effect to anti-cancer treatment. 5) Low expression of BRCA1, DNAPK, p21, RAD51 and SIRT1 was confirmed in SOX17 sensitized xenograft tissues derived from radio-resistant ESCC cells.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6657" target="_blank" rel="noopener noreferrer">6657</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48431" target="_blank" rel="noopener noreferrer">P48431</a>', 'HUGO Gene symbol': 'SOX2', 'Protein name': 'Transcription factor SOX-2 ', 'Function': 'forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23867475%2C%2032130794%2C%2028165651%5Buid%5D" target="_blank" rel="noopener noreferrer">23867475, 32130794, 28165651</a>', 'Notes': '1) SOX2-expressing cells display enhanced apoptosis resistance in response to conventional chemotherapies (such as platinum). 2) SOX2\xa0associates with stem cell state in ovarian carcinoma and induction of\xa0SOX2\xa0imposes CSC properties on SOC cells. 3) SOX2 mediates cisplatin resistance in small‐cell lung cancer with downregulated expression of hsa‐miR‐340‐5p. 4) knockdown of SOX2 expression in SKOV3 or HO8910 ovarian cancer spheroid cells decreased spheroid formation, cell proliferation, cell migration, resistance to Cisplatin treatment, tumorigenicity, and the expression of stemness-related genes and epithelial to mesenchymal transition-related genes, 5) overexpression of SOX2 in SKOV3 or HO8910 ovarian cancer cells showed the opposite effects. 6) SOX2 expression was closely associated with chemo-resistance and poor prognosis in EOC patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/30812" target="_blank" rel="noopener noreferrer">30812</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P57073" target="_blank" rel="noopener noreferrer">P57073</a>', 'HUGO Gene symbol': 'SOX8', 'Protein name': 'Transcription factor SOX-8', 'Function': 'Transcription factor that may play a role in central nervous system, limb and facial development.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29071717%5Buid%5D" target="_blank" rel="noopener noreferrer">29071717</a>', 'Notes': '1) SOX8 was upregulated in cisplatin-resistant tongue squamous cell carcinoma TSCC cells, which displayed CSC-like properties and exhibited EMT. 2) SOX8 was also overexpressed in chemoresistant patients with TSCC and was associated with higher lymph node metastasis, advanced tumor stage and shorter overall survival. 3) Stable knockdown of SOX8 in cisplatin-resistant TSCC cells inhibited chemoresistance, tumorsphere formation, and EMT. 4) The Wnt/β-catenin pathway mediated the cancer stem-like properties in cisplatin-resistant TSCC cells. 5) the transfection of active β-catenin in SOX8 stable-knockdown cells partly rescued the SOX8 silencing-induced repression of stem-like features and chemoresistance. 6) SOX8 bound to the promoter region of Frizzled-7 (FZD7) and induced the FZD7-mediated activation of the Wnt/β-catenin pathway.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6662" target="_blank" rel="noopener noreferrer">6662</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P48436" target="_blank" rel="noopener noreferrer">P48436</a>', 'HUGO Gene symbol': 'SOX9', 'Protein name': 'Transcription factor SOX-9', 'Function': 'Transcription factor that plays a key role in chondrocytes differentiation and skeletal development. A master transcription factor that regulates development and stem cell programs.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Redox<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29099271%2C%2027625374%2C%2031658996%20%5Buid%5D" target="_blank" rel="noopener noreferrer">29099271, 27625374, 31658996¬†</a>', 'Notes': '1) we screened for candidate miRNAs potentially regulate CTR1, among which miR-130a has been proved to promote cervical cancer cell proliferation through targeting PTEN in our previous study. 2) we investigated the role of miR-130a in cervical cancer chemoresistance to DDP, and confirmed the binding of miR-130a to CTR1. 3) SOX9 also reportedly act on cancer chemoresistance to DDP. 4) SOX9 inversely regulated miR-130a through direct targeting the promoter of miR-130a. 5) FBW7 is either mutated or downregulated in medulloblastoma, and in cases where FBW7 mRNA levels are low, SOX9 protein is significantly elevated and this phenotype is associated with metastasis at diagnosis and poor patient outcome. 6) SOX9 expression is elevated in NSCLC cells after treatment with the chemotherapeutic cisplatin and that overexpression of SOX9 correlates with worse overall survival in lung cancer patients. 7) SOX9 knockdown increases cellular sensitivity to cisplatin, 8) its overexpression promotes drug resistance. 9) SOX9 promotes the stem-like properties and increases their aldehyde dehydrogenase (ALDH) activity, which was identified to be the key mechanism of SOX9-induced chemoresistance. 10) ALDH1A1 is a direct transcriptional target of SOX9, based on chromatin immunoprecipitation and luciferase reporter assays. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SOX9" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6678" target="_blank" rel="noopener noreferrer">6678</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09486" target="_blank" rel="noopener noreferrer">P09486</a>', 'HUGO Gene symbol': 'SPARC', 'Protein name': 'Secreted protein acidic and rich in cysteine', 'Function': 'calcium binding glycoprotein; antiadhesive and antiproliferative; regulates cell growth through interactions with the ECM and cytokines. Binds copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18992864%2C%2025014664%2C%2017235047%5Buid%5D" target="_blank" rel="noopener noreferrer">18992864, 25014664, 17235047</a>', 'Notes': '1) In vivo, tumor growth was more aggressive in the absence of host-derived SPARC resulting in decreased survival compared with WT mice (P = .005). 2) Cisplatin did not improve survival of WT mice. In contrast, cisplatin therapy resulted in a significant survival advantage (P = .0048) and decreased tumor volume (P = .02) in SP-/- animals. 3) SPARC appears to control tumor cell growth but also impede the efficacy of cisplatin therapy. 4) SPARC expression induces cisplatin resistance in medulloblastoma cells. 5) autophagy was involved in SPARC expression mediated resistance to cisplatin. Suppression of autophagy by either autophagy inhibitor, 3-methyladenosine (3MA) or Atg5 siRNA enhanced cisplatin sensitivity in SPARC expressed cells. 6) SPARC expression suppressed miR-let-7f-1 expression which resulted in disrupted repression of High Mobility Group Box 1 (HMGB1), a critical regulator of autophagy. 7) By Kaplan-Meier analysis, patients whose pancreatic cancer stromal fibroblasts expressed SPARC\n(median survival, 15 months) had a significantly worse prognosis than patients whose tumor\nstroma did not express SPARC (median survival, 30 months; log-rank P< .001).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SPARC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84651" target="_blank" rel="noopener noreferrer">84651</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P58062" target="_blank" rel="noopener noreferrer">P58062</a>', 'HUGO Gene symbol': 'SPINK7', 'Protein name': 'Serine protease inhibitor Kazal-type 7 / Esophagus cancer-related gene 2 ', 'Function': 'transcriptional target of p53, inhibits tumor cell growth and migration/invasion; promotes cell apoptosis\xa0in vivo\xa0and\xa0in vitro', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28348485%2C%2019717562%5Buid%5D" target="_blank" rel="noopener noreferrer">28348485, 19717562</a>', 'Notes': '1) The anti-proliferative effect of ECRG2 in combination with DDP was superior when compared to ECRG2 or DDP alone.\xa02) The combination of ECRG2 and DDP significantly upregulated p53 mRNA and protein levels and downregulated PCNA mRNA and protein levels compared to ECRG2 or DDP alone. 3) lower expression of ECRG2 in multiple human malignancies correlated with reduced disease-free survival in patients.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SPINK7" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6696" target="_blank" rel="noopener noreferrer">6696</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10451" target="_blank" rel="noopener noreferrer">P10451</a>', 'HUGO Gene symbol': 'SPP1', 'Protein name': 'Osteopontin / secreted phosphoprotein 1', 'Function': 'Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30627777%5Buid%5D" target="_blank" rel="noopener noreferrer">30627777</a>', 'Notes': '1) SPP1 was overexpressed in cervical cancer tissues and cell lines. 2) Compared to normal HeLa cells, expression of SPP1 was significantly enhanced in cisplatin resistant res-HeLa cells. 3) SPP1 knockdown resulted in repressed proliferation and enhanced apoptosis of res-HeLa cells, which could be reversed by SPP1 overexpression in HeLa cells. 4) downregulation of SPP1 improved the DDP sensitivity of HeLa by inhibiting the PI3K/Akt signaling pathway.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SPP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8878" target="_blank" rel="noopener noreferrer">8878</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13501" target="_blank" rel="noopener noreferrer">Q13501</a>', 'HUGO Gene symbol': 'SQSTM1', 'Protein name': 'Sequestosome-1', 'Function': 'Autophagy receptor required for selective macroautophagy (aggrephagy). Functions as a bridge between polyubiquitinated cargo and autophagosomes;\xa0p62 accumulation may activate transcription factor Nrf2 (25269472) and the activity of the nuclear factor kappa B (NF‐κB) (28498503)', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> NF-kB signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21371883%2C%2025269472%2C%2028455291%2C%2026201611%2C%2028498503%5Buid%5D" target="_blank" rel="noopener noreferrer">21371883, 25269472, 28455291, 26201611, 28498503</a>', 'Notes': '1) cisplatin-resistant SKOV3/DDP cells express much higher levels of p62 than do cisplatin-sensitive SKOV3 cells. 2) The protein p62 binds ubiquitinated proteins for transport to autophagic degradation, reducing apoptosis induced by endoplasmic reticulum (ER) stress in SKOV3/DDP cells. 3) Knockdown of p62 or inhibition of autophagy using 3-methyladenine resensitises SKOV3/DDP cells to cisplatin. 4) SQSTM1 expression was localized in cancer cells of clinical high-grade serous tumors. 5) PCA analysis identified a distinctive phosphoproteomic signature between cisplatin sensitive and resistant cell lines. The most phosphorylated protein in cisplatin resistant cells was sequestosome-1 (p62/SQSTM1). 6) deletion of the ZZ domain of p62 that interacts with RIP1 in SKOV3 cells markedly decreased K63‐linked ubiquitination of RIP1 and inhibited the activation of the NF‐κB signaling pathway. 7) loss of the ZZ domain from p62 led to poor proliferative capacity and high levels of apoptosis in SKOV3 cells and made them more sensitive to cisplatin treatment.', 'Up / down in Pt-resistant cells': 'UP/PHOS', 'Up / down to promote Pt-resistance': 'UP/PHOS', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SQSTM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6714" target="_blank" rel="noopener noreferrer">6714</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12931" target="_blank" rel="noopener noreferrer">P12931</a>', 'HUGO Gene symbol': 'SRC', 'Protein name': 'Proto-oncogene tyrosine-protein kinase Src', 'Function': 'non-receptor tyrosine kinase that regulates various aspects of tumor progression via multiple signaling pathways including cell survival (AKT), growth (Ras/MEK/ERK), metastasis (FAK/Paxillin/c-Jun), and angiogenesis (STAT3/VEGF).  ', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21737505%5Buid%5D" target="_blank" rel="noopener noreferrer">21737505</a>', 'Notes': '1) Patients with advanced-stage mucinous ovarian cancer had significantly worse survival than those with serous histology. 2) Among multiple ovarian cancer cell lines, RMUG-S-ip2 mucinous ovarian cancer cells showed the highest Src kinase activity. 3) oxaliplatin treatment induced phosphorylation of Src kinase. 4) This induced activity by oxaliplatin therapy was inhibited by concurrent administration of dasatinib. 5) Targeting Src with dasatinib in vivo showed significant antitumor effects in the RMUG-S-ip2 model but not in the serous ovarian carcinoma (SKOV3-TR) model. 6) Combination therapy of oxaliplatin with dasatinib further showed significant effects on reducing cell viability, increasing apoptosis, and in vivo antitumor effects in the RMUG-S-ip2 model. 7) Src inhibition sensitizes ovarian cancer cells to chemotherapeutic agents such as paclitaxel and cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6721" target="_blank" rel="noopener noreferrer">6721</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12772" target="_blank" rel="noopener noreferrer">Q12772</a>', 'HUGO Gene symbol': 'SREBF2', 'Protein name': 'Sterol regulatory element-binding protein 2', 'Function': 'Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the cholesterol and to a lesser degree the fatty acid synthesis pathway', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/cholesterol<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29466876%5Buid%5D" target="_blank" rel="noopener noreferrer">29466876</a>', 'Notes': '1) EZH2 and SREBP2 differentially expressed between cisplatin resistant and cisplatin sensitive cells. 2) siRNA knockdown of SREBP2 in A2780 cell line resulted in a decrease of cell viability after cisplatin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SREBF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6732" target="_blank" rel="noopener noreferrer">6732</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96SB4" target="_blank" rel="noopener noreferrer">Q96SB4</a>', 'HUGO Gene symbol': 'SRPK1', 'Protein name': 'SRSF protein kinase 1', 'Function': 'Serine/arginine-rich protein-specific kinase specifically phosphorylates serine in arginine/serine-rich RS domains and phosphorylates SR splicing factors and regulates splicing.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25866223%2C%2032461560%2C%2011585720%2C%2023236423%2C%2033808326%5Buid%5D" target="_blank" rel="noopener noreferrer">25866223, 32461560, 11585720, 23236423, 33808326</a>', 'Notes': '1) Expression of UCA1 RNA in SKOV3 cells enhanced the cell migration, invasion and cisplatin resistance. 2) Increased expression of SRPK1 and anti-apoptosis proteins were found in SKOV3/pcDNA-UCA1 cells. 3) Knocking-down SRPK1 could partly rescue the effect of UCA1 expression on cell migration, invasion and cisplatin resistance in SKOV3 cells. 4) Tip60-mediated acetylation of SRPK1 is closely associated with chemotherapy sensitivity. In breast cancer cells, cisplatin induced SRPK1 acetylation but in the corresponding resistant cells, it reduced acetylation yet increased phosphorylation and kinase activity of SRPK1, favouring the splicing of some anti-apoptotic variants. Significantly, the cisplatin-resistant cells could be re-sensitized by enhancing SRPK1 acetylation or inhibiting its kinase activity. 5) down-regulation of SRPK1 conferred a 4-fold resistance to cisplatin. 6) Reduction of SRPK1 expression led to reduced cell proliferation rate and compromised anchorage-independent growth in vitro; decreased level of phosphorylation of multiple serine-arginine proteins, and P44/42MAPK and AKT proteins, and enhanced sensitivity to cisplatin. 7) ATR/ATM-dependent phosphorylation of threonine 326 and serine 408 in the spacer domain of SRPK1 was essential for the redistribution of the kinase to the nucleus. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'Acetylation/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRPK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6733" target="_blank" rel="noopener noreferrer">6733</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P78362" target="_blank" rel="noopener noreferrer">P78362</a>', 'HUGO Gene symbol': 'SRPK2', 'Protein name': 'SRSF protein kinase 2', 'Function': 'Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31898732%2C%2033808326%5Buid%5D" target="_blank" rel="noopener noreferrer">31898732, 33808326</a>', 'Notes': '1) SRPK2 negatively regulated Numb and wild-type p53 (wtp53) in response to 5-fluorouracil or cisplatin treatment in HCT116 cells. 2) overexpression of SRPK2 increased cell migration and invasion and decreased chemosensitivity to 5-fluorouracil or cisplatin in HCT116 cells. 3) SRPK2 silencing decreased cell migration and invasion and increased chemosensitivity to 5-fluorouracil or cisplatin, yet these effects could be reversed by p53 knockdown under chemical agent treatment.\xa04) nuclear SRPKs did not protect from, but on the contrary, mediated the cytotoxic effects of genotoxic agents, such as 5-fluorouracil (5-FU) and cisplatin. 5) SRPIN340, a selective SRPK1/2 inhibitor, blocked the nuclear accumulation of the kinases, thus diminishing the cytotoxic effects of the drugs. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRPK2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6427" target="_blank" rel="noopener noreferrer">6427</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01130" target="_blank" rel="noopener noreferrer">Q01130</a>', 'HUGO Gene symbol': 'SRSF2', 'Protein name': 'Serine/arginine-rich splicing factor 2', 'Function': "Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly.\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30375398%5Buid%5D" target="_blank" rel="noopener noreferrer">30375398</a>', 'Notes': '1) PANDAR (the promoter of CDKN1A antisense DNA damage activated RNA)-reduced cisplatin sensitivity was likely or partly due to the PANDAR-binding protein SFRS2 (arginine/serine-rich 2), a splicing factor with the ability to negative regulate p53 and its phosphorylation at Serine 15 (Ser15). 2) This feedback regulation of PANDAR-SFRS2-p53 leads to a reduced transactivation of p53-related pro-apoptotic genes, such as PUMA (p53-upregulated modulator of apoptosis). 3) in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRSF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6429" target="_blank" rel="noopener noreferrer">6429</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q08170" target="_blank" rel="noopener noreferrer">Q08170</a>', 'HUGO Gene symbol': 'SRSF4', 'Protein name': 'Serine/arginine-rich splicing factor 4', 'Function': 'plays a role in alternative splice site selection during pre-mRNA splicing. ', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25884497%5Buid%5D" target="_blank" rel="noopener noreferrer">25884497</a>', 'Notes': '1) Although the downregulation of SRSF4 had no effect on growth when cisplatin was absent, it strongly reduced cell death observed in the presence of cisplatin. \xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRSF4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6480" target="_blank" rel="noopener noreferrer">6480</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15907" target="_blank" rel="noopener noreferrer">P15907</a>', 'HUGO Gene symbol': 'ST6GAL1', 'Protein name': 'Beta-galactoside alpha-2,6-sialyltransferase 1', 'Function': 'catalyzes the addition of the negatively-charged sugar, sialic acid, to the termini of N-linked glycans; α2-6 sialylation enhances the surface retention of other types of receptor glycoproteins (31423157); α2-6 sialylation of Fas prevents apoptosis stimulated by FasL as well as the Fas-activating antibody, CH11 by blocking the association of FADD with Fas cytoplasmic tails (21550977)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR<br><br> Glycosylation<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23578204%5Buid%5D" target="_blank" rel="noopener noreferrer">23578204</a>', 'Notes': '1) forced expression of ST6Gal-I in OV4 ovarian cancer cells that lack endogenous ST6Gal-I increased cell viability following cisplatin treatment. 2) forced ST6Gal-I knockdown in Pa-1 cells with high endogenous ST6Gal-I increases cisplatin-induced cell death. 3) A2780 ovarian cancer cells selected for stable cisplatin resistance display upregulated endogenous ST6Gal-I when compared with parental, cisplatin-sensitive, A2780 cells. 4) extended low dose cisplatin treatment of a Pa-1 polyclonal ST6Gal-I shRNA knockdown population led to selection for subclones with elevated ST6Gal-I expression.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ST6GAL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6772" target="_blank" rel="noopener noreferrer">6772</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42224" target="_blank" rel="noopener noreferrer">P42224</a>', 'HUGO Gene symbol': 'STAT1', 'Protein name': 'Signal transducer and activator of transcription 1-alpha/beta', 'Function': 'Mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21571862%2C%2025826225%2C%2015726096%2C%2026141950%2C%2026695443%5Buid%5D" target="_blank" rel="noopener noreferrer">21571862, 25826225, 15726096, 26141950, 26695443</a>', 'Notes': '1) Significantly enhanced apoptotic response to platinum treatment in resistant ovarian cancer cells was observed following knockdown of HDAC4, FOLR2, PIK3R1, or STAT1. 2) HDAC4-overexpressing tumor cells promotes STAT1 deacetylation to enhance cisplatin resistance. 3) Higher STAT1 expression in HGSOC patients is significantly associated with increased progression-free survival in platinum-based chemotherapy.  4) Increased Stat1 expression were three- to five-fold resistant to cisplatin in OC cells. 5) In HNSCC cells, cisplatin consistently increased the levels of p-S727-STAT1, and STAT1 siRNA knockdown attenuated cisplatin-induced cell death. 6) Treatment-induced activation of the IFN/STAT1 pathway in tumour cells is associated with chemotherapy response in ER- breast cancer.', 'Up / down in Pt-resistant cells': 'DOWN/UP/PHOS/acetylated in S', 'Up / down to promote Pt-resistance': 'DOWN/UP/PHOS', 'Up / down after Pt-treatment': 'PHOS/nuclear loc', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STAT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6774" target="_blank" rel="noopener noreferrer">6774</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40763" target="_blank" rel="noopener noreferrer">P40763</a>', 'HUGO Gene symbol': 'STAT3', 'Protein name': 'Signal transducer and activator of transcription 3', 'Function': 'Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Immune response<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27340780%2C%2023665025%2C%2030056367%2C%2020127005%2C%2021549414%5Buid%5D" target="_blank" rel="noopener noreferrer">27340780, 23665025, 30056367, 20127005, 21549414</a>', 'Notes': '1) Inhibition of STAT3 significantly enhanced the CDDP-induced apoptosis of the osteosarcoma tumor cells. 2) STAT3 activation increase expression of downstream pro-chemoresistant genes, such as MRP and MDR-1. 3) Targeting STAT3 by siRNA markedly enhanced cisplatin-induced apoptosis in cisplatin-resistant ovarian cancer cells that expressed a high level of pSTAT3. 4) IL-6 could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. 5) The STAT3 siRNA treatment also blocked IL-6-induced STAT3 phosphorylation, and that the combination of cisplatin and STAT3 siRNA resulted in apoptosis. \xa06) high levels of ROR2 in platinum-resistant ovarian cancer patient samples were associated with upregulation of Wnt5a, STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB signaling pathways. 7) Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant cell-line model. 8) high expression levels of Stat3 and Notch1 were closely associated with cisplatin resistance respectively (P=0.014, P=0.000). 9) cisplatin resistance of HNSCC was decreased after inhibition of Stat3 or Notch signaling in vitro. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STAT3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6776" target="_blank" rel="noopener noreferrer">6776</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42229" target="_blank" rel="noopener noreferrer">P42229</a>', 'HUGO Gene symbol': 'STAT5A', 'Protein name': 'Signal transducer and activator of transcription 5A', 'Function': 'As STAT5B; STAT proteins are transcription factors that provide a direct link between the cytokine receptors and cytokine-induced gene transcription. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20585448%5Buid%5D" target="_blank" rel="noopener noreferrer">20585448</a>', 'Notes': 'As STAT5B', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STAT5A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6777" target="_blank" rel="noopener noreferrer">6777</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P51692" target="_blank" rel="noopener noreferrer">P51692</a>', 'HUGO Gene symbol': 'STAT5B', 'Protein name': 'Signal transducer and activator of transcription 5B', 'Function': 'Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Mediates cellular responses to ERBB4.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20585448%5Buid%5D" target="_blank" rel="noopener noreferrer">20585448</a>', 'Notes': '1) Proteins upregulated in recurrent tumors included FN1, STIM1, CD97, SYK, WNK1, SERPINA3, CTSS, AIF1, RELA, IL18, STAT5A, STAT5B. 2) The expression of the 24 candidate proteins was validated using quantitative RT-PCR in the same set of clinical samples, as well as in the three pairs of carboplatin-naïve and resistant (CR) ovarian cancer cell lines. 3) simultaneous knockdown of RELA and STAT5B was most effective in sensitizing tumor cells for carboplatin treatment. 4) both RELA and STAT5 are known to bind to the promoter region of Bcl-X, regulating its promoter activity. Augmented Bcl-xL expression was detected in carboplatin-resistant cells. 5) Combined ectopic expression of RELA and STAT5B enhanced Bcl-xL promoter activity while treatment with BMS-345541 and Dasatinib decreased it. 6) Chromatin IP of the Bcl-X promoter region using a STAT5 antibody showed induction of RELA and STAT5 DNA-binding segments both in naïve cells treated with a high concentration of carboplatin as well as in carboplatin-resistant cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STAT5B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6778" target="_blank" rel="noopener noreferrer">6778</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P42226" target="_blank" rel="noopener noreferrer">P42226</a>', 'HUGO Gene symbol': 'STAT6', 'Protein name': 'Signal transducer and activator of transcription 6', 'Function': 'Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21765211%5Buid%5D" target="_blank" rel="noopener noreferrer">21765211</a>', 'Notes': '1) platinum-based chemotherapeutics downregulate PD-L2 in a STAT6-dependent manner, resulting in enhanced T cell activation and increased tumor cell recognition. 2) patients with STAT6-expressing head and neck cancer displayed enhanced recurrence-free survival upon treatment with cisplatin-based chemoradiation compared with patients with STAT6-negative tumors, demonstrating the clinical relevance of platinum-induced STAT6 modulation.\xa0', 'Up / down in Pt-resistant cells': 'DOWN/stroma immune cells', 'Up / down to promote Pt-resistance': 'DOWN/stroma immune cells', 'Up / down after Pt-treatment': 'DOWN/DEPHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STAT6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6786" target="_blank" rel="noopener noreferrer">6786</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13586" target="_blank" rel="noopener noreferrer">Q13586</a>', 'HUGO Gene symbol': 'STIM1', 'Protein name': 'Stromal interaction molecule 1', 'Function': 'Ca2+\xa0sensor in ER via its EF-hand domain. Upon Ca2+\xa0depletion, translocates to the plasma membrane where it activates the Ca2+\xa0release-activated Ca2+\xa0(CRAC) channel subunit ORAI1', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Calcium signaling<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28326487%2C%2025015419%2C%2021364678%5Buid%5D" target="_blank" rel="noopener noreferrer">28326487, 25015419, 21364678</a>', 'Notes': '1) Stim1 expression was significantly increased in chemo-resistant osteosarcoma tissues compared with chemo-sensitivity tissues.\xa02) Patients with Stim1 expression exhibited poorer overall survival than Stim1-negative patients. 3) un-regulation of Stim1 expression and SOCE were also observed in cisplatin-resistant MG63/CDDP cells compared with their parental cells. 4) Cisplatin reduced Stim1 expression and SOCE in cisplatin-sensitive MG63 cells, but had no effects on MG63/CDDP cells. 5) Knockdown of Stim1 enhanced cisplatin-induced apoptosis and ER stress in MG63/CDDP cells, thereby sensitizing cancer cells to cisplatin. 6) overexpression of Stim1 markedly reversed apoptosis and ER stress following cisplatin treatment. 7) SOCE was decreased by Akt inhibitor III (SH-6, 10 µM) in A2780cis but not A2780 cells and 8) decreased in both cell lines by Orai1 inhibitor 2-aminoethoxydiphenyl borate (2-ABP, 50 µM). ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STIM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/340061" target="_blank" rel="noopener noreferrer">340061</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86WV6" target="_blank" rel="noopener noreferrer">Q86WV6</a>', 'HUGO Gene symbol': 'STING1', 'Protein name': 'Stimulator of interferon genes protein', 'Function': 'Facilitator of innate immune signaling that acts as a sensor of cytosolic DNA from bacteria and viruses and promotes the production of type I interferon (IFN-alpha and IFN-beta)\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32068166%2C%2032678307%2C%2025300616%5Buid%5D" target="_blank" rel="noopener noreferrer">32068166, 32678307, 25300616</a>', 'Notes': '1) STING pathway activation in NSCLC predicts features of immunotherapy response and is enhanced by cisplatin treatment. 2) This suggests a possible predictive biomarker and mechanism for improved response to chemoimmunotherapy combinations. 3) USP35 can directly deubiquitinate and inactivate STING. 4) activation of STING promotes its binding to USP35 in a STING phosphorylation-dependent manner. 5) knockdown of USP35 sensitizes ovarian cancer cells to the DNA-damage chemotherapeutic drug cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STING1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6794" target="_blank" rel="noopener noreferrer">6794</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15831" target="_blank" rel="noopener noreferrer">Q15831</a>', 'HUGO Gene symbol': 'STK11', 'Protein name': 'Tumor suppressor serine/threonine-protein kinase ', 'Function': 'controls the activity of AMP-activated protein kinase (AMPK) family members. interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'AMPK signaling<br><br> Apoptotic signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22576699%5Buid%5D" target="_blank" rel="noopener noreferrer">22576699</a>', 'Notes': '1) Exogenous expression of LKB1 could enhance the sensitivity of both A549 and H460 cell lines to cisplatin. 2) Cationic LPs-mediated LKB1 gene therapy could sensitize the response of lung cancer cells to cisplatin. 3) Dramatic upregulations of p-p53 and p-JNK protein levels were detected in LPs-pVAX-LKB1 plus cisplatin-treated cells. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STK11" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9263" target="_blank" rel="noopener noreferrer">9263</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UEE5" target="_blank" rel="noopener noreferrer">Q9UEE5</a>', 'HUGO Gene symbol': 'STK17A', 'Protein name': 'Serine/threonine-protein kinase 17A / DAPK-related apoptosis-inducing protein kinase', 'Function': 'mediates apoptosis by associating with DAPK. Also acts as a regulator of cellular reactive oxygen species.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Detox<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27446402%2C%2021489989%5Buid%5D" target="_blank" rel="noopener noreferrer">27446402, 21489989</a>', 'Notes': '1) STK17A was significantly downregulated in oxaliplatin resistant colon cancer cells. 2) reduced expression of STK17A, result in resistance to paclitaxel and carboplatin.3)  overexpression of STK17A reduced resistance to paclitaxel and carboplatin. 4) STK17A is a novel p53 target gene; Cisplatin-mediated induction of STK17A in the testicular EC cell line NT2/D1 was prevented with p53 siRNA. 5) Knockdown of STK17A conferred resistance to cisplatin-induced growth suppression and apoptotic cell death in EC cells. 6) This was associated with the up-regulation of detoxifying and antioxidant genes, including metallothioneins MT1H, MT1M, and MT1X that have previously been implicated in cisplatin resistance. 6) knockdown of STK17A resulted in decreased cellular reactive oxygen species, whereas STK17A overexpression increased reactive oxygen species. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STK17A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6789" target="_blank" rel="noopener noreferrer">6789</a>', 'Uniprot_link': 'Q13043', 'HUGO Gene symbol': 'STK4', 'Protein name': 'Serine/threonine-protein kinase 4 / mammalian Ste20-like kinase-1', 'Function': 'Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation. Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18381433%5Buid%5D" target="_blank" rel="noopener noreferrer">18381433</a>', 'Notes': '1) Hsp70 has been identified as an Mst1-interacting protein. 2) Hsp70 colocalized with Mst1 in the cytoplasm of LNCaP cells. 3) Overexpression of Hsp70 mediates proteasomal degradation of Mst1. 4) the proapoptotic effect of Mst1 was markedly inhibited by overexpression of Hsp70. 5) in response to the treatment of cisplatin, the induction of Hsp70 expression is higher in the androgen-independent DU145 cells compared with the androgen-dependent LNCaP cells. 6) The higher levels of Hsp70 induction and subsequent Mst1 degradation mediate cisplatin resistance in prostate cancer DU145 cells. 7) overexpression of Mst1 sensitizes prostate cancer cells to cisplatin treatment.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STK4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/56241" target="_blank" rel="noopener noreferrer">56241</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UGT4" target="_blank" rel="noopener noreferrer">Q9UGT4</a>', 'HUGO Gene symbol': 'SUSD2', 'Protein name': 'Sushi domain-containing protein 2', 'Function': 'type I membrane protein, roles in cell-to-cell and cell-matrix adhesion; cytokine receptor for C10ORF99. May be a tumor suppressor', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> CSC<br><br> Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29305171%5Buid%5D" target="_blank" rel="noopener noreferrer">29305171</a>', 'Notes': '1) SUSD2 is one of Notch3-regulating genes and 2) the elevated protein expression of SUSD2 in HGSOC. 3) its high expression level was significantly correlated with worse overall survival, early recurrence and lymph nodes metastasis. 4) overexpression of SUSD2 in ovarian cancer cells promoted epithelial-mesenchymal transition (EMT) and the metastatic capacity of malignant cells. 5) silencing SUSD2 in aggressive ovarian cancer cells inhibited these processes both in vitro and in vivo. 6) SUSD2 promoted EMT through regulating the expression of EpCAM and EpCAM silencing reversed SUSD2-induced E-cadherin reduction and cells migration. 7) a role of SUSD2 in conferring cisplatin resistance in ovarian cancer probably through enhancing autophagy in vitro. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SUSD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10454" target="_blank" rel="noopener noreferrer">10454</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15750" target="_blank" rel="noopener noreferrer">Q15750</a>', 'HUGO Gene symbol': 'TAB1', 'Protein name': 'TGF-beta-activated kinase 1 and MAP3K7-binding protein 1', 'Function': 'a regulator of the MAP kinase kinase kinase MAP3K7/TAK1; also interacts with and activates the mitogen-activated protein kinase 14 (MAPK14/p38alpha)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/MAPK<br><br> p53 signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23934659%5Buid%5D" target="_blank" rel="noopener noreferrer">23934659</a>', 'Notes': '1) TAB1 interacts with MDM2 and regulates p53-mediated cell death in response to cisplatin. 2) p38α is activated by TAB1 to phosphorylate p53 N-terminal sites, leading to selective induction of p53 targets such as NOXA. MDMX is stabilized in a TAB1-dependent manner and is required for cell death after cisplatin treatment. 3) TAB1 expression is decreased in ovarian tumors and cisplatin-resistant ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TAB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/257397" target="_blank" rel="noopener noreferrer">257397</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8N5C8" target="_blank" rel="noopener noreferrer">Q8N5C8</a>', 'HUGO Gene symbol': 'TAB3', 'Protein name': 'TGF-beta-activated kinase 1 and MAP3K7-binding protein 3', 'Function': 'Adapter linking MAP3K7/TAK1 and TRAF6 or TRAF2. Mediator of MAP3K7 activation, respectively in the IL1 and TNF signaling pathways.\xa0Binds preferentially to Lys63‐linked polyubiquitin chains', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27651027%2C%2026476534%5Buid%5D" target="_blank" rel="noopener noreferrer">27651027, 26476534</a>', 'Notes': '1) Expressions of TAB3 and PCNA mRNA were found to be gradually increased in EOC tissues and cell lines. 2) knockdown of TAB3 expression in HO8910 or SKOV3 ovarian cancer cells significantly promoted chemical sensitivity to cisplatin and paclitaxel treatment via inhibiting NF-κB pathways. 3) upregulation of TAB3 expression correlated with a more invasive tumor phenotype and poor prognosis in NSCLC patients;  downregulation of TAB3 enhanced CDDP-induced lung cancer A549 cell apoptosis through the inhibition of the NF-κB pathway.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TAB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6890" target="_blank" rel="noopener noreferrer">6890</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q03518" target="_blank" rel="noopener noreferrer">Q03518</a>', 'HUGO Gene symbol': 'TAP1', 'Protein name': 'Antigen peptide transporter 1', 'Function': 'Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29097421%2C%2027206315%5Buid%5D" target="_blank" rel="noopener noreferrer">29097421, 27206315</a>', 'Notes': '1) Cisplatin-induced increases in transporter of antigen proteins (TAP1 and TAP2) only in the UMSCC-74A cells with wild type\xa0TP53, an established inducer of TAP1. \xa02) inability to increase TAP1/2 may be a form of immune escape in HNSCC. 3) treatment of OC cell lines with TNFα and IL6 induced a selective increase in the expression of TAP1 and multidrug resistance protein 1, 4) TAP1 silencing sensitized cells to cisplatin-induced apoptosis. ', 'Up / down in Pt-resistant cells': 'DOWN/UP/stroma immune cells/cancer cells', 'Up / down to promote Pt-resistance': 'DOWN/UP/stroma immune cells/cancer cells', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6905" target="_blank" rel="noopener noreferrer">6905</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15813" target="_blank" rel="noopener noreferrer">Q15813</a>', 'HUGO Gene symbol': 'TBCE', 'Protein name': 'tubulin-specific chaperone E', 'Function': 'Tubulin-folding protein; involved in the second step of the tubulin folding pathway. Cisplatin stops tubulin assembly into microtubules (11251225). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18571892%5Buid%5D" target="_blank" rel="noopener noreferrer">18571892</a>', 'Notes': '1) In comparison of the gene expressions between KFR and KF-1 ovarian cancer cell lines, TBCE and CITED2 were overexpressed in KFR compared to KF-1. 2) These genes are overexpressed in MKN74, an oxaliplatin-resistant gastric cancer cell line, compared to oxaliplatin-sensitive MKN28. 3) siRNA knockdown of TBCE and CITED2 enhanced the cytotoxicity of diplatin to KFR. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TBCE" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6909" target="_blank" rel="noopener noreferrer">6909</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13207" target="_blank" rel="noopener noreferrer">Q13207</a>', 'HUGO Gene symbol': 'TBX2', 'Protein name': 'T-box 2 transcription factor', 'Function': 'transcriptional regulation of genes required for mesoderm differentiation; a negative regulator of PML in cellular senescence; promotes proliferation and invasion through EMT and ERK pathway (30651856); a player in Wnt signaling (20624445). ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> EMT<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29435041%5Buid%5D" target="_blank" rel="noopener noreferrer">29435041</a>', 'Notes': '1) silencing TBX2 induces senescence. 2) Ectopic expression of TBX2 is associated with conferred resistance to the DNA-damaging chemotherapeutic drugs cisplatin and doxorubicin. 3) A total of 54 patients with ovarian serous carcinoma (FIGO stages III and IV) were divided into platinum-sensitive (n=27) and resistant (n=27) groups. 4) The TBX2-weighted score was significantly lower in the platinum-sensitive group than the platinum-resistant group (P=0.005) and the low TBX2 expression group was significantly more sensitive to platinum-based chemotherapy (P=0.004). Sensitivity to cisplatin and carboplatin significantly increased when TBX2 expression was inhibited in human ovarian serous carcinoma cells in vitro (P<0.05). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TBX2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7003" target="_blank" rel="noopener noreferrer">7003</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P28347" target="_blank" rel="noopener noreferrer">P28347</a>', 'HUGO Gene symbol': 'TEAD1', 'Protein name': 'TEA domain transcription factor 1 / Transcriptional enhancer factor TEF-1', 'Function': 'Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25369529%5Buid%5D" target="_blank" rel="noopener noreferrer">25369529</a>', 'Notes': '1) YAP and TEAD family members, except for TEAD2, were all expressed at significantly higher levels by ovarian cancer initiating cells (OCICs) than by differentiated ovarian cancer cells. 2) mRNA levels of known YAP/TEAD target genes, including\xa0Runx2,\xa0Itgb2, and\xa0Erbb4, were all significantly increased in OCIC cells. 3) Compared with primary tumor cells, OCICs exhibited enhanced resistance to cisplatin, taxol, and bleomycin. 4) OCICs with Yap and Tead1/3/4 knockdown had decreased survival rates. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TEAD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7005" target="_blank" rel="noopener noreferrer">7005</a>', 'Uniprot_link': 'Q99594', 'HUGO Gene symbol': 'TEAD3', 'Protein name': 'Transcriptional enhancer factor TEF-5', 'Function': 'As TEAD1', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25369529%5Buid%5D" target="_blank" rel="noopener noreferrer">25369529</a>', 'Notes': 'AS TEAD1', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TEAD3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7004" target="_blank" rel="noopener noreferrer">7004</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15561" target="_blank" rel="noopener noreferrer">Q15561</a>', 'HUGO Gene symbol': 'TEAD4', 'Protein name': 'Transcriptional enhancer factor TEF-3', 'Function': 'As TEAD1', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25369529%5Buid%5D" target="_blank" rel="noopener noreferrer">25369529</a>', 'Notes': 'AS TEAD1', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TEAD4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7015" target="_blank" rel="noopener noreferrer">7015</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14746" target="_blank" rel="noopener noreferrer">O14746</a>', 'HUGO Gene symbol': 'TERT', 'Protein name': 'Telomerase reverse transcriptase', 'Function': 'Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells; high in CSC', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> DDR/telomere', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25375122%2C%2028765565%2C%2026020272%5Buid%5D" target="_blank" rel="noopener noreferrer">25375122, 28765565, 26020272</a>', 'Notes': '1) Tert inhibitor Eribulin inhibits growth of cisplatin-resistant ovarian adenocarcinoma cell lines. 2) higher telomerase reverse transcriptase(TERT) expression in cisplatin resistant osteosarcoma cells. 3) TERT translocates from the nucleus to mitochondria in cisplatin treated osteosarcoma cells. 4) decreased apoptosis rate and improved mitochondrial function in TERT-overexpressing cells following cisplatin treatment. 5) TERT inhibits cisplatin-induced apoptosis independently of telomerase reverse transcriptase activity. 6) TERT suppressed cisplatin-induced apoptosis and improved mitochondrial function via alleviating intracellular ROS in osteosarcoma cells. 7) Seven polymorphisms of TERT were assessed, and a total of 1004 inoperable advanced NSCLC patients treated with platinum-based chemotherapy were enrolled. It is exhibited that the variant heterozygote of rs4975605 showed significant association with a low rate of clinical benefit. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'TRANSLOCATED', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TERT" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/80312" target="_blank" rel="noopener noreferrer">80312</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8NFU7" target="_blank" rel="noopener noreferrer">Q8NFU7</a>', 'HUGO Gene symbol': 'TET1', 'Protein name': 'Methylcytosine dioxygenase TET1', 'Function': 'Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation; forms protein-to-protein complexes with HIF-1α that target it to binding 5-mC genomic loci (25517638)', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> DDR/direct repair<br><br> EMT<br><br> Hypoxia signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28150354%2C%2028643947%5Buid%5D" target="_blank" rel="noopener noreferrer">28150354, 28643947</a>', 'Notes': '1) TET1 was significantly upregulated in cisplatin-resistant CP70 cells compared with that in cisplatin-sensitive A2780 cells. 2) Ectopic expression of TET1 in A2780 cells promoted cisplatin resistance and decreased cytotoxicity induced by cisplatin, 3) inhibition of TET1 by siRNA attenuated cisplatin resistance and enhanced cytotoxicity of cisplatin. 4) Increased TET1 induced re-expression of vimentin through active DNA demethylation, and cause partial epithelial-to-mesenchymal (EMT) in A2780 cells. 5) knocking down of TET1 in CP70 cells reduced vimentin expression and reversed EMT process. 6) Immunohistochemical analysis of TET1 in human ovarian cancer tissues revealed that TET1 existed in nucleus and cytoplasm in ovarian cancer tissues. 7) the expression of nuclear TET1 was positively correlated with residual tumor and chemotherapeutic response. 8) Knocking down TET1 in OSCC stem cells stimulate MGMT promoter methylation, inhibiting MGMT expression, and strengthens the sensitivity to cisplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TET1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54790" target="_blank" rel="noopener noreferrer">54790</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6N021" target="_blank" rel="noopener noreferrer">Q6N021</a>', 'HUGO Gene symbol': 'TET2', 'Protein name': 'Methylcytosine dioxygenase TET2', 'Function': 'Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Immune response<br><br> TGF-β signaling<br><br> Transcription/Epigenetics', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31570278%2C%2030404004%2C%2032355773%2C%2032817374%5Buid%5D" target="_blank" rel="noopener noreferrer">31570278, 30404004, 32355773, 32817374</a>', 'Notes': '1) TET2 was significantly decreased in cisplatin resistance SGC7901/DDP cells compared with non-resistant cells and TET2. 2) overexpression markedly reduced the tolerance to cisplatin. 3) TET2 regulated interleukin-6 levels in the tumor microenvironment through histone acetylation and therefore served an important role in the development of cisplatin resistance in GC cells.\xa04) TET2 also plays a crucial role in controlling cellular susceptibility to cisplatin- or UV-induced DNA damage. 5) The loss of TET2, of its product 5hmC, and of APE1 recruitment to stalled RFs promoted resistance to the chemotherapeutic cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TET2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7019" target="_blank" rel="noopener noreferrer">7019</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q00059" target="_blank" rel="noopener noreferrer">Q00059</a>', 'HUGO Gene symbol': 'TFAM', 'Protein name': 'Transcription factor A, mitochondrial', 'Function': 'a key mitochondrial transcription factor containing two high mobility group motifs. The encoded protein also functions in mitochondrial DNA replication and repair.', 'Putative_mechanism_associated_with_Pt_resistance': 'Metabolism/OXPHOS<br><br> mitochondria/DNA', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27779689%5Buid%5D" target="_blank" rel="noopener noreferrer">27779689</a>', 'Notes': '1) the ER‑negative cells were more sensitive to cisplatin, compared with the ER‑positive cells. 2) mitochondrial transcription factor A (TFAM) was expressed at a high level in ER‑positive cell lines and patient tissues, compared with ER‑negative cell lines and tissues. 3) The sensitivity of estrogen receptor (ER)-positive breast cancer to cisplatin was reported to increase when the PGC1α downstream gene TFAM was knocked down, and cisplatin resistance was restored when TFAM was reintroduced into ER-positive breast cancer cells.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TFAM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7037" target="_blank" rel="noopener noreferrer">7037</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P02786" target="_blank" rel="noopener noreferrer">P02786</a>', 'HUGO Gene symbol': 'TFRC', 'Protein name': 'Transferrin receptor protein 1', 'Function': 'Cellular uptake of iron occurs via receptor-mediated endocytosis of ligand-occupied transferrin receptor into specialized endosomes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'endocytosis<br><br> Hypoxia signaling<br><br> Platinum uptake', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11968124%2C%2019259415%2C%209381969%2C%207637237%5Buid%5D" target="_blank" rel="noopener noreferrer">11968124, 19259415, 9381969, 7637237</a>', 'Notes': '1) the ability of cisplatin to bind transferrin is well established. 2) reduced expression of TFRC mRNA after cisplatin treatment. 3) there is evidence that the cisplatin-transferrin complex can be transported into cells via the transferrin receptor. 4) cisplatin-induced transferrin modulation was found to be accompanied by severe spermatogenic damage in rat testes. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TFRC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7040" target="_blank" rel="noopener noreferrer">7040</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01137" target="_blank" rel="noopener noreferrer">P01137</a>', 'HUGO Gene symbol': 'TGFB1', 'Protein name': 'Transforming growth factor beta-1 proprotein', 'Function': 'Multifunctional protein that regulates the growth and differentiation of various cell types and is involved in various processes, such as normal development, immune function, microglia function and responses to neurodegeneration', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29795279%2C%2030594239%2C%2010675495%2C%2030087144%2C%2027769097%2C%2028918673%5Buid%5D" target="_blank" rel="noopener noreferrer">29795279, 30594239, 10675495, 30087144, 27769097, 28918673</a>', 'Notes': '1) Downregulation of TGFB inhibitor (TGFBI) induce cisplatin resistance in nasopharyngeal carcinoma. 2) TGF-β1 knockdown increased chemosensitivity. 3) TGF-beta production and lack of response to TGF-beta growth inhibitory effects have been associated with tumor progression and therapeutic resistance. 4) Analysis of HNSCC specimens in situ and in vitro showed that HPV associated with loss of TGFβ signaling that increased response to radiation or cisplatin. 5) the expression of TGFβ1 in CAFs was significantly associated with overall survival of patients treated with chemoradiotherapy. 6) cisplatin-resistant A549 cells (A549/DDP) acquire EMT phenotype with high expression of drug-resistant proteins, P-gp and ERCC1; Knockdown of TGF-β1 may reverse EMT and significantly reduce the expression of P-gp and ERCC1. Moreover, A549/DDP cells become more sensitive to cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7042" target="_blank" rel="noopener noreferrer">7042</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61812" target="_blank" rel="noopener noreferrer">P61812</a>', 'HUGO Gene symbol': 'TGFB2', 'Protein name': 'Transforming growth factor beta-2 proprotein', 'Function': 'Multifunctional protein that regulates various processes such as angiogenesis and heart development', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25504440%2C%2027779704%5Buid%5D" target="_blank" rel="noopener noreferrer">25504440, 27779704</a>', 'Notes': '1) human HNSCC cell line: The drug resistance and slow-cycling state of BM-HEp3 cells depended on enhanced positive feedback of the signaling axis of SDF-1-CXCR4 via their overexpression. Interestingly, 2) BM-DTCs highly expressed TGF-β2 to maintain SDF-1-CXCR4 overexpression. Inhibition of SDF-1-CXCR4 signaling by down-regulating TGF-β2 fully reversed the drug resistance of BM-HEp3 cells via reactivation of cell proliferation.\xa03) overexpression of miR-422a was able to inhibit cell proliferation and the ability of invasion, and enhance paclitaxel and cisplatin-mediated apoptosis in OS cells. 4) downregulation of miR-422a exhibited an opposite role. 5) miR-422a directly targeted TGFβ2 and regulated its expression and the activation of downstream molecules, smad2 and smad3 in osteosarcoma cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7043" target="_blank" rel="noopener noreferrer">7043</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10600" target="_blank" rel="noopener noreferrer">P10600</a>', 'HUGO Gene symbol': 'TGFB3', 'Protein name': 'Transforming growth factor beta-3 proprotein', 'Function': 'Multifunctional protein that regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31436806%5Buid%5D" target="_blank" rel="noopener noreferrer">31436806</a>', 'Notes': '1) TGFβ3 protein levels in extracellular vesicles (EVs) released by HNSCC cells as a predictor for response to chemoradiation therapy (CRT): To this end, specific EV-fractions were isolated from cell lines or HNSCC patient plasma, and TGFβ3 protein was quantified. 2) In patients treated with CRT, TGFβ3 levels were found to be significantly higher in plasma EV-fractions or non-responders compared with responders. 3) High levels of TGFβ3 levels in Annexin V-EVs were associated with the worst progression-free survival. 4) TGFβ3 silencing sensitized HNSCC cells to cytotoxic therapies, and this phenotype could be rescued by treatment with exogenous. 5) specific EV-fractions shed by cisplatin-resistant cells were sufficient to transfer the resistant phenotype to sensitive cells through activation of TGFβ-signaling pathway.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7045" target="_blank" rel="noopener noreferrer">7045</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15582" target="_blank" rel="noopener noreferrer">Q15582</a>', 'HUGO Gene symbol': 'TGFBI', 'Protein name': 'Transforming growth factor-beta-induced protein ig-h3', 'Function': 'Plays a role in cell adhesion. May play a role in cell-collagen interactions', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29795279%5Buid%5D" target="_blank" rel="noopener noreferrer">29795279</a>', 'Notes': '1) In vitro shRNA-mediated downregulation of TGFBI induced phosphorylation of PTEN and AKT, increasing cisplatin resistance. 2) the overexpression of TGFBI sensitized the NPC cells to cisplatin. 3) In NPC patients treated with concurrent chemoradiotherapy (CRT), the overall survival (OS) was significantly inversely correlated with miR-449b, and directly correlated with both TGFBI mRNA and protein expression. 3) co-immunoprecipitation demonstrated that TGFBI competes with pro-TGFβ1 for integrin receptor binding. 4) Decreased TGFBI led to increased pro-TGFβ1 activation and TGFβ1 canonical/noncanonical pathway-induced cisplatin resistance.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFBI" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7046" target="_blank" rel="noopener noreferrer">7046</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P36897" target="_blank" rel="noopener noreferrer">P36897</a>', 'HUGO Gene symbol': 'TGFBR1', 'Protein name': 'TGF-beta receptor type-1', 'Function': 'Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26191185%5Buid%5D" target="_blank" rel="noopener noreferrer">26191185</a>', 'Notes': '1) TGF-β type I (TβRI) and type II (TβRII) kinase inhibitor LY2109761 was sufficient to induce spontaneous apoptosis of ovarian cancer cells. 2) Combination with LY2109761 significantly augmented the cytotoxicity of cisplatin in both parental and cisplatin resistant ovarian cancer cells. 3) LY2109761 significantly increased apoptotic cell death in cisplatin-resistant cells. 4) Combination treatment of LY2109761 and cisplatin showed antiproliferative effects and induced a greater rate of apoptosis than the sum of the single-treatment rates and promoted tumor regression in established parental and cisplatin resistant ovarian cancer xenograft models.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFBR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7048" target="_blank" rel="noopener noreferrer">7048</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P37173" target="_blank" rel="noopener noreferrer">P37173</a>', 'HUGO Gene symbol': 'TGFBR2', 'Protein name': 'TGF-beta receptor type-2', 'Function': 'Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26191185%2C%2031002371%5Buid%5D" target="_blank" rel="noopener noreferrer">26191185, 31002371</a>', 'Notes': '1) in triple‑negative breast cancer patients that received a cisplatin/doxorubicin‑based neoadjuvant treatment. 2) low levels of miR‑145‑5p were associated with increased disease‑free survival. 3) miR‑145‑5p was downregulated in four breast cancer cell lines relative to normal cells. 4) ectopic expression of miR‑145‑5p resulted in a significant inhibition of cell proliferation and also induced apoptosis. 5) miR‑145‑5p led to sensitization of breast cancer cells to cisplatin therapy. 6) miR‑145‑5p downregulated the TGFβR2 protein.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGFBR2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7052" target="_blank" rel="noopener noreferrer">7052</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21980" target="_blank" rel="noopener noreferrer">P21980</a>', 'HUGO Gene symbol': 'TGM2', 'Protein name': 'Tissue transglutaminase', 'Function': 'TG2 cross-links proteins by acyl transfer between glutamine and lysine residues and participates in Ca++-dependent post-translational protein modification by incorporating polyamines into peptide chains', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> EMT<br><br> Hypoxia signaling<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18667446%2C%2019763620%20%5Buid%5D" target="_blank" rel="noopener noreferrer">18667446, 19763620¬†</a>', 'Notes': '1) TG2 knockdown and a TG2 enzymatic inhibitor (KCC009) sensitized ovarian cancer SKOV3 cells to cisplatin. 2) Overexpression of the constitutively active p65 subunit of NF-kappaB, but not constitutively active Akt, rescued cells with diminished TG2 expression from cisplatin-induced apoptosis. 3) NF-kappaB activity is decreased and the level of the inhibitory subunit I kappaB alpha is increased in ovarian cancer cells engineered to express diminished levels of TG2 or treated with the enzymatic inhibitor, KCC009. 4) In one-third of NSCLC cell lines, TGM2 was silenced by promoter methylation. 5) The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGM2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7053" target="_blank" rel="noopener noreferrer">7053</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q08188" target="_blank" rel="noopener noreferrer">Q08188</a>', 'HUGO Gene symbol': 'TGM3', 'Protein name': 'Protein-glutamine gamma-glutamyltransferase E', 'Function': 'Catalyzes the calcium-dependent formation of isopeptide cross-links between glutamine and lysine residues. Epidermal terminal differentiation and formation of the cornified cell envelope through cross-linking structural proteins. TGM3 functions as a tumor suppressor by repressing epithelial‑to‑mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer (32020212)', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29953521%5Buid%5D" target="_blank" rel="noopener noreferrer">29953521</a>', 'Notes': 'TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Oral squamous cell carcinoma patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TGM3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7057" target="_blank" rel="noopener noreferrer">7057</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P07996" target="_blank" rel="noopener noreferrer">P07996</a>', 'HUGO Gene symbol': 'THBS1', 'Protein name': 'Thrombospondin-1', 'Function': 'Secreted adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions.\xa0Plays a role in ER stress response, via its interaction with the activating transcription factor 6 alpha (ATF6). (21765615)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ECM signaling<br><br> ER stress response<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27779244%2C%2019052713%2C%2020051827%2C%2023463593%5Buid%5D" target="_blank" rel="noopener noreferrer">27779244, 19052713, 20051827, 23463593</a>', 'Notes': '1) Patients with high TXN and THBS1 expression presented longer PFS (P=0.001 and P<0.001, respectively) and OS (P=0.024 and P<0.001, respectively). 2) 5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas. 3) Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression. 4) Peripheral blood samples were obtained from 60 patients before first line platinum-based chemotherapy ± bevacizumab, and after the third cycle of treatment: Decreased levels of TSP-1 and increased levels of VEGF were associated with shorter survival. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=THBS1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7075" target="_blank" rel="noopener noreferrer">7075</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35590" target="_blank" rel="noopener noreferrer">P35590</a>', 'HUGO Gene symbol': 'TIE1', 'Protein name': 'tyrosine kinase with immunoglobulin-like and EGF-like domains 1', 'Function': 'Transmembrane tyrosine-protein kinase that may modulate TEK/TIE2 activity and contribute to the regulation of angiogenesis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30181600%5Buid%5D" target="_blank" rel="noopener noreferrer">30181600</a>', 'Notes': '1) functional siRNA screening identified TIE-1 as a gene that confers cells resistant to cisplatin. 2) over-expression of TIE-1 decrease cisplatin sensitivity in multiple ovarian cancer cell lines. 3) up-regulation of TIE-1 was correlated with poor prognosis and cisplatin resistance in patients with ovarian cancer. 4) TIE-1 up-regulates the nucleotide excision repair (NER) system mediated by XPC, thereby leading to decreased susceptibility to cisplatin-induced cell death without affecting cisplatin uptake and excretion.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIE1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57103" target="_blank" rel="noopener noreferrer">57103</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NQ88" target="_blank" rel="noopener noreferrer">Q9NQ88</a>', 'HUGO Gene symbol': 'TIGAR', 'Protein name': 'Fructose-2,6-bisphosphatase TIGAR / TP53-induced glycolysis and apoptosis\nregulator', 'Function': 'hydrolyzing fructose-2,6-bisphosphate as well as fructose-1,6-bisphosphate; a negative regulator of glycolysis by lowering intracellular levels of fructose-2,6-bisphosphate in a p53/TP53-dependent manner, resulting in the pentose phosphate pathway (PPP) activation and NADPH production', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/nucleotide synthesis<br><br> Metabolism/Glycolysis<br><br> Metabolism/PPP<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28384067%2C%2029587485%5Buid%5D" target="_blank" rel="noopener noreferrer">28384067, 29587485</a>', 'Notes': '1) upregulation of miR-101 inhibited viability, induced apoptosis, increased glycolysis rate and fructose-2,6-bisphosphate levels, decreased glucose-6-phosphate dehydrogenase expression and NADPH levels, and enhanced\xa0cisplatin-induced DNA damage in prostate cancer cells. 2)\xa0TIGAR\xa0was a direct target of miR-101 by using luciferase activity assay. 3) the roles of knockdown of\xa0TIGAR\xa0were similar to miR-101 upregulation in prostate cancer cells.\xa04) TP53-induced glycolysis and apoptosis regulator (TIGAR), which scavenges intracellular reactive oxygen species (ROS), was upregulated in spiral ganglion neurons (SGNs) in response to cisplatin administration. 5) Overexpression of TIGAR reduced ROS and decreased caspase 3 expression, as well as increased the survival of SGNs in Wnt-inhibited SGNs. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIGAR" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8914" target="_blank" rel="noopener noreferrer">8914</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UNS1" target="_blank" rel="noopener noreferrer">Q9UNS1</a>', 'HUGO Gene symbol': 'TIMELESS', 'Protein name': 'Protein timeless homolog', 'Function': 'Plays an important role in the control of DNA replication, maintenance of replication fork stability, maintenance of genome stability throughout normal DNA replication and in the regulation of the circadian clock.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28583847%5Buid%5D" target="_blank" rel="noopener noreferrer">28583847</a>', 'Notes': '1) High TIMELESS expression was associated with poorer overall survival and progression free survival. 2) Stable ectopic overexpression of TIMELESS in nasopharyngeal carcinoma cell lines conferred resistance to cisplatin-induced apoptosis in vitro and in vivo, promoted an epithelial-to-mesenchymal transition phenotype, and activated the Wnt/β-catenin pathway and downstream gene transcription; 3) knockdown of TIMELESS had the opposite effects. \xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIMELESS" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7077" target="_blank" rel="noopener noreferrer">7077</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P16035" target="_blank" rel="noopener noreferrer">P16035</a>', 'HUGO Gene symbol': 'TIMP2', 'Protein name': 'Metalloproteinase inhibitor 2', 'Function': 'Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, MMP-14, MMP-15, MMP-16 and MMP-19.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22511598%2C%2023415672%5Buid%5D" target="_blank" rel="noopener noreferrer">22511598, 23415672</a>', 'Notes': '1) a significant association between enhanced stromal expression of TIMP-2 and better clinical response to cisplatin- and paclitaxel-based chemotherapy: increased expression of TIMP-2 in the stromal compartment and simultaneous overexpression in both stromal and tumor compartments strongly correlated with increased survival. 2) No significant correlations were found in vitro between resistance to cisplatin, paclitaxel, or topotecan and the expression of TIMP-2 in the OC cell lines, suggesting stromal influences on tumor chemoresistance in the physiological environment. 3) Serum from 68 cervical cancer patients treated within a phase-III-trial with either simultaneous\xa0cisplatin\xa0radiochemotherapy or sequential systemic carboplatin and paclitaxel followed by percutaneous irradiation was analyzed by ELISA: A TIMP2 concentration of lower than 90 ng/ml was significantly associated with poorer OS and PFS (p=0.009 and p=0.043, respectively). In the multivariate analysis, TIMP2 expression in serum was the only independent prognostic factor for OS (p=0.032, HR=6.51, 95% CI=1.17-36.01).', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIMP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7078" target="_blank" rel="noopener noreferrer">7078</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35625" target="_blank" rel="noopener noreferrer">P35625</a>', 'HUGO Gene symbol': 'TIMP3', 'Protein name': 'Metalloproteinase (collagenases) inhibitor 3', 'Function': 'inhibits matrix metalloproteinases to limit extracellular matrix degradation', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29731768%5Buid%5D" target="_blank" rel="noopener noreferrer">29731768</a>', 'Notes': '1) The expression of TIMP3 was higher in patients with cisplatin-sensitive osteosarcoma than in those with insensitive osteosarcoma. 2) TIMP3 overexpression suppressed cell proliferation and enhanced cisplatin sensitivity by activating apoptosis-related signal pathways and inhibiting IL-6 expression in vitro and in vivo. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TIMP3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9874" target="_blank" rel="noopener noreferrer">9874</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UKI8" target="_blank" rel="noopener noreferrer">Q9UKI8</a>', 'HUGO Gene symbol': 'TLK1', 'Protein name': 'Tousled-like kinase 1', 'Function': 'inhibited by phosphorylation following DNA double-stranded breaks during S-phase; regulates DNA replication and DNA repair pathways; regulates processes involved in chromatin assembly.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20381954%5Buid%5D" target="_blank" rel="noopener noreferrer">20381954</a>', 'Notes': '1) TLK1 is abundantly expressed in cholangiocarcinoma as well as in cell lines derived from cholangiocarcinoma. 2) siRNA knockdown of TLK1 did not affect the viability of cholangiocarcinoma cells, it sensitized cholangiocarcinoma cells to cisplatin-induced apoptosis. 3) Immunofluorescence analysis of gammaH2AX foci showed that silencing of TLK1 enhanced DNA damage induced by cisplatin treatment.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TLK1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7099" target="_blank" rel="noopener noreferrer">7099</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00206" target="_blank" rel="noopener noreferrer">O00206</a>', 'HUGO Gene symbol': 'TLR4', 'Protein name': 'Toll-like receptor 4', 'Function': 'Cooperates with LY96 and CD14 to mediate the innate immune response', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18256356%2C%2028275299%2C%2029746926%2C%2029343281%5Buid%5D" target="_blank" rel="noopener noreferrer">18256356, 28275299, 29746926, 29343281</a>', 'Notes': '1) Cisplatin-treated wild-type mice had significantly more renal dysfunction, histologic damage, and leukocytes infiltrating the kidney than similarly treated mice with a targeted deletion of TLR4 [Tlr4(−/−)].\xa02) activation of TLR4 on renal parenchymal cells may activate p38 MAPK pathways, leading to increased production of inflammatory cytokines, such as TNF-α and subsequent kidney injury. 3) Down-regulationo f TLR4 gene in CDDP-resistant gastric cancer SGC7901/DDP cells. 4) Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells. 5) P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TLR4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/30012" target="_blank" rel="noopener noreferrer">30012</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43711" target="_blank" rel="noopener noreferrer">O43711</a>', 'HUGO Gene symbol': 'TLX3', 'Protein name': 'T-cell leukemia homeobox protein 3', 'Function': 'an orphan homeobox protein. A translocation [t(5;14)(q35;q32)] is associated with T-cell acute lymphoblastic leukemia (T-ALL); directly constraining STAT3 phosphorylation and inhibiting EMT (31360112);', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Immune response<br><br> Transcription<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21617853%5Buid%5D" target="_blank" rel="noopener noreferrer">21617853</a>', 'Notes': '1) TLX3 was unmethylated in cisplatin sensitive cells and methylated in resistant cells. 2) shRNA suppression of TLX3 expression increased cisplatin resistance. 3) overexpression of TLX3 in resistant cells induced increased sensitivity to cisplatin. 4) 22 (21%) out of 110 clinical samples of bladder cancer showed the methylated pattern using the COBRA assay in TLX3. 5) a correlation between TLX3 methylation and the sensitivity to cisplatin in the clinical samples by SDI test. Cisplatin sensitivity was closely associated with the methylation status of TLX3.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TLX3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/374882" target="_blank" rel="noopener noreferrer">374882</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6UW68" target="_blank" rel="noopener noreferrer">Q6UW68</a>', 'HUGO Gene symbol': 'TMEM205', 'Protein name': 'Transmembrane protein 205', 'Function': 'In cancer cells, plays a role in resistance to the chemotherapeutic agent cisplatin.', 'Putative_mechanism_associated_with_Pt_resistance': 'Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20589834%2C%2021969054%5Buid%5D" target="_blank" rel="noopener noreferrer">20589834, 21969054</a>', 'Notes': '1) TMEM205 is located at the cell surface. but in the presence of the chemotherapeutic drug, the protein is translocated in an intracellular compartment at the periphery of the nucleus. 2) Its expression is increased in our cisplatin-selected CP-r epidermoid carcinoma cell lines. 3) Stable transfection of the TMEM205 gene confers resistance to cisplatin by approximately 2.5-fold. 4) Uptake assays with Alexa Fluor-cisplatin showed reduced accumulation in CP-r KB-CP.3 and KB-CP.5 cells, and in TMEM205-transfected cells. 5) TMEM205 colocalized with RAB8, a marker of recycling endosomes. Interestingly, TMEM205 also colocalized with syntaxin 6 (STXR6), a regulator of protein trafficking, which is translocated at the same subcellular localization that TMEM205 in the presence of cisplatin. Then, the translocation of TMEM205 may allow the exocytosis of platinum containing vesicles, which thus results in the accumulation of the drug outside the cell.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'TRANSLOCATED', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TMEM205" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/92162" target="_blank" rel="noopener noreferrer">92162</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6PEY1" target="_blank" rel="noopener noreferrer">Q6PEY1</a>', 'HUGO Gene symbol': 'TMEM88', 'Protein name': 'Transmembrane protein 88', 'Function': 'Inhibits the Wnt/beta-catenin signaling pathway.', 'Putative_mechanism_associated_with_Pt_resistance': 'WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27374141%5Buid%5D" target="_blank" rel="noopener noreferrer">27374141</a>', 'Notes': '1) Genome-wide DNA methylation analysis of OC xenografts identified 6 genes (SSH3, SLC12A4, TMEM88, PCDHGC3, DAXX, MEST) whose promoters were significantly hypomethylated in resistant compared to sensitive (control) xenografts (p<0.001). 2) TMEM88 and DAXX mRNA expression levels were increased in platinum resistant compared to control xenografts. 3) treatment of OC cells with SGI-110 (guadecitabine), a DNA methyl transferase (DNMT) inhibitor, increased TMEM88 mRNA expression levels. 4) TMEM88 was detectable by IHC in all histological types of ovarian tumors 5) its knock-down by using siRNA promoted OC cell proliferation and colony formation and re-sensitized cells to platinum. 6) TMEM88 knock down induced upregulation of cyclin D1 and c-Myc, known Wnt target genes, supporting that TMEM88 inhibits Wnt signaling.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TMEM88" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27346" target="_blank" rel="noopener noreferrer">27346</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q5BJF2" target="_blank" rel="noopener noreferrer">Q5BJF2</a>', 'HUGO Gene symbol': 'TMEM97', 'Protein name': 'Sigma intracellular receptor 2', 'Function': 'Intracellular orphan receptor that binds numerous drugs, highly expressed in various proliferating cancer cells. The sigma-2 receptor, regulating cell survival, morphology and differentiation', 'Putative_mechanism_associated_with_Pt_resistance': 'Calcium signaling<br><br> Metabolism/Lipid<br><br> Oncogene signaling/PKC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26376695%2C%2027688262%5Buid%5D" target="_blank" rel="noopener noreferrer">26376695, 27688262</a>', 'Notes': '1) the high expression level of TMEM97 has been correlated with the resistance of cancer to platinum-based treatment but also with poor patient survival. 2) only 4% of patients with elevated expression of TMEM97 showed responses to therapy while 65% of patients with low expression of TMEM97 responded to the treatment.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TMEM97" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/26022" target="_blank" rel="noopener noreferrer">26022</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9Y2Y6" target="_blank" rel="noopener noreferrer">Q9Y2Y6</a>', 'HUGO Gene symbol': 'TMEM98', 'Protein name': 'Transmembrane protein 98', 'Function': 'Functions as a negative regulator of MYRF in oligodendrocyte differentiation and myelination. Interacts with the C-terminal of MYRF inhibiting MYRF self-cleavage and N-fragment nuclear translocation.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24608572%5Buid%5D" target="_blank" rel="noopener noreferrer">24608572</a>', 'Notes': '1) TMEM98 has been identified as a chemoresistance-associated gene. Indeed, its expression is increased in two chemoresistant hepatocellular carcinoma cell lines, MHCC97L/CisR and MHCC97L/DoxR resistant to cisplatin and doxorubicin respectively. 2) the level of the upregulation increased with the degree of chemoresistance. 3) TMEM98 mRNA expression was higher in tumor tissue of patients who received a transarterial chemoembolization treatment. 4) the patients who did not respond well to the treatment had higher TMEM98 expression level.\xa05) In the absence of TMEM88 in resistant cell lines, a repression of activation of AKT in association with a repression of its downstream targets had been observed. 6) the silencing of TMEM88 restored p53 phosphorylation and activation under cisplatin or doxorubicin treatment. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TMEM98" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7124" target="_blank" rel="noopener noreferrer">7124</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P01375" target="_blank" rel="noopener noreferrer">P01375</a>', 'HUGO Gene symbol': 'TNF', 'Protein name': 'Tumor necrosis factor', 'Function': 'Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31364751%2C%2027206315%2C%2017253597%2C%2021307147%20%5Buid%5D" target="_blank" rel="noopener noreferrer">31364751, 27206315, 17253597, 21307147¬†</a>', 'Notes': '1) TNF‑α mediated SOD‑2 upregulation is involved in cisplatin resistance in ESCC cell line Eca‑109. 2) Upregulation of SOD‑2 by TNF‑α was inhibited by blocking the NF‑κB pathway. 3) TNF‑α could induce cisplatin resistance in Eca109 cells, while transfection with SOD‑2 siRNA could significantly increase the chemosensitivity of ESCC to cisplatin. 4) treatment of OC cell lines with TNFα or IL6 induced a selective increase in the expression of ABCB2 (TAP1) and ABCB1 (MRP1), and enhanced cisplatin resistance. 5) TNF-a can increase mRNA and protein levels of IAP-1, IAP-2, and XIAP, but not livin or survivin in MPM cell lines (n=4). 6) Co-incubation of MPM cells with TNF-a and pyrrolidine dithiocarbamate (PDTC), an NF-kB inhibitor, prevented TNF-mediated up-regulation of IAP gene expression levels. 7) MPM cells exposed to TNF-a were twice as resistant to cisplatin. 8) The combination of NGR-hTNF 0.8 μg/m(2) with cisplatin 80 mg/m(2) showed favorable toxicity profile and promising antitumor activity', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNF" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25816" target="_blank" rel="noopener noreferrer">25816</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95379" target="_blank" rel="noopener noreferrer">O95379</a>', 'HUGO Gene symbol': 'TNFAIP8', 'Protein name': 'Tumor necrosis factor alpha-induced protein 8', 'Function': 'Acts as a negative mediator of apoptosis and may play a role in tumor progression.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> Immune response<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24767861%2C%2030944654%2C%2030107189%5Buid%5D" target="_blank" rel="noopener noreferrer">24767861, 30944654, 30107189</a>', 'Notes': '1) TNFAIP8 overexpression at both mRNA and protein levels in platinum-resistant disease was clearly higher than that in platinum-sensitive disease (P < .05). 2) Platinum resistance was independently correlated with residual tumor size (P = .025), ascites (P = .027), and TNFAIP8 overexpression (P = .003). 4) In particular, TNFAIP8 overexpression was correlated with platinum resistance in EOCs with optimal cytoreduction (P = .001). TNFAIP8 mRNA expression was strongly associated with residual tumor size (P = .019). 5) TNFAIP8 protein expression levels were significantly increased in cervical cancer tissues compared with the non-tumor adjacent tissues using immunohistochemistry. 6) TNFAIP8 overexpression is associated with cisplatin resistance. 7) depletion of TNFAIP8 impaired HeLa cell proliferation and viability in vitro, improved cisplatin sensitivity, and promoted cisplatin-induced cellular apoptosis and death. 8) TNFAIP8 silencing promoted caspase-8/-3 activation and p38 phosphorylation in HeLa cells treated with cisplatin, whereas apoptosis regulator Bcl2 expression was inhibited with TNFAIP8-silenced HeLa cells following treatment with cisplatin. 9) TNFAIP8 serves as an anti-apoptotic protein against cisplatin-induced cell death, which eventually leads to chemotherapeutic drug-treatment failure. 10) the extent of decreased TNFAIP8 expression after NACT was positively associated with response to neoadjuvant chemotherapy (NACT) (P = .013).', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFAIP8" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/79626" target="_blank" rel="noopener noreferrer">79626</a>', 'Uniprot_link': 'Q6P589', 'HUGO Gene symbol': 'TNFAIP8L2', 'Protein name': 'Tumor necrosis factor alpha-induced protein 8-like protein 2', 'Function': 'Negative regulator of Toll-like receptor and T-cell receptor function. Inhibits JUN/AP1 and NF-kappa-B activation. Promotes Fas-induced apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> NF-kB signaling<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31917287%2C%2030114619%5Buid%5D" target="_blank" rel="noopener noreferrer">31917287, 30114619</a>', 'Notes': '1) TIPE2 was down-regulated in cisplatin (DDP)-resistant NSCLC tissues and DDP-resistant NSCLC cells compared with the sensitive control. 2) The inhibition of TIPE2 contributed to cell cisplatin-resistance, and the overexpression of TIPE2 enhanced cisplatin sensitivity and autophagy. 3) increased TIPE2 elevated apoptosis in DDP-resistant NSCLC cells. 4) TIPE2 restored the activity of mTOR signalling. 5) Preconditioning with the mTOR activator 3BDO abrogated TIPE2-mediated depression in cisplatin-evoked autophagy. 6) overexpression of TIPE2 effectively inhibited MDR1 expression and greatly sensitized osteosarcoma cells to cisplatin, both in vivo and in vitro. 7) TIPE2 inhibited the transcription of the MDR1 promoter by interfering with the TAK1-NF-κB and -AP-1 pathways. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFAIP8L2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8797" target="_blank" rel="noopener noreferrer">8797</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00220" target="_blank" rel="noopener noreferrer">O00220</a>', 'HUGO Gene symbol': 'TNFRSF10A', 'Protein name': 'Tumor necrosis factor receptor superfamily member 10A / death receptor 4', 'Function': 'Receptor for TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19110234%2C%2021472713%2C%2023907406%2C%2026492363%5Buid%5D" target="_blank" rel="noopener noreferrer">19110234, 21472713, 23907406, 26492363</a>', 'Notes': '1) Azacitidine enhanced the sensitivity of platinum-resistant ovarian cancer cells to carboplatin associated with caspase-3- and -8-dependent apoptosis pathway and reexpression of DR4. 2) 30 patients: DR4 methylation in peripheral blood leukocytes was decreased during treatment in 3 of 4 objective responders (to platinum) (75%), but in only 5 of 13 nonresponders (38%). 3) cisplatin-resistant cell lines displayed a marked increase in sensitivity to death receptor-induced apoptosis, in particular TRAIL-mediated execution. 4) a significant increase in the localization of TRAIL death receptor, DR4, to the lipid raft subdomains of plasma membrane was detected in the resistant variants; exposure of cisplatin-resistant cells to TRAIL resulted in upregulation of inducible nitric oxide synthase (iNOS) and increase in nitric oxide (NO) production that triggered the generation of peroxynitrite (ONOO(-)). 5) Scavenging ONOO(-) rescued cells from TRAIL-induced apoptosis, thereby suggesting a critical role of ONOO(-) in TRAIL-induced execution of cisplatin-resistant cells. Notably, preincubation of cells with TRAIL restored sensitivity of resistant cells to cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFRSF10A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8795" target="_blank" rel="noopener noreferrer">8795</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14763" target="_blank" rel="noopener noreferrer">O14763</a>', 'HUGO Gene symbol': 'TNFRSF10B', 'Protein name': 'Tumor necrosis factor receptor superfamily member 10B / death receptor 5', 'Function': 'As TNFRSF10A. One major physiologic role of TRAIL is the mediation of natural immunity and the elimination of developing tumors ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20371719%2C%2014716031%5Buid%5D" target="_blank" rel="noopener noreferrer">20371719, 14716031</a>', 'Notes': '1) joint presence of TRAILR2 (DR5) agonistic antibody (AD5-10) with TRAIL and natural killer (NK) cells expressing TRAIL resensitizes ovarian cancer cells to apoptosis in vitro and 2) in vivo, respectively. 3) The combination of AD5-10 with carboplatin exerts a more than additive effect in vitro, which may at least partially be explained by the fact that carboplatin triggers DR5 expression on ovarian cancer cells. 4) AD5-10 restores the sensitivity of platin-resistant ovarian cancer to carboplatin in vivo. 5) TRAIL expression and NK cells are abundant in the tumor microenvironment and that depletion of NK cells abolishes the antitumor activity of AD5-10. 6) NK-mediated immunosurveillance against ovarian cancer might be mediated by TRAIL. 7) 34 chemotherapy naïve patients with advanced NSCLC:  the response rate was significantly higher in patients with DR5 expression than those without DR5 expression (91% vs 39%; p = 0.008). 8) Patients with Bcl-2 expression were apparently less responsive than those without Bcl-2 expression (21% vs 80%; p = 0.001). ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFRSF10B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51330" target="_blank" rel="noopener noreferrer">51330</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NP84" target="_blank" rel="noopener noreferrer">Q9NP84</a>', 'HUGO Gene symbol': 'TNFRSF12A', 'Protein name': 'Tumor necrosis factor receptor superfamily member 12A', 'Function': 'Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31023317%5Buid%5D" target="_blank" rel="noopener noreferrer">31023317</a>', 'Notes': '1) Fn14 was significantly downregulated in patients with cisplatin resistance. 2) Patients with low Fn14 expression were associated with shorter progression-free survival and overall survival. 3) Overexpression of Fn14 suppressed cisplatin resistance in OVCAR-3 cells, whereas knockdown of Fn14 did not affect cisplatin resistance in SKOV-3 cells. 4) Fn14 could exert anti-chemoresistance effect only in OVCAR-3 cells harboring a p53-R248Q mutation, but not in SKOV-3 cells with a p53-null mutation. 5) In primary cells from two patients with the p53-R248Q mutation from HGSOC patients and the anti-chemoresistance effect of Fn14 was observed in both primary cells. 6) overexpression of Fn14 could reduce the formation of a Mdm2-p53-R248Q-Hsp90 complex by downregulating Hsp90 expression, indicating that degradation of p53-R248Q was accelerated via Mdm2-mediated ubiquitin-proteasomal pathway.', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFRSF12A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8743" target="_blank" rel="noopener noreferrer">8743</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P50591" target="_blank" rel="noopener noreferrer">P50591</a>', 'HUGO Gene symbol': 'TNFSF10', 'Protein name': 'Tumor necrosis factor ligand superfamily member 10', 'Function': 'Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG; induces apoptosis\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11371126%2C%2020157422%2C%2021877938%5Buid%5D" target="_blank" rel="noopener noreferrer">11371126, 20157422, 21877938</a>', 'Notes': '1) The majority of the chemoresistant cells were also resistant to TRAIL alone. 2) the combination of TRAIL and chemotherapy resulted in a significant growth inhibition over a wide range of concentrations. 3) This interaction was synergistic by dose-effect analysis. Flow cytometry demonstrated a significant increase in the fraction of apoptotic cells by the combination compared to each reagent alone. 4) A significant enhancement in caspase and PARP cleavage was observed upon treatment with the combination. Finally, no correlation between induction of apoptosis and level of death receptors was found. 5) The prosurvival activity of ascites against TRAIL is associated with shorter disease-free interval, which may be explained, at least in part, by ascites-induced cisplatin/paclitaxel resistance. 6) Treatment with cisplatin in Glioblastoma-derived stem cells leads to the upregulation of DR5 and downregulation of c-FLIP and restores TRAIL apoptotic pathway in the neurospheres. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFSF10" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7150" target="_blank" rel="noopener noreferrer">7150</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11387" target="_blank" rel="noopener noreferrer">P11387</a>', 'HUGO Gene symbol': 'TOP1', 'Protein name': 'DNA topoisomerase 1', 'Function': 'Releases the supercoiling and torsional tension of DNA.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27315793%5Buid%5D" target="_blank" rel="noopener noreferrer">27315793</a>', 'Notes': 'High expression of TOP1 and TOP2A were found to be correlated to worse OS in all patients and serous patients, but not in endometrioid patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7153" target="_blank" rel="noopener noreferrer">7153</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P11388" target="_blank" rel="noopener noreferrer">P11388</a>', 'HUGO Gene symbol': 'TOP2A', 'Protein name': 'DNA topoisomerase 2-alpha', 'Function': 'Topoisomerase II makes double-strand breaks. Essential for DNA replication, RNA transcription, chromosomal condensation, and mitotic chromatid separation. \xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=16533424%2C%201646065%2C%201657425%5Buid%5D" target="_blank" rel="noopener noreferrer">16533424, 1646065, 1657425</a>', 'Notes': '1) TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells. 2) The same expression pattern was found by immunohistochemistry (P = .0001). 3) specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), 4) it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023). 5) Novobiocin, a commercially available oral antibiotic, inhibits DNA topoisomerase II in a manner shown in cell culture to enhance the cytotoxicity of alkylating agents and cisplatin. 6) GLC4/cDDP is the cisplatin-resistant subline, which displays increased Topo II activity. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOP2A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7156" target="_blank" rel="noopener noreferrer">7156</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13472" target="_blank" rel="noopener noreferrer">Q13472</a>', 'HUGO Gene symbol': 'TOP3A', 'Protein name': 'DNA topoisomerase 3-alpha', 'Function': 'Releases the supercoiling and torsional tension of DNA', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24743803%2C%2028355294%5Buid%5D" target="_blank" rel="noopener noreferrer">24743803, 28355294</a>', 'Notes': "1) 18 proteins' abundances were increased in all chemoresistance cells for more than 2-fold, 13 of which were identified by mass spectrometry. Compared with the parental gastric cancer cell MGC-803, SLMAP, TOP3A, DYNC1H1, RHPN1, PUF60 and SIAH1 were significantly up-regulated in DDP-resistant cells.\xa02) Especially, high expression of two topoisomerase isoforms, TOP2A and TOP3A, was found to be correlated to worse overall survival (OS) in all NSCLC and lung adenocarcinoma (Ade) patients, but not in lung squamous cell carcinoma (SCC) patients.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOP3A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8940" target="_blank" rel="noopener noreferrer">8940</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95985" target="_blank" rel="noopener noreferrer">O95985</a>', 'HUGO Gene symbol': 'TOP3B', 'Protein name': 'DNA topoisomerase 3-beta-1', 'Function': 'Releases the supercoiling and torsional tension of DNA', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21263267%5Buid%5D" target="_blank" rel="noopener noreferrer">21263267</a>', 'Notes': '1) Predicting Response to Chemotherapy With Early-Stage Lung Cancer: In the univariate analysis, the deregulation of 9 genes (BRCA1, XRCC3, XRCC5, UBE2V2, OGG1, UNG, TYMS, RRM1 and TOP3B) was found to be significantly associated with poor prognosis.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOP3B" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11073" target="_blank" rel="noopener noreferrer">11073</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92547" target="_blank" rel="noopener noreferrer">Q92547</a>', 'HUGO Gene symbol': 'TOPBP1', 'Protein name': 'DNA topoisomerase 2-binding protein 1', 'Function': 'DNA topoisomerase 2-binding protein 1, required for DNA replication. Plays a role in the rescue of stalled replication forks and checkpoint control. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29028101%2C%2026003539%5Buid%5D" target="_blank" rel="noopener noreferrer">29028101, 26003539</a>', 'Notes': '1) TopBP1 knockdown decreased the chemoresistance of OS cells to both doxorubicin and cisplatin. 2) Retrospective cohort study showed that high TopBP1\xa0expression\xa0was not only associated with high local recurrence and low necrosis rate, but also correlated with poor overall survival and disease-free survival of OS\xa0patients. 3) A total of 101 NSCLC patients treated with platinum-based chemotherapy: A significant correlation between the positive expression of BRCA1 and the positive expression of TopBP1 was observed (P < 0.001, r = 0.326). No significant correlation between BRCA1/TopBP1 and age, gender, smoking status, performance status score, pathohistological type, or clinical stage was detected (P > 0.05). 4) The survival rate of patients with negative BRCA1 protein expression was higher than that in patients with positive BRCA1 protein expression [median overall survival (OS) 34 vs. 21 months, HR 1.913, 95 % CI 1.161-3.150, P = 0.011]. 5) Similarly, the survival rate of patients with negative TopBP1 expression was higher than that in patients with positive TopBP1 (median OS 36 vs. 23 months, HR 1.931, 95 % CI 1.157-3.224, P = 0.012). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TOPBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7157" target="_blank" rel="noopener noreferrer">7157</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P04637" target="_blank" rel="noopener noreferrer">P04637</a>', 'HUGO Gene symbol': 'TP53', 'Protein name': 'Cellular tumor antigen p53', 'Function': 'Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Cell cycle<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17220511%2C%2030375398%2C%2028148293%2C%2028038466%2C%2017072341%2C%207712469%5Buid%5D" target="_blank" rel="noopener noreferrer">17220511, 30375398, 28148293, 28038466, 17072341, 7712469</a>', 'Notes': '1) PANDAR (the promoter of CDKN1A antisense DNA damage activated RNA)-reduced cisplatin sensitivity was likely or partly due to the PANDAR-binding protein SFRS2 (arginine/serine-rich 2), a splicing factor with the ability to negative regulate p53 and its phosphorylation at Serine 15 (Ser15). 2) This feedback regulation of PANDAR-SFRS2-p53 leads to a reduced transactivation of p53-related pro-apoptotic genes, such as PUMA (p53-upregulated modulator of apoptosis). 3) in platinum-treated patients with relapsed ovarian cancer, resistant period was positively correlated with the expression of PANDAR and SFRS2, and inversely associated with expression of p53-Ser15 and PUMA in these clinical tissues. 4) HE staining and the quantification of DNA content indicated a significantly higher proportion of polyploidy and aneuploidy cells in the TP53 mutant group than in the wild-type group (p\u2009<\u20090.05). 5) In relapse patients, the proportion of chemoresistant cases in the TP53 wild-type group was significantly lower than in the mutant group (63.6% vs. 91.8%, p\u2009<\u20090.05). 6) High nuclear p53 expression levels were associated with better outcome for overall survival (OS) (P = 0.0023) and disease-free survival (P = 0.0338) at 5-years. 7) High cytoplasmic p53 expression levels were associated with better outcome for OS (P = 0.0002). 8) Relative to sensitive A2780 cells harboring wild-type p53, the 2780CP/Cl-16, OVCAR-10, Hey and OVCA-433 cell lines were 10- to 30-fold resistant to cis-Pt, but was substantially circumvented by oxali-Pt. 9) Mutant p53 in 2780CP/Cl-16 (p53V172F) and OVCAR-10 (p53V172F and p53G266R) cells, predicted as non-functional in p53 database, displayed attenuated response to cis-Pt, as did the polymorphic p53P72R (functionally equivalent to wild-type p53) in HEY and OVCA-433 cell lines. 10) However, p53 was robustly activated by oxali-Pt in all cell lines, with resultant drug potency confirmed as p53-dependent by p53 knockout using CRISPR/Cas9 system. 11) knockdown of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells. 12) p53 disruption sensitized breast cancer MCF-7 cells to cisplatin but not to several other DNA-damaging agents. 13) CDDP sensitization was not limited to MCF-7 cells since p53 disruption in human colon carcinoma RKO cells also enhanced sensitivity to CDDP. ', 'Up / down in Pt-resistant cells': 'DOWN/DEPHOS/mutation', 'Up / down to promote Pt-resistance': 'DOWN/UP/DEPHOS/mutation', 'Up / down after Pt-treatment': 'UP/PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7158" target="_blank" rel="noopener noreferrer">7158</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12888" target="_blank" rel="noopener noreferrer">Q12888</a>', 'HUGO Gene symbol': 'TP53BP1', 'Protein name': 'TP53-binding protein 1', 'Function': 'Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR<br><br> DDR/NHEJ<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24085845%2C%2029928364%5Buid%5D" target="_blank" rel="noopener noreferrer">24085845, 29928364</a>', 'Notes': '1) Resistant cells also acquired a TP53BP1 mutation that facilitated DNA end resection in the absence of a BRCA1 protein capable of binding CtIP. 2) concomitant increased mutant BRCA1 and decreased 53BP1 protein expression occur in clinical samples of BRCA1-mutated recurrent ovarian carcinomas that have developed resistance to platinum. 3) 53BP1 overexpression resulted in decreased migrating SKOV3/pLPC-53BP1 cells and 4) the protein expression of MMP-9 was significantly inhibited. 5) 53BP1 overexpression resulted in increased resistance to cisplatin. 6) Decreased chemosensitivity to cisplatin may be associated with increased expression of Akt and Cdk2 and with decreased expression of p21 and Bcl-2 associated X/Bcl-2 ratio. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53BP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/94241" target="_blank" rel="noopener noreferrer">94241</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96A56" target="_blank" rel="noopener noreferrer">Q96A56</a>', 'HUGO Gene symbol': 'TP53INP1', 'Protein name': 'Tumor protein p53-inducible nuclear protein 1', 'Function': "Antiproliferative and proapoptotic protein involved in cell stress response which acts as a dual regulator of transcription and autophagy.\xa0Positively regulates p53/TP53 and p73/TP73 and stimulates their capacity to induce apoptosis and regulate cell cycle. In response to double-strand DNA breaks, promotes p53/TP53 phosphorylation on 'Ser-46' and subsequent apoptosis.", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Autophagy<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31410122%5Buid%5D" target="_blank" rel="noopener noreferrer">31410122</a>', 'Notes': "1) miR-3934-5p was upregulated in NSCLC tissues and A549 cells. Increases in the half-maximal inhibitory concentration (IC50) and the expression of miR-3934-5p were observed in the A549/DDP group. 2) miR-3934-5p mimic promoted the expression of miR-3934-5p and the IC50\xa0of the A549 cells. miR-3934-5p inhibitor downregulated miR-3934-5p and reduced the IC50\xa0of A549/DDP cells. 3) miR-3934-5p was revealed to target the 3'-untranslated region of TP53INP1. 4) The downregulation of miR-3934-5p significantly suppressed the proliferation and promoted the apoptosis of A549/DDP cells, which were reversed by transfection with TP53INP1 siRNA. 5) The protein and mRNA expression levels of TP53INP1, Bcl-2-associated-X and p21 were significantly increased, whereas those of Bcl-2 were significantly decreased in the miR-3934-5p inhibitor group, which was significantly reduced by TP53INP1 siRNA transfection.\xa0", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53INP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8626" target="_blank" rel="noopener noreferrer">8626</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9H3D4" target="_blank" rel="noopener noreferrer">Q9H3D4</a>', 'HUGO Gene symbol': 'TP63', 'Protein name': 'Tumor protein 63', 'Function': 'Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24823795%2C%2030641908%2C%2020959455%2C%2016123597%5Buid%5D" target="_blank" rel="noopener noreferrer">24823795, 30641908, 20959455, 16123597</a>', 'Notes': '1) In response to genotoxic stress the TP53 induce cell cycle arrest or apoptosis. These canonical activities can be repressed by TP63 in normal stratifying epithelia to maintain proliferative capacity or drive proliferation of squamous cell carcinomas, where TP63 is frequently overexpressed/amplified. 2) TP53 can induce or repress transcription of an extensive network of genes by direct binding and/or modulation of TP63 activity.  3) in the absence of genotoxic stress TP63 plays an important role in maintaining expression of DNA repair genes, loss of which results in defective repair. 4) IL-1β particularly upregulates the expression of the tumor protein 63 (TP63) isoform ΔNP63α. 5) Upregulation of ΔNP63α leads to an increase in the expression of EGFR and phosphatase 1D (Wip1), and a decrease in ATM. 6) The participation of these processes in the increase of resistance to\xa0cisplatin\xa0was confirmed by silencing\xa0TP63\xa0expression or by inhibition of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) activity in the IL-1β/IL-1RI/β-catenin signaling pathway.\xa07) Head and neck squamous cell carcinoma cells exposed to cisplatin display ATM-dependent phosphorylation of the most predominant TP63 isoform (ΔNp63α), leading to its activation as a transcription factor. 8) DeltaNp63alpha levels correlate with clinical tumor response to cisplatin in head and neck cancer patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'PHOS', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP63" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7161" target="_blank" rel="noopener noreferrer">7161</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O15350" target="_blank" rel="noopener noreferrer">O15350</a>', 'HUGO Gene symbol': 'TP73', 'Protein name': 'Tumor protein p73', 'Function': 'Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30127981%2C%2026313152%2C%2021837762%2C%2015292937%5Buid%5D" target="_blank" rel="noopener noreferrer">30127981, 26313152, 21837762, 15292937</a>', 'Notes': '1) the expression of\xa0TP73-AS1 was increased in GC tissues and cell lines and increased expression level of\xa0TP73-AS1 was associated with poor prognosis in patients with GC. 2) silencing of\xa0TP73-AS1 may suppress cell proliferation and enhance the chemotherapeutic response of GC cells to\xa0cisplatin\xa0through targeting the HMGB1/receptor for advanced glycation endproducts signaling pathway.\xa03) Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells. 4) p73 can activate transcription of p53-responsive genes, thereby inhibiting cell growth. 5) TAp73 is considered pro-apoptotic, and ΔNp73 anti-apoptotic. 6) an allelic imbalance of TP73 was the most remarkable independent predictive factor of poor patient survival (P=0.0002, risk ratio: 3382) in invasive bladder cancer. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP73" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7178" target="_blank" rel="noopener noreferrer">7178</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13693" target="_blank" rel="noopener noreferrer">P13693</a>', 'HUGO Gene symbol': 'TPT1', 'Protein name': 'Translationally-controlled tumor protein', 'Function': 'heat shock protein, calcium binding and microtubule stabilization; plays a significant role in anti-apoptosis by interacting with Mcl-1; may also serve as a molecular chaperone and cofactor of Mcl-1 (15798198, 23122550)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> CSC<br><br> mTOR signaling<br><br> Notch signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25564355%5Buid%5D" target="_blank" rel="noopener noreferrer">25564355</a>', 'Notes': '1) TCTP was overexpressed in carcinoma tissues compared with normal tissues. 2) TCTP expression was significantly associated with clinicopathologic variables. 3) high TCTP expression was significantly related to poor prognosis of the patients. 4) siRNA knockdown of CTPT in HO8910 cells resulted in increased sensitivity to  cisplatin. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TPT1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 5},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7186" target="_blank" rel="noopener noreferrer">7186</a>', 'Uniprot_link': '<a href="https://ebi14.uniprot.org/uniprot/Q12933" target="_blank" rel="noopener noreferrer">Q12933</a>', 'HUGO Gene symbol': 'TRAF2', 'Protein name': 'TNF receptor-associated factor 2', 'Function': 'Regulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response<br><br> Immune response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32238696%5Buid%5D" target="_blank" rel="noopener noreferrer">32238696</a>', 'Notes': '1) TRAF2 deficient cells exhibit significant resistance to cell death induced by cisplatin, accompanied by the reduction of both p53 protein level and caspase-3 activation. 2) cisplatin-induced JNK activation was attenuated in TRAF2-deficient cells, and pharmacological inhibition of JNK signaling suppressed p53 stabilization.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRAF2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10131" target="_blank" rel="noopener noreferrer">10131</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12931" target="_blank" rel="noopener noreferrer">Q12931</a>', 'HUGO Gene symbol': 'TRAP1', 'Protein name': 'Heat shock protein 75 kDa, mitochondrial / necrosis factor receptor-associated protein 1', 'Function': 'mitochondrial chaperone protein that is member of the heat shock protein 90 (HSP90) family. The encoded protein has ATPase activity and interacts with tumor necrosis factor type I. This protein may function in regulating cellular stress responses.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Chaperone<br><br> Immune response<br><br> Metabolism/OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27206315%2C%2025438697%5Buid%5D" target="_blank" rel="noopener noreferrer">27206315, 25438697</a>', 'Notes': '1) TRAP1 expression inversely correlated with grade, stage and lower survival in a large cohort of OC patients. 2) TRAP1 silencing induced resistance to cisplatin, 3) resistant cells showed increased oxidative metabolism compared with their sensitive counterpart, and the bioenergetics cellular index of higher grade tumours indicated increased mitochondrial respiration. 4) cisplatin resistance was reversible upon pharmacological inhibition of mitochondrial oxidative phosphorylation by metformin/oligomycin. 5) increased oxidative metabolism in low TRAP1-expressing OC cells and tissues enhanced production of inflammatory mediators such as IL-6 and IL-8. 6) members of MDR were key mediators of such metabolism-driven, inflammation-induced process. 7) treatment of OC cell lines with TNFα and IL6 induced a selective increase in the expression of TAP1 and multidrug resistance protein 1, whereas TAP1 silencing sensitized cells to cisplatin-induced apoptosis. 8) high TRAP1/HSP75 expression correlated with poor prognosis in esophageal squamous cell cancer (ESCC) patients.  ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/28951" target="_blank" rel="noopener noreferrer">28951</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92519" target="_blank" rel="noopener noreferrer">Q92519</a>', 'HUGO Gene symbol': 'TRIB2', 'Protein name': 'Tribbles homolog 2', 'Function': 'pseudokinase belonging to the CAMK‐family (calcium/calmodulin ‐dependent kinase). Interacts with MAPK kinases and regulates activation of MAP kinases. Adapter molecule for the ubiquitin–proteasome degradation machinery. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28670762%2C%2029312632%5Buid%5D" target="_blank" rel="noopener noreferrer">28670762, 29312632</a>', 'Notes': "1) Experiments revealed 37 commonly hypermethylated genes in resistant cells of which Tribbles 2 (TRIB2) showed the most pronounced downregulation on mRNA level. 2) TRIB2 showed a reactivation after 5'-Aza-Cytidine treatment in resistant cells 3) a cisplatin-dependent, prominent upregulation on mRNA level in sensitive cells, only. 4) Re-expression in resistant  cells increased the sensitivity to cisplatin. 5) knockdown of TRIB2 increased resistance to cisplatin in sensitive cells. 6) TRIB2 was involved in the induction of a cisplatin-dependent cell cycle arrest and apoptosis by influencing p21 and survivin expression. 6) patient stratification of two homogenous cohorts of EOC-Type-II patients from Jena (n\u2009=\u200938) and the TCGA (n\u2009=\u2009149) by TRIB2 mRNA expression consistently revealed a significantly decreased PFS for patients with low TRIB2 levels (log-rank p\u2009<\u20090.05). Tumors from resistant patients expressed the lowest levels of TRIB2. ", 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRIB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/5987" target="_blank" rel="noopener noreferrer">5987</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P14373" target="_blank" rel="noopener noreferrer">P14373</a>', 'HUGO Gene symbol': 'TRIM27', 'Protein name': 'Zinc finger protein RFP', 'Function': "E3 ubiquitin-protein ligase that mediates ubiquitination of PIK3C2B and inhibits its activity; mediates the formation of 'Lys-48'-linked polyubiquitin chains; interacts with the enhancer of polycomb protein and represses gene transcription; regulates TNFa-induced apoptosis (24144979)\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> Immune response<br><br> Redox<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=23342271%5Buid%5D" target="_blank" rel="noopener noreferrer">23342271</a>', 'Notes': '1) In ovarian cancer cell line, RFP confers cancer cell resistance to anticancer drugs. 2) RFP was expressed in 62% of ovarian cancer patients and its positivity significantly correlated with drug resistance. 3) siRNA depletion of RFP in ovarian cancer cell lines, SKOV3 and HEY, significantly increased carboplatin- or paclitaxel-induced apoptosis and resulted in reduced anticancer drug resistance. 4) In a nude mouse tumor xenograft model, inoculated RFP-knockdown ovarian cancer cells exhibited lower carboplatin resistance than control cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRIM27" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/201292" target="_blank" rel="noopener noreferrer">201292</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6PJ69" target="_blank" rel="noopener noreferrer">Q6PJ69</a>', 'HUGO Gene symbol': 'TRIM65', 'Protein name': 'Tripartite motif-containing protein 65', 'Function': 'Tripartite motif (TRIM)-containing proteins have more than 80 members in humans, most of which could be defined as E3 ubiquitin ligase.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31160576%5Buid%5D" target="_blank" rel="noopener noreferrer">31160576</a>', 'Notes': '1) TRIM65 was significantly increased in NSCLC A549/DDP cells as compared to A549 cells. 2) Knockdown of TRIM65 can inhibit autophagy and enhance cisplatin-induced apoptosis in A549/DDP cells. 3) knockdown of TRIM65 significantly decreased the expression of an important autophagy mediator, ATG7, which was a potential target of miR-138-5p. 4) miR-138-5p inhibitor significantly abolished the effects of TRIM65 knockdown on autophagy and cisplatin-induced apoptosis. 5) TRIM65 induced the ubiquitination and degradation of TNRC6A, resulting in the suppressed expression of miR-138-5p. 6) TRIM65 knockdown inhibited the growth of tumors derived from A549/DDP cells. 7) cisplatin-resistant NSCLC tissues displayed higher expression of TRIM65 mRNA and lower expression of miR-138-5p as compared to cisplatin non-resistant ones. 8) miR-138-5p expression was negatively correlated with TRIM65 mRNA in NSCLC tissues. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRIM65" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9319" target="_blank" rel="noopener noreferrer">9319</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15645" target="_blank" rel="noopener noreferrer">Q15645</a>', 'HUGO Gene symbol': 'TRIP13', 'Protein name': 'Thyroid hormone receptor-interacting protein 13 / Pachytene checkpoint protein 2 homolog', 'Function': 'Promotes early steps of the DNA double-strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> DDR/HR<br><br> DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30111544%2C%2025078033%2C%2028157697%5Buid%5D" target="_blank" rel="noopener noreferrer">30111544, 25078033, 28157697</a>', 'Notes': '1) p31comet and TRIP13 participate in the active opening of Rev7 and its dissociation from Rev3. 2) the Rev7 dimerization interface is required for cell viability after treatment with cisplatin. 3) The Rev7 dimerization mutant Is unable to restore cisplatin resistance of Rev7−/− Cells. 4) Cells treated with siTRIP13+CDDP grew significantly slower than control siNT+CDDP, suggesting a role for TRIP13 in chemoresistance. 5) High expression of TRIP13 in SCCHN leads to aggressive, treatment-resistant tumors and enhanced repair of DNA damage. 6) high TRIP13 expression levels were positively correlated with progression, disease relapse, and poor prognosis in multiple myeloma (MM) patients. Overexpressing human TRIP13 in myeloma cells prompted cell growth and drug resistance, ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRIP13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7216" target="_blank" rel="noopener noreferrer">7216</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q12816" target="_blank" rel="noopener noreferrer">Q12816</a>', 'HUGO Gene symbol': 'TRO', 'Protein name': 'Trophinin', 'Function': 'a homophilic adhesion molecule, mediates an initial attachment of the blastocyst to uterine epithelial cells at the time of the embryo implantation. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/DR<br><br> Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17597582%5Buid%5D" target="_blank" rel="noopener noreferrer">17597582</a>', 'Notes': '1) cDNA microarray analysis revealed TROPHONIN was among the genes most downregulated by RAS induction. 2) TRO expression is higher in cisplatin-sensitive cancer cell lines and 3) positively correlates with prognoses in ovarian cancers. 4) TRO knockdown by RNA interference conferred cisplatin resistance and led to increased invasiveness of cultured ovarian cancer cells. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRO" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10381" target="_blank" rel="noopener noreferrer">10381</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13509" target="_blank" rel="noopener noreferrer">Q13509</a>', 'HUGO Gene symbol': 'TUBB3', 'Protein name': 'Tubulin beta-3 chain', 'Function': 'Tubulin is the major constituent of microtubules; acts through the PTEN/AKT signaling to promote tumorigenesis and anoikis resistance (25414139, 31497344); modulates the behavior of Snail overexpressed during EMT (27188792)', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30643929%2C%2025107571%5Buid%5D" target="_blank" rel="noopener noreferrer">30643929, 25107571</a>', 'Notes': '1) of 30 patients with stage II to III esophageal squamous cell carcinoma, 30 successfully completed neoadjuvant chemotherapy and underwent R0 resection, the median DFS and OS in TUBB3 negative patients was better than those in TUBB3 positive patients. 2) TUBB3 prior treatment and pCR were independent prognostic factors in ESCC patients undergoing sequential surgery after preoperative chemotherapy. 3) advanced NSCLC Patients with negative expression of APE1, ERCC1 or TUBB3 benefited from platinum plus paclitaxel regimen chemotherapy. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'clinical outcome; patient tissue', 'Scores': 3.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TUBB3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7291" target="_blank" rel="noopener noreferrer">7291</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q15672" target="_blank" rel="noopener noreferrer">Q15672</a>', 'HUGO Gene symbol': 'TWIST1', 'Protein name': ' transcriptional regulator', 'Function': 'a master regulator of EMT. Acts as a transcriptional regulator. Inhibits myogenesis by sequestering E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27876874%2C%2025867064%2C%2030066890%20%5Buid%5D" target="_blank" rel="noopener noreferrer">27876874, 25867064, 30066890¬†</a>', 'Notes': '1)\xa0TWIST1 expression led to increased tumour engraftment in mice, as well as cisplatin resistance\xa0in vitro. 2) TWIST1, in part via GAS6 and L1CAM, led to higher expression and activation of Akt upon cisplatin treatment, and inhibition of Akt activation sensitized cells to cisplatin. 3) the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. 4) TWIST protein expression was elevated in liver cancer, and was positively correlated with multidrug resistance protein 1 (MDR1) expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TWIST1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7295" target="_blank" rel="noopener noreferrer">7295</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P10599" target="_blank" rel="noopener noreferrer">P10599</a>', 'HUGO Gene symbol': 'TXN', 'Protein name': 'Thioredoxin', 'Function': 'Participates in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Redox<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22248473%2C%2027779244%2C%2015150118%2C%2025656992%5Buid%5D" target="_blank" rel="noopener noreferrer">22248473, 27779244, 15150118, 25656992</a>', 'Notes': 'reconstituting TRX1 protein in\xa0cisplatin-resistant cells, we\xa0increased\xa0sensitivity to\xa0cisplatin. 1) Patients with high TXN and THBS1 expression presented longer PFS and OS. 2) High TXR1 expression was associated with decreased PFS and OS.  low TXN expression was correlated with decreased PFS and OS. \xa03) TRX is downstream of Smad7 in a pathway that confers a growth advantage to pancreatic cancer cells and that increases their resistance to CDDP-mediated apoptosis, implying novel regulatory functions for Smad7. 4) Intranuclear Trx-1 enhances the DNA-binding activity of HIF-1α via its interaction with and reducing action on Ref-1, resulting in increased expression of glycolysis-related proteins (PDHK1, HKII, and LDHA), glucose uptake, and lactate generation under hypoxia, and cisplatin resistance. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN/secretion', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXN" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/84817" target="_blank" rel="noopener noreferrer">84817</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BRA2" target="_blank" rel="noopener noreferrer">Q9BRA2</a>', 'HUGO Gene symbol': 'TXNDC17', 'Protein name': 'Thioredoxin domain-containing protein 17', 'Function': 'Disulfide reductase. May participate in various redox reactions. Modulates TNF-alpha signaling and NF-kappa-B activation. Has peroxidase activity and may contribute to the elimination of cellular hydrogen peroxide.', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> mTOR signaling<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31524236%5Buid%5D" target="_blank" rel="noopener noreferrer">31524236</a>', 'Notes': "1) Exposure to cisplatin induced an upregulation in the expression of thioredoxin‑related protein of 14 kDa (TRP14). 2) TRP14 knockdown or overexpression decreased or increased the autophagy response and cisplatin resistance, and this effect was reversed by treatment with Rapa or ATG5 knockdown. 3) TRP14 induced autophagy and chemoresistance via the 5'AMP‑activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/p70S6K signaling pathway. 4) a positive association between TRP14 and Beclin1 in human ovarian cancer and marginal tissues. 5) TRP14 induces autophagy and consequently cisplatin resistance in ovarian cancer cells via the AMPK/mTOR/p70S6K signaling pathway. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXNDC17" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9352" target="_blank" rel="noopener noreferrer">9352</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43396" target="_blank" rel="noopener noreferrer">O43396</a>', 'HUGO Gene symbol': 'TXNL1', 'Protein name': 'Thioredoxin-like protein 1', 'Function': 'a two-domain of 32\u2009kDa protein composed of an N-terminal Trx domain and a C-terminal domain that interacts with the 26S proteasome (19349277)', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR/HR<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24525731%2C%2025348020%5Buid%5D" target="_blank" rel="noopener noreferrer">24525731, 25348020</a>', 'Notes': '1) cisplatin resistance developed in the gastric cancer cells is at least in part because of the XRCC1 overexpression as a result of inhibition of TXNL1, presumably leading to a super strong capacity of DNA repair. 2) irinotecan has a role in inducing TXNL1 expression to further trigger ubiquitin (Ub)-proteasome-mediated XRCC1 degradation in cisplatin-resistant gastric cancer cells', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXNL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7296" target="_blank" rel="noopener noreferrer">7296</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16881" target="_blank" rel="noopener noreferrer">Q16881</a>', 'HUGO Gene symbol': 'TXNRD1', 'Protein name': 'Thioredoxin reductase 1, cytoplasmic', 'Function': 'Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10490269%5Buid%5D" target="_blank" rel="noopener noreferrer">10490269</a>', 'Notes': 'AS in TXND2', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXNRD1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10587" target="_blank" rel="noopener noreferrer">10587</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NNW7" target="_blank" rel="noopener noreferrer">Q9NNW7</a>', 'HUGO Gene symbol': 'TXNRD2', 'Protein name': 'Thioredoxin reductase 2, mitochondrial', 'Function': 'Involved in the control of reactive oxygen species levels and the regulation of mitochondrial redox homeostasis', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10490269%5Buid%5D" target="_blank" rel="noopener noreferrer">10490269</a>', 'Notes': '1) HeLa, a human cervical carcinoma cell line, cultured with CDDP showed a time- and dose-dependent reduction of intracellular TRXR activity, which was\xa0well\xa0correlated with the decrease in cell viability after exposure to CDDP. 2) In a cell-free system, CDDP was found to directly inactivate the reduced form of purified human TRXR. 3) The CDDP-resistant variants of HeLa cells, established by continuous exposure to CDDP, exhibited an increased expression and activity of TRXR as\xa0well\xa0as TRX compared with the parental cells. 4) sodium selenate, an inhibitor of TRXR, was found to increase the susceptibility to CDDP in the CDDP-resistant cells. 5) the HeLa cells transfected with an antisense TRXR RNA expression vector to reduce the intracellular enzyme activity displayed an enhanced\xa0sensitivity\xa0to CDDP.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXNRD2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/114112" target="_blank" rel="noopener noreferrer">114112</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86VQ6" target="_blank" rel="noopener noreferrer">Q86VQ6</a>', 'HUGO Gene symbol': 'TXNRD3', 'Protein name': 'Thioredoxin reductase 3', 'Function': 'Displays thioredoxin reductase, glutaredoxin and glutathione reductase activities. Catalyzes disulfide bond isomerization.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=10490269%5Buid%5D" target="_blank" rel="noopener noreferrer">10490269</a>', 'Notes': 'AS in TXND2', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TXNRD3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/27338" target="_blank" rel="noopener noreferrer">27338</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16763" target="_blank" rel="noopener noreferrer">Q16763</a>', 'HUGO Gene symbol': 'UBE2S', 'Protein name': 'Ubiquitin-conjugating enzyme E2 S / E2-EPF ubiquitin carrier protein', 'Function': "Catalyzes 'Lys-11'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C)", 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> Hypoxia signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19083192%5Buid%5D" target="_blank" rel="noopener noreferrer">19083192</a>', 'Notes': '1) UCP was the only factor significantly associated with the extent of tumor burden in esophageal cancer patients. 2) UCP positivity was linked to poor response to neoadjuvant therapy and worse survival. 3) Inhibited UCP significantly decrease tumor growth and the capacity for metastasis. 4) EMT induced by VHL/HIF-1alpha-TGF-beta1 pathway might be the underlying mechanism responsible to the more aggressive tumor growth in UCP-positive esophageal cancer. 5) UCP was significantly associated with poor prognosis of esophageal cancer', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UBE2S" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/29089" target="_blank" rel="noopener noreferrer">29089</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NPD8" target="_blank" rel="noopener noreferrer">Q9NPD8</a>', 'HUGO Gene symbol': 'UBE2T', 'Protein name': 'Ubiquitin-conjugating enzyme E2 T', 'Function': 'Associates with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2; also monoubiquitinates FANCL and FANCI; may contribute to ubiquitination and degradation of BRCA1 ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26119737%2C%2017938197%2C%2016916645%5Buid%5D" target="_blank" rel="noopener noreferrer">26119737, 17938197, 16916645</a>', 'Notes': '1) Overexpression of\xa0UBE2T\xa0rescued cellular hypersensitivity to crosslinking agents MMC, DEB and cisplatin. 2) Two independently derived ΔUBE2T cell lines show hypersensitivity to cisplatin and are defective in the monoubiquitination of FANCD2. 3) UBE2T Is the E2 in the Fanconi Anemia Pathway and Undergoes Negative Autoregulation.  ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UBE2T" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51366" target="_blank" rel="noopener noreferrer">51366</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95071" target="_blank" rel="noopener noreferrer">O95071</a>', 'HUGO Gene symbol': 'UBR5', 'Protein name': 'HECT family E3 ubiquitin ligase', 'Function': 'protein kinase DYRK2, with some substrates being targeted for phosphorylation by DYRK2 prior to ubiquitination by UBR5. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27721409%5Buid%5D" target="_blank" rel="noopener noreferrer">27721409</a>', 'Notes': '1) UBR5 interacts physically with MOAP-1, ubiquitylates MOAP-1 in vitro and inhibits MOAP-1 stability in cultured cells. 2) UBR5 knockdown increased MOAP-1 expression, enhanced Bax activation and sensitized otherwise resistant cells to cisplatin-induced apoptosis. 3) UBR5 expression was higher in ovarian cancers from cisplatin-resistant patients than from cisplatin-responsive patient. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UBR5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7345" target="_blank" rel="noopener noreferrer">7345</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P09936" target="_blank" rel="noopener noreferrer">P09936</a>', 'HUGO Gene symbol': 'UCHL1', 'Protein name': 'Ubiquitin carboxyl terminal hydrolase 1', 'Function': 'processing of ubiquitin precursors and of ubiquitinated proteins', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24155778%5Buid%5D" target="_blank" rel="noopener noreferrer">24155778</a>', 'Notes': '1) in 7 ovarian cancer cell lines. 4 of them with UCHL1 silencing showed heavy promoter methylation while the other 3 with relative high UCHL1 expression showed little promoter methylation. 2) inhibition of UCHL1 promoted cell proliferation also increased cisplatin resistance. 3) the expression level of UCHL1 in several ovarian cancer cell lines correlated negatively with their cisplatin resistance levels. 4) Several apoptosis related genes were increased after UCHL1 knockdown, including apoptosis regulator BCL2, BCL11A, AEN and XIAP. 5) up-regulation of Bcl-2 and pAKT as well as down-regulation of Bax in UCHL1 knockdown cells, while no significant alteration of p53 and AKT1 was found. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UCHL1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7351" target="_blank" rel="noopener noreferrer">7351</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P55851" target="_blank" rel="noopener noreferrer">P55851</a>', 'HUGO Gene symbol': 'UCP2', 'Protein name': 'Uncoupling protein 2', 'Function': 'UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29928365%5Buid%5D" target="_blank" rel="noopener noreferrer">29928365</a>', 'Notes': '1) Downregulation of UCP2 significantly causes increased cell death following chemotherapy. 2) The UCP2 weighted score was lower in the platinum-sensitive group than in the platinum resistant-group (P=0.005). 3) patients in the low UCP2 expression group were more sensitive to platinum-based chemotherapy than those in the high UCP2 expression group (P=0.001). 4) Sensitivity to carboplatin was significantly increased when UCP2 was inhibited in human ovarian serous carcinoma cells in vitro. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UCP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7357" target="_blank" rel="noopener noreferrer">7357</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q16739" target="_blank" rel="noopener noreferrer">Q16739</a>', 'HUGO Gene symbol': 'UGCG', 'Protein name': 'Ceramide glucosyltransferase', 'Function': 'Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide.\xa0Solely responsible for the first glycosylation step of ceramides leading to complex GSLs and allows cells to escape from ceramide-induced cellular apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling/ceramide<br><br> Glycosylation<br><br> Platinum efflux', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29409484%2C%2027191984%2C%2019693666%5Buid%5D" target="_blank" rel="noopener noreferrer">29409484, 27191984, 19693666</a>', 'Notes': "1) There was a statistically negative correlation between GCS CpG islands methylation and GCSphenotype in patients with breast cancer. 2) GCS CpG islands methylation was negatively associated with high ER, meanwhile positively with high HER-2 status. 3) Similar results were obtained from the analysis of breast cancer cell lines. Treatment with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dc) changed the GCS promoter methylation pattern in three sensitive cells and also caused increased drug resistance of them.\xa04) Inhibition of the UGCG leads to high ceramide levels in breast cancer cells and results in caspase-3 activation and subsequently cell death. 5) in a mice xenograft model treatment with shRNA against the UGCG leads to decreased tumor growth and 6) the MDR1 gene expression and subsequently P-gp protein is inhibited in vivo. ", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UGCG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51720" target="_blank" rel="noopener noreferrer">51720</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q96RL1" target="_blank" rel="noopener noreferrer">Q96RL1</a>', 'HUGO Gene symbol': 'UIMC1', 'Protein name': 'BRCA1-A complex subunit RAP80 / Receptor-associated protein 80', 'Function': "Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs).\xa0", 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30705591%2C%2029396516%2C%2025806231%2C%2028569838%2C%2025806229%5Buid%5D" target="_blank" rel="noopener noreferrer">30705591, 29396516, 25806231, 28569838, 25806229</a>', 'Notes': '1) Inhibition of RAP80 expression can induce apoptosis in breast cancer MCF7 cells and improve chemosensitivity to cisplatin. 2) the RAP80 mRNA level was validated to be an independent prognosis biomarker for the overall survival time of ESCC patients. 3) RAP80, a component of the BRCA1-A complex, influenced outcome in patients with low BRCA1 expression treated with cisplatin/gemcitabine, and in patients with intermediate/high BRCA1 levels receiving cisplatin/docetaxel or docetaxel alone.  4) participated in G2/M checkpoint regulation. 5) ATM phosphorylates RAP80 at different serine sites upon DNA damage. 6) RAP80 positively regulated the ATM activity via proteasome–ubiquitination pathway to promote the transition of G2/M phase in cell cycle. 7) RAP80 positively regulated the stability of USP13 to promote cell proliferation of EC cells. 8) Preclinical data and retrospective analyses showed that BRCA1 is able to induce resistance to cisplatin and sensitivity to antimicrotubule agents. In addition, the mRNA levels of expression of RAP80, encoding for a protein cooperating with BRCA1 in homologous recombination (HR), have demonstrated to further sub-classify low BRCA1 NSCLC tumors, improving the predictive model. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UIMC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7374" target="_blank" rel="noopener noreferrer">7374</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13051" target="_blank" rel="noopener noreferrer">P13051</a>', 'HUGO Gene symbol': 'UNG', 'Protein name': 'Uracil-DNA glycosylase', 'Function': 'Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or due to deamination of cytosine; prevents mtDNA oxidation (27480846)', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> DDR/BER<br><br> Redox', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21357694%2C%2028110804%5Buid%5D" target="_blank" rel="noopener noreferrer">21357694, 28110804</a>', 'Notes': '1) Blocking BER with MX as well as deficiency of Polβ and UNG conferred resistance to cisplatin treatment. 2) Uracil DNA glycosylase (UNG) is the primary glycosylase responsible for the removal of uracils adjacent to cisplatin ICLs, whereas other uracil glycosylases can process uracils in the context of undamaged DNA. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UNG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8725" target="_blank" rel="noopener noreferrer">8725</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94763" target="_blank" rel="noopener noreferrer">O94763</a>', 'HUGO Gene symbol': 'URI1', 'Protein name': 'Unconventional prefoldin RPB5 interactor 1', 'Function': '1) transcriptional repressor that regulates androgen receptor (AR) transcription.\xa02) A mitochondrial inhibitor of mitochondria-associated phosphatase 1 gamma (PP1γ) and PP1γ-mediated feedback inhibition of S6K1-BAD survival signaling ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> mTOR signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24997567%2C%2021397856%2C%2019193619%20%5Buid%5D" target="_blank" rel="noopener noreferrer">24997567, 21397856, 19193619¬†</a>', 'Notes': '1) By constitutively detaining PP1γ in inactive complexes, URI sustains S6K1 survival signaling under growth factor–limiting conditions and mediates resistance of cells to cisplatin. 2) the 19q12 amplicon has been shown in a genomewide screen to correlate with resistance against platinum-based chemotherapy in ovarian cancer. 3) URI depletion selectively reduced colony formation of platinum-resistant OVCAR-3 and FU-OV-1 cells. This effect was considerably less pronounced or absent in platinum-sensitive SKOV-3 or TOV-21G cells, respectively. 4) URI knockdown in URI-amplified OVCAR-3 cells abolished their ability to form tumors in immunodeficient mice. 5) URI amplification correlates with the failure of ovarian cancer cells to respond to platin-based chemotherapy', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=URI1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7398" target="_blank" rel="noopener noreferrer">7398</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O94782" target="_blank" rel="noopener noreferrer">O94782</a>', 'HUGO Gene symbol': 'USP1', 'Protein name': 'Ubiquitin carboxyl-terminal hydrolase 1', 'Function': 'Negative regulator of DNA damage repair which specifically deubiquitinates monoubiquitinated FANCD2', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/FA<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27029531%5Buid%5D" target="_blank" rel="noopener noreferrer">27029531</a>', 'Notes': '1) The translation of the mRNA encoding USP1, a Ubiquitin peptidase with important function in multiple DNA repair pathways, is inhibited by CDDP exposure in the sensitive cells, but not in the resistant cells. 2) This lack of down-regulation of USP1 expression at the translational level plays a primary role in CDDP resistance since inhibition of USP1 expression or activity by siRNA or the small molecule inhibitor ML323, respectively is sufficient to re-sensitize resistant cells to CDDP. 3) We involved the USP1 mRNA translation as a major mechanism of CDDP resistance in NSCLC cells and suggest that USP1 could be evaluated as a candidate predictive marker and as a therapeutic target to overcome CDDP resistance.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S; UNCHANGED in R', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=USP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/8975" target="_blank" rel="noopener noreferrer">8975</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q92995" target="_blank" rel="noopener noreferrer">Q92995</a>', 'HUGO Gene symbol': 'USP13', 'Protein name': 'Ubiquitin carboxyl-terminal hydrolase 13', 'Function': 'Deubiquitinase that mediates deubiquitination of target proteins such as BECN1, MITF, SKP2 and USP10 and is involved in various processes such as autophagy and endoplasmic reticulum-associated degradation (ERAD).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28569838%5Buid%5D" target="_blank" rel="noopener noreferrer">28569838</a>', 'Notes': '1) USP13 is phosphorylated by ATM following DNA damage which, in turn, facilitates its DSB localization. 2) USP13, in turn, deubiquitinates RAP80 and promotes RAP80 recruitment and proper DDR. 3) Depleting or inhibiting USP13 sensitizes ovarian cancer cells to cisplatin and PARP inhibitor (olaparib) 4) overexpression of USP13 renders ovarian cancer cells resistant to chemotherapy.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=USP13" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/23326" target="_blank" rel="noopener noreferrer">23326</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9UPT9" target="_blank" rel="noopener noreferrer">Q9UPT9</a>', 'HUGO Gene symbol': 'USP22', 'Protein name': 'Ubiquitin carboxyl-terminal hydrolase 22', 'Function': 'Histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. Catalyzes the deubiquitination of both histones H2A and H2B, thereby acting as a coactivator. Recruited to specific gene promoters by activators such as MYC', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> MYC signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31842906%5Buid%5D" target="_blank" rel="noopener noreferrer">31842906</a>', 'Notes': '1) Overexpression of USP22 was observed in 49.0% (99/202) of NSCLC tissues; higher USP22 immunostaining was found to be associated with enhanced angiogenesis and recurrence of NSCLC. 2) USP22 knockout dramatically suppressed in vitro proliferation, colony formation; and angiogenesis, growth, metastasis of A549 and H1299 in mouse xenograft model, and significantly prolonged survival of metastatic cancer-bearing mice. 3) USP22 knockout significantly impaired non-homologous DNA damage repair capacity, enhanced cisplatin and irradiation-induced apoptosis in these cells. 4) USP22 knockout significantly suppressed angiogenesis, proliferation, EMT, RAS, c-Myc pathways, concurrently enhanced oxidative phosphorylation and tight junction pathways in A549 and H1299 NSCLC cells; upregulated E-cadherin, p16; reduced ALDH1A3, Cyclin E1, c-Myc, and attenuated activation of AKT and ERK.  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=USP22" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57558" target="_blank" rel="noopener noreferrer">57558</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P2H5" target="_blank" rel="noopener noreferrer">Q9P2H5</a>', 'HUGO Gene symbol': 'USP35', 'Protein name': 'Ubiquitin carboxyl-terminal hydrolase 35', 'Function': 'a member of the peptidase C19 family of ubiquitin-specific proteases (DUBs); catalyzes the removal of ubiquitin from other proteins; associates with polarized mitochondria and has been shown to inhibit NF-kappa B activation and delay PARK2-mediated degradation of mitochondria.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Immune response<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=32678307%5Buid%5D" target="_blank" rel="noopener noreferrer">32678307</a>', 'Notes': '1) USP35 can directly deubiquitinate and inactivate STING. 2) activation of STING promotes its binding to USP35 in a STING phosphorylation-dependent manner. 3) knockdown of USP35 sensitizes ovarian cancer cells to the DNA-damage chemotherapeutic drug cisplatin.\xa04) High level of USP35 was correlated with diminished CD8+ T cell infiltration and poor prognosis in ovarian cancer patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=USP35" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57695" target="_blank" rel="noopener noreferrer">57695</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q86T82" target="_blank" rel="noopener noreferrer">Q86T82</a>', 'HUGO Gene symbol': 'USP37', 'Protein name': 'Ubiquitin carboxyl-terminal hydrolase 37', 'Function': 'Deubiquitinase that antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hedgehog signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30482232%5Buid%5D" target="_blank" rel="noopener noreferrer">30482232</a>', 'Notes': '1) USP37 gene was elevated in breast cancer tissues and its overexpression was strongly correlated with the increased mortality rate. 2) GSEA analysis showed that USP37 expression was positively associated with cell growth and metastasis while negatively related to cell apoptosis in the TCGA breast cancer samples. 3) USP37 knockdown inhibited tumorigenicity and increased anticancer effect of\xa0cisplatin\xa0in vivo. 4) Knockdown of USP37 significantly decreased hedgehog (Hh) pathway components\xa0Smo\xa0and Gli-1. Gli-1 was stabilized by USP37 and they interacted with each other.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=USP37" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7405" target="_blank" rel="noopener noreferrer">7405</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9P2Y5" target="_blank" rel="noopener noreferrer">Q9P2Y5</a>', 'HUGO Gene symbol': 'UVRAG', 'Protein name': 'UV radiation resistance-associated gene protein', 'Function': 'This gene complements the ultraviolet sensitivity of xeroderma pigmentosum group C cells and encodes a protein with a C2 domain. The protein activates the Beclin1-PI(3)KC3 complex, promoting autophagy', 'Putative_mechanism_associated_with_Pt_resistance': 'Autophagy<br><br> DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21606679%5Buid%5D" target="_blank" rel="noopener noreferrer">21606679</a>', 'Notes': '1) Following genetic and metabolic stress (e.g., doxorubicin, cisplatin and UV radiation), an upregulation of UVRAG mRNA and protein levels was observed.\xa02) knockdown of UVRAG in human tumor cells (e.g., HL60 leukemia cells, HCT116 clone cancer cells and HeLa cervical cancer cells) significantly increases the population of apoptotic annexin V+ cells following doxorubicin, cisplatin and UV radiation treatment. ', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=UVRAG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7412" target="_blank" rel="noopener noreferrer">7412</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P19320" target="_blank" rel="noopener noreferrer">P19320</a>', 'HUGO Gene symbol': 'VCAM1', 'Protein name': 'Vascular cell adhesion protein 1', 'Function': 'Integrin ligand important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction.', 'Putative_mechanism_associated_with_Pt_resistance': 'ECM signaling<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24029657%2C%2024378876%5Buid%5D" target="_blank" rel="noopener noreferrer">24029657, 24378876</a>', 'Notes': '1) VCAM-1 expression correlated with tumor stage. All specimens from stage I patients were negative, whereas 29% of stage II patients and 73% of stage III/IV patients were positive. 2) VCAM-1 expression was reduced among women who received neoadjuvant chemotherapy - chemotherapy in regulating VCAM-1 expression. 3) Treatment of mesothelial cells in culture with carboplatin resulted in a transient decrease in VCAM-1 expression 4 h after treatment that returned to baseline within 16-24 h. 4) an acute decrease in VCAM-1 expression 4 h after carboplatin administration that recovered within 48 h in mice harboring platinum-resistant tumors. 5) carboplatin treatment of mice with platinum-sensitive tumors showed reduced VCAM-1 expression, which correlated with reduced tumor burden; 6) mice with platinum-resistant tumors retained elevated VCAM-1 expression and tumor burden after treatment.  7) the combined treatment of anti-α4β1 integrin or anti-VCAM-1 with carboplatin significantly reduced tumor burden. 8) In vitro, the combination of carboplatin and anti-α4β1 integrin antibodies resulted in increased cell death and doubling time', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN in S', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VCAM1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7416" target="_blank" rel="noopener noreferrer">7416</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P21796" target="_blank" rel="noopener noreferrer">P21796</a>', 'HUGO Gene symbol': 'VDAC1', 'Protein name': 'Voltage-dependent anion-selective channel protein 1', 'Function': 'Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> OXPHOS', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=18362892%2C%2020937774%2C%2019770592%2C%2022285227%2C%2022954696%20%5Buid%5D" target="_blank" rel="noopener noreferrer">18362892, 20937774, 19770592, 22285227, 22954696¬†</a>', 'Notes': '1) Knockdown of VDAC1 was particularly efficient in preventing cell death induced by cisplatin in non-small cell lung cancer cells. 2) Hexokinase II Detachment from the Mitochondria potentiates cisplatin Induced cytotoxicity through a caspase-2 dependent Mechanism. 3) Resistance could be correlated with upregulation of hexokinase-II and VDAC, which are known to form a survival-promoting mitochondrial complex. 4) VDAC1 oligomerization in apoptosis and of the VDAC1 N-terminal domain in the release of apoptogenic proteins as well as into regulation of VDAC by anti-apoptotic proteins, such as HK and Bcl2. 5) Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by cisplatin. ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VDAC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7422" target="_blank" rel="noopener noreferrer">7422</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P15692" target="_blank" rel="noopener noreferrer">P15692</a>', 'HUGO Gene symbol': 'VEGFA', 'Protein name': 'vascular endothelial growth factor', 'Function': 'Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> Oncogene signaling/VEGF<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20663925%2C%2018004244%2C%2021970881%2C%2031235595%5Buid%5D" target="_blank" rel="noopener noreferrer">20663925, 18004244, 21970881, 31235595</a>', 'Notes': '1) VEGF was strongly expressed both in early-stage and advanced-stage CCC of the ovary. 2) In early-stage CCCs, patients who had tumors with high levels of VEGF had significantly shorter survival than those with low levels of VEGF. 3) VEGF expression was significantly higher in cisplatin-refractory human CCC cells (RMG1-CR and KOC7C-CR), compared with the respective parental cells (RMG1 and KOC7C) in the presence of cisplatin. 4) In vivo treatment with bevacizumab markedly inhibited the growth of both parental CCC cell-derived (RMG1 and KOC7C) and cisplatin-refractory CCC cell-derived (RMG1-CR and KOC7C-CR) tumors as a result of inhibition of tumor angiogenesis. 5) Progressive decrease of LLC-9 and LLC-19 sensitivity to action of cis-DDP evidenced in vitro and in vivo was accompanied by the significant changes of tumor angiogenic potential. 6) angiotensin II (Ang II) induced significantly VEGF production in cisplatin resistant bladder cancer T24PR and 5637PR cells than in their corresponding parent cells in vitro. 7) Rad51 is a YAP/TAZ target gene and that VEGF–neuropilin 2–YAP/TAZ–mediated cisplatin resistance occurs through downstream Rad51 expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': 'Yes', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VEGFA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7428" target="_blank" rel="noopener noreferrer">7428</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P40337" target="_blank" rel="noopener noreferrer">P40337</a>', 'HUGO Gene symbol': 'VHL', 'Protein name': 'von Hippel-Lindau disease tumor suppressor', 'Function': 'Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hypoxia signaling<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=20301636%2C%2019509240%2C%2018481984%2C%2031375625%5Buid%5D" target="_blank" rel="noopener noreferrer">20301636, 19509240, 18481984, 31375625</a>', 'Notes': '1) IGF1R expression is inhibited by the von Hippel-Lindau (VHL) tumor suppressor, and the IGF1R is up-regulated in CC-RCC, in which\xa0VHL\xa0is frequently inactivated.\xa02) CC-RCC cells expressing mutant VHL and higher IGF1R were more chemoresistant than cells expressing functional VHL. 3) VHL as a transcriptional regulator is its ability of targeting HIF1-α subunit for ubiquitin-mediated proteolysis.  4)\xa0Combination therapy using ERK inhibitors, however, resensitizes VHL- and EglN3-deficient cells that are otherwise cisplatin-resistant.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VHL" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7431" target="_blank" rel="noopener noreferrer">7431</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P08670" target="_blank" rel="noopener noreferrer">P08670</a>', 'HUGO Gene symbol': 'VIM', 'Protein name': 'Vimentin', 'Function': 'Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27322682%5Buid%5D" target="_blank" rel="noopener noreferrer">27322682</a>', 'Notes': '1) The expression of vimentin was downregulated in drug-resistant ovarian cancer cell lines A2780-DR and HO-8910 as compared to their respective control cells. 2) Overexpression of vimentin in A2780-DR cells markedly increased their sensitivity to\xa0cisplatin, whereas knockdown of vimentin in A2780, HO-8910-PM and HO-8910 cells increased the resistance to\xa0cisplatin. 3) Quantitative proteomic analysis identified 95 differentially expressed proteins between the vimentin silenced A2780 cells (A2780-VIM-KN) and the control cells, in which downregulation of endocytic proteins and the upregulation of exocytotic proteins CHMP2B and PDZK1 were proposed to contribute the decreased\xa0cisplatin\xa0accumulation in vimentin knockdown cells. 4) Silencing of vimentin induced upregulation of cancer stem cell markers and both A2780-DR and A2780-VIM-KN cells were more facile to form spheroids than control cells under serum-free culture condition. 5) vimentin knockdown increased the 14-3-3 mediated retention of Cdc25C in the cytoplasm, leading to inactivation of Cdk1 and the prolonged G2 phase arrest that allowed the longer period of time for cells to repair\xa0cisplatin-damaged DNA.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VIM" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/57599" target="_blank" rel="noopener noreferrer">57599</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q8TAF3" target="_blank" rel="noopener noreferrer">Q8TAF3</a>', 'HUGO Gene symbol': 'WDR48', 'Protein name': 'WD repeat-containing protein 48\xa0(USP1-associated factor 1)', 'Function': 'Regulator of deubiquitinating complexes. Acts as a strong activator of USP1 and USP46. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> ubiquitin', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22118673%2C%2024531842%5Buid%5D" target="_blank" rel="noopener noreferrer">22118673, 24531842</a>', 'Notes': '1) The top inhibitors, pimozide and GW7647, inhibited USP1/UAF1 noncompetitively with a K(i) of 0.5 and 0.7 μM, respectively, and displayed selectivity against a number of deubiquitinases, deSUMOylase, and cysteine proteases. 2) The USP1/UAF1 inhibitors act synergistically with cisplatin in inhibiting cisplatin-resistant non-small cell lung cancer (NSCLC) cell proliferation.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WDR48" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10406" target="_blank" rel="noopener noreferrer">10406</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q14508" target="_blank" rel="noopener noreferrer">Q14508</a>', 'HUGO Gene symbol': 'WFDC2', 'Protein name': 'WAP four-disulfide core domain protein 2 / Human epididymal secretory protein E4', 'Function': 'secreted glycosylated protein; broad range protease inhibitor.', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24389815%2C%2025354091%2C%2027184254%2C%2027862665%5Buid%5D" target="_blank" rel="noopener noreferrer">24389815, 25354091, 27184254, 27862665</a>', 'Notes': '1) elevated HE4 serum levels correlate with chemoresistance and decreased survival rates in EOC patients. 2) HE4 overexpression promoted xenograft tumor growth and chemoresistance against cisplatin in an animal model resulting in reduced survival rates. 3) HE4 displayed responses to tumor microenvironment constituents and presented increased expression as well as nuclear translocation upon EGF, VEGF and Insulin treatment and nucleolar localization with Insulin treatment. 4) HE4 interacts with EGFR, IGF1R, and transcription factor HIF1α. 5) Constructs of antisense phosphorothio-oligonucleotides targeting HE4 arrested tumor growth in nude mice. 6) The exogenous recombinant HE4 protein enhanced cell viability, promoted accumulation of cells in the G2/M phase and 7) attenuated carboplatin-induced apoptosis. HE4 markedly decreased the Bax/Bcl-2 ratio. 8) Based on the results of multivariate analysis, the risk of death was significantly higher in patients with an H-score > 4.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WFDC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51741" target="_blank" rel="noopener noreferrer">51741</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9NZC7" target="_blank" rel="noopener noreferrer">Q9NZC7</a>', 'HUGO Gene symbol': 'WWOX', 'Protein name': 'WW domain-containing oxidoreductase', 'Function': 'Plays a role in TGFB1 signaling and TGFB1-mediated cell death. ', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> DDR/HR<br><br> EMT<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25789010%2C%2027869163%5Buid%5D" target="_blank" rel="noopener noreferrer">25789010, 27869163</a>', 'Notes': '1) WWOX-expressing cells were more sensitive to treatment with cisplatin, doxorubicin and mitoxantrone. 2) Compared with control cells, the expression levels of stem cell markers, including CD133, CD117, ABCG2, Nanog, OCT4 and breast cancer resistance protein, were significantly lower in WWOX-expressing cells, while the level of the differentiation marker E-cadherin was significantly higher in WWOX-expressing cells. 3) Wwox-deficient cells exhibit enhanced HR and decreased NHEJ. 4) Wwox interact with Brca1: Brca1-Wwox interaction supports NHEJ as the dominant DSB repair pathway in Wwox-sufficient cells. 5) Enhanced homology directed repair (HDR) in Wwox-deficient cells permits significantly increased resistance to cisplatin and radiation treatment-associated cell killing,', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WWOX" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/11060" target="_blank" rel="noopener noreferrer">11060</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O00308" target="_blank" rel="noopener noreferrer">O00308</a>', 'HUGO Gene symbol': 'WWP2', 'Protein name': 'NEDD4-like E3 ubiquitin-protein ligase', 'Function': 'E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Notch signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25356737%5Buid%5D" target="_blank" rel="noopener noreferrer">25356737</a>', 'Notes': '1) WWP2 interacted with N3-ICD but not with intracellular domains from other Notch receptors. 2) Wild-type WWP2 but not ligase-deficient mutant WWP2 increases mono-ubiquitination of the membrane-tethered Notch3 fragment, therefore attenuating Notch3 pathway activity in cancer cells and leading to cell cycle arrest. 3) the majority of ovarian carcinomas harbored homozygous or heterozygous deletions in WWP2 locus, and there was an inverse correlation in the expression levels between WWP2 and Notch3 in ovarian carcinomas. 4) ectopic expression of WWP2 decreased tumor development in a mouse xenograft model and suppressed the Notch3-induced phenotypes including increase in cancer stem cell-like cell population and platinum resistance. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WWP2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/25937" target="_blank" rel="noopener noreferrer">25937</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9GZV5" target="_blank" rel="noopener noreferrer">Q9GZV5</a>', 'HUGO Gene symbol': 'WWTR1', 'Protein name': 'WW domain-containing transcription regulator protein 1', 'Function': 'Transcriptional coactivator which acts as a downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Hippo signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28749195%5Buid%5D" target="_blank" rel="noopener noreferrer">28749195</a>', 'Notes': '1) drug resistance cells displayed EMT characteristics. 2) DDP-resistant Nasopharyngeal carcinoma (NPC) cells exhibited enhanced migration and invasion potential. 3) overexpression of TAZ is closely associated with the DDP resistance of NPC cells and its EMT properties. 4) Depletion of TAZ in DDP-resistant cells reversed EMT phenotypes to MET characteristics and restored chemosensitivity of DDP-resistant cells to DDP treatment.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=WWTR1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54739" target="_blank" rel="noopener noreferrer">54739</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q6GPH4" target="_blank" rel="noopener noreferrer">Q6GPH4</a>', 'HUGO Gene symbol': 'XAF1', 'Protein name': 'XIAP-associated factor 1', 'Function': 'functions as a negative regulator of members of the IAP (inhibitor of apoptosis protein) family. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22759793%2C%2018555708%5Buid%5D" target="_blank" rel="noopener noreferrer">22759793, 18555708</a>', 'Notes': '1) Tissues from 94 patients with advanced epithelial ovarian cancer (EOC) and 30 ovarian cystadenomas were obtained. 2) Low XAF1 expression was associated with high-grade tumors and poor overall survival for patients who received platin-based combination chemotherapy after surgery. 3) Overexpression of XAF1 suppressed cell proliferation and enhanced SKOV3 cells sensitivity to cisplatin, 4) Overexpression of XAF1 induced XIAP inactivation, caspase-3 activation and cytosolic expression of cytochrome c. 5) XAF1 as a novel predictive and prognostic factor in bladder cancer patients treated with neoadjuvant chemotherapy. ', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XAF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7494" target="_blank" rel="noopener noreferrer">7494</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P17861" target="_blank" rel="noopener noreferrer">P17861</a>', 'HUGO Gene symbol': 'XBP1', 'Protein name': 'X-box-binding protein 1', 'Function': 'Functions as a transcription factor during endoplasmic reticulum (ER) stress by regulating the unfolded protein response (UPR).\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'ER stress response', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15339968%2C%2018386815%2C%2025368386%5Buid%5D" target="_blank" rel="noopener noreferrer">15339968, 18386815, 25368386</a>', 'Notes': '1) VST also inhibited the production of the UPR transcriptional activators XBP1 and ATF4 during glucose deprivation: VST alone and in combination with cisplatin statistically significantly (P =.004 and P<.001 for comparisons with untreated control, respectively) inhibited tumor growth of MKN74 xenografts. 2) XBP1u is associated with longer survival of breast patients treated with tamoxifen, whereas XBP1s is associated with shorter survival. 3) XBP1s-overexpressing MCF-7 cells displayed much higher basal levels of autophagy as demonstrated with increased basal LC3II levels and decreased p62 levels.123 Autophagy induced by XBP1s overexpression protects the cells against apoptosis.', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XBP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/331" target="_blank" rel="noopener noreferrer">331</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P98170" target="_blank" rel="noopener noreferrer">P98170</a>', 'HUGO Gene symbol': 'XIAP', 'Protein name': 'X-linked inhibitor of apoptosis protein', 'Function': 'regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptosis<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=22403616%2C%2029565481%5Buid%5D" target="_blank" rel="noopener noreferrer">22403616, 29565481</a>', 'Notes': "1) XIAP was expressed in 17 (20.83%) of the 60 advanced HNSCC samples and the expression was significantly associated with cisplatin resistance (P = 0.036) and poor clinical outcome (P = 0.025). 2) Cisplatin-based chemotherapy induced XIAP expression in those post-chemotherapy samples (P = 0.011), was further associated with poorer clinical outcome (P = 0.029).\xa03) Down-regulation of miR-377 was found in chemoresistant OS tissues and cisplatin-resistant OS cell lines. Overexpression of miR-377 re-sensitizes cisplatin resistant OS cells to cisplatin-induced caspase-3 dependent apoptosis. 4) MiR-377 directly represses XIAP expression through binding to its 3' untranslated region (UTR) of mRNA. 5) Overexpression of XIAP partially cancelled the cisplatin-sensitizing effect of miR-377.", 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XIAP" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7507" target="_blank" rel="noopener noreferrer">7507</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P23025" target="_blank" rel="noopener noreferrer">P23025</a>', 'HUGO Gene symbol': 'XPA', 'Protein name': 'DNA repair protein complementing XP-A cells', 'Function': 'Initiates repair by binding to damaged sites with various affinities, depending on the photoproduct and the transcriptional state of the region.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26880244,26156020,22467238" target="_blank" rel="noopener noreferrer">26880244, 26156020, 22467238</a>', 'Notes': '1) XPA\xa0was expressed at higher levels in\xa0cisplatin-resistant melanoma cells than in\xa0cisplatin-sensitive ones. 2) the knockdown of\xa0XPA\xa0not only increased cellular apoptosis but also inhibited\xa0cisplatin-induced autophagy, which rendered the melanoma cells more sensitive to\xa0cisplatin. 3) the increased\xa0XPA\xa0in resistant melanoma cells promoted PARP1 activation and that the inhibition of PARP1 could attenuate the\xa0cisplatin-induced autophagy. 4) the inhibition of PARP1 and the autophagy process made resistant melanoma cells more susceptible to\xa0cisplatin\xa0treatment. 5) High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. 6) HIF1α was found to bind with strong affinity to a hypoxia response element sequence in the promoter of XPA. Modulating expression of HIF1α by small interfering RNA or cobalt chloride markedly reduced or increased transcription of XPA in lung cancer cell lines, respectively. 7) Expression of XPA determined in 54 primary lung tumors was elevated on average 5.2-fold when compared with normal bronchial epithelial cells and correlated with levels of HIF1α (r = 0.58; P < 0.01). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XPA" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7508" target="_blank" rel="noopener noreferrer">7508</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q01831" target="_blank" rel="noopener noreferrer">Q01831</a>', 'HUGO Gene symbol': 'XPC', 'Protein name': 'xeroderma pigmentosum group C\xa0', 'Function': 'A DNA damage recognition protein that binds to damaged DNA templates at a very early stage during the DNA repair process.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NER', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=25634215%2C%2012807748%2C%2020028083%2C%2030386247%2C%2022174370%2C%2030628719%2C%2028746345%5Buid%5D" target="_blank" rel="noopener noreferrer">25634215, 12807748, 20028083, 30386247, 22174370, 30628719, 28746345</a>', 'Notes': '1) XPC-\xa0cells show defective DNA repair activity toward both psoralen and cisplatin-damaged plasmid DNA. 2) The defect was partially restored when a functional\xa0XPC\xa0protein was supplemented into the\xa0XPC\xa0nuclear extract prior to the reaction.\xa03) human XPC−Rad23B complex makes direct contact with both the cisplatin-damaged DNA strand and the complementary undamaged strand of a duplex DNA substrate. 4) gastric cancer MKN45 cells are sensitive to CDDP due to low levels of XPC and the absence of translocation of XPA and XPD to the nucleus after stimuli. 5) XPC enhances apoptosis induced by DNA damage in a p53 nullizygous background, acting downstream of mitochondrial permeabilization and upstream of caspase-9 activation in the DNA damage–induced apoptosis cascade. 6) XPC overexpression in various p53-deficient cancer cells resistant to cisplatin improved their sensitivity to cisplatin-induced apoptosis. 7) High expression of XPC was noted in A549/DDP cells compared with that in A549 cells, which was associated with DDP resistance. 8) XPC silencing significantly inhibited A549/DDP cell proliferation and increased the induction of apoptosis. 9) XPC knockdown decreased the expression levels of the Akt/mTOR signaling proteins and the expression of their downstream mediator. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XPC" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7514" target="_blank" rel="noopener noreferrer">7514</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O14980" target="_blank" rel="noopener noreferrer">O14980</a>', 'HUGO Gene symbol': 'XPO1', 'Protein name': 'Exportin-1', 'Function': 'Mediates the nuclear export of cellular proteins (cargos) bearing a leucine-rich nuclear export signal (NES) and of RNAs;\xa0the only known transporter for a number of well-characterized ovarian cancer–associated proteins, including p53, BRCA1, IκBα, KLF6, SQSTM1, and PP2A; ', 'Putative_mechanism_associated_with_Pt_resistance': 'Cell cycle<br><br> NF-kB signaling<br><br> Nuclear export<br><br> p53 signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=27649553%5Buid%5D" target="_blank" rel="noopener noreferrer">27649553</a>', 'Notes': '1) XPO1 RNA overexpression and protein nuclear localization were correlated with decreased survival and platinum resistance in ovarian cancer. 2) Targeted XPO1 inhibition decreased cell viability and synergistically restored platinum sensitivity in both immortalized ovarian cancer cells and PDCL. 3) The XPO1 inhibitor-mediated apoptosis occurred through both p53-dependent and p53-independent signaling pathways. 4) Selinexor treatment, alone and in combination with platinum, markedly decreased tumor growth and prolonged survival in platinum-resistant Mouse experiment and mice. 5) In selinexor-treated patients, tumor growth was halted in 3 of 5 patients, including one with a partial response, and was safely tolerated by all.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XPO1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7515" target="_blank" rel="noopener noreferrer">7515</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P18887" target="_blank" rel="noopener noreferrer">P18887</a>', 'HUGO Gene symbol': 'XRCC1', 'Protein name': 'X-ray repair cross complementing group1', 'Function': 'Involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes.', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/BER<br><br> DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=24525731%5Buid%5D" target="_blank" rel="noopener noreferrer">24525731</a>', 'Notes': '1) reduced expression of XRCC1 in gastric cancerous tissues correlates with a significant survival benefit from adjuvant first-line platinum-based chemotherapy. 2) the protein expression of XRCC1 was significantly increased in cisplatin-resistant cells (BGC823/DDP) and independently contributed to cisplatin resistance. 3)Irinotecan, another chemotherapeutic agent to induce DNA damaging used to treat patients with advanced gastric cancer that progressed on cisplatin, was found to inhibit the expression of XRCC1 effectively, and leading to an increase in the sensitivity of resistant cells to cisplatin. 4) Our proteomic studies further identified a cofactor of 26S proteasome, the thioredoxin-like protein 1 (TXNL1) that downregulated XRCC1 in BGC823/DDP cells via the ubiquitin-proteasome pathway.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7516" target="_blank" rel="noopener noreferrer">7516</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43543" target="_blank" rel="noopener noreferrer">O43543</a>', 'HUGO Gene symbol': 'XRCC2', 'Protein name': 'DNA repair protein XRCC2', 'Function': 'homologous recombination repair (HRR) pathway of double-stranded DNA, thought to repair chromosomal fragmentation, translocations and deletions. ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31275435%2C%2019192406%5Buid%5D" target="_blank" rel="noopener noreferrer">31275435, 19192406</a>', 'Notes': '1) XRCC2-deficient cells have increased levels of spontaneous chromosome instability, and exhibit hypersensitivity to DNA interstrand crosslinking agents such as mitomycin C and\xa0cisplatin\xa0as well as ionizing radiation, alkylating agents and aldehydes.\xa02) The sensitivity levels to CBP and DDP in the patients with at least one T allele was 2.06 times (pathological type adjusted OR = 2.06, 95% CI = 1.02 - 4.18) and 2.07 times (pathological type adjusted OR = 2.07, 95% CI = 1.04 - 4.14) higher than those in the patients with C/C genotype. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7517" target="_blank" rel="noopener noreferrer">7517</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O43542" target="_blank" rel="noopener noreferrer">O43542</a>', 'HUGO Gene symbol': 'XRCC3', 'Protein name': 'DNA repair protein XRCC3', 'Function': 'Part of the RAD21 paralog protein complex CX3 which acts in the BRCA1-BRCA2-dependent HR pathway.\xa0Involved in HJ resolution and thus in processing HR intermediates late in the DNA repair process', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=15843498%5Buid%5D" target="_blank" rel="noopener noreferrer">15843498</a>', 'Notes': 'Xrcc3 overexpression in MCF-7 cells resulted in 1) a 2- to 6-fold resistance to cisplatin/melphalan, 2) a 2-fold increase in drug-induced Rad51 foci, 3) an increased cisplatin-induced S-phase arrest, 4) decreased cisplatin-induced apoptosis, and 5) increased cisplatin-induced DNA synthesis arrest.\xa0', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC3" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7518" target="_blank" rel="noopener noreferrer">7518</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q13426" target="_blank" rel="noopener noreferrer">Q13426</a>', 'HUGO Gene symbol': 'XRCC4', 'Protein name': 'DNA repair protein XRCC4', 'Function': 'XRCC4 is indispensable to NHEJ and functions together with DNA ligase IV in the rejoining of broken DNA ends.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/HR', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=21785230%5Buid%5D" target="_blank" rel="noopener noreferrer">21785230</a>', 'Notes': "The XRCC4-deficient cells were highly sensitive to etoposide and 5-fluoro-2'-deoxyuridine as well as IR, and moderately sensitive to camptothecin, methyl methanesulfonate, cisplatin, mitomycin C, aphidicolin and hydroxyurea, compared to the parental HCT116 cells (colon adenocarcinoma).\xa0", 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC4" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7520" target="_blank" rel="noopener noreferrer">7520</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P13010" target="_blank" rel="noopener noreferrer">P13010</a>', 'HUGO Gene symbol': 'XRCC5', 'Protein name': 'X-ray repair cross-complementing protein 5', 'Function': 'Single-stranded DNA-dependent ATP-dependent helicase. Involved in NHEJ required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as a regulatory subunit of DNA-PK', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11925933%2C%2024044516%2C%2028399858%2C%2023181744%2C%2011095672%5Buid%5D" target="_blank" rel="noopener noreferrer">11925933, 24044516, 28399858, 23181744, 11095672</a>', 'Notes': '1) DNA repair associated genes, i.e., XRCC5, XRCC6, ERCC5, hMLH1 were over-expressed in three-fold\xa0cisplatin-resistant cell line,\xa02) Cisplatin treatment led to an increment in H2AX-γ, RAD50, NPM1, XRCC5 and p53 in all treated sets. 3) Impaired XRCC5 and cisplatin treatment leads to cellular apoptosis. 4) Tissue samples from the nonresponse group (to platinum) exhibited higher Ku80 mRNA levels compared to the response group. 5) Ku80 knockdown by shRNA augmented cisplatin/pemetrexed-induced decline in viability, whereas Ku80 overexpression attenuated viability reduction induced by these drugs compared to control A549 cells. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'DOWN/UP', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC5" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/2547" target="_blank" rel="noopener noreferrer">2547</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P12956" target="_blank" rel="noopener noreferrer">P12956</a>', 'HUGO Gene symbol': 'XRCC6', 'Protein name': 'X-ray repair cross-complementing protein 6', 'Function': 'Single-stranded DNA-dependent ATP-dependent helicase. Involved in NHEJ required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as a regulatory subunit of DNA-PK', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR/NHEJ', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11925933%2C%2029397516%2C%2020924094%2C%2018546291%2C%2011095672%5Buid%5D" target="_blank" rel="noopener noreferrer">11925933, 29397516, 20924094, 18546291, 11095672</a>', 'Notes': '1) DNA repair associated genes, i.e., XRCC5, XRCC6, ERCC5, hMLH1 were over-expressed in three-fold\xa0cisplatin-resistant cell line,\xa02) In patients with HNSCC:  Ku70 mRNA was the marker most significantly associated with response to IC. 3) high tumor Ku70 mRNA expression was associated with significantly longer local recurrence-free survival (LRFS). ', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'DOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=XRCC6" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10413" target="_blank" rel="noopener noreferrer">10413</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P46937" target="_blank" rel="noopener noreferrer">P46937</a>', 'HUGO Gene symbol': 'YAP1', 'Protein name': 'Transcriptional regulator YAP1', 'Function': 'critical downstream regulatory target in the Hippo signaling pathway that restricts proliferation and promoting apoptosis', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Hippo signaling<br><br> TGF-β signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=26716514%5Buid%5D" target="_blank" rel="noopener noreferrer">26716514</a>', 'Notes': '1) YAP1 ablation significantly improved sensitivities not only to cisplatin but also to ionizing radiation (lung cancer PC9 cells). 2) A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin. 3) overexpression of YAP1 could contribute to progression and poor prognosis of NSCLC, while knockdown of YAP1 sensitized ovarian cancer cells to cisplatin, erlotinib (EGFR Tyrosine kinase inhibitor) and S12 (survivin inhibitor).  ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YAP1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/4904" target="_blank" rel="noopener noreferrer">4904</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P67809" target="_blank" rel="noopener noreferrer">P67809</a>', 'HUGO Gene symbol': 'YBX1', 'Protein name': 'Y-box-binding protein 1', 'Function': 'Mediates pre-mRNA alternative splicing regulation. Also regulates the transcription of the multidrug resistance gene MDR1 and MVP', 'Putative_mechanism_associated_with_Pt_resistance': 'RNA processing', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=8797596%2C%2015703814%2C%2015750632%5Buid%5D" target="_blank" rel="noopener noreferrer">8797596, 15703814, 15750632</a>', 'Notes': 'YB-1 is overexpressed in\xa0human\xa0cancer\xa0cell lines that are resistant to cisplatin and that the depletion of YB-1 by transfection of a vector expressing YB-1 antisense RNA increases the sensitivity of\xa0human\xa0cancer\xa0cells to cisplatin.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YBX1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/54915" target="_blank" rel="noopener noreferrer">54915</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q9BYJ9" target="_blank" rel="noopener noreferrer">Q9BYJ9</a>', 'HUGO Gene symbol': 'YTHDF1', 'Protein name': 'YTH domain-containing family protein 1', 'Function': 'Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and promotes mRNA translation efficiency (such as keap1); drives intestinal immune response against bacterial infection', 'Putative_mechanism_associated_with_Pt_resistance': 'NF-kB signaling<br><br> Redox<br><br> Translation<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=31653849%5Buid%5D" target="_blank" rel="noopener noreferrer">31653849</a>', 'Notes': '1) YTHDF1 is one of evolutionary positively selected genes for high-altitude adaptation, is amplified in various cancers. 2) YTHDF1 deficiency inhibits NSCLC cell proliferation and xenograft tumor formation through regulating the translational efficiency of CDK2, CDK4, and cyclin D1, 3) YTHDF1 depletion restrains de novo lung adenocarcinomas (ADC) progression. 4) YTHDF1 high expression correlates with better clinical outcome, with its depletion rendering cancerous cells resistant to cisplatin (DDP) treatment. 5) the Keap1-Nrf2-AKR1C1 axis as the downstream mediator of YTHDF1.\xa0', 'Up / down in Pt-resistant cells': 'DOWN', 'Up / down to promote Pt-resistance': 'DOWN', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; patient tissue', 'Scores': 4.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YTHDF1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7532" target="_blank" rel="noopener noreferrer">7532</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P61981" target="_blank" rel="noopener noreferrer">P61981</a>', 'HUGO Gene symbol': 'YWHAG', 'Protein name': '14-3-3 protein gamma', 'Function': 'Adapter protein implicated in a large spectrum of signaling pathways. Binds to a phosphoserine or phosphothreonine motif.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11577088%5Buid%5D" target="_blank" rel="noopener noreferrer">11577088</a>', 'Notes': '1) 14-3-3 inhibitor difopein enhances the ability of cisplatin to kill cells. 2) The ability of 14-3-3 to inhibit Bad and other proapoptotic proteins argues that 14-3-3 can support\xa0cell\xa0survival.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YWHAG" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7533" target="_blank" rel="noopener noreferrer">7533</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/Q04917" target="_blank" rel="noopener noreferrer">Q04917</a>', 'HUGO Gene symbol': 'YWHAH', 'Protein name': '14-3-3 protein eta', 'Function': 'Adapter protein implicated in the regulation of a large spectrum of signaling pathways in cell signaling, cycle control, and apoptotic death.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=11577088%5Buid%5D" target="_blank" rel="noopener noreferrer">11577088</a>', 'Notes': '1) 14-3-3 inhibitor difopein enhances the ability of cisplatin to kill cells. 2) The ability of 14-3-3 to inhibit Bad and other proapoptotic proteins argues that 14-3-3 can support\xa0cell\xa0survival.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YWHAH" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/10971" target="_blank" rel="noopener noreferrer">10971</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P27348" target="_blank" rel="noopener noreferrer">P27348</a>', 'HUGO Gene symbol': 'YWHAQ', 'Protein name': '14-3-3 protein theta', 'Function': 'Adapter protein implicated in a large spectrum of signaling pathways. Binds to a phosphoserine or phosphothreonine motif.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'Oncogene signaling/AKT', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=14701673%5Buid%5D" target="_blank" rel="noopener noreferrer">14701673</a>', 'Notes': '1) Cisplatin\xa0causes the\xa0phosphorylation\xa0of FKHRL1 via a phosphatidylinositol 3-kinase/Akt cascade, 2) Cisplatin induced the association of 14-3-3 theta protein with phosphorylated-FKHRL1 in cisplatin-resistant Caov-3 cells. 3)\xa0Inhibition\xa0of this cascade\xa0sensitizes\xa0ovariancancer\xa0cells\xa0to\xa0cisplatin.', 'Up / down in Pt-resistant cells': 'UNKNOWN', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'interaction', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YWHAQ" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 1},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7534" target="_blank" rel="noopener noreferrer">7534</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P63104" target="_blank" rel="noopener noreferrer">P63104</a>', 'HUGO Gene symbol': 'YWHAZ', 'Protein name': '14-3-3 protein zeta/delta', 'Function': 'Adapter protein implicated in the regulation of a large spectrum of signaling pathways in cell signaling, cycle control, and apoptotic death.\xa0', 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> Oncogene signaling/AKT<br><br> TGF-β signaling<br><br> WNT signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17699796%5Buid%5D" target="_blank" rel="noopener noreferrer">17699796</a>', 'Notes': '1) Down-regulation\xa0of 14-3-3zeta in lung cancer cells led to a dose-dependent increased sensitivity to cisplatin-induced cell death\xa02) The increased 14-3-3zeta expression was positively correlated with a more advanced pathologic stage and grade of NSCLCs and was associated with overall and cancer-specific survival rates of the patients. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YWHAZ" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7528" target="_blank" rel="noopener noreferrer">7528</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P25490" target="_blank" rel="noopener noreferrer">P25490</a>', 'HUGO Gene symbol': 'YY1', 'Protein name': 'Transcriptional repressor, GLI-Krüppel type zinc finger protein', 'Function': 'Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes. Acts synergistically with SMAD1 and SMAD4 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Involved in DNA repair. In vitro, binds to DNA recombination intermediate structures (Holliday junctions). ', 'Putative_mechanism_associated_with_Pt_resistance': 'DDR<br><br> Oncogene signaling/AKT<br><br> Platinum efflux<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=29970878%2C%2019208743%5Buid%5D" target="_blank" rel="noopener noreferrer">29970878, 19208743</a>', 'Notes': '1) knockdown of YY1 by shRNA enhanced cisplatin-induced apoptosis and 2) inhibition of the xenograft tumor growth. 3) knockdown of YY1 downregulated both S473 and T308 phosphorylation of AKT, 4) overexpression of YY1 upregulated both S473 and T308 phosphorylation. 5) Cisplatin upregulated YY1 mRNA and protein expression and both S473 and T308 phosphorylation of AKT. 6) PP2A antagonist, okadaic acid, upregulated T308, but not S473, phosphorylation, abolished YY1 knockdown-mediated enhancement of cisplatin-induced inhibition of cell proliferation. 7) Analysis of the MDR1 promoter revealed four putative YY1-binding sites. 8) YY1 silencing resulted in the inhibition of MDR1 expression and function. 9) Expression of both YY1 and MDR1 proteins was increased in ALL patients compared to controls. 10) a positive correlation was identified between YY1 and MDR1 expression. 11) High levels of YY1 were associated with decreased overall survival. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UP', 'Druggable': '', 'Source of the supporting data': 'cell line; clinical outcome; patient tissue; xenograft', 'Scores': 5.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=YY1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/51341" target="_blank" rel="noopener noreferrer">51341</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O95365" target="_blank" rel="noopener noreferrer">O95365</a>', 'HUGO Gene symbol': 'ZBTB7A', 'Protein name': 'Zinc finger and BTB domain-containing protein 7A', 'Function': 'Transcription factor that represses the transcription of a wide range of genes involved in cell proliferation and differentiation; negatively regulates SMAD4 transcriptional activity in the TGF-beta signaling pathway  (25514493); independently of its transcriptional activity, in double-strand break repair via classical non-homologous end joining/cNHEJ', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR/NHEJ<br><br> Immune response<br><br> TGF-β signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28942243%2C%2032083004%2C%2026451776%5Buid%5D" target="_blank" rel="noopener noreferrer">28942243, 32083004, 26451776</a>', 'Notes': '1) ZBTB7A is increased in cisplatin-resistant osteosarcoma cells. 2) elevated ZBTB7A inhibits cisplatin-induced apoptosis by repressing LINC00473 expression. 3) ZBTB7A directly binds to the promoter and suppresses the transcription of LINC00473. 4) LINC00473 interacts with the transcript factor C/EBPβ, facilitating its binding to the promoter of IL24, leading to decrease chemoresistance.\xa05) ZBTB7A is able to modulate expression of the death receptors TRAIL-R1, TRAIL-R2, Fas and p53 phosphorylated at serine-15. 6) ZBTB7A transactivates TRAIL-R2, which sensitizes cells to cisplatin-induced apoptosis. The ZBTB7A-TRAIL-R2 cascade is involved in both the extrinsic and intrinsic cisplatin-induced pathways of apoptosis. 6) expression level of and the copy status of ZBTB7A and TRAIL-R2 are important survival predictors for head and neck cancers. 7) The expression level of Pokemon in NSCLC patients was higher than that in healthy controls; 8) a poor response and shorter survival time in patients with pretreatment Pokemon levels in excess of 135.09 ng/ml compared to those with Pokemon levels below 135.09 ng/ml (p = 0.013). Pokemon ≥ 135.09 ng/ml was an independent risk factor for survival time in NSCLC patients undergoing combination chemotherapy (p = 0.018)..', 'Up / down in Pt-resistant cells': 'DOWN/UP', 'Up / down to promote Pt-resistance': 'DOWN/UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZBTB7A" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/6935" target="_blank" rel="noopener noreferrer">6935</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P37275" target="_blank" rel="noopener noreferrer">P37275</a>', 'HUGO Gene symbol': 'ZEB1', 'Protein name': 'Zinc finger E-box-binding homeobox 1', 'Function': 'transcriptional repressor. Inhibits IL-2 gene expression. Enhances or represses ATP1A1; represses E-cadherin and induces EMT by recruiting SMARCA4/BRG1; represses BCL6 with corepressor CTBP1.', 'Putative_mechanism_associated_with_Pt_resistance': 'CSC<br><br> EMT<br><br> Redox/Glutathione<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=30481785,19584296" target="_blank" rel="noopener noreferrer">30481785, 19584296</a>', 'Notes': '1) ZEB1 was increased in cisplatin-resistant ovarian cancer SKOV3/DPP cells. 2) Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, and decreased migration and invasion. 3) downregulation of ZEB1 decreased the volume and weight of implanted tumors. 4) ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2 (CD98hc, amino acid transporter). 5) Independent validation experiment using five new pancreatic cancer cell lines confirmed that an inverse correlation between E-cadherin and Zeb-1 correlated closely with resistance to gemcitabine, 5-FU, and cisplatin. 6) Silencing Zeb-1 in the mesenchymal lines not only increased the expression of E-cadherin but also other epithelial markers, such as EVA1 and MAL2, and restored drug sensitivity. 7) immunohistochemical analysis of E-cadherin and Zeb-1 in primary tumors confirmed that expression of the two proteins was mutually exclusive (P = 0.012). ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line; xenograft', 'Scores': 2.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZEB1" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 4},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/9839" target="_blank" rel="noopener noreferrer">9839</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/O60315" target="_blank" rel="noopener noreferrer">O60315</a>', 'HUGO Gene symbol': 'ZEB2', 'Protein name': 'Zinc finger E-box-binding homeobox 2\xa0/ Smad-interacting protein 1', 'Function': "Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters. Represses transcription of E-cadherin. Represses expression of MEOX2", 'Putative_mechanism_associated_with_Pt_resistance': 'EMT<br><br> NF-kB signaling', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=28485807,28534959,31024010" target="_blank" rel="noopener noreferrer">28485807, 28534959, 31024010</a>', 'Notes': '1) Transfection with ZEB2 siRNA in cisplatin-resistant gastric cancer SGC7901/DDP cells resulted in a significant decrease in cell viability in response to the cisplatin treatment. 2) miR-200c could enhance the sensitivity of gastric cancer SGC7901/DDP cells to DDP through targeted regulation of ZEB2 expression. 3) PAX6 is commonly correlated with EMT-mediated stem cell transformation, thereby inducing cisplatin resistance through directly regulating ZEB2 expression. ', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZEB2" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/7702" target="_blank" rel="noopener noreferrer">7702</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P52747" target="_blank" rel="noopener noreferrer">P52747</a>', 'HUGO Gene symbol': 'ZNF143', 'Protein name': 'Zinc finger protein 143', 'Function': 'involved in selenocystyl tRNA transcription; ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA.', 'Putative_mechanism_associated_with_Pt_resistance': 'Apoptotic signaling<br><br> DDR<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=17297437%5Buid%5D" target="_blank" rel="noopener noreferrer">17297437</a>', 'Notes': '1) ZNF143 was overexpressed in cisplatin-resistant cells. 2) ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. 3) ZNF143 is associated with tumor suppressor gene product p73 but not with p53: p73 could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. 4) both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells.\xa0', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZNF143" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 3},
{'NCBI_link': '<a href="https://www.ncbi.nlm.nih.gov/gene/81931" target="_blank" rel="noopener noreferrer">81931</a>', 'Uniprot_link': '<a href="https://www.uniprot.org/uniprot/P35789" target="_blank" rel="noopener noreferrer">P35789</a>', 'HUGO Gene symbol': 'ZNF93', 'Protein name': 'Zinc finger protein 93', 'Function': 'represses long interspersed nuclear element 1 (L1) retrotransposons; may be linked to MYC and G2/M relating to signaling pathways (32509065)', 'Putative_mechanism_associated_with_Pt_resistance': 'MYC signaling<br><br> Transcription', 'PMID': '<a href="https://pubmed.ncbi.nlm.nih.gov/?term=19742314%5Buid%5D" target="_blank" rel="noopener noreferrer">19742314</a>', 'Notes': '1) ZNF93 was overexpressed in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line. 2) ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased sensitivity for ET-743, PM00104, and cisplatin. 3) ZNF93 transfected CS-1 cells are relatively resistant to ET-743, PM00104 and cisplatin.', 'Up / down in Pt-resistant cells': 'UP', 'Up / down to promote Pt-resistance': 'UP', 'Up / down after Pt-treatment': 'UNKNOWN', 'Druggable': '', 'Source of the supporting data': 'cell line', 'Scores': 1.0, 'COSMIC': '<a href="https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZNF93" target="_blank" rel="noopener noreferrer"><img src="https://cosmic-blog.sanger.ac.uk/static/news/cosmic_square_icon_lite.png" style="height:30px;width:30px;"></img></a>', '# associated putative mechanisms': 2},
]
